<?xml version="1.0" encoding="UTF-8"?>
<search_results count="623">
  <query>irritable bowel disease</query>
  <!-- Additional study fields may be added over time -->
  <study rank="1">
    <nct_id>NCT02372201</nct_id>
    <title>Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome</title>
    <acronym>MicFFGAH2013</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Hydro Colon Therapy plus probiotic</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>microbiota structure, using 16 S ribosomal based gradient electrophoresis ( DGGE)</outcome_measure>
      <outcome_measure>Gastrointestinal comfort, measured by Visual Analog Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vienna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>MicrobColonIrrFFG2013</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>October 2014</completion_date>
    <study_first_posted>February 26, 2015</study_first_posted>
    <last_update_posted>February 26, 2015</last_update_posted>
    <locations>
      <location>Dep. for Nutritional Sciences, University of Vienna, Vienna, Select your state, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02372201</url>
  </study>
  <study rank="2">
    <nct_id>NCT02026518</nct_id>
    <title>Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Soy isoflavones</intervention>
      <intervention type="Dietary Supplement">cholecalciferol</intervention>
      <intervention type="Dietary Supplement">Placebo of soy isoflavones</intervention>
      <intervention type="Dietary Supplement">placebo of cholecalciferol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in Clinical Outcomes (pain, flatulence, diarrhea, constipation ) at 6 weeks</outcome_measure>
      <outcome_measure>Change of baseline in gut permeability as efficacy at 6 weeks</outcome_measure>
      <outcome_measure>Change of baseline in antioxidant status as efficacy at 6 weeks</outcome_measure>
      <outcome_measure>Change of baseline in inflammation status as efficacy at 6 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>459</other_id>
    </other_ids>
    <start_date>January 2014</start_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>January 3, 2014</study_first_posted>
    <last_update_posted>November 18, 2014</last_update_posted>
    <locations>
      <location>Gastrointestinal Clinics of Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02026518</url>
  </study>
  <study rank="3">
    <nct_id>NCT03549143</nct_id>
    <title>Multicenter Observational Prospective Study to Describe Irritable Bowel Syndrome in the Russian Federation</title>
    <acronym>ROMERUS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">IBS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by sex</outcome_measure>
      <outcome_measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by education</outcome_measure>
      <outcome_measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by region of living</outcome_measure>
      <outcome_measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by marriage status</outcome_measure>
      <outcome_measure>Proportion of patients with IBS according to Rome IV Diagnostic Criteria by type of IBS</outcome_measure>
      <outcome_measure>Findings of routine examination</outcome_measure>
      <outcome_measure>Comorbidity</outcome_measure>
      <outcome_measure>Routine treatment regimens</outcome_measure>
      <outcome_measure>Absolute score of the IBS symptoms measured by IBS-QoL scale</outcome_measure>
      <outcome_measure>Changes from baseline of the IBS symptoms measured by IBS-QoL scale</outcome_measure>
      <outcome_measure>Assesment by Global Patient Assessment scale</outcome_measure>
      <outcome_measure>Assesment by Physician Global Assessment scale</outcome_measure>
      <outcome_measure>Adherence to treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>EPIDI060</other_id>
    </other_ids>
    <start_date>December 25, 2017</start_date>
    <primary_completion_date>April 19, 2019</primary_completion_date>
    <completion_date>April 19, 2019</completion_date>
    <study_first_posted>June 7, 2018</study_first_posted>
    <last_update_posted>April 25, 2019</last_update_posted>
    <locations>
      <location>City Clinical Hospital #8, Chelyabinsk, Russian Federation</location>
      <location>Railway Clinical Hospital, Irkutsk, Russian Federation</location>
      <location>City Clinical Hospital #4, Ivanovo, Russian Federation</location>
      <location>The First Republican Clinical Hospital of MoH UR, Izhevsk, Russian Federation</location>
      <location>Interregional Clinical Diagnostic Center, Kazan, Russian Federation</location>
      <location>Medical Center &quot;Dobryj Doctor&quot;, Kemerovo, Russian Federation</location>
      <location>Branch Hospital AT ST. Krasnodar JSC &quot;RZD&quot;, Krasnodar, Russian Federation</location>
      <location>The Medical ON Group Lyubertsy, Lyubertsy, Russian Federation</location>
      <location>Institute of Health, Lyubertsy, Russian Federation</location>
      <location>SM-Clinic, Lyubertsy, Russian Federation</location>
      <location>Multidisciplinary Medical Clinic, Moscow, Russian Federation</location>
      <location>Research Institute of gastroenterology, Moscow, Russian Federation</location>
      <location>Medical Center 'Golden Orchid', Moscow, Russian Federation</location>
      <location>Outpatient Dpt of City Clinical Hospital #85, Moscow, Russian Federation</location>
      <location>Blokhin Oncology Center, Moscow, Russian Federation</location>
      <location>9 MDC Ministry of Defense, Moscow, Russian Federation</location>
      <location>Medical Center on Timur Frunze Street, Moscow, Russian Federation</location>
      <location>MEDSI Clinic, Moscow, Russian Federation</location>
      <location>CP Litfonda, Moscow, Russian Federation</location>
      <location>Diamed Clinic, Moscow, Russian Federation</location>
      <location>MC Larmed, Moscow, Russian Federation</location>
      <location>Clinic 'Medic City', Moscow, Russian Federation</location>
      <location>MSMSU them. A. I. Evdokimov, Moscow, Russian Federation</location>
      <location>CPM LLC, Novosibirsk, Russian Federation</location>
      <location>LLC Multidisciplinary Medical Center ALTAME+, Odintsovo, Russian Federation</location>
      <location>LLC Industrial Medicine Clinic, polyclinic No1, Orenburg, Russian Federation</location>
      <location>Treatment and Rehabilitation Center No1, Rostov-on-Don, Russian Federation</location>
      <location>Medi Com LLC (SM-clinic), Saint Petersburg, Russian Federation</location>
      <location>LLC 'Avesta MDC-M', Saratov, Russian Federation</location>
      <location>Stavropol Regional Clinical Diagnostic Center, Stavropol, Russian Federation</location>
      <location>OKD Diagnostic Center, Surgut, Russian Federation</location>
      <location>Consulvative and Diagnostic Center Endos, Tyumen, Russian Federation</location>
      <location>Kuvatov RCH, Ufa, Russian Federation</location>
      <location>Diamed Llc, Vladivostok, Russian Federation</location>
      <location>MC Medic LLC, Yekaterinburg, Russian Federation</location>
      <location>MC Chance LLC, Yekaterinburg, Russian Federation</location>
      <location>LLC &quot;Medical Center&quot; Doctor Plus, Yekaterinburg, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03549143</url>
  </study>
  <study rank="4">
    <nct_id>NCT03379064</nct_id>
    <title>Culturally Adapted Psychological Intervention for the Management of Irritable Bowel Syndrome (IBS)</title>
    <acronym>IBS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Culturally adapted Cognitive Behavior Therapy for IBS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS-symptom severity scale</outcome_measure>
      <outcome_measure>IBS Rome III</outcome_measure>
      <outcome_measure>IBS quality of Life III</outcome_measure>
      <outcome_measure>IBS pain scale-Pain Vigilance and Awareness Questionnaire</outcome_measure>
      <outcome_measure>Brief Disability Questionnaire (BDQ)</outcome_measure>
      <outcome_measure>Client Satisfaction Questionnaire</outcome_measure>
      <outcome_measure>Global Improvement Scale (GIS)</outcome_measure>
      <outcome_measure>EQ-5D (EuroQol-5 Dimensions)</outcome_measure>
      <outcome_measure>Mini International neuropsychiatric Interview (MINI)</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS)</outcome_measure>
      <outcome_measure>The Illness Perception Questionnaire (IPQ)</outcome_measure>
      <outcome_measure>Short Explanatory Model Interview</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pakistan Institute of Living and Learning</lead_sponsor>
      <collaborator>Karachi Medical and Dental College</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PILL-IBS-001</other_id>
    </other_ids>
    <start_date>June 2015</start_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>December 20, 2017</study_first_posted>
    <last_update_posted>December 20, 2017</last_update_posted>
    <locations>
      <location>Abasi Shaheed Hospital, Karachi, Sindh, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03379064</url>
  </study>
  <study rank="5">
    <nct_id>NCT00676975</nct_id>
    <title>The Efficacy of Tradition Chinese Medicine in Patients With Irritable Bowel Syndrome</title>
    <acronym>TCM-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Traditional Chinese Medicine</intervention>
      <intervention type="Drug">Traditional Chinese Medicine Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patient reported global symptom improvement, based on this question: &quot;Have you had adequate relief of your symptoms over the last two weeks&quot;? (yes/no)</outcome_measure>
      <outcome_measure>Bowel Symptom Scale (BSS): to assess changes in individual IBS and global IBS symptoms. QoL assessment:one disease-specific (IBS-QoL) and one generic (SF-36), will be used.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
      <collaborator>University of Maryland</collaborator>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TCM-IBS</other_id>
      <other_id>1U19AT003266-01</other_id>
    </other_ids>
    <start_date>May 26, 2008</start_date>
    <primary_completion_date>December 30, 2010</primary_completion_date>
    <completion_date>August 30, 2011</completion_date>
    <study_first_posted>May 13, 2008</study_first_posted>
    <last_update_posted>April 25, 2017</last_update_posted>
    <locations>
      <location>Li Ka Shing Specialist Clinic, Prince of Wales Hospital, Hong Kong (SAR), China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00676975</url>
  </study>
  <study rank="6">
    <nct_id>NCT02161120</nct_id>
    <title>Effect of Two Different Rye Bread Types in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Traditional Finnish rye bread</intervention>
      <intervention type="Other">Low FODMAP rye bread</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change is IBS symptoms by using IBS-SSS questionaire</outcome_measure>
      <outcome_measure>IBS quality of life by using IBS QoL questionnaire</outcome_measure>
      <outcome_measure>Changes in specific IBS symptoms measured by 100 mm VAS scale</outcome_measure>
      <outcome_measure>Changes is intestinal microbiota evaluated by fecal samples</outcome_measure>
      <outcome_measure>Changes in hydrogen excretion evaluated by 6 hours breath test after standard rye bread breakfast</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oy Karl Fazer Ab</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>87</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BSTN-2014-rye</other_id>
    </other_ids>
    <start_date>April 2014</start_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <study_first_posted>June 11, 2014</study_first_posted>
    <last_update_posted>March 31, 2015</last_update_posted>
    <locations>
      <location>Aava Medical Centre, Helsinki, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02161120</url>
  </study>
  <study rank="7">
    <nct_id>NCT01529359</nct_id>
    <title>Irritable Bowel Syndrome and Lactibiane Tolerance</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Lactibiane Tolerance</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of bowel symptoms according to the Francis Score</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Severity of Anxiety/Depression</outcome_measure>
      <outcome_measure>Impact of the complementation on fatigue</outcome_measure>
      <outcome_measure>Impact of the intervention on immunological parameters in stools</outcome_measure>
      <outcome_measure>Impact of the intervention on immunological parameters in blood</outcome_measure>
      <outcome_measure>severity of the anxiety/depression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pileje</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PiLeJe-LactiTol-0210</other_id>
    </other_ids>
    <start_date>April 2010</start_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>February 8, 2012</study_first_posted>
    <last_update_posted>February 8, 2012</last_update_posted>
    <locations>
      <location>Chu L'Archet 2, Nice, Alpes Maritimes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01529359</url>
  </study>
  <study rank="8">
    <nct_id>NCT01297556</nct_id>
    <title>Patient Attributes for Optimal Treatment Outcome in Irritable Bowel Syndrome.</title>
    <acronym>IBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive Behavior Therapy(CBT)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Quality of Life Inventory(IBS QOLF)</outcome_measure>
      <outcome_measure>Behavioral Symptom Inventory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Michigan Gastroenterology Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MGI-IKA-IBS-2011</other_id>
    </other_ids>
    <start_date>April 2011</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>February 16, 2011</study_first_posted>
    <last_update_posted>February 16, 2011</last_update_posted>
    <locations>
      <location>Michigan Gastroenterology Institute, East Lansing, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01297556</url>
  </study>
  <study rank="9">
    <nct_id>NCT03620994</nct_id>
    <title>The Predictive Value of Alarm Symptoms in Patients With Irritable Bowel Syndrome Based on Rome IV</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The incidence of organic bowel diseases</outcome_measure>
      <outcome_measure>The incidence of organic bowel diseases in different subtypes of IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Second Affiliated Hospital of Xi'an Jiaotong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Crossover</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>20188517</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>March 1, 2019</primary_completion_date>
    <completion_date>March 1, 2019</completion_date>
    <study_first_posted>August 8, 2018</study_first_posted>
    <last_update_posted>January 11, 2019</last_update_posted>
    <locations>
      <location>The second affiliated hospital of xi'an jiaotong university, Xi'an, Shanxi, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03620994</url>
  </study>
  <study rank="10">
    <nct_id>NCT00761007</nct_id>
    <title>Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)</title>
    <acronym>IRIS</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibodutant</intervention>
      <intervention type="Drug">Ibodutant</intervention>
      <intervention type="Drug">Ibodutant</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Response of Overall IBS Symptom Relief - 50% Rule</outcome_measure>
      <outcome_measure>Response of Overall IBS Symptom Relief - 75% Rule</outcome_measure>
      <outcome_measure>Response of Overall IBS Symptom Relief in the Subgroup of Patients With IBS With Diarrhea (IBS-D) - 75% Rule</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Menarini Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>554</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NAK 03</other_id>
      <other_id>2008-000214-71</other_id>
    </other_ids>
    <start_date>July 2008</start_date>
    <primary_completion_date>February 2009</primary_completion_date>
    <completion_date>March 2009</completion_date>
    <study_first_posted>September 26, 2008</study_first_posted>
    <results_first_posted>October 1, 2010</results_first_posted>
    <last_update_posted>March 21, 2012</last_update_posted>
    <locations>
      <location>Center for Clinical and Basic Research (CCBR), Ballerup, Denmark</location>
      <location>emovis GmbH, Berlin, Germany</location>
      <location>Digestive Diseases Center &quot;Gastro&quot;, Riga, Latvia</location>
      <location>Federal State Institution &quot;Outpatient clinic #3&quot; of President's Management Department of the Russian Federation, Moscow, Russian Federation</location>
      <location>Academy of Medical Science of Ukraine, Dnipropetrovsk, Ukraine</location>
      <location>Synexus Midlands Clinical Research Centre, Birmingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00761007</url>
  </study>
  <study rank="11">
    <nct_id>NCT02788071</nct_id>
    <title>Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">FMT capsules</intervention>
      <intervention type="Dietary Supplement">FMT placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>symptoms score</outcome_measure>
      <outcome_measure>Change in microbiota diversity</outcome_measure>
      <outcome_measure>Microbiota diversity IBS patients</outcome_measure>
      <outcome_measure>Microbiota diversity in healthy donors</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome-Quality of Life (IBS-QOL) Questionnaire Scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aleris-Hamlet Hospitaler København</lead_sponsor>
      <collaborator>Hvidovre University Hospital</collaborator>
      <collaborator>University of Aarhus</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-15016343</other_id>
    </other_ids>
    <start_date>October 2016</start_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <completion_date>July 2017</completion_date>
    <study_first_posted>June 2, 2016</study_first_posted>
    <last_update_posted>August 2, 2017</last_update_posted>
    <locations>
      <location>Aleris Hamlet Hospitaler, København, Copenhagen, Søborg, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02788071</url>
  </study>
  <study rank="12">
    <nct_id>NCT01854060</nct_id>
    <title>Predictive Factors for a Clinical Diagnosis of Irritable Bowel Syndrome in a Large Cohort of Young Adults.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of clinical diagnosis of irritable bowel syndrome</outcome_measure>
      <outcome_measure>predictive factors for the clinical diagnosis of irritable bowel syndrome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical Corps, Israel Defense Force</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>39 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>440822</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IDF-1083-2011</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <completion_date>May 2013</completion_date>
    <study_first_posted>May 15, 2013</study_first_posted>
    <last_update_posted>May 15, 2013</last_update_posted>
    <locations>
      <location>Israel Defence Forces, Medical Corps, Ramat Gan, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01854060</url>
  </study>
  <study rank="13">
    <nct_id>NCT03454386</nct_id>
    <title>SMART Program in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Stress Management and Resilience Training Program</intervention>
      <intervention type="Behavioral">Self-Management Stress Reduction Program</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in perceived stress score from baseline</outcome_measure>
      <outcome_measure>IBS symptom severity responder rate</outcome_measure>
      <outcome_measure>IBS related quality of life responder rate</outcome_measure>
      <outcome_measure>Change from baseline in resilience scores as measured by the Brief Resilience scale</outcome_measure>
      <outcome_measure>Change from baseline in resilience score as measured by the Connor-Davidson Resilience Scale</outcome_measure>
      <outcome_measure>Change from baseline in adaptive resilience score</outcome_measure>
      <outcome_measure>Change in gratitude scores from baseline</outcome_measure>
      <outcome_measure>Change in mindfulness scores from baseline</outcome_measure>
      <outcome_measure>Change in patient satisfaction from baseline</outcome_measure>
      <outcome_measure>Change in anxiety symptoms from baseline</outcome_measure>
      <outcome_measure>Change in gastrointestinal symptom related anxiety from baseline</outcome_measure>
      <outcome_measure>Change in somatic symptom severity from baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB#18-000235</other_id>
    </other_ids>
    <start_date>July 1, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>March 5, 2018</study_first_posted>
    <last_update_posted>October 11, 2018</last_update_posted>
    <locations>
      <location>UCLA, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03454386</url>
  </study>
  <study rank="14">
    <nct_id>NCT02299973</nct_id>
    <title>Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">FMT with donor stool</intervention>
      <intervention type="Procedure">FMT with own stool</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction of overall IBS symptoms (Key question 1)</outcome_measure>
      <outcome_measure>Reduction of abdominal bloating (Key question 2)</outcome_measure>
      <outcome_measure>Changes in fecal microbiome composition (Illumina sequencing)</outcome_measure>
      <outcome_measure>Changes in IBS symptom scores at three months after FMT</outcome_measure>
      <outcome_measure>Changes in IBS symptom scores at six months post FMT</outcome_measure>
      <outcome_measure>Changes in IBS symtom scores at 9 months post FMT</outcome_measure>
      <outcome_measure>Changes in IBS symptom scores at 1 year post FMT</outcome_measure>
      <outcome_measure>Composition of mucosal-adherent microbiota (Illumina sequencing)</outcome_measure>
      <outcome_measure>Changes of IBS symptom scores in patients who undergo an off-trial FMT</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Ghent</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UGent_Gastro_001</other_id>
    </other_ids>
    <start_date>October 2014</start_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>November 24, 2014</study_first_posted>
    <last_update_posted>December 8, 2017</last_update_posted>
    <locations>
      <location>Ghent University Hospital, Ghent, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02299973</url>
  </study>
  <study rank="15">
    <nct_id>NCT01403493</nct_id>
    <title>Multidisciplinary Versus a Nurse Based Patient Education For Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Patient education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect on GI symptoms as measured by IBS-SSS and satisfactory relief of IBS symptoms</outcome_measure>
      <outcome_measure>Effects on Quality of life (IBSQOL), Psychological symptoms (HAD), GI specific anxiety (VSI) and knowledge about IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S-487-02 amendment</other_id>
    </other_ids>
    <start_date>August 2007</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>July 27, 2011</study_first_posted>
    <last_update_posted>August 11, 2011</last_update_posted>
    <locations>
      <location>Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01403493</url>
  </study>
  <study rank="16">
    <nct_id>NCT00626288</nct_id>
    <title>Mesalazine Therapy in Patients With Irritable Bowel Syndrome</title>
    <acronym>IBS-02/07</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalazine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>&quot;Responder&quot; is the patient who affirmatively answers on at least 50% of the weekly question:&quot;Did you have satisfactory relief of your abdominal discomfort or pain during the last week?&quot;.</outcome_measure>
      <outcome_measure>&quot;Responder&quot; is the patient who affirmatively answers on at least 50% of the weekly question:&quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot;. VAS scale IBS-QoL questionnaire and SF-36 questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SOFAR S.p.A.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>187</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS</other_id>
    </other_ids>
    <start_date>December 2007</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <completion_date>July 2012</completion_date>
    <study_first_posted>February 29, 2008</study_first_posted>
    <last_update_posted>July 26, 2013</last_update_posted>
    <locations>
      <location>U.O. Medicina Interna- Osp. S.S.Annunziata, Cento, Ferrara, Italy</location>
      <location>Azienda Sanitaria Unità Locale di Ferrara- Ospedale del Delta, Lagosanto, Ferrara, Italy</location>
      <location>Policlinico S.Donato, San Donato, Milano, Italy</location>
      <location>Ospedale S. Andrea, Vercelli, VC, Italy</location>
      <location>Ospedale Umberto I Venezia-Mestre, Mestre, Venezia, Italy</location>
      <location>Ospedali Riuniti Torrette, Ancona, Italy</location>
      <location>Azienda ULSS 1, Belluno, Italy</location>
      <location>Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy</location>
      <location>Azienda Ospedaliero-Universitaria S.Orsola Malpighi, Bologna, Italy</location>
      <location>Ospedale SS. Annunziata, Chieti, Italy</location>
      <location>Ospedale Careggi, Firenze, Italy</location>
      <location>Opera Padre Pio, Foggia, Italy</location>
      <location>Azienda Ospedaliera Polo Universitario L.Sacco, Milano, Italy</location>
      <location>Fondazione IRCCS Policlinico, Milano, Italy</location>
      <location>A.O.U. Policlinico Seconda Università, Napoli, Italy</location>
      <location>Policlinico, Napoli, Italy</location>
      <location>U.O. Gastroenterologia Universitaria, Pisa, Italy</location>
      <location>Ospedale S. Maria delle Croci, Ravenna, Italy</location>
      <location>Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy</location>
      <location>Ospedale Universitario Sant'Andrea, Roma, Italy</location>
      <location>Università Campus Biomedico, Roma, Italy</location>
      <location>Policlinico G.B. Rossi, Verona, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00626288</url>
  </study>
  <study rank="17">
    <nct_id>NCT02420158</nct_id>
    <title>Trans-cutaneous Vagal Nerve Electrical Stimulation and Irritable Bowel Syndrome</title>
    <acronym>StVSII</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Trans-cutaneous vagal nerve electrical stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of clinical symptoms of IBS, based on the evolution of symptom score (Francis) and symptom scale (UCLA-SSS)</outcome_measure>
      <outcome_measure>Safety and tolerance of trans-cutaneous nerve stimulation as measured by any symptom occurring in relation with electrical stimulation, number of hours per day of system use</outcome_measure>
      <outcome_measure>Evolution of digestive physiology during vagal nerve stimulation</outcome_measure>
      <outcome_measure>Effect of vagal nerve stimulation on quality of life</outcome_measure>
      <outcome_measure>Evaluation of sympatho-vagal balance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014.844</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>August 2018</primary_completion_date>
    <completion_date>August 2018</completion_date>
    <study_first_posted>April 17, 2015</study_first_posted>
    <last_update_posted>January 4, 2019</last_update_posted>
    <locations>
      <location>Clinique Universitaire d'Hépato-Gastroentérologie - CHU de Grenoble, Grenoble, France</location>
      <location>Service d'Exploration Fonctionnelle Digestive - Hôpital Edouard Herriot - Hospices Civils de Lyon, LYON Cedex 03, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02420158</url>
  </study>
  <study rank="18">
    <nct_id>NCT03806127</nct_id>
    <title>Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vibegron</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of irritable bowel syndrome (IBS) with predominantly diarrhea (IBS-D) participants who are abdominal pain intensity (API) weekly responders at Week 12</outcome_measure>
      <outcome_measure>Global Improvement Scale (GIS) score at Week 12 for IBS-D participants, IBS with mixed episodes of diarrhea and constipation (IBS-M) participants, and all IBS participants</outcome_measure>
      <outcome_measure>Number of participants with any adverse event</outcome_measure>
      <outcome_measure>Number of participants with clinically significant clinical laboratory values</outcome_measure>
      <outcome_measure>Number of participants with clinically significant vital sign values</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Urovant Sciences GmbH</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>URO-901-2001</other_id>
    </other_ids>
    <start_date>December 31, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>April 2020</completion_date>
    <study_first_posted>January 16, 2019</study_first_posted>
    <last_update_posted>May 27, 2019</last_update_posted>
    <locations>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Alabama Medical Group, PC, Mobile, Alabama, United States</location>
      <location>Hope Research Institute, Chandler, Arizona, United States</location>
      <location>Synexus Clinical Research US, Inc. - East Valley Family Physicians, PLC, Chandler, Arizona, United States</location>
      <location>Synexus - Clinical Research Advantage, Inc. - Central Phoenix Medical Clinic LLC, Phoenix, Arizona, United States</location>
      <location>GW Research Inc - ClinEdge-PPDS, Chula Vista, California, United States</location>
      <location>Triwest Research Associates, LLC, La Mesa, California, United States</location>
      <location>VA Long Beach Healthcare System - NAVREF, Long Beach, California, United States</location>
      <location>Southern California Research Institute Medical Group, Inc., Los Angeles, California, United States</location>
      <location>Desta Digestive Disease Medical Center, San Diego, California, United States</location>
      <location>Medical Associates Research Group, Inc., San Diego, California, United States</location>
      <location>Torrance Clinical Research, Torrance, California, United States</location>
      <location>Medical Research Center of Connecticut LLC, Hamden, Connecticut, United States</location>
      <location>Mayo Clinic - Division of Gastroenterology, Jacksonville, Florida, United States</location>
      <location>Florida Center For Gastroenterology, Largo, Florida, United States</location>
      <location>Clinical Research Center of Florida, Pompano Beach, Florida, United States</location>
      <location>Palm Beach Research - ClinEdge - PPDS, West Palm Beach, Florida, United States</location>
      <location>RNA America, LLC, Sugar Hill, Georgia, United States</location>
      <location>Investigators Research Group, LLC, Indianapolis, Indiana, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Clinical Research Institute of Michigan, Chesterfield, Michigan, United States</location>
      <location>Advanced Research Institute, Reno, Nevada, United States</location>
      <location>UNC School of Medicine, Charlotte Campus, Charlotte, North Carolina, United States</location>
      <location>Carolina Digestive Diseases, Greenville, North Carolina, United States</location>
      <location>East Carolina Gastroenterology, Jacksonville, North Carolina, United States</location>
      <location>Dayton Gastroenterology, Inc., Beavercreek, Ohio, United States</location>
      <location>Cleveland Clinic, Cleveland, Ohio, United States</location>
      <location>Central Sooner Research, Norman, Oklahoma, United States</location>
      <location>Synexus Clinical Research US, Inc. - Anderson, Anderson, South Carolina, United States</location>
      <location>Chattanooga Medical Research Inc, Chattanooga, Tennessee, United States</location>
      <location>Clinical Research Solutions PC, Jackson, Tennessee, United States</location>
      <location>MW Clinical Research Center (research Clinic), Beaumont, Texas, United States</location>
      <location>DHAT Research Institute, Garland, Texas, United States</location>
      <location>University of Texas Health Science Center at Houston, Houston, Texas, United States</location>
      <location>Advanced Research Institute, South Ogden, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03806127</url>
  </study>
  <study rank="19">
    <nct_id>NCT01018498</nct_id>
    <title>Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Restricted FODMAPs diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in pain frequency</outcome_measure>
      <outcome_measure>Changes in GI Transit Time</outcome_measure>
      <outcome_measure>Changes in Breath Hydrogen and Methane production</outcome_measure>
      <outcome_measure>Changes in GI Permeability</outcome_measure>
      <outcome_measure>Changes in fecal microbiome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>American College of Gastroenterology</collaborator>
      <collaborator>Texas Medical Center Digestive Disease Center</collaborator>
      <collaborator>NASPGHAN Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-25005</other_id>
    </other_ids>
    <start_date>October 2009</start_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <completion_date>September 2011</completion_date>
    <study_first_posted>November 23, 2009</study_first_posted>
    <last_update_posted>January 18, 2018</last_update_posted>
    <locations>
      <location>Children's Nutrition Research Center, Houston, Texas, United States</location>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01018498</url>
  </study>
  <study rank="20">
    <nct_id>NCT02364830</nct_id>
    <title>Clinical Effectiveness of Enteric Coated(E.C.) Anise-oil on Irritable Bowel Syndrome</title>
    <acronym>IBS-Anise</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anise-oil EC Capsule</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">Colpermin®</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite of Quality of Life (QOL), pain, flatulence, diarrhea, constipation, reflux, headache and tiredness</outcome_measure>
      <outcome_measure>Composite of Change in Quality of Life (QOL), pain, flatulence, diarrhea, constipation, reflux, headache and tiredness at end of treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shiraz University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>E.C. Anise-oil on IBS</other_id>
      <other_id>Dr.Mosaffa</other_id>
    </other_ids>
    <start_date>April 2013</start_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <completion_date>January 2015</completion_date>
    <study_first_posted>February 18, 2015</study_first_posted>
    <last_update_posted>February 18, 2015</last_update_posted>
    <locations>
      <location>Dr. Kamran Bagheri Lankarani, Shiraz, Fars, Iran, Islamic Republic of</location>
      <location>Dr. Maryam Mosaffa-Jahromi, Shiraz, Fars, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02364830</url>
  </study>
  <study rank="21">
    <nct_id>NCT02371499</nct_id>
    <title>Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Lactobacillus casei DG</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain/discomfort as measured by 11-point Numerical Rating Scale</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome degree-of-relief as measured by 7-point balanced ordinal scale</outcome_measure>
      <outcome_measure>Stool frequency and consistency as assessed by Bristol Scale</outcome_measure>
      <outcome_measure>Microbiota of fecal sample as characterized by Ion Torrent Personal Genome Machine sequencing of 16S ribosomal RNA-based amplicons</outcome_measure>
      <outcome_measure>Overall satisfaction with treatment as measured by Visual Analogue Scale</outcome_measure>
      <outcome_measure>Quality of life as measured by Short-Form 12 Items Health Survey</outcome_measure>
      <outcome_measure>Anxiety and Depression as assessed by Hospital Anxiety and Depression Scale (HADS)</outcome_measure>
      <outcome_measure>Consumption of rescue medication</outcome_measure>
      <outcome_measure>Secretory Immunoglobulin A and cytokines levels in fecal samples as measured by ELISA test.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SOFAR S.p.A.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PROBE-IBS/14</other_id>
    </other_ids>
    <start_date>December 2014</start_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>February 25, 2015</study_first_posted>
    <last_update_posted>February 2, 2016</last_update_posted>
    <locations>
      <location>Policlinico S.Donato, San Donato, Milano, Italy</location>
      <location>Azienda ULSS 1, Belluno, Italy</location>
      <location>Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy</location>
      <location>U.O. Gastroenterologia Universitaria, Pisa, Italy</location>
      <location>Policlinico Universitario Campus Biomedico, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02371499</url>
  </study>
  <study rank="22">
    <nct_id>NCT00399438</nct_id>
    <title>A Study of BMS-562086 in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">BMS-562086</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Radioscintigraphy will be used to determine the effects of BMS-562086 on gastrointestinal transit</outcome_measure>
      <outcome_measure>Daily diary will be used to record the effects of BMS-562086 on bowel patterns and visceral symptoms.</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Blood pharmacokinetics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bristol-Myers Squibb</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CN148-013</other_id>
    </other_ids>
    <start_date>December 2006</start_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <completion_date>January 2008</completion_date>
    <study_first_posted>November 14, 2006</study_first_posted>
    <last_update_posted>September 26, 2008</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00399438</url>
  </study>
  <study rank="23">
    <nct_id>NCT00934973</nct_id>
    <title>Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)</title>
    <acronym>MIBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">mebeverine</intervention>
      <intervention type="Drug">methylcellulose</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Behavioral">CBT website with support</intervention>
      <intervention type="Behavioral">No website</intervention>
      <intervention type="Behavioral">CBT website with minimal support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Symptom Severity Score</outcome_measure>
      <outcome_measure>IBS QOL</outcome_measure>
      <outcome_measure>Subjects Global Assessment of relief</outcome_measure>
      <outcome_measure>Enablement</outcome_measure>
      <outcome_measure>HADs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hazel Everitt</lead_sponsor>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
      <collaborator>University of Southampton</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>135</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>5953</other_id>
    </other_ids>
    <start_date>April 2010</start_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <completion_date>October 2011</completion_date>
    <study_first_posted>July 8, 2009</study_first_posted>
    <last_update_posted>January 17, 2013</last_update_posted>
    <locations>
      <location>University of Southampton, Southampton, Hampshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00934973</url>
  </study>
  <study rank="24">
    <nct_id>NCT00774007</nct_id>
    <title>A Randomized Controlled Pilot Trial of Mesalazine in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">mesalazine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary endpoint in the study was to assess the effect of mesalazine treatment on total number of mucosal immune cells in the colonic mucosa of patients with IBS.</outcome_measure>
      <outcome_measure>Effect of mesalazine on: 1) mucosal immune cell subsets; 2) inflammatory mediator release from mucosal biopsies; 3) symptom relief, as detected by means of visual analogue scales.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SOFAR S.p.A.</lead_sponsor>
      <collaborator>St. Orsola Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-01/03</other_id>
    </other_ids>
    <start_date>September 2004</start_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <completion_date>November 2005</completion_date>
    <study_first_posted>October 16, 2008</study_first_posted>
    <last_update_posted>October 16, 2008</last_update_posted>
    <locations>
      <location>Department of Internal Medicine &amp; Gastroenterology, Bologna, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00774007</url>
  </study>
  <study rank="25">
    <nct_id>NCT00401258</nct_id>
    <title>An Open-Label Trial of Duloxetine for the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">duloxetine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain, as Determined by Daily Pain Diaries (Patterned After Item 3 From the Brief Pain Inventory; Cleeland and Ryan, 1994).</outcome_measure>
      <outcome_measure>Brief Pain Inventory</outcome_measure>
      <outcome_measure>Short Form McGill Pain Questionnaire</outcome_measure>
      <outcome_measure>Clinical Global Impression Scale</outcome_measure>
      <outcome_measure>Hamilton Depression Rating Scale</outcome_measure>
      <outcome_measure>Hamilton Anxiety Rating Scale</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome-Quality of Life Scale</outcome_measure>
      <outcome_measure>Sheehan Disability Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mclean Hospital</lead_sponsor>
      <collaborator>Eli Lilly and Company</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-P-001723</other_id>
    </other_ids>
    <start_date>November 2006</start_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <completion_date>February 2008</completion_date>
    <study_first_posted>November 20, 2006</study_first_posted>
    <results_first_posted>August 27, 2010</results_first_posted>
    <last_update_posted>March 9, 2018</last_update_posted>
    <locations>
      <location>McLean Hospital, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00401258</url>
  </study>
  <study rank="26">
    <nct_id>NCT00706758</nct_id>
    <title>Structured Patient Education Versus Written Information for Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">IBS school</intervention>
      <intervention type="Behavioral">IBS-guidebook</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect on GI symptoms as measured by IBS-SSS</outcome_measure>
      <outcome_measure>Effects on Quality of life (IBSQOL), Psychological symptoms (HAD), GI specific anxiety (VSI) and knowledge about IBS.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>143</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S487-02</other_id>
    </other_ids>
    <start_date>August 2004</start_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <completion_date>June 2008</completion_date>
    <study_first_posted>June 30, 2008</study_first_posted>
    <last_update_posted>July 20, 2011</last_update_posted>
    <locations>
      <location>Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00706758</url>
  </study>
  <study rank="27">
    <nct_id>NCT00957398</nct_id>
    <title>Comparing of the Gastrointestinal Motility in Irritable Bowel Syndrome (IBS) Patients With Healthy Volunteers</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>20090009,JLF</other_id>
    </other_ids>
    <start_date>August 2009</start_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <completion_date>April 2012</completion_date>
    <study_first_posted>August 12, 2009</study_first_posted>
    <last_update_posted>May 10, 2012</last_update_posted>
    <locations>
      <location>Analfysiologisk Klinik, University of Aarhus, Aarhus, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00957398</url>
  </study>
  <study rank="28">
    <nct_id>NCT01837472</nct_id>
    <title>Probiotics in the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Isfahan University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>132</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>390506</other_id>
    </other_ids>
    <start_date>April 2012</start_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <completion_date>April 2013</completion_date>
    <study_first_posted>April 23, 2013</study_first_posted>
    <last_update_posted>April 23, 2013</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Alzahra Hospital, Isfahan, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01837472</url>
  </study>
  <study rank="29">
    <nct_id>NCT01837485</nct_id>
    <title>Probiotics in the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lactol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain</outcome_measure>
      <outcome_measure>Constipation</outcome_measure>
      <outcome_measure>Diarrhea</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Islamic Azad University, Najafabad Branch</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>15010101882058</other_id>
    </other_ids>
    <start_date>August 2011</start_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <completion_date>March 2013</completion_date>
    <study_first_posted>April 23, 2013</study_first_posted>
    <last_update_posted>April 23, 2013</last_update_posted>
    <locations>
      <location>Shariati Hospital, Isfahan, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01837485</url>
  </study>
  <study rank="30">
    <nct_id>NCT02330029</nct_id>
    <title>Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pinaverium</intervention>
      <intervention type="Device">Atractylodes</intervention>
      <intervention type="Device">Paeonia Lactiflora</intervention>
      <intervention type="Device">Tangerine Peel</intervention>
      <intervention type="Drug">Ledebouriella Root</intervention>
      <intervention type="Drug">Radix codonopsitis</intervention>
      <intervention type="Drug">Radix curcumae</intervention>
      <intervention type="Drug">Fingered citron</intervention>
      <intervention type="Drug">Tuckahoe</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain</outcome_measure>
      <outcome_measure>Primary endpoint --- vi) Form (appearance) of stool</outcome_measure>
      <outcome_measure>Frequency of the pain</outcome_measure>
      <outcome_measure># of stools per day</outcome_measure>
      <outcome_measure>Abdominal discomfort</outcome_measure>
      <outcome_measure>Frequency of discomfort</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Macrohard Institute of Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>D00320141210</other_id>
    </other_ids>
    <start_date>August 2012</start_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <completion_date>May 2017</completion_date>
    <study_first_posted>January 1, 2015</study_first_posted>
    <last_update_posted>November 22, 2016</last_update_posted>
    <locations>
      <location>Second Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China</location>
      <location>Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China</location>
      <location>Beijing Xuanwu Hospital of Traditional Chinese Medicine affiliated to Capital Medical University., Beijing, China</location>
      <location>Shanghai First People's Hospital affiliated to Shanghai Tiao Tong University, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02330029</url>
  </study>
  <study rank="31">
    <nct_id>NCT00486876</nct_id>
    <title>A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextofisopam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The percentage of weeks for which patients record adequate overall relief of IBS symptoms during the double blind period (12 weeks of treatment).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pharmos</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>324</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>VPI-TOFP-203</other_id>
    </other_ids>
    <start_date>June 2007</start_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <completion_date>October 2009</completion_date>
    <study_first_posted>June 15, 2007</study_first_posted>
    <last_update_posted>August 2, 2011</last_update_posted>
    <locations>
      <location>Alliance Clinical Research, Birmingham, Alabama, United States</location>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Mobile Medical and Diagnostic Center, Mobile, Alabama, United States</location>
      <location>Radiant Research, Phoenix Southwest, Chandler, Arizona, United States</location>
      <location>Mayo Clinic Arizona, Scottsdale, Arizona, United States</location>
      <location>Arkansas Gastroenterology, Sherwood, Arkansas, United States</location>
      <location>Providence Clinical Research, Burbank, California, United States</location>
      <location>Discovery Clinical Research, Encinitas, California, United States</location>
      <location>Digestive and Liver Disease Specialists, Garden Grove, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>Advance Clinical Research Institute, Orange, California, United States</location>
      <location>Northern California Research, Sacramento, California, United States</location>
      <location>Medical Associates Research Group, San Diego, California, United States</location>
      <location>Westlake Medical Research, Westlake Village, California, United States</location>
      <location>Lynn Institute of the Rockies, Colorado Springs, Colorado, United States</location>
      <location>Rx Clinical Trials, Washington, District of Columbia, United States</location>
      <location>Meridien Research, Brooksville, Florida, United States</location>
      <location>Borland-Groover Clinic, Jacksonville, Florida, United States</location>
      <location>Genesis Research International, Longwood, Florida, United States</location>
      <location>Well Pharma Medical Research, Corp., Miami, Florida, United States</location>
      <location>Renstar Medical Research, Ocala, Florida, United States</location>
      <location>Compass Research, LLC, Orlando, Florida, United States</location>
      <location>The Clinical Research Center of Northwest Florida, Panama City, Florida, United States</location>
      <location>ACCORD Clinical Research, LLC, Port Orange, Florida, United States</location>
      <location>Meridien Research, St. Petersburg, Florida, United States</location>
      <location>Palm Beach Research Center, West Palm Beach, Florida, United States</location>
      <location>Mount Vernon Clinical Research, Atlanta, Georgia, United States</location>
      <location>Perimeter Institute for Clinical Research, Inc. (PICR), Atlanta, Georgia, United States</location>
      <location>North Georgia Clinical Research, Woodstock, Georgia, United States</location>
      <location>Rosemark Women Care Specialists, Idaho Falls, Idaho, United States</location>
      <location>Rockford Gastroenterology Associates, Rockford, Illinois, United States</location>
      <location>Heartland Research Associates, LLC, Arkansas City, Kansas, United States</location>
      <location>Heartland Research Associates, Wichita, Kansas, United States</location>
      <location>Trover Health System, Madisonville, Kentucky, United States</location>
      <location>Clinical Trials of America, Shreveport, Louisiana, United States</location>
      <location>Maryland Digestive Disease Research, LLC, Laurel, Maryland, United States</location>
      <location>Capital Gastroenterology Consultants, PA, Silver Spring, Maryland, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Gastrointestinal Associates, Jackson, Mississippi, United States</location>
      <location>Meridan Clinical Research, Omaha, Nebraska, United States</location>
      <location>Digestive Disease Specialists, Las Vegas, Nevada, United States</location>
      <location>New Mexico Clinical Research &amp; Osteoporosis Center, Inc, Albuquerque, New Mexico, United States</location>
      <location>Long Island Clinical Research Associates, Great Neck, New York, United States</location>
      <location>Long Island Gastrointestinal Research Group, Great Neck, New York, United States</location>
      <location>Winthrop University Hospital, Mineola, New York, United States</location>
      <location>The Weill Medical College Of Cornell University, New York, New York, United States</location>
      <location>Asheville Gastroenterology Associates, Asheville, North Carolina, United States</location>
      <location>Cumberland Research Associates, LLC., Fayetteville, North Carolina, United States</location>
      <location>Clinical Trials of America, Inc., Hickory, North Carolina, United States</location>
      <location>Clinical Trials of America, Winston-Salem, North Carolina, United States</location>
      <location>Medical Frontiers, LLC, Carlisle, Ohio, United States</location>
      <location>Consultants for Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Digestive Health Network, Cincinnati, Ohio, United States</location>
      <location>Gastroenterology Research Consultants of Greater Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Rapid Medical Research, Inc., Cleveland,, Ohio, United States</location>
      <location>Gastrointestinal &amp; Liver Diseases Consultants, PC, Dayton, Ohio, United States</location>
      <location>Toledo Center for Clinical Research, Sylvania, Ohio, United States</location>
      <location>Family Practice Center of Wadsworth, Inc., Wadsworth, Ohio, United States</location>
      <location>Lynn Institute of Norman, Norman, Oklahoma, United States</location>
      <location>Lynn Health Science Institute, Oklahoma City, Oklahoma, United States</location>
      <location>Aquilo Research, Yukon, Oklahoma, United States</location>
      <location>TriValley Primary Care-Pennridge, Perkasie, Pennsylvania, United States</location>
      <location>Coastal Carolina Research Center, Mt Pleasant, South Carolina, United States</location>
      <location>TriCities Medical Research, Bristol, Tennessee, United States</location>
      <location>ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Memphis Gastroenterology Group, Germantown, Tennessee, United States</location>
      <location>Gastroenterology Associates, Kingsport, Tennessee, United States</location>
      <location>Austin Gastroenterology, PA, Austin, Texas, United States</location>
      <location>Radiant Research of Dallas-North, Dallas, Texas, United States</location>
      <location>Research Across America, Dallas, Texas, United States</location>
      <location>Sun Research Institute, San Antonio, Texas, United States</location>
      <location>Quality Research, Inc., San Antonio, Texas, United States</location>
      <location>Gastroenterology Clinic of San Antonio, San Antonio, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States</location>
      <location>Professional Place Medical Group, LLC, Chesapeake, Virginia, United States</location>
      <location>New River Valley Research Institute, Christiansburg, Virginia, United States</location>
      <location>National Clinical Recruiters, Inc, Richmond, Virginia, United States</location>
      <location>Wenatchee Valley Medical Center, Wenatchee, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00486876</url>
  </study>
  <study rank="32">
    <nct_id>NCT01151657</nct_id>
    <title>Probiotics for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotics</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate relief</outcome_measure>
      <outcome_measure>gastrointestinal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Southern Denmark</lead_sponsor>
      <collaborator>Mejeribrugets ForskningsFond</collaborator>
      <collaborator>Arla Foods</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MFF080409-2</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <completion_date>June 2011</completion_date>
    <study_first_posted>June 28, 2010</study_first_posted>
    <last_update_posted>October 25, 2011</last_update_posted>
    <locations>
      <location>Research Unit for General Practice, Department of gastroenterology, Odense University hospital, Odense, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01151657</url>
  </study>
  <study rank="33">
    <nct_id>NCT00454688</nct_id>
    <title>Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asimadoline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Relief of IBS Pain - total months</outcome_measure>
      <outcome_measure>Relief of IBS Pain - percent of patients</outcome_measure>
      <outcome_measure>Relief of IBS Symptoms</outcome_measure>
      <outcome_measure>Lower GI function - change from baseline</outcome_measure>
      <outcome_measure>Abdominal Pain Score - change from baseline</outcome_measure>
      <outcome_measure>Abdominal Discomfort Score - change from baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tioga Pharmaceuticals</lead_sponsor>
      <collaborator>RTI Health Solutions</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>596</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ASMP2003</other_id>
    </other_ids>
    <start_date>August 2006</start_date>
    <primary_completion_date>November 2007</primary_completion_date>
    <completion_date>December 2007</completion_date>
    <study_first_posted>April 2, 2007</study_first_posted>
    <last_update_posted>October 18, 2011</last_update_posted>
    <locations>
      <location>Medical Affiliated Research Center, Huntsville, Alabama, United States</location>
      <location>Lovelace Scientific Resources, Pheonix, Arizona, United States</location>
      <location>Lovelace Scientific Resources, Phoenix, Arizona, United States</location>
      <location>Redpoint Research, Phoenix, Arizona, United States</location>
      <location>Mayo Clinic Scottsdale - Division of Gastroenterology, Scottsdale, Arizona, United States</location>
      <location>Genova Clinical Research, Tucson, Arizona, United States</location>
      <location>Arkansas Gastroenterology, North Little Rock, Arkansas, United States</location>
      <location>Sutter Institute for Medical Research, Elk Grove, California, United States</location>
      <location>Digestive &amp; Liver Disease Specialists, Garden Grove, California, United States</location>
      <location>Irvine Center for Clinical Research Inc., Irvine, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>Sutter Institute for Medical Research, Sacramento, California, United States</location>
      <location>Nothern California Research, Sacramento, California, United States</location>
      <location>Westlake Medical Research, Westlake Village, California, United States</location>
      <location>Lynn Institute of the Rockies, Colorado Springs, Colorado, United States</location>
      <location>Longmont Medical Research Network, Longmont, Colorado, United States</location>
      <location>Western States Clinical Research Inc, Wheat Ridge, Colorado, United States</location>
      <location>Clinical Research Consultants, LLC, Stratford, Connecticut, United States</location>
      <location>Phoenix Internal Medicine Associates, LLC, Waterbury, Connecticut, United States</location>
      <location>Meridian Research, Brooksville, Florida, United States</location>
      <location>Florida Medical Research Institute, Gainesville, Florida, United States</location>
      <location>Research Consultants Group, Hialeah, Florida, United States</location>
      <location>Suncoast Clinical Research, New Port Richey, Florida, United States</location>
      <location>Universal Clinical Research &amp; Technology, Orlando, Florida, United States</location>
      <location>Penninsula Research, Inc, Ormond Beach, Florida, United States</location>
      <location>Radiant Research - St. Petersburg, Pinellas Park, Florida, United States</location>
      <location>Lovelace Scientific Resources, Sarasota, Florida, United States</location>
      <location>Meridien Research, St Petersburg, Florida, United States</location>
      <location>Meridien Research, Tampa, Florida, United States</location>
      <location>Michael S. Levine, MD, Marietta, Georgia, United States</location>
      <location>Mount Vernon Clinical Research, Sandy Springs, Georgia, United States</location>
      <location>Clinical Research Atlanta, Stockbridge, Georgia, United States</location>
      <location>Northwest Gastroenterologists S.C., Arlington Heights, Illinois, United States</location>
      <location>Illinois Center for Clinical Research, Chicago, Illinois, United States</location>
      <location>University Digestive Health Center, Oak Forest, Illinois, United States</location>
      <location>BHS Digestive Disease Associates, Riverside, Illinois, United States</location>
      <location>Rockford Gastroenterology Associates Ltd, Rockford, Illinois, United States</location>
      <location>Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States</location>
      <location>Heartland Medical Research, Inc, Clive, Iowa, United States</location>
      <location>Professional Research Network of Kansas, Wichita, Kansas, United States</location>
      <location>Heartland Research Associates, LLC, Wichita, Kansas, United States</location>
      <location>University of Louisville GI Research, Louisville, Kentucky, United States</location>
      <location>Commonwealth Biomedical Research, LLC, Madisonville, Kentucky, United States</location>
      <location>Digestive Health Center of Louisianna, Baton Rouge, Louisiana, United States</location>
      <location>Digestive Disorders Associate, Annapolis, Maryland, United States</location>
      <location>Woodholme Gastroenterology Associates, PA, Baltimore, Maryland, United States</location>
      <location>Digestive Diseases Associates, PA, Baltimore, Maryland, United States</location>
      <location>Chevy Chase Clinical Research MGG, Chevy Chase, Maryland, United States</location>
      <location>Clinical Associates Research, Reisterstown, Maryland, United States</location>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>Northeast Medical Research Associates, North Dartmouth, Massachusetts, United States</location>
      <location>Ridgeview Research, Chaska, Minnesota, United States</location>
      <location>Gastrointestinal Associates, PA, Jackson, Mississippi, United States</location>
      <location>Olive Branch Family Medical Center, Olive Branch, Mississippi, United States</location>
      <location>St. Louis Center for Clinical Research, St. Louis, Missouri, United States</location>
      <location>Montana Health Research Institute, Billings, Montana, United States</location>
      <location>Gastroenterology Specialties, PC, Lincoln, Nebraska, United States</location>
      <location>Dr. Meera Dewan, PC, Omaha, Nebraska, United States</location>
      <location>University of Nebraska Medical Center, Omaha, Nebraska, United States</location>
      <location>New Mexico Clinical Research &amp; Osteoporosis Center, Albuquerque, New Mexico, United States</location>
      <location>Long Island Clinical Research Associates, Great Neck, New York, United States</location>
      <location>Cornell Weill Medical College, New York, New York, United States</location>
      <location>Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States</location>
      <location>Cary Medical Research Associates, Cary, North Carolina, United States</location>
      <location>UNC Chapel Hill, Chapel Hill, North Carolina, United States</location>
      <location>Charlotte Gastroenterology and Hepatology, Charlotte, North Carolina, United States</location>
      <location>Metrolina Medical Research, Charlotte, North Carolina, United States</location>
      <location>Cumberland Research Associates, Fayetteville, North Carolina, United States</location>
      <location>LeBauer research Associates, PA, Greensboro, North Carolina, United States</location>
      <location>Unifour Medical Research Associates, Hickory, North Carolina, United States</location>
      <location>Triangle Medical Research Associates, Raleigh, North Carolina, United States</location>
      <location>Crescent Medical Research, Salisbury, North Carolina, United States</location>
      <location>Hanover Medical Specialists, PA, Wilmington, North Carolina, United States</location>
      <location>New Hannover Medical Research, Wilmington, North Carolina, United States</location>
      <location>Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States</location>
      <location>Akron Gastroenterology Assoc, Inc., Akron, Ohio, United States</location>
      <location>Digestive Health Network, Cincinnati, Ohio, United States</location>
      <location>Radiant Research, Cincinnati, Ohio, United States</location>
      <location>Radiant Research, Columbus, Ohio, United States</location>
      <location>Wells Institute for Health Awareness, Kettering, Ohio, United States</location>
      <location>Radiant Research - Akron, Mogadore, Ohio, United States</location>
      <location>Lion Research, Norman, Oklahoma, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Options Health Research, LLC, Tulsa, Oklahoma, United States</location>
      <location>Castlerock Clinical Research Consultants, LLC, Tulsa, Oklahoma, United States</location>
      <location>NW Gastroenterology Clinic, Portland, Oregon, United States</location>
      <location>West Hills Gastroenterology Associates, PC, Portland, Oregon, United States</location>
      <location>Allegheny Center for Digestive Health, Pittsburgh, Pennsylvania, United States</location>
      <location>Guthrie Clinical Research, Sayre, Pennsylvania, United States</location>
      <location>Safe Harbor Clinical Research, East Providence, Rhode Island, United States</location>
      <location>Coastal Carolina Research Center, Mt. Pleasant, South Carolina, United States</location>
      <location>Palmetto Medical Research, Mt. Pleasant, South Carolina, United States</location>
      <location>Hillcrest Clinical Research, Simpsonville, South Carolina, United States</location>
      <location>ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Alpha Clinical Research,LLC, Clarksville, Tennessee, United States</location>
      <location>Memphis Gastroenterology Group, Germantown, Tennessee, United States</location>
      <location>Gastroenterology Associates, Kingsport, Tennessee, United States</location>
      <location>Dial Research Associates, Inc, Nashville, Tennessee, United States</location>
      <location>Covance CRU-Austin, Austin, Texas, United States</location>
      <location>Sadler Clinic, Conroe, Texas, United States</location>
      <location>Texas Tech University Health Sciences Center, El Paso, Texas, United States</location>
      <location>Discovery Alliance, Houston, Texas, United States</location>
      <location>NationsMed Clinical Research, Houston, Texas, United States</location>
      <location>Clinical Trials Network, Houston, Texas, United States</location>
      <location>Texas Tech University Health Sciences Center, Lubbock, Texas, United States</location>
      <location>Sun Research Institute, San Antonio, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>J. Lewis Research Inc., Foothills Family Clinic, Salt Lake City, Utah, United States</location>
      <location>Charlottesville Medical Research, Charlottesville, Virginia, United States</location>
      <location>New River Valley Research Institute, Christiansburg, Virginia, United States</location>
      <location>National Clinical Research Inc, Richmond, Virginia, United States</location>
      <location>Wisconsin Center for Advanced Research, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00454688</url>
  </study>
  <study rank="34">
    <nct_id>NCT00583128</nct_id>
    <title>Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AST-120</intervention>
      <intervention type="Drug">Celphere® CP-305</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent of patients who achieve at least a 50% reduction in the number of days with abdominal pain during the final 2 weeks of the double-blind treatment course.</outcome_measure>
      <outcome_measure>Safety endpoint is adverse events (AEs) deemed possibly, probably, or definitely related to treatment with investigational product during the double-blind treatment course.</outcome_measure>
      <outcome_measure>Percent change in the IBS QOL score.</outcome_measure>
      <outcome_measure>Percent change in HADS score.</outcome_measure>
      <outcome_measure>Percent change in Bristol Scale score.</outcome_measure>
      <outcome_measure>Percent change in individual items in the IBS Symptom Severity questionnaire.</outcome_measure>
      <outcome_measure>Durability of effect after the first eight weeks of treatment.</outcome_measure>
      <outcome_measure>Change in clinical laboratory tests from Baseline to Week 8 and to Week 18.</outcome_measure>
      <outcome_measure>Any adverse event occurring after Week 8.</outcome_measure>
      <outcome_measure>Physical examinations, vital signs (blood pressure, heart rate, respiration and temperature).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ocera Therapeutics</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AST014</other_id>
    </other_ids>
    <start_date>August 2007</start_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <completion_date>June 2010</completion_date>
    <study_first_posted>December 31, 2007</study_first_posted>
    <last_update_posted>June 18, 2014</last_update_posted>
    <locations>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Northern California Research, Sacramento, California, United States</location>
      <location>Medical Center for Clinical Research, San Diego, California, United States</location>
      <location>Madeleine DuPree, MD, Boynton Beach, Florida, United States</location>
      <location>Michael Epstein, MD, Annapolis, Maryland, United States</location>
      <location>Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Long Island Gastrointestinal Research Group, Great Neck, New York, United States</location>
      <location>LeBauer Research Associates, Greensboro, North Carolina, United States</location>
      <location>Peters Medical Research, LLC, High Point, North Carolina, United States</location>
      <location>Ohio Gastroenterology and Liver Institute, Cincinnatti, Ohio, United States</location>
      <location>Oklahoma Foundation for Digestive Disease, Oklahoma City, Oklahoma, United States</location>
      <location>Breco Research LTD, Houston, Texas, United States</location>
      <location>Wisconsin Center for Advanced Research, Milwaukee, Wisconsin, United States</location>
      <location>AZ St. Lucas Assebroek, Assebroek, Belgium</location>
      <location>Zuid-Oost Limburg Campus St. Jan, Genk, Belgium</location>
      <location>UZ Leuven, Leuven, Belgium</location>
      <location>UCL St. Luc, Woluwe, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00583128</url>
  </study>
  <study rank="35">
    <nct_id>NCT02794376</nct_id>
    <title>Mindfulness for Irritable Bowel Syndrome</title>
    <acronym>MIBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mindfulness Based Cognitive Therapy (MBCT)</intervention>
      <intervention type="Behavioral">Waiting Period</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in IBS symptom Severity (GSRS - IBS)</outcome_measure>
      <outcome_measure>Changes in IBS quality of Life (IBS-QOL)</outcome_measure>
      <outcome_measure>Changes in Psychological Distress (DASS)</outcome_measure>
      <outcome_measure>Changes in Positive and Negative Emotions (PANAS)</outcome_measure>
      <outcome_measure>Changes in IBS catastrophizing (GI-Cognitions Questionniare)</outcome_measure>
      <outcome_measure>Changes in Visceral Anxiety Sensitivity (VSI)</outcome_measure>
      <outcome_measure>Changes in Mindfulness (FFMQ-short)</outcome_measure>
      <outcome_measure>Changes in Attentional Control (ANT)</outcome_measure>
      <outcome_measure>Changes in Illness Identification (IAT)</outcome_measure>
      <outcome_measure>Changes in Shame Identification (IAT)</outcome_measure>
      <outcome_measure>Changes in Attention to Health Threat (Dot-probe)</outcome_measure>
      <outcome_measure>Changes in Shame Association (SRET)</outcome_measure>
      <outcome_measure>Change in IBS symptom Severity (GSRS - IBS) at Follow up</outcome_measure>
      <outcome_measure>Baseline levels of Social Anxiety (SIAS-SPS)</outcome_measure>
      <outcome_measure>Baseline levels of Alexithymia (TAS-20)</outcome_measure>
      <outcome_measure>Baseline levels of Somatosensory Amplification (SSATS)</outcome_measure>
      <outcome_measure>Baseline levels of Thought Suppression (WBSI)</outcome_measure>
      <outcome_measure>Baseline levels of Rumination (RRS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oxford</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>11626</other_id>
    </other_ids>
    <start_date>April 14, 2016</start_date>
    <primary_completion_date>July 10, 2017</primary_completion_date>
    <completion_date>July 10, 2017</completion_date>
    <study_first_posted>June 9, 2016</study_first_posted>
    <last_update_posted>October 27, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02794376</url>
  </study>
  <study rank="36">
    <nct_id>NCT03370614</nct_id>
    <title>Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome</title>
    <acronym>IBS</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">IBS Group</intervention>
      <intervention type="Other">Healthy Control Group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Combined PET/MRI to define IBS activity and inflammation pattern.</outcome_measure>
      <outcome_measure>Use combined PET/MRI to demonstrate brain and body activity in responders and non-responders.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>17D.184</other_id>
    </other_ids>
    <start_date>May 4, 2017</start_date>
    <primary_completion_date>May 3, 2019</primary_completion_date>
    <completion_date>May 3, 2020</completion_date>
    <study_first_posted>December 12, 2017</study_first_posted>
    <last_update_posted>January 5, 2018</last_update_posted>
    <locations>
      <location>Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Philadelphia, Pennsylvania, United States</location>
      <location>Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Villanova, Pennsylvania, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan: Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03370614/Prot_SAP_000.pdf</url>
      </study_document>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan: Cover Page</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03370614/Prot_SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03370614</url>
  </study>
  <study rank="37">
    <nct_id>NCT02651532</nct_id>
    <title>Confocal Endomicroscopy Utility (p-CLE) in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Confocal Laser Endomicroscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Confocal Laser Endomicroscopy (CLE) utility for diagnosing microscopic inflammation of the mucosa in patients with irritable bowel syndrome (IBS)</outcome_measure>
      <outcome_measure>Relationship between microscopic inflammation and sex, age and the subtypes of IBS.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto Ecuatoriano de Enfermedades Digestivas</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>ENE12016</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <completion_date>March 2017</completion_date>
    <study_first_posted>January 11, 2016</study_first_posted>
    <last_update_posted>November 20, 2018</last_update_posted>
    <locations>
      <location>Ecuadorian Institute of Digestive Diseases, Guayaquil, Guayas, Ecuador</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02651532</url>
  </study>
  <study rank="38">
    <nct_id>NCT02294760</nct_id>
    <title>Long-term Sacral Nerve Stimulation for Irritable Bowel Syndrome.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Subsensory</intervention>
      <intervention type="Device">OFF</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Gastrointestinal Symptom Rating Scale - Irritable Bowel Syndrome version</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome - Impact Scale questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>44418</other_id>
    </other_ids>
    <start_date>November 2014</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>November 19, 2014</study_first_posted>
    <last_update_posted>May 17, 2018</last_update_posted>
    <locations>
      <location>Surgical Research Unit, Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02294760</url>
  </study>
  <study rank="39">
    <nct_id>NCT00101985</nct_id>
    <title>Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">talnetant</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Determine whether talnetant provided adequate relief from IBS pain and discomfort for at least one of three talnetant dose groups compared with placebo and to determine the safety and tolerability of talnetant in subjects with IBS.</outcome_measure>
      <outcome_measure>- Explore response among subgroups IBS. - Evaluate positive treatment effects within bowel subgroups. - Compare treatment groups for global improvement of IBS symptoms. - Improvement of IBS pain or discomfort, Quality of Life.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>741</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>223412/068</other_id>
    </other_ids>
    <start_date>October 2004</start_date>
    <primary_completion_date>July 2005</primary_completion_date>
    <completion_date>July 2005</completion_date>
    <study_first_posted>January 19, 2005</study_first_posted>
    <last_update_posted>April 13, 2015</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Chandler, Arizona, United States</location>
      <location>GSK Investigational Site, Phoenix, Arizona, United States</location>
      <location>GSK Investigational Site, North Little Rock, Arkansas, United States</location>
      <location>GSK Investigational Site, Carmichael, California, United States</location>
      <location>GSK Investigational Site, Concord, California, United States</location>
      <location>GSK Investigational Site, Garden Grove, California, United States</location>
      <location>GSK Investigational Site, Orange, California, United States</location>
      <location>GSK Investigational Site, Roseville, California, United States</location>
      <location>GSK Investigational Site, Spring Valley, California, United States</location>
      <location>GSK Investigational Site, Torrance, California, United States</location>
      <location>GSK Investigational Site, Boulder, Colorado, United States</location>
      <location>GSK Investigational Site, Centennial, Colorado, United States</location>
      <location>GSK Investigational Site, Wheat Ridge, Colorado, United States</location>
      <location>GSK Investigational Site, Bristol, Connecticut, United States</location>
      <location>GSK Investigational Site, Stamford, Connecticut, United States</location>
      <location>GSK Investigational Site, Torrington, Connecticut, United States</location>
      <location>GSK Investigational Site, Newark, Delaware, United States</location>
      <location>GSK Investigational Site, Deland, Florida, United States</location>
      <location>GSK Investigational Site, Miami, Florida, United States</location>
      <location>GSK Investigational Site, St. Petersburg, Florida, United States</location>
      <location>GSK Investigational Site, St. Petersburg, Florida, United States</location>
      <location>GSK Investigational Site, Atlanta, Georgia, United States</location>
      <location>GSK Investigational Site, Riverside, Illinois, United States</location>
      <location>GSK Investigational Site, Rockford, Illinois, United States</location>
      <location>GSK Investigational Site, Indianapolis, Indiana, United States</location>
      <location>GSK Investigational Site, Florence, Kentucky, United States</location>
      <location>GSK Investigational Site, Louisville, Kentucky, United States</location>
      <location>GSK Investigational Site, Slidell, Louisiana, United States</location>
      <location>GSK Investigational Site, Silver Spring, Maryland, United States</location>
      <location>GSK Investigational Site, Boston, Massachusetts, United States</location>
      <location>GSK Investigational Site, Salisbury, Massachusetts, United States</location>
      <location>GSK Investigational Site, Springfield, Massachusetts, United States</location>
      <location>GSK Investigational Site, Chesterfield, Michigan, United States</location>
      <location>GSK Investigational Site, St. Joseph, Michigan, United States</location>
      <location>GSK Investigational Site, Chaska, Minnesota, United States</location>
      <location>GSK Investigational Site, St. Louis, Missouri, United States</location>
      <location>GSK Investigational Site, Lincoln, Nebraska, United States</location>
      <location>GSK Investigational Site, Omaha, Nebraska, United States</location>
      <location>GSK Investigational Site, Blackwood, New Jersey, United States</location>
      <location>GSK Investigational Site, Bronx, New York, United States</location>
      <location>GSK Investigational Site, East Syracuse, New York, United States</location>
      <location>GSK Investigational Site, Fishkill, New York, United States</location>
      <location>GSK Investigational Site, Great Neck, New York, United States</location>
      <location>GSK Investigational Site, Rochester, New York, United States</location>
      <location>GSK Investigational Site, Rochester, New York, United States</location>
      <location>GSK Investigational Site, Greensboro, North Carolina, United States</location>
      <location>GSK Investigational Site, Raleigh, North Carolina, United States</location>
      <location>GSK Investigational Site, Wilmington, North Carolina, United States</location>
      <location>GSK Investigational Site, Wilmington, North Carolina, United States</location>
      <location>GSK Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>GSK Investigational Site, Akron, Ohio, United States</location>
      <location>GSK Investigational Site, Kettering, Ohio, United States</location>
      <location>GSK Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>GSK Investigational Site, Eugene, Oregon, United States</location>
      <location>GSK Investigational Site, Medford, Oregon, United States</location>
      <location>GSK Investigational Site, Portland, Oregon, United States</location>
      <location>GSK Investigational Site, Newtown, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Pittsburgh, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Greer, South Carolina, United States</location>
      <location>GSK Investigational Site, Bristol, Tennessee, United States</location>
      <location>GSK Investigational Site, Chattanooga, Tennessee, United States</location>
      <location>GSK Investigational Site, Memphis, Tennessee, United States</location>
      <location>GSK Investigational Site, Memphis, Tennessee, United States</location>
      <location>GSK Investigational Site, Austin, Texas, United States</location>
      <location>GSK Investigational Site, El Paso, Texas, United States</location>
      <location>GSK Investigational Site, San Antonio, Texas, United States</location>
      <location>GSK Investigational Site, Ogden, Utah, United States</location>
      <location>GSK Investigational Site, Charlottesville, Virginia, United States</location>
      <location>GSK Investigational Site, Christiansburg, Virginia, United States</location>
      <location>GSK Investigational Site, Lacey, Washington, United States</location>
      <location>GSK Investigational Site, Garran, Australian Capital Territory, Australia</location>
      <location>GSK Investigational Site, Concord, New South Wales, Australia</location>
      <location>GSK Investigational Site, Newtown, New South Wales, Australia</location>
      <location>GSK Investigational Site, Kippa Ring, Queensland, Australia</location>
      <location>GSK Investigational Site, Spring Hill, Queensland, Australia</location>
      <location>GSK Investigational Site, Adelaide, South Australia, Australia</location>
      <location>GSK Investigational Site, Bedford Park, South Australia, Australia</location>
      <location>GSK Investigational Site, Port Lincoln, South Australia, Australia</location>
      <location>GSK Investigational Site, Box Hill, Victoria, Australia</location>
      <location>GSK Investigational Site, Fitzroy, Victoria, Australia</location>
      <location>GSK Investigational Site, Malvern, Victoria, Australia</location>
      <location>GSK Investigational Site, Melbourne, Victoria, Australia</location>
      <location>GSK Investigational Site, Edmonton, Alberta, Canada</location>
      <location>GSK Investigational Site, Halifax, Nova Scotia, Canada</location>
      <location>GSK Investigational Site, Truro, Nova Scotia, Canada</location>
      <location>GSK Investigational Site, Mississauga, Ontario, Canada</location>
      <location>GSK Investigational Site, Sudbury, Ontario, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Montreal, Quebec, Canada</location>
      <location>GSK Investigational Site, Pointe-Claire, Quebec, Canada</location>
      <location>GSK Investigational Site, Sainte Jerome, Quebec, Canada</location>
      <location>GSK Investigational Site, Sainte-Foy, Quebec, Canada</location>
      <location>GSK Investigational Site, Sherbrooke, Quebec, Canada</location>
      <location>GSK Investigational Site, Sherbrooke, Quebec, Canada</location>
      <location>GSK Investigational Site, Saskatoon, Saskatchewan, Canada</location>
      <location>GSK Investigational Site, Quebec, Canada</location>
      <location>GSK Investigational Site, Caen, France</location>
      <location>GSK Investigational Site, Clermont-Ferrand Cedex, France</location>
      <location>GSK Investigational Site, Grenoble Cedex, France</location>
      <location>GSK Investigational Site, Issoire, France</location>
      <location>GSK Investigational Site, Marseille, France</location>
      <location>GSK Investigational Site, Miramas, France</location>
      <location>GSK Investigational Site, Nice, France</location>
      <location>GSK Investigational Site, Vitry sur Seine, France</location>
      <location>GSK Investigational Site, Chemnitz, Sachsen, Germany</location>
      <location>GSK Investigational Site, Dresden, Sachsen, Germany</location>
      <location>GSK Investigational Site, Leipzig, Sachsen, Germany</location>
      <location>GSK Investigational Site, Leipzig, Sachsen, Germany</location>
      <location>GSK Investigational Site, Bad Segeberg, Schleswig-Holstein, Germany</location>
      <location>GSK Investigational Site, Berlin, Germany</location>
      <location>GSK Investigational Site, Berlin, Germany</location>
      <location>GSK Investigational Site, Berlin, Germany</location>
      <location>GSK Investigational Site, Hamburg, Germany</location>
      <location>GSK Investigational Site, Stadskanaal, Netherlands</location>
      <location>GSK Investigational Site, Claremont, South Africa</location>
      <location>GSK Investigational Site, N1 City, South Africa</location>
      <location>GSK Investigational Site, Parktown, South Africa</location>
      <location>GSK Investigational Site, Somerset West, South Africa</location>
      <location>GSK Investigational Site, Badalona, Spain</location>
      <location>GSK Investigational Site, Barcelona, Spain</location>
      <location>GSK Investigational Site, Barcelona, Spain</location>
      <location>GSK Investigational Site, Madrid, Spain</location>
      <location>GSK Investigational Site, Oviedo, Spain</location>
      <location>GSK Investigational Site, Göteborg, Sweden</location>
      <location>GSK Investigational Site, Nacka, Sweden</location>
      <location>GSK Investigational Site, Stockholm, Sweden</location>
      <location>GSK Investigational Site, Stockholm, Sweden</location>
      <location>GSK Investigational Site, Blackpool, Lancashire, United Kingdom</location>
      <location>GSK Investigational Site, Blackpool, Lancashire, United Kingdom</location>
      <location>GSK Investigational Site, Northwood, Middlesex, United Kingdom</location>
      <location>GSK Investigational Site, Leeds, United Kingdom</location>
      <location>GSK Investigational Site, Portergate, Sheffield, United Kingdom</location>
      <location>GSK Investigational Site</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00101985</url>
  </study>
  <study rank="40">
    <nct_id>NCT02579902</nct_id>
    <title>Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin D3 (Cholecalciferol)</intervention>
      <intervention type="Dietary Supplement">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical signs including abdominal pain, bloating, rumbling, abdominal distention, dissatisfaction with stool consistency</outcome_measure>
      <outcome_measure>Symptom Severity Score</outcome_measure>
      <outcome_measure>Dietary intake</outcome_measure>
      <outcome_measure>Body Weight</outcome_measure>
      <outcome_measure>Body Mass Index (BMI)</outcome_measure>
      <outcome_measure>Waist Circumference (WC)</outcome_measure>
      <outcome_measure>Hip Circumference (HC)</outcome_measure>
      <outcome_measure>Waist to Hip Ratio (WHR)</outcome_measure>
      <outcome_measure>Blood Pressure (BP)</outcome_measure>
      <outcome_measure>Health-related Quality of Life</outcome_measure>
      <outcome_measure>Tumor Necrosis Factor-α (TNF-α)</outcome_measure>
      <outcome_measure>Interleukin-10 (IL-10)</outcome_measure>
      <outcome_measure>Interleukin-17 (IL-17)</outcome_measure>
      <outcome_measure>Malondialdehyde (MDA)</outcome_measure>
      <outcome_measure>Total Antioxidant Capacity (TAC)</outcome_measure>
      <outcome_measure>25-hydroxy vitamin D (25(OH)D)</outcome_measure>
      <outcome_measure>Calcium</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ahvaz Jundishapur University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ir.ajums.rec.1394.306</other_id>
    </other_ids>
    <start_date>February 2015</start_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <completion_date>September 2015</completion_date>
    <study_first_posted>October 20, 2015</study_first_posted>
    <last_update_posted>November 30, 2015</last_update_posted>
    <locations>
      <location>Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Khuzestan, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02579902</url>
  </study>
  <study rank="41">
    <nct_id>NCT02573844</nct_id>
    <title>Pain Relief In Irritable Bowel Syndrome</title>
    <acronym>PRITON</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Proklama</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recorded pain in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded abdominal distension in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded abdominal discomfort in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded abdominal meteorism in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded flatulence in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded borborygms in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded nausea in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded belching in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded asthenia in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded headache in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded &quot;empty- head&quot; feeling in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded attention deficity in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded vomiting feeling in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Recorded heartburn in a diary using a 11-points Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Number of evacuations recorded in a diary</outcome_measure>
      <outcome_measure>Recorded stool consistency in a diary using a 7- point Bristol Stool Form Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Geophyt S.r.l.s.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Geophyt</other_id>
    </other_ids>
    <start_date>January 2015</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>October 12, 2015</study_first_posted>
    <last_update_posted>October 12, 2015</last_update_posted>
    <locations>
      <location>Policlinico San Matteo Pavia Fondazione IRCCS, Pavia, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02573844</url>
  </study>
  <study rank="42">
    <nct_id>NCT02953171</nct_id>
    <title>Probiotics in the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Raw, lacto-fermented sauerkraut</intervention>
      <intervention type="Dietary Supplement">Mutaflor</intervention>
      <intervention type="Other">Pasteurized sauerkraut</intervention>
      <intervention type="Other">Placebo capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Symptom Severity Scale (IBS-SSS).</outcome_measure>
      <outcome_measure>Body weight</outcome_measure>
      <outcome_measure>Fecal microbiome diversity</outcome_measure>
      <outcome_measure>The Quality of Life Scale (QOLS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Copenhagen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016/1129/REK</other_id>
    </other_ids>
    <start_date>September 2016</start_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <completion_date>July 2017</completion_date>
    <study_first_posted>November 2, 2016</study_first_posted>
    <last_update_posted>November 2, 2016</last_update_posted>
    <locations>
      <location>Volvat Medisinske Senter, Majorstuen, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02953171</url>
  </study>
  <study rank="43">
    <nct_id>NCT02977975</nct_id>
    <title>Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Raw sauerkraut</intervention>
      <intervention type="Other">Pasteurized sauerkraut</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Symptom Severity Scale (IBS-SSS).</outcome_measure>
      <outcome_measure>Body weight</outcome_measure>
      <outcome_measure>Fecal microbiome diversity</outcome_measure>
      <outcome_measure>The Quality of Life Scale (QOLS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Copenhagen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016/1130/REK</other_id>
    </other_ids>
    <start_date>September 2016</start_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <completion_date>March 2017</completion_date>
    <study_first_posted>November 30, 2016</study_first_posted>
    <last_update_posted>December 19, 2017</last_update_posted>
    <locations>
      <location>Volvat Medisinske Senter, Majorstuen, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02977975</url>
  </study>
  <study rank="44">
    <nct_id>NCT01641341</nct_id>
    <title>Irritable Bowel Syndrome Evaluation and Treatment in Primary Care</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bifidobacterium infantis</intervention>
      <intervention type="Drug">Pancrelipase</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>A reduction in IBS symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>American Academy of Family Physicians</lead_sponsor>
      <collaborator>Genova Diagnostics</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>10-108</other_id>
    </other_ids>
    <start_date>November 2010</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <completion_date>March 2012</completion_date>
    <study_first_posted>July 16, 2012</study_first_posted>
    <last_update_posted>January 23, 2019</last_update_posted>
    <locations>
      <location>Torrance Clinical Research, Lomita, California, United States</location>
      <location>Overland Park Family Health Partners, Leawood, Kansas, United States</location>
      <location>American Academy of Family Physicians-National Research Network, Leawood, Kansas, United States</location>
      <location>Baton Rouge Family Practice, Baton Rouge, Louisiana, United States</location>
      <location>Family Medicine of SE Missouri, Sikeston, Missouri, United States</location>
      <location>Missouri Delta Physician Services, Sikeston, Missouri, United States</location>
      <location>Silver Sage Center for Family Medicine, Reno, Nevada, United States</location>
      <location>Raj Kachoria, Macedon, New York, United States</location>
      <location>Southwest Family Medicine Associates, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01641341</url>
  </study>
  <study rank="45">
    <nct_id>NCT01641224</nct_id>
    <title>A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pinaverium</intervention>
      <intervention type="Device">Atractylodes</intervention>
      <intervention type="Device">Paeonia Lactiflora</intervention>
      <intervention type="Device">Tangerine Peel</intervention>
      <intervention type="Drug">Ledebouriella Root</intervention>
      <intervention type="Drug">Radix codonopsitis</intervention>
      <intervention type="Drug">Radix curcumae</intervention>
      <intervention type="Drug">Fingered citron</intervention>
      <intervention type="Drug">Tuckahoe</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The relief of irritable bowel syndrome symptoms was used to measure the effectiveness of the drugs</outcome_measure>
      <outcome_measure>The side effect associated with the treatments</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota - Clinical and Translational Science Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1106E00524</other_id>
    </other_ids>
    <start_date>May 2012</start_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <completion_date>May 2014</completion_date>
    <study_first_posted>July 16, 2012</study_first_posted>
    <last_update_posted>May 12, 2014</last_update_posted>
    <locations>
      <location>Second Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China</location>
      <location>Jiangsu Provincial Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, China</location>
      <location>Beijing Xuanwu Hospital of Traditional Chinese Medicine affiliated to Capital Medical University., Beijing, China</location>
      <location>Shanghai First People's Hospital affiliated to Shanghai Tiao Tong University, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01641224</url>
  </study>
  <study rank="46">
    <nct_id>NCT02421627</nct_id>
    <title>Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">moxibustion</intervention>
      <intervention type="Device">Placebo moxibustion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total efficacy (Adequate relief responder)</outcome_measure>
      <outcome_measure>Symptom severity score (SSS)</outcome_measure>
      <outcome_measure>Bristol stool form scale (BSS)</outcome_measure>
      <outcome_measure>Quality of life questionnaire (IBS-QOL)</outcome_measure>
      <outcome_measure>hospital anxiety and depression score (HADS)</outcome_measure>
      <outcome_measure>Self-rating anxiety scale</outcome_measure>
      <outcome_measure>Self-rating Depression Scale</outcome_measure>
      <outcome_measure>Diarrhea frequency per day</outcome_measure>
      <outcome_measure>Urgency of defecation</outcome_measure>
      <outcome_measure>Safety evaluation (Number of participants with treatment-related adverse events as assessed by CTCAE v4.0)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Institute of Acupuncture, Moxibustion and Meridian</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ZYS2015-01</other_id>
    </other_ids>
    <start_date>April 1, 2015</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>December 31, 2018</completion_date>
    <study_first_posted>April 20, 2015</study_first_posted>
    <last_update_posted>April 4, 2019</last_update_posted>
    <locations>
      <location>Shanghai Institute of Acupuncture, Moxibustion and Meridian, Shanghai, Shanghai, China</location>
      <location>Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China</location>
      <location>Yueyang Integrated Chinese and Western Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02421627</url>
  </study>
  <study rank="47">
    <nct_id>NCT02186743</nct_id>
    <title>Irritable Bowel Syndrome and Food Sensitivity</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Personalized Dietary Advice</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome Global Improvement Scale (IBS-GIS)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Adequate Relief (IBS-AR)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Quality of Life Questionnaire (IBS-QoL)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>Cell Science Systems, Corp.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1404013784</other_id>
    </other_ids>
    <start_date>July 2014</start_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <completion_date>January 2016</completion_date>
    <study_first_posted>July 10, 2014</study_first_posted>
    <last_update_posted>October 18, 2017</last_update_posted>
    <locations>
      <location>Yale University, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02186743</url>
  </study>
  <study rank="48">
    <nct_id>NCT01948973</nct_id>
    <title>Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Subsensory</intervention>
      <intervention type="Device">OFF</intervention>
      <intervention type="Drug">Suprasensory</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Gastrointestinal Symptom Rating Scale - Irritable Bowel Syndrome version questionnaire</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome - Impact Scale questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
      <collaborator>Medtronic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1-10-72-170-13, JLF</other_id>
      <other_id>1-10-72-170-13</other_id>
    </other_ids>
    <start_date>September 2013</start_date>
    <primary_completion_date>March 2018</primary_completion_date>
    <completion_date>March 2018</completion_date>
    <study_first_posted>September 24, 2013</study_first_posted>
    <last_update_posted>May 17, 2018</last_update_posted>
    <locations>
      <location>Surgical Research Unit, Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01948973</url>
  </study>
  <study rank="49">
    <nct_id>NCT00904696</nct_id>
    <title>Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The primary endpoint is patient's tolerance with the treatment.</outcome_measure>
      <outcome_measure>Secondary endpoints are the resolution of gastrointestinal symptoms as assessed by a symptom questionnaire, patient's perception of effectiveness of the treatment and their overall satisfaction with the treatment.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>E/08/532</other_id>
    </other_ids>
    <start_date>May 2009</start_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <completion_date>September 2009</completion_date>
    <study_first_posted>May 20, 2009</study_first_posted>
    <last_update_posted>April 28, 2014</last_update_posted>
    <locations>
      <location>National University Hospital, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00904696</url>
  </study>
  <study rank="50">
    <nct_id>NCT01171053</nct_id>
    <title>Internet-delivered CBT for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internet-delivered CBT</intervention>
      <intervention type="Behavioral">Therapist support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Health economic data</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Gastrointestinal symptom-specific anxiety</outcome_measure>
      <outcome_measure>Depressive symptoms</outcome_measure>
      <outcome_measure>Functional impairments in work, social and family life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Stockholm County Council, Sweden</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-S</other_id>
    </other_ids>
    <start_date>June 2008</start_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <completion_date>June 2010</completion_date>
    <study_first_posted>July 28, 2010</study_first_posted>
    <last_update_posted>July 28, 2010</last_update_posted>
    <locations>
      <location>Internetpsykatrienheten, M46, Psykiatri sydväst, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01171053</url>
  </study>
  <study rank="51">
    <nct_id>NCT02528929</nct_id>
    <title>Gluten-free Diet in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Gluten-free diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome Symptom Severity Scores. This validated questionaire will be self-completed at baseline and at week 6. The investigators will compare the changes in scores over this time point.</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression scores. This validated questionaire will be self-completed at baseline and at week 6. The investigators will compare the changes in scores over this time point.</outcome_measure>
      <outcome_measure>Fatigue Impact Scores. This validated questionaire will be self-completed at baseline and at week 6. The investigators will compare the changes in scores over this time point.</outcome_measure>
      <outcome_measure>Short-form 36 Quality of Life Scores. This validated questionaire will be self-completed at baseline and at week 6. The investigators will compare the changes in scores over this time point.</outcome_measure>
      <outcome_measure>Assess whether patients opt to continue with a GFD of their own volition</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sheffield Teaching Hospitals NHS Foundation Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STH16497</other_id>
    </other_ids>
    <start_date>September 2012</start_date>
    <primary_completion_date>July 31, 2018</primary_completion_date>
    <completion_date>November 13, 2018</completion_date>
    <study_first_posted>August 19, 2015</study_first_posted>
    <last_update_posted>April 4, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02528929</url>
  </study>
  <study rank="52">
    <nct_id>NCT01542268</nct_id>
    <title>Effect of Pentoxifylline on Tight Junctions (TJs) of Intestinal Mucosa in Patients With Irritable Bowel Syndrome(IBS)</title>
    <acronym>IBS-PTX</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pentoxifylline</intervention>
      <intervention type="Drug">pentoxifylline placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of abdominal pain</outcome_measure>
      <outcome_measure>Mucosal byopsies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Universitario de Canarias</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-PTX</other_id>
    </other_ids>
    <start_date>March 2012</start_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>March 2, 2012</study_first_posted>
    <last_update_posted>March 6, 2012</last_update_posted>
    <locations>
      <location>Complejo Hospitalario Universitario de Canarias, La Laguna, S/c Tenerife, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01542268</url>
  </study>
  <study rank="53">
    <nct_id>NCT00316550</nct_id>
    <title>Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AV608</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint is the effect of AV608 on regional brain responses as measured by fMRI during conditioned and unconditioned visceral pain due to rectal distension.</outcome_measure>
      <outcome_measure>The effect of AV608 on regional brain responses to emotional visceral cues as measured by fMRI and the visceral pain threshold during rectal distension will be evaluated as secondary efficacy endpoints.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Avera Pharmaceuticals</lead_sponsor>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AV608-107</other_id>
    </other_ids>
    <start_date>April 2006</start_date>
    <primary_completion_date>June 2007</primary_completion_date>
    <completion_date>September 2007</completion_date>
    <study_first_posted>April 21, 2006</study_first_posted>
    <last_update_posted>February 25, 2008</last_update_posted>
    <locations>
      <location>UCLA Center for Neurovisceral Sciences and Women's Health, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00316550</url>
  </study>
  <study rank="54">
    <nct_id>NCT02565654</nct_id>
    <title>Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>the proportion of patients who had adequate relief of global IBS symptoms</outcome_measure>
      <outcome_measure>the proportion of patients who with positive lactulose hydrogen breath test change to be negative</outcome_measure>
      <outcome_measure>the composition of patients's fecal microbiota</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>0717-201506</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>October 1, 2015</study_first_posted>
    <last_update_posted>October 1, 2015</last_update_posted>
    <locations>
      <location>The first Affiliated Hospital of Sun Yat-Sen university, Guang zhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02565654</url>
  </study>
  <study rank="55">
    <nct_id>NCT03265002</nct_id>
    <title>Fibre and Gas in Irritable Bowel Syndrome</title>
    <acronym>EFIGI</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Placebo</intervention>
      <intervention type="Dietary Supplement">Inulin</intervention>
      <intervention type="Dietary Supplement">Psyllium</intervention>
      <intervention type="Dietary Supplement">Inulin and psyllium</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from the baseline in colonic gas</outcome_measure>
      <outcome_measure>Change from the baseline in colonic volume</outcome_measure>
      <outcome_measure>Change from the baseline in small bowel water content</outcome_measure>
      <outcome_measure>Change from the baseline in breath hydrogen</outcome_measure>
      <outcome_measure>Change from the baseline in severity of pain, bloating and flatulence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>17056</other_id>
    </other_ids>
    <start_date>March 8, 2018</start_date>
    <primary_completion_date>June 2019</primary_completion_date>
    <completion_date>July 2019</completion_date>
    <study_first_posted>August 29, 2017</study_first_posted>
    <last_update_posted>April 17, 2019</last_update_posted>
    <locations>
      <location>University of Nottingham, Nottingham, Nottinghamshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03265002</url>
  </study>
  <study rank="56">
    <nct_id>NCT02614963</nct_id>
    <title>Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clostridium Butyricum</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the changes of Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) scores</outcome_measure>
      <outcome_measure>IBS patients'quality of life</outcome_measure>
      <outcome_measure>Composition of Microorganisms in stool</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
      <collaborator>Linyi People's Hospital</collaborator>
      <collaborator>Taian City Central Hospital</collaborator>
      <collaborator>Qingdao Eastsea Pharmaceutical Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015SDU-QILU-G13</other_id>
    </other_ids>
    <start_date>December 2015</start_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <completion_date>July 2016</completion_date>
    <study_first_posted>November 25, 2015</study_first_posted>
    <last_update_posted>May 17, 2016</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02614963</url>
  </study>
  <study rank="57">
    <nct_id>NCT02188680</nct_id>
    <title>Irritable Bowel Syndrome and Low FODMAP Diet</title>
    <acronym>FructIBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low FODMAPS diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Fructose expiration rate (ppm)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Rouen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013/011/HP</other_id>
    </other_ids>
    <start_date>January 2014</start_date>
    <primary_completion_date>January 2018</primary_completion_date>
    <completion_date>January 2018</completion_date>
    <study_first_posted>July 11, 2014</study_first_posted>
    <last_update_posted>June 14, 2017</last_update_posted>
    <locations>
      <location>Service de Physiologie Digestive, Urinaire, Respiratoire et Sportive, Rouen, Haute Normandie, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02188680</url>
  </study>
  <study rank="58">
    <nct_id>NCT02270268</nct_id>
    <title>Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Pectin</intervention>
      <intervention type="Dietary Supplement">maltodextrin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>efficacy: change of stool frequency, faecal form and clinical symptoms score</outcome_measure>
      <outcome_measure>efficacy: gut microbiota</outcome_measure>
      <outcome_measure>efficacy: cytokine ratios</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nanjing PLA General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011NLY073</other_id>
    </other_ids>
    <start_date>November 2011</start_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <completion_date>October 2013</completion_date>
    <study_first_posted>October 21, 2014</study_first_posted>
    <last_update_posted>March 24, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02270268</url>
  </study>
  <study rank="59">
    <nct_id>NCT01167673</nct_id>
    <title>The Effect of Coltect (Selenium, Curcumin and Green Tea) on Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">coltect</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>improvement of IBS symptoms and quality of life</outcome_measure>
      <outcome_measure>change in bacterial stool flora</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NAFTALI TIMNA</lead_sponsor>
      <collaborator>Meir Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>bp004</other_id>
    </other_ids>
    <start_date>April 2011</start_date>
    <primary_completion_date>December 2017</primary_completion_date>
    <completion_date>June 2018</completion_date>
    <study_first_posted>July 22, 2010</study_first_posted>
    <last_update_posted>June 14, 2016</last_update_posted>
    <locations>
      <location>Gastroenterology institute Meir Hospital, Kfar Saba, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01167673</url>
  </study>
  <study rank="60">
    <nct_id>NCT03803319</nct_id>
    <title>Effects of Dietary Fibre in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Fibre 1 (combined fibres)</intervention>
      <intervention type="Dietary Supplement">Fibre 2 (natural fibres)</intervention>
      <intervention type="Dietary Supplement">Dietary Supplement: placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Relative abundance of faecal bifidobacteria as assessed using 16S rRNA community profiling (Illumina Miseq) of bacterial genomic DNA isolated from stool samples</outcome_measure>
      <outcome_measure>IBS symptoms as assessed using the Global Symptom Question (GSQ)</outcome_measure>
      <outcome_measure>Whole gut and regional gut transit time as assessed using a telemetric device (wireless motility capsule: SmartPill)</outcome_measure>
      <outcome_measure>Colonic pH units as assessed using a telemetric device (wireless motility capsule: SmartPill)</outcome_measure>
      <outcome_measure>Pressure (mmHg) as assessed using a telemetric device (wireless motility capsule: SmartPill)</outcome_measure>
      <outcome_measure>Faecal short-chain fatty acids (SCFAs) as assessed using gas-liquid chromatography</outcome_measure>
      <outcome_measure>Faecal gut microbiota (α and β diversity) as assessed using 16S rRNA community profiling (Illumina Miseq) of bacterial genomic DNA isolated from stool samples</outcome_measure>
      <outcome_measure>Faecal volatile organic compounds (VOCs) as assessed using gas chromatography sensor device</outcome_measure>
      <outcome_measure>Serum/plasma appetite hormones (ghrelin, pg/ml) as determined by enzyme-linked immunosorbent assay (ELISA)</outcome_measure>
      <outcome_measure>Serum/plasma (leptin, pg/ml) as determined by enzyme-linked immunosorbent assay (ELISA)</outcome_measure>
      <outcome_measure>Serum/plasma metabolites as determined using metabolomics</outcome_measure>
      <outcome_measure>Stool consistency as assessed using the Bristol Stool Form Scale (BSFS) (7 point scale; Type 1 to Type 7)</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms as assessed using the Gastrointestinal Symptom Rating Scale (GSRS) over 7 days (absent - severe)</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms as assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) (visual analogue scale: no pain - severe)</outcome_measure>
      <outcome_measure>Quality of Life (QoL) general as assessed using the SF-36</outcome_measure>
      <outcome_measure>Disease-specific QoL as assessed using the IBS-QoL (5 point scale: not at all - a great deal)</outcome_measure>
      <outcome_measure>Perceived stress as assessed using the Perceived Stress Score (PSS) (5 point scale: never- very often)</outcome_measure>
      <outcome_measure>Dietary fibre acceptability as assessed using an acceptability questionnaire (5 point scale: not at all acceptable - extremely acceptable)</outcome_measure>
      <outcome_measure>Nutrient intake as assessed using a 7-day food diary</outcome_measure>
      <outcome_measure>Physical activity as assessed using the International Physical Activity Questionnaire (IPAQ)</outcome_measure>
      <outcome_measure>Waist circumference as assessed using a standard measuring tape (inches)</outcome_measure>
      <outcome_measure>Hydrogen/methane breath testing as assessed using the Gastrocheck Gastrolyzer V9.0 in parts per million</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
      <collaborator>Guy's and St Thomas' NHS Foundation Trust</collaborator>
      <collaborator>Universidad Veracruzana</collaborator>
      <collaborator>University of Liverpool</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>135</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>18/WA/0313</other_id>
    </other_ids>
    <start_date>January 2, 2019</start_date>
    <primary_completion_date>January 11, 2020</primary_completion_date>
    <completion_date>January 11, 2020</completion_date>
    <study_first_posted>January 14, 2019</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>King's College London, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03803319</url>
  </study>
  <study rank="61">
    <nct_id>NCT01471379</nct_id>
    <title>Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Milnacipran</intervention>
      <intervention type="Drug">Milnacipran</intervention>
      <intervention type="Drug">Milnacipran</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants With Pain Response</outcome_measure>
      <outcome_measure>Quality of Life ( IBS-QOL)</outcome_measure>
      <outcome_measure>Subject Self Reported Adequate Relief of Pain</outcome_measure>
      <outcome_measure>Treatment Efficacy Questionnaire (TEQ)</outcome_measure>
      <outcome_measure>Dose Related Incremental Benefit in Pain Reduction Based on VAS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Spencer Dorn, MD, MPH</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
      <collaborator>University of North Carolina, Chapel Hill</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-1105a</other_id>
    </other_ids>
    <start_date>April 2012</start_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <completion_date>February 2013</completion_date>
    <study_first_posted>November 16, 2011</study_first_posted>
    <results_first_posted>December 24, 2013</results_first_posted>
    <last_update_posted>April 13, 2017</last_update_posted>
    <locations>
      <location>UNC Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01471379</url>
  </study>
  <study rank="62">
    <nct_id>NCT01803724</nct_id>
    <title>Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Adequate relief for global IBS symptoms</outcome_measure>
      <outcome_measure>Evaluation of IBS severity using IBSSS</outcome_measure>
      <outcome_measure>Adequate relief for bloating.</outcome_measure>
      <outcome_measure>Drug induced side effects.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pontificia Universidad Catolica de Chile</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PUC-0003</other_id>
    </other_ids>
    <start_date>May 2013</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>March 4, 2013</study_first_posted>
    <last_update_posted>March 4, 2013</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Pontificia Universidad Catolica de Chile, Santiago, Metropolitan, Chile</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01803724</url>
  </study>
  <study rank="63">
    <nct_id>NCT02079857</nct_id>
    <title>Symptom Management for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard protocol</intervention>
      <intervention type="Other">Individualized protocol</intervention>
      <intervention type="Other">Sham acupuncture/Placebo moxa</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom severity-abdominal pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>183</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-02325</other_id>
      <other_id>R01NR013695</other_id>
    </other_ids>
    <start_date>November 2012</start_date>
    <primary_completion_date>November 2019</primary_completion_date>
    <completion_date>November 2019</completion_date>
    <study_first_posted>March 6, 2014</study_first_posted>
    <last_update_posted>January 29, 2019</last_update_posted>
    <locations>
      <location>NYU Division of Special Studies in Symptom Management, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02079857</url>
  </study>
  <study rank="64">
    <nct_id>NCT00385099</nct_id>
    <title>Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GW876008</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent change from Baseline in Laser Doppler regional Rectal Mucosal Blood Flow (RMBF) measured in response to physiological stress (cold water pressor test)</outcome_measure>
      <outcome_measure>Percent Change from Baseline in Laser Doppler regional RMBF measured in response to psychological stress (dichotomous listening test)</outcome_measure>
      <outcome_measure>Number of participants with adverse events (AE) and serious adverse events (SAE)</outcome_measure>
      <outcome_measure>Number of participants with abnormal clinical chemistry data of clinical concern</outcome_measure>
      <outcome_measure>Number of participants with abnormal hematology data of clinical concern</outcome_measure>
      <outcome_measure>Participant perceived stress as assessed by a Visual Analogue Scale</outcome_measure>
      <outcome_measure>Systemic autonomic nervous system response as assessed by systolic blood pressure (SBP) and diastolic blood pressure (SBP)</outcome_measure>
      <outcome_measure>Systemic autonomic nervous system response as assessed by heart rate (HR).</outcome_measure>
      <outcome_measure>Percent change from Baseline in participant reported threshold for pain as a measure to assess Visceral (rectal) electro sensitivity</outcome_measure>
      <outcome_measure>Percent change from Baseline in participant reported threshold for perception of an electrical stimulus as a measure to assess Visceral (rectal) electro sensitivity</outcome_measure>
      <outcome_measure>Change from Baseline in RMBF at 90 minutes post-dose</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CRI103143</other_id>
    </other_ids>
    <start_date>December 8, 2006</start_date>
    <primary_completion_date>October 15, 2007</primary_completion_date>
    <completion_date>October 15, 2007</completion_date>
    <study_first_posted>October 6, 2006</study_first_posted>
    <last_update_posted>August 8, 2017</last_update_posted>
    <locations>
      <location>GSK Investigational Site, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00385099</url>
  </study>
  <study rank="65">
    <nct_id>NCT02721836</nct_id>
    <title>Yoga for Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Yoga</intervention>
      <intervention type="Behavioral">Nutrition Counselling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome Symptoms</outcome_measure>
      <outcome_measure>disease specific quality of life</outcome_measure>
      <outcome_measure>Generic Health-related Quality of life</outcome_measure>
      <outcome_measure>Emotional distress</outcome_measure>
      <outcome_measure>Subjective Stress</outcome_measure>
      <outcome_measure>Subjective improvement of symptoms</outcome_measure>
      <outcome_measure>Gut microbiome</outcome_measure>
      <outcome_measure>Adverse Event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universität Duisburg-Essen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>15-6653-BO</other_id>
    </other_ids>
    <start_date>April 2016</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>May 2017</completion_date>
    <study_first_posted>March 29, 2016</study_first_posted>
    <last_update_posted>May 24, 2017</last_update_posted>
    <locations>
      <location>Universität Duisburg-Essen, Essen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02721836</url>
  </study>
  <study rank="66">
    <nct_id>NCT03332537</nct_id>
    <title>Precision Pain Self-Management in Young Adults With Irritable Bowel Syndrome</title>
    <acronym>IBS-SM</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Personalized IBS Pain SM</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in pain sensitivity</outcome_measure>
      <outcome_measure>Change in gut microbiome</outcome_measure>
      <outcome_measure>Genetic variations (Pain-susceptibility SNPs genotyping)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Connecticut</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>29 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>H16-152</other_id>
      <other_id>1P20NR016605-01</other_id>
    </other_ids>
    <start_date>October 1, 2016</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>December 31, 2018</completion_date>
    <study_first_posted>November 6, 2017</study_first_posted>
    <last_update_posted>June 4, 2019</last_update_posted>
    <locations>
      <location>UConn Health Center, Farmington, Connecticut, United States</location>
      <location>University of Connecticut, Storrs, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03332537</url>
  </study>
  <study rank="67">
    <nct_id>NCT03869359</nct_id>
    <title>The Effect of Gluten in Patients With Irritable Bowel Syndrome and Healthy Volunteers</title>
    <acronym>PROT-IBS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Gluten-free diet with gluten powder</intervention>
      <intervention type="Other">Gluten-free diet with placebo powder</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS)</outcome_measure>
      <outcome_measure>Change in Gastrointestinal Symptom Rating Scale - Irritable Bowel Syndrome (GSRS-IBS)</outcome_measure>
      <outcome_measure>Change in stool frequency, measured by Bristol Stool Form (BSF)</outcome_measure>
      <outcome_measure>Change in Visceral Sensitivity and Bacterial Fermentation</outcome_measure>
      <outcome_measure>Change in Central Sensitization Inventory (CSI) score</outcome_measure>
      <outcome_measure>Change in Hospital Anxiety and Depression Scale (HADS) score</outcome_measure>
      <outcome_measure>Change in Highly Sensitive Person Scale (HSPS)</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome Quality of Life Questionnaire (IBSQOL)</outcome_measure>
      <outcome_measure>Change in Patient health questionnaire-15 (PHQ-15)</outcome_measure>
      <outcome_measure>Change in Visceral Sensitivity Index (VSI)</outcome_measure>
      <outcome_measure>Change in immunological profile of frozen serum samples</outcome_measure>
      <outcome_measure>Change in metabolic profile of frozen urine samples</outcome_measure>
      <outcome_measure>Change in microbiota content of frozen fecal samples</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>627-17</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>June 1, 2019</primary_completion_date>
    <completion_date>June 1, 2019</completion_date>
    <study_first_posted>March 11, 2019</study_first_posted>
    <last_update_posted>March 11, 2019</last_update_posted>
    <locations>
      <location>Magnus Simrén, Gothenburg, Västra Götland, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03869359</url>
  </study>
  <study rank="68">
    <nct_id>NCT03801057</nct_id>
    <title>Marine Protein Hydrolysate as Dietary Supplement in Irritable Bowel Syndrome</title>
    <acronym>MPH_IBS</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">MPH_active</intervention>
      <intervention type="Dietary Supplement">MPH_placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS-SSS</outcome_measure>
      <outcome_measure>SF-NDI_HRQOL</outcome_measure>
      <outcome_measure>Fecal Calprotectin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Helse Møre og Romsdal HF</lead_sponsor>
      <collaborator>Haukeland University Hospital</collaborator>
      <collaborator>University of Bergen</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018/1825</other_id>
    </other_ids>
    <start_date>January 14, 2019</start_date>
    <primary_completion_date>March 29, 2019</primary_completion_date>
    <completion_date>June 21, 2019</completion_date>
    <study_first_posted>January 11, 2019</study_first_posted>
    <last_update_posted>February 21, 2019</last_update_posted>
    <locations>
      <location>Haukeland University Hospital, Bergen, Norway</location>
      <location>Ålesund Hospital, Helse Møre og Romsdal HF, Ålesund, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03801057</url>
  </study>
  <study rank="69">
    <nct_id>NCT02092402</nct_id>
    <title>Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Fecal transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)</outcome_measure>
      <outcome_measure>Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)</outcome_measure>
      <outcome_measure>Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)</outcome_measure>
      <outcome_measure>Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)</outcome_measure>
      <outcome_measure>Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)</outcome_measure>
      <outcome_measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)</outcome_measure>
      <outcome_measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)</outcome_measure>
      <outcome_measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)</outcome_measure>
      <outcome_measure>Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Örebro University, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013/180</other_id>
    </other_ids>
    <start_date>September 2013</start_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <completion_date>June 2019</completion_date>
    <study_first_posted>March 20, 2014</study_first_posted>
    <last_update_posted>August 21, 2018</last_update_posted>
    <locations>
      <location>University Hospital Örebro, Örebro, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02092402</url>
  </study>
  <study rank="70">
    <nct_id>NCT01624610</nct_id>
    <title>Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Dietary intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients with adequate relief.</outcome_measure>
      <outcome_measure>Composite endpoint</outcome_measure>
      <outcome_measure>Abdominal Pain</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
      <outcome_measure>Individual symptoms</outcome_measure>
      <outcome_measure>Quality of life measures</outcome_measure>
      <outcome_measure>Stool Microbiome</outcome_measure>
      <outcome_measure>Serum Biomarker Panel</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMGI-DIETIBS</other_id>
    </other_ids>
    <start_date>July 2012</start_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>June 20, 2012</study_first_posted>
    <last_update_posted>March 31, 2016</last_update_posted>
    <locations>
      <location>Indiana University, Indianapolis, Indiana, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01624610</url>
  </study>
  <study rank="71">
    <nct_id>NCT03457324</nct_id>
    <title>Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">JCM-16021</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy judgement standard of single symptom</outcome_measure>
      <outcome_measure>Comprehensive efficacy judgement standard of cardinal symptoms</outcome_measure>
      <outcome_measure>Quality of life scoring (IBS-QoL)</outcome_measure>
      <outcome_measure>TCM pattern improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ZhaoXiang Bian</lead_sponsor>
      <collaborator>Chinese University of Hong Kong</collaborator>
      <collaborator>Hong Kong Baptist University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>392</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ITS-148-14FP</other_id>
    </other_ids>
    <start_date>November 8, 2018</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>March 7, 2018</study_first_posted>
    <last_update_posted>November 21, 2018</last_update_posted>
    <locations>
      <location>Chinese Medicine Clinics of Hong Kong Baptist University, Hong Kong, Hong Kong, China</location>
      <location>Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03457324</url>
  </study>
  <study rank="72">
    <nct_id>NCT00793494</nct_id>
    <title>Efficacy of Probaclac in Irritable Bowel Syndrome in Children Aged 8 to 18 Years</title>
    <acronym>POPSII</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Probaclac</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective assessment of improvement of symptoms</outcome_measure>
      <outcome_measure>Change in severity of symptoms (likert scale)</outcome_measure>
      <outcome_measure>Presence and intensity of pain episodes</outcome_measure>
      <outcome_measure>Presence or absence of urgency, incomplete evacuation, gas</outcome_measure>
      <outcome_measure>Number and consistance of the stools</outcome_measure>
      <outcome_measure>School and social absenteism</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Justine's Hospital</lead_sponsor>
      <collaborator>Nicar Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Probaclac-HSJ</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <completion_date>May 2015</completion_date>
    <study_first_posted>November 19, 2008</study_first_posted>
    <last_update_posted>April 13, 2016</last_update_posted>
    <locations>
      <location>Hôpital Sainte Justine, Montreal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00793494</url>
  </study>
  <study rank="73">
    <nct_id>NCT03359499</nct_id>
    <title>Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bacillus clausii</intervention>
      <intervention type="Drug">Trimebutine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatic response</outcome_measure>
      <outcome_measure>Symptomatic relapse</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Britanico</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HB744</other_id>
    </other_ids>
    <start_date>August 12, 2017</start_date>
    <primary_completion_date>October 25, 2017</primary_completion_date>
    <completion_date>November 23, 2017</completion_date>
    <study_first_posted>December 2, 2017</study_first_posted>
    <last_update_posted>March 13, 2018</last_update_posted>
    <locations>
      <location>Hospital Britanico, Buenos Aires, Caba, Argentina</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03359499</url>
  </study>
  <study rank="74">
    <nct_id>NCT01886027</nct_id>
    <title>Stress Management for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Emotional Awareness and Expression Training</intervention>
      <intervention type="Behavioral">Relaxation Training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS symptom severity scale (IBS-SSS)</outcome_measure>
      <outcome_measure>McGill Pain Questionnaire, Short Form (SF-MPQ-2)</outcome_measure>
      <outcome_measure>Bristol Stool Form Scale (BSFS)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome, Quality of Life (IBS-QOL)</outcome_measure>
      <outcome_measure>Positive and Negative Affect Scale (PANAS)</outcome_measure>
      <outcome_measure>Impact of Events Scale - Revised (IES-R)</outcome_measure>
      <outcome_measure>Toronto Alexithymia Scale -20 (TAS-20)</outcome_measure>
      <outcome_measure>Rathus Assertiveness Schedule (RAS)</outcome_measure>
      <outcome_measure>Ambivalence over Emotional Expression Scale (AEQ)</outcome_measure>
      <outcome_measure>Emotional Approach Coping Scale (EAC)</outcome_measure>
      <outcome_measure>IBS self-efficacy questionnaire</outcome_measure>
      <outcome_measure>Communicating Thoughts and Feelings Questionnaire</outcome_measure>
      <outcome_measure>Clinical Global Impressions (CGI) Improvement Scale - IBS version</outcome_measure>
      <outcome_measure>Health care Utilization Scale</outcome_measure>
      <outcome_measure>Brief Symptom Inventory</outcome_measure>
      <outcome_measure>Early Trauma Inventory Self-Report Short Form</outcome_measure>
      <outcome_measure>Experiences in Close Relationships Questionnaire</outcome_measure>
      <outcome_measure>General Social Constraints Scale</outcome_measure>
      <outcome_measure>Medication use</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wayne State University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>WSU-022413B3E</other_id>
    </other_ids>
    <start_date>June 2013</start_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <completion_date>March 2015</completion_date>
    <study_first_posted>June 25, 2013</study_first_posted>
    <last_update_posted>May 6, 2015</last_update_posted>
    <locations>
      <location>Wayne State University, Detroit, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01886027</url>
  </study>
  <study rank="75">
    <nct_id>NCT00268879</nct_id>
    <title>Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Renzapride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of months a patient is a Responder for overall relief of IBS symptoms</outcome_measure>
      <outcome_measure>Number of months a patient is a Responder for relief of abdominal pain/discomfort, bowel problems, and bloating/abdominal distention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Alizyme</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1821</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ATL1251/038/CL</other_id>
    </other_ids>
    <start_date>December 2005</start_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <completion_date>January 2008</completion_date>
    <study_first_posted>December 23, 2005</study_first_posted>
    <last_update_posted>February 15, 2008</last_update_posted>
    <locations>
      <location>Alizyme, Cambridge, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00268879</url>
  </study>
  <study rank="76">
    <nct_id>NCT03300804</nct_id>
    <title>Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS)</title>
    <acronym>TCM-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">20-herb formulation</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global IBS symptom improvement</outcome_measure>
      <outcome_measure>The Bowel Symptom Scale (BSS):</outcome_measure>
      <outcome_measure>SF-36</outcome_measure>
      <outcome_measure>IBS-QoL</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Maryland</lead_sponsor>
      <collaborator>Chinese University of Hong Kong</collaborator>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HP-00041236</other_id>
      <other_id>1U19AT003266-01</other_id>
    </other_ids>
    <start_date>May 2008</start_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <completion_date>June 2011</completion_date>
    <study_first_posted>October 4, 2017</study_first_posted>
    <last_update_posted>October 4, 2017</last_update_posted>
    <locations>
      <location>Medical Gastroenterelogy Clinic Of the Prince Of Wales, Chinese University of Hong Kong, Shatin, N.T., Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03300804</url>
  </study>
  <study rank="77">
    <nct_id>NCT02737410</nct_id>
    <title>Resilience in Irritable Bowel Syndrome and Gut-focused Hypnotherapy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Gut-directed Hypnotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Resilience assessed using the Connor-Davidson Resilience Scale</outcome_measure>
      <outcome_measure>Self-efficacy assessed by the Skala zur allgemeinen Selbstwirksamkeitserwartung</outcome_measure>
      <outcome_measure>Humor assessed by the State-Trait Cheerfulness Inventory</outcome_measure>
      <outcome_measure>Social support assessed by the Fragebogen zur Sozialen Unterstützung</outcome_measure>
      <outcome_measure>Emotion regulation assessed by the Cognitive Emotion Regulation Questionnaire</outcome_measure>
      <outcome_measure>Neuroticism assessed by the Big Five Inventory</outcome_measure>
      <outcome_measure>Psychological distress assessed by the Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Quality of life assessed by visual analogue scales</outcome_measure>
      <outcome_measure>Symptom severity assessed by the Irritable Bowel Syndrome - Severity Scoring System</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>1488/2012</other_id>
    </other_ids>
    <start_date>June 2012</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>October 2014</completion_date>
    <study_first_posted>April 13, 2016</study_first_posted>
    <last_update_posted>April 13, 2016</last_update_posted>
    <locations>
      <location>Medical University of Vienna, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02737410</url>
  </study>
  <study rank="78">
    <nct_id>NCT03721107</nct_id>
    <title>A Trial for New Treatment of Adult Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MRx1234 [Blautia Hydrogenotrophica]</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The number of patients who demonstrate more or equal to 50% improvement in their cohort specific symptoms as measured by responses to Abdominal Pain Intensity Scale, Stool Frequency and Stool Consistency questionnaires</outcome_measure>
      <outcome_measure>The number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>4D pharma plc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BHT-II-002</other_id>
    </other_ids>
    <start_date>November 6, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>October 26, 2018</study_first_posted>
    <last_update_posted>January 30, 2019</last_update_posted>
    <locations>
      <location>Elite Clinical Studies, Phoenix, Arizona, United States</location>
      <location>Anaheim Clinical Trials (ACT), Anaheim, California, United States</location>
      <location>Translational Research Group, Inc, North Hollywood, California, United States</location>
      <location>Connecticut Gastroenterology Clinical Research, Bristol, Connecticut, United States</location>
      <location>Borland-Groover Clinic, Jacksonville, Florida, United States</location>
      <location>Orlando Florida BioClinica Research Network, Orlando, Florida, United States</location>
      <location>Aventiv Research Inc., Columbus, Ohio, United States</location>
      <location>Coastal Carolina Research Center, Mount Pleasant, South Carolina, United States</location>
      <location>WR-ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Houston Methodist Gastroenterology Associates, Houston, Texas, United States</location>
      <location>Cork University Hospital, Cork, Ireland</location>
      <location>Wythenshawe Hospital, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03721107</url>
  </study>
  <study rank="79">
    <nct_id>NCT03135821</nct_id>
    <title>Traditional Chinese Medicine for Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">TCM</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in IBS-Symptom Severity Score at 8 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Singapore General Hospital</lead_sponsor>
      <collaborator>Singapore College of Traditional Chinese Medicine</collaborator>
      <collaborator>Duke-NUS Graduate Medical School</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SGH-TCM-GASTR-TCMIBS</other_id>
    </other_ids>
    <start_date>March 2015</start_date>
    <primary_completion_date>November 2017</primary_completion_date>
    <completion_date>November 2017</completion_date>
    <study_first_posted>May 1, 2017</study_first_posted>
    <last_update_posted>May 1, 2017</last_update_posted>
    <locations>
      <location>Singapore General Hospital, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03135821</url>
  </study>
  <study rank="80">
    <nct_id>NCT02932111</nct_id>
    <title>Irritable Bowel Syndrome and Osteopathic Manipulative Therapy</title>
    <acronym>IBSOMT</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">osteopathic session</intervention>
      <intervention type="Procedure">Placebo manipulative session</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes from baseline of IBSSS at V4.</outcome_measure>
      <outcome_measure>Clinical improvement (IBSSS)</outcome_measure>
      <outcome_measure>Percentage of patients with improvement at V4, V5 and V6.</outcome_measure>
      <outcome_measure>Cardinal signs of IBS measured by visual analogic scales</outcome_measure>
      <outcome_measure>Shape of the stool</outcome_measure>
      <outcome_measure>Changes of the severity of IBS</outcome_measure>
      <outcome_measure>Depression and anxiety quantified using the Beck Depression Inventory II(BDI-II) questionnaires.</outcome_measure>
      <outcome_measure>Quality of life defined by IBS-QOL.</outcome_measure>
      <outcome_measure>Depression and anxiety quantified using the STAI questionnaires.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>P150920</other_id>
    </other_ids>
    <start_date>December 2016</start_date>
    <primary_completion_date>February 2019</primary_completion_date>
    <completion_date>May 2019</completion_date>
    <study_first_posted>October 13, 2016</study_first_posted>
    <last_update_posted>December 8, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02932111</url>
  </study>
  <study rank="81">
    <nct_id>NCT03174561</nct_id>
    <title>Inuline Supplement in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Inuline, Choline and Silymarin</intervention>
      <intervention type="Other">diet restriction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS symptoms severity score</outcome_measure>
      <outcome_measure>number of bowel movements</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SC Fiterman Pharma SRL</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STCL009</other_id>
    </other_ids>
    <start_date>May 1, 2017</start_date>
    <primary_completion_date>February 28, 2018</primary_completion_date>
    <completion_date>April 30, 2018</completion_date>
    <study_first_posted>June 2, 2017</study_first_posted>
    <last_update_posted>June 2, 2017</last_update_posted>
    <locations>
      <location>Institute of Gastroenterology and Hepatology of Clinical Emergency Hospital &quot;Sf. Spiridon&quot;, Iasi, Romania</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03174561</url>
  </study>
  <study rank="82">
    <nct_id>NCT02566629</nct_id>
    <title>Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">collect faeces from participants</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>microbiota community among IBS patients in episodes phase,remission phase and healthy controls</outcome_measure>
      <outcome_measure>quality of life in IBS patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015SDU-QILU-G11</other_id>
    </other_ids>
    <start_date>July 2015</start_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>October 2, 2015</study_first_posted>
    <last_update_posted>October 2, 2015</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02566629</url>
  </study>
  <study rank="83">
    <nct_id>NCT00269412</nct_id>
    <title>Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary objective of this trial is to evaluate the efficacy of a 14-day course of oral rifaximin at 550 mg BID versus placebo in providing adequate relief from Diarrhea-associated IBS (DIBS) symptoms.</outcome_measure>
      <outcome_measure>To evaluate the dose-response relationship of placebo administered for 28 days and rifaximin administered at 275 mg BID, 550 mg BID, or 1100 mg BID for 14 days;</outcome_measure>
      <outcome_measure>to evaluate the efficacy of 550 mg BID for 4 weeks to determine if there are any differences when treatment is extended for an additional 2-week period when compared to a similar dosing regimen for 2 weeks;</outcome_measure>
      <outcome_measure>to evaluate the durability of response over a 12-week Post-treatment Phase in subjects with DIBS who achieved a response during the acute Treatment Phase of the study.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>525</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RFIB2001</other_id>
    </other_ids>
    <start_date>December 2005</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <completion_date>September 2008</completion_date>
    <study_first_posted>December 23, 2005</study_first_posted>
    <last_update_posted>December 23, 2009</last_update_posted>
    <locations>
      <location>Mayo Clinic Scottsdale, Scottsdale, Arizona, United States</location>
      <location>Premeire Pharmaceutical Research, Tempe, Arizona, United States</location>
      <location>Advanced Clinical Research Institute, Anaheim, California, United States</location>
      <location>Lovelace Scientific Resources, Irvine, California, United States</location>
      <location>West Gastroenterology Medical Group, Los Angeles, California, United States</location>
      <location>Beverly Hills Gastroenterology, Los Angeles, California, United States</location>
      <location>Medical Associates Research Group, San Diego, California, United States</location>
      <location>Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States</location>
      <location>Connecticut Gastroenterology Institute, Bristol, Connecticut, United States</location>
      <location>Litchfield County Gastroenterology Associates, LLC, Torrington, Connecticut, United States</location>
      <location>Clinical Research of West Florida, Clearwater, Florida, United States</location>
      <location>University Clinical Research, Deland, Florida, United States</location>
      <location>Research Consultants Group, Hialeah, Florida, United States</location>
      <location>Borland-Groover Clinic, Jacksonville, Florida, United States</location>
      <location>Miami Research Associates, Miami, Florida, United States</location>
      <location>Advanced Gastroenterology Associates, Palm Harbor, Florida, United States</location>
      <location>Shafran Gastroenterology, Winter Park, Florida, United States</location>
      <location>Florida Medical Clinic, Zephyrhills, Florida, United States</location>
      <location>Rockford Gastroenterology, Rockford, Illinois, United States</location>
      <location>Community Clinical Research Center, Anderson, Indiana, United States</location>
      <location>Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States</location>
      <location>Gastrointestinal Clinic of Quad Citites, Davenport, Iowa, United States</location>
      <location>University of Kansas Medical Center, Kansas City, Kansas, United States</location>
      <location>Digestive Disorders Associates, Annapolis, Maryland, United States</location>
      <location>Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Washington County Hospital, Hagerstown, Maryland, United States</location>
      <location>Maryland Clinical Trials, Severna Park, Maryland, United States</location>
      <location>Capital Gastroenterology Consultants, PA, Silver Springs, Maryland, United States</location>
      <location>Coastal Research Associates, Braintree, Massachusetts, United States</location>
      <location>Henry Ford Hospital, Chesterfield, Michigan, United States</location>
      <location>Gastrointestinal Associates, PA, Jackson, Mississippi, United States</location>
      <location>Digestive Health Specialists, PA, Tupelo, Mississippi, United States</location>
      <location>Gastroenterology and Hepatology, Kansas City, Missouri, United States</location>
      <location>Center for Digestive &amp; Liver Diseases, Inc., Mexico, Missouri, United States</location>
      <location>Specialist in Gastroenterology, St. Louis, Missouri, United States</location>
      <location>Gastroenterology Specialities, Lincoln, Nebraska, United States</location>
      <location>Long Island Clinical Research, Great Neck, New York, United States</location>
      <location>New York Center for Clinical Research, Lake Success, New York, United States</location>
      <location>Asheville Gastroenterology Associates, Asheville, North Carolina, United States</location>
      <location>University of North Carolina, Chapel Hill, North Carolina, United States</location>
      <location>Charlotte Gastroenterology &amp; Hepatology, Charlotte, North Carolina, United States</location>
      <location>Vital re:Search, Greensboro, North Carolina, United States</location>
      <location>Carolina Research, Greenville, North Carolina, United States</location>
      <location>Bethany Medical Center, High Point, North Carolina, United States</location>
      <location>East Carolina Gastroenterology, Jacksonville, North Carolina, United States</location>
      <location>Wake Research Associates, Raleigh, North Carolina, United States</location>
      <location>Rocky Mount, North Carolina, United States</location>
      <location>Hanover Medical Specialists, PA, Wilmington, North Carolina, United States</location>
      <location>Consultants for Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Digestive Health Network, Cincinnati, Ohio, United States</location>
      <location>GI &amp; Liver Diseases Consultants, Dayton, Ohio, United States</location>
      <location>Wells Institute for Health Awareness, Kettering, Ohio, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Digestive Health Specialists, PA, Oklahoma City, Oklahoma, United States</location>
      <location>West Hills Gastroenterology Associates, PC, Portland, Oregon, United States</location>
      <location>Columbia Gastroenterology Associates, Columbia, South Carolina, United States</location>
      <location>ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Regional Research Institute, Jackson, Tennessee, United States</location>
      <location>Holston Valley Physicians, Kingsport, Tennessee, United States</location>
      <location>Austin Gastroenterology, Austin, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>University of Utah School of Medicine, Salt Lake City, Utah, United States</location>
      <location>Internal Medicine Associates, Danville, Virginia, United States</location>
      <location>Northwest Gastroenterology Associates, Bellevue, Washington, United States</location>
      <location>North Pacific Clinical Research, Redmond, Washington, United States</location>
      <location>Spokane Digestive Disease Center, Spokane, Washington, United States</location>
      <location>Wisconsin Center for Advanced Research, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00269412</url>
  </study>
  <study rank="84">
    <nct_id>NCT01248013</nct_id>
    <title>Irritable Bowel Syndrome Hypnotherapy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">gut focused hypnotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effectiveness of Group Hypnotherapy in Irritable Bowel Syndrome</outcome_measure>
      <outcome_measure>Percentage of Patients With Significant Reduction in Their IBS Symptom Severity Score One Year After Completion of Therapy.</outcome_measure>
      <outcome_measure>Outcome Predictors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mind-Body Digestive Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>05-0575</other_id>
    </other_ids>
    <start_date>September 2005</start_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <completion_date>December 2009</completion_date>
    <study_first_posted>November 25, 2010</study_first_posted>
    <results_first_posted>January 6, 2011</results_first_posted>
    <last_update_posted>January 6, 2011</last_update_posted>
    <locations>
      <location>Mind Body Digestive Center, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01248013</url>
  </study>
  <study rank="85">
    <nct_id>NCT03074227</nct_id>
    <title>The FAIS-Trial: Faecal Transplantation in Adolescents With Refractory Irritable Bowel Syndrome</title>
    <acronym>FAIS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Allogeneic faecal transplantation</intervention>
      <intervention type="Other">Autologous faecal transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of patients with &gt; 50% reduction of their abdominal pain intensity and pain frequency at t=12 weeks after the first faecal transplantation</outcome_measure>
      <outcome_measure>Intra-individual changes in faecal gut microbiota composition</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>The proportion of patients with &gt; 50% reduction of their abdominal pain intensity and pain frequency</outcome_measure>
      <outcome_measure>Total IBS-SSS score</outcome_measure>
      <outcome_measure>Health related quality of life</outcome_measure>
      <outcome_measure>Depression and anxiety</outcome_measure>
      <outcome_measure>Absence of school or work, health care resources and costs</outcome_measure>
      <outcome_measure>Adequate relief</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CRP, liver profile and renal profile</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FAIS2016</other_id>
    </other_ids>
    <start_date>November 23, 2017</start_date>
    <primary_completion_date>April 1, 2019</primary_completion_date>
    <completion_date>April 1, 2020</completion_date>
    <study_first_posted>March 8, 2017</study_first_posted>
    <last_update_posted>June 27, 2018</last_update_posted>
    <locations>
      <location>AMC, Amsterdam, Noord Holland, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03074227</url>
  </study>
  <study rank="86">
    <nct_id>NCT03366389</nct_id>
    <title>Serum Levels of Apelin, Chemerin and Adiponectin Adipokines in Irritable Bowel Syndrome and Healthy Subjects</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Serum levels of Apelin, Chemerin and adiponectin</outcome_measure>
      <outcome_measure>IBS-Quality of life (IBS-QoL)</outcome_measure>
      <outcome_measure>IBS severity score system (IBSSS)</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Somatic Symptom</outcome_measure>
      <outcome_measure>Personality</outcome_measure>
      <outcome_measure>Perceived Stress Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Amir Abbasnezhad</lead_sponsor>
      <collaborator>Lorestan University of Medical Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>Lums.REC.1396.266</other_id>
    </other_ids>
    <start_date>June 7, 2017</start_date>
    <primary_completion_date>September 16, 2017</primary_completion_date>
    <completion_date>October 20, 2017</completion_date>
    <study_first_posted>December 8, 2017</study_first_posted>
    <last_update_posted>December 8, 2017</last_update_posted>
    <locations>
      <location>Lorestan university of medical sciences, Khorramabad, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03366389</url>
  </study>
  <study rank="87">
    <nct_id>NCT00167635</nct_id>
    <title>Nursing Management of Irritable Bowel Syndrome:Improving Outcomes</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">cognitive-behavioral</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Psychological distress</outcome_measure>
      <outcome_measure>Cognitive Scale for Functional Bowel Disorders (CFBD) describes 25 cognitive beliefs related to functional bowel disorders.</outcome_measure>
      <outcome_measure>Health Related Quality Of Life (HRQOL) will be measures with the Disease Specific Questionnaire-IBS (IBS-DSQ), a 42-item questionnaire.</outcome_measure>
      <outcome_measure>Sleep disturbance</outcome_measure>
      <outcome_measure>Sexual dysfunction</outcome_measure>
      <outcome_measure>Catecholamine and cortisol levels (urine)</outcome_measure>
      <outcome_measure>Stool frequency/consistency</outcome_measure>
      <outcome_measure>Health care utilization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>12707-C</other_id>
      <other_id>2R01NR04142-5</other_id>
      <other_id>97-3895-C 11</other_id>
    </other_ids>
    <start_date>January 2003</start_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <completion_date>February 2008</completion_date>
    <study_first_posted>September 14, 2005</study_first_posted>
    <last_update_posted>May 25, 2009</last_update_posted>
    <locations>
      <location>Northgate Executive 1, Seattle, Washington, United States</location>
      <location>University of Washington, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00167635</url>
  </study>
  <study rank="88">
    <nct_id>NCT03899779</nct_id>
    <title>Face-to-face Versus Online Hypnotherapy for the Treatment of Irritable Bowel Syndrome</title>
    <acronym>FORTITUDE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Face-to-face hypnotherapy</intervention>
      <intervention type="Other">Online hypnotherapy</intervention>
      <intervention type="Other">Online psychoeducation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain response rate after 12 weeks of treatment</outcome_measure>
      <outcome_measure>Degree of relief response rate after 12 weeks of treatment</outcome_measure>
      <outcome_measure>Improvement of symptom severity</outcome_measure>
      <outcome_measure>Indirect costs</outcome_measure>
      <outcome_measure>Direct costs</outcome_measure>
      <outcome_measure>General Quality of life (by EQ-5D)</outcome_measure>
      <outcome_measure>IBS related Quality of life (by IBS-QoL)</outcome_measure>
      <outcome_measure>Use of over the counter medication and rescue medication</outcome_measure>
      <outcome_measure>Number and severity of side effects</outcome_measure>
      <outcome_measure>Expectation</outcome_measure>
      <outcome_measure>Response rates in relation to comorbid anxiety</outcome_measure>
      <outcome_measure>Response rates in relation to comorbid depression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL67607.068.18</other_id>
      <other_id>852001924</other_id>
      <other_id>METC18-037</other_id>
    </other_ids>
    <start_date>April 2019</start_date>
    <primary_completion_date>August 2022</primary_completion_date>
    <completion_date>August 2022</completion_date>
    <study_first_posted>April 2, 2019</study_first_posted>
    <last_update_posted>April 2, 2019</last_update_posted>
    <locations>
      <location>Medisch Centrum Leeuwarden, Leeuwarden, Friesland, Netherlands</location>
      <location>Rijnstate, Arnhem, Gelderland, Netherlands</location>
      <location>Gelderse Vallei, Ede, Gelderland, Netherlands</location>
      <location>Maastricht University Medical Center, Maastricht, Limburg, Netherlands</location>
      <location>Jeroen Bosch Ziekenhuis, Den Bosch, Noord-Brabant, Netherlands</location>
      <location>Bernhoven, Uden, Noord-Brabant, Netherlands</location>
      <location>Maxima Medisch Centrum, Veldhoven, Noord-Brabant, Netherlands</location>
      <location>AMC, Amsterdam, Noord-Holland, Netherlands</location>
      <location>VU Medisch Centrum, Amsterdam, Noord-Holland, Netherlands</location>
      <location>Tergooi Hilversum, Hilversum, Noord-Holland, Netherlands</location>
      <location>Medisch Spectrum Twente, Enschede, Overijssel, Netherlands</location>
      <location>Alrijne Ziekenhuis, Leiden, Zuid-Holland, Netherlands</location>
      <location>Martini Ziekenhuis, Groningen, Netherlands</location>
      <location>Diakonessenhuis, Utrecht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03899779</url>
  </study>
  <study rank="89">
    <nct_id>NCT03339128</nct_id>
    <title>Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eluxadoline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in stool consistency averaged over the 4-week Treatment Period</outcome_measure>
      <outcome_measure>Change from baseline in stool consistency for daily daytime and nighttime stool consistency scores</outcome_measure>
      <outcome_measure>Change from baseline for daytime, nighttime, and 24-hour abdominal pain scores</outcome_measure>
      <outcome_measure>Change from baseline for daytime, nighttime, and 24-hour bowel movement frequency</outcome_measure>
      <outcome_measure>Change from baseline for daytime, nighttime, and 24 hour urgency-free days</outcome_measure>
      <outcome_measure>Change from baseline for daytime, nighttime, and 24 hour number of fecal incontinence-free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Allergan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>3030-202-002</other_id>
      <other_id>2017-003770-14</other_id>
    </other_ids>
    <start_date>November 15, 2017</start_date>
    <primary_completion_date>January 25, 2021</primary_completion_date>
    <completion_date>February 8, 2021</completion_date>
    <study_first_posted>November 13, 2017</study_first_posted>
    <last_update_posted>May 24, 2019</last_update_posted>
    <locations>
      <location>University Of Arizona, Tucson, Arizona, United States</location>
      <location>Applied Research of Arkansas, Little Rock, Arkansas, United States</location>
      <location>Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States</location>
      <location>VVCRD Clinical Research, Garden Grove, California, United States</location>
      <location>University of California, San Francisco, San Francisco, California, United States</location>
      <location>Wellness Clinical Research, LLC, Hialeah, Florida, United States</location>
      <location>Clinical Neuroscience Solutions Inc dba CNS Healthcare, Jacksonville, Florida, United States</location>
      <location>Sunrise Research Institute, Miami, Florida, United States</location>
      <location>Florida Research Center, Inc, Miami, Florida, United States</location>
      <location>Nemours Children's Clinic, Orlando, Orlando, Florida, United States</location>
      <location>Children's Center for Digestive Health Care, Atlanta, Georgia, United States</location>
      <location>Sleep Care Research Institute/Global Research Associates, Stockbridge, Georgia, United States</location>
      <location>Center for Children's Digestive Health, Park Ridge, Illinois, United States</location>
      <location>Unity Point Health Pediatric Gastroenterology, Peoria, Illinois, United States</location>
      <location>MBAL Sv. Ivan Rilski Kozlodui, Indianapolis, Indiana, United States</location>
      <location>Michael W. Simon, MD, PSC, Nicholasville, Kentucky, United States</location>
      <location>Willis-Knighton Physician Network, Shreveport, Louisiana, United States</location>
      <location>Certified Research Consultants Virgo-Carter Pediatrics, Silver Spring, Maryland, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Celen Medical Group, Corp, Marlton, New Jersey, United States</location>
      <location>Ubmd Ddnc, Buffalo, New York, United States</location>
      <location>UH Rainbow Babies &amp; Children's Hospital, Cleveland, Ohio, United States</location>
      <location>IPS Research Company, Oklahoma City, Oklahoma, United States</location>
      <location>St. Christopher's Hospital for Children - Drexel University, Philadelphia, Pennsylvania, United States</location>
      <location>Preferred Primary Care Physicians Inc., Pittsburgh, Pennsylvania, United States</location>
      <location>Coastal Pediatrics Associates, Mount Pleasant, South Carolina, United States</location>
      <location>Cook Children's Digestive Health, Fort Worth, Texas, United States</location>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
      <location>Envision Clinical Research, LLC, Laredo, Texas, United States</location>
      <location>Sun Research Institute, San Antonio, Texas, United States</location>
      <location>Multicare Health Institute for Research and Innovation, Tacoma, Washington, United States</location>
      <location>Korczowski Bartosz, Gabinet Lekarski, Kozlodui, Bulgaria</location>
      <location>Edmonton Clinic Health Academy (ECHA), Edmonton, Alberta, Canada</location>
      <location>Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada</location>
      <location>Mentahaz Maganorvosi Kozpont, Székesfehérvár, Hungary</location>
      <location>Specjalistyczny Gabinet Naurologiczny Marta Banach, Krakow, Poland</location>
      <location>Korczowski Bartosz, Gabinet Lekarski, Rzeszow, Poland</location>
      <location>The Children's Memorial Health Institute, Warsaw, Poland</location>
      <location>Hospital Universitario Dr. Peset, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03339128</url>
  </study>
  <study rank="90">
    <nct_id>NCT01412372</nct_id>
    <title>The Effect of Long-Acting Mesalamine on Post-Infective Irritable Bowel Syndrome- A Pilot Study</title>
    <acronym>Mesalamine</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalamine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in gastrointestinal symptoms and IBS specific quality of life after an 8 week treatment period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Utah</lead_sponsor>
      <collaborator>Shire Human Genetic Therapies, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>39402</other_id>
    </other_ids>
    <start_date>June 2010</start_date>
    <primary_completion_date>April 22, 2019</primary_completion_date>
    <completion_date>April 22, 2019</completion_date>
    <study_first_posted>August 9, 2011</study_first_posted>
    <last_update_posted>May 8, 2019</last_update_posted>
    <locations>
      <location>University of Utah, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01412372</url>
  </study>
  <study rank="91">
    <nct_id>NCT02857257</nct_id>
    <title>Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome</title>
    <acronym>ACHIM2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ACHIM</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom relief according to irritable bowel syndrome-symptom severity scale (IBS-SSS)</outcome_measure>
      <outcome_measure>Differential bacterial species population as defined by 16S RNA</outcome_measure>
      <outcome_measure>Normalization of stool consistency as determined by the Bristol stool scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uppsala University</lead_sponsor>
      <collaborator>Karolinska Institutet</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACHIM2</other_id>
    </other_ids>
    <start_date>January 2015</start_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>August 5, 2016</study_first_posted>
    <last_update_posted>August 8, 2018</last_update_posted>
    <locations>
      <location>Mag-tarm/endoskopienheten Hötorget, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02857257</url>
  </study>
  <study rank="92">
    <nct_id>NCT02423421</nct_id>
    <title>Faecal Microbiota Transplantation in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Faecal microbiota transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global Assessment of relief of IBS symptoms.</outcome_measure>
      <outcome_measure>Primary symptoms of IBS</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Depression and Anxiety</outcome_measure>
      <outcome_measure>Safety as measured by occurrence of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College Cork</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>APC053</other_id>
    </other_ids>
    <start_date>March 2015</start_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>April 22, 2015</study_first_posted>
    <last_update_posted>April 22, 2015</last_update_posted>
    <locations>
      <location>Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02423421</url>
  </study>
  <study rank="93">
    <nct_id>NCT03003260</nct_id>
    <title>The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">CBD chewing gum</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of pain scores on the Visual analoge scale (VAS) between baseline and 3, 5 and 8 weeks of treatment</outcome_measure>
      <outcome_measure>Change of IBS-QOL baseline vs 3, 5 and 8 weeks of treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wageningen University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL58588.081.16</other_id>
    </other_ids>
    <start_date>December 2016</start_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <completion_date>June 2017</completion_date>
    <study_first_posted>December 26, 2016</study_first_posted>
    <last_update_posted>December 26, 2016</last_update_posted>
    <locations>
      <location>Wageningen University, Wageningen, Gelderland, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03003260</url>
  </study>
  <study rank="94">
    <nct_id>NCT01342718</nct_id>
    <title>Effect of Herbal Extract Granules Combined With Probiotics on Irritable Bowel Syndrome With Diarrhea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Herbal extract granule and probiotics</intervention>
      <intervention type="Dietary Supplement">Herbal extract granule and placebo probiotics</intervention>
      <intervention type="Dietary Supplement">Placebo herbal extract granule and probiotics</intervention>
      <intervention type="Dietary Supplement">Placebo herbal extract granule and placebo probiotics</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate relief (AR) of IBS pain &amp; discomfort</outcome_measure>
      <outcome_measure>Proportion of responders</outcome_measure>
      <outcome_measure>Daily assessment of bowel function scores</outcome_measure>
      <outcome_measure>Daily assessment of severity of individual symptoms related to defecation</outcome_measure>
      <outcome_measure>Changes on population of intestinal microbes</outcome_measure>
      <outcome_measure>Intestinal permeability test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kyunghee University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KHNMC-OH-IRB 2010-011</other_id>
    </other_ids>
    <start_date>April 2011</start_date>
    <primary_completion_date>April 2012</primary_completion_date>
    <completion_date>April 2012</completion_date>
    <study_first_posted>April 27, 2011</study_first_posted>
    <last_update_posted>June 5, 2012</last_update_posted>
    <locations>
      <location>Kyung Hee University Hospital at Gangdong, Seoul, Gangdong-gu, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01342718</url>
  </study>
  <study rank="95">
    <nct_id>NCT02970591</nct_id>
    <title>A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome</title>
    <acronym>Car-IBS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Traditional dietary advice and low FODMAP content</intervention>
      <intervention type="Other">Low carbohydrate diet</intervention>
      <intervention type="Other">Optimized Medical treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in IBS-SSS</outcome_measure>
      <outcome_measure>Change in metabolic profile</outcome_measure>
      <outcome_measure>Change in microbiota content</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>Car-IBS 1511-01</other_id>
    </other_ids>
    <start_date>January 2017</start_date>
    <primary_completion_date>June 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>November 22, 2016</study_first_posted>
    <last_update_posted>April 8, 2019</last_update_posted>
    <locations>
      <location>Magnus Simren, Gothenburg, Non-US/Non-Canadian, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02970591</url>
  </study>
  <study rank="96">
    <nct_id>NCT02360384</nct_id>
    <title>Caecal pH as a Biomarker for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
      <intervention type="Dietary Supplement">FODMAP diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the change in pH around the ileocaecal valve in response to dietary intervention or linaclotide.</outcome_measure>
      <outcome_measure>Change in caecal pH and its association with the degree in symptomatic improvement using the IBS-symptom scale</outcome_measure>
      <outcome_measure>Motility patterns and transit in subtype IBS patients, according to the Rome III criteria, using the wireless motility capsule</outcome_measure>
      <outcome_measure>The effect of the interventions on symptoms using the validated questionnaires of IBS-SSS</outcome_measure>
      <outcome_measure>The effect of the interventions on quality of life measures using the validated Eq-5D</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wingate Institute of Neurogastroenterology</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>WMC1</other_id>
    </other_ids>
    <start_date>November 2015</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>February 10, 2015</study_first_posted>
    <last_update_posted>November 3, 2016</last_update_posted>
    <locations>
      <location>Wingate Institute of Neurogastroenterology, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02360384</url>
  </study>
  <study rank="97">
    <nct_id>NCT02249169</nct_id>
    <title>Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change in gut microbiome in patients with IBS compared to healthy individuals measured over 6 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>University of Minnesota - Clinical and Translational Science Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-000305</other_id>
    </other_ids>
    <start_date>May 2014</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>September 25, 2014</study_first_posted>
    <last_update_posted>February 5, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02249169</url>
  </study>
  <study rank="98">
    <nct_id>NCT00971711</nct_id>
    <title>Safety Study of Probiotics in Adults With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Probiotic</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety</outcome_measure>
      <outcome_measure>Pain and Stooling Improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
      <collaborator>University of Washington</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>24041</other_id>
      <other_id>R01NR005337</other_id>
      <other_id>005337</other_id>
    </other_ids>
    <start_date>September 2009</start_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <completion_date>December 2013</completion_date>
    <study_first_posted>September 4, 2009</study_first_posted>
    <last_update_posted>March 8, 2016</last_update_posted>
    <locations>
      <location>Baylor Clinic, Houston, Texas, United States</location>
      <location>Univerisity of Washington, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00971711</url>
  </study>
  <study rank="99">
    <nct_id>NCT02638870</nct_id>
    <title>Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amitriptyline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>treatment response of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>treatment responses of urgency of defecation</outcome_measure>
      <outcome_measure>treatment responses of bloating</outcome_measure>
      <outcome_measure>treatment responses of overall IBS symptoms scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Samsung Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>118</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015-08-109</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <completion_date>October 2016</completion_date>
    <study_first_posted>December 23, 2015</study_first_posted>
    <last_update_posted>December 24, 2015</last_update_posted>
    <locations>
      <location>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02638870</url>
  </study>
  <study rank="100">
    <nct_id>NCT02545413</nct_id>
    <title>Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic VSL#3</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Comparison of the intensity of abdominal pain relief and change in stool consistency before and after treatment, between the two arms</outcome_measure>
      <outcome_measure>Comparison of Quality of Life parameters as measured by IBS-QoL Questionnaire before and after treatment, between the 2 arms</outcome_measure>
      <outcome_measure>Comparison of Quality of Life parameters as measured by SF-36 Questionnaire before and after treatment, between the 2 arms</outcome_measure>
      <outcome_measure>Comparison of Visceral hypersensitivity/Rectal sensitivity before and after treatment between the two arms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Next Gen Pharma India Pvt. Ltd.</lead_sponsor>
      <collaborator>Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRC/2015/protocol/24</other_id>
    </other_ids>
    <start_date>May 2016</start_date>
    <primary_completion_date>June 2017</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>September 10, 2015</study_first_posted>
    <last_update_posted>March 23, 2016</last_update_posted>
    <locations>
      <location>Department of Gastroeneterology, Government Medical College, Kozhikode, Kerala, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02545413</url>
  </study>
  <study rank="101">
    <nct_id>NCT00108446</nct_id>
    <title>Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">dextromethorphan</intervention>
      <intervention type="Drug">naloxone</intervention>
      <intervention type="Drug">fentanyl</intervention>
      <intervention type="Drug">lidocaine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>US Department of Veterans Affairs</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLIN-008-02F</other_id>
    </other_ids>
    <start_date>October 2003</start_date>
    <completion_date>March 2006</completion_date>
    <study_first_posted>April 18, 2005</study_first_posted>
    <last_update_posted>January 21, 2009</last_update_posted>
    <locations>
      <location>Malcom Randall VAMC, Gainesville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00108446</url>
  </study>
  <study rank="102">
    <nct_id>NCT00680693</nct_id>
    <title>Mindfulness vs. Support Groups for Irritable Bowel Syndrome</title>
    <acronym>M-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mindfulness training</intervention>
      <intervention type="Behavioral">Psycho-educational support group for women with IBS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS-S</outcome_measure>
      <outcome_measure>Visceral Sensitivity Index</outcome_measure>
      <outcome_measure>Work Productivity and Activity Impairment for IBS (WPAI:IBS)</outcome_measure>
      <outcome_measure>Recent Physical Symptoms Questionnaire (RPSQ)</outcome_measure>
      <outcome_measure>Brief Symptom Inventory (BSI)</outcome_measure>
      <outcome_measure>State Trait-Anger Expression Inventory (STAXI)</outcome_measure>
      <outcome_measure>Coping Strategies Questionnaire (CSQ)</outcome_measure>
      <outcome_measure>IBS QOL</outcome_measure>
      <outcome_measure>Daily Symptom Diary</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R21AT003619-02</other_id>
    </other_ids>
    <start_date>October 2006</start_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <completion_date>August 2010</completion_date>
    <study_first_posted>May 20, 2008</study_first_posted>
    <last_update_posted>November 18, 2011</last_update_posted>
    <locations>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00680693</url>
  </study>
  <study rank="103">
    <nct_id>NCT00786123</nct_id>
    <title>Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">VSL#3</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Resolution of symptoms</outcome_measure>
      <outcome_measure>Rectal sensitivity</outcome_measure>
      <outcome_measure>Saliva and fecal melatonin levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>68 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>D/06/136</other_id>
    </other_ids>
    <start_date>May 2006</start_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <completion_date>December 2009</completion_date>
    <study_first_posted>November 6, 2008</study_first_posted>
    <last_update_posted>March 4, 2011</last_update_posted>
    <locations>
      <location>National University Hospital, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00786123</url>
  </study>
  <study rank="104">
    <nct_id>NCT01855711</nct_id>
    <title>Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GR68755 (Alosetron hydrochloride) 1 mg tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global Improvement Scale(GIS)</outcome_measure>
      <outcome_measure>Satisfactory control of IBS related bowel urgency</outcome_measure>
      <outcome_measure>Adequate relief of IBS pain and discomfort</outcome_measure>
      <outcome_measure>Days without abdominal pain and discomfort</outcome_measure>
      <outcome_measure>Severity score of abdominal pain and/or discomfort</outcome_measure>
      <outcome_measure>Intestine function(Number of bowel movement,Stool form,Feeling of incomplete evacuation,Abdominal bloating)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S3B20032</other_id>
    </other_ids>
    <start_date>September 18, 2003</start_date>
    <primary_completion_date>May 10, 2005</primary_completion_date>
    <completion_date>May 10, 2005</completion_date>
    <study_first_posted>May 16, 2013</study_first_posted>
    <last_update_posted>May 1, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01855711</url>
  </study>
  <study rank="105">
    <nct_id>NCT02955316</nct_id>
    <title>Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China</title>
    <acronym>IRONS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>IBS prevalence in GI adult outpatients in China</outcome_measure>
      <outcome_measure>Overall and subgroups' prevalence of medically diagnosed IBS in GI adult outpatients</outcome_measure>
      <outcome_measure>Overall and subgroups' prevalence of IBS sufferers in GI adult patients without medical diagnosis</outcome_measure>
      <outcome_measure>Identify demographic features of IBS and non-IBS outpatients</outcome_measure>
      <outcome_measure>Identify disease characteristics of IBS outpatients</outcome_measure>
      <outcome_measure>Assess the current treatment status of IBS outpatients</outcome_measure>
      <outcome_measure>Estimate the overall and subgroups' prevalence of IBS diagnosed by Rome III criteria in GI adult patients</outcome_measure>
      <outcome_measure>Estimate the overall and subgroups' prevalence of IBS diagnosed by Rome IV criteria in GI adult patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>D1844R00004</other_id>
    </other_ids>
    <start_date>February 10, 2017</start_date>
    <primary_completion_date>September 30, 2017</primary_completion_date>
    <completion_date>September 30, 2017</completion_date>
    <study_first_posted>November 4, 2016</study_first_posted>
    <last_update_posted>November 7, 2018</last_update_posted>
    <locations>
      <location>Research Site, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02955316</url>
  </study>
  <study rank="106">
    <nct_id>NCT00477165</nct_id>
    <title>Citalopram in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Citalopram</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Count of Participants Who Self-reported &quot;Adequate Relief&quot;</outcome_measure>
      <outcome_measure>Change From Baseline in IBS-QOL Score at Week 8</outcome_measure>
      <outcome_measure>Mean Sensation Score as a Function of Distending Pressure at the End of the Study</outcome_measure>
      <outcome_measure>Urgency Score as a Function of Distending Pressure at the End of the Study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H10539-18502</other_id>
    </other_ids>
    <start_date>April 2001</start_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <completion_date>June 2009</completion_date>
    <study_first_posted>May 22, 2007</study_first_posted>
    <results_first_posted>April 17, 2017</results_first_posted>
    <last_update_posted>April 17, 2017</last_update_posted>
    <locations>
      <location>UCSF, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00477165</url>
  </study>
  <study rank="107">
    <nct_id>NCT01303224</nct_id>
    <title>Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)</title>
    <acronym>IRIS-2</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibodutant</intervention>
      <intervention type="Drug">Ibodutant</intervention>
      <intervention type="Drug">Ibodutant</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With Satisfactory Relief During 8 Weeks of Treatment (75% Rule); Intention-to-treat (ITT).</outcome_measure>
      <outcome_measure>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 4 Weeks With Satisfactory Relief During 8 Weeks of Treatment (50% Rule) in the ITT Population</outcome_measure>
      <outcome_measure>Quality of Life Changes (Using EuroQoL EQ-5D Questionnaire)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Menarini Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>565</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NAK-04</other_id>
      <other_id>2010-018300-85</other_id>
    </other_ids>
    <start_date>October 2010</start_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <completion_date>July 2012</completion_date>
    <study_first_posted>February 24, 2011</study_first_posted>
    <results_first_posted>March 25, 2013</results_first_posted>
    <last_update_posted>October 7, 2015</last_update_posted>
    <locations>
      <location>MHAT &quot;Haskovo&quot;, Second Internal Department, Haskovo, Bulgaria</location>
      <location>UMHAT &quot;Dr. Georgi Stranski&quot;, Clinic of Gastroenterology, Pleven, Bulgaria</location>
      <location>MHAT &quot;Kaspela&quot;, Department of Gastroenterology, Plovdiv, Bulgaria</location>
      <location>UMHAT &quot;Sveti Georgi&quot;, Internal Consultative Department, Plovdiv, Bulgaria</location>
      <location>MHAT &quot;Ruse&quot;, Clinic of Gastroenterology, Ruse, Bulgaria</location>
      <location>Fifth City Hospital, Gastroenterology Department, Sofia, Bulgaria</location>
      <location>UMHAT &quot;Alexandrovska&quot;, Clinic of Propedeutic of Internal Disease, Sofia, Bulgaria</location>
      <location>MHAT &quot;Sveta Anna&quot;, Department of Gastroenterology, Endocrinology, and Nephrology, Sofia, Bulgaria</location>
      <location>UMHAT &quot;St. Marina&quot;, Clinic of Gastroenterology, Varna, Bulgaria</location>
      <location>MHAT &quot;Dr. Stefan Cherkezov&quot;, Gastroenterology Department, Veliko Tarnovo, Bulgaria</location>
      <location>Poliklinika III, Hepato-Gastroenterologie HK, Hradec Kralove, Czech Republic</location>
      <location>Gastromedic s.r.o., Soukroma ordinace, Pardubice, Czech Republic</location>
      <location>IKEM, Klinika hepatogastroenterologie, Prague, Czech Republic</location>
      <location>Hospital Slany, Internal Department, Slany, Czech Republic</location>
      <location>District Hospital, Internal Department, Strakonice, Czech Republic</location>
      <location>Regional Hospital Tabor, Gastroenterology, Tabor, Czech Republic</location>
      <location>Kojecký Soukroma Ordinace, Zlin, Czech Republic</location>
      <location>CCBR Aalborg, Aalborg, Denmark</location>
      <location>CCBR Ballerup, Ballerup, Denmark</location>
      <location>Gentofte Hospital, Medicinsk Afdeling F, Hellerup, Denmark</location>
      <location>Regionshospitalet Silkeborg, Medicinsk Afdeling F, Silkeborg, Denmark</location>
      <location>CCBR Vejle, Vejle, Denmark</location>
      <location>Klinische Forschung Berlin, Berlin, Germany</location>
      <location>Universitätsklinik Köln, Gastroenterologie, Cologne, Germany</location>
      <location>ABX-CRO Clinical Research GmbH, Dresden, Germany</location>
      <location>Private Practice Dr. Schaefer, Essen, Germany</location>
      <location>Clinical Research Hamburg, Hamburg, Germany</location>
      <location>Israelitisches Krankenhaus, Innere Medizin, Hamburg, Germany</location>
      <location>Gemeinschaftspraxis Kuchta, Wegner, Schiefke, Leipzig, Germany</location>
      <location>Praxis Prof. Kellner, Munich, Germany</location>
      <location>Ospedale Valduce, Unità Operativa Complessa di Gastroenterologia, Como, Italy</location>
      <location>Azienda Ospedaliera Sant'Anna, U.O. Di Gastroenterologia, Ferrara, Italy</location>
      <location>Azienda Ospedaliero Universitaria Careggi, USOD Gastroenterologia 1, Florence, Italy</location>
      <location>Università degli Studi di Genova, Dipartimento di Medicina Interna e Specialità Mediche, Genoa, Italy</location>
      <location>Azienda Ospedaliera - Università di Padova, Struttura Operativa Complessa di Gastroenterologia, Padua, Italy</location>
      <location>IRCCS Policlinico San Matteo, Dipartimento di Medicina Interna I e Gastroenterologia, Pavia, Italy</location>
      <location>&quot;Ospedale Nuovo Santa Chiara-Cisanello, Dipartimento di Medicina Interna, Pisa, Italy</location>
      <location>IRCCS Istituto Clinico Humanitas, Dipartimento di Gastroenterologia, Rozzano, Italy</location>
      <location>IRCCS Ospedale Casa Sollievo della Sofferenza, Divisione di Gastroenterologia, San Giovanni Rotondo, Italy</location>
      <location>NZOZ Specjalistyczne Centrum Gastrologii &quot;Gastromed&quot;, Białystok, Poland</location>
      <location>Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Bydgoszcz, Poland</location>
      <location>Gabinet Lekarski Janusz Rudziński, Bydgoszcz, Poland</location>
      <location>Mazowieckie Centrum Badań Klinicznych I.Czajkowska M.Śmietańska s.c., Grodzisk Mazowiecki, Poland</location>
      <location>Specjalistyczne Centrum Medyczne &quot;NOWOMED&quot;, Krakov, Poland</location>
      <location>5 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w Krakowie, Krakov, Poland</location>
      <location>NZOZ Krakowskie Centrum Medyczne, Krakov, Poland</location>
      <location>Instytut Medycyny Wsi im. Witolda Chodźki Publiczny Zakład Opieki Zdrowotnej, Lublin, Poland</location>
      <location>NZOZ &quot;Centrum Alergologii&quot;, Lublin, Poland</location>
      <location>NZOZ Solumed, Poznań, Poland</location>
      <location>NZOZ Zaspół Poradni Specjalistycznych &quot;Artmed&quot;, Poznań, Poland</location>
      <location>Endoskopia Sp. z o.o., Sopot, Poland</location>
      <location>NZOZ &quot;Nasz Lekarz&quot; Praktyka Grupowa Lekarzy Rodzinnych, Toruń, Poland</location>
      <location>NZOZ Remedis Sp z o.o., Toruń, Poland</location>
      <location>Centrum Badawcze Współczesnej Terapii, Prywatny Gabinet Lekarski, Warsaw, Poland</location>
      <location>Centrum Medyczne &quot;Osteomed&quot; Sp. z o. o, Warsaw, Poland</location>
      <location>Centralny Szpital Kliniczny MSWiA, Warsaw, Poland</location>
      <location>NZOZ Vivamed, Warsaw, Poland</location>
      <location>Hospital Germans Trias i Pujol, Digestive Unit, Badalona, Spain</location>
      <location>Centro Medico Teknon, Gastroenteloroly Service, Barcelona, Spain</location>
      <location>&quot;Hospital Universitario Virgen de la Arrixaca, Servicio de Medicina del Aparato Digestivo, El Palmar (Murcia), Spain</location>
      <location>Hospital Clinico San Carlos, Digestive Diseases, Madrid, Spain</location>
      <location>Hospital de Mataró, Unitat d'Exploracions Funcionals Digestives, Mataró, Spain</location>
      <location>Corporació Sanitària Parc Tauli, Sabadell, Spain</location>
      <location>Complejo Hospitalario Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain</location>
      <location>Hospital Virgen Macarena, Digestive Service, Sevilla, Spain</location>
      <location>Sahlgrenska Universitetssjukhuset, Mag-tarm lab, Gothenburg, Sweden</location>
      <location>Probare, Lund, Sweden</location>
      <location>Kärnsjukhuset, Skövde, Sweden</location>
      <location>Gastrocentrum Aleris specialistvård Sabbatsberg,, Stockholm, Sweden</location>
      <location>Akademiska sjukhuset, Gastromottagningen, Uppsala, Sweden</location>
      <location>Clinical Research Support, S-huset, Södra Grev Rosengatan, Örebro, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01303224</url>
  </study>
  <study rank="108">
    <nct_id>NCT01400048</nct_id>
    <title>Aloe Vera in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Aloe vera effervescent tablet (AVH200)</intervention>
      <intervention type="Dietary Supplement">Placebo control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
      <collaborator>Calmino group AB</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>173</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Aloe Vera AVH200</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>March 2017</completion_date>
    <study_first_posted>July 22, 2011</study_first_posted>
    <last_update_posted>September 10, 2018</last_update_posted>
    <locations>
      <location>Mag-tarmlab, Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01400048</url>
  </study>
  <study rank="109">
    <nct_id>NCT02565550</nct_id>
    <title>Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">low FODMAPs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>changes of symptom scores</outcome_measure>
      <outcome_measure>proportion of responders</outcome_measure>
      <outcome_measure>quality of life in IBS patients</outcome_measure>
      <outcome_measure>microbial composition in different response to low FODMAPs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015SDU-QILU-G10</other_id>
    </other_ids>
    <start_date>July 2015</start_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>October 1, 2015</study_first_posted>
    <last_update_posted>October 1, 2015</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02565550</url>
  </study>
  <study rank="110">
    <nct_id>NCT02313246</nct_id>
    <title>A Pilot Study of Cognitive-Behaviour Therapy for Irritable Bowel Syndrome and the Gut Microbiome</title>
    <acronym>IBS</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Group Cognitive Behaviour Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Birmingham IBS Symptom Scale</outcome_measure>
      <outcome_measure>IBS Quality of Life</outcome_measure>
      <outcome_measure>Changes in gut microbiome as assessed through analyzing fecal samples</outcome_measure>
      <outcome_measure>GI-Cognitions Questionnaire</outcome_measure>
      <outcome_measure>Visceral Sensitivity Index</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Penn State Worry Questionnaire</outcome_measure>
      <outcome_measure>UCLA Symptom Severity Scale</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Symptom Severity Scale</outcome_measure>
      <outcome_measure>Anxiety Sensitivity Index</outcome_measure>
      <outcome_measure>Birmingham IBS Severity Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hamilton Health Sciences Corporation</lead_sponsor>
      <collaborator>St. Joseph's Healthcare Hamilton</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CBT-IBS-2015</other_id>
    </other_ids>
    <start_date>August 2015</start_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>December 10, 2014</study_first_posted>
    <last_update_posted>March 25, 2016</last_update_posted>
    <locations>
      <location>McMaster University Medical Centre, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02313246</url>
  </study>
  <study rank="111">
    <nct_id>NCT00919672</nct_id>
    <title>Treatment of Irritable Bowel Syndrome (IBS) With Sacral Nerve Stimulation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Sacral nerve stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Comparing the investigations with MTS and impedance planimetry as well as the GSRS-IBS and IBS-IS scores in the the two periods (ON/OFF periods) in the single IBS patient. Nonparametrics tests.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
      <collaborator>Medtronic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20070218,JLF</other_id>
    </other_ids>
    <start_date>April 2009</start_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <completion_date>November 2013</completion_date>
    <study_first_posted>June 12, 2009</study_first_posted>
    <last_update_posted>May 17, 2018</last_update_posted>
    <locations>
      <location>Analfysiologisk Klinik, University Hospital of Aarhus, Aarhus, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00919672</url>
  </study>
  <study rank="112">
    <nct_id>NCT02327780</nct_id>
    <title>The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">FODMAP diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome (IBS) severity score</outcome_measure>
      <outcome_measure>IBS quality of life score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tel-Aviv Sourasky Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>77 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>407-14-TLV</other_id>
    </other_ids>
    <start_date>January 2015</start_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <completion_date>March 2016</completion_date>
    <study_first_posted>December 30, 2014</study_first_posted>
    <last_update_posted>December 30, 2014</last_update_posted>
    <locations>
      <location>Clinical Nutrition Unit, Sourasky Medical Center, Tel Aviv, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02327780</url>
  </study>
  <study rank="113">
    <nct_id>NCT00900965</nct_id>
    <title>Effect of Electroacupuncture in Patients With Irritable Bowel Syndrome</title>
    <acronym>IBS_FBM</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))</intervention>
      <intervention type="Device">Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensory and pain thresholds as determined by rectal barostat</outcome_measure>
      <outcome_measure>Degree of cortical activation as determined by functional MRI</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS_FBM</other_id>
    </other_ids>
    <start_date>April 2008</start_date>
    <primary_completion_date>December 2008</primary_completion_date>
    <completion_date>December 2008</completion_date>
    <study_first_posted>May 13, 2009</study_first_posted>
    <last_update_posted>July 2, 2009</last_update_posted>
    <locations>
      <location>The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00900965</url>
  </study>
  <study rank="114">
    <nct_id>NCT01056107</nct_id>
    <title>Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Constipation Predominant</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ROSE-010</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Transit, Colonic Geometric Center at 24 Hours</outcome_measure>
      <outcome_measure>Change Between Postprandial and Fasting Whole Gastric Volume by Technetium-99m (99mTc)-SPECT Imaging (Gastric Accommodation)</outcome_measure>
      <outcome_measure>Half Time (t1/2) of Gastric Emptying of Solids Measured by Scintigraphy (Gastric Transit)</outcome_measure>
      <outcome_measure>Gastric Residual at 2 and 4 Hours Measured by Scintigraphy</outcome_measure>
      <outcome_measure>Colonic Geometric Center at 4 h Measured by Scintigraphy</outcome_measure>
      <outcome_measure>Colonic Filling at 6 h Measured by Scintigraphy</outcome_measure>
      <outcome_measure>Ascending Colon Emptying Half-time (AC t1/2) Measured by Scintigraphy</outcome_measure>
      <outcome_measure>Colonic Transit, Colonic Geometric Center at 48 h Measured by Scintigraphy, as Compared to Placebo.</outcome_measure>
      <outcome_measure>Stool Frequency</outcome_measure>
      <outcome_measure>Stool Consistency Post Treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Rose Pharma A/S</collaborator>
      <collaborator>National Center for Research Resources (NCRR)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>09-005871</other_id>
      <other_id>UL1RR024150</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>January 26, 2010</study_first_posted>
    <results_first_posted>May 31, 2013</results_first_posted>
    <last_update_posted>May 31, 2013</last_update_posted>
    <locations>
      <location>Mayo Clinic Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01056107</url>
  </study>
  <study rank="115">
    <nct_id>NCT02179580</nct_id>
    <title>A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Xiang-Sha-Liu-Jun-Zi-Tang</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gastrointestinal System Rating Scale-IBS Questionnaire</outcome_measure>
      <outcome_measure>IBS-QOL Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>China Medical University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CMUH103-REC2-016</other_id>
    </other_ids>
    <start_date>June 2014</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>July 2, 2014</study_first_posted>
    <last_update_posted>July 2, 2014</last_update_posted>
    <locations>
      <location>China Medical University Hospital, Taichung, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02179580</url>
  </study>
  <study rank="116">
    <nct_id>NCT01100684</nct_id>
    <title>Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Asimadoline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>12 Week Abdominal Pain and Stool (APS) Frequency Responder</outcome_measure>
      <outcome_measure>Compare the two treatment groups with respect to IBS-related abdominal pain</outcome_measure>
      <outcome_measure>Compare the two treatment groups with respect to stool frequency</outcome_measure>
      <outcome_measure>Compare the two treatment groups with respect to stool urgency</outcome_measure>
      <outcome_measure>Compare the two treatment groups with respect to IBS symptoms</outcome_measure>
      <outcome_measure>Compare the two treatment groups with respect to stool consistency scores</outcome_measure>
      <outcome_measure>Incidence of adverse events as a measure of tolerability</outcome_measure>
      <outcome_measure>Abnormalities of laboratory tests as a measure of tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tioga Pharmaceuticals</lead_sponsor>
      <collaborator>RTI Health Solutions</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>611</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ASMP3001</other_id>
    </other_ids>
    <start_date>May 2010</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>June 2013</completion_date>
    <study_first_posted>April 9, 2010</study_first_posted>
    <last_update_posted>December 18, 2013</last_update_posted>
    <locations>
      <location>North Alabama Research Center, LLC, Athens, Alabama, United States</location>
      <location>Alliance Clinical Research, Birmingham, Alabama, United States</location>
      <location>Medical Affliated Research Center, Inc., Huntsville, Alabama, United States</location>
      <location>Saadat Ansari MD LLC, Huntsville, Alabama, United States</location>
      <location>Connect Clinical Research Center, Chandler, Arizona, United States</location>
      <location>Digestive Health Research Unit, Scottsdale, Arizona, United States</location>
      <location>Adobe Clinical Research, LLC, Tucson, Arizona, United States</location>
      <location>ACRC/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States</location>
      <location>Genova Clinical Research, Tucson, Arizona, United States</location>
      <location>W/C Clinical Research, Tucson, Arizona, United States</location>
      <location>Lynn Institute of the Ozarks, Little Rock, Arkansas, United States</location>
      <location>Applied Research Center of Arkansas, Little Rock, Arkansas, United States</location>
      <location>Arkansas Gastroenterology, Sherwood, Arkansas, United States</location>
      <location>Providence Clinical Research, Burbank, California, United States</location>
      <location>GW Research Inc,, Chula Vista, California, United States</location>
      <location>La Jolla Clinical Research, Inc, Chula Vista, California, United States</location>
      <location>Discovery Clinical Research, Encinitas, California, United States</location>
      <location>Digestive &amp; Liver Disease Specialist, Garden Grove, California, United States</location>
      <location>Collaborative Neuroscience Network Inc, Long Beach, California, United States</location>
      <location>California Gastroenterology Associates, Madera, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>Sutter Medical Group Gastroenterology, Sacramento, California, United States</location>
      <location>Medical Center for Clinical Research, San Diego, California, United States</location>
      <location>Medical Associates Research Group, Inc., San Diego, California, United States</location>
      <location>Westlake Medical Research, Westlake Village, California, United States</location>
      <location>Lynne Institute of the Rockies, Colorado Springs, Colorado, United States</location>
      <location>Arapahoe Gastroenterology, Littleton, Colorado, United States</location>
      <location>Lynn Institute of Pueblo, Pueblo, Colorado, United States</location>
      <location>Rocky Mountain Gastroenterology Associates, Thornton, Colorado, United States</location>
      <location>Danbury Clinical Research, LLC, Danbury, Connecticut, United States</location>
      <location>Chase Medical Research, LLC, Waterbury, Connecticut, United States</location>
      <location>Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States</location>
      <location>Meridien Research, Brookville, Florida, United States</location>
      <location>BioPharma Research, Coral Gables, Florida, United States</location>
      <location>Riverside Clinical Research, Edgewater, Florida, United States</location>
      <location>A.G.A. Clinical Trials, Hialeah, Florida, United States</location>
      <location>Altus Research, Lake Worth, Florida, United States</location>
      <location>Center for Advanced Gastroenterology, Maitland, Florida, United States</location>
      <location>FIRC, Miami, Florida, United States</location>
      <location>DMI Research, Pinellas Park, Florida, United States</location>
      <location>Accord Clinical Research, LLC, Port Orange, Florida, United States</location>
      <location>International Clinical Research-US,LLC, Sanford, Florida, United States</location>
      <location>Lakeview Medical Research, Summerfield, Florida, United States</location>
      <location>Venra Clinical Studies, LLC, Wellington, Florida, United States</location>
      <location>Alliance Clinical Research, Winter Park, Florida, United States</location>
      <location>Atlanta Center for Gastroenterology, Decatur, Georgia, United States</location>
      <location>Tri County Research, Hartwell, Georgia, United States</location>
      <location>Northwest Gastroenterologist S.C., Arlington Heights, Illinois, United States</location>
      <location>Illinois Center for Clinical Research, Chicago, Illinois, United States</location>
      <location>Southwest Gastroenterology, Oak Lawn, Illinois, United States</location>
      <location>Elkhart Clinic, LLC/Indiana Medical Research, LLC, Elkhart, Indiana, United States</location>
      <location>MediSphere Medical Research Center, LLC, Evansville, Indiana, United States</location>
      <location>Mercy Gastroenterology Clinic, Clive, Iowa, United States</location>
      <location>Gastrointestinal Clinic of Quad Cities, Davenport, Iowa, United States</location>
      <location>Heartland Research Associates, LLC, Newton, Kansas, United States</location>
      <location>Heartland Research Associates, LLC, Wichita, Kansas, United States</location>
      <location>Graves-Gilbert Clinic, Bowling Green, Kentucky, United States</location>
      <location>Tri-State Gastroenterology Associates, PSC, Crestview Hills, Kentucky, United States</location>
      <location>Hometown Urgent Care and Research, Hebron, Kentucky, United States</location>
      <location>The Research Group of Lexington, LLC, Lexington, Kentucky, United States</location>
      <location>University of Louisville Medical-Dental Complex, Louisville, Kentucky, United States</location>
      <location>Tover Health Systems Center for Clinical Research, Madisonville, Kentucky, United States</location>
      <location>Investigative Clinical Research, Annapolis, Maryland, United States</location>
      <location>Meritus Center for Clinical Resarch, Hagerstown, Maryland, United States</location>
      <location>Spectrum Clinical Research Inc., Towson, Maryland, United States</location>
      <location>Commonwealth Clinical Studies, Brockton, Massachusetts, United States</location>
      <location>NECCR Internal Medicine and Cardiology Associates LLC, Fall River, Massachusetts, United States</location>
      <location>ActivMed Practices and Research, Haverhill, Massachusetts, United States</location>
      <location>University of Michigan Health System, Ann Arbor, Michigan, United States</location>
      <location>Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States</location>
      <location>Saginaw Valley Medical Research Group, LLC, Saginaw, Michigan, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Gastrointestinal Accociates, PA, Jackson, Mississippi, United States</location>
      <location>Digestive Research Specialist, Tupelo, Mississippi, United States</location>
      <location>Midwest Center for Clinical Research, Lees Summit, Missouri, United States</location>
      <location>Center for Digestive and Liver Diseases, Inc., Mexico, Missouri, United States</location>
      <location>St. Louis Center for Clinical Research, St. Louis, Missouri, United States</location>
      <location>Montana Health Research Institute, Inc., Billings, Montana, United States</location>
      <location>Dr. Meera Dewan PC, Omaha, Nebraska, United States</location>
      <location>Anderson &amp; Collins Clinical Research, Edison, New Jersey, United States</location>
      <location>South Jersey Gastroenterology. P.A., Marlton, New Jersey, United States</location>
      <location>Atlantic Research Affiliates, Morristown, New Jersey, United States</location>
      <location>Life Medi-Research, Brooklyn, New York, United States</location>
      <location>Long Island Clinical Research Associates, LLP, Great Neck, New York, United States</location>
      <location>Long Island Gastrointestinal Research Group, Great Neck, New York, United States</location>
      <location>Winthrop University Hospital Clinical Trials Center, Mineola, New York, United States</location>
      <location>Research Associates of New York, New York,, New York, United States</location>
      <location>Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, United States</location>
      <location>Gastrointestinal Research Associates, LLC, Setauket, New York, United States</location>
      <location>The UNC Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, United States</location>
      <location>PMG Research of Charlotte, LLC, Charlotte, North Carolina, United States</location>
      <location>LeBauer Research Associates, P.A., Greensboro, North Carolina, United States</location>
      <location>PMG Research of Hickory, LLC, Hickory, North Carolina, United States</location>
      <location>Peters Medical Research, High Point, North Carolina, United States</location>
      <location>Kinston Medical Specialist, P.A., Kinston, North Carolina, United States</location>
      <location>Wake Research Associates, Raleigh, North Carolina, United States</location>
      <location>Trial Management Associates LLC, Wilmington, North Carolina, United States</location>
      <location>PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States</location>
      <location>Lillestol Research LLC, Fargo, North Dakota, United States</location>
      <location>Akron Gastroenterology Associates, Akron, Ohio, United States</location>
      <location>Gastroenterology Research Consultants of Greater Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Hometown Urgent Care, Columbus, Ohio, United States</location>
      <location>Hometown Urgent Care, Dayton, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Groveport, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Miamisburg, Ohio, United States</location>
      <location>Physicians Research, Inc, Zanesville, Ohio, United States</location>
      <location>Journey Clinical Research, Duncan, Oklahoma, United States</location>
      <location>Central Sooner Research, Norman, Oklahoma, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Lynn Health Science Institute, Oklahoma City, Oklahoma, United States</location>
      <location>Sooner Clinical Research, Oklahoma City, Oklahoma, United States</location>
      <location>Northwest Gastroenterology Clinic, LLC, Portland, Oregon, United States</location>
      <location>Safe Harbor Clinical Research, East Providence, Rhode Island, United States</location>
      <location>Southeast Medical Research, Charleston, South Carolina, United States</location>
      <location>SC Clinical Research, LLC, Columbia, South Carolina, United States</location>
      <location>Coastal Carolina Research Center in Goose Creek, Goose Creek, South Carolina, United States</location>
      <location>Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States</location>
      <location>Midwest Medical Care, Sioux Falls, South Dakota, United States</location>
      <location>Gastroenterology Associates, Bristol, Tennessee, United States</location>
      <location>ClinSearch, LLC, Chattanooga, Tennessee, United States</location>
      <location>Alpha Clinical Research, Clarksville, Tennessee, United States</location>
      <location>Memphis Gastroenterology Group, Germantown, Tennessee, United States</location>
      <location>Associates in Gastroenterology, Hermitage, Tennessee, United States</location>
      <location>Gastroenterology Associates Clinical Research, Kingsport, Tennessee, United States</location>
      <location>Columbia Medical Group -The First Clinic, Inc., Nashville, Tennessee, United States</location>
      <location>Dial Research Associates, INC, Nashville, Tennessee, United States</location>
      <location>TN Medical Research, Spring Hill, Tennessee, United States</location>
      <location>Research Across America/ Family Medicine Associates of Texas, Carrollton, Texas, United States</location>
      <location>Corsicana Medical Research, PLLC, Corsicana, Texas, United States</location>
      <location>Texas University Health Sciences Center, El Paso, Texas, United States</location>
      <location>Gastroenterology Consultants, P.A., Houston, Texas, United States</location>
      <location>Houston S. Endoscopy and Research Center, Houston, Texas, United States</location>
      <location>Pioneer Research Solutions, Inc, Houston, Texas, United States</location>
      <location>Digestive Health Associates of Texas, Plano, Texas, United States</location>
      <location>Sun Research Institute, San Antonio, Texas, United States</location>
      <location>Clinical Trials of Texas, San Antonio, Texas, United States</location>
      <location>Advanced Research Institute, Clinton, Utah, United States</location>
      <location>Advanced Research Institute, Logan, Utah, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>Advanced Research Institute, Sandy, Utah, United States</location>
      <location>Gastroenterology, Ltd., Virginia Beach, Virginia, United States</location>
      <location>Wisconsin Center for Advanced Research, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01100684</url>
  </study>
  <study rank="117">
    <nct_id>NCT02179905</nct_id>
    <title>Brain Imaging, Heart Rate Variability and Serum Fatty Acid in Subjects With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The relationship between brain structure, heart rate variability and fatty acid of the irritable bowel syndrome patients.</outcome_measure>
      <outcome_measure>The relationship between thickness of brain cortex and the symptoms of irritable bowel syndrome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shin Kong Wu Ho-Su Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>20 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
    </study_designs>
    <other_ids>
      <other_id>SKH-8302-102-DR-14</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <completion_date>September 2013</completion_date>
    <study_first_posted>July 2, 2014</study_first_posted>
    <last_update_posted>July 2, 2014</last_update_posted>
    <locations>
      <location>Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02179905</url>
  </study>
  <study rank="118">
    <nct_id>NCT00779493</nct_id>
    <title>Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial</title>
    <acronym>CuTIBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">curcumin</intervention>
      <intervention type="Dietary Supplement">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Disease severity will be assessed using the irritable bowel severity score (IBSS) which utilizes a visual analog scale (VAS) (28). The primary outcome will be defined as at least 50% reduction in IBSS.</outcome_measure>
      <outcome_measure>Changes in bowel movement frequency, consistency, frequency of as-needed medication use and bloating as measured by the VAS, and improvement SF-36 Quality of Life survey.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kaiser Permanente</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>4893</other_id>
    </other_ids>
    <start_date>November 2008</start_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <completion_date>June 2009</completion_date>
    <study_first_posted>October 24, 2008</study_first_posted>
    <last_update_posted>March 11, 2015</last_update_posted>
    <locations>
      <location>Kaiser Permanente, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00779493</url>
  </study>
  <study rank="119">
    <nct_id>NCT02450370</nct_id>
    <title>Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Low FODMAP diet</intervention>
      <intervention type="Behavioral">Conventional IBS diet group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in IBS symptoms after adopting the low FOMDAP diet versus conventional IBS diet using IBS Global Improvement Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hong Kong Sanatorium &amp; Hospital</lead_sponsor>
      <collaborator>The Hong Kong Society of Gastrointestinal Motility</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>103</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>REC-201405</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>November 20, 2017</primary_completion_date>
    <completion_date>November 20, 2017</completion_date>
    <study_first_posted>May 21, 2015</study_first_posted>
    <last_update_posted>June 25, 2018</last_update_posted>
    <locations>
      <location>Dietetic Service, HKSH, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02450370</url>
  </study>
  <study rank="120">
    <nct_id>NCT02559817</nct_id>
    <title>A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation</title>
    <acronym>LIN-MD-63</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide Dose A</intervention>
      <intervention type="Drug">Linaclotide Dose B</intervention>
      <intervention type="Drug">Linaclotide Dose C</intervention>
      <intervention type="Drug">Linaclotide Approved Adult Dose</intervention>
      <intervention type="Drug">Matching Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in 4-week overall spontaneous bowel movement (SBM) frequency rate (SBMs/week) during the Treatment Period</outcome_measure>
      <outcome_measure>Change from baseline in 4-week abdominal pain daytime symptoms based on evening assessment of abdominal pain symptoms</outcome_measure>
      <outcome_measure>Change from baseline in 4-week stool consistency</outcome_measure>
      <outcome_measure>Change from baseline in 4-week severity of straining</outcome_measure>
      <outcome_measure>Change from baseline in 4-week abdominal bloating daytime symptoms based on evening assessment</outcome_measure>
      <outcome_measure>Change from baseline in 4-week overall complete spontaneous bowel movement (CSBM) frequency rate (CSBMs per Week)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Forest Laboratories</lead_sponsor>
      <collaborator>Ironwood Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIN-MD-63</other_id>
    </other_ids>
    <start_date>November 1, 2015</start_date>
    <primary_completion_date>October 18, 2020</primary_completion_date>
    <completion_date>October 18, 2020</completion_date>
    <study_first_posted>September 24, 2015</study_first_posted>
    <last_update_posted>January 24, 2019</last_update_posted>
    <locations>
      <location>HealthStar Research, LLC, Hot Springs, Arkansas, United States</location>
      <location>Applied Research Center of Arkansas, Little Rock, Arkansas, United States</location>
      <location>Advanced Research Center - Site 069, Anaheim, California, United States</location>
      <location>Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States</location>
      <location>WCCT Global, LLC, Costa Mesa, California, United States</location>
      <location>Ark Clinical Research, Long Beach, California, United States</location>
      <location>ACTCA, Inc, Los Angeles, California, United States</location>
      <location>Children's Hospital Los Angeles, Los Angeles, California, United States</location>
      <location>Center for Clinical Trials, LLC, Paramount, California, United States</location>
      <location>UCSD Rady Children's Hospital, San Diego, California, United States</location>
      <location>University of California at San Francisco, San Francisco, California, United States</location>
      <location>Ventura Clinical Trials, Ventura, California, United States</location>
      <location>Colorado Springs Health Partners, HCP-Clinical Research, LLC, Colorado Springs, Colorado, United States</location>
      <location>Homestead Research Institute, Homestead, Florida, United States</location>
      <location>RM Medical Research, Homestead, Florida, United States</location>
      <location>Advanced Medical Research Center, Miami, Florida, United States</location>
      <location>Children's Center for Digestive Health Care LLC, Atlanta, Georgia, United States</location>
      <location>Sleepcare Clinical Research Institute, Stockbridge, Georgia, United States</location>
      <location>Methodist Medical Center, Peoria, Illinois, United States</location>
      <location>Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States</location>
      <location>Heartland Research Associates, LLC, Wichita, Kansas, United States</location>
      <location>Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States</location>
      <location>Willis-Knighton Physician Network, Shreveport, Louisiana, United States</location>
      <location>University of Maryland Children's Hospital, Baltimore, Maryland, United States</location>
      <location>Certified Research Consultants Virgo/Carter Pediatrics, Silver Spring, Maryland, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>Boston Children's Hospital, Boston, Massachusetts, United States</location>
      <location>University Of Minnesota, Minneapolis, Minnesota, United States</location>
      <location>GI Associates and Endoscopy Center, Jackson, Mississippi, United States</location>
      <location>Children's Mercy Hospital, Kansas City, Missouri, United States</location>
      <location>Boys Town National Research Hospital, Boys Town, Nebraska, United States</location>
      <location>Midwest Children Health Research Institute, Lincoln, Nebraska, United States</location>
      <location>Midwest Children Health Research Institute, Lincoln, Nebraska, United States</location>
      <location>Goryeb Children's Hospital, Morristown, New Jersey, United States</location>
      <location>New Jersey Medical School, Rutgers University, Newark, New Jersey, United States</location>
      <location>Novel Research of New York, LLC, Bronx, New York, United States</location>
      <location>Columbia University Medical Center and Morgan Stanley Children's Hospital of New York, New York, New York, United States</location>
      <location>Asheboro Research Associates - Site 022, Asheboro, North Carolina, United States</location>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
      <location>Capital Pediatrics and Adolescent Center PLLC, Raleigh, North Carolina, United States</location>
      <location>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States</location>
      <location>Ohio Pediatric Research Association, Dayton, Ohio, United States</location>
      <location>IPS Research Company, Oklahoma City, Oklahoma, United States</location>
      <location>St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States</location>
      <location>Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States</location>
      <location>Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States</location>
      <location>Frontier Clinical Research, LLC, Scottdale, Pennsylvania, United States</location>
      <location>Montgomery Medical Inc., Smithfield, Pennsylvania, United States</location>
      <location>Rhode Island Hospital, Providence, Rhode Island, United States</location>
      <location>Coastal Pediatric Research, Charleston, South Carolina, United States</location>
      <location>Coastal Pediatrics Associates, Mount Pleasant, South Carolina, United States</location>
      <location>Cook Children's Medical Center, Fort Worth, Texas, United States</location>
      <location>Texas Children's Hospital/Baylor College Medicine, Houston, Texas, United States</location>
      <location>Houston Clinical Research Associates, Houston, Texas, United States</location>
      <location>Sun Research Institute, San Antonio, Texas, United States</location>
      <location>ClinPoint Trials, Waxahachie, Texas, United States</location>
      <location>Pediatric Specialists of Virginia, Fairfax, Virginia, United States</location>
      <location>Children's Hospital of The King's Daughters, Norfolk, Virginia, United States</location>
      <location>Virginia Tech Carilion School of Medicine Pediatric Gastroenterology, Roanoke, Virginia, United States</location>
      <location>Seattle Children's Hospital, Seattle, Washington, United States</location>
      <location>MultiCare Institute for Research and Innovation, Tacoma, Washington, United States</location>
      <location>Aurora Health Care, Aurora Medical Center in Summit, Summit, Wisconsin, United States</location>
      <location>Stollery Children's Hospital, Edmonton, Alberta, Canada</location>
      <location>Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada</location>
      <location>Children's Hospital of Western Ontario, London, Ontario, Canada</location>
      <location>Physician's Clinical Research Inc., Vaughan, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02559817</url>
  </study>
  <study rank="121">
    <nct_id>NCT02544152</nct_id>
    <title>Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall abdominal pain response</outcome_measure>
      <outcome_measure>Overall assessment of the proportion of subjects reporting ≥50% reduction from baseline in percentage of days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7).</outcome_measure>
      <outcome_measure>Weekly assessment of the proportion of subjects reporting ≥50% reduction from baseline in percentage of days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7).</outcome_measure>
      <outcome_measure>Monthly assessment of the proportion of subjects reporting ≥50% reduction from baseline in percentage of days with extreme stool consistency (Bristol Stool Form Scale ratings of 1, 2, 6 or 7).</outcome_measure>
      <outcome_measure>Weekly assessment of abdominal pain response.</outcome_measure>
      <outcome_measure>Monthly assessment of abdominal pain response.</outcome_measure>
      <outcome_measure>Overall assessment of stool consistency response.</outcome_measure>
      <outcome_measure>Weekly assessment of stool consistency response.</outcome_measure>
      <outcome_measure>Monthly assessment of stool consistency response.</outcome_measure>
      <outcome_measure>Overall mean change from baseline in abdominal pain</outcome_measure>
      <outcome_measure>Overall mean change from baseline in abdominal bloating</outcome_measure>
      <outcome_measure>Overall mean change from baseline in straining</outcome_measure>
      <outcome_measure>Overall mean change from baseline in stool consistency</outcome_measure>
      <outcome_measure>Overall mean change from baseline in improvement of most bothersome IBS symptom</outcome_measure>
      <outcome_measure>Weekly mean change from baseline in abdominal pain</outcome_measure>
      <outcome_measure>Weekly mean change from baseline in abdominal bloating</outcome_measure>
      <outcome_measure>Weekly mean change from baseline in straining</outcome_measure>
      <outcome_measure>Weekly mean change from baseline stool consistency</outcome_measure>
      <outcome_measure>Weekly mean change from baseline in improvement of most bothersome IBS symptom</outcome_measure>
      <outcome_measure>Monthly mean change from baseline in abdominal pain</outcome_measure>
      <outcome_measure>Monthly mean change from baseline in abdominal bloating</outcome_measure>
      <outcome_measure>Monthly mean change from baseline in straining</outcome_measure>
      <outcome_measure>Monthly mean change from baseline in stool consistency</outcome_measure>
      <outcome_measure>Monthly mean change from baseline in improvement of most bothersome IBS symptom</outcome_measure>
      <outcome_measure>Weekly global adequate relief questionnaire</outcome_measure>
      <outcome_measure>Overall health-related quality of life (IBS-QoL)</outcome_measure>
      <outcome_measure>Overall health-related status (EQ-5D)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sucampo AG</lead_sponsor>
      <collaborator>Sucampo Pharma Americas, LLC</collaborator>
      <collaborator>Takeda</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>71</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SCMP-0211-201</other_id>
    </other_ids>
    <start_date>February 2015</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>September 9, 2015</study_first_posted>
    <last_update_posted>February 26, 2018</last_update_posted>
    <locations>
      <location>E Squared Research, Inc., Huntsville, Alabama, United States</location>
      <location>Arkansas Gastroenterology, North Little Rock, Arkansas, United States</location>
      <location>GW Research Inc., Chula Vista, California, United States</location>
      <location>Inland Empire Liver Foundation, Rialto, California, United States</location>
      <location>Prestige Clinical Research Center, Miami, Florida, United States</location>
      <location>Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States</location>
      <location>Meritus Center for Clinical Research, Hagerstown, Maryland, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>PMG Research of Charlotte, Charlotte, North Carolina, United States</location>
      <location>PMG Research of Charlotte, Concord, North Carolina, United States</location>
      <location>Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States</location>
      <location>Wake Research Associates, LLC, Raleigh, North Carolina, United States</location>
      <location>Clinical Research Solutions, Jackson, Tennessee, United States</location>
      <location>Houston Endoscopy Research Center, Houston, Texas, United States</location>
      <location>Wellness Clinical Research Associates, McKinney, Texas, United States</location>
      <location>Advanced Clinical Research Associates, Plano, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02544152</url>
  </study>
  <study rank="122">
    <nct_id>NCT02391220</nct_id>
    <title>Assessment of the Symbiotic Fermented Milk in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">LCA symbiotic fermented milk</intervention>
      <intervention type="Other">heat-treated fermented milk</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Improvements in IBS symptoms (bloating, abdominal pain, satisfaction with bowel movement, stool frequency and stool consistency)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Clinres Farmacija d.o.o.</lead_sponsor>
      <collaborator>Competence Centre for Biotechnology Research and Innovation</collaborator>
      <collaborator>European Regional Development Fund</collaborator>
      <collaborator>Ministry of Education, Science and Sport of the Republic of Slovenia</collaborator>
      <collaborator>Institute of Dairy Science and probiotics, Biotechnical Faculty, UL</collaborator>
      <collaborator>Dairy Celeia</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>76</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KC_BRIN</other_id>
    </other_ids>
    <start_date>February 2012</start_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>March 18, 2015</study_first_posted>
    <last_update_posted>July 28, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02391220</url>
  </study>
  <study rank="123">
    <nct_id>NCT03977155</nct_id>
    <title>Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BOS-589</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>24-hour worst abdominal pain scores (WAP) at Day 29 compared to baseline (averaged over the week prior to each respective time point)</outcome_measure>
      <outcome_measure>Number of participants with any adverse event and any serious adverse event</outcome_measure>
      <outcome_measure>Number of participants who discontinued the study because of an adverse event</outcome_measure>
      <outcome_measure>Number of participants with any treatment-related severe adverse event</outcome_measure>
      <outcome_measure>Change in stool consistency, measured by the daily Bristol Stool Form Score (BSFS) at Day 29 compared to baseline (averaged over the week prior to each respective time point)</outcome_measure>
      <outcome_measure>Change in stool frequency, measured by the total number of spontaneous bowel movements in 24 hours at Day 29 compared to baseline (averaged over the week prior to each respective time point)</outcome_measure>
      <outcome_measure>Change in the Irritable Bowel Syndrome Severity Score (IBS-SS) at Day 29 compared to baseline</outcome_measure>
      <outcome_measure>Change in the IBS Global Scale (IBS-GS) at Day 29 compared to baseline (averaged over the week prior to each respective time point)</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to Cmax (Tmax)</outcome_measure>
      <outcome_measure>Minimum plasma concentration (Cmin)</outcome_measure>
      <outcome_measure>Area under the concentration versus time curve (AUC) from time zero to 4 hours post dose (AUC0-4)</outcome_measure>
      <outcome_measure>AUC from time zero to the last quantifiable concentration (AUC0-t)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>132</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BOS-589-201</other_id>
    </other_ids>
    <start_date>June 4, 2019</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>January 2020</completion_date>
    <study_first_posted>June 6, 2019</study_first_posted>
    <last_update_posted>June 6, 2019</last_update_posted>
    <locations>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Synexus Clinical Research US, Inc. - East Valley Family Physicians, PLC, Chandler, Arizona, United States</location>
      <location>Synexus Clinical Research US, Inc. - Phoenix Southeast, Chandler, Arizona, United States</location>
      <location>Synexus Clinical Research US, Inc., Glendale, Arizona, United States</location>
      <location>Synexus Clinical Research US, Inc. - Desert Clinical Research, LLC, Mesa, Arizona, United States</location>
      <location>Synexus Clinical Research US, Inc. - Central Arizona Medical Associates, PC, Mesa, Arizona, United States</location>
      <location>Elite Clinical Studies, Phoenix, Arizona, United States</location>
      <location>Hope Research Institute LLC, Phoenix, Arizona, United States</location>
      <location>Synexus Clinical Research US, Inc., Carlsbad, California, United States</location>
      <location>Paragon Rx Clinical, Inc., Garden Grove, California, United States</location>
      <location>eStudySite, La Mesa, California, United States</location>
      <location>Grossmont Center For Clinical Research, La Mesa, California, United States</location>
      <location>Clinical Trials Research, Sacramento, California, United States</location>
      <location>Millennium ClinicalTrials, Thousand Oaks, California, United States</location>
      <location>Advanced Rx Clinical Research, Westminster, California, United States</location>
      <location>Mayo Clinic, Jacksonville, Florida, United States</location>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>West Michigan Clinical Research, Wyoming, Michigan, United States</location>
      <location>Sundance Clinical Research, Saint Louis, Missouri, United States</location>
      <location>NY Scientific, Brooklyn, New York, United States</location>
      <location>Peters Medical Research, LLC, High Point, North Carolina, United States</location>
      <location>Synexus Clinical Research US, Inc., Akron, Ohio, United States</location>
      <location>Synexus Clinical Research US, Inc., Columbus, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Dayton, Ohio, United States</location>
      <location>Synexus Clinical Research US, Inc., Anderson, South Carolina, United States</location>
      <location>Synexus Clinical Research US, Inc., Greer, South Carolina, United States</location>
      <location>WR-ClinSearch, LLC, Chattanooga, Tennessee, United States</location>
      <location>New Phase Research &amp; Development, Knoxville, Tennessee, United States</location>
      <location>L12 Clinical Research, Dallas, Texas, United States</location>
      <location>Synexus Clinical Research US, Inc., Dallas, Texas, United States</location>
      <location>Southwest Clinical Trials, Houston, Texas, United States</location>
      <location>Quality Research Inc., San Antonio, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03977155</url>
  </study>
  <study rank="124">
    <nct_id>NCT03964103</nct_id>
    <title>qQ-lab Daily-IBS for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">gQ-lab daily</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom questionnaire survey (VAS score)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IlDong Pharmaceutical Co Ltd</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>qQ-lab daily-IBS</other_id>
    </other_ids>
    <start_date>October 4, 2016</start_date>
    <primary_completion_date>November 8, 2017</primary_completion_date>
    <completion_date>January 22, 2018</completion_date>
    <study_first_posted>May 27, 2019</study_first_posted>
    <last_update_posted>June 4, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03964103</url>
  </study>
  <study rank="125">
    <nct_id>NCT00543478</nct_id>
    <title>Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome</title>
    <acronym>SBIBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Saccharomyces boulardii</intervention>
      <intervention type="Drug">Methyl cellulose powder (low viscosity)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Any Improvement in symptoms of number of bowel habits, urgency, straining,sense of incomplete evacuation, stool form (evaluated by Bristol stool form scale, abdominal pain and bloating/flatulence</outcome_measure>
      <outcome_measure>Improvement in quality of life in diarrhea dominant IBS by validated IBS-QOL questionnaire.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aga Khan University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SB</other_id>
      <other_id>URC 071006MED</other_id>
    </other_ids>
    <start_date>October 2007</start_date>
    <completion_date>July 2008</completion_date>
    <study_first_posted>October 15, 2007</study_first_posted>
    <last_update_posted>October 15, 2007</last_update_posted>
    <locations>
      <location>Gastroenterology outpatients clinics,Aga Khan University hospital, Karachi., Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00543478</url>
  </study>
  <study rank="126">
    <nct_id>NCT01886781</nct_id>
    <title>Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lactobacillus plantarum 299v</intervention>
      <intervention type="Drug">Placebo comparator</intervention>
      <intervention type="Other">Run in period</intervention>
      <intervention type="Other">Wash - out period</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>A Change in Abdominal Pain Severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Stellenbosch</lead_sponsor>
      <collaborator>Nestlè Nutrition Institute Africa</collaborator>
      <collaborator>National Research Foundation (NRF) (RSA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>N10-08-270</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>June 2013</completion_date>
    <study_first_posted>June 26, 2013</study_first_posted>
    <results_first_posted>September 29, 2014</results_first_posted>
    <last_update_posted>September 29, 2014</last_update_posted>
    <locations>
      <location>Netcare Greenacres Hospital, Port Elizabeth, Eastern Cape, South Africa</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01886781</url>
  </study>
  <study rank="127">
    <nct_id>NCT01243853</nct_id>
    <title>Alpha-galactosidase Enzyme and Irritable Bowel Syndrome</title>
    <acronym>ALFA</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Alpha-galactosidase</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS symptom severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Verman Oy Ab</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>VER001</other_id>
    </other_ids>
    <start_date>December 2010</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>February 2012</completion_date>
    <study_first_posted>November 19, 2010</study_first_posted>
    <last_update_posted>January 17, 2011</last_update_posted>
    <locations>
      <location>Gastrolääkärit Oy, Helsinki, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01243853</url>
  </study>
  <study rank="128">
    <nct_id>NCT01613456</nct_id>
    <title>Effect of Saccharomyces Cerevisiae on the Symptoms of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Saccharomyces cerevisiae CNCM I-3856</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in discomfort score,obtained by Daily Likert Scale averaged by week</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lesaffre International</lead_sponsor>
      <collaborator>BioFortis</collaborator>
      <collaborator>University of Nottingham</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>364</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEC11010</other_id>
      <other_id>ID RCB: 2011-A00915-36</other_id>
    </other_ids>
    <start_date>December 2011</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>June 2013</completion_date>
    <study_first_posted>June 7, 2012</study_first_posted>
    <last_update_posted>May 14, 2015</last_update_posted>
    <locations>
      <location>Biofortis, Saint Herblain, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01613456</url>
  </study>
  <study rank="129">
    <nct_id>NCT01178593</nct_id>
    <title>Group Hypnosis for Irritable Bowel Syndrome</title>
    <acronym>IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Gut-focused hypnotherapy in group sessions</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome - Impact Scale, IBS-IS</outcome_measure>
      <outcome_measure>Short-Form 36 (SF-36)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FA716E0126</other_id>
    </other_ids>
    <start_date>April 2008</start_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>August 10, 2010</study_first_posted>
    <last_update_posted>December 13, 2011</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01178593</url>
  </study>
  <study rank="130">
    <nct_id>NCT01815164</nct_id>
    <title>Effect of Hypnotherapy and Educational Intervention in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Hypnotherapy</intervention>
      <intervention type="Behavioral">Educational intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome Symptom Severity Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Linkoeping</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>20 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>M71-09</other_id>
    </other_ids>
    <start_date>August 2007</start_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <completion_date>September 2011</completion_date>
    <study_first_posted>March 20, 2013</study_first_posted>
    <last_update_posted>March 21, 2013</last_update_posted>
    <locations>
      <location>University Hospital, Linköping, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01815164</url>
  </study>
  <study rank="131">
    <nct_id>NCT03948854</nct_id>
    <title>Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Registered dietitian</intervention>
      <intervention type="Other">On-line video program</intervention>
      <intervention type="Other">Printed handout</intervention>
      <intervention type="Other">Dietitian-led group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in IBS symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-011391</other_id>
    </other_ids>
    <start_date>May 22, 2019</start_date>
    <primary_completion_date>May 22, 2020</primary_completion_date>
    <completion_date>May 22, 2020</completion_date>
    <study_first_posted>May 14, 2019</study_first_posted>
    <last_update_posted>May 14, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic in Florida, Jacksonville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03948854</url>
  </study>
  <study rank="132">
    <nct_id>NCT01829932</nct_id>
    <title>The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Factor Altered Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Area under the Curve of Hydrogen Gas on Lactulose Breath Test</outcome_measure>
      <outcome_measure>Change in Area Under the Curve on Lactulose Breath Test from Baseline</outcome_measure>
      <outcome_measure>Change in IBS Symptom Severity Score from Baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DMED-1443-11</other_id>
    </other_ids>
    <start_date>April 2013</start_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>April 11, 2013</study_first_posted>
    <last_update_posted>October 14, 2015</last_update_posted>
    <locations>
      <location>Hotel Dieu Hospital, Kingston, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01829932</url>
  </study>
  <study rank="133">
    <nct_id>NCT00461526</nct_id>
    <title>Diarrhea Predominant Irritable Bowel Syndrome in Females</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">crofelemer</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess the safety of TRN-002 when administered twice daily for 12 consecutive weeks.</outcome_measure>
      <outcome_measure>To assess the efficacy of TRN-002 when administered twice daily for 12 consecutive weeks.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TRN-002-202</other_id>
    </other_ids>
    <start_date>October 2006</start_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <completion_date>December 2007</completion_date>
    <study_first_posted>April 18, 2007</study_first_posted>
    <last_update_posted>November 22, 2010</last_update_posted>
    <locations>
      <location>Clinical Research Associates, LLC, Huntsville, Alabama, United States</location>
      <location>Radiant Research, Chandler, Arizona, United States</location>
      <location>Genova Clinical Research, Tucson, Arizona, United States</location>
      <location>Advanced Clinical Research Institute, Anaheim, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>Advanced Clinical Research Institute, Orange, California, United States</location>
      <location>Medical Associates Research Group, San Diego, California, United States</location>
      <location>Boulder Medical Center, PC, Boulder, Colorado, United States</location>
      <location>Rocky Mountain Gastroenterology Associates, Thornton, Colorado, United States</location>
      <location>Litchfield County Gastroenterology Associates, LLC, Torrington, Connecticut, United States</location>
      <location>Washington Gastroenterology, PC, Washington, District of Columbia, United States</location>
      <location>Consultants of Clinical Research of South Florida, Boynton Beach, Florida, United States</location>
      <location>University Clinical Research - DeLand, DeLand, Florida, United States</location>
      <location>Stedman Clinical Trials, Tampa, Florida, United States</location>
      <location>Mount Vernon Clinical Research, Atlanta, Georgia, United States</location>
      <location>Clinical Research Atlanta, Stockbridge, Georgia, United States</location>
      <location>Digestive and Liver Disease Consultants, PC, Clive, Iowa, United States</location>
      <location>Trover Center for Clinical Studies, Madisonville, Kentucky, United States</location>
      <location>Maryland Digestive Disease Research, Laurel, Maryland, United States</location>
      <location>Gastroenterology Associates, Jackson, Mississippi, United States</location>
      <location>Toby Village Office Park, Pittsford, New York, United States</location>
      <location>LeBauer Research Associates, PA, Greensboro, North Carolina, United States</location>
      <location>Vital re:Search, Greensboro, North Carolina, United States</location>
      <location>Bethany Medical Center, High Point, North Carolina, United States</location>
      <location>Hanover Medical Specialist, PA, Wilmington, North Carolina, United States</location>
      <location>Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States</location>
      <location>Akron Gastroenterology Associates, Inc., Akron, Ohio, United States</location>
      <location>Research Solutions Corp., Cincinnati, Ohio, United States</location>
      <location>Gastrointestinal &amp; Liver Disease Consultants, Dayton, Ohio, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Sooner Clinical Research, Oklahoma City, Oklahoma, United States</location>
      <location>Grand View Medical Research, Sellersville, Pennsylvania, United States</location>
      <location>Anderson Gastroenterology Associates, LLC, Anderson, South Carolina, United States</location>
      <location>ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Gastroenterology Center of the MidSouth, PC, Germantown, Tennessee, United States</location>
      <location>Memphis Gastroenterology Group, Germantown, Tennessee, United States</location>
      <location>The Jackson Clinic, Jackson, Tennessee, United States</location>
      <location>Gastroenterology Associates, Kingsport, Tennessee, United States</location>
      <location>Austin Gastroenterology, PA, Austin, Texas, United States</location>
      <location>Trinity Clinic - Corsicana, Corsicana, Texas, United States</location>
      <location>Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States</location>
      <location>Vantage Clinical Research Group, Olympia, Washington, United States</location>
      <location>Northside Internal Medicine, Spokane, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00461526</url>
  </study>
  <study rank="134">
    <nct_id>NCT01192672</nct_id>
    <title>Use of Expressive Writing in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Expressive Writing</intervention>
      <intervention type="Behavioral">Control Writing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS-Specific Quality of Life (IBS-QOL)</outcome_measure>
      <outcome_measure>CT3</outcome_measure>
      <outcome_measure>Health care Utilization (HCU)</outcome_measure>
      <outcome_measure>IBSSS</outcome_measure>
      <outcome_measure>Demographics (DEM-MED)</outcome_measure>
      <outcome_measure>Cognitive Scale for Functional Bowel Disorders (CGFBD)</outcome_measure>
      <outcome_measure>Writing Evaluation Questionnaire (WEQ)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston University</lead_sponsor>
      <collaborator>Takeda Pharmaceuticals North America, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>4764-8</other_id>
    </other_ids>
    <start_date>September 2008</start_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <completion_date>November 2010</completion_date>
    <study_first_posted>September 1, 2010</study_first_posted>
    <last_update_posted>March 15, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01192672</url>
  </study>
  <study rank="135">
    <nct_id>NCT01940848</nct_id>
    <title>Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">STW5 (Iberogast, BAY98-7411)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of responders with decrease in pain intensity compared with baseline for at least 14 single days within 4 weeks of treatment</outcome_measure>
      <outcome_measure>Number of responders with decrease in pain intensity compared with baseline for at least 7 single days within first 2 weeks of treatment</outcome_measure>
      <outcome_measure>Score on IBS-QOL (Irritable Bowel Syndrome - Quality of Life Measure) scale</outcome_measure>
      <outcome_measure>Stool consistency (IBS-D): Decrease in weekly average of &gt;1 in terms of BSS (Bristol Stool Form Scale)</outcome_measure>
      <outcome_measure>Stool frequency (IBS-C): Increase of 1 or more complete spontaneous bowel movements (CSBM) per week compared with Baseline</outcome_measure>
      <outcome_measure>Numbers of participants with adverse events (AEs)</outcome_measure>
      <outcome_measure>Vital signs</outcome_measure>
      <outcome_measure>Laboratory parameters</outcome_measure>
      <outcome_measure>Global assessment of tolerability on a 5-point Likert scale by Investigator and patient</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bayer</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>243</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>17063</other_id>
      <other_id>STW5/212-D-011-III-V</other_id>
      <other_id>2011-002613-10</other_id>
    </other_ids>
    <start_date>October 11, 2013</start_date>
    <primary_completion_date>October 25, 2017</primary_completion_date>
    <completion_date>October 25, 2017</completion_date>
    <study_first_posted>September 12, 2013</study_first_posted>
    <last_update_posted>October 29, 2018</last_update_posted>
    <locations>
      <location>Ludwigsburg, Baden-Württemberg, Germany</location>
      <location>Mannheim, Baden-Württemberg, Germany</location>
      <location>Sinzheim, Baden-Württemberg, Germany</location>
      <location>Potsdam, Brandenburg, Germany</location>
      <location>Lollar, Hessen, Germany</location>
      <location>Wiesbaden, Hessen, Germany</location>
      <location>Wardenburg, Niedersachsen, Germany</location>
      <location>Winsen, Niedersachsen, Germany</location>
      <location>Essen, Nordrhein-Westfalen, Germany</location>
      <location>Hagen, Nordrhein-Westfalen, Germany</location>
      <location>Löhne, Nordrhein-Westfalen, Germany</location>
      <location>Marl, Nordrhein-Westfalen, Germany</location>
      <location>Ludwigshafen, Rheinland-Pfalz, Germany</location>
      <location>Halle, Sachsen-Anhalt, Germany</location>
      <location>Reinfeld, Schleswig-Holstein, Germany</location>
      <location>Apolda, Thüringen, Germany</location>
      <location>Blankenhain, Thüringen, Germany</location>
      <location>Berlin, Germany</location>
      <location>Berlin, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01940848</url>
  </study>
  <study rank="136">
    <nct_id>NCT00945334</nct_id>
    <title>Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome</title>
    <acronym>C-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Neomycin</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Rifaximin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of Constipation in Each Arm at Week 1 After Completion of Therapy</outcome_measure>
      <outcome_measure>Change in Methane From Baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mark Pimentel, MD</lead_sponsor>
      <collaborator>Bausch Health Americas, Inc.</collaborator>
      <collaborator>Cedars-Sinai Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>18709</other_id>
    </other_ids>
    <start_date>August 2009</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>June 2013</completion_date>
    <study_first_posted>July 24, 2009</study_first_posted>
    <results_first_posted>August 10, 2015</results_first_posted>
    <last_update_posted>August 10, 2015</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
      <location>Georgia Health Sciences University, Augusta, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00945334</url>
  </study>
  <study rank="137">
    <nct_id>NCT01632488</nct_id>
    <title>Assessment of Small Intestinal Bowel Epithelial Gaps in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012SDU-QILU-G02</other_id>
    </other_ids>
    <start_date>June 2012</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>July 3, 2012</study_first_posted>
    <last_update_posted>July 3, 2012</last_update_posted>
    <locations>
      <location>Facility: Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01632488</url>
  </study>
  <study rank="138">
    <nct_id>NCT01404923</nct_id>
    <title>Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">anti spasmodic agents</intervention>
      <intervention type="Drug">alverine citrate, simeticone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score</outcome_measure>
      <outcome_measure>Percentage of Improvement of the Total IBSQoL Scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Laboratoires Mayoly Spindler</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>436</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FMTO901</other_id>
    </other_ids>
    <start_date>December 2009</start_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <completion_date>October 2011</completion_date>
    <study_first_posted>July 28, 2011</study_first_posted>
    <results_first_posted>November 4, 2014</results_first_posted>
    <last_update_posted>November 4, 2014</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01404923</url>
  </study>
  <study rank="139">
    <nct_id>NCT02320318</nct_id>
    <title>12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)</title>
    <acronym>IRIS-05</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibodutant 10 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Weekly response for abdominal pain intensity AND stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).</outcome_measure>
      <outcome_measure>Weekly response for abdominal pain intensity over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).</outcome_measure>
      <outcome_measure>Weekly response for stool consistency over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).</outcome_measure>
      <outcome_measure>Weekly Response for relief of overall IBS signs and symptoms over 12 weeks of treatment in at least 50% of the weeks of treatment (6 out of 12 weeks).</outcome_measure>
      <outcome_measure>Evaluation of rebound effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Menarini Group</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NAK-08</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>December 19, 2014</study_first_posted>
    <last_update_posted>May 19, 2016</last_update_posted>
    <locations>
      <location>Busan, Korea, Republic of</location>
      <location>Daegu, Korea, Republic of</location>
      <location>Gangwon-do, Korea, Republic of</location>
      <location>Gyeonggi-do, Korea, Republic of</location>
      <location>Gyeonggi-do, Korea, Republic of</location>
      <location>Seoul, Korea, Republic of</location>
      <location>Seoul, Korea, Republic of</location>
      <location>Seoul, Korea, Republic of</location>
      <location>Singapore, Singapore</location>
      <location>Singapore, Singapore</location>
      <location>Singapore, Singapore</location>
      <location>Kaohsiung, Taiwan</location>
      <location>Kaohsiung, Taiwan</location>
      <location>Taichung, Taiwan</location>
      <location>Tainan, Taiwan</location>
      <location>Taipei City, Taiwan</location>
      <location>Taipei City, Taiwan</location>
      <location>Taipei, Taiwan</location>
      <location>Taoyuan, Taiwan</location>
      <location>Yunlin, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02320318</url>
  </study>
  <study rank="140">
    <nct_id>NCT01545037</nct_id>
    <title>Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Adequate Relief (IBS-AR)</outcome_measure>
      <outcome_measure>IBS Global Assessment of Improvement Scale</outcome_measure>
      <outcome_measure>IBS Symptom Severity Scale</outcome_measure>
      <outcome_measure>IBS Quality of Life</outcome_measure>
      <outcome_measure>Abdominal Pain</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
      <outcome_measure>Concomitant medication use</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bio-K Plus International Inc.</lead_sponsor>
      <collaborator>Sprim Advanced Life Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>111005-SCN-BIO-IBS-RA</other_id>
    </other_ids>
    <start_date>July 2012</start_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <completion_date>January 2015</completion_date>
    <study_first_posted>March 6, 2012</study_first_posted>
    <last_update_posted>July 31, 2017</last_update_posted>
    <locations>
      <location>Digestive and Liver Disease Specialists A Medical Group. Inc, Garden Grove, California, United States</location>
      <location>Sprim ALS, San Francisco, California, United States</location>
      <location>Westlake Medical Research, Westlake Village, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01545037</url>
  </study>
  <study rank="141">
    <nct_id>NCT01786109</nct_id>
    <title>Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dronabinol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2)</outcome_measure>
      <outcome_measure>Postprandial Change in Colonic Tone</outcome_measure>
      <outcome_measure>Post-treatment Sensory Threshold for First Perception of Pain</outcome_measure>
      <outcome_measure>Post-Treatment Overall Sensory Rating in Response to 16, 24, 32, and 40 mm Hg Distensions</outcome_measure>
      <outcome_measure>Fasting Colonic Tone</outcome_measure>
      <outcome_measure>Postprandial Colonic Motility Index</outcome_measure>
      <outcome_measure>Post-treatment Sensory Threshold for First Sensation</outcome_measure>
      <outcome_measure>Post-Treatment Sensory Threshold for First Perception of Gas</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Michael Camilleri</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>National Center for Research Resources (NCRR)</collaborator>
      <collaborator>Mayo Clinic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-008314 Part B</other_id>
      <other_id>R01DK079866</other_id>
      <other_id>UL1RR024150</other_id>
    </other_ids>
    <start_date>September 2009</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>February 7, 2013</study_first_posted>
    <results_first_posted>March 13, 2013</results_first_posted>
    <last_update_posted>March 14, 2013</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01786109</url>
  </study>
  <study rank="142">
    <nct_id>NCT01107977</nct_id>
    <title>Iyengar Yoga for Young People With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Iyengar yoga</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable bowel symptoms</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <max_age>26 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1K01AT005093</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <completion_date>December 2013</completion_date>
    <study_first_posted>April 21, 2010</study_first_posted>
    <last_update_posted>November 28, 2016</last_update_posted>
    <locations>
      <location>UCLA Pediatric Pain Program, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01107977</url>
  </study>
  <study rank="143">
    <nct_id>NCT01279382</nct_id>
    <title>Effect of Hypnotherapy in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Hypnotherapy (HYP)</intervention>
      <intervention type="Behavioral">Relaxation training (RT)</intervention>
      <intervention type="Other">Care as usual (CON)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean symptom score (MSS)</outcome_measure>
      <outcome_measure>Psychological measures, i.e. anxiety and depression (HADS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>P113/99</other_id>
    </other_ids>
    <start_date>January 2002</start_date>
    <completion_date>January 2006</completion_date>
    <study_first_posted>January 19, 2011</study_first_posted>
    <last_update_posted>January 19, 2011</last_update_posted>
    <locations>
      <location>LUMC - Leiden, Leiden, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01279382</url>
  </study>
  <study rank="144">
    <nct_id>NCT00616200</nct_id>
    <title>Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Very low carbohydrate diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Subjects Reporting &quot;Adequate Relief&quot; From IBS Symptoms for the Previous Week. Adequate Relief Was a &quot;True/False&quot; Item.</outcome_measure>
      <outcome_measure>Impact of Very Low Carbohydrate Diet on Stool Frequency</outcome_measure>
      <outcome_measure>Sickness Impact Profile</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>05-2899</other_id>
      <other_id>GCRC 2392</other_id>
    </other_ids>
    <start_date>August 2009</start_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <completion_date>May 2010</completion_date>
    <study_first_posted>February 15, 2008</study_first_posted>
    <results_first_posted>November 11, 2011</results_first_posted>
    <last_update_posted>October 16, 2017</last_update_posted>
    <locations>
      <location>UNC Center for Functional GI &amp; Motility Disorders, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00616200</url>
  </study>
  <study rank="145">
    <nct_id>NCT02120027</nct_id>
    <title>52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)</title>
    <acronym>IRIS-4</acronym>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibodutant 10 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over the First 24 Weeks of Treatment in at Least 50% of the Weeks of Treatment (12 Out of 24 Weeks).</outcome_measure>
      <outcome_measure>Weekly Response for Abdominal Pain Intensity Over the First 24 Weeks of Treatment in at Least 50% of the Weeks of Treatment (12 Out of 24 Weeks).</outcome_measure>
      <outcome_measure>Weekly Response for Stool Consistency Over the First 24 Weeks of Treatment in at Least 50% of the Weeks of Treatment (12 Out of 24 Weeks).</outcome_measure>
      <outcome_measure>Weekly Response for Relief of Overall IBS Signs and Symptoms Over the First 24 Weeks of Treatment in at Least 50% of the Weeks (12 Out of 24)</outcome_measure>
      <outcome_measure>Sustained Analysis of Response for Abdominal Pain AND Stool Consistency Over First 24-week Double-blind Treatment Period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Menarini Group</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>558</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NAK-07</other_id>
      <other_id>2013-000895-14</other_id>
    </other_ids>
    <start_date>February 2014</start_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>April 22, 2014</study_first_posted>
    <results_first_posted>January 18, 2017</results_first_posted>
    <last_update_posted>March 3, 2017</last_update_posted>
    <locations>
      <location>Chandler, Arizona, United States</location>
      <location>Glendale, Arizona, United States</location>
      <location>Mesa, Arizona, United States</location>
      <location>Phoenix, Arizona, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>North Little Rock, Arkansas, United States</location>
      <location>Encino, California, United States</location>
      <location>Gold River, California, United States</location>
      <location>Laguna Hills, California, United States</location>
      <location>Lincoln, California, United States</location>
      <location>North Hollywood, California, United States</location>
      <location>Orange, California, United States</location>
      <location>Pasadena, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>Centennial, Colorado, United States</location>
      <location>Colorado Springs, Colorado, United States</location>
      <location>Fort Myers, Florida, United States</location>
      <location>Hialeah, Florida, United States</location>
      <location>Hialeah, Florida, United States</location>
      <location>Inverness, Florida, United States</location>
      <location>Kissimmee, Florida, United States</location>
      <location>Lauderdale Lakes, Florida, United States</location>
      <location>Miami Lakes, Florida, United States</location>
      <location>Miami Lakes, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Pinellas Park, Florida, United States</location>
      <location>Tamarac, Florida, United States</location>
      <location>Tampa, Florida, United States</location>
      <location>Addison, Illinois, United States</location>
      <location>Oak Lawn, Illinois, United States</location>
      <location>Rockford, Illinois, United States</location>
      <location>Evansville, Indiana, United States</location>
      <location>Clive, Iowa, United States</location>
      <location>Shawnee, Kansas, United States</location>
      <location>Metairie, Louisiana, United States</location>
      <location>Shreveport, Louisiana, United States</location>
      <location>Columbia, Maryland, United States</location>
      <location>Brockton, Massachusetts, United States</location>
      <location>Brockton, Massachusetts, United States</location>
      <location>Wyoming, Michigan, United States</location>
      <location>St. Louis, Missouri, United States</location>
      <location>Billings, Montana, United States</location>
      <location>Newington, New Hampshire, United States</location>
      <location>Brooklyn, New York, United States</location>
      <location>Great Neck, New York, United States</location>
      <location>New York, New York, United States</location>
      <location>Hickory, North Carolina, United States</location>
      <location>High Point, North Carolina, United States</location>
      <location>Kinston, North Carolina, United States</location>
      <location>Salisbury, North Carolina, United States</location>
      <location>Winston-Salem, North Carolina, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Franklin, Ohio, United States</location>
      <location>Mentor, Ohio, United States</location>
      <location>Levittown, Pennsylvania, United States</location>
      <location>Anderson, South Carolina, United States</location>
      <location>Germantown, Tennessee, United States</location>
      <location>Jackson, Tennessee, United States</location>
      <location>Kingsport, Tennessee, United States</location>
      <location>Arlington, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>Logan, Utah, United States</location>
      <location>Ogden, Utah, United States</location>
      <location>Sandy, Utah, United States</location>
      <location>Lynchburgh, Virginia, United States</location>
      <location>Seattle, Washington, United States</location>
      <location>Spokane, Washington, United States</location>
      <location>Ceske Budejovice, Czech Republic</location>
      <location>Hradec Kralove, Czech Republic</location>
      <location>Kralove, Czech Republic</location>
      <location>Prague, Czech Republic</location>
      <location>Pribram, Czech Republic</location>
      <location>Slany, Czech Republic</location>
      <location>Zlin, Czech Republic</location>
      <location>Berlin, Germany</location>
      <location>Berlin, Germany</location>
      <location>Bochum, Germany</location>
      <location>Frankfurt, Germany</location>
      <location>Hamburg, Germany</location>
      <location>Hannover, Germany</location>
      <location>Karlsruhe, Germany</location>
      <location>Leipzig, Germany</location>
      <location>Mainz, Germany</location>
      <location>Schwerin, Germany</location>
      <location>Budapest, Hungary</location>
      <location>Budapest, Hungary</location>
      <location>Budapest, Hungary</location>
      <location>Debrecen, Hungary</location>
      <location>Debrecen, Hungary</location>
      <location>Gyula, Hungary</location>
      <location>Mateszalka, Hungary</location>
      <location>Pécs, Hungary</location>
      <location>Szekszard, Hungary</location>
      <location>Vac, Hungary</location>
      <location>Daugavpils, Latvia</location>
      <location>Riga III, Latvia</location>
      <location>Riga, Latvia</location>
      <location>Riga, Latvia</location>
      <location>Valmiera, Latvia</location>
      <location>Katowice, Poland</location>
      <location>Lodz, Poland</location>
      <location>Poznan, Poland</location>
      <location>Poznan, Poland</location>
      <location>Sopot, Poland</location>
      <location>Staszow, Poland</location>
      <location>Warszawa, Poland</location>
      <location>Warszawa, Poland</location>
      <location>Warszawa, Poland</location>
      <location>Warszawa, Poland</location>
      <location>Wroclaw, Poland</location>
      <location>Wroclaw, Poland</location>
      <location>Bratislava, Slovakia</location>
      <location>Bratislava, Slovakia</location>
      <location>Bratislava, Slovakia</location>
      <location>Ilava, Slovakia</location>
      <location>Nitra, Slovakia</location>
      <location>Trencin, Slovakia</location>
      <location>Trnava, Slovakia</location>
      <location>Goteborg, Sweden</location>
      <location>Lund, Sweden</location>
      <location>Stockholm, Sweden</location>
      <location>Uppsala, Sweden</location>
      <location>Bexhill-on-Sea, United Kingdom</location>
      <location>Chorley, United Kingdom</location>
      <location>Coventry, United Kingdom</location>
      <location>Edgbaston, United Kingdom</location>
      <location>Glasgow, United Kingdom</location>
      <location>Llanishen, United Kingdom</location>
      <location>North Manchester, United Kingdom</location>
      <location>Northumberland, United Kingdom</location>
      <location>Norwich, United Kingdom</location>
      <location>Reading, United Kingdom</location>
      <location>Waterloo, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02120027</url>
  </study>
  <study rank="146">
    <nct_id>NCT00067457</nct_id>
    <title>Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alosetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events &amp; laboratory abnormalities.</outcome_measure>
      <outcome_measure>Comparison of treatment groups with respect to subject relief of IBS pain &amp; discomfort; lower GI symptoms, changes in quality of life, lost workplace productivity, &amp; lost household/leisure activity, &amp; subject satisfaction with assigned study drug.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>700</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S3B30048</other_id>
    </other_ids>
    <start_date>June 2003</start_date>
    <primary_completion_date>December 2005</primary_completion_date>
    <completion_date>December 2005</completion_date>
    <study_first_posted>August 21, 2003</study_first_posted>
    <last_update_posted>April 16, 2015</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Birmingham, Alabama, United States</location>
      <location>GSK Investigational Site, Birmingham, Alabama, United States</location>
      <location>GSK Investigational Site, Huntsville, Alabama, United States</location>
      <location>GSK Investigational Site, Mobile, Alabama, United States</location>
      <location>GSK Investigational Site, Pell City, Alabama, United States</location>
      <location>GSK Investigational Site, Tallassee, Alabama, United States</location>
      <location>GSK Investigational Site, Tucson, Arizona, United States</location>
      <location>GSK Investigational Site, Little Rock, Arkansas, United States</location>
      <location>GSK Investigational Site, North Little Rock, Arkansas, United States</location>
      <location>GSK Investigational Site, Beverly Hills, California, United States</location>
      <location>GSK Investigational Site, Carlsbad, California, United States</location>
      <location>GSK Investigational Site, Concord, California, United States</location>
      <location>GSK Investigational Site, Encinitas, California, United States</location>
      <location>GSK Investigational Site, Fresno, California, United States</location>
      <location>GSK Investigational Site, Garden Grove, California, United States</location>
      <location>GSK Investigational Site, Los Angeles, California, United States</location>
      <location>GSK Investigational Site, Orange, California, United States</location>
      <location>GSK Investigational Site, Roseville, California, United States</location>
      <location>GSK Investigational Site, San Diego, California, United States</location>
      <location>GSK Investigational Site, San Diego, California, United States</location>
      <location>GSK Investigational Site, San Diego, California, United States</location>
      <location>GSK Investigational Site, San Francisco, California, United States</location>
      <location>GSK Investigational Site, San Francisco, California, United States</location>
      <location>GSK Investigational Site, San Francisco, California, United States</location>
      <location>GSK Investigational Site, Santa Ana, California, United States</location>
      <location>GSK Investigational Site, Spring Valley, California, United States</location>
      <location>GSK Investigational Site, Torrance, California, United States</location>
      <location>GSK Investigational Site, Van Nuys, California, United States</location>
      <location>GSK Investigational Site, Centennial, Colorado, United States</location>
      <location>GSK Investigational Site, Colorado Springs, Colorado, United States</location>
      <location>GSK Investigational Site, Littleton, Colorado, United States</location>
      <location>GSK Investigational Site, Longmont, Colorado, United States</location>
      <location>GSK Investigational Site, Bristol, Connecticut, United States</location>
      <location>GSK Investigational Site, Belleair Bluffs, Florida, United States</location>
      <location>GSK Investigational Site, Boca Raton, Florida, United States</location>
      <location>GSK Investigational Site, Bradenton, Florida, United States</location>
      <location>GSK Investigational Site, Clearwater, Florida, United States</location>
      <location>GSK Investigational Site, Clearwater, Florida, United States</location>
      <location>GSK Investigational Site, Deland, Florida, United States</location>
      <location>GSK Investigational Site, Gainesville, Florida, United States</location>
      <location>GSK Investigational Site, Hollywood, Florida, United States</location>
      <location>GSK Investigational Site, Jacksonville, Florida, United States</location>
      <location>GSK Investigational Site, Jacksonville, Florida, United States</location>
      <location>GSK Investigational Site, Kissimmee, Florida, United States</location>
      <location>GSK Investigational Site, Melbourne, Florida, United States</location>
      <location>GSK Investigational Site, North Miami Beach, Florida, United States</location>
      <location>GSK Investigational Site, Spring Hill, Florida, United States</location>
      <location>GSK Investigational Site, Stuart, Florida, United States</location>
      <location>GSK Investigational Site, Zephyrhills, Florida, United States</location>
      <location>GSK Investigational Site, Atlanta, Georgia, United States</location>
      <location>GSK Investigational Site, Atlanta, Georgia, United States</location>
      <location>GSK Investigational Site, Blue Ridge, Georgia, United States</location>
      <location>GSK Investigational Site, Dunwoody, Georgia, United States</location>
      <location>GSK Investigational Site, Fayetteville, Georgia, United States</location>
      <location>GSK Investigational Site, Rome, Georgia, United States</location>
      <location>GSK Investigational Site, Savannah, Georgia, United States</location>
      <location>GSK Investigational Site, Boise, Idaho, United States</location>
      <location>GSK Investigational Site, Coeur D'Alene, Idaho, United States</location>
      <location>GSK Investigational Site, Meridian, Idaho, United States</location>
      <location>GSK Investigational Site, Chicago, Illinois, United States</location>
      <location>GSK Investigational Site, Chicago, Illinois, United States</location>
      <location>GSK Investigational Site, Libertyville, Illinois, United States</location>
      <location>GSK Investigational Site, Moline, Illinois, United States</location>
      <location>GSK Investigational Site, Morton Grove, Illinois, United States</location>
      <location>GSK Investigational Site, Oakbrook Terrace, Illinois, United States</location>
      <location>GSK Investigational Site, Peoria, Illinois, United States</location>
      <location>GSK Investigational Site, Rockford, Illinois, United States</location>
      <location>GSK Investigational Site, Indianapolis, Indiana, United States</location>
      <location>GSK Investigational Site, Indianapolis, Indiana, United States</location>
      <location>GSK Investigational Site, Jeffersonville, Indiana, United States</location>
      <location>GSK Investigational Site, Clive, Iowa, United States</location>
      <location>GSK Investigational Site, Haysville, Kansas, United States</location>
      <location>GSK Investigational Site, Kansas City, Kansas, United States</location>
      <location>GSK Investigational Site, Wichita, Kansas, United States</location>
      <location>GSK Investigational Site, Florence, Kentucky, United States</location>
      <location>GSK Investigational Site, Lexington, Kentucky, United States</location>
      <location>GSK Investigational Site, Lexington, Kentucky, United States</location>
      <location>GSK Investigational Site, Madisonville, Kentucky, United States</location>
      <location>GSK Investigational Site, Covington, Louisiana, United States</location>
      <location>GSK Investigational Site, Lafayette, Louisiana, United States</location>
      <location>GSK Investigational Site, Monroe, Louisiana, United States</location>
      <location>GSK Investigational Site, New Orleans, Louisiana, United States</location>
      <location>GSK Investigational Site, New Orleans, Louisiana, United States</location>
      <location>GSK Investigational Site, Shreveport, Louisiana, United States</location>
      <location>GSK Investigational Site, Annapolis, Maryland, United States</location>
      <location>GSK Investigational Site, Baltimore, Maryland, United States</location>
      <location>GSK Investigational Site, Baltimore, Maryland, United States</location>
      <location>GSK Investigational Site, Lanham, Maryland, United States</location>
      <location>GSK Investigational Site, Oxon Hill, Maryland, United States</location>
      <location>GSK Investigational Site, Severna Park, Maryland, United States</location>
      <location>GSK Investigational Site, Silver Spring, Maryland, United States</location>
      <location>GSK Investigational Site, Towson, Maryland, United States</location>
      <location>GSK Investigational Site, Towson, Maryland, United States</location>
      <location>GSK Investigational Site, Wheaton, Maryland, United States</location>
      <location>GSK Investigational Site, Burlington, Massachusetts, United States</location>
      <location>GSK Investigational Site, Farmington Hills, Michigan, United States</location>
      <location>GSK Investigational Site, Northville, Michigan, United States</location>
      <location>GSK Investigational Site, Petoskey, Michigan, United States</location>
      <location>GSK Investigational Site, Saginaw, Michigan, United States</location>
      <location>GSK Investigational Site, Brooklyn Center, Minnesota, United States</location>
      <location>GSK Investigational Site, Chesterfield, Missouri, United States</location>
      <location>GSK Investigational Site, St. Louis, Missouri, United States</location>
      <location>GSK Investigational Site, Lincoln, Nebraska, United States</location>
      <location>GSK Investigational Site, Omaha, Nebraska, United States</location>
      <location>GSK Investigational Site, Las Vegas, Nevada, United States</location>
      <location>GSK Investigational Site, Berlin, New Jersey, United States</location>
      <location>GSK Investigational Site, Blackwood, New Jersey, United States</location>
      <location>GSK Investigational Site, Cedar Knolls, New Jersey, United States</location>
      <location>GSK Investigational Site, Oakhurst, New Jersey, United States</location>
      <location>GSK Investigational Site, Passaic, New Jersey, United States</location>
      <location>GSK Investigational Site, South Bound Brook, New Jersey, United States</location>
      <location>GSK Investigational Site, Willingboro, New Jersey, United States</location>
      <location>GSK Investigational Site, Albuquerque, New Mexico, United States</location>
      <location>GSK Investigational Site, Albany, New York, United States</location>
      <location>GSK Investigational Site, Binghamton, New York, United States</location>
      <location>GSK Investigational Site, Endwell, New York, United States</location>
      <location>GSK Investigational Site, Great Neck, New York, United States</location>
      <location>GSK Investigational Site, Pittsford, New York, United States</location>
      <location>GSK Investigational Site, Pomona, New York, United States</location>
      <location>GSK Investigational Site, Cary, North Carolina, United States</location>
      <location>GSK Investigational Site, Charlotte, North Carolina, United States</location>
      <location>GSK Investigational Site, Gastonia, North Carolina, United States</location>
      <location>GSK Investigational Site, Greensboro, North Carolina, United States</location>
      <location>GSK Investigational Site, Greenville, North Carolina, United States</location>
      <location>GSK Investigational Site, Jacksonville, North Carolina, United States</location>
      <location>GSK Investigational Site, Raleigh, North Carolina, United States</location>
      <location>GSK Investigational Site, Wilmington, North Carolina, United States</location>
      <location>GSK Investigational Site, Wilmington, North Carolina, United States</location>
      <location>GSK Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>GSK Investigational Site, Bellbrook, Ohio, United States</location>
      <location>GSK Investigational Site, Cincinnati, Ohio, United States</location>
      <location>GSK Investigational Site, Columbus, Ohio, United States</location>
      <location>GSK Investigational Site, Columbus, Ohio, United States</location>
      <location>GSK Investigational Site, Wandsworth, Ohio, United States</location>
      <location>GSK Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>GSK Investigational Site, Tulsa, Oklahoma, United States</location>
      <location>GSK Investigational Site, Portland, Oregon, United States</location>
      <location>GSK Investigational Site, Portland, Oregon, United States</location>
      <location>GSK Investigational Site, Bensalem, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Duncansville, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Feasterville, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Levittown, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Media, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Morrisville, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Penndel, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Philadelphia, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Philadelphia, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Philadelphia, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Pittsburgh, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Reading, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Sellersville, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Stoneboro, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Anderson, South Carolina, United States</location>
      <location>GSK Investigational Site, Charleston, South Carolina, United States</location>
      <location>GSK Investigational Site, Summerville, South Carolina, United States</location>
      <location>GSK Investigational Site, Sioux Falls, South Dakota, United States</location>
      <location>GSK Investigational Site, Bristol, Tennessee, United States</location>
      <location>GSK Investigational Site, Clarksville, Tennessee, United States</location>
      <location>GSK Investigational Site, Jackson, Tennessee, United States</location>
      <location>GSK Investigational Site, Johnson City, Tennessee, United States</location>
      <location>GSK Investigational Site, Kingsport, Tennessee, United States</location>
      <location>GSK Investigational Site, Knoxville, Tennessee, United States</location>
      <location>GSK Investigational Site, Memphis, Tennessee, United States</location>
      <location>GSK Investigational Site, Nashville, Tennessee, United States</location>
      <location>GSK Investigational Site, Austin, Texas, United States</location>
      <location>GSK Investigational Site, Conroe, Texas, United States</location>
      <location>GSK Investigational Site, Dallas, Texas, United States</location>
      <location>GSK Investigational Site, Houston, Texas, United States</location>
      <location>GSK Investigational Site, Humble, Texas, United States</location>
      <location>GSK Investigational Site, North Richland Hills, Texas, United States</location>
      <location>GSK Investigational Site, Pasadena, Texas, United States</location>
      <location>GSK Investigational Site, San Antonio, Texas, United States</location>
      <location>GSK Investigational Site, San Antonio, Texas, United States</location>
      <location>GSK Investigational Site, Sugar Land, Texas, United States</location>
      <location>GSK Investigational Site, Woodlands, Texas, United States</location>
      <location>GSK Investigational Site, Salt Lake City, Utah, United States</location>
      <location>GSK Investigational Site, Chesapeake, Virginia, United States</location>
      <location>GSK Investigational Site, Christiansburg, Virginia, United States</location>
      <location>GSK Investigational Site, Danville, Virginia, United States</location>
      <location>GSK Investigational Site, Norfolk, Virginia, United States</location>
      <location>GSK Investigational Site, Norfolk, Virginia, United States</location>
      <location>GSK Investigational Site, Richmond, Virginia, United States</location>
      <location>GSK Investigational Site, Virginia Beach, Virginia, United States</location>
      <location>GSK Investigational Site, Weber City, Virginia, United States</location>
      <location>GSK Investigational Site, Bellevue, Washington, United States</location>
      <location>GSK Investigational Site, Gig Harbor, Washington, United States</location>
      <location>GSK Investigational Site, Lacey, Washington, United States</location>
      <location>GSK Investigational Site, Tacoma, Washington, United States</location>
      <location>GSK Investigational Site, La Crosse, Wisconsin, United States</location>
      <location>GSK Investigational Site, Madison, Wisconsin, United States</location>
      <location>GSK Investigational Site, Nedlands, Western Australia, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00067457</url>
  </study>
  <study rank="147">
    <nct_id>NCT00737841</nct_id>
    <title>Effect of Bifidobacterium on Irritable Bowel Syndrome</title>
    <acronym>PBIBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bifidobacterium breve</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate relief and SIBSQ</outcome_measure>
      <outcome_measure>Psychometric test, bowel gas, blood, and feces.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tohoku University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>Probio-Bifid-IBS</other_id>
    </other_ids>
    <start_date>January 2006</start_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <completion_date>September 2008</completion_date>
    <study_first_posted>August 20, 2008</study_first_posted>
    <last_update_posted>August 20, 2008</last_update_posted>
    <locations>
      <location>Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00737841</url>
  </study>
  <study rank="148">
    <nct_id>NCT02107196</nct_id>
    <title>12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)</title>
    <acronym>IRIS-3</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibodutant 10 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).</outcome_measure>
      <outcome_measure>Weekly Response for Abdominal Pain Intensity Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).</outcome_measure>
      <outcome_measure>Weekly Response for Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).</outcome_measure>
      <outcome_measure>Weekly Response for Relief of Overall IBS Signs and Symptoms Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).</outcome_measure>
      <outcome_measure>Evaluation of Rebound Effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Menarini Group</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>535</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NAK-06</other_id>
      <other_id>2013-000894-56</other_id>
    </other_ids>
    <start_date>March 2014</start_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <completion_date>June 2015</completion_date>
    <study_first_posted>April 8, 2014</study_first_posted>
    <results_first_posted>September 27, 2016</results_first_posted>
    <last_update_posted>January 19, 2017</last_update_posted>
    <locations>
      <location>Huntsville, Alabama, United States</location>
      <location>Sherwood, Arizona, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>Artesia, California, United States</location>
      <location>Chula Vista, California, United States</location>
      <location>Encino, California, United States</location>
      <location>Mission Hills, California, United States</location>
      <location>Sacramento, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>Upland, California, United States</location>
      <location>Littleton, Colorado, United States</location>
      <location>Bristol, Connecticut, United States</location>
      <location>Boynton Beach, Florida, United States</location>
      <location>Brandon, Florida, United States</location>
      <location>Brooksville, Florida, United States</location>
      <location>Coral Gables, Florida, United States</location>
      <location>Gainesville, Florida, United States</location>
      <location>Hialeah, Florida, United States</location>
      <location>Jupiter, Florida, United States</location>
      <location>Miami Lakes, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Addison, Illinois, United States</location>
      <location>Chicago, Illinois, United States</location>
      <location>Augusta, Kansas, United States</location>
      <location>Newton, Kansas, United States</location>
      <location>Wichita, Kansas, United States</location>
      <location>Lexington, Kentucky, United States</location>
      <location>Madisonville, Kentucky, United States</location>
      <location>Owensboro, Kentucky, United States</location>
      <location>Crowley, Louisiana, United States</location>
      <location>Baltimore, Maryland, United States</location>
      <location>Ann Arbor, Michigan, United States</location>
      <location>Chesterfield, Michigan, United States</location>
      <location>Saginaw, Michigan, United States</location>
      <location>Troy, Michigan, United States</location>
      <location>Las Vegas, Nevada, United States</location>
      <location>Hartsdale, New York, United States</location>
      <location>Fayetteville, North Carolina, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>Fargo, North Dakota, United States</location>
      <location>Akron, Ohio, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Cleveland, Ohio, United States</location>
      <location>Columbus, Ohio, United States</location>
      <location>Dayton, Ohio, United States</location>
      <location>Reading, Pennsylvania, United States</location>
      <location>Greer, South Carolina, United States</location>
      <location>Simpsonville, South Carolina, United States</location>
      <location>Chattanooga, Tennessee, United States</location>
      <location>Knoxville, Tennessee, United States</location>
      <location>Knoxville, Tennessee, United States</location>
      <location>Nashville, Tennessee, United States</location>
      <location>Smyrna, Tennessee, United States</location>
      <location>Beaumont, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Hurst, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>Ste. Channelview, Texas, United States</location>
      <location>West Jordan, Utah, United States</location>
      <location>Morgantown, West Virginia, United States</location>
      <location>Haskovo, Bulgaria</location>
      <location>Plovdiv, Bulgaria</location>
      <location>Ruse, Bulgaria</location>
      <location>Sofia, Bulgaria</location>
      <location>Sofia, Bulgaria</location>
      <location>Veliko Tarnovo, Bulgaria</location>
      <location>Karlovy Vary, Czech Republic</location>
      <location>Prague, Czech Republic</location>
      <location>Prague, Czech Republic</location>
      <location>Usti nad Labem, Czech Republic</location>
      <location>Usti nad Orlici, Czech Republic</location>
      <location>Bobigny, Ile-de-France, France</location>
      <location>Bordeaux, France</location>
      <location>Nantes Cedex, France</location>
      <location>NICE Cedex, France</location>
      <location>Rouen, France</location>
      <location>Stuttgart, Baden-Wuerttemberg, Germany</location>
      <location>Berlin, Germany</location>
      <location>Berlin, Germany</location>
      <location>Essen, Germany</location>
      <location>Hamburg, Germany</location>
      <location>Hamburg, Germany</location>
      <location>Bari, Italy</location>
      <location>Bari, Italy</location>
      <location>Bologna, Italy</location>
      <location>Florence, Italy</location>
      <location>Pavia, Italy</location>
      <location>Rome, Italy</location>
      <location>Bydgoszcz, Poland</location>
      <location>Czestochowa, Poland</location>
      <location>Krakow, Poland</location>
      <location>Lublin, Poland</location>
      <location>Wroclaw, Poland</location>
      <location>Targu Mures, Jud. Mures, Romania</location>
      <location>Tirgu Mures, Mures, Romania</location>
      <location>Timisoara, Timis, Romania</location>
      <location>Timisoara, Timis, Romania</location>
      <location>Brasov, Romania</location>
      <location>Brasov, Romania</location>
      <location>Bucharest, Romania</location>
      <location>Bucharest, Romania</location>
      <location>Kaluga, Russian Federation</location>
      <location>Moscow, Russian Federation</location>
      <location>Saint-Petersburg, Russian Federation</location>
      <location>Smolensk, Russian Federation</location>
      <location>St. Petersburg, Russian Federation</location>
      <location>St.Petersburg, Russian Federation</location>
      <location>Yaroslavl, Russian Federation</location>
      <location>Badalona, Barcelona, Spain</location>
      <location>Mataro, Barcelona, Spain</location>
      <location>Sabadell, Barcelona, Spain</location>
      <location>Barcelona, Spain</location>
      <location>Barcelona, Spain</location>
      <location>Madrid, Spain</location>
      <location>Sevilla, Spain</location>
      <location>Penzance, Cornwall, United Kingdom</location>
      <location>Chesterfield, Derbyshire, United Kingdom</location>
      <location>Inverness, Scotland, United Kingdom</location>
      <location>Doncaster, South Yorkshire, United Kingdom</location>
      <location>Leicestershire, United Kingdom</location>
      <location>Manchester, United Kingdom</location>
      <location>Plymouth, Devon, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02107196</url>
  </study>
  <study rank="149">
    <nct_id>NCT02074579</nct_id>
    <title>A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome in Females</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TU-100</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal bloating rating</outcome_measure>
      <outcome_measure>AUC for abdominal bloating ratings using lactulose challenge</outcome_measure>
      <outcome_measure>Abdominal bloating ratings</outcome_measure>
      <outcome_measure>Overall IBS Severity</outcome_measure>
      <outcome_measure>GI symptom ratings</outcome_measure>
      <outcome_measure>Quality of Life effect</outcome_measure>
      <outcome_measure>Mood symptom ratings</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tsumura USA</lead_sponsor>
      <collaborator>ICON Clinical Research</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TU100CPT6</other_id>
    </other_ids>
    <start_date>July 2014</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>April 2016</completion_date>
    <study_first_posted>February 28, 2014</study_first_posted>
    <last_update_posted>May 2, 2017</last_update_posted>
    <locations>
      <location>Oppenheimer Family Center for Neurobiology of Stress Division of Digestive Diseases David Geffen School of Medicine at UCLA, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02074579</url>
  </study>
  <study rank="150">
    <nct_id>NCT01457378</nct_id>
    <title>Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Danone Research</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NU357</other_id>
    </other_ids>
    <start_date>September 2011</start_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <completion_date>November 2011</completion_date>
    <study_first_posted>October 24, 2011</study_first_posted>
    <last_update_posted>September 20, 2016</last_update_posted>
    <locations>
      <location>Eurofins Optimed, Gieres, France</location>
      <location>Biofortis, Nantes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01457378</url>
  </study>
  <study rank="151">
    <nct_id>NCT00932841</nct_id>
    <title>The Use of VSL#3 in Irritable Bowel Syndrome in Children</title>
    <acronym>VSL#3</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">VSL#3 900 billion bacteria</intervention>
      <intervention type="Drug">VSL#3 90 billion bacteria</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Gastrointestinal Symptom Rating Scale</outcome_measure>
      <outcome_measure>Coddington life events questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dayton Children's Hospital</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>04-007</other_id>
      <other_id>R21AT003400-01A2</other_id>
    </other_ids>
    <start_date>January 2008</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>August 2011</completion_date>
    <study_first_posted>July 3, 2009</study_first_posted>
    <last_update_posted>March 20, 2012</last_update_posted>
    <locations>
      <location>Children's Medical Center of Dayton, Dayton, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00932841</url>
  </study>
  <study rank="152">
    <nct_id>NCT01418053</nct_id>
    <title>The Effect of Hot Cataplasm With Caraway Oil in the Treatment of Irritable Bowel Syndrome</title>
    <acronym>CarO</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">caraway oil</intervention>
      <intervention type="Drug">Olive oil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome - Symptom Severity Score</outcome_measure>
      <outcome_measure>Frequency of abdominal discomfort/Pain</outcome_measure>
      <outcome_measure>Intensity of abdominal discomfort/Pain</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Quality of life - ibs specific</outcome_measure>
      <outcome_measure>Depression and Anxiety</outcome_measure>
      <outcome_measure>Global improvement</outcome_measure>
      <outcome_measure>h-BD2</outcome_measure>
      <outcome_measure>Adequate Relief Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universität Duisburg-Essen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-4627 CarO</other_id>
    </other_ids>
    <start_date>August 2011</start_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <completion_date>September 2013</completion_date>
    <study_first_posted>August 16, 2011</study_first_posted>
    <last_update_posted>May 10, 2018</last_update_posted>
    <locations>
      <location>Klinik für Naturheilkunde und Integrative Medizin, Essen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01418053</url>
  </study>
  <study rank="153">
    <nct_id>NCT03178877</nct_id>
    <title>The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors</title>
    <acronym>IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Anxiety and depression</outcome_measure>
      <outcome_measure>Sleep Quality</outcome_measure>
      <outcome_measure>Spiritual status</outcome_measure>
      <outcome_measure>Academic Stress</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Indonesia University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <max_age>30 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>16-11-430</other_id>
    </other_ids>
    <start_date>November 1, 2016</start_date>
    <primary_completion_date>December 31, 2016</primary_completion_date>
    <completion_date>December 31, 2016</completion_date>
    <study_first_posted>June 7, 2017</study_first_posted>
    <last_update_posted>June 7, 2017</last_update_posted>
    <locations>
      <location>Cipto Mangunkusumo Hospital, Jakarta Pusat, DKI Jakarta, Indonesia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03178877</url>
  </study>
  <study rank="154">
    <nct_id>NCT00607971</nct_id>
    <title>Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation-Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Renzapride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Vital signs, routine clinical laboratory data, 12-lead ECG</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Alizyme</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>939</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
    </study_designs>
    <other_ids>
      <other_id>ATL1251/052/CL</other_id>
    </other_ids>
    <start_date>April 2006</start_date>
    <primary_completion_date>June 2008</primary_completion_date>
    <completion_date>June 2008</completion_date>
    <study_first_posted>February 6, 2008</study_first_posted>
    <last_update_posted>July 8, 2008</last_update_posted>
    <locations>
      <location>Research Site, Huntsville, Alabama, United States</location>
      <location>Research Site, Chandler, Arizona, United States</location>
      <location>Research Site, Phoenix, Arizona, United States</location>
      <location>Research Site, Sierra Vista, Arizona, United States</location>
      <location>Research Site, Little Rock, Arkansas, United States</location>
      <location>Research Site, North Little Rock, Arkansas, United States</location>
      <location>Research Site, Anaheim, California, United States</location>
      <location>Research Site, Beverley Hills, California, United States</location>
      <location>Research Site, Burbank, California, United States</location>
      <location>Research Site, Carmichael, California, United States</location>
      <location>Research Site, Cerritos, California, United States</location>
      <location>Research Site, Chula Vista, California, United States</location>
      <location>Research Site, Cypress, California, United States</location>
      <location>Research Site, Laguna Hills, California, United States</location>
      <location>Research Site, Los Angeles, California, United States</location>
      <location>Research Site, Orange, California, United States</location>
      <location>Research Site, Orange, California, United States</location>
      <location>Research Site, San Carlos, California, United States</location>
      <location>Research Site, San Diego, California, United States</location>
      <location>Research Site, San Diego, California, United States</location>
      <location>Research Site, San Francisco, California, United States</location>
      <location>Research Site, Colorado Springs, Colorado, United States</location>
      <location>Research Site, Lakewood, Colorado, United States</location>
      <location>Research Site, Littleton, Colorado, United States</location>
      <location>Research Site, Bristol, Connecticut, United States</location>
      <location>Research Site, Boynton Beach, Florida, United States</location>
      <location>Research Site, Coral Gables, Florida, United States</location>
      <location>Research Site, Gainesville, Florida, United States</location>
      <location>Research Site, Hialeah, Florida, United States</location>
      <location>Research Site, Inverness, Florida, United States</location>
      <location>Research Site, Jacksonville, Florida, United States</location>
      <location>Research Site, Jacksonville, Florida, United States</location>
      <location>Research Site, Kissimmee, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, New Port Richey, Florida, United States</location>
      <location>Research Site, Palm Harbor, Florida, United States</location>
      <location>Research Site, Pembrook Pines, Florida, United States</location>
      <location>Research Site, Pensacola, Florida, United States</location>
      <location>Research Site, Plantation, Florida, United States</location>
      <location>Research Site, Port Orange, Florida, United States</location>
      <location>Research Site, Vero Beach, Florida, United States</location>
      <location>Research Site, West Palm Beach, Florida, United States</location>
      <location>Research Site, Marietta, Georgia, United States</location>
      <location>Research Site, Newnan, Georgia, United States</location>
      <location>Research Site, Rockford, Illinois, United States</location>
      <location>Research Site, Indianapolis, Indiana, United States</location>
      <location>Research Site, Des Moines, Iowa, United States</location>
      <location>Research Site, Arkansas City, Kansas, United States</location>
      <location>Research Site, Overland Park, Kansas, United States</location>
      <location>Research Site, Topeka, Kansas, United States</location>
      <location>Research Site, Wichita, Kansas, United States</location>
      <location>Research Site, Wichita, Kansas, United States</location>
      <location>Research Site, Shreveport, Louisiana, United States</location>
      <location>Research Site, Annapolis, Maryland, United States</location>
      <location>Research Site, Hagerstown, Maryland, United States</location>
      <location>Research Site, Laurel, Maryland, United States</location>
      <location>Research Site, Pasadena, Maryland, United States</location>
      <location>Research Site, Severna Park, Maryland, United States</location>
      <location>Research Site, Boston, Massachusetts, United States</location>
      <location>Research Site, Boston, Massachusetts, United States</location>
      <location>Research Site, Chesterfield, Michigan, United States</location>
      <location>Research Site, Kalamazoo, Michigan, United States</location>
      <location>Research Site, Lansing, Michigan, United States</location>
      <location>Research Site, Troy, Michigan, United States</location>
      <location>Research Site, Tupelo, Mississippi, United States</location>
      <location>Research Site, Mexico, Missouri, United States</location>
      <location>Research Site, Springfield, Missouri, United States</location>
      <location>Research Site, Scottsbluff, Nebraska, United States</location>
      <location>Research Site, Cedar Knolls, New Jersey, United States</location>
      <location>Research Site, Passaic, New Jersey, United States</location>
      <location>Research Site, Sicklerville, New Jersey, United States</location>
      <location>Research Site, Great Neck, New York, United States</location>
      <location>Research Site, Great Neck, New York, United States</location>
      <location>Research Site, Johnson City, New York, United States</location>
      <location>Research Site, Kingston, New York, United States</location>
      <location>Research Site, Mineola, New York, United States</location>
      <location>Research Site, New York, New York, United States</location>
      <location>Research Site, Burlington, North Carolina, United States</location>
      <location>Research Site, Charlotte, North Carolina, United States</location>
      <location>Research Site, Elkin, North Carolina, United States</location>
      <location>Research Site, Fayetteville, North Carolina, United States</location>
      <location>Research Site, Greensboro, North Carolina, United States</location>
      <location>Research Site, Greensboro, North Carolina, United States</location>
      <location>Research Site, New Bern, North Carolina, United States</location>
      <location>Research Site, Pinehurst, North Carolina, United States</location>
      <location>Research Site, Raleigh, North Carolina, United States</location>
      <location>Research Site, Wilmington, North Carolina, United States</location>
      <location>Research Site, Wilmington, North Carolina, United States</location>
      <location>Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Research Site, Bismark, North Dakota, United States</location>
      <location>Research Site, Fargo, North Dakota, United States</location>
      <location>Research Site, Cincinnati, Ohio, United States</location>
      <location>Research Site, Columbus, Ohio, United States</location>
      <location>Research Site, Mogadore, Ohio, United States</location>
      <location>Research Site, Sylvania, Ohio, United States</location>
      <location>Research Site, Zanesville, Ohio, United States</location>
      <location>Research Site, Norman, Oklahoma, United States</location>
      <location>Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Research Site, Downington, Pennsylvania, United States</location>
      <location>Research Site, Lancaster, Pennsylvania, United States</location>
      <location>Research Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Research Site, Greer, South Carolina, United States</location>
      <location>Research Site, Simpsonville, South Carolina, United States</location>
      <location>Research Site, Chattanooga, Tennessee, United States</location>
      <location>Research Site, Chattanooga, Tennessee, United States</location>
      <location>Research Site, Germantown, Tennessee, United States</location>
      <location>Research Site, Jackson, Tennessee, United States</location>
      <location>Research Site, Kingsport, Tennessee, United States</location>
      <location>Research Site, Knoxville, Tennessee, United States</location>
      <location>Research Site, Memphis, Tennessee, United States</location>
      <location>Research Site, Nashville, Tennessee, United States</location>
      <location>Research Site, Austin, Texas, United States</location>
      <location>Research Site, Corsicana, Texas, United States</location>
      <location>Research Site, Dallas, Texas, United States</location>
      <location>Research Site, Dallas, Texas, United States</location>
      <location>Research Site, FT. Worth, Texas, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, Murray, Utah, United States</location>
      <location>Research Site, Chesapeake, Virginia, United States</location>
      <location>Research Site, Richmond, Virginia, United States</location>
      <location>Research Site, Suffolk, Virginia, United States</location>
      <location>Research Site, Virginia Beach, Virginia, United States</location>
      <location>Research Site, Bellevue, Washington, United States</location>
      <location>Research Site, Spokane, Washington, United States</location>
      <location>Research Site, Spokane, Washington, United States</location>
      <location>Research Site, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00607971</url>
  </study>
  <study rank="155">
    <nct_id>NCT03449628</nct_id>
    <title>L. Casei DG® in Patients With Irritable Bowel Syndrome.</title>
    <acronym>PROBE2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">L.casei DG</intervention>
      <intervention type="Dietary Supplement">PLACEBO</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients who have a response in pain</outcome_measure>
      <outcome_measure>Proportion of patients who have a response in stool consistencies</outcome_measure>
      <outcome_measure>Evaluation of Pain relief</outcome_measure>
      <outcome_measure>Evaluation of global symptom score</outcome_measure>
      <outcome_measure>Relief of IBS symptoms</outcome_measure>
      <outcome_measure>IBS-SSS score questionnaire (Severity Scoring System )</outcome_measure>
      <outcome_measure>Improvement in stool consistency</outcome_measure>
      <outcome_measure>Satisfaction with treatment</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Intake of rescue medication</outcome_measure>
      <outcome_measure>gut microbiota composition</outcome_measure>
      <outcome_measure>Short Chain Fatty Acids (SCFA)</outcome_measure>
      <outcome_measure>Free Aminoacids</outcome_measure>
      <outcome_measure>Biogenic Amines</outcome_measure>
      <outcome_measure>Gut permeability for zonulin</outcome_measure>
      <outcome_measure>Gut permeability for citrulline</outcome_measure>
      <outcome_measure>Gut permeability for PV-1 (Plasmalemma vesicle-associated) protein</outcome_measure>
      <outcome_measure>L. casei DG® strain in the feces</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SOFAR S.p.A.</lead_sponsor>
      <collaborator>1Med</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PSC-DS PROBE2-IBS/17</other_id>
    </other_ids>
    <start_date>November 6, 2017</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>February 28, 2018</study_first_posted>
    <last_update_posted>March 21, 2019</last_update_posted>
    <locations>
      <location>A.O. Bolognini, Seriate, BG, Italy</location>
      <location>Policlinico San Donato, San Donato Milanese, MI, Italy</location>
      <location>Gastroenterologia Universitaria Policlinico Giovanni XXIII, Bari, Italy</location>
      <location>Azienda ULSS 1, Belluno, Italy</location>
      <location>Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna, Italy</location>
      <location>Ospedale SS. Annunziata, Chieti, Italy</location>
      <location>Fondazione IRCCS Policlinico, Milano, Italy</location>
      <location>Policlinico, Napoli, Italy</location>
      <location>Policlinico Federico II, Napoli, Italy</location>
      <location>Azienda Ospedaliera di Padova, Padova, Italy</location>
      <location>Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy</location>
      <location>U.O. Gastroenterologia Universitaria, Pisa, Italy</location>
      <location>Policlinico Universitario Campus Biomedico, Roma, Italy</location>
      <location>A.O. San Camillo-Forlanini, Roma, Italy</location>
      <location>hospitall Sant'Andrea, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03449628</url>
  </study>
  <study rank="156">
    <nct_id>NCT00880594</nct_id>
    <title>Irritable Bowel Syndrome (IBS) Functional Magnetic Resonance Imaging (fMRI) With Desipramine</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in brain activations using functional MR following desipramine therapy in IBS populations.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>09-0013</other_id>
    </other_ids>
    <start_date>February 2009</start_date>
    <primary_completion_date>May 2019</primary_completion_date>
    <completion_date>May 2019</completion_date>
    <study_first_posted>April 14, 2009</study_first_posted>
    <last_update_posted>July 3, 2018</last_update_posted>
    <locations>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00880594</url>
  </study>
  <study rank="157">
    <nct_id>NCT01304355</nct_id>
    <title>An Assessment of Cognitive Function in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>CANTAB Assessments</outcome_measure>
      <outcome_measure>IBS Symptom Severity</outcome_measure>
      <outcome_measure>Kynurenine Pathway Metabolies</outcome_measure>
      <outcome_measure>Glucocorticoids</outcome_measure>
      <outcome_measure>Cytokines</outcome_measure>
      <outcome_measure>Psychiatric Comorbidity</outcome_measure>
      <outcome_measure>Sleep Quality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College Cork</lead_sponsor>
      <collaborator>Science Foundation Ireland</collaborator>
      <collaborator>American Neurogastroenterology and Motility Society</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>85</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>APC024-GC/ANMS</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>January 2012</completion_date>
    <study_first_posted>February 25, 2011</study_first_posted>
    <last_update_posted>February 25, 2011</last_update_posted>
    <locations>
      <location>Cork University Hospial, Cork, Ireland</location>
      <location>University College Cork, Cork, Ireland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01304355</url>
  </study>
  <study rank="158">
    <nct_id>NCT01629212</nct_id>
    <title>Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tiropramide HCl 100mg</intervention>
      <intervention type="Drug">Octylonium bromide 20mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of abdominal pain VAS scores from baseline to week 4</outcome_measure>
      <outcome_measure>Change of abdominal pain VAS scores from baseline to week 2</outcome_measure>
      <outcome_measure>Change of abdominal discomfort VAS scores from baseline to week 2 and 4</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Daewoong Pharmaceutical Co. LTD.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DW-TRP001</other_id>
    </other_ids>
    <start_date>December 2011</start_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <completion_date>February 2013</completion_date>
    <study_first_posted>June 27, 2012</study_first_posted>
    <last_update_posted>June 27, 2012</last_update_posted>
    <locations>
      <location>Han Yang University Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01629212</url>
  </study>
  <study rank="159">
    <nct_id>NCT02841878</nct_id>
    <title>Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome</title>
    <acronym>PROTIBS</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">Analysis on colorectal biopsy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical criteria</outcome_measure>
      <outcome_measure>Experimental criteria</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-PP-20</other_id>
    </other_ids>
    <start_date>September 2016</start_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <completion_date>September 2018</completion_date>
    <study_first_posted>July 22, 2016</study_first_posted>
    <last_update_posted>February 21, 2018</last_update_posted>
    <locations>
      <location>Department of gastroenterology, Hopital Archet 2, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02841878</url>
  </study>
  <study rank="160">
    <nct_id>NCT03432078</nct_id>
    <title>Individual vs. Group Hypnotherapy in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Hypnotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of Gastrointestinal symptom severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>67 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>686-11</other_id>
    </other_ids>
    <start_date>August 15, 2011</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2025</completion_date>
    <study_first_posted>February 13, 2018</study_first_posted>
    <last_update_posted>April 8, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03432078</url>
  </study>
  <study rank="161">
    <nct_id>NCT00977197</nct_id>
    <title>A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pregabalin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean Pain Bowel Symptom Scale (BSS) Score Over Last 4 Weeks of Study (Weeks 9-12)</outcome_measure>
      <outcome_measure>Mean Overall Severity of Irritable Bowel Syndrome (IBS) Symptoms BSS Score Last 4 Weeks of the Study (Weeks 9-12)</outcome_measure>
      <outcome_measure>Mean Constipation BSS Score Over Last 4 Weeks of Study (Weeks 9-12)</outcome_measure>
      <outcome_measure>Mean Diarrhea BSS Score Over the Last 4 Weeks of the Study (Weeks 9-12)</outcome_measure>
      <outcome_measure>Mean Bloating BSS Score Over the Last 4 Weeks of the Study (Weeks 9-12)</outcome_measure>
      <outcome_measure>Number of Subjects With Adequate Relief of IBS Symptoms at Least 50% of the Last 4 Weeks of Therapy</outcome_measure>
      <outcome_measure>Mean Pain BSS Score at Week 12</outcome_measure>
      <outcome_measure>Mean Overall Severity BSS Score at Week 12</outcome_measure>
      <outcome_measure>Mean Constipation BSS Score at Week 12</outcome_measure>
      <outcome_measure>Mean Diarrhea BSS Score at Week 12</outcome_measure>
      <outcome_measure>Mean Bloating BSS Score at Week 12</outcome_measure>
      <outcome_measure>Number of Subjects With Greater Than or Equal to a 30 Point Change in Pain BSS Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>85</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>09-004404</other_id>
    </other_ids>
    <start_date>March 2010</start_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <completion_date>June 2015</completion_date>
    <study_first_posted>September 15, 2009</study_first_posted>
    <results_first_posted>July 14, 2016</results_first_posted>
    <last_update_posted>October 28, 2016</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Mayo Clinic Health System - Franciscan Healthcare in La Crosse, La Crosse, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00977197</url>
  </study>
  <study rank="162">
    <nct_id>NCT01844180</nct_id>
    <title>A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym>RESTORE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ONO-2952</intervention>
      <intervention type="Drug">ONO-2952 Matching Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain or stool symptoms in female subjects with IBS-D by using a numeric pain rating scale and the Bristol Stool Scale (BSS)</outcome_measure>
      <outcome_measure>Change in IBS related symptoms and quality of life (QoL) by questionaire assessments</outcome_measure>
      <outcome_measure>Safety assessed through adverse events and clinical laboratory values</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ono Pharma USA Inc</lead_sponsor>
      <collaborator>Ono Pharmaceutical Co. Ltd</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ONO-2952POU004</other_id>
    </other_ids>
    <start_date>April 2013</start_date>
    <primary_completion_date>July 2014</primary_completion_date>
    <study_first_posted>May 1, 2013</study_first_posted>
    <last_update_posted>April 15, 2016</last_update_posted>
    <locations>
      <location>Anniston Clinical Site, Anniston, Alabama, United States</location>
      <location>Goodyear Clinical Site, Goodyear, Arizona, United States</location>
      <location>Tucson Clinical Site, Tucson, Arizona, United States</location>
      <location>North Little Rock Clinical Site, North Little Rock, Arkansas, United States</location>
      <location>Carlsbad Clinical Site, Carlsbad, California, United States</location>
      <location>San Diego Clinical Site, San Diego, California, United States</location>
      <location>Boynton Beach Clinical Site, Boynton Beach, Florida, United States</location>
      <location>Clearwater Clinical Site, Clearwater, Florida, United States</location>
      <location>Deland Clinical Site, Deland, Florida, United States</location>
      <location>Hialeah Clinical Site, Hialeah, Florida, United States</location>
      <location>Lauderdale Lakes Clinical Site, Lauderdale Lakes, Florida, United States</location>
      <location>Orlando Clinical Site, Orlando, Florida, United States</location>
      <location>Port Orange Clinical Site, Port Orange, Florida, United States</location>
      <location>South Miami Clinical Site, South Miami, Florida, United States</location>
      <location>St. Petersburg Clinical Site, St. Petersburg, Florida, United States</location>
      <location>Tampa Clinical Site, Tampa, Florida, United States</location>
      <location>West Palm Clinical Site, West Palm, Florida, United States</location>
      <location>Oak Lawn Clinical Site, Oak Lawn, Illinois, United States</location>
      <location>Wichita Clinical Site, Wichita, Kansas, United States</location>
      <location>New Orleans Clinical Site, New Orleans, Louisiana, United States</location>
      <location>Chesterfield Clincial Site, Chesterfield, Michigan, United States</location>
      <location>Billings Clinical Site, Billings, Montana, United States</location>
      <location>Reno Clinical Site, Reno, Nevada, United States</location>
      <location>Lebanon Clinical Site, Lebanon, New Hampshire, United States</location>
      <location>Albuquerque Clinical Site, Albuquerque, New Mexico, United States</location>
      <location>Great Neck Clinical Site, Great Neck, New York, United States</location>
      <location>Cary Clinical Site, Cary, North Carolina, United States</location>
      <location>Highpoint Clinical Site, Highpoint, North Carolina, United States</location>
      <location>Raleigh Clinical Site, Raleigh, North Carolina, United States</location>
      <location>Winston-Salem Clinical Site, Winston-Salem, North Carolina, United States</location>
      <location>Akron Clinical Site, Akron, Ohio, United States</location>
      <location>Columbus Clinical Site, Columbus, Ohio, United States</location>
      <location>Dayton Clinical Site, Dayton, Ohio, United States</location>
      <location>Groveport Clinical Site, Groveport, Ohio, United States</location>
      <location>Mentor Clinical Site, Mentor, Ohio, United States</location>
      <location>Norman Clinical Site, Norman, Oklahoma, United States</location>
      <location>Lansdale Clinical Site, Landsdale, Pennsylvania, United States</location>
      <location>Greer Clinical Site, Greer, South Carolina, United States</location>
      <location>Mt. Pleasant Clinical Site, Mt. Pleasant, South Carolina, United States</location>
      <location>Chattanooga Clinical Site, Chattanooga, Tennessee, United States</location>
      <location>Germantown Clinical Site, Germantown, Tennessee, United States</location>
      <location>Pasadena Clinical Site, Pasadena, Texas, United States</location>
      <location>Plano Clinial Site, Plano, Texas, United States</location>
      <location>San Antonio Clinical Site, San Antonio, Texas, United States</location>
      <location>Logan Clinical Site, Logan, Utah, United States</location>
      <location>Ogden Clinical Site, Ogden, Utah, United States</location>
      <location>Salt Lake City Clinical Site, Salt Lake City, Utah, United States</location>
      <location>Sandy Clinical Site, Sandy, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01844180</url>
  </study>
  <study rank="163">
    <nct_id>NCT01327300</nct_id>
    <title>Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)</title>
    <acronym>IBS</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalamine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo</outcome_measure>
      <outcome_measure>Number of Participants Who Had Evidence of Increased Levels of Pathologic Indicators of Colonic Mucosal Inflammation at 12 Weeks Compared to Baseline.</outcome_measure>
      <outcome_measure>Functional Bowel Disorder Severity Index (FBDSI)</outcome_measure>
      <outcome_measure>IBS - Quality of Life (IBS-QOL)Score.</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS)</outcome_measure>
      <outcome_measure>Intestinal Permeability Testing</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>106-2010</other_id>
    </other_ids>
    <start_date>March 2010</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <completion_date>March 2012</completion_date>
    <study_first_posted>April 1, 2011</study_first_posted>
    <results_first_posted>February 12, 2014</results_first_posted>
    <last_update_posted>February 12, 2014</last_update_posted>
    <locations>
      <location>University of Florida, Gainesville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01327300</url>
  </study>
  <study rank="164">
    <nct_id>NCT01553747</nct_id>
    <title>Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eluxadoline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</outcome_measure>
      <outcome_measure>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</outcome_measure>
      <outcome_measure>Change From Baseline in Daily Abdominal Discomfort Scores</outcome_measure>
      <outcome_measure>Change From Baseline in Daily Abdominal Bloating Scores</outcome_measure>
      <outcome_measure>Number of Bowel Movements Per Day</outcome_measure>
      <outcome_measure>Number of Bowel Incontinence Episodes</outcome_measure>
      <outcome_measure>Number of Bowel Incontinence Free Days</outcome_measure>
      <outcome_measure>Number of Urgency Episodes Per Day</outcome_measure>
      <outcome_measure>Change From Baseline in IBS-QoL Total Scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Furiex Pharmaceuticals, Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1146</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>27018966IBS3002</other_id>
      <other_id>2012-001601-24</other_id>
    </other_ids>
    <start_date>May 29, 2012</start_date>
    <primary_completion_date>January 9, 2014</primary_completion_date>
    <completion_date>January 9, 2014</completion_date>
    <study_first_posted>March 14, 2012</study_first_posted>
    <results_first_posted>July 30, 2018</results_first_posted>
    <last_update_posted>July 30, 2018</last_update_posted>
    <locations>
      <location>Furiex Research Site, Birmingham, Alabama, United States</location>
      <location>Furiex Research Site, Birmingham, Alabama, United States</location>
      <location>Furiex Research Site, Decatur, Alabama, United States</location>
      <location>Furiex Research Site, Huntsville, Alabama, United States</location>
      <location>Furiex Research Site, Mobile, Alabama, United States</location>
      <location>Furiex Research Site, Montgomery, Alabama, United States</location>
      <location>Furiex Research Site, Sheffield, Alabama, United States</location>
      <location>Furiex Research Site, Tuscaloosa, Alabama, United States</location>
      <location>Furiex Research Site, Glendale, Arizona, United States</location>
      <location>Furiex Research Site, Glendale, Arizona, United States</location>
      <location>Furiex Research Site, Mesa, Arizona, United States</location>
      <location>Furiex Research Site, Phoenix, Arizona, United States</location>
      <location>Furiex Research Site, Phoenix, Arizona, United States</location>
      <location>Furiex Research Site, Tucson, Arizona, United States</location>
      <location>Furiex Research Site, Tucson, Arizona, United States</location>
      <location>Furiex Research Site, Jonesboro, Arkansas, United States</location>
      <location>Furiex Research Site, Little Rock, Arkansas, United States</location>
      <location>Furiex Research Site, Sherwood, Arkansas, United States</location>
      <location>Furiex Research Site, Anaheim, California, United States</location>
      <location>Furiex Research Site, Chula Vista, California, United States</location>
      <location>Furiex Research Site, Encinitas, California, United States</location>
      <location>Furiex Research Site, Garden Grove, California, United States</location>
      <location>Furiex Research Site, Huntington Beach, California, United States</location>
      <location>Furiex Research Site, Irvine, California, United States</location>
      <location>Furiex Research Site, La Mesa, California, United States</location>
      <location>Furiex Research Site, La Mirada, California, United States</location>
      <location>Furiex Research Site, Laguna Hills, California, United States</location>
      <location>Furiex Research Site, Lakewood, California, United States</location>
      <location>Furiex Research Site, Lincoln, California, United States</location>
      <location>Furiex Research Site, Loma Linda, California, United States</location>
      <location>Furiex Research Site, Lomita, California, United States</location>
      <location>Furiex Research Site, Long Beach, California, United States</location>
      <location>Furiex Research Site, Los Angeles, California, United States</location>
      <location>Furiex Research Site, Newport Beach, California, United States</location>
      <location>Furiex Research Site, North Hollywood, California, United States</location>
      <location>Furiex Research Site, Northridge, California, United States</location>
      <location>Furiex Research Site, Pasadena, California, United States</location>
      <location>Furiex Research Site, Sacramento, California, United States</location>
      <location>Furiex Research Site, San Diego, California, United States</location>
      <location>Furiex Research Site, San Diego, California, United States</location>
      <location>Furiex Research Site, Santa Ana, California, United States</location>
      <location>Furiex Research Site, Ventura, California, United States</location>
      <location>Furiex Research Site, Walnut Creek, California, United States</location>
      <location>Furiex Research Site, Denver, Colorado, United States</location>
      <location>Furiex Research Site, Denver, Colorado, United States</location>
      <location>Furiex Research Site, Boca Raton, Florida, United States</location>
      <location>Furiex Research Site, Boynton Beach, Florida, United States</location>
      <location>Furiex Research Site, Bradenton, Florida, United States</location>
      <location>Furiex Research Site, Brooksville, Florida, United States</location>
      <location>Furiex Research Site, Clearwater, Florida, United States</location>
      <location>Furiex Research Site, Cooper City, Florida, United States</location>
      <location>Furiex Research Site, Coral Springs, Florida, United States</location>
      <location>Furiex Research Site, Eustis, Florida, United States</location>
      <location>Furiex Research Site, Fort Lauderdale, Florida, United States</location>
      <location>Furiex Research Site, Hallandale Beach, Florida, United States</location>
      <location>Furiex Research Site, Hialeah, Florida, United States</location>
      <location>Furiex Research Site, Jacksonville, Florida, United States</location>
      <location>Furiex Research Site, Jupiter, Florida, United States</location>
      <location>Furiex Research Site, Lauderdale Lakes, Florida, United States</location>
      <location>Furiex Research Site, Melbourne, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miramar, Florida, United States</location>
      <location>Furiex Research Site, New Port Richey, Florida, United States</location>
      <location>Furiex Research Site, Orlando, Florida, United States</location>
      <location>Furiex Research Site, Plant City, Florida, United States</location>
      <location>Furiex Research Site, Port Orange, Florida, United States</location>
      <location>Furiex Research Site, Saint Petersburg, Florida, United States</location>
      <location>Furiex Research Site, Saint Petersburg, Florida, United States</location>
      <location>Furiex Research Site, South Miami, Florida, United States</location>
      <location>Furiex Research Site, Tampa, Florida, United States</location>
      <location>Furiex Research Site, Wellington, Florida, United States</location>
      <location>Furiex Research Site, Winter Haven, Florida, United States</location>
      <location>Furiex Research Site, Winter Park, Florida, United States</location>
      <location>Furiex Research Site, Alpharetta, Georgia, United States</location>
      <location>Furiex Research Site, Athens, Georgia, United States</location>
      <location>Furiex Research Site, Atlanta, Georgia, United States</location>
      <location>Furiex Research Site, Atlanta, Georgia, United States</location>
      <location>Furiex Research Site, Dunwoody, Georgia, United States</location>
      <location>Furiex Research Site, Lawrenceville, Georgia, United States</location>
      <location>Furiex Research Site, Macon, Georgia, United States</location>
      <location>Furiex Research Site, Marietta, Georgia, United States</location>
      <location>Furiex Research Site, Norcross, Georgia, United States</location>
      <location>Furiex Research Site, Savannah, Georgia, United States</location>
      <location>Furiex Research Site, Stockbridge, Georgia, United States</location>
      <location>Furiex Research Site, Boise, Idaho, United States</location>
      <location>Furiex Research Site, Eagle, Idaho, United States</location>
      <location>Furiex Research Site, Idaho Falls, Idaho, United States</location>
      <location>Furiex Research Site, Addison, Illinois, United States</location>
      <location>Furiex Research Site, Chicago, Illinois, United States</location>
      <location>Furiex Research Site, Chicago, Illinois, United States</location>
      <location>Furiex Research Site, Evergreen Park, Illinois, United States</location>
      <location>Furiex Research Site, Hammond, Illinois, United States</location>
      <location>Furiex Research Site, Springfield, Illinois, United States</location>
      <location>Furiex Research Site, Brownsburg, Indiana, United States</location>
      <location>Furiex Research Site, Evansville, Indiana, United States</location>
      <location>Furiex Research Site, Granger, Indiana, United States</location>
      <location>Furiex Research Site, Clive, Iowa, United States</location>
      <location>Furiex Research Site, Pratt, Kansas, United States</location>
      <location>Furiex Research Site, Shawnee Mission, Kansas, United States</location>
      <location>Furiex Research Site, Topeka, Kansas, United States</location>
      <location>Furiex Research Site, Lexington, Kentucky, United States</location>
      <location>Furiex Research Site, Lexington, Kentucky, United States</location>
      <location>Furiex Research Site, Owensboro, Kentucky, United States</location>
      <location>Furiex Research Site, Paducah, Kentucky, United States</location>
      <location>Furiex Research Site, Lake Charles, Louisiana, United States</location>
      <location>Furiex Research Site, Monroe, Louisiana, United States</location>
      <location>Furiex Research Site, Hagerstown, Maryland, United States</location>
      <location>Furiex Research Site, Hollywood, Maryland, United States</location>
      <location>Furiex Research Site, Boston, Massachusetts, United States</location>
      <location>Furiex Research Site, Boston, Massachusetts, United States</location>
      <location>Furiex Research Site, Brockton, Massachusetts, United States</location>
      <location>Furiex Research Site, Watertown, Massachusetts, United States</location>
      <location>Furiex Research Site, Ann Arbor, Michigan, United States</location>
      <location>Furiex Research Site, Bay City, Michigan, United States</location>
      <location>Furiex Research Site, Cadillac, Michigan, United States</location>
      <location>Furiex Research Site, Grand Rapids, Michigan, United States</location>
      <location>Furiex Research Site, Kalamazoo, Michigan, United States</location>
      <location>Furiex Research Site, Troy, Michigan, United States</location>
      <location>Furiex Research Site, Ypsilanti, Michigan, United States</location>
      <location>Furiex Research Site, Plymouth, Minnesota, United States</location>
      <location>Furiex Research Site, Biloxi, Mississippi, United States</location>
      <location>Furiex Research Site, Hazelwood, Missouri, United States</location>
      <location>Furiex Research Site, Saint Louis, Missouri, United States</location>
      <location>Furiex Research Site, Saint Louis, Missouri, United States</location>
      <location>Furiex Research Site, Saint Louis, Missouri, United States</location>
      <location>Furiex Research Site, Saint Peters, Missouri, United States</location>
      <location>Furiex Research Site, Billings, Montana, United States</location>
      <location>Furiex Research Site, Bellevue, Nebraska, United States</location>
      <location>Furiex Research Site, Elkhorn, Nebraska, United States</location>
      <location>Furiex Research Site, Lincoln, Nebraska, United States</location>
      <location>Furiex Research Site, Omaha, Nebraska, United States</location>
      <location>Furiex Research Site, Omaha, Nebraska, United States</location>
      <location>Furiex Research Site, Las Vegas, Nevada, United States</location>
      <location>Furiex Research Site, Reno, Nevada, United States</location>
      <location>Furiex Research Site, Lebanon, New Hampshire, United States</location>
      <location>Furiex Research Site, Blackwood, New Jersey, United States</location>
      <location>Furiex Research Site, Edison, New Jersey, United States</location>
      <location>Furiex Research Site, Elizabeth, New Jersey, United States</location>
      <location>Furiex Research Site, Marlton, New Jersey, United States</location>
      <location>Furiex Research Site, Albuquerque, New Mexico, United States</location>
      <location>Furiex Research Site, Albuquerque, New Mexico, United States</location>
      <location>Furiex Research Site, Albuquerque, New Mexico, United States</location>
      <location>Furiex Research Site, Flushing, New York, United States</location>
      <location>Furiex Research Site, Hollis, New York, United States</location>
      <location>Furiex Research Site, Mineola, New York, United States</location>
      <location>Furiex Research Site, New York, New York, United States</location>
      <location>Furiex Research Site, Chapel Hill, North Carolina, United States</location>
      <location>Furiex Research Site, Dunn, North Carolina, United States</location>
      <location>Furiex Research Site, Greensboro, North Carolina, United States</location>
      <location>Furiex Research Site, Huntersville, North Carolina, United States</location>
      <location>Furiex Research Site, Kinston, North Carolina, United States</location>
      <location>Furiex Research Site, Wilmington, North Carolina, United States</location>
      <location>Furiex Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Furiex Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Furiex Research Site, Akron, Ohio, United States</location>
      <location>Furiex Research Site, Beavercreek, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Cleveland, Ohio, United States</location>
      <location>Furiex Research Site, Columbus, Ohio, United States</location>
      <location>Furiex Research Site, Columbus, Ohio, United States</location>
      <location>Furiex Research Site, Columbus, Ohio, United States</location>
      <location>Furiex Research Site, Dayton, Ohio, United States</location>
      <location>Furiex Research Site, Dayton, Ohio, United States</location>
      <location>Furiex Research Site, Groveport, Ohio, United States</location>
      <location>Furiex Research Site, Kettering, Ohio, United States</location>
      <location>Furiex Research Site, Lima, Ohio, United States</location>
      <location>Furiex Research Site, Tiffin, Ohio, United States</location>
      <location>Furiex Research Site, Toledo, Ohio, United States</location>
      <location>Furiex Research Site, Norman, Oklahoma, United States</location>
      <location>Furiex Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Furiex Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Furiex Research Site, Portland, Oregon, United States</location>
      <location>Furiex Research Site, Salem, Oregon, United States</location>
      <location>Furiex Research Site, Carnegie, Pennsylvania, United States</location>
      <location>Furiex Research Site, Philadelphia, Pennsylvania, United States</location>
      <location>Furiex Research Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Furiex Research Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Furiex Research Site, Scottdale, Pennsylvania, United States</location>
      <location>Furiex Research Site, Uniontown, Pennsylvania, United States</location>
      <location>Furiex Research Site, Warwick, Rhode Island, United States</location>
      <location>Furiex Research Site, Anderson, South Carolina, United States</location>
      <location>Furiex Research Site, Columbia, South Carolina, United States</location>
      <location>Furiex Research Site, Columbia, South Carolina, United States</location>
      <location>Furiex Research Site, Columbia, South Carolina, United States</location>
      <location>Furiex Research Site, Easley, South Carolina, United States</location>
      <location>Furiex Research Site, Mount Pleasant, South Carolina, United States</location>
      <location>Furiex Research Site, North Myrtle Beach, South Carolina, United States</location>
      <location>Furiex Research Site, Rapid City, South Dakota, United States</location>
      <location>Furiex Research Site, Athens, Tennessee, United States</location>
      <location>Furiex Research Site, Chattanooga, Tennessee, United States</location>
      <location>Furiex Research Site, Columbia, Tennessee, United States</location>
      <location>Furiex Research Site, Jackson, Tennessee, United States</location>
      <location>Furiex Research Site, Knoxville, Tennessee, United States</location>
      <location>Furiex Research Site, Smyrna, Tennessee, United States</location>
      <location>Furiex Research Site, Austin, Texas, United States</location>
      <location>Furiex Research Site, Beaumont, Texas, United States</location>
      <location>Furiex Research Site, Bedford, Texas, United States</location>
      <location>Furiex Research Site, Corsicana, Texas, United States</location>
      <location>Furiex Research Site, Dallas, Texas, United States</location>
      <location>Furiex Research Site, Dallas, Texas, United States</location>
      <location>Furiex Research Site, Fort Worth, Texas, United States</location>
      <location>Furiex Research Site, Frisco, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Humble, Texas, United States</location>
      <location>Furiex Research Site, Hurst, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, Bountiful, Utah, United States</location>
      <location>Furiex Research Site, Salt Lake City, Utah, United States</location>
      <location>Furiex Research Site, West Valley City, Utah, United States</location>
      <location>Furiex Research Site, Burlington, Vermont, United States</location>
      <location>Furiex Research Site, Alexandria, Virginia, United States</location>
      <location>Furiex Research Site, Christiansburg, Virginia, United States</location>
      <location>Furiex Research Site, Midlothian, Virginia, United States</location>
      <location>Furiex Research Site, Norfolk, Virginia, United States</location>
      <location>Furiex Research Site, Richmond, Virginia, United States</location>
      <location>Furiex Research Site, Richmond, Virginia, United States</location>
      <location>Furiex Research Site, Charleston, West Virginia, United States</location>
      <location>Furiex Research Site, Monroe, Wisconsin, United States</location>
      <location>Furiex Research Site, Kelowna, British Columbia, Canada</location>
      <location>Furiex Research Site, St. John's, Newfoundland and Labrador, Canada</location>
      <location>Furiex Research Site, Burlington, Ontario, Canada</location>
      <location>Furiex Research Site, Hawkesbury, Ontario, Canada</location>
      <location>Furiex Research Site, London, Ontario, Canada</location>
      <location>Furiex Research Site, Newmarket, Ontario, Canada</location>
      <location>Furiex Research Site, Sarnia, Ontario, Canada</location>
      <location>Furiex Research Site, Sudbury, Ontario, Canada</location>
      <location>Furiex Research Site, Toronto, Ontario, Canada</location>
      <location>Furiex Research Site, Vaughan, Ontario, Canada</location>
      <location>Furiex Research Site, San Juan, Puerto Rico</location>
      <location>Furiex Research Site, Chestfield, Kent, United Kingdom</location>
      <location>Furiex Research Site, Blackpool, Lancashire, United Kingdom</location>
      <location>Furiex Research Site, Birmingham, United Kingdom</location>
      <location>Furiex Research Site, County Durham, United Kingdom</location>
      <location>Furiex Research Site, Coventry, United Kingdom</location>
      <location>Furiex Research Site, Durham, United Kingdom</location>
      <location>Furiex Research Site, Edinburgh, United Kingdom</location>
      <location>Furiex Research Site, Manchester, United Kingdom</location>
      <location>Furiex Research Site, Sheffield, United Kingdom</location>
      <location>Furiex Research Site, Wigan, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01553747</url>
  </study>
  <study rank="165">
    <nct_id>NCT01497847</nct_id>
    <title>Post-Infectious Irritable Bowel Syndrome (PI-IBS)</title>
    <acronym>PI-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>postinfectious IBS symptoms (ROME III criteria) 1 year after travelers diarrhea episode</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KU Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>S51501</other_id>
    </other_ids>
    <start_date>March 2010</start_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <completion_date>February 2013</completion_date>
    <study_first_posted>December 23, 2011</study_first_posted>
    <last_update_posted>April 26, 2013</last_update_posted>
    <locations>
      <location>University hospitals Leuven, Leuven, Vlaams-Brabant, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01497847</url>
  </study>
  <study rank="166">
    <nct_id>NCT01887002</nct_id>
    <title>Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym>RESTORE</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ONO-2952</intervention>
      <intervention type="Drug">Placebo comparator</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in pain intensity rating during rectal distention by using a numeric pain rating scale</outcome_measure>
      <outcome_measure>Safety assessed through adverse events and clinical laboratory values</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ono Pharma USA Inc</lead_sponsor>
      <collaborator>Ono Pharmaceutical Co. Ltd</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ONO-2952POU005</other_id>
    </other_ids>
    <start_date>June 2013</start_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <study_first_posted>June 26, 2013</study_first_posted>
    <last_update_posted>February 25, 2016</last_update_posted>
    <locations>
      <location>Boston Clinical Site, Boston, Massachusetts, United States</location>
      <location>St. Louis Clinical Site, St. Louis, Missouri, United States</location>
      <location>Chapel Hill Clinical Site, Chapel Hill, North Carolina, United States</location>
      <location>Oklahoma City Clinical Site, Oklahoma, Oklahoma, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01887002</url>
  </study>
  <study rank="167">
    <nct_id>NCT00693732</nct_id>
    <title>Validation of Surrogate Measures in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram treatment</intervention>
      <intervention type="Behavioral">Quantitative sensory testing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To correlate clinical measures of IBS activity with experimental measures of central sensitisation and endogenous pain modulation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
      <collaborator>NMRC, Singapore</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>D/06/264</other_id>
    </other_ids>
    <start_date>February 2009</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>January 2012</completion_date>
    <study_first_posted>June 9, 2008</study_first_posted>
    <last_update_posted>January 7, 2014</last_update_posted>
    <locations>
      <location>NUH, Singapore, Singapore</location>
      <location>National University Hospital, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00693732</url>
  </study>
  <study rank="168">
    <nct_id>NCT01253408</nct_id>
    <title>Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor Functions in Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dronabinol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Transit Geometric Center at 24 Hours</outcome_measure>
      <outcome_measure>Colonic Transit Geometric Center</outcome_measure>
      <outcome_measure>Gastric Emptying Half-Time (t1/2)</outcome_measure>
      <outcome_measure>Colonic Filling at 6 Hours</outcome_measure>
      <outcome_measure>Ascending Colon Emptying T 1/2</outcome_measure>
      <outcome_measure>Gastric Emptying at 2 and 4 Hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>National Center for Research Resources (NCRR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-008314 Part A</other_id>
      <other_id>R01DK079866</other_id>
      <other_id>UL1RR024150</other_id>
    </other_ids>
    <start_date>September 2009</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>December 3, 2010</study_first_posted>
    <results_first_posted>May 7, 2013</results_first_posted>
    <last_update_posted>May 7, 2013</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01253408</url>
  </study>
  <study rank="169">
    <nct_id>NCT01051973</nct_id>
    <title>Cognitive Behavior Therapy (CBT) Compared to Stress Management for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive behavior therapy</intervention>
      <intervention type="Behavioral">Stress management</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Level of IBS symptoms</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Use of health care resources and societal production loss because of illness</outcome_measure>
      <outcome_measure>Level of IBS-symptoms</outcome_measure>
      <outcome_measure>Anxiety related to gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Level of daily stress</outcome_measure>
      <outcome_measure>Subjective relief of IBS-symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Stockholm County Council, Sweden</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-X</other_id>
    </other_ids>
    <start_date>October 2009</start_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <completion_date>December 2010</completion_date>
    <study_first_posted>January 20, 2010</study_first_posted>
    <last_update_posted>January 5, 2012</last_update_posted>
    <locations>
      <location>Internetpsykatrienheten, M57, Psykiatri sydväst, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01051973</url>
  </study>
  <study rank="170">
    <nct_id>NCT01414244</nct_id>
    <title>Glutamine for the Treatment of Patients With Irritable Bowel Syndrome</title>
    <acronym>AT005291</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Diarrhea-Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Glutamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the Irritable Bowel Symptom Severity Scale</outcome_measure>
      <outcome_measure>Intestinal Permeability</outcome_measure>
      <outcome_measure>Stool Frequency</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tulane University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>72 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-271</other_id>
    </other_ids>
    <start_date>November 2010</start_date>
    <primary_completion_date>December 30, 2015</primary_completion_date>
    <completion_date>December 30, 2015</completion_date>
    <study_first_posted>August 11, 2011</study_first_posted>
    <results_first_posted>August 9, 2017</results_first_posted>
    <last_update_posted>August 9, 2017</last_update_posted>
    <locations>
      <location>Tulane University School of Medicine, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01414244</url>
  </study>
  <study rank="171">
    <nct_id>NCT00587860</nct_id>
    <title>A Placebo-Controlled Trial of St. John's Wort for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">St. John's wort</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall Bowel Symptom Scores (BSS)</outcome_measure>
      <outcome_measure>Bowel Symptom Score (BSS) Amongst Subgroups</outcome_measure>
      <outcome_measure>Adequate Relief ≤ 50% During the Last 4 Weeks of Therapy</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome - Quality of Life (IBS-QoL) Score</outcome_measure>
      <outcome_measure>Center for Epidemiologic Studies Depression Scale (CES-D) Score</outcome_measure>
      <outcome_measure>IBS Symptoms Moderately or a Lot Better</outcome_measure>
      <outcome_measure>Bowel Symptom Score (BSS) at 24 Weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>132-06</other_id>
    </other_ids>
    <start_date>February 2006</start_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <completion_date>March 2008</completion_date>
    <study_first_posted>January 8, 2008</study_first_posted>
    <results_first_posted>March 1, 2010</results_first_posted>
    <last_update_posted>March 9, 2010</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00587860</url>
  </study>
  <study rank="172">
    <nct_id>NCT03245645</nct_id>
    <title>FODMAP Reintroduction in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
      <condition>Irritable Bowel Syndrome With Mixed Bowel Habits</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Dietary Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate relief of IBS symptoms in past 7 days</outcome_measure>
      <outcome_measure>Highest amount of grams of sugar in solutions that do not significantly increase IBS symptoms</outcome_measure>
      <outcome_measure>Change in IBS-symptom severity scale</outcome_measure>
      <outcome_measure>Change in Visceral Sensitivity Index (VSI)</outcome_measure>
      <outcome_measure>Change in Personal Health Questionnaire (PHQ-15)</outcome_measure>
      <outcome_measure>Change in abdominal pain severity</outcome_measure>
      <outcome_measure>Change in overall severity of gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Change in severity of the sensation of bloating, abdominal fullness or visible distension</outcome_measure>
      <outcome_measure>Change in intestinal microbiota</outcome_measure>
      <outcome_measure>Change in visceral sensitivity index score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>16-000934</other_id>
    </other_ids>
    <start_date>March 24, 2017</start_date>
    <primary_completion_date>July 24, 2019</primary_completion_date>
    <completion_date>July 24, 2019</completion_date>
    <study_first_posted>August 10, 2017</study_first_posted>
    <last_update_posted>October 11, 2018</last_update_posted>
    <locations>
      <location>UCLA, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03245645</url>
  </study>
  <study rank="173">
    <nct_id>NCT00931294</nct_id>
    <title>Saliva Testosterone Increases in Irritable Bowel Syndrome (IBS) Patients Beginning Choir Singing</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Choir singing</intervention>
      <intervention type="Behavioral">Information Group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>More reduction in bowel pain according to standardised international IBS questionnaire in choir group than in study group after one year.</outcome_measure>
      <outcome_measure>Significant increase in saliva testosterone concentration during study period in choir group.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stockholm University</lead_sponsor>
      <collaborator>The Swedish Research Council</collaborator>
      <collaborator>Stockholm County Council, Sweden</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SI 5.1 2007-17</other_id>
    </other_ids>
    <start_date>May 2006</start_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <completion_date>May 2007</completion_date>
    <study_first_posted>July 2, 2009</study_first_posted>
    <last_update_posted>July 2, 2009</last_update_posted>
    <locations>
      <location>Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00931294</url>
  </study>
  <study rank="174">
    <nct_id>NCT00093327</nct_id>
    <title>Acupuncture for Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Acupuncture</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Complementary and Integrative Health (NCCIH)</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>287</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01AT001414-01</other_id>
    </other_ids>
    <start_date>September 2003</start_date>
    <completion_date>April 2006</completion_date>
    <study_first_posted>October 8, 2004</study_first_posted>
    <last_update_posted>August 18, 2006</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, General Clinical Research Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00093327</url>
  </study>
  <study rank="175">
    <nct_id>NCT01130272</nct_id>
    <title>Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Irritable Bowel Syndrome With Diarrhea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">JNJ-27018966</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical response to treatment based upon improvement from baseline in both of the following co-primary endpoints: pain intensity as assessed by average daily pain scores; and stool consistency as assessed by Bristol Stool Scores.</outcome_measure>
      <outcome_measure>Average daily pain scores</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Furiex Pharmaceuticals, Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>807</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>27018966IBS2001</other_id>
    </other_ids>
    <start_date>May 2010</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>May 25, 2010</study_first_posted>
    <last_update_posted>June 13, 2012</last_update_posted>
    <locations>
      <location>Furiex Research Site, Anniston, Alabama, United States</location>
      <location>Furiex Research Site, Birmingham, Alabama, United States</location>
      <location>Furiex Research Site, Birmingham, Alabama, United States</location>
      <location>Furiex Research Site, Dothan, Alabama, United States</location>
      <location>Furiex Research Site, Huntsville, Alabama, United States</location>
      <location>Furiex Research Site, Huntsville, Alabama, United States</location>
      <location>Furiex Research Site, Mobile, Alabama, United States</location>
      <location>Furiex Research Site, Montgomery, Alabama, United States</location>
      <location>Furiex Research Site, Pell City, Alabama, United States</location>
      <location>Furiex Research Site, Chandler, Arizona, United States</location>
      <location>Furiex Research Site, Glendale, Arizona, United States</location>
      <location>Furiex Research Site, Mesa, Arizona, United States</location>
      <location>Furiex Research Site, Phoenix, Arizona, United States</location>
      <location>Furiex Research Site, Phoenix, Arizona, United States</location>
      <location>Furiex Research Site, Phoenix, Arizona, United States</location>
      <location>Furiex Research Site, Tempe, Arizona, United States</location>
      <location>Furiex Research Site, Tempe, Arizona, United States</location>
      <location>Furiex Research Site, Tucson, Arizona, United States</location>
      <location>Furiex Research Site, Tucson, Arizona, United States</location>
      <location>Furiex Research Site, Jonesboro, Arkansas, United States</location>
      <location>Furiex Research Site, Little Rock, Arkansas, United States</location>
      <location>Furiex Research Site, Searcy, Arkansas, United States</location>
      <location>Furiex Research Site, Sherwood, Arkansas, United States</location>
      <location>Furiex Research Site, Aliso Viejo, California, United States</location>
      <location>Furiex Resarch Site, Anaheim, California, United States</location>
      <location>Furiex Research Site, Anaheim, California, United States</location>
      <location>Furiex Research Site, Azusa, California, United States</location>
      <location>Furiex Research Site, Burbank, California, United States</location>
      <location>Furiex Research Site, Carlsbad, California, United States</location>
      <location>Furiex Research Site, Encinitas, California, United States</location>
      <location>Furiex Research Site, Garden Grove, California, United States</location>
      <location>Furiex Research Site, Garden Grove, California, United States</location>
      <location>Furiex Research Site, Inglewood, California, United States</location>
      <location>Furiex Research Site, Laguna Hills, California, United States</location>
      <location>Furiex Research Site, Long Beach, California, United States</location>
      <location>Furiex Research Site, Los Angeles, California, United States</location>
      <location>Furiex Research Site, Los Angeles, California, United States</location>
      <location>Furiex Research Site, Murietta, California, United States</location>
      <location>Furiex Research Site, Oakland, California, United States</location>
      <location>Furiex Research Site, Orange, California, United States</location>
      <location>Furiex Research Site, Sacramento, California, United States</location>
      <location>Furiex Research Site, San Carlos, California, United States</location>
      <location>Furiex Research Site, San Diego, California, United States</location>
      <location>Furiex Research Site, San Diego, California, United States</location>
      <location>Furiex Research Site, Colorado Springs, Colorado, United States</location>
      <location>Furiex Research Site, Colorado Springs, Colorado, United States</location>
      <location>Furiex Resarch Site, Colorado Springs, Colorado, United States</location>
      <location>Furiex Resarch Site, Colorado Springs, Colorado, United States</location>
      <location>Furiex Research Site, Denver, Colorado, United States</location>
      <location>Furiex Research Site, Denver, Colorado, United States</location>
      <location>Furiex Research Site, Lakewood, Colorado, United States</location>
      <location>Furiex Research Site, Littleton, Colorado, United States</location>
      <location>Furiex Research Site, Thornton, Colorado, United States</location>
      <location>Furiex Research Site, Bristol, Connecticut, United States</location>
      <location>Furiex Research Site, Waterbury, Connecticut, United States</location>
      <location>Furiex Research Site, Aventura, Florida, United States</location>
      <location>Furiex Resarch Site, Boca Raton, Florida, United States</location>
      <location>Furiex Research Site, Boca Raton, Florida, United States</location>
      <location>Furiex Research Site, Bradenton, Florida, United States</location>
      <location>Furiex Research Site, Brandon, Florida, United States</location>
      <location>Furiex Research Site, Chipley, Florida, United States</location>
      <location>Furiex Research Site, Deland, Florida, United States</location>
      <location>Furiex Research Site, DelRay Beach, Florida, United States</location>
      <location>Furiex Research Site, Doral, Florida, United States</location>
      <location>Furiex Research Site, Fort Lauderdale, Florida, United States</location>
      <location>Furiex Research Site, Hialeah, Florida, United States</location>
      <location>Furiex Research Site, Hialeah, Florida, United States</location>
      <location>Furiex Research Site, Inverness, Florida, United States</location>
      <location>Furiex research Site, Jacksonville, Florida, United States</location>
      <location>Furiex Research Site, Jacksonville, Florida, United States</location>
      <location>Furiex Research Site, Jupiter, Florida, United States</location>
      <location>Furiex Research Site, Kissimmee, Florida, United States</location>
      <location>Furiex Research Site, Largo, Florida, United States</location>
      <location>Furiex Research Site, Lauderdale Lakes, Florida, United States</location>
      <location>Furiex Research Site, Melbourne, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Resarch Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Naples, Florida, United States</location>
      <location>Furiex Resarch Site, Naples, Florida, United States</location>
      <location>Furiex Research Site, New Port Richey, Florida, United States</location>
      <location>Furiex Research Site, New Smyrna Beach, Florida, United States</location>
      <location>Furiex Research Site, Newport Richey, Florida, United States</location>
      <location>Furiex Research Site, Orlando, Florida, United States</location>
      <location>Furiex Research Site, Plantation, Florida, United States</location>
      <location>Furiex Research Site, Port Orange, Florida, United States</location>
      <location>Furiex Research Site, South Miami, Florida, United States</location>
      <location>Furiex Research Site, St. Petersburg, Florida, United States</location>
      <location>Furiex Research Site, Tampa, Florida, United States</location>
      <location>Furiex Research Site, Tampa, Florida, United States</location>
      <location>Furiex Research Site, Atlanta, Georgia, United States</location>
      <location>Furiex Research Site, Atlanta, Georgia, United States</location>
      <location>Furiex Research Site, Columbus, Georgia, United States</location>
      <location>Furiex Research Site, Duluth, Georgia, United States</location>
      <location>Furiex Research Site, Macon, Georgia, United States</location>
      <location>Furiex Research Site, Marietta, Georgia, United States</location>
      <location>Furiex Research Site, Newnan, Georgia, United States</location>
      <location>Furiex Research Site, Rome, Georgia, United States</location>
      <location>Furiex Research Site, Sandy Springs, Georgia, United States</location>
      <location>Furiex Research Site, Savannah, Georgia, United States</location>
      <location>Furiex Research Site, Boise, Idaho, United States</location>
      <location>Furiex Research Site, Boise, Idaho, United States</location>
      <location>Furiex Research Site, Idaho Falls, Idaho, United States</location>
      <location>Furiex Research Site, Meridian, Idaho, United States</location>
      <location>Furiex Research Site, Nampa, Idaho, United States</location>
      <location>Furiex Research Site, Champaign, Illinois, United States</location>
      <location>Furiex Research Site, Chicago, Illinois, United States</location>
      <location>Furiex Resarch Site, Morton, Illinois, United States</location>
      <location>Furiex Research Site, Anderson, Indiana, United States</location>
      <location>Furiex Research Site, Bloomington, Indiana, United States</location>
      <location>Furiex Research Site, Evansville, Indiana, United States</location>
      <location>Furiex Resarch Site, Indianapolis, Indiana, United States</location>
      <location>Furiex Research Site, Indianapolis, Indiana, United States</location>
      <location>Furiex Research Site, Indianapolis, Indiana, United States</location>
      <location>Furiex Research Site, Lenexa, Kansas, United States</location>
      <location>Furiex Research Site, Mission, Kansas, United States</location>
      <location>Furiex Research Site, Overland Park, Kansas, United States</location>
      <location>Furiex Research Site, Overland Park, Kansas, United States</location>
      <location>Furiex Research Site, Topeka, Kansas, United States</location>
      <location>Furiex Research Site, Wichita, Kansas, United States</location>
      <location>Furiex Research Site, Bowling Green, Kentucky, United States</location>
      <location>Furiex Research Site, Lexington, Kentucky, United States</location>
      <location>Furiex Research Site, Louisville, Kentucky, United States</location>
      <location>Furiex Research Site, Metairie, Louisiana, United States</location>
      <location>Furiex Research Site, Monroe, Louisiana, United States</location>
      <location>Furiex Resarch Site, Opelousas, Louisiana, United States</location>
      <location>Furiex Research Site, Shreveport, Louisiana, United States</location>
      <location>Furiex Research Site, Shreveport, Louisiana, United States</location>
      <location>Furiex Research Site, Annapolis, Maryland, United States</location>
      <location>Furiex Research Site, Chevy Chase, Maryland, United States</location>
      <location>Furiex Research Site, Hollywood, Maryland, United States</location>
      <location>Furiex Resarch Site, Laurel, Maryland, United States</location>
      <location>Furiex Research Site, Lutherville, Maryland, United States</location>
      <location>Furiex Research Site, Prince Frederick, Maryland, United States</location>
      <location>Furiex Research Site, Rockville, Maryland, United States</location>
      <location>Furiex research Site, Boston, Massachusetts, United States</location>
      <location>Furiex Research Site, Boston, Massachusetts, United States</location>
      <location>Furiex Research Site, Boston, Massachusetts, United States</location>
      <location>Furiex Research Site, Brockton, Massachusetts, United States</location>
      <location>Furiex Research Site, Hyannis, Massachusetts, United States</location>
      <location>Furiex Resarch Site, Springfield, Massachusetts, United States</location>
      <location>Furiex Research Site, Chesterfield, Michigan, United States</location>
      <location>Furiex Resarch Site, Interlochen, Michigan, United States</location>
      <location>Furiex Research Site, Kalamazoo, Michigan, United States</location>
      <location>Furiex Research Site, Novi, Michigan, United States</location>
      <location>Furiex Research Site, Troy, Michigan, United States</location>
      <location>Furiex Research Site, Chaska, Minnesota, United States</location>
      <location>Furiex Research Site, Jackson, Mississippi, United States</location>
      <location>Furiex Research Site, Tupelo, Mississippi, United States</location>
      <location>Furiex Research Site, Mexico, Missouri, United States</location>
      <location>Furiex Research Site, St. Louis, Missouri, United States</location>
      <location>Furiex Research Site, St. Peters, Missouri, United States</location>
      <location>Furiex Research Site, Billings, Montana, United States</location>
      <location>Furiex Research Site, Bozeman, Montana, United States</location>
      <location>Furiex Research Site, Bellevue, Nebraska, United States</location>
      <location>Furiex Research Site, Omaha, Nebraska, United States</location>
      <location>Furiex Research Site, Omaha, Nebraska, United States</location>
      <location>Furiex Research Site, Henderson, Nevada, United States</location>
      <location>Furiex Research Site, Las Vegas, Nevada, United States</location>
      <location>Furiex Research Site, Las Vegas, Nevada, United States</location>
      <location>Furiex Research Site, Atco, New Jersey, United States</location>
      <location>Furiex Research Site, Blackwood, New Jersey, United States</location>
      <location>Furiex Research Site, Elizabeth, New Jersey, United States</location>
      <location>Furiex Research Site, Marlton, New Jersey, United States</location>
      <location>Furiex Research Site, Morristown, New Jersey, United States</location>
      <location>Furiex Resarch Site, South Bound Brook, New Jersey, United States</location>
      <location>Furiex Research Site, Vineland, New Jersey, United States</location>
      <location>Furiex Research Site, Albuquerque, New Mexico, United States</location>
      <location>Furiex Research Site, Albuquerque, New Mexico, United States</location>
      <location>Furiex Research Site, Binghamton, New York, United States</location>
      <location>Furiex Research Site, Brooklyn, New York, United States</location>
      <location>Furiex Research Site, Brooklyn, New York, United States</location>
      <location>Furiex Research Site, Great Neck, New York, United States</location>
      <location>Furiex Research Site, Great Neck, New York, United States</location>
      <location>Furiex Research Site, Mineola, New York, United States</location>
      <location>Furiex Research Site, New York, New York, United States</location>
      <location>Furiex Research Site, Boone, North Carolina, United States</location>
      <location>Furiex Research Site, Chapel Hill, North Carolina, United States</location>
      <location>Furiex Research Site, Charlotte, North Carolina, United States</location>
      <location>Furiex Research Site, Charlotte, North Carolina, United States</location>
      <location>Furiex Research Site, Fayetteville, North Carolina, United States</location>
      <location>Furiex Resarch Site, Greensboro, North Carolina, United States</location>
      <location>Furiex Research Site, Greensboro, North Carolina, United States</location>
      <location>Furiex Resarch Site, Greenville, North Carolina, United States</location>
      <location>Furiex Research Site, Harrisburg, North Carolina, United States</location>
      <location>Furiex Research Site, Hickory, North Carolina, United States</location>
      <location>Furiex Research Site, Hickory, North Carolina, United States</location>
      <location>Furiex Resarch Site, High Point, North Carolina, United States</location>
      <location>Furiex Research Site, High Point, North Carolina, United States</location>
      <location>Furiex Research Site, Jacksonville, North Carolina, United States</location>
      <location>Furiex Research Site, New Bern, North Carolina, United States</location>
      <location>Furiex Research Site, Raleigh, North Carolina, United States</location>
      <location>Furiex Research Site, Raleigh, North Carolina, United States</location>
      <location>Furiex Research Site, Wilmington, North Carolina, United States</location>
      <location>Furiex Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Furiex Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Furiex Research SIte, Fargo, North Dakota, United States</location>
      <location>Furiex Research Site, Fargo, North Dakota, United States</location>
      <location>Furiex Research Site, Akron, Ohio, United States</location>
      <location>Furiex Research Site, Beachwood, Ohio, United States</location>
      <location>Furiex Resarch Site, Beaver Creek, Ohio, United States</location>
      <location>Furiex Research Site, Beaver Creek, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Cleveland, Ohio, United States</location>
      <location>Furiex Research Site, Columbus, Ohio, United States</location>
      <location>Furiex Research Site, Columbus, Ohio, United States</location>
      <location>Furiex Research Site, Dayton, Ohio, United States</location>
      <location>Furiex Resarch Site, Franklin, Ohio, United States</location>
      <location>Furiex Research Site, Mentor, Ohio, United States</location>
      <location>Furiex Research Site, Miamisburg, Ohio, United States</location>
      <location>Furiex Research Site, Springfield, Ohio, United States</location>
      <location>Furiex Research Site, Wadsworth, Ohio, United States</location>
      <location>Furiex Resarch Site, Norman, Oklahoma, United States</location>
      <location>Furiex Research Site, Norman, Oklahoma, United States</location>
      <location>Furiex Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Furiex Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Furiex Research Site, Yukon, Oklahoma, United States</location>
      <location>Furiex Research Site, Dingmans Ferry, Pennsylvania, United States</location>
      <location>Furiex Research Site, Hermitage, Pennsylvania, United States</location>
      <location>Furiex Research Site, Jenkintown, Pennsylvania, United States</location>
      <location>Furiex Research Site, Lancaster, Pennsylvania, United States</location>
      <location>Furiex Research Site, Lansdale, Pennsylvania, United States</location>
      <location>Furiex Resarch Site, Newton, Pennsylvania, United States</location>
      <location>Furiex Research Site, Sayre, Pennsylvania, United States</location>
      <location>Furiex Research Site, Uniontown, Pennsylvania, United States</location>
      <location>Furiex Research Site, Washington, Pennsylvania, United States</location>
      <location>Furiex Research Site, Cumberland, Rhode Island, United States</location>
      <location>Furiex Research Site, East Providence, Rhode Island, United States</location>
      <location>Furiex Research Site, Warwick, Rhode Island, United States</location>
      <location>Furiex Research Site, Anderson, South Carolina, United States</location>
      <location>Furiex Research Site, Columbia, South Carolina, United States</location>
      <location>Furiex Research Site, Columbia, South Carolina, United States</location>
      <location>Furiex Research Site, Greer, South Carolina, United States</location>
      <location>Furiex Research Site, Mt. Pleasant, South Carolina, United States</location>
      <location>Furiex Research Site, Rapid City, South Dakota, United States</location>
      <location>Furiex Research Site, Bristol, Tennessee, United States</location>
      <location>Furiex Research Site, Chattanooga, Tennessee, United States</location>
      <location>Furiex Research Site, Chattanooga, Tennessee, United States</location>
      <location>Furiex Research Site, Germantown, Tennessee, United States</location>
      <location>Furiex Research Site, Jackson, Tennessee, United States</location>
      <location>Furiex Research Site, Johnson City, Tennessee, United States</location>
      <location>Furiex Research Site, Kingsport, Tennessee, United States</location>
      <location>Furiex Research Site, Nashville, Tennessee, United States</location>
      <location>Furiex Research Site, Nashville, Tennessee, United States</location>
      <location>Furiex Research Site, Austin, Texas, United States</location>
      <location>Furiex Research Site, Bedford, Texas, United States</location>
      <location>Furiex Research Site, Colleyville, Texas, United States</location>
      <location>Furiex Research Site, El Paso, Texas, United States</location>
      <location>Furiex Research Site, Fort Worth, Texas, United States</location>
      <location>Furiex Research Site, Ft. Worth, Texas, United States</location>
      <location>Furiex Research Site, Grand Prairie, Texas, United States</location>
      <location>Furiex Research Site, Grapevine, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Resarch Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Hurst, Texas, United States</location>
      <location>Furiex Research Site, Irving, Texas, United States</location>
      <location>Furiex Research Site, Lake Jackson, Texas, United States</location>
      <location>Furiex Research Site, Marshall, Texas, United States</location>
      <location>Furiex Research Site, North Richland Hills, Texas, United States</location>
      <location>Furiex Research Site, Odessa, Texas, United States</location>
      <location>Furiex Research Site, Plano, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, Sugar Land, Texas, United States</location>
      <location>Furiex Research Site, Sugar Land, Texas, United States</location>
      <location>Furiex Research Site, Webster, Texas, United States</location>
      <location>Furiex Research Site, Logan, Utah, United States</location>
      <location>Furiex Research Site, Ogden, Utah, United States</location>
      <location>Furiex Research Site, Salt Lake City, Utah, United States</location>
      <location>Furiex Resarch Site, Salt Lake City, Utah, United States</location>
      <location>Furiex Research Site, South Jordan, Utah, United States</location>
      <location>Furiex Research Site, West Jordan, Utah, United States</location>
      <location>Furiex Research Site, West Valley City, Utah, United States</location>
      <location>Furiex Research Site, Alexandria, Virginia, United States</location>
      <location>Furiex Research Site, Chesapeake, Virginia, United States</location>
      <location>Furiex Resarch Site, Christiansburg, Virginia, United States</location>
      <location>Furiex Research Site, Danville, Virginia, United States</location>
      <location>Furiex Research Site, Fairfax, Virginia, United States</location>
      <location>Furiex Resarch Site, Virginia Beach, Virginia, United States</location>
      <location>Furiex Research Site, Mill Creek, Washington, United States</location>
      <location>Furiex Research Site, Madison, Wisconsin, United States</location>
      <location>Furiex Research Site, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01130272</url>
  </study>
  <study rank="176">
    <nct_id>NCT00368771</nct_id>
    <title>A Six-month Study to Compare Outcome Differences and Visceral Response ... Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">IBS Stress Management</intervention>
      <intervention type="Behavioral">IBS Symptom Management</intervention>
      <intervention type="Behavioral">IBS Educational Training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in Symptoms</outcome_measure>
      <outcome_measure>IBS-specific Quality of Life increase</outcome_measure>
      <outcome_measure>IBS-Specific Beliefs and Coping</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>163</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01NR007768</other_id>
      <other_id>DK-NR07768</other_id>
    </other_ids>
    <start_date>July 2002</start_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <completion_date>May 2010</completion_date>
    <study_first_posted>August 25, 2006</study_first_posted>
    <last_update_posted>November 28, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00368771</url>
  </study>
  <study rank="177">
    <nct_id>NCT00955994</nct_id>
    <title>Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">asimadoline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of abdominal pain 2 hours after treatment of pain</outcome_measure>
      <outcome_measure>Average pain reduction within 2 hours after first dose each day (&amp;#61508; pain intensity on VAS before and two hours after the first dose on each day with at least moderate pain)</outcome_measure>
      <outcome_measure>The primary efficacy analysis includes all days with complete data sets for VAS before and two hours after intake of study medication and a before-treatment pain intensity of at least 30 mm on the VAS</outcome_measure>
      <outcome_measure>For each of these days the pain reduction of the first dose will be calculated: PID (pain intensity difference) = Pain2h ? Pain0h</outcome_measure>
      <outcome_measure>The average pain reduction on all these days will be calculated by: first, summing up all PID over the treatment period and second, dividing this result by the number of days with pain</outcome_measure>
      <outcome_measure>Maximum pain during each day</outcome_measure>
      <outcome_measure>Frequency of bowel movements (number)</outcome_measure>
      <outcome_measure>Consistency of bowel movements (Bristol stool scale)</outcome_measure>
      <outcome_measure>Ease of passage</outcome_measure>
      <outcome_measure>Adequate relief of IBS pain and</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2394-03</other_id>
      <other_id>IND 67,533</other_id>
    </other_ids>
    <start_date>January 2005</start_date>
    <primary_completion_date>March 2007</primary_completion_date>
    <completion_date>March 2007</completion_date>
    <study_first_posted>August 10, 2009</study_first_posted>
    <last_update_posted>March 23, 2011</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00955994</url>
  </study>
  <study rank="178">
    <nct_id>NCT01870895</nct_id>
    <title>A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YM060</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Monthly responder rate of global assessment of relief of overall IBS symptoms at final point</outcome_measure>
      <outcome_measure>Monthly responder rate of stool form normalization at final point</outcome_measure>
      <outcome_measure>Monthly responder rate of global assessment of relief of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Monthly responder rate of global assessment of improvement of abnormal bowel habits</outcome_measure>
      <outcome_measure>Change in weekly average scores of severity of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Change in weekly average scores of stool form</outcome_measure>
      <outcome_measure>Safety assessment of YM060</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>577</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-702</other_id>
    </other_ids>
    <start_date>February 2013</start_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <completion_date>February 2014</completion_date>
    <study_first_posted>June 6, 2013</study_first_posted>
    <last_update_posted>October 12, 2015</last_update_posted>
    <locations>
      <location>Hokkaido, Japan</location>
      <location>Kansai, Japan</location>
      <location>Kantou, Japan</location>
      <location>Kyushu, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01870895</url>
  </study>
  <study rank="179">
    <nct_id>NCT00844961</nct_id>
    <title>Effectiveness of Internet Delivered Cognitive Behavior Therapy (CBT) for Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internet delivered cognitive behavior therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Gastrointestinal Symptom Rating Scale - IBS Version (GSRS-IBS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Allmänna arvsfonden</collaborator>
      <collaborator>Stockholm County Council, Sweden</collaborator>
      <collaborator>Königska-Söderströmska sjukhemmet</collaborator>
      <collaborator>Aleris Helse</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-K</other_id>
    </other_ids>
    <start_date>November 2008</start_date>
    <primary_completion_date>February 2011</primary_completion_date>
    <completion_date>February 2011</completion_date>
    <study_first_posted>February 16, 2009</study_first_posted>
    <last_update_posted>November 9, 2011</last_update_posted>
    <locations>
      <location>Internetpsykatrienheten, M57, Psykiatri sydväst, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00844961</url>
  </study>
  <study rank="180">
    <nct_id>NCT00813098</nct_id>
    <title>Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LX1031 High Dose</intervention>
      <intervention type="Drug">LX1031 Low Dose</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline at Week 4 in Proportion of Days Per Week When Experiencing Urgency to Defecate</outcome_measure>
      <outcome_measure>Change From Baseline at Week 4 in Stool Consistency Scores</outcome_measure>
      <outcome_measure>Change From Baseline at Week 4 in Stool Frequency</outcome_measure>
      <outcome_measure>Change From Baseline at Week 4 on the Severity of Bloating</outcome_measure>
      <outcome_measure>Change From Baseline at Week 4 on the Global Improvement Score.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lexicon Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>155</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Protocol LX1031.1-201-IBS</other_id>
      <other_id>LX1031.201</other_id>
    </other_ids>
    <start_date>December 2008</start_date>
    <primary_completion_date>July 2009</primary_completion_date>
    <completion_date>August 2010</completion_date>
    <study_first_posted>December 22, 2008</study_first_posted>
    <results_first_posted>December 2, 2010</results_first_posted>
    <last_update_posted>December 2, 2010</last_update_posted>
    <locations>
      <location>Genova Clinical Research, Tucson, Arizona, United States</location>
      <location>Arkansas Gastroenterology, Sherwood, Arkansas, United States</location>
      <location>Advanced Clinical Research Institute, Anaheim, California, United States</location>
      <location>Edinger Medical Group Clinical Research Center, Fountain Valley, California, United States</location>
      <location>Impact Clinical Trials, Los Angeles, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>AGMG - Orange, Orange, California, United States</location>
      <location>Medical Associates Research Group, San Diego, California, United States</location>
      <location>Lynn Instiute of the Rockies, Colorado Springs, Colorado, United States</location>
      <location>Clinical Trials Management of Boca Raton, Inc., Boca Raton, Florida, United States</location>
      <location>Consultants for Clinical Research of S. Florida, Boynton Beach, Florida, United States</location>
      <location>Research Consultants Group, Hialeah, Florida, United States</location>
      <location>Accord Clinical Research, LLC, Port Orange, Florida, United States</location>
      <location>Clinical Research Atlanta, Stockbridge, Georgia, United States</location>
      <location>Northwest Clinical Trials, Boise, Idaho, United States</location>
      <location>ActivMed Practice and Research, Haverhill, Massachusetts, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Affiliated Clinical Research, Las Vegas, Nevada, United States</location>
      <location>Long Island Clinical Research, Great Neck, New York, United States</location>
      <location>Cary Medical Research, Cary, North Carolina, United States</location>
      <location>The UNC Center for Functional GI &amp; Motility Disorders, Chapel Hill, North Carolina, United States</location>
      <location>Medoff Medical/Vital re:Search, Greensboro, North Carolina, United States</location>
      <location>Unifour Medical Research, Hickory, North Carolina, United States</location>
      <location>Piedmont Medical Associates, Winston-Salem, North Carolina, United States</location>
      <location>Consultants for Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Gastroenterology Research Consultant of Greater Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Lynn Health Science Institute, Oklahoma City, Oklahoma, United States</location>
      <location>Coastal Carolina Research Center in Goose Creek, Goose Creek, South Carolina, United States</location>
      <location>ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Pioneer Research Solutions, Houston, Texas, United States</location>
      <location>Houston Medical Research Associates, Houston, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>Utah Clinical Trials, LLC, Salt Lake City, Utah, United States</location>
      <location>National Clinical Research Norfolk Inc., Norfolk, Virginia, United States</location>
      <location>Aurora Health Center - Waukesha, Waukesha, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00813098</url>
  </study>
  <study rank="181">
    <nct_id>NCT00659763</nct_id>
    <title>Diagnostic Strategies in Patients Suspected of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Exclusion diagnosis</intervention>
      <intervention type="Other">Clinical diagnosis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>health related quality of life measured by SF-36</outcome_measure>
      <outcome_measure>Symptoms measured by GSRS and GSRS-IBS</outcome_measure>
      <outcome_measure>sick days and reduced productivity measured by WPAI:IBS</outcome_measure>
      <outcome_measure>differential diagnoses in both arms</outcome_measure>
      <outcome_measure>Health related quality of life measured by IBS-QOL measurement</outcome_measure>
      <outcome_measure>The overall satisfaction with the diagnostic strategy</outcome_measure>
      <outcome_measure>The use of resources in the health care system measured by the number of doctor visits, ambulatory visits, emergency room visits, hospitalizations and diagnostic tests over 1 year follow up.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zealand University Hospital</lead_sponsor>
      <collaborator>Statens Serum Institut</collaborator>
      <collaborator>University of Copenhagen</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>149</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>SJ-40</other_id>
    </other_ids>
    <start_date>February 2008</start_date>
    <primary_completion_date>November 2010</primary_completion_date>
    <completion_date>November 2010</completion_date>
    <study_first_posted>April 16, 2008</study_first_posted>
    <last_update_posted>March 28, 2019</last_update_posted>
    <locations>
      <location>Medical Departement, Koege Hospital, Køge, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00659763</url>
  </study>
  <study rank="182">
    <nct_id>NCT01139736</nct_id>
    <title>Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">VSL#3</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical symptoms</outcome_measure>
      <outcome_measure>Differences in gut microbiota between IBS patients and controls</outcome_measure>
      <outcome_measure>Difference in gut microbiota post probiotic in IBS patients</outcome_measure>
      <outcome_measure>Differences in blood and mucosal SERT polymorphisms between IBS patients and controls</outcome_measure>
      <outcome_measure>Rectal sensitivity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS Probiotics</other_id>
    </other_ids>
    <start_date>July 2010</start_date>
    <primary_completion_date>March 2011</primary_completion_date>
    <completion_date>March 2011</completion_date>
    <study_first_posted>June 9, 2010</study_first_posted>
    <last_update_posted>January 21, 2013</last_update_posted>
    <locations>
      <location>Prince of Wales Hospital, Shatin, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01139736</url>
  </study>
  <study rank="183">
    <nct_id>NCT00542295</nct_id>
    <title>Efficacy and Safety of Meteospasmyl® in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alverine citrate and simeticone</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subject self assessment of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>IBS life impact, overall treatment assessment, concomitant factors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Laboratoires Mayoly Spindler</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IMTO601</other_id>
    </other_ids>
    <start_date>July 2007</start_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <completion_date>September 2008</completion_date>
    <study_first_posted>October 11, 2007</study_first_posted>
    <last_update_posted>October 1, 2008</last_update_posted>
    <locations>
      <location>Budapest, Hungary</location>
      <location>Budapest, Hungary</location>
      <location>Budapest, Hungary</location>
      <location>Budapest, Hungary</location>
      <location>Debrecen, Hungary</location>
      <location>Gyor, Hungary</location>
      <location>Gyula, Hungary</location>
      <location>Miskolc, Hungary</location>
      <location>Miskolc, Hungary</location>
      <location>Siofolk, Hungary</location>
      <location>Szeged, Hungary</location>
      <location>Székesfehérvár, Hungary</location>
      <location>Bydgoszcz, Poland</location>
      <location>Katowice, Poland</location>
      <location>Olawa, Poland</location>
      <location>Szczecin, Poland</location>
      <location>Wroclaw, Poland</location>
      <location>Wroclaw, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00542295</url>
  </study>
  <study rank="184">
    <nct_id>NCT01331213</nct_id>
    <title>Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pregabalin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Compliance</outcome_measure>
      <outcome_measure>Postprandial Colonic Tone [Reported as the Symmetric Percent [Change} in Baseline Colonic Barostat Balloon Volume</outcome_measure>
      <outcome_measure>Sensory Threshold for Pain</outcome_measure>
      <outcome_measure>Overall Sensory Ratings in Response to 16, 24, 30 and 36 mm Hg Distensions.</outcome_measure>
      <outcome_measure>Fasting Colonic Tone</outcome_measure>
      <outcome_measure>Colonic Motility Index</outcome_measure>
      <outcome_measure>Post-treatment Sensory Threshold for Gas</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>National Center for Research Resources (NCRR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-000485</other_id>
      <other_id>UL1RR024150</other_id>
    </other_ids>
    <start_date>April 2011</start_date>
    <primary_completion_date>February 2013</primary_completion_date>
    <completion_date>February 2013</completion_date>
    <study_first_posted>April 7, 2011</study_first_posted>
    <results_first_posted>March 3, 2014</results_first_posted>
    <last_update_posted>March 3, 2014</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01331213</url>
  </study>
  <study rank="185">
    <nct_id>NCT03931785</nct_id>
    <title>A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea (IBS-D)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MD-7246</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Abdominal Pain at its Worst at Each Week on a Numerical Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Proportion of 6/12 Week Abdominal Pain 30% Change Responders</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Allergan Sales, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>368</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-205</other_id>
    </other_ids>
    <start_date>May 1, 2019</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 30, 2019</study_first_posted>
    <last_update_posted>June 4, 2019</last_update_posted>
    <locations>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Elite Clinical Studies, Phoenix, Arizona, United States</location>
      <location>Arkansas Gastroenterology, North Little Rock, Arkansas, United States</location>
      <location>GW Research, Inc., Chula Vista, California, United States</location>
      <location>Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States</location>
      <location>Diagnamics Inc., Encinitas, California, United States</location>
      <location>St. Joseph Heritage Healthcare, Fullerton, California, United States</location>
      <location>Paragon Rx Clinical, Garden Grove, California, United States</location>
      <location>Grossmont Center For Clinical Research, La Mesa, California, United States</location>
      <location>Facey Medical Foundation, Mission Hills, California, United States</location>
      <location>Providence Clinical Research, North Hollywood, California, United States</location>
      <location>Precision Research Institute, San Diego, California, United States</location>
      <location>Paragon Rx Clinical, Inc. - Santa Ana, Santa Ana, California, United States</location>
      <location>Shahram Jacobs MD Inc, Sherman Oaks, California, United States</location>
      <location>Millennium Clinical Trials, Thousand Oaks, California, United States</location>
      <location>Advanced Rx Clinical Research, Westminster, California, United States</location>
      <location>Connecticut Clinical Research Institute, Bristol, Connecticut, United States</location>
      <location>Chase Medical Research of Greater New Haven LLC, Hamden, Connecticut, United States</location>
      <location>The Chappel Group Research, LLC, Kissimmee, Florida, United States</location>
      <location>Well Pharma Medical Research Corporation, Miami, Florida, United States</location>
      <location>New Horizon Research Center, Miami, Florida, United States</location>
      <location>Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States</location>
      <location>Meridien Research, Saint Petersburg, Florida, United States</location>
      <location>Research Institute of Central Florida, LLC, Winter Park, Florida, United States</location>
      <location>Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States</location>
      <location>Clinical Trials Management LLC, Metairie, Louisiana, United States</location>
      <location>Meridian Clinical Research, Rockville, Maryland, United States</location>
      <location>Boston Clinical Trials Inc, Boston, Massachusetts, United States</location>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>MedVadis Research Corporation, Watertown, Massachusetts, United States</location>
      <location>Clinical Research of South Nevada, Las Vegas, Nevada, United States</location>
      <location>Advanced Biomedical Research of America, Las Vegas, Nevada, United States</location>
      <location>Healthwise Medical Associates, Brooklyn, New York, United States</location>
      <location>Long Island Gastrointestinal Research Group LLP, Great Neck, New York, United States</location>
      <location>Carolina Digestive Health Associates, Concord, North Carolina, United States</location>
      <location>Peters Medical Research, LLC, High Point, North Carolina, United States</location>
      <location>Clinical Trials of America-NC, LLC, Mount Airy, North Carolina, United States</location>
      <location>M3 Wake Research, Inc, Raleigh, North Carolina, United States</location>
      <location>PMG Research of Wilmington, Wilmington, North Carolina, United States</location>
      <location>Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States</location>
      <location>PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States</location>
      <location>Progressive Medicine of the Triad, LLC, Winston-Salem, North Carolina, United States</location>
      <location>Lillestol Research, Fargo, North Dakota, United States</location>
      <location>Hightop Medical Research Center, Cincinnati, Ohio, United States</location>
      <location>New Horizons Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Remington Davis Inc, Columbus, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Dayton, Ohio, United States</location>
      <location>IPS Research Company, Oklahoma City, Oklahoma, United States</location>
      <location>Digestive Disease Specialists, Inc., Oklahoma City, Oklahoma, United States</location>
      <location>Oregon Center For Clinical Investigations Inc, Salem, Oregon, United States</location>
      <location>Partners In Clinical Research, Cumberland, Rhode Island, United States</location>
      <location>Ocean State Clinical Research Partners, Lincoln, Rhode Island, United States</location>
      <location>Mountain View Clinical Research Inc, Greer, South Carolina, United States</location>
      <location>WR-ClinSearch, LLC, Chattanooga, Tennessee, United States</location>
      <location>New Phase Research &amp; Development, Knoxville, Tennessee, United States</location>
      <location>Texas Tech University Health Sciences Center, El Paso, Texas, United States</location>
      <location>Southwest Clinical Trials, Houston, Texas, United States</location>
      <location>Southwest Clinical Trials, Houston, Texas, United States</location>
      <location>Quality Research Inc, San Antonio, Texas, United States</location>
      <location>Diagnostics Research Group, San Antonio, Texas, United States</location>
      <location>DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>New River Valley Research Institute, Christiansburg, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03931785</url>
  </study>
  <study rank="186">
    <nct_id>NCT00677976</nct_id>
    <title>Use of Functional Magnetic Resonance Imaging (fMRI) to Study Brain Activation in Children With Irritable Bowel Syndrome</title>
    <acronym>fMRI</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>We intend to measure the degree of brain activation following rectal stimulation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHW 06/163</other_id>
    </other_ids>
    <start_date>June 2007</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>January 2020</completion_date>
    <study_first_posted>May 15, 2008</study_first_posted>
    <last_update_posted>May 21, 2019</last_update_posted>
    <locations>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00677976</url>
  </study>
  <study rank="187">
    <nct_id>NCT00610909</nct_id>
    <title>Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paroxetine CR</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in: Changes in Mean composite pain scores (on IVRS)</outcome_measure>
      <outcome_measure>Change from baseline in Associated symptoms of IBS (diarrhea, constipation, incomplete emptying, etc.) scores IBS Quality of Life scores Clinical Global Impression scores of 1 or 2 Beck Depression Inventory II Beck Anxiety Inventory</outcome_measure>
      <outcome_measure>Recording of spontaneous adverse events throughout the screening, run-in, and treatment phases of the study Conducting the DOTES at defined points during the study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>GlaxoSmithKline</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>3611</other_id>
      <other_id>IRB#3611</other_id>
    </other_ids>
    <start_date>January 2002</start_date>
    <primary_completion_date>December 2002</primary_completion_date>
    <completion_date>December 2002</completion_date>
    <study_first_posted>February 8, 2008</study_first_posted>
    <last_update_posted>June 20, 2013</last_update_posted>
    <locations>
      <location>Department of Psychiatry Clinical Trial Team, Duke University, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00610909</url>
  </study>
  <study rank="188">
    <nct_id>NCT00305968</nct_id>
    <title>Evaluation of Patient Education in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">patient education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Quality of life</outcome_measure>
      <outcome_measure>Change in Gastrointestinal symptom score</outcome_measure>
      <outcome_measure>Change in health related costs</outcome_measure>
      <outcome_measure>Evaluation of further patient needs after education</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sorlandet Hospital HF</lead_sponsor>
      <collaborator>Sykehuset Telemark</collaborator>
      <collaborator>The Hospital of Vestfold</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
    </study_designs>
    <other_ids>
      <other_id>SSHFIBS-1</other_id>
    </other_ids>
    <start_date>January 2006</start_date>
    <primary_completion_date>January 2008</primary_completion_date>
    <completion_date>January 2008</completion_date>
    <study_first_posted>March 22, 2006</study_first_posted>
    <last_update_posted>December 21, 2011</last_update_posted>
    <locations>
      <location>Sorlandet Sykehus HF, Kristiansand, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00305968</url>
  </study>
  <study rank="189">
    <nct_id>NCT00742118</nct_id>
    <title>Effects of the Soluble Mediators of Mastocytes on the Intestinal Epithelial Barrier and of the Enteric Nervous System During the Syndrome of the Irritable Bowel</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Colic biopsies</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Para-cellular permeability</outcome_measure>
      <outcome_measure>Gap junction protein expression</outcome_measure>
      <outcome_measure>Inflammation molecule expression</outcome_measure>
      <outcome_measure>Digestive discomfort degree</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
      <collaborator>Fondation de l'Avenir</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>05-API-08</other_id>
    </other_ids>
    <start_date>February 2008</start_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <completion_date>July 2016</completion_date>
    <study_first_posted>August 27, 2008</study_first_posted>
    <last_update_posted>September 30, 2015</last_update_posted>
    <locations>
      <location>Department of gastroenterology, Hopital Archet 2, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00742118</url>
  </study>
  <study rank="190">
    <nct_id>NCT02651740</nct_id>
    <title>Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
      <intervention type="Procedure">Fecal microbiota transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with relief of IBS condition</outcome_measure>
      <outcome_measure>Number of patients with relief of IBS related anxiety or depression status</outcome_measure>
      <outcome_measure>Number of patients with relief of IBS single symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Zhongshan Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SXZ-WSD01-2015</other_id>
    </other_ids>
    <start_date>April 2016</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>April 2020</completion_date>
    <study_first_posted>January 11, 2016</study_first_posted>
    <last_update_posted>September 26, 2018</last_update_posted>
    <locations>
      <location>Zhongshan Hospital, Fudan University, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02651740</url>
  </study>
  <study rank="191">
    <nct_id>NCT01543178</nct_id>
    <title>Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study</title>
    <acronym>TARGET3</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">open-label rifaximin</intervention>
      <intervention type="Drug">double-blind placebo</intervention>
      <intervention type="Drug">double-blind rifaximin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Repeat Treatment Responders</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2583</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RFIB3053</other_id>
    </other_ids>
    <start_date>February 2012</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>March 2, 2012</study_first_posted>
    <results_first_posted>July 8, 2015</results_first_posted>
    <last_update_posted>December 12, 2017</last_update_posted>
    <locations>
      <location>Anniston, Alabama, United States</location>
      <location>Birmingham, Alabama, United States</location>
      <location>Birmingham, Alabama, United States</location>
      <location>Birmingham, Alabama, United States</location>
      <location>Birmingham, Alabama, United States</location>
      <location>Dothan, Alabama, United States</location>
      <location>Huntsville, Alabama, United States</location>
      <location>Montgomery, Alabama, United States</location>
      <location>Montgomery, Alabama, United States</location>
      <location>Selma, Alabama, United States</location>
      <location>Chandler, Arizona, United States</location>
      <location>Peoria, Arizona, United States</location>
      <location>Phoenix, Arizona, United States</location>
      <location>Scottsdale, Arizona, United States</location>
      <location>Tempe, Arizona, United States</location>
      <location>Tucson, Arizona, United States</location>
      <location>Tucson, Arizona, United States</location>
      <location>Tucson, Arizona, United States</location>
      <location>Jonesboro, Arkansas, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>North Little Rock, Arkansas, United States</location>
      <location>Sherwood, Arkansas, United States</location>
      <location>Anaheim, California, United States</location>
      <location>Artesia, California, United States</location>
      <location>Carlsbad, California, United States</location>
      <location>Chula Vista, California, United States</location>
      <location>Chula Vista, California, United States</location>
      <location>Concord, California, United States</location>
      <location>Encinitas, California, United States</location>
      <location>Encino, California, United States</location>
      <location>Escondido, California, United States</location>
      <location>Garden Grove, California, United States</location>
      <location>Garden Grove, California, United States</location>
      <location>Garden Grove, California, United States</location>
      <location>Glendale, California, United States</location>
      <location>Huntington Beach, California, United States</location>
      <location>La Mesa, California, United States</location>
      <location>La Mirada, California, United States</location>
      <location>Laguna Hills, California, United States</location>
      <location>Lakewood, California, United States</location>
      <location>Lincoln, California, United States</location>
      <location>Lomita, California, United States</location>
      <location>Long Beach, California, United States</location>
      <location>Long Beach, California, United States</location>
      <location>Los Angeles, California, United States</location>
      <location>Los Angeles, California, United States</location>
      <location>Los Angeles, California, United States</location>
      <location>Madera, California, United States</location>
      <location>Mill Valley, California, United States</location>
      <location>Montebello, California, United States</location>
      <location>North Hollywood, California, United States</location>
      <location>Orange, California, United States</location>
      <location>Redlands, California, United States</location>
      <location>Sacramento, California, United States</location>
      <location>San Carlos, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>Vista, California, United States</location>
      <location>Colorado Springs, Colorado, United States</location>
      <location>Colorado Springs, Colorado, United States</location>
      <location>Denver, Colorado, United States</location>
      <location>Denver, Colorado, United States</location>
      <location>Lakewood, Colorado, United States</location>
      <location>Lone Tree, Colorado, United States</location>
      <location>Bridgeport, Connecticut, United States</location>
      <location>Bristol, Connecticut, United States</location>
      <location>Danbury, Connecticut, United States</location>
      <location>Torrington, Connecticut, United States</location>
      <location>Boca Raton, Florida, United States</location>
      <location>Boca Raton, Florida, United States</location>
      <location>Boynton Beach, Florida, United States</location>
      <location>Boynton Beach, Florida, United States</location>
      <location>Brandon, Florida, United States</location>
      <location>Clearwater, Florida, United States</location>
      <location>Gainesville, Florida, United States</location>
      <location>Hialeah, Florida, United States</location>
      <location>Hialeah, Florida, United States</location>
      <location>Hialeah, Florida, United States</location>
      <location>Hollywood, Florida, United States</location>
      <location>Jupiter, Florida, United States</location>
      <location>Kissimmee, Florida, United States</location>
      <location>Lake Worth, Florida, United States</location>
      <location>Largo, Florida, United States</location>
      <location>Lauderdale Lakes, Florida, United States</location>
      <location>Maitland, Florida, United States</location>
      <location>Miami Springs, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Naples, Florida, United States</location>
      <location>Orange Park, Florida, United States</location>
      <location>Orlando, Florida, United States</location>
      <location>Ormond Beach, Florida, United States</location>
      <location>Plant City, Florida, United States</location>
      <location>Pompano Beach, Florida, United States</location>
      <location>Port Orange, Florida, United States</location>
      <location>Saint Petersburg, Florida, United States</location>
      <location>Sarasota, Florida, United States</location>
      <location>Seminole, Florida, United States</location>
      <location>Tampa, Florida, United States</location>
      <location>Tampa, Florida, United States</location>
      <location>Wellington, Florida, United States</location>
      <location>West Palm Beach, Florida, United States</location>
      <location>West Palm Beach, Florida, United States</location>
      <location>Winter Haven, Florida, United States</location>
      <location>Winter Park, Florida, United States</location>
      <location>Zephyrhills, Florida, United States</location>
      <location>Athens, Georgia, United States</location>
      <location>Atlanta, Georgia, United States</location>
      <location>Atlanta, Georgia, United States</location>
      <location>Augusta, Georgia, United States</location>
      <location>Augusta, Georgia, United States</location>
      <location>Columbus, Georgia, United States</location>
      <location>Columbus, Georgia, United States</location>
      <location>Macon, Georgia, United States</location>
      <location>Marietta, Georgia, United States</location>
      <location>Norcross, Georgia, United States</location>
      <location>Boise, Idaho, United States</location>
      <location>Boise, Idaho, United States</location>
      <location>Hayden Lake, Idaho, United States</location>
      <location>Idaho Falls, Idaho, United States</location>
      <location>Arlington Heights, Illinois, United States</location>
      <location>Chicago, Illinois, United States</location>
      <location>Evanston, Illinois, United States</location>
      <location>Oak Lawn, Illinois, United States</location>
      <location>Elkhart, Indiana, United States</location>
      <location>Evansville, Indiana, United States</location>
      <location>Evansville, Indiana, United States</location>
      <location>Indianapolis, Indiana, United States</location>
      <location>Mishawaka, Indiana, United States</location>
      <location>Clive, Iowa, United States</location>
      <location>Iowa City, Iowa, United States</location>
      <location>Kansas City, Kansas, United States</location>
      <location>Overland Park, Kansas, United States</location>
      <location>Topeka, Kansas, United States</location>
      <location>Wichita, Kansas, United States</location>
      <location>Bowling Green, Kentucky, United States</location>
      <location>Crestview Hills, Kentucky, United States</location>
      <location>Hebron, Kentucky, United States</location>
      <location>Lexington, Kentucky, United States</location>
      <location>Lexington, Kentucky, United States</location>
      <location>Louisville, Kentucky, United States</location>
      <location>Madisonville, Kentucky, United States</location>
      <location>Metairie, Louisiana, United States</location>
      <location>New Orleans, Louisiana, United States</location>
      <location>Shreveport, Louisiana, United States</location>
      <location>Annapolis, Maryland, United States</location>
      <location>Baltimore, Maryland, United States</location>
      <location>Baltimore, Maryland, United States</location>
      <location>Hagerstown, Maryland, United States</location>
      <location>Hollywood, Maryland, United States</location>
      <location>Boston, Massachusetts, United States</location>
      <location>Brockton, Massachusetts, United States</location>
      <location>Marlborough, Massachusetts, United States</location>
      <location>Watertown, Massachusetts, United States</location>
      <location>Ann Arbor, Michigan, United States</location>
      <location>Kalamazoo, Michigan, United States</location>
      <location>Kalamazoo, Michigan, United States</location>
      <location>Saginaw, Michigan, United States</location>
      <location>Wyoming, Michigan, United States</location>
      <location>Jackson, Mississippi, United States</location>
      <location>Ocean Springs, Mississippi, United States</location>
      <location>Kansas City, Missouri, United States</location>
      <location>Lee's Summit, Missouri, United States</location>
      <location>Mexico, Missouri, United States</location>
      <location>Saint Louis, Missouri, United States</location>
      <location>Saint Louis, Missouri, United States</location>
      <location>Saint Louis, Missouri, United States</location>
      <location>Missoula, Montana, United States</location>
      <location>Bellevue, Nebraska, United States</location>
      <location>Fremont, Nebraska, United States</location>
      <location>Omaha, Nebraska, United States</location>
      <location>Henderson, Nevada, United States</location>
      <location>Las Vegas, Nevada, United States</location>
      <location>Las Vegas, Nevada, United States</location>
      <location>Reno, Nevada, United States</location>
      <location>Lebanon, New Hampshire, United States</location>
      <location>Newington, New Hampshire, United States</location>
      <location>Haddon Heights, New Jersey, United States</location>
      <location>Marlton, New Jersey, United States</location>
      <location>Albuquerque, New Mexico, United States</location>
      <location>Albuquerque, New Mexico, United States</location>
      <location>Brooklyn, New York, United States</location>
      <location>Great Neck, New York, United States</location>
      <location>Great Neck, New York, United States</location>
      <location>Hollis, New York, United States</location>
      <location>Mineola, New York, United States</location>
      <location>New York, New York, United States</location>
      <location>Poughkeepsie, New York, United States</location>
      <location>Rochester, New York, United States</location>
      <location>Asheboro, North Carolina, United States</location>
      <location>Asheville, North Carolina, United States</location>
      <location>Boone, North Carolina, United States</location>
      <location>Cary, North Carolina, United States</location>
      <location>Chapel Hill, North Carolina, United States</location>
      <location>Charlotte, North Carolina, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>High Point, North Carolina, United States</location>
      <location>Kinston, North Carolina, United States</location>
      <location>Raleigh, North Carolina, United States</location>
      <location>Salisbury, North Carolina, United States</location>
      <location>Wilmington, North Carolina, United States</location>
      <location>Winston-Salem, North Carolina, United States</location>
      <location>Fargo, North Dakota, United States</location>
      <location>Akron, Ohio, United States</location>
      <location>Akron, Ohio, United States</location>
      <location>Centerville, Ohio, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Cleveland, Ohio, United States</location>
      <location>Columbus, Ohio, United States</location>
      <location>Columbus, Ohio, United States</location>
      <location>Dayton, Ohio, United States</location>
      <location>Dayton, Ohio, United States</location>
      <location>Groveport, Ohio, United States</location>
      <location>Kettering, Ohio, United States</location>
      <location>Mentor, Ohio, United States</location>
      <location>Norman, Oklahoma, United States</location>
      <location>Oklahoma City, Oklahoma, United States</location>
      <location>Oklahoma City, Oklahoma, United States</location>
      <location>Tulsa, Oklahoma, United States</location>
      <location>Tulsa, Oklahoma, United States</location>
      <location>Medford, Oregon, United States</location>
      <location>Portland, Oregon, United States</location>
      <location>Downingtown, Pennsylvania, United States</location>
      <location>Pittsburgh, Pennsylvania, United States</location>
      <location>Reading, Pennsylvania, United States</location>
      <location>Sayre, Pennsylvania, United States</location>
      <location>East Providence, Rhode Island, United States</location>
      <location>Warwick, Rhode Island, United States</location>
      <location>Charleston, South Carolina, United States</location>
      <location>Charleston, South Carolina, United States</location>
      <location>Columbia, South Carolina, United States</location>
      <location>Fort Mill, South Carolina, United States</location>
      <location>Gaffney, South Carolina, United States</location>
      <location>Greer, South Carolina, United States</location>
      <location>Brentwood, Tennessee, United States</location>
      <location>Bristol, Tennessee, United States</location>
      <location>Chattanooga, Tennessee, United States</location>
      <location>Franklin, Tennessee, United States</location>
      <location>Germantown, Tennessee, United States</location>
      <location>Hermitage, Tennessee, United States</location>
      <location>Kingsport, Tennessee, United States</location>
      <location>Nashville, Tennessee, United States</location>
      <location>Arlington, Texas, United States</location>
      <location>Austin, Texas, United States</location>
      <location>Austin, Texas, United States</location>
      <location>Austin, Texas, United States</location>
      <location>Austin, Texas, United States</location>
      <location>Corsicana, Texas, United States</location>
      <location>Dallas, Texas, United States</location>
      <location>El Paso, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Lake Jackson, Texas, United States</location>
      <location>Odessa, Texas, United States</location>
      <location>Pasadena, Texas, United States</location>
      <location>Plano, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>Sealy, Texas, United States</location>
      <location>Southlake, Texas, United States</location>
      <location>Tyler, Texas, United States</location>
      <location>Bountiful, Utah, United States</location>
      <location>Ogden, Utah, United States</location>
      <location>Salt Lake City, Utah, United States</location>
      <location>West Jordan, Utah, United States</location>
      <location>Charlottesville, Virginia, United States</location>
      <location>Chesapeake, Virginia, United States</location>
      <location>Danville, Virginia, United States</location>
      <location>Fairfax, Virginia, United States</location>
      <location>Richmond, Virginia, United States</location>
      <location>Suffolk, Virginia, United States</location>
      <location>Bellevue, Washington, United States</location>
      <location>Seattle, Washington, United States</location>
      <location>Spokane, Washington, United States</location>
      <location>Milwaukee, Wisconsin, United States</location>
      <location>Milwaukee, Wisconsin, United States</location>
      <location>Berlin, Germany</location>
      <location>Hamburg, Germany</location>
      <location>Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01543178</url>
  </study>
  <study rank="192">
    <nct_id>NCT03304041</nct_id>
    <title>Efficacy of Low-FODMAPs Dietary Therapy for Irritable Bowel Syndrome in China</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Diet Modification</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">low-FODMAPs diet</intervention>
      <intervention type="Dietary Supplement">standard diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Compare response to diet intervention between different groups.</outcome_measure>
      <outcome_measure>Improvement in abdominal pain between different groups.</outcome_measure>
      <outcome_measure>Improvement in stool consistency between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in abdominal pain score between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in abdominal frequency between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in bloating score between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in excessive wind score between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in stool consistency between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in stool frequency between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in urgency score between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in incomplete defecation score between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in quality of life between different groups.</outcome_measure>
      <outcome_measure>Compare changes from baseline in mental health between different groups.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sir Run Run Shaw Hospital</lead_sponsor>
      <collaborator>First Affiliated Hospital of Zhejiang University</collaborator>
      <collaborator>Second Affiliated Hospital, School of Medicine, Zhejiang University</collaborator>
      <collaborator>Zhejiang Provincial Hospital of TCM</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20170116-2</other_id>
    </other_ids>
    <start_date>March 1, 2017</start_date>
    <primary_completion_date>March 1, 2018</primary_completion_date>
    <completion_date>September 1, 2018</completion_date>
    <study_first_posted>October 6, 2017</study_first_posted>
    <last_update_posted>October 6, 2017</last_update_posted>
    <locations>
      <location>Sir Run Run Shaw Hospital , College of Medicine, Zhejiang University, Hangzhou, Zhe Jiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03304041</url>
  </study>
  <study rank="193">
    <nct_id>NCT02328547</nct_id>
    <title>Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fecal microbiota transplantation capsules</intervention>
      <intervention type="Drug">Placebo capsules</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS)</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome-Symptom Severity Score (IBS-SSS)</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome-Quality of Life (IBS-QOL) Questionnaire Scores</outcome_measure>
      <outcome_measure>Change in fecal bacterial composition</outcome_measure>
      <outcome_measure>Number of doctors appointments or emergency room visits for treatment of uncontrolled IBS symptoms</outcome_measure>
      <outcome_measure>Number of new medications initiated for treatment of uncontrolled IBS symptoms</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Montefiore Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014-3941</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <completion_date>March 2018</completion_date>
    <study_first_posted>December 31, 2014</study_first_posted>
    <last_update_posted>April 20, 2018</last_update_posted>
    <locations>
      <location>Medical Research Center of Connecticut, Hamden, Connecticut, United States</location>
      <location>Montefiore Medical Center, Bronx, New York, United States</location>
      <location>Concorde Medical Group, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02328547</url>
  </study>
  <study rank="194">
    <nct_id>NCT00948818</nct_id>
    <title>Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide 290 micrograms</intervention>
      <intervention type="Drug">Matching placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks</outcome_measure>
      <outcome_measure>Abdominal Pain Responder, 9 Out of 12 Weeks</outcome_measure>
      <outcome_measure>Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks.</outcome_measure>
      <outcome_measure>12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency Rate</outcome_measure>
      <outcome_measure>12-Week Spontaneous Bowl Movement (SBM) Frequency Rate</outcome_measure>
      <outcome_measure>12-Week Stool Consistency</outcome_measure>
      <outcome_measure>12-Week Severity of Straining</outcome_measure>
      <outcome_measure>12-Week Change in Abdominal Pain Score</outcome_measure>
      <outcome_measure>12-Week Change in Abdominal Discomfort</outcome_measure>
      <outcome_measure>12-Week Change in Bloating</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment</outcome_measure>
      <outcome_measure>Abdominal Pain Responder for 6 Out of 12 Weeks</outcome_measure>
      <outcome_measure>12-Week Percent of Abdominal Pain-free (APF) Days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Forest Laboratories</lead_sponsor>
      <collaborator>Ironwood Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>803</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIN-MD-31</other_id>
    </other_ids>
    <start_date>July 2009</start_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <completion_date>August 2010</completion_date>
    <study_first_posted>July 29, 2009</study_first_posted>
    <results_first_posted>January 30, 2013</results_first_posted>
    <last_update_posted>January 30, 2013</last_update_posted>
    <locations>
      <location>Forest Investigative Site 037, Birmingham, Alabama, United States</location>
      <location>Forest Investigative Site 036, Birmingham, Alabama, United States</location>
      <location>Forest Investigative Site 135, Hueytown, Alabama, United States</location>
      <location>Forest Investigative Site 014, Huntsville, Alabama, United States</location>
      <location>Forest Investigative Site 080, Chandler, Arizona, United States</location>
      <location>Forest Investigative Site 053, Mesa, Arizona, United States</location>
      <location>Forest Investigative Site 078, Peoria, Arizona, United States</location>
      <location>Forest Investigative Site 101, Phoenix, Arizona, United States</location>
      <location>Forest Investigative Site 128, Phoenix, Arizona, United States</location>
      <location>Forest Investigative Site 051, Scottsdale, Arizona, United States</location>
      <location>Forest Investigative Site 136, Tucson, Arizona, United States</location>
      <location>Forest Investigative Site 087, Tucson, Arizona, United States</location>
      <location>Forest Investigative Site 094, Burbank, California, United States</location>
      <location>Forest Investigative Site 026, Encinitas, California, United States</location>
      <location>Forest Investigative Site 096, Foothill Ranch, California, United States</location>
      <location>Forest Investigative Site 057, Los Angeles, California, United States</location>
      <location>Forest Investigative Site 097, Mission Hills, California, United States</location>
      <location>Forest Investigative Site 005, Orange, California, United States</location>
      <location>Forest Investigative Site 024, Westlake Village, California, United States</location>
      <location>Forest Investigative Site 021, Boulder, Colorado, United States</location>
      <location>Forest Investigative Site 019, Colorado Springs, Colorado, United States</location>
      <location>Forest Investigative Site 034, Denver, Colorado, United States</location>
      <location>Forest Investigative Site 074, Longmont, Colorado, United States</location>
      <location>Forest Investigative Site 010, Wheat Ridge, Colorado, United States</location>
      <location>Forest Investigative Site 058, Waterbury, Connecticut, United States</location>
      <location>Forest Investigative Site 042, Boca Raton, Florida, United States</location>
      <location>Forest Investigative Site 003, Bradenton, Florida, United States</location>
      <location>Forest Investigative Site 137, Brandon, Florida, United States</location>
      <location>Forest Investigative Site 070, Brooksville, Florida, United States</location>
      <location>Forest Investigative Site 018, Ft. Myers, Florida, United States</location>
      <location>Forest Investigative Site 030, Jupiter, Florida, United States</location>
      <location>Forest Investigative Site 077, Kissimmee, Florida, United States</location>
      <location>Forest Investigative Site 133, Miami, Florida, United States</location>
      <location>Forest Investigative Site 031, Miami, Florida, United States</location>
      <location>Forest Investigative Site 129, New Smyrna Beach, Florida, United States</location>
      <location>Forest Investigative Site 108, Ocala, Florida, United States</location>
      <location>Forest Investigative Site 092, Orlando, Florida, United States</location>
      <location>Forest Investigative Site 038, Panama City, Florida, United States</location>
      <location>Forest Investigative Site 027, Pembroke Pines, Florida, United States</location>
      <location>Forest Investigative Site 045, St. Petersburg, Florida, United States</location>
      <location>Forest Investigative Site 015, Tampa, Florida, United States</location>
      <location>Forest Investigative Site 104, Trinity, Florida, United States</location>
      <location>Forest Investigative Site 068, Zephyrhills, Florida, United States</location>
      <location>Forest Investigative Site 032, Atlanta, Georgia, United States</location>
      <location>Forest Investigative Site 103, Atlanta, Georgia, United States</location>
      <location>Forest Investigative Site 033, Marietta, Georgia, United States</location>
      <location>Forest Investigative Site 020, Marietta, Georgia, United States</location>
      <location>Forest Investigative Site 040, Woodstock, Georgia, United States</location>
      <location>Forest Investigative Site 055, Idaho Falls, Idaho, United States</location>
      <location>Forest Investigative Site 043, Rockford, Illinois, United States</location>
      <location>Forest Investigative Site 047, Evansville, Indiana, United States</location>
      <location>Forest Investigative Site 046, Iowa City, Iowa, United States</location>
      <location>Forest Investigative Site 029, Arkansas City, Kansas, United States</location>
      <location>Forest Investigative Site 009, Newton, Kansas, United States</location>
      <location>Forest Investigative Site 023, Wichita, Kansas, United States</location>
      <location>Forest Investigative Site 093, Wichita, Kansas, United States</location>
      <location>Forest Investigative Site 067, Lexington, Kentucky, United States</location>
      <location>Forest Investigative Site 114, Madisonville, Kentucky, United States</location>
      <location>Forest Investigative Site 132, Baton Rouge, Louisiana, United States</location>
      <location>Forest Investigative Site 124, Shreveport, Louisiana, United States</location>
      <location>Forest Investigative Site 013, Chevy Chase, Maryland, United States</location>
      <location>Forest Investigative Site 006, Hagerstown, Maryland, United States</location>
      <location>Forest Investigative Site 073, Lutherville, Maryland, United States</location>
      <location>Forest Investigative Site 001, Boston, Massachusetts, United States</location>
      <location>Forest Investigative Site 125, Kalamazoo, Michigan, United States</location>
      <location>Forest Investigative Site 064, Chaska, Minnesota, United States</location>
      <location>Forest Investigative Site 004, St. Louis, Missouri, United States</location>
      <location>Forest Investigative Site 085, Vineland, New Jersey, United States</location>
      <location>Forest Investigative Site 052, Albuquerque, New Mexico, United States</location>
      <location>Forest Investigative Site 035, Brooklyn, New York, United States</location>
      <location>Forest Investigative Site 017, Great Neck, New York, United States</location>
      <location>Forest Investigative Site 011, Great Neck, New York, United States</location>
      <location>Forest Investigative Site 134, Setauket, New York, United States</location>
      <location>Forest Investigative Site 122, Boone, North Carolina, United States</location>
      <location>Forest Investigative Site 072, Fayetteville, North Carolina, United States</location>
      <location>Forest Investigative Site 016, Greensboro, North Carolina, United States</location>
      <location>Forest Investigative Site 119, Hickory, North Carolina, United States</location>
      <location>Forest Investigative Site 088, Raleigh, North Carolina, United States</location>
      <location>Forest Investigative Site 056, Wilmington, North Carolina, United States</location>
      <location>Forest Investigative Site 065, Winston-Salem, North Carolina, United States</location>
      <location>Forest Investigative Site 028, Cincinnati, Ohio, United States</location>
      <location>Forest Investigative Site 044, Cleveland, Ohio, United States</location>
      <location>Forest Investigative Site 123, Columbus, Ohio, United States</location>
      <location>Forest Investigative Site 130, Dayton, Ohio, United States</location>
      <location>Forest Investigative Site 082, Oklahoma City, Oklahoma, United States</location>
      <location>Forest Investigative Site 102, Tulsa, Oklahoma, United States</location>
      <location>Forest Investigative Site 039, Pittsburgh, Pennsylvania, United States</location>
      <location>Forest Investigative Site 121, Greenville, South Carolina, United States</location>
      <location>Forest Investigative Site 069, Greer, South Carolina, United States</location>
      <location>Forest Investigative Site 131, Greer, South Carolina, United States</location>
      <location>Forest Investigative Site 025, Nashville, Tennessee, United States</location>
      <location>Forest Investigative Site 099, Austin, Texas, United States</location>
      <location>Forest Investigative Site 002, Dallas, Texas, United States</location>
      <location>Forest Investigative Site 041, Houston, Texas, United States</location>
      <location>Forest Investigative Site 110, Houston, Texas, United States</location>
      <location>Forest Investigative Site 063, Lake Jackson, Texas, United States</location>
      <location>Forest Investigative Site 095, San Antonio, Texas, United States</location>
      <location>Forest Investigative Site 076, San Antonio, Texas, United States</location>
      <location>Forest Investigative Site 089, Salt Lake City, Utah, United States</location>
      <location>Forest Investigative Site 091, Salt Lake City, Utah, United States</location>
      <location>Forest Investigative Site 100, Salt Lake City, Utah, United States</location>
      <location>Forest Investigative Site 054, Charlottesville, Virginia, United States</location>
      <location>Forest Investigative Site 061, Christianburg, Virginia, United States</location>
      <location>Forest Investigative Site 007, Newport News, Virginia, United States</location>
      <location>Forest Investigative Site 060, Norfolk, Virginia, United States</location>
      <location>Forest Investigative Site 075, Norfolk, Virginia, United States</location>
      <location>Forest Investigative Site 050, Richmond, Virginia, United States</location>
      <location>Forest Investigative Site 049, Bellevue, Washington, United States</location>
      <location>Forest Investigative Site 098, Lakewood, Washington, United States</location>
      <location>Forest Investigative Site 066, Wenatchee, Washington, United States</location>
      <location>Forest Investigative Site 083, Milwaukee, Wisconsin, United States</location>
      <location>Forest Investigative Site 107, Hamilton, Ontario, Canada</location>
      <location>Forest Investigative Site 112, New Market, Ontario, Canada</location>
      <location>Forest Investigative Site 106, Ottawa, Ontario, Canada</location>
      <location>Forest Investigative Site 115, Sarnia, Ontario, Canada</location>
      <location>Forest Investigative Site 113, Sudbury, Ontario, Canada</location>
      <location>Forest Investigative Site 008, Toronto, Ontario, Canada</location>
      <location>Forest Investigative Site 116, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00948818</url>
  </study>
  <study rank="195">
    <nct_id>NCT00220090</nct_id>
    <title>DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">dexloxiglumide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to relapse, i.e. loss of responder status, which is based on a global patient-based weekly assessment of relief and control of symptoms</outcome_measure>
      <outcome_measure>abdominal discomfort/pain</outcome_measure>
      <outcome_measure>bloating</outcome_measure>
      <outcome_measure>straining</outcome_measure>
      <outcome_measure>incomplete evacuation</outcome_measure>
      <outcome_measure>urgency</outcome_measure>
      <outcome_measure>stool frequency and consistency</outcome_measure>
      <outcome_measure>quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rottapharm</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DEX-MD-05</other_id>
      <other_id>DARWIN Study</other_id>
    </other_ids>
    <start_date>July 2003</start_date>
    <primary_completion_date>September 2006</primary_completion_date>
    <study_first_posted>September 22, 2005</study_first_posted>
    <last_update_posted>May 14, 2008</last_update_posted>
    <locations>
      <location>Academic Department of Medicine Wythenshawe Hospital, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00220090</url>
  </study>
  <study rank="196">
    <nct_id>NCT00219531</nct_id>
    <title>Effect of Menstrual Cycle on Central Nervous System (CNS) Processing of Gut Stimuli in Irritable Bowel Syndrome (IBS) and Control</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">perception of rectal balloon distention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensitivity to rectal distention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Penn State University</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>American College of Gastroenterology</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>99-073</other_id>
      <other_id>NIDDK R21 DK57053</other_id>
      <other_id>ACG Research Award 2000-2001</other_id>
    </other_ids>
    <start_date>March 1999</start_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <completion_date>February 2015</completion_date>
    <study_first_posted>September 22, 2005</study_first_posted>
    <last_update_posted>November 29, 2017</last_update_posted>
    <locations>
      <location>Hershey Medical Center, Hershey, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00219531</url>
  </study>
  <study rank="197">
    <nct_id>NCT00394186</nct_id>
    <title>A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GW427353</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>completion of questionnaires by the subject, determining the average adequate relief rate</outcome_measure>
      <outcome_measure>Blood levels of GW427353</outcome_measure>
      <outcome_measure>Questionnaire</outcome_measure>
      <outcome_measure>ECG, vital signs, adverse events</outcome_measure>
      <outcome_measure>clinical lab tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>B3I105940</other_id>
    </other_ids>
    <start_date>August 2006</start_date>
    <study_first_posted>October 31, 2006</study_first_posted>
    <last_update_posted>May 18, 2009</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Concord, New South Wales, Australia</location>
      <location>GSK Investigational Site, Caboolture, Queensland, Australia</location>
      <location>GSK Investigational Site, Kippa Ring, Queensland, Australia</location>
      <location>GSK Investigational Site, Spring Hill, Queensland, Australia</location>
      <location>GSK Investigational Site, Adelaide, South Australia, Australia</location>
      <location>GSK Investigational Site, Box Hill, Victoria, Australia</location>
      <location>GSK Investigational Site, Malvern, Victoria, Australia</location>
      <location>GSK Investigational Site, Issoire, France</location>
      <location>GSK Investigational Site, Les Sables d'Olonne, France</location>
      <location>GSK Investigational Site, Lille, France</location>
      <location>GSK Investigational Site, Saint Quentin, France</location>
      <location>GSK Investigational Site, Vitry sur Seine, France</location>
      <location>GSK Investigational Site, Witten, Nordrhein-Westfalen, Germany</location>
      <location>GSK Investigational Site, Leipzg, Sachsen, Germany</location>
      <location>GSK Investigational Site, Berlin, Germany</location>
      <location>GSK Investigational Site, Berlin, Germany</location>
      <location>GSK Investigational Site, Berlin, Germany</location>
      <location>GSK Investigational Site, Hamburg, Germany</location>
      <location>GSK Investigational Site, Hamburg, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00394186</url>
  </study>
  <study rank="198">
    <nct_id>NCT02079675</nct_id>
    <title>Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-constipation Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SKI3246 Low Dose</intervention>
      <intervention type="Drug">SKI3246 High Dose</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global Assessment of Relief During the Double-Blind Treatment Phase Using the Subject Global Assessment (SGA)</outcome_measure>
      <outcome_measure>Patient satisfaction using 5- Likert Scale</outcome_measure>
      <outcome_measure>Subject Self Reported Adequate Relief of Pain</outcome_measure>
      <outcome_measure>Mean Change From Baseline in Quality of Life as Measured by the Medical Outcomes Survey</outcome_measure>
      <outcome_measure>Visual Analog Scale (VAS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SK Chemicals Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>279</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SKI3246_IBS_II_2012</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <completion_date>April 2014</completion_date>
    <study_first_posted>March 6, 2014</study_first_posted>
    <last_update_posted>June 1, 2015</last_update_posted>
    <locations>
      <location>SK Chemicals, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02079675</url>
  </study>
  <study rank="199">
    <nct_id>NCT02316899</nct_id>
    <title>Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASP0456</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Responder rate of Global assessment of relief of IBS symptoms during 12 weeks.</outcome_measure>
      <outcome_measure>Responder rate of CSBM during 12 weeks</outcome_measure>
      <outcome_measure>Responder rate of SBM during 12 weeks</outcome_measure>
      <outcome_measure>Responder rate of Abnormal bowel habits improvement during 12 weeks</outcome_measure>
      <outcome_measure>Responder rate of Abdominal pain/discomfort relief during 12 weeks</outcome_measure>
      <outcome_measure>Weekly responder rate of Global assessment of relief of IBS symptoms</outcome_measure>
      <outcome_measure>Weekly responder rate of CSBM</outcome_measure>
      <outcome_measure>Weekly responder rate of SBM</outcome_measure>
      <outcome_measure>Weekly responder rate of Abnormal bowel habits improvement</outcome_measure>
      <outcome_measure>Weekly responder rate of Abdominal pain/discomfort relief</outcome_measure>
      <outcome_measure>Changes in weekly average of SBM frequency, CSBM frequency, stool form scores, abdominal pain/discomfort severity, abdominal bloating severity, and straining severity.</outcome_measure>
      <outcome_measure>Changes in IBS-QOL-J scores (entire scores or scores on the sub-scales)</outcome_measure>
      <outcome_measure>Percentage of subjects with SBM within 24 hours after start of the initial administration</outcome_measure>
      <outcome_measure>Percentage of subjects with CSBM within 24 hours after start of the initial administration</outcome_measure>
      <outcome_measure>Safety assessed by development of incidence of adverse events, vital signs, and clinical laboratory tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0456-CL-0031</other_id>
    </other_ids>
    <start_date>October 21, 2014</start_date>
    <primary_completion_date>September 19, 2015</primary_completion_date>
    <completion_date>March 29, 2016</completion_date>
    <study_first_posted>December 15, 2014</study_first_posted>
    <last_update_posted>May 2, 2019</last_update_posted>
    <locations>
      <location>Site JP00004, Aichi, Japan</location>
      <location>Site JP00048, Aichi, Japan</location>
      <location>Site JP00049, Aichi, Japan</location>
      <location>Site JP00038, Chiba, Japan</location>
      <location>Site JP00039, Chiba, Japan</location>
      <location>Site JP00040, Chiba, Japan</location>
      <location>Site JP00041, Chiba, Japan</location>
      <location>Site JP00042, Chiba, Japan</location>
      <location>Site JP00002, Fukuoka, Japan</location>
      <location>Site JP00060, Fukuoka, Japan</location>
      <location>Site JP00061, Fukuoka, Japan</location>
      <location>Site JP00001, Hokkaido, Japan</location>
      <location>Site JP00006, Hokkaido, Japan</location>
      <location>Site JP00007, Hokkaido, Japan</location>
      <location>Site JP00057, Hyogo, Japan</location>
      <location>Site JP00058, Hyogo, Japan</location>
      <location>Site JP00059, Hyogo, Japan</location>
      <location>Site JP00030, Kanagawa, Japan</location>
      <location>Site JP00031, Kanagawa, Japan</location>
      <location>Site JP00032, Kanagawa, Japan</location>
      <location>Site JP00033, Kanagawa, Japan</location>
      <location>Site JP00034, Kanagawa, Japan</location>
      <location>Site JP00035, Kanagawa, Japan</location>
      <location>Site JP00036, Kanagawa, Japan</location>
      <location>Site JP00037, Kanagawa, Japan</location>
      <location>Site JP00056, Kyoto, Japan</location>
      <location>Site JP00003, Osaka, Japan</location>
      <location>Site JP00050, Osaka, Japan</location>
      <location>Site JP00051, Osaka, Japan</location>
      <location>Site JP00052, Osaka, Japan</location>
      <location>Site JP00053, Osaka, Japan</location>
      <location>Site JP00054, Osaka, Japan</location>
      <location>Site JP00055, Osaka, Japan</location>
      <location>Site JP00043, Saitama, Japan</location>
      <location>Site JP00044, Saitama, Japan</location>
      <location>Site JP00045, Saitama, Japan</location>
      <location>Site JP00046, Saitama, Japan</location>
      <location>Site JP00047, Saitama, Japan</location>
      <location>Site JP00005, Tokyo, Japan</location>
      <location>Site JP00008, Tokyo, Japan</location>
      <location>Site JP00009, Tokyo, Japan</location>
      <location>Site JP00010, Tokyo, Japan</location>
      <location>Site JP00011, Tokyo, Japan</location>
      <location>Site JP00012, Tokyo, Japan</location>
      <location>Site JP00013, Tokyo, Japan</location>
      <location>Site JP00014, Tokyo, Japan</location>
      <location>Site JP00015, Tokyo, Japan</location>
      <location>Site JP00016, Tokyo, Japan</location>
      <location>Site JP00017, Tokyo, Japan</location>
      <location>Site JP00018, Tokyo, Japan</location>
      <location>Site JP00019, Tokyo, Japan</location>
      <location>Site JP00020, Tokyo, Japan</location>
      <location>Site JP00021, Tokyo, Japan</location>
      <location>Site JP00022, Tokyo, Japan</location>
      <location>Site JP00023, Tokyo, Japan</location>
      <location>Site JP00024, Tokyo, Japan</location>
      <location>Site JP00025, Tokyo, Japan</location>
      <location>Site JP00026, Tokyo, Japan</location>
      <location>Site JP00027, Tokyo, Japan</location>
      <location>Site JP00028, Tokyo, Japan</location>
      <location>Site JP00029, Tokyo, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02316899</url>
  </study>
  <study rank="200">
    <nct_id>NCT00135031</nct_id>
    <title>Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bifidobacterium infantis 35624</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary efficacy variable was the abdominal pain score</outcome_measure>
      <outcome_measure>Bloating/distension, sense of incomplete evacuation, straining, urgency, passage of gas, number of bowel movements, passage of mucus, a composite symptom score, subject's assessment of IBS symptom relief, and quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Procter and Gamble</lead_sponsor>
      <collaborator>Alimentary Health Ltd</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>362</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2002089</other_id>
    </other_ids>
    <start_date>January 2004</start_date>
    <primary_completion_date>September 2004</primary_completion_date>
    <completion_date>September 2004</completion_date>
    <study_first_posted>August 25, 2005</study_first_posted>
    <last_update_posted>June 15, 2011</last_update_posted>
    <locations>
      <location>Yaxley Group Practice, The Health Centre, Peterborough, Cambridgeshire, United Kingdom</location>
      <location>The Staploe Medical Centre, Soham, Cambridgeshire, United Kingdom</location>
      <location>Wansford Surgery, Wansford, Cambridgeshire, United Kingdom</location>
      <location>Old School Surgery, Greenisland, County Antrim, United Kingdom</location>
      <location>Springhill Surgery, Bangor, County Down, United Kingdom</location>
      <location>Downpatrick Health Centre, Downpatrick, County Down, United Kingdom</location>
      <location>Little Common Surgery, Bexhill-on-Sea, East Sussex, United Kingdom</location>
      <location>Sea Road Surgery, Bexhill-on-Sea, East Sussex, United Kingdom</location>
      <location>Valleyfield Health Centre, High Valleyfield, Fife, United Kingdom</location>
      <location>Stanwell Road Surgery, Ashford, Middlesex, United Kingdom</location>
      <location>Belmont Health Centre, Harrow, Middlesex, United Kingdom</location>
      <location>The Frome Medical Practice, Frome, Somerset, United Kingdom</location>
      <location>The Burns Practice, Doncaster, South Yorkshire, United Kingdom</location>
      <location>The Burngreave Surgery, Sheffield, South Yorkshire, United Kingdom</location>
      <location>The Medical Centre, East Horsley, Surrey, United Kingdom</location>
      <location>The Penylan Surgery, Cardiff, Wales, United Kingdom</location>
      <location>Sherbourne Medical Centre, Leamington Spa, Warwickshire, United Kingdom</location>
      <location>Hathaway Surgery, Chippenham, Wiltshire, United Kingdom</location>
      <location>Swindon Medical Research Centre, Abbeymeads Medical, Swindon, Wiltshire, United Kingdom</location>
      <location>The Orchard Medical Centre, Bristol, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00135031</url>
  </study>
  <study rank="201">
    <nct_id>NCT00742872</nct_id>
    <title>Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Constipation-Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mosapride Citrate</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate Relief of Symptoms Associated With Constipation-predominant Irritable Bowel Syndrome.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>American University of Beirut Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AUB-IM.AS1.21</other_id>
    </other_ids>
    <start_date>September 2008</start_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <completion_date>June 2010</completion_date>
    <study_first_posted>August 28, 2008</study_first_posted>
    <results_first_posted>April 9, 2013</results_first_posted>
    <last_update_posted>April 9, 2013</last_update_posted>
    <locations>
      <location>American University of Beirut Medical Center, Beirut, Lebanon</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00742872</url>
  </study>
  <study rank="202">
    <nct_id>NCT01418066</nct_id>
    <title>Ayurvedic Herbs in Diarrhea Predominant Irritable Bowel Syndrome</title>
    <acronym>AHIB</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ayurvedic Herbs</intervention>
      <intervention type="Drug">Placebo tea</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>irritable bowel syndrome- symptom severity score</outcome_measure>
      <outcome_measure>Frequency of abdominal discomfort/Pain</outcome_measure>
      <outcome_measure>Intensity of Abdominal Pain/Discomfort</outcome_measure>
      <outcome_measure>Stool and diarrhea Frequency</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>IBS Specific Quality of life</outcome_measure>
      <outcome_measure>Depression and Anxiety</outcome_measure>
      <outcome_measure>Adequate Relief Score</outcome_measure>
      <outcome_measure>Global improvement</outcome_measure>
      <outcome_measure>adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universität Duisburg-Essen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-4673 AHIB</other_id>
    </other_ids>
    <start_date>August 2011</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>August 16, 2011</study_first_posted>
    <last_update_posted>December 6, 2012</last_update_posted>
    <locations>
      <location>Klinik für Naturheilkunde und Integrative Medizin, Essen, NRW, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01418066</url>
  </study>
  <study rank="203">
    <nct_id>NCT00189813</nct_id>
    <title>A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YM060</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
      <collaborator>Astellas Pharma Europe B.V.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>691</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-305</other_id>
    </other_ids>
    <start_date>March 2005</start_date>
    <primary_completion_date>December 2005</primary_completion_date>
    <completion_date>December 2005</completion_date>
    <study_first_posted>September 19, 2005</study_first_posted>
    <last_update_posted>August 28, 2014</last_update_posted>
    <locations>
      <location>Plovdiv, Bulgaria</location>
      <location>Sofia, Bulgaria</location>
      <location>Varna, Bulgaria</location>
      <location>Ceske Budejovice, Czech Republic</location>
      <location>Hradec Kralove, Czech Republic</location>
      <location>Ostrava Hrabuvka, Czech Republic</location>
      <location>Praha, Czech Republic</location>
      <location>Tabor, Czech Republic</location>
      <location>Usti nad Orlici, Czech Republic</location>
      <location>Tallinn, Estonia</location>
      <location>Tartu, Estonia</location>
      <location>Viljandi, Estonia</location>
      <location>Berlin, Germany</location>
      <location>Bochum, Germany</location>
      <location>Dietzenbach, Germany</location>
      <location>Essen, Germany</location>
      <location>Frankfurt, Germany</location>
      <location>Friedberg, Germany</location>
      <location>Hamburg, Germany</location>
      <location>Hassloch, Germany</location>
      <location>Koenigstein, Germany</location>
      <location>Leipzig, Germany</location>
      <location>Mainz, Germany</location>
      <location>Marburg, Germany</location>
      <location>Potsdam, Germany</location>
      <location>Waltershausen, Germany</location>
      <location>Kaunas, Lithuania</location>
      <location>Klaipeda, Lithuania</location>
      <location>Vilnius, Lithuania</location>
      <location>Bialystok, Poland</location>
      <location>Bydgoszcz, Poland</location>
      <location>Krakow, Poland</location>
      <location>Leszno, Poland</location>
      <location>Lublin, Poland</location>
      <location>Olawa, Poland</location>
      <location>Warszawa, Poland</location>
      <location>Moscow, Russian Federation</location>
      <location>St. Petersburg, Russian Federation</location>
      <location>Yaroslavl, Russian Federation</location>
      <location>Dnipropetrovsk, Ukraine</location>
      <location>Kiev, Ukraine</location>
      <location>Lviv, Ukraine</location>
      <location>Odessa, Ukraine</location>
      <location>Simferopol, Ukraine</location>
      <location>Sumy, Ukraine</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00189813</url>
  </study>
  <study rank="204">
    <nct_id>NCT01242163</nct_id>
    <title>Application of Chemical Sensors for Diagnosis of Inflammatory Bowel Diseases and Irritable Bowel Syndrome by Respiratory Samples</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Rambam Health Care Campus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>0481-10CTIL</other_id>
    </other_ids>
    <start_date>December 2010</start_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>November 16, 2010</study_first_posted>
    <last_update_posted>November 23, 2010</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01242163</url>
  </study>
  <study rank="205">
    <nct_id>NCT02436603</nct_id>
    <title>Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Nutrition/Mind-Body Coaching</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Symptom Severity Scale</outcome_measure>
      <outcome_measure>IBS Quality of Life (IBS-QOL)</outcome_measure>
      <outcome_measure>Patient Global Impression of Change (PGIC)</outcome_measure>
      <outcome_measure>Perceived Stress Scale (PSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>010-15</other_id>
    </other_ids>
    <start_date>April 2015</start_date>
    <primary_completion_date>June 28, 2017</primary_completion_date>
    <completion_date>June 28, 2017</completion_date>
    <study_first_posted>May 7, 2015</study_first_posted>
    <last_update_posted>February 14, 2018</last_update_posted>
    <locations>
      <location>Center for Health and Healing, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02436603</url>
  </study>
  <study rank="206">
    <nct_id>NCT03555188</nct_id>
    <title>TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial</title>
    <acronym>TRITON</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ondansetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Weekly responder for abdominal pain and stool consistency</outcome_measure>
      <outcome_measure>Stool Frequency</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>Urgency of defecation</outcome_measure>
      <outcome_measure>Satisfactory relief of IBS symptoms</outcome_measure>
      <outcome_measure>Functional dyspepsia</outcome_measure>
      <outcome_measure>IBS Symptom Severity Scale</outcome_measure>
      <outcome_measure>Rescue Medication</outcome_measure>
      <outcome_measure>Abdominal pain score</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Stool frequency post treatment</outcome_measure>
      <outcome_measure>Stool consistency post treatment</outcome_measure>
      <outcome_measure>Urgency of defecation post treatment</outcome_measure>
      <outcome_measure>Abdominal pain post treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Leeds</lead_sponsor>
      <collaborator>Barnsley Hospital NHS Foundation Trust</collaborator>
      <collaborator>Barts &amp; The London NHS Trust</collaborator>
      <collaborator>County Durham and Darlington NHS Foundation Trust</collaborator>
      <collaborator>Flinders University</collaborator>
      <collaborator>The Leeds Teaching Hospitals NHS Trust</collaborator>
      <collaborator>London North West Healthcare NHS Trust</collaborator>
      <collaborator>NHS Lothian</collaborator>
      <collaborator>Queen Mary University of London</collaborator>
      <collaborator>Sandwell &amp; West Birmingham Hospitals NHS Trust</collaborator>
      <collaborator>Sheffield Teaching Hospitals NHS Foundation Trust</collaborator>
      <collaborator>University College London Hospitals</collaborator>
      <collaborator>University Hospitals of North Midlands NHS Trust</collaborator>
      <collaborator>Manchester University NHS Foundation Trust</collaborator>
      <collaborator>University of Manchester</collaborator>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>15/74/01</other_id>
    </other_ids>
    <start_date>March 29, 2018</start_date>
    <primary_completion_date>February 1, 2020</primary_completion_date>
    <completion_date>February 28, 2020</completion_date>
    <study_first_posted>June 13, 2018</study_first_posted>
    <last_update_posted>June 13, 2018</last_update_posted>
    <locations>
      <location>Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom</location>
      <location>Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom</location>
      <location>County Durham and Darlington NHS Foundation Trust, Durham, United Kingdom</location>
      <location>Westen General Hosptal, Edinburgh, Edinburgh, United Kingdom</location>
      <location>Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom</location>
      <location>London North West NHS Foundation Trust, London, United Kingdom</location>
      <location>Queen Mary, University of London, London, United Kingdom</location>
      <location>University College London Hospitals NHS Foundation Trust, London, United Kingdom</location>
      <location>Salford Royal Hospital, Manchester, United Kingdom</location>
      <location>University Hospital of South Manchester, Manchester, United Kingdom</location>
      <location>Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom</location>
      <location>Royal Hallamshire Hospital, Sheffield, United Kingdom</location>
      <location>University Hospitals of North Midlands NHS Trust, Stoke, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03555188</url>
  </study>
  <study rank="207">
    <nct_id>NCT01076699</nct_id>
    <title>A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0.075 mg RVX-100</intervention>
      <intervention type="Drug">0.125 mg RVX-100</intervention>
      <intervention type="Drug">0.250 mg RVX-100</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in weekly average abdominal pain severity score from baseline.</outcome_measure>
      <outcome_measure>Change in weekly average Abdominal Pain Severity score from baseline to week 8</outcome_measure>
      <outcome_measure>Time to response, based on abdominal pain severity scores.</outcome_measure>
      <outcome_measure>Proportion of subjects in each treatment arm who are weekly responders.</outcome_measure>
      <outcome_measure>Proportion of subjects in each treatment arm who are end-of-treatment responders</outcome_measure>
      <outcome_measure>Number of pain-free days per week, based on responses to the Abdominal Pain Severity scale</outcome_measure>
      <outcome_measure>Bowel urgency</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
      <outcome_measure>Fecal incontinence</outcome_measure>
      <outcome_measure>Bloating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Revogenex, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>192</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RVG-09-005</other_id>
    </other_ids>
    <start_date>March 2010</start_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <completion_date>March 2011</completion_date>
    <study_first_posted>February 26, 2010</study_first_posted>
    <last_update_posted>July 19, 2010</last_update_posted>
    <locations>
      <location>Metropolitan Gastroenterology Group, Chevy Chase, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01076699</url>
  </study>
  <study rank="208">
    <nct_id>NCT01274000</nct_id>
    <title>A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YM060</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Responder rate of patients reported global assessment of relief of IBS symptoms</outcome_measure>
      <outcome_measure>Responder rate of patients reported assessment of relief of abdominal discomfort and/or pain</outcome_measure>
      <outcome_measure>Responder rate of patients reported assessment of improvement of abnormal bowel habits</outcome_measure>
      <outcome_measure>Change in weekly average scores of stool form (appearance)</outcome_measure>
      <outcome_measure>Safety assessed by the incidence of adverse events and abnormal values in lab-tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>409</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-701</other_id>
    </other_ids>
    <start_date>November 2010</start_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <completion_date>October 2011</completion_date>
    <study_first_posted>January 11, 2011</study_first_posted>
    <last_update_posted>October 12, 2015</last_update_posted>
    <locations>
      <location>Hokkaido, Japan</location>
      <location>Kansai, Japan</location>
      <location>Kantou, Japan</location>
      <location>Kyusyu, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01274000</url>
  </study>
  <study rank="209">
    <nct_id>NCT01736423</nct_id>
    <title>A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YM060</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Monthly responder rate of global assessment of relief of overall IBS symptoms</outcome_measure>
      <outcome_measure>Monthly responder rate of stool form normalization</outcome_measure>
      <outcome_measure>Monthly responder rate of global assessment of relief of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Monthly responder rate of global assessment of improvement of abnormal bowel habits</outcome_measure>
      <outcome_measure>Change in weekly average of scores of severity of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Change in weekly average of scores of stool form</outcome_measure>
      <outcome_measure>Change in weekly average of stool frequency</outcome_measure>
      <outcome_measure>Rate of days without urgency</outcome_measure>
      <outcome_measure>Rate of days without feeling of incomplete bowel movement</outcome_measure>
      <outcome_measure>Change in entire Japanese version of Irritable Bowel Syndrome Quality of Life (IBS-QOL-J) scores and pairwise IBS-QOL-J scores on the sub-scales</outcome_measure>
      <outcome_measure>Safety assessed through AEs and clinical laboratory values</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>151</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-703</other_id>
    </other_ids>
    <start_date>September 2012</start_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <completion_date>May 2014</completion_date>
    <study_first_posted>November 29, 2012</study_first_posted>
    <last_update_posted>October 12, 2015</last_update_posted>
    <locations>
      <location>Hokkaido, Japan</location>
      <location>Kansai, Japan</location>
      <location>Kantou, Japan</location>
      <location>Kyushu, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01736423</url>
  </study>
  <study rank="210">
    <nct_id>NCT03557788</nct_id>
    <title>Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin Oral Tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in IBS-SSS questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
      <collaborator>National University, Singapore</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017/00977</other_id>
    </other_ids>
    <start_date>May 7, 2018</start_date>
    <primary_completion_date>May 7, 2019</primary_completion_date>
    <completion_date>May 7, 2019</completion_date>
    <study_first_posted>June 15, 2018</study_first_posted>
    <last_update_posted>June 15, 2018</last_update_posted>
    <locations>
      <location>Soh Yu Sen, Alex, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03557788</url>
  </study>
  <study rank="211">
    <nct_id>NCT03923322</nct_id>
    <title>Botanical Tincture for Symptoms of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Botanical Tincture</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of subjects recruited</outcome_measure>
      <outcome_measure>Proportion of subjects who complete the study</outcome_measure>
      <outcome_measure>Proportion of dosages of drug/placebo that are taken by participants</outcome_measure>
      <outcome_measure>Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score scale of 0 (No pain) -10 (Worst imaginable pain)</outcome_measure>
      <outcome_measure>Abdominal Bloating Intensity: weekly average of worst daily (in past 24 hours) abdominal bloating rating on a scale of 0 (absent) - 4 (very severe)</outcome_measure>
      <outcome_measure>Bowel movement frequency: Number of Complete Spontaneous Bowel Movements (CSBMs) each week</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stamford Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TSH_Family Medicine_2018001</other_id>
    </other_ids>
    <start_date>September 2019</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>January 2021</completion_date>
    <study_first_posted>April 22, 2019</study_first_posted>
    <last_update_posted>April 22, 2019</last_update_posted>
    <locations>
      <location>Stamford Health, Stamford, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03923322</url>
  </study>
  <study rank="212">
    <nct_id>NCT01225237</nct_id>
    <title>A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ramosetron</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Responder rate of stool form normalization</outcome_measure>
      <outcome_measure>Responder rate of patients reported global assessment of relief of IBS symptoms</outcome_measure>
      <outcome_measure>Responder rate of patients reported assessment of relief of abdominal discomfort and/or pain</outcome_measure>
      <outcome_measure>Responder rate of patients reported assessment of improvement of abnormal bowel habits</outcome_measure>
      <outcome_measure>Safety assessed by the incidence of adverse events and abnormal values in labo-tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>296</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-501</other_id>
    </other_ids>
    <start_date>October 2010</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>August 2011</completion_date>
    <study_first_posted>October 20, 2010</study_first_posted>
    <last_update_posted>October 15, 2014</last_update_posted>
    <locations>
      <location>Hokkaido, Japan</location>
      <location>Kansai, Japan</location>
      <location>Kantou, Japan</location>
      <location>Kyusyu, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01225237</url>
  </study>
  <study rank="213">
    <nct_id>NCT02213172</nct_id>
    <title>Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome</title>
    <acronym>14PIHL</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome-Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Bifidobacterium longum R0175</intervention>
      <intervention type="Dietary Supplement">Lactobacillus paracasei HA-196</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Symptom Severity Score</outcome_measure>
      <outcome_measure>IBS Symptom Severity Score by IBS Subtype</outcome_measure>
      <outcome_measure>Number of Responders</outcome_measure>
      <outcome_measure>Anxiety and Depression</outcome_measure>
      <outcome_measure>Abdominal pain frequency</outcome_measure>
      <outcome_measure>Abdominal distension/tightness</outcome_measure>
      <outcome_measure>Abdominal Pain Intensity</outcome_measure>
      <outcome_measure>Severity of straining</outcome_measure>
      <outcome_measure>Health Status</outcome_measure>
      <outcome_measure>Impact of IBS symptoms on Quality of Life</outcome_measure>
      <outcome_measure>Severity of IBS Symptoms</outcome_measure>
      <outcome_measure>Bowel Habit Satisfaction</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>Stool Frequency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KGK Science Inc.</lead_sponsor>
      <collaborator>Lallemand Health Solutions</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>14PIHL</other_id>
    </other_ids>
    <start_date>October 30, 2014</start_date>
    <primary_completion_date>February 15, 2018</primary_completion_date>
    <completion_date>March 2018</completion_date>
    <study_first_posted>August 11, 2014</study_first_posted>
    <last_update_posted>April 11, 2018</last_update_posted>
    <locations>
      <location>KGK Synergize Inc., London, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02213172</url>
  </study>
  <study rank="214">
    <nct_id>NCT01553591</nct_id>
    <title>Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eluxadoline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</outcome_measure>
      <outcome_measure>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</outcome_measure>
      <outcome_measure>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</outcome_measure>
      <outcome_measure>Change From Baseline in Daily Abdominal Discomfort Scores</outcome_measure>
      <outcome_measure>Change From Baseline in Daily Abdominal Bloating Scores</outcome_measure>
      <outcome_measure>Number of Bowel Movements Per Day</outcome_measure>
      <outcome_measure>Number of Bowel Incontinence Episodes</outcome_measure>
      <outcome_measure>Number of Bowel Incontinence Free Days</outcome_measure>
      <outcome_measure>Number of Urgency Episodes Per Day</outcome_measure>
      <outcome_measure>IBS-QoL Total Scores</outcome_measure>
      <outcome_measure>Change From Baseline in IBS-QoL Total Scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Furiex Pharmaceuticals, Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1282</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>27018966IBS3001</other_id>
      <other_id>2012-001600-38</other_id>
    </other_ids>
    <start_date>May 29, 2012</start_date>
    <primary_completion_date>July 29, 2014</primary_completion_date>
    <completion_date>July 29, 2014</completion_date>
    <study_first_posted>March 14, 2012</study_first_posted>
    <results_first_posted>September 3, 2018</results_first_posted>
    <last_update_posted>September 3, 2018</last_update_posted>
    <locations>
      <location>Furiex Research Site, Athens, Alabama, United States</location>
      <location>Furiex Research Site, Birmingham, Alabama, United States</location>
      <location>Furiex Research Site, Foley, Alabama, United States</location>
      <location>Furiex Research Site, Huntsville, Alabama, United States</location>
      <location>Furiex Research Site, Ozark, Alabama, United States</location>
      <location>Furiex Research Site, Chandler, Arizona, United States</location>
      <location>Furiex Research Site, Glendale, Arizona, United States</location>
      <location>Furiex Research Site, Mesa, Arizona, United States</location>
      <location>Furiex Research Site, Phoenix, Arizona, United States</location>
      <location>Furiex Research Site, Tucson, Arizona, United States</location>
      <location>Furiex Research Site, Little Rock, Arkansas, United States</location>
      <location>Furiex Research Site, Little Rock, Arkansas, United States</location>
      <location>Furiex Research Site, North Little Rock, Arkansas, United States</location>
      <location>Furiex Research Site, Azusa, California, United States</location>
      <location>Furiex Research Site, Bell Gardens, California, United States</location>
      <location>Furiex Research Site, Beverly Hills, California, United States</location>
      <location>Furiex Research Site, Carson, California, United States</location>
      <location>Furiex Research Site, Chula Vista, California, United States</location>
      <location>Furiex Research Site, Corona, California, United States</location>
      <location>Furiex Research Site, El Cajon, California, United States</location>
      <location>Furiex Research Site, Encino, California, United States</location>
      <location>Furiex Research Site, Garden Grove, California, United States</location>
      <location>Furiex Research Site, Lomita, California, United States</location>
      <location>Furiex Research Site, Los Angeles, California, United States</location>
      <location>Furiex Research Site, Monterey Park, California, United States</location>
      <location>Furiex Research Site, Murrieta, California, United States</location>
      <location>Furiex Research Site, Newport Beach, California, United States</location>
      <location>Furiex Research Site, North Hollywood, California, United States</location>
      <location>Furiex Research Site, Oakland, California, United States</location>
      <location>Furiex Research Site, Oxnard, California, United States</location>
      <location>Furiex Research Site, Pismo Beach, California, United States</location>
      <location>Furiex Research Site, Poway, California, United States</location>
      <location>Furiex Research Site, Riverside, California, United States</location>
      <location>Furiex Research Site, Roseville, California, United States</location>
      <location>Furiex Research Site, Sacramento, California, United States</location>
      <location>Furiex Research Site, San Diego, California, United States</location>
      <location>Furiex Research Site, San Diego, California, United States</location>
      <location>Furiex Research Site, Santa Monica, California, United States</location>
      <location>Furiex Research Site, Thousand Oaks, California, United States</location>
      <location>Furiex Research Site, Colorado Springs, Colorado, United States</location>
      <location>Furiex Research Site, Colorado Springs, Colorado, United States</location>
      <location>Furiex Research Site, Lafayette, Colorado, United States</location>
      <location>Furiex Research Site, Lakewood, Colorado, United States</location>
      <location>Furiex Research Site, Longmont, Colorado, United States</location>
      <location>Furiex Research Site, Norwalk, Connecticut, United States</location>
      <location>Furiex Research Site, Ridgefield, Connecticut, United States</location>
      <location>Furiex Research Site, Boca Raton, Florida, United States</location>
      <location>Furiex Research Site, Brandon, Florida, United States</location>
      <location>Furiex Research Site, Clearwater, Florida, United States</location>
      <location>Furiex Research Site, Cooper City, Florida, United States</location>
      <location>Furiex Research Site, Coral Springs, Florida, United States</location>
      <location>Furiex Research Site, Crystal River, Florida, United States</location>
      <location>Furiex Research Site, Doral, Florida, United States</location>
      <location>Furiex Research Site, Eustis, Florida, United States</location>
      <location>Furix Research Site, Hialeah, Florida, United States</location>
      <location>Furiex Research Site, Hialeah, Florida, United States</location>
      <location>Furiex Research Site, Inverness, Florida, United States</location>
      <location>Furiex Research Site, Jacksonville, Florida, United States</location>
      <location>Furiex Research Site, Kissimmee, Florida, United States</location>
      <location>Furiex Research Site, Maitland, Florida, United States</location>
      <location>Furiex Research Site, Melbourne, Florida, United States</location>
      <location>Furiex Research Site, Miami Springs, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miami, Florida, United States</location>
      <location>Furiex Research Site, Miramar, Florida, United States</location>
      <location>Furiex Research Site, Naples, Florida, United States</location>
      <location>Furiex Research Site, New Port Richey, Florida, United States</location>
      <location>Furiex Research Site, New Smyrna Beach, Florida, United States</location>
      <location>Furiex Research Site, Orlando, Florida, United States</location>
      <location>Furiex Research Site, Orlando, Florida, United States</location>
      <location>Furiex Research Site, Orlando, Florida, United States</location>
      <location>Furiex Research Site, Ormond Beach, Florida, United States</location>
      <location>Furiex Research Site, Oviedo, Florida, United States</location>
      <location>Furiex Research Site, Palm Beach, Florida, United States</location>
      <location>Furiex Research Site, Pinellas Park, Florida, United States</location>
      <location>Furiex Research Site, Pinellas Park, Florida, United States</location>
      <location>Furiex Research Site, Port Orange, Florida, United States</location>
      <location>Furiex Research Site, Sanford, Florida, United States</location>
      <location>Furiex Research Site, Sebastian, Florida, United States</location>
      <location>Furiex Research Site, South Miami, Florida, United States</location>
      <location>Furiex Research Site, Tampa, Florida, United States</location>
      <location>Furiex Research Site, Tampa, Florida, United States</location>
      <location>Furiex Research Site, Venice, Florida, United States</location>
      <location>Furiex Research Site, Wellington, Florida, United States</location>
      <location>Furiex Research Site, Winter Haven, Florida, United States</location>
      <location>Furiex Research Site, Winter Park, Florida, United States</location>
      <location>Furiex Research Site, Atlanta, Georgia, United States</location>
      <location>Furiex Research Site, Blue Ridge, Georgia, United States</location>
      <location>Furiex Research Site, Johns Creek, Georgia, United States</location>
      <location>Furiex Research Site, Lilburn, Georgia, United States</location>
      <location>Furiex Research Site, Oakwood, Georgia, United States</location>
      <location>Furiex Research Site, Perry, Georgia, United States</location>
      <location>Furiex Research Site, Snellville, Georgia, United States</location>
      <location>Furiex Research Site, Eagle, Idaho, United States</location>
      <location>Furiex Research Site, Addison, Illinois, United States</location>
      <location>Furiex Research Site, Chicago, Illinois, United States</location>
      <location>Furiex Research Site, Morton, Illinois, United States</location>
      <location>Furiex Research Site, Brownsburg, Indiana, United States</location>
      <location>Furiex Research Site, Evansville, Indiana, United States</location>
      <location>Furiex Research Site, Indianapolis, Indiana, United States</location>
      <location>Furiex Research Site, Clive, Iowa, United States</location>
      <location>Furiex Research Site, Davenport, Iowa, United States</location>
      <location>Furiex Research Site, Iowa City, Iowa, United States</location>
      <location>Furiex Research Site, West Des Moines, Iowa, United States</location>
      <location>Furiex Research Site, Newton, Kansas, United States</location>
      <location>Furiex Research Site, Prairie Village, Kansas, United States</location>
      <location>Furiex Research Site, Shawnee Mission, Kansas, United States</location>
      <location>Furiex Research Site, Wichita, Kansas, United States</location>
      <location>Furiex Research Site, Wichita, Kansas, United States</location>
      <location>Furiex Research Site, Crestview Hills, Kentucky, United States</location>
      <location>Furiex Research Site, Hawesville, Kentucky, United States</location>
      <location>Furiex Research Site, Lexington, Kentucky, United States</location>
      <location>Furiex Research Site, Lexington, Kentucky, United States</location>
      <location>Furiex Research Site, Louisville, Kentucky, United States</location>
      <location>Furiex Research Site, Madisonville, Kentucky, United States</location>
      <location>Furiex Research Site, Owensboro, Kentucky, United States</location>
      <location>Furiex Research Site, Baker, Louisiana, United States</location>
      <location>Furiex Research Site, Covington, Louisiana, United States</location>
      <location>Furiex Research Site, Hammond, Louisiana, United States</location>
      <location>Furiex Research Site, Metairie, Louisiana, United States</location>
      <location>Furiex Research Site, New Orleans, Louisiana, United States</location>
      <location>Furiex Research Site, Opelousas, Louisiana, United States</location>
      <location>Furiex Research Site, Shreveport, Louisiana, United States</location>
      <location>Furiex Research Site, Shreveport, Louisiana, United States</location>
      <location>Furiex Research Site, Bangor, Maine, United States</location>
      <location>Furiex Research Site, Annapolis, Maryland, United States</location>
      <location>Furiex Research Site, Chevy Chase, Maryland, United States</location>
      <location>Furiex Research Site, Brockton, Massachusetts, United States</location>
      <location>Furiex Research Site, Watertown, Massachusetts, United States</location>
      <location>Furiex Research Site, Ann Arbor, Michigan, United States</location>
      <location>Furiex Research Site, Southfield, Michigan, United States</location>
      <location>Furiex Research Site, Stevensville, Michigan, United States</location>
      <location>Furiex Research Site, Chaska, Minnesota, United States</location>
      <location>Furiex Research Site, Jackson, Mississippi, United States</location>
      <location>Furiex Research Site, Jefferson City, Missouri, United States</location>
      <location>Furiex Research Site, Saint Louis, Missouri, United States</location>
      <location>Furiex Research Site, Saint Louis, Missouri, United States</location>
      <location>Furiex Research Site, Saint Peters, Missouri, United States</location>
      <location>Furiex Research Site, Billings, Montana, United States</location>
      <location>Furiex Research Site, Bellevue, Nebraska, United States</location>
      <location>Furiex Research Site, Omaha, Nebraska, United States</location>
      <location>Furiex Research Site, Omaha, Nebraska, United States</location>
      <location>Furiex Research Site, Las Vegas, Nevada, United States</location>
      <location>Furiex Research Site, Las Vegas, Nevada, United States</location>
      <location>Furiex Research Site, Collingswood, New Jersey, United States</location>
      <location>Furiex Research Site, Edison, New Jersey, United States</location>
      <location>Furiex Research Site, Albuquerque, New Mexico, United States</location>
      <location>Furiex Research Site, Brooklyn, New York, United States</location>
      <location>Furiex Research Site, Endwell, New York, United States</location>
      <location>Furiex Research Site, Great Neck, New York, United States</location>
      <location>Furiex Research Site, Hartsdale, New York, United States</location>
      <location>Furiex Research Site, Kew Gardens, New York, United States</location>
      <location>Furiex Research Site, New Windsor, New York, United States</location>
      <location>Furiex Research Site, New York, New York, United States</location>
      <location>Furiex Research Site, North Massapequa, New York, United States</location>
      <location>Furiex Research Site, Poughkeepsie, New York, United States</location>
      <location>Furiex Research Site, Asheville, North Carolina, United States</location>
      <location>Furiex Research Site, Asheville, North Carolina, United States</location>
      <location>Furiex Research Site, Charlotte, North Carolina, United States</location>
      <location>Furiex Research Site, Durham, North Carolina, United States</location>
      <location>Furiex Research Site, Fayetteville, North Carolina, United States</location>
      <location>Furiex Research Site, Greensboro, North Carolina, United States</location>
      <location>Furiex Research Site, Hickory, North Carolina, United States</location>
      <location>Furiex Research Site, High Point, North Carolina, United States</location>
      <location>Furiex Research Site, Kinston, North Carolina, United States</location>
      <location>Furiex Research Site, Lenoir, North Carolina, United States</location>
      <location>Furiex Research Site, Raleigh, North Carolina, United States</location>
      <location>Furiex Research Site, Raleigh, North Carolina, United States</location>
      <location>Furiex Research Site, Salisbury, North Carolina, United States</location>
      <location>Furiex Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Furiex Research Site, Fargo, North Dakota, United States</location>
      <location>Furiex Research Site, Fargo, North Dakota, United States</location>
      <location>Furiex Research Site, Beavercreek, Ohio, United States</location>
      <location>Furiex Research Site, Berea, Ohio, United States</location>
      <location>Furiex Research Site, Centerville, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Cincinnati, Ohio, United States</location>
      <location>Furiex Research Site, Columbus, Ohio, United States</location>
      <location>Furiex Research Site, Dayton, Ohio, United States</location>
      <location>Furiex Research Site, Dayton, Ohio, United States</location>
      <location>Furiex Research Site, Englewood, Ohio, United States</location>
      <location>Furiex Research Site, Franklin, Ohio, United States</location>
      <location>Furiex Research Site, Marion, Ohio, United States</location>
      <location>Furiex Research Site, Miamisburg, Ohio, United States</location>
      <location>Furiex Research Site, Middleburg Heights, Ohio, United States</location>
      <location>Furiex Research Site, Wadsworth, Ohio, United States</location>
      <location>Furiex Research Site, Zanesville, Ohio, United States</location>
      <location>Furiex Research Site, Tulsa, Oklahoma, United States</location>
      <location>Furiex Research Site, Tulsa, Oklahoma, United States</location>
      <location>Furiex Research Site, Tulsa, Oklahoma, United States</location>
      <location>Furiex Research Site, Belle Vernon, Pennsylvania, United States</location>
      <location>Furiex Research Site, Jenkintown, Pennsylvania, United States</location>
      <location>Furiex Research Site, Johnstown, Pennsylvania, United States</location>
      <location>Furiex Research Site, Lansdale, Pennsylvania, United States</location>
      <location>Furiex Research Site, Philadelphia, Pennsylvania, United States</location>
      <location>Furiex Research Site, Philadelphia, Pennsylvania, United States</location>
      <location>Furiex Research Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Furiex Research Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Furiex Research Site, Uniontown, Pennsylvania, United States</location>
      <location>Furiex Research Site, Upper Saint Clair, Pennsylvania, United States</location>
      <location>Furiex Research Site, Cumberland, Rhode Island, United States</location>
      <location>Furiex Research Site, East Providence, Rhode Island, United States</location>
      <location>Furiex Research Site, Anderson, South Carolina, United States</location>
      <location>Furiex Research Site, Charleston, South Carolina, United States</location>
      <location>Furiex Research Site, Fort Mill, South Carolina, United States</location>
      <location>Furiex Research Site, Greenville, South Carolina, United States</location>
      <location>Furiex Research Site, Greer, South Carolina, United States</location>
      <location>Furiex Research Site, Greer, South Carolina, United States</location>
      <location>Furiex Research Site, Myrtle Beach, South Carolina, United States</location>
      <location>Furiex Research Site, Myrtle Beach, South Carolina, United States</location>
      <location>Furiex Research Site, Simpsonville, South Carolina, United States</location>
      <location>Furiex Research Site, Summerville, South Carolina, United States</location>
      <location>Furiex Research Site, Bristol, Tennessee, United States</location>
      <location>Furiex Research Site, Chattanooga, Tennessee, United States</location>
      <location>Furiex Research Site, Clarksville, Tennessee, United States</location>
      <location>Furiex Research Site, Columbia, Tennessee, United States</location>
      <location>Furiex Research Site, Franklin, Tennessee, United States</location>
      <location>Furiex Research Site, Johnson City, Tennessee, United States</location>
      <location>Furiex Research Site, Memphis, Tennessee, United States</location>
      <location>Furiex Research Site, Smyrna, Tennessee, United States</location>
      <location>Furiex Research Site, Austin, Texas, United States</location>
      <location>Furiex Research Site, Austin, Texas, United States</location>
      <location>Furiex Research Site, Baytown, Texas, United States</location>
      <location>Furiex Research Site, Beaumont, Texas, United States</location>
      <location>Furiex Research Site, Dallas, Texas, United States</location>
      <location>Furiex Research Site, El Paso, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Houston, Texas, United States</location>
      <location>Furiex Research Site, Marshall, Texas, United States</location>
      <location>Furiex Research Site, Plano, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, San Antonio, Texas, United States</location>
      <location>Furiex Research Site, Sugar Land, Texas, United States</location>
      <location>Furiex Research Site, Clinton, Utah, United States</location>
      <location>Furiex Research Site, Draper, Utah, United States</location>
      <location>Furiex Research Site, Logan, Utah, United States</location>
      <location>Furiex Research Site, Ogden, Utah, United States</location>
      <location>Furiex Research Site, Salt Lake City, Utah, United States</location>
      <location>Furiex Research Site, West Jordan, Utah, United States</location>
      <location>Furiex Research Site, Lynchburg, Virginia, United States</location>
      <location>Furiex Research Site, Richmond, Virginia, United States</location>
      <location>Furiex Research Site, Williamsburg, Virginia, United States</location>
      <location>Furiex Research Site, Spokane, Washington, United States</location>
      <location>Furiex Research Site, Spokane, Washington, United States</location>
      <location>Furiex Research Site, Spokane, Washington, United States</location>
      <location>Furiex Research Site, Wenatchee, Washington, United States</location>
      <location>Furiex Research Site, Morgantown, West Virginia, United States</location>
      <location>Furiex Research Site, Wauwatosa, Wisconsin, United States</location>
      <location>Furiex Research Site, Kamloops, British Columbia, Canada</location>
      <location>Furiex Research Site, Kelowna, British Columbia, Canada</location>
      <location>Furiex Research Site, Winnipeg, Manitoba, Canada</location>
      <location>Furiex Research Site, Bridgewater, Nova Scotia, Canada</location>
      <location>Furiex Research Site, Halifax, Nova Scotia, Canada</location>
      <location>Furiex Research Site, Cambridge, Ontario, Canada</location>
      <location>Furiex Research Site, London, Ontario, Canada</location>
      <location>Furiex Research Site, Niagara Falls, Ontario, Canada</location>
      <location>Furiex Research Site, Oshawa, Ontario, Canada</location>
      <location>Furiex Research Site, Chesterfield, Derbyshire, United Kingdom</location>
      <location>Furiex Research Site, Blackpool, Lancashire, United Kingdom</location>
      <location>Furiex Research Site, Thornton-Cleveleys, Lancashire, United Kingdom</location>
      <location>Furiex Research Site, Burbage, Leicestershire, United Kingdom</location>
      <location>Furiex Research Site, Leamington Spa, Warwickshire, United Kingdom</location>
      <location>Furiex Research Site, Chippenham, Wiltshire, United Kingdom</location>
      <location>Furiex Research Site, Bath, United Kingdom</location>
      <location>Furiex Research Site, Bath, United Kingdom</location>
      <location>Furiex Research Site, Coventry, United Kingdom</location>
      <location>Furiex Research Site, Dorking, United Kingdom</location>
      <location>Furiex Research Site, Haxey, United Kingdom</location>
      <location>Furiex Research Site, London, United Kingdom</location>
      <location>Furiex Research Site, Shrewsbury, United Kingdom</location>
      <location>Furiex Research Site, Southampton, United Kingdom</location>
      <location>Furiex Research Site, Strensall, United Kingdom</location>
      <location>Furiex Research Site, Thornton, United Kingdom</location>
      <location>Furiex Research Site, Torpoint, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01553591</url>
  </study>
  <study rank="215">
    <nct_id>NCT03596905</nct_id>
    <title>Efficacy and Safety of Plecanatide in Children 6 to &lt;18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym>(IBS-C)</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plecanatide</intervention>
      <intervention type="Drug">Matching placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in weekly SBM frequency over the 4 Week Treatment Period compared to placebo and across treatment groups</outcome_measure>
      <outcome_measure>Change from baseline in frequency and severity of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Change from baseline in frequency of BMs and CSBMs</outcome_measure>
      <outcome_measure>Change from baseline in stool consistency (BSFS or mBSFS-C)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SP304202-14</other_id>
    </other_ids>
    <start_date>June 30, 2018</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>July 24, 2018</study_first_posted>
    <last_update_posted>May 24, 2019</last_update_posted>
    <locations>
      <location>Synergy Research Site, Corona, California, United States</location>
      <location>Synergy Research Site, Doral, Florida, United States</location>
      <location>Synergy Research Site, Hialeah, Florida, United States</location>
      <location>Synergy Research Site, Miami, Florida, United States</location>
      <location>Synergy Research Site, Miami, Florida, United States</location>
      <location>Synergy Research Site, Miami, Florida, United States</location>
      <location>Synergy Research Site, Tampa, Florida, United States</location>
      <location>Synergy Research Site, Crowley, Louisiana, United States</location>
      <location>Synergy Research Site, Houston, Texas, United States</location>
      <location>Synergy Research Site, San Antonio, Texas, United States</location>
      <location>Synergy Research Site, Newport News, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03596905</url>
  </study>
  <study rank="216">
    <nct_id>NCT02822118</nct_id>
    <title>Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chang'an I Recipe</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change of Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS)</outcome_measure>
      <outcome_measure>Serum markers regarding liver and kidney function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xiyuan Hospital of China Academy of Chinese Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>216</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Digestion-03</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>May 2016</completion_date>
    <study_first_posted>July 4, 2016</study_first_posted>
    <last_update_posted>September 5, 2016</last_update_posted>
    <locations>
      <location>Xiyuan Hospital, Beijing, Beijing, China</location>
      <location>Wangjing Hospital, Beijing, Beijing, China</location>
      <location>Dongzhimen Hospital, Beijing, Beijing, China</location>
      <location>Longhua Hospital, Shanghai, Shanghai, China</location>
      <location>Zhejiang Provincial Hospital of TCM, Hangzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02822118</url>
  </study>
  <study rank="217">
    <nct_id>NCT03806959</nct_id>
    <title>Interest of Pan-capsule in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy</title>
    <acronym>IPSILON</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pan Capsule and colonoscopy in patients with IBS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with digestive pathology and / or significant gastrointestinal lesion.</outcome_measure>
      <outcome_measure>Acceptability of the pan-capsule, preference of one of the carried out explorations (pan-capsule or iléo-colonoscopy).</outcome_measure>
      <outcome_measure>Acceptability to complete the questionnaires (number of completed questionnaires).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Avicenne</lead_sponsor>
      <collaborator>Adeprina</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017-A03229-44</other_id>
    </other_ids>
    <start_date>November 7, 2018</start_date>
    <primary_completion_date>November 7, 2020</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>January 16, 2019</study_first_posted>
    <last_update_posted>January 16, 2019</last_update_posted>
    <locations>
      <location>Centre de Recherche sur Volontaires (CRV), Hospital Avicenne, Bobigny, Ile-de-France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03806959</url>
  </study>
  <study rank="218">
    <nct_id>NCT01494233</nct_id>
    <title>A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">250 mg LX1033 tablets</intervention>
      <intervention type="Drug">Placebo tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in stool consistency</outcome_measure>
      <outcome_measure>Change from baseline in plasma 5-HIAA levels</outcome_measure>
      <outcome_measure>Change from baseline in worst abdominal pain in past 24 hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lexicon Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>373</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LX1033.1-201-IBS</other_id>
      <other_id>LX1033.201</other_id>
    </other_ids>
    <start_date>February 2012</start_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <study_first_posted>December 16, 2011</study_first_posted>
    <last_update_posted>March 23, 2015</last_update_posted>
    <locations>
      <location>Lexicon Investigational Site, Huntsville, Alabama, United States</location>
      <location>Lexicon Investigational Site, Tempe, Arizona, United States</location>
      <location>Lexicon Investigational Site, Tucson, Arizona, United States</location>
      <location>Lexicon Investigational Site, Tucson, Arizona, United States</location>
      <location>Lexicon Investigational Site, Little Rock, Arkansas, United States</location>
      <location>Lexicon Investigational Site, North Little Rock, Arkansas, United States</location>
      <location>Lexicon Investigational Site, Anaheim, California, United States</location>
      <location>Lexicon Investigational Site, Encinitas, California, United States</location>
      <location>Lexicon Investigational Site, Los Angeles, California, United States</location>
      <location>Lexicon Investigational Site, Oakland, California, United States</location>
      <location>Lexicon Investigational Site, Orange, California, United States</location>
      <location>Lexicon Investigational Site, San Diego, California, United States</location>
      <location>Lexicon Investigational Site, Santa Monica, California, United States</location>
      <location>Lexicon Investigational Site, Tustin, California, United States</location>
      <location>Lexicon Investigational Site, Westlake Village, California, United States</location>
      <location>Lexicon Investigational Site, Littleton, Colorado, United States</location>
      <location>Lexicon Investigational Site, Littleton, Colorado, United States</location>
      <location>Lexicon Investigational Site, Wheat Ridge, Colorado, United States</location>
      <location>Lexicon Investigational Site, Waterbury, Connecticut, United States</location>
      <location>Lexicon Investigational Site, Boynton Beach, Florida, United States</location>
      <location>Lexicon Investigational Site, Bradenton, Florida, United States</location>
      <location>Lexicon Investigational Site, Brooksville, Florida, United States</location>
      <location>Lexicon Investigational Site, DeLand, Florida, United States</location>
      <location>Lexicon Investigational Site, Jacksonville, Florida, United States</location>
      <location>Lexicon Investigational Site, Kissimmee, Florida, United States</location>
      <location>Lexicon Investigational Site, Lauderdale Lakes, Florida, United States</location>
      <location>Lexicon Investigational Site, Maitland, Florida, United States</location>
      <location>Lexicon Investigational Site, Orlando, Florida, United States</location>
      <location>Lexicon Investigational Site, Port Orange, Florida, United States</location>
      <location>Lexicon Investigational Site, Tampa, Florida, United States</location>
      <location>Lexicon Investigational Site, Boise, Idaho, United States</location>
      <location>Lexicon Investigational Site, Meridian, Idaho, United States</location>
      <location>Lexicon Investigational Site, Addison, Illinois, United States</location>
      <location>Lexicon Investigational Site, Chicago, Illinois, United States</location>
      <location>Lexicon Investigational Site, Rockford, Illinois, United States</location>
      <location>Lexicon Investigational Site, Wichita, Kansas, United States</location>
      <location>Lexicon Investigational Site, Bowling Green, Kentucky, United States</location>
      <location>Lexicon Investigational Site, Lexington, Kentucky, United States</location>
      <location>Lexicon Investigational Site, Chevy Chase, Maryland, United States</location>
      <location>Lexicon Investigational Site, Towson, Maryland, United States</location>
      <location>Lexicon Investigational Site, Brockton, Massachusetts, United States</location>
      <location>Lexicon Investigational Site, Chesterfield, Michigan, United States</location>
      <location>Lexicon Investigational Site, Kalamazoo, Michigan, United States</location>
      <location>Lexicon Investigational Site, Troy, Michigan, United States</location>
      <location>Lexicon Investigational Site, Jackson, Mississippi, United States</location>
      <location>Lexicon Investigational Site, Mexico, Missouri, United States</location>
      <location>Lexicon Investigational Site, Billings, Montana, United States</location>
      <location>Lexicon Investigational Site, Berlin, New Jersey, United States</location>
      <location>Lexicon Investigational Site, Albuquerque, New Mexico, United States</location>
      <location>Lexicon Investigational Site, Great Neck, New York, United States</location>
      <location>Lexicon Investigational Site, Great Neck, New York, United States</location>
      <location>Lexicon Investigational Site, New York, New York, United States</location>
      <location>Lexicon Investigational Site, Boone, North Carolina, United States</location>
      <location>Lexicon Investigational Site, Cary, North Carolina, United States</location>
      <location>Lexicon Investigational Site, Chapel Hill, North Carolina, United States</location>
      <location>Lexicon Investigational Site, Greensboro, North Carolina, United States</location>
      <location>Lexicon Investigational Site, High Point, North Carolina, United States</location>
      <location>Lexicon Investigational Site, Raleigh, North Carolina, United States</location>
      <location>Lexicon Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>Lexicon Investigational Site, Fargo, North Dakota, United States</location>
      <location>Lexicon Investigational Site, Kettering, Ohio, United States</location>
      <location>Lexicon Investigational Site, Lima, Ohio, United States</location>
      <location>Lexicon Investigational Site, Mentor, Ohio, United States</location>
      <location>Lexicon Investigational Site, Wadsworth, Ohio, United States</location>
      <location>Lexicon Investigational Site, Norman, Oklahoma, United States</location>
      <location>Lexicon Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>Lexicon Investigational Site, Eugene, Oregon, United States</location>
      <location>Lexicon Investigational Site, Mount Pleasant, South Carolina, United States</location>
      <location>Lexicon Investigational Site, Chattanooga, Tennessee, United States</location>
      <location>Lexicon Investigational Site, Austin, Texas, United States</location>
      <location>Lexicon Investigational Site, El Paso, Texas, United States</location>
      <location>Lexicon Investigational Site, Lake Jackson, Texas, United States</location>
      <location>Lexicon Investigational Site, Plano, Texas, United States</location>
      <location>Lexicon Investigational Site, San Antonio, Texas, United States</location>
      <location>Lexicon Investigational Site, Clinton, Utah, United States</location>
      <location>Lexicon Investigational Site, Logan, Utah, United States</location>
      <location>Lexicon Investigational Site, Ogden, Utah, United States</location>
      <location>Lexicon Investigational Site, Sandy, Utah, United States</location>
      <location>Lexicon Investigational Site, West Jordan, Utah, United States</location>
      <location>Lexicon Investigational Site, Lynchburg, Virginia, United States</location>
      <location>Lexicon Investigational Site, Virginia Beach, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01494233</url>
  </study>
  <study rank="219">
    <nct_id>NCT03687814</nct_id>
    <title>Low FODMAP Plus PEG 3350 for the Treatment of Patients With Irritable Bowel Syndrome-Constipation</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low FODMAP diet/PEG 3350</intervention>
      <intervention type="Other">sham diet/PEG 3350</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of abdominal pain as measured by 11-point numerical rating scale</outcome_measure>
      <outcome_measure>Bloating</outcome_measure>
      <outcome_measure>abdominal discomfort</outcome_measure>
      <outcome_measure>Mean number of SBMs per day</outcome_measure>
      <outcome_measure>Mean weekly number of spontaneous complete bowel movements</outcome_measure>
      <outcome_measure>Composite endpoint: Full responder was defined as a patient with &gt;3 SBM per week, an increase of ≥1 SBM per week and &gt;30% pain reduction.</outcome_measure>
      <outcome_measure>stool consistency</outcome_measure>
      <outcome_measure>Straining</outcome_measure>
      <outcome_measure>IBS-QOL</outcome_measure>
      <outcome_measure>HADS score</outcome_measure>
      <outcome_measure>WPAI questionnaire</outcome_measure>
      <outcome_measure>Sleep Assessment questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HUM00139784</other_id>
    </other_ids>
    <start_date>November 8, 2018</start_date>
    <primary_completion_date>November 3, 2020</primary_completion_date>
    <completion_date>November 3, 2020</completion_date>
    <study_first_posted>September 27, 2018</study_first_posted>
    <last_update_posted>November 22, 2018</last_update_posted>
    <locations>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03687814</url>
  </study>
  <study rank="220">
    <nct_id>NCT01177410</nct_id>
    <title>Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Mesalamine Granules 750 mg</intervention>
      <intervention type="Drug">Mesalamine Granules 1500 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Number of Months That Subjects Are Monthly Responders in Both IBS-related Abdominal Pain AND Stool Consistency During the Entire Three Months.</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Are Monthly Responders in Both Abdominal Pain and Stool Consistency for at Least 2 Months During the 3-month Treatment Period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>148</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MGIB2051</other_id>
    </other_ids>
    <start_date>July 2010</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>August 2011</completion_date>
    <study_first_posted>August 9, 2010</study_first_posted>
    <results_first_posted>September 27, 2012</results_first_posted>
    <last_update_posted>September 27, 2012</last_update_posted>
    <locations>
      <location>Sherwood, Arkansas, United States</location>
      <location>Anaheim, California, United States</location>
      <location>Sacramento, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>San Francisco, California, United States</location>
      <location>Bristol, Connecticut, United States</location>
      <location>Boynton Beach, Florida, United States</location>
      <location>St. Petersburg, Florida, United States</location>
      <location>Macon, Georgia, United States</location>
      <location>Shreveport, Louisiana, United States</location>
      <location>Ann Arbor, Michigan, United States</location>
      <location>Wyoming, Michigan, United States</location>
      <location>Mexico, Missouri, United States</location>
      <location>St. Louis, Missouri, United States</location>
      <location>Albuquerque, New Mexico, United States</location>
      <location>New York, New York, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>Plano, Texas, United States</location>
      <location>Ogden, Utah, United States</location>
      <location>Lynchburg, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01177410</url>
  </study>
  <study rank="221">
    <nct_id>NCT02431533</nct_id>
    <title>The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">PX0612</intervention>
      <intervention type="Dietary Supplement">Di-Calcium Phosphate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary outcome is the difference in change in the bowel movements (stool frequency) between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Difference in the overall symptoms relief between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Differences in upper GI symptoms (i.e. heartburn, early satiety, postprandial fullness, sensation of prolonged digestion, nausea and vomiting) between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Differences in quality of life using SF-36 between the 'intervention' group and the 'placebo' group over the study period</outcome_measure>
      <outcome_measure>Differences in abdominal pain/discomfort between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Differences in stool consistency between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Differences in stool frequency between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Feeling of straining between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Feeling of urgency between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Feeling of bloating between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Feeling of incomplete defecation between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
      <outcome_measure>Differences in passage of mucus between the 'intervention' group and the 'placebo' group over the study period.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pharmabiotix Inc</lead_sponsor>
      <collaborator>University of Alberta</collaborator>
      <collaborator>The Northern Alberta Clinical Trial and Research Centre (NACTRC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>01-PBI-2012</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>June 2017</primary_completion_date>
    <completion_date>August 2017</completion_date>
    <study_first_posted>May 1, 2015</study_first_posted>
    <last_update_posted>September 27, 2016</last_update_posted>
    <locations>
      <location>University of Alberta Hospital, Edmonton, Alberta, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02431533</url>
  </study>
  <study rank="222">
    <nct_id>NCT00918411</nct_id>
    <title>A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ramosetron</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS severity index (Japanese version)</outcome_measure>
      <outcome_measure>Patient reported global assessment of relief of IBS symptoms</outcome_measure>
      <outcome_measure>Patient reported assessment of relief of abdominal discomfort and/or pain</outcome_measure>
      <outcome_measure>Patient reported assessment of improvement of abdominal bowel habits</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>98</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-500</other_id>
    </other_ids>
    <start_date>June 2009</start_date>
    <primary_completion_date>December 2009</primary_completion_date>
    <completion_date>December 2009</completion_date>
    <study_first_posted>June 11, 2009</study_first_posted>
    <last_update_posted>October 12, 2015</last_update_posted>
    <locations>
      <location>Hokkaido, Japan</location>
      <location>Kansai, Japan</location>
      <location>Kantou, Japan</location>
      <location>Kyusyu, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00918411</url>
  </study>
  <study rank="223">
    <nct_id>NCT01714843</nct_id>
    <title>A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation-predominant Irritable Bowel Syndrome (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASP0456</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global assessment of relief of IBS symptoms Responder</outcome_measure>
      <outcome_measure>SBM (Spontaneous Bowel Movement) Responder</outcome_measure>
      <outcome_measure>CSBM (Complete SBM) Responder</outcome_measure>
      <outcome_measure>Abnormal bowel habits improvement Responder</outcome_measure>
      <outcome_measure>Abdominal pain/discomfort relief Responder</outcome_measure>
      <outcome_measure>Changes in weekly average of SBM frequency</outcome_measure>
      <outcome_measure>Changes in weekly average of CSBM frequency</outcome_measure>
      <outcome_measure>Changes in weekly average of stool form scores</outcome_measure>
      <outcome_measure>Changes in weekly average of abdominal pain/discomfort severity</outcome_measure>
      <outcome_measure>Changes in weekly average of straining severity</outcome_measure>
      <outcome_measure>Changes in IBS-QOL-J scores (entire scores or scores on the sub-scales)</outcome_measure>
      <outcome_measure>Safety assessed by the incidence of adverse events, vital signs, clinical laboratory tests and 12-lead ECGs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>559</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0456-CL-0021</other_id>
    </other_ids>
    <start_date>August 2012</start_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <completion_date>December 2013</completion_date>
    <study_first_posted>October 26, 2012</study_first_posted>
    <last_update_posted>May 1, 2014</last_update_posted>
    <locations>
      <location>Hokkaido, Japan</location>
      <location>Kansai, Japan</location>
      <location>Kantou, Japan</location>
      <location>Kyusyu, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01714843</url>
  </study>
  <study rank="224">
    <nct_id>NCT01027260</nct_id>
    <title>Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Itopride HCI 50 mg</intervention>
      <intervention type="Drug">Itopride HCI 100 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patients will be asked a simple but well validated question &quot;If there is a satisfactory relief of the symptoms&quot;</outcome_measure>
      <outcome_measure>Subjects will be assessed based on Irritable Bowel Syndrome Severity Score (IBSSS).</outcome_measure>
      <outcome_measure>Safety based on the laboratory tests before and at the end of the treatment.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>268</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R10-257</other_id>
    </other_ids>
    <start_date>June 2008</start_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <completion_date>September 2010</completion_date>
    <study_first_posted>December 7, 2009</study_first_posted>
    <last_update_posted>June 18, 2013</last_update_posted>
    <locations>
      <location>Site Reference ID/Investigator# 5870, Karachi, Pakistan</location>
      <location>Site Reference ID/Investigator# 21441, Karachi, Pakistan</location>
      <location>Site Reference ID/Investigator# 6130, Lahore, Pakistan</location>
      <location>Site Reference ID/Investigator# 8535, Rawalpindi, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01027260</url>
  </study>
  <study rank="225">
    <nct_id>NCT01505777</nct_id>
    <title>Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Without Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotics (Medirac)</intervention>
      <intervention type="Drug">Probiotics (Medirac)</intervention>
      <intervention type="Drug">Probiotics (Medirac)</intervention>
      <intervention type="Drug">Probiotics (Medirac)</intervention>
      <intervention type="Drug">Probiotics (Medirac) placebo/mosapride placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline in patient's overall satisfaction relief over 4 weeks of treatment of IBS symptoms</outcome_measure>
      <outcome_measure>Change from Baseline in improvment of abdominal discomfort, pain, bloating, stool frequency, stool consistency, straining urgency over 4 weeks of treatment and during each week(4 weeks,6 weeks)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hanmi Pharmaceutical Company Limited</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HM-MEMO-201</other_id>
    </other_ids>
    <start_date>May 2011</start_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <completion_date>June 2012</completion_date>
    <study_first_posted>January 9, 2012</study_first_posted>
    <last_update_posted>April 5, 2013</last_update_posted>
    <locations>
      <location>16 institutions including Gangnam Severance hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01505777</url>
  </study>
  <study rank="226">
    <nct_id>NCT00731679</nct_id>
    <title>Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)</title>
    <acronym>TARGET 1</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Non-Constipation Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>623</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RFIB3007</other_id>
    </other_ids>
    <start_date>July 2008</start_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <completion_date>September 2009</completion_date>
    <study_first_posted>August 11, 2008</study_first_posted>
    <results_first_posted>July 28, 2014</results_first_posted>
    <last_update_posted>July 28, 2014</last_update_posted>
    <locations>
      <location>Hueytown, Alabama, United States</location>
      <location>Phoenix, Arizona, United States</location>
      <location>Sierra Vista, Arizona, United States</location>
      <location>Tucson, Arizona, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>Little Rock, Arkansas, United States</location>
      <location>Sherwood, Arkansas, United States</location>
      <location>Anaheim, California, United States</location>
      <location>Lancaster, California, United States</location>
      <location>Los Angeles, California, United States</location>
      <location>Murrietta, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>Lakewood, Colorado, United States</location>
      <location>Bridgeport, Connecticut, United States</location>
      <location>Torrington, Connecticut, United States</location>
      <location>Altamonte Springs, Florida, United States</location>
      <location>Boynton Beach, Florida, United States</location>
      <location>Gainesville, Florida, United States</location>
      <location>Hollywood, Florida, United States</location>
      <location>Jupiter, Florida, United States</location>
      <location>Lauderdale Lakes, Florida, United States</location>
      <location>Maitland, Florida, United States</location>
      <location>Naples, Florida, United States</location>
      <location>New Port Richey, Florida, United States</location>
      <location>Orlando, Florida, United States</location>
      <location>West Palm Beach, Florida, United States</location>
      <location>Winter Garden, Florida, United States</location>
      <location>Winter Park, Florida, United States</location>
      <location>Topeka, Kansas, United States</location>
      <location>Shreveport, Louisiana, United States</location>
      <location>Baltimore, Maryland, United States</location>
      <location>Hagerstown, Maryland, United States</location>
      <location>Silver Spring, Maryland, United States</location>
      <location>Boston, Massachusetts, United States</location>
      <location>Detroit, Michigan, United States</location>
      <location>Kalamazoo, Michigan, United States</location>
      <location>Paw Paw, Michigan, United States</location>
      <location>Jackson, Mississippi, United States</location>
      <location>St. Louis, Missouri, United States</location>
      <location>Lebanon, New Hampshire, United States</location>
      <location>Elizabeth, New Jersey, United States</location>
      <location>Lumberton, New Jersey, United States</location>
      <location>Bayside, New York, United States</location>
      <location>Brooklyn, New York, United States</location>
      <location>New York, New York, United States</location>
      <location>Troy, New York, United States</location>
      <location>Asheboro, North Carolina, United States</location>
      <location>Charlotte, North Carolina, United States</location>
      <location>Durham, North Carolina, United States</location>
      <location>Fayetteville, North Carolina, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>High Point, North Carolina, United States</location>
      <location>Mooresville, North Carolina, United States</location>
      <location>Raleigh, North Carolina, United States</location>
      <location>Salisbury, North Carolina, United States</location>
      <location>Wilmington, North Carolina, United States</location>
      <location>Fargo, North Dakota, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Cleveland, Ohio, United States</location>
      <location>Columbus, Ohio, United States</location>
      <location>Dayton, Ohio, United States</location>
      <location>Zanesville, Ohio, United States</location>
      <location>Tulsa, Oklahoma, United States</location>
      <location>Portland, Oregon, United States</location>
      <location>Portland, Oregon, United States</location>
      <location>Lancaster, Pennsylvania, United States</location>
      <location>Germantown, Tennessee, United States</location>
      <location>Jackson, Tennessee, United States</location>
      <location>Johnson City, Tennessee, United States</location>
      <location>Nashville, Tennessee, United States</location>
      <location>Austin, Texas, United States</location>
      <location>Fort Worth, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Pasadena, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>Tyler, Texas, United States</location>
      <location>Ogden, Utah, United States</location>
      <location>West Jordan, Utah, United States</location>
      <location>Chesapeake, Virginia, United States</location>
      <location>Lynchburg, Virginia, United States</location>
      <location>Bellevue, Washington, United States</location>
      <location>Spokane, Washington, United States</location>
      <location>West Bend, Wisconsin, United States</location>
      <location>St. John's, Newfoundland and Labrador, Canada</location>
      <location>Corunna, Ontario, Canada</location>
      <location>Hamilton, Ontario, Canada</location>
      <location>Hamilton, Ontario, Canada</location>
      <location>Hamilton, Ontario, Canada</location>
      <location>London, Ontario, Canada</location>
      <location>London, Ontario, Canada</location>
      <location>Newmarket, Ontario, Canada</location>
      <location>Niagara Falls, Ontario, Canada</location>
      <location>Sarnia, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00731679</url>
  </study>
  <study rank="227">
    <nct_id>NCT00724126</nct_id>
    <title>Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)</title>
    <acronym>TARGET 2</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Non-Constipation Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6).</outcome_measure>
      <outcome_measure>Proportion of Subjects Who Had Adequate Relief of IBS-related Bloating for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>637</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RFIB3008</other_id>
    </other_ids>
    <start_date>July 2008</start_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <completion_date>September 2009</completion_date>
    <study_first_posted>July 29, 2008</study_first_posted>
    <results_first_posted>July 28, 2014</results_first_posted>
    <last_update_posted>July 28, 2014</last_update_posted>
    <locations>
      <location>Anniston, Alabama, United States</location>
      <location>Birmingham, Alabama, United States</location>
      <location>Huntsville, Alabama, United States</location>
      <location>Tempe, Arizona, United States</location>
      <location>Anaheim, California, United States</location>
      <location>Carmichael, California, United States</location>
      <location>Chula Vista, California, United States</location>
      <location>Concord, California, United States</location>
      <location>Garden Grove, California, United States</location>
      <location>Laguna Hills, California, United States</location>
      <location>Lakewood, California, United States</location>
      <location>Los Angeles, California, United States</location>
      <location>Monterey, California, United States</location>
      <location>Orange, California, United States</location>
      <location>Roseville, California, United States</location>
      <location>San Carlos, California, United States</location>
      <location>San Francisco, California, United States</location>
      <location>Bristol, Connecticut, United States</location>
      <location>Hamden, Connecticut, United States</location>
      <location>Newark, Delaware, United States</location>
      <location>Boca Raton, Florida, United States</location>
      <location>Hollywood, Florida, United States</location>
      <location>Largo, Florida, United States</location>
      <location>New Port Richey, Florida, United States</location>
      <location>New Smyrna Beach, Florida, United States</location>
      <location>Port Orange, Florida, United States</location>
      <location>St. Petersburg, Florida, United States</location>
      <location>Tampa, Florida, United States</location>
      <location>Zephyrhills, Florida, United States</location>
      <location>Atlanta, Georgia, United States</location>
      <location>Macon, Georgia, United States</location>
      <location>Elkhart, Indiana, United States</location>
      <location>Kansas City, Kansas, United States</location>
      <location>Topeka, Kansas, United States</location>
      <location>Bowling Green, Kentucky, United States</location>
      <location>Metairie, Louisiana, United States</location>
      <location>Monroe, Louisiana, United States</location>
      <location>Baltimore, Maryland, United States</location>
      <location>Elkridge, Maryland, United States</location>
      <location>Wellesley, Massachusetts, United States</location>
      <location>Ann Arbor, Michigan, United States</location>
      <location>Troy, Michigan, United States</location>
      <location>Wyoming, Michigan, United States</location>
      <location>Mexico, Missouri, United States</location>
      <location>Sicklerville, New Jersey, United States</location>
      <location>Vorhees, New Jersey, United States</location>
      <location>Albuquerque, New Mexico, United States</location>
      <location>Great Neck, New York, United States</location>
      <location>Mineola, New York, United States</location>
      <location>New York, New York, United States</location>
      <location>North Massapequa, New York, United States</location>
      <location>Pomona, New York, United States</location>
      <location>Stony Brook, New York, United States</location>
      <location>Boone, North Carolina, United States</location>
      <location>Chapel Hill, North Carolina, United States</location>
      <location>Charlotte, North Carolina, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>New Bern, North Carolina, United States</location>
      <location>Wilmington, North Carolina, United States</location>
      <location>Winston-Salem, North Carolina, United States</location>
      <location>Canton, Ohio, United States</location>
      <location>Cincinnati, Ohio, United States</location>
      <location>Dayton, Ohio, United States</location>
      <location>Downingtown, Pennsylvania, United States</location>
      <location>Newtown, Pennsylvania, United States</location>
      <location>Pittsburgh, Pennsylvania, United States</location>
      <location>Sayre, Pennsylvania, United States</location>
      <location>Anderson, South Carolina, United States</location>
      <location>Columbia, South Carolina, United States</location>
      <location>Bristol, Tennessee, United States</location>
      <location>Chattanooga, Tennessee, United States</location>
      <location>Franklin, Tennessee, United States</location>
      <location>Germantown, Tennessee, United States</location>
      <location>Jackson, Tennessee, United States</location>
      <location>Kingsport, Tennessee, United States</location>
      <location>El Paso, Texas, United States</location>
      <location>Houston, Texas, United States</location>
      <location>Lewisville, Texas, United States</location>
      <location>Plano, Texas, United States</location>
      <location>San Antonio, Texas, United States</location>
      <location>Salt Lake City, Utah, United States</location>
      <location>Burlington, Vermont, United States</location>
      <location>Chesapeake, Virginia, United States</location>
      <location>Fairfax, Virginia, United States</location>
      <location>Spokane, Washington, United States</location>
      <location>Milwaukee, Wisconsin, United States</location>
      <location>Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00724126</url>
  </study>
  <study rank="228">
    <nct_id>NCT02757105</nct_id>
    <title>Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BEKINDA</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Summary and Analysis of Overall Stool Consistency Response Rate - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Stool Consistency Response Rate Males - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Stool Consistency Response Rate Females - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Stool Consistency Response Rate: Sensitivity Analysis Without Imputation for Use of Rescue Medication - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Stool Consistency Response Rate by Baseline CRP &gt; Median - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Stool Consistency Response Rate by Baseline CRP ≤ Median - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Worst Abdominal Pain Response Rate - mITT Population</outcome_measure>
      <outcome_measure>Summary and Analysis of Overall Study Response Rate - mITT Population</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>RedHill Biopharma Limited</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>127</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RHB-102-02</other_id>
    </other_ids>
    <start_date>May 19, 2016</start_date>
    <primary_completion_date>June 16, 2017</primary_completion_date>
    <completion_date>July 14, 2017</completion_date>
    <study_first_posted>April 29, 2016</study_first_posted>
    <results_first_posted>July 31, 2018</results_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Clinical Research Associates, LLC, Huntsville, Alabama, United States</location>
      <location>E Squared Research, Inc., Huntsville, Alabama, United States</location>
      <location>Endoscoopy Center of AR, Little Rock, Arkansas, United States</location>
      <location>Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States</location>
      <location>Prx Clinical, Garden Grove, California, United States</location>
      <location>Providence Clinical Research, North Hollywood, California, United States</location>
      <location>Shahram Jacobs MD, Inc., Sherman Oaks, California, United States</location>
      <location>Advanced Rx Clinical Research Group, Inc., Westminster, California, United States</location>
      <location>Bristol Hospital Dba Connecticut Gastroenterology Institute, Bristol, Connecticut, United States</location>
      <location>Clinical Research of Homestead, Homestead, Florida, United States</location>
      <location>PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States</location>
      <location>Great Lakes Medical Research, Mentor, Ohio, United States</location>
      <location>Clinsearch, Chattanooga, Tennessee, United States</location>
      <location>New Phase Research &amp; Development, Knoxville, Tennessee, United States</location>
      <location>Aztec Medical Research, LLC, Channelview, Texas, United States</location>
      <location>Gastroenterology Research of San Antonio, San Antonio, Texas, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02757105/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT02757105/SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT02757105</url>
  </study>
  <study rank="229">
    <nct_id>NCT03573908</nct_id>
    <title>A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Abdominal Score (abdominal bloating, abdominal discomfort, and abdominal pain) at Each Week</outcome_measure>
      <outcome_measure>Change from Baseline in 12-week Abdominal Score</outcome_measure>
      <outcome_measure>Number of 6/12 Week Abdominal Score Responder</outcome_measure>
      <outcome_measure>Change From Baseline in Abdominal Score at Each Week (Time Course Analysis)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Allergan Sales, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>614</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-312</other_id>
    </other_ids>
    <start_date>June 20, 2018</start_date>
    <primary_completion_date>April 2019</primary_completion_date>
    <completion_date>June 2019</completion_date>
    <study_first_posted>June 29, 2018</study_first_posted>
    <last_update_posted>January 14, 2019</last_update_posted>
    <locations>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Elite Clinical Studies, Phoenix, Arizona, United States</location>
      <location>Adobe Clinical Research, LLC, Tucson, Arizona, United States</location>
      <location>Arkansas Gastroenterology, North Little Rock, Arkansas, United States</location>
      <location>GW Research, Inc., Chula Vista, California, United States</location>
      <location>Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States</location>
      <location>Diagnamics, Inc., Encinitas, California, United States</location>
      <location>MD Studies, Inc., Fountain Valley, California, United States</location>
      <location>Paragon Rx Clinical, Inc. - Garden Grove, Garden Grove, California, United States</location>
      <location>Grossmont Center For Clinical Research, La Mesa, California, United States</location>
      <location>Facey Medical Foundation, Mission Hills, California, United States</location>
      <location>Providence Clinical Research, North Hollywood, California, United States</location>
      <location>Precision Research Institute, San Diego, California, United States</location>
      <location>Paragon Rx Clinical, Inc.- Santa Ana, Santa Ana, California, United States</location>
      <location>Millennium Clinical Trials, Thousand Oaks, California, United States</location>
      <location>St. Joseph Heritage Healthcare, Yorba Linda, California, United States</location>
      <location>Connecticut Clinical Research Institute, Bristol, Connecticut, United States</location>
      <location>Chase Medical Research, LLC, Waterbury, Connecticut, United States</location>
      <location>Clinical Research of South Florida, Coral Gables, Florida, United States</location>
      <location>Avail Clinical Research, LLC, DeLand, Florida, United States</location>
      <location>Palmetto Research, LLC, Hialeah, Florida, United States</location>
      <location>Nature Coast Clinical Research, LLC, Inverness, Florida, United States</location>
      <location>The Chappel Group Research, Kissimmee, Florida, United States</location>
      <location>San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States</location>
      <location>Ocean Blue Medical Research Center, Inc., Miami Springs, Florida, United States</location>
      <location>Jesscan Medical Research, Miami, Florida, United States</location>
      <location>Well Pharma Medical Research Corporation, Miami, Florida, United States</location>
      <location>New Horizon Research Center, Miami, Florida, United States</location>
      <location>Ormond Medical Arts Pharmaceutical Research Center, Ormond Beach, Florida, United States</location>
      <location>Precision Clinical Research, Sunrise, Florida, United States</location>
      <location>Meridien Research - Tampa, Tampa, Florida, United States</location>
      <location>Palm Beach Research Center, West Palm Beach, Florida, United States</location>
      <location>Research Institute of Central Florida, LLC, Winter Park, Florida, United States</location>
      <location>Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States</location>
      <location>Clinical Trials Management, LLC, Metairie, Louisiana, United States</location>
      <location>Delta Research Partners, LLC, Monroe, Louisiana, United States</location>
      <location>Louisiana Research Center, LLC, Shreveport, Louisiana, United States</location>
      <location>Alan A. Rosen, MD, PA, Baltimore, Maryland, United States</location>
      <location>Meritus Center For Clinical Research, Hagerstown, Maryland, United States</location>
      <location>Boston Clinical Trials, Inc., Boston, Massachusetts, United States</location>
      <location>MedVadis Research Corporation, Watertown, Massachusetts, United States</location>
      <location>Gastroenterology Associates of West Michigan, Wyoming, Michigan, United States</location>
      <location>Gastrointestinal Associates PA, Flowood, Mississippi, United States</location>
      <location>St. Louis Center For Clinical Research, Saint Louis, Missouri, United States</location>
      <location>Bozeman Health Deaconess Hospital, Bozeman, Montana, United States</location>
      <location>Clinical Research of South Nevada, Las Vegas, Nevada, United States</location>
      <location>Healthwise Medical Associates, Brooklyn, New York, United States</location>
      <location>Long Island Gastrointestinal Research Group, LLP, Great Neck, New York, United States</location>
      <location>Carolina Digestive Health Associates, Charlotte, North Carolina, United States</location>
      <location>Carolina Digestive Health Associates, Concord, North Carolina, United States</location>
      <location>Cumberland Research Associates, Fayetteville, North Carolina, United States</location>
      <location>Peters Medical Research, LLC, High Point, North Carolina, United States</location>
      <location>Wake Research Associates, LLC, Raleigh, North Carolina, United States</location>
      <location>PMG Research of Wilmington, Wilmington, North Carolina, United States</location>
      <location>Clinical Trials of America - North Carolina, LLC, Winston-Salem, North Carolina, United States</location>
      <location>Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States</location>
      <location>PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States</location>
      <location>Lillestol Research, Fargo, North Dakota, United States</location>
      <location>Hightop Medical Research Center, Cincinnati, Ohio, United States</location>
      <location>New Horizons Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Remington Davis, Inc., Columbus, Ohio, United States</location>
      <location>Dayton Gastroenterology, Inc., Dayton, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Dayton, Ohio, United States</location>
      <location>Great Lakes Gastroenterology Research, LLC, Mentor, Ohio, United States</location>
      <location>IPS Research Company, Oklahoma City, Oklahoma, United States</location>
      <location>Partners In Clinical Research, Cumberland, Rhode Island, United States</location>
      <location>Mountain View Clinical Research, Inc., Greer, South Carolina, United States</location>
      <location>Meridian Clinical Research, Dakota Dunes, South Dakota, United States</location>
      <location>ClinSearch, LLC, Chattanooga, Tennessee, United States</location>
      <location>New Phase Research &amp; Development, Knoxville, Tennessee, United States</location>
      <location>MW Clinical Research Center, Beaumont, Texas, United States</location>
      <location>Southwest Clinical Trials, Houston, Texas, United States</location>
      <location>Southwest Clinical Trials, Houston, Texas, United States</location>
      <location>Quality Research, Inc., San Antonio, Texas, United States</location>
      <location>Diagnostics Research Group, San Antonio, Texas, United States</location>
      <location>Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>New River Valley Research Institute, Christiansburg, Virginia, United States</location>
      <location>Blue Ridge Medical Research, Lynchburg, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03573908</url>
  </study>
  <study rank="230">
    <nct_id>NCT02559206</nct_id>
    <title>Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
      <intervention type="Drug">Matching Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Weekly Change from Baseline in Abdominal Pain</outcome_measure>
      <outcome_measure>The Weekly Change from Baseline Complete Spontaneous Bowel Movement (CSBM) Frequency</outcome_measure>
      <outcome_measure>6/12 Week Abdominal Pain and Constipation (APC) +1 Responder</outcome_measure>
      <outcome_measure>6/12 Week CSBM +1 Responder</outcome_measure>
      <outcome_measure>6/12 Week Abdominal Pain Responder</outcome_measure>
      <outcome_measure>Weekly CSBM +1 Responder</outcome_measure>
      <outcome_measure>Weekly Abdominal Pain Responder</outcome_measure>
      <outcome_measure>Weekly APC +1 Responder</outcome_measure>
      <outcome_measure>Change from Baseline in 12-week Abdominal Pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>532</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-204</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <study_first_posted>September 24, 2015</study_first_posted>
    <last_update_posted>January 23, 2017</last_update_posted>
    <locations>
      <location>Ironwood Investigational Site, Huntsville, Alabama, United States</location>
      <location>Ironwood Investigational Site, Pheonix, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tucson, Arizona, United States</location>
      <location>Ironwood Investigational Site, North Little Rock, Arkansas, United States</location>
      <location>Ironwood Investigational Site, Anaheim, California, United States</location>
      <location>Ironwood Investigational Site, Chula Vista, California, United States</location>
      <location>Ironwood Investigational Site, Garden Grove, California, United States</location>
      <location>Ironwood Investigational Site, La Mesa, California, United States</location>
      <location>Ironwood Investigational Site, Newport Beach, California, United States</location>
      <location>Ironwood Investigational Site, Orange, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, Thousand Oaks, California, United States</location>
      <location>Ironwood Investigational Site, Colorado Springs, Colorado, United States</location>
      <location>Ironwood Investigational Site, Bristol, Connecticut, United States</location>
      <location>Ironwood Investigational Site, Waterbury, Connecticut, United States</location>
      <location>Ironwood Investigational Site, Hialeah, Florida, United States</location>
      <location>Ironwood Investigational Site, Kissimmee, Florida, United States</location>
      <location>Ironwood Investigational Site, Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Orlando, Florida, United States</location>
      <location>Ironwood Investigational Site, South Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Tampa, Florida, United States</location>
      <location>Ironwood Investigational Site, West Palm Beach, Florida, United States</location>
      <location>Ironwood Investigational Site, Atlanta, Georgia, United States</location>
      <location>Ironwood Investigational Site, Oakwood, Georgia, United States</location>
      <location>Ironwood Investigational Site, Sandy Springs, Georgia, United States</location>
      <location>Ironwood Investigational Site, Evansville, Indiana, United States</location>
      <location>Ironwood Investigational Site, Bastrop, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Metairie, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Shreveport, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Baltimore, Maryland, United States</location>
      <location>Ironwood Investigational Site, Chevy Chase, Maryland, United States</location>
      <location>Ironwood Investigational Site, Boston, Massachusetts, United States</location>
      <location>Ironwood Investigational Site, Watertown, Massachusetts, United States</location>
      <location>Ironwood Investigational Site, Chesterfield, Michigan, United States</location>
      <location>Ironwood Investigational Site, Wyoming, Michigan, United States</location>
      <location>Ironwood Investigational Site, Jackson, Mississippi, United States</location>
      <location>Ironwood Investigational Site, Saint Louis, Missouri, United States</location>
      <location>Ironwood Investigational Site, Bozeman, Montana, United States</location>
      <location>Ironwood Investigational Site, Las Vegas, Nevada, United States</location>
      <location>Ironwood Investigational Site, Las Vegas, Nevada, United States</location>
      <location>Ironwood Investigational Site, Brooklyn, New York, United States</location>
      <location>Ironwood Investigational Site, Charlotte, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Concord, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Davidson, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Fayetteville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Wilmington, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Winston Salem, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Ironwood Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Ironwood Investigational Site, Mentor, Ohio, United States</location>
      <location>Ironwood Investigational Site, Xenia, Ohio, United States</location>
      <location>Ironwood Investigational Site, Pittsburg, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Dakota Dunes, South Dakota, United States</location>
      <location>Ironwood Investigational Site, Bristol, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Chattanooga, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Knoxville, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Arlington, Texas, United States</location>
      <location>Ironwood Investigational Site, Beaumont, Texas, United States</location>
      <location>Ironwood Investigational Site, El Paso, Texas, United States</location>
      <location>Ironwood Investigational Site, Houston, Texas, United States</location>
      <location>Ironwood Investigational Site, San Antonio, Texas, United States</location>
      <location>Ironwood Investigational Site, San Antonio, Texas, United States</location>
      <location>Ironwood Investigational Site, San Antonio, Texas, United States</location>
      <location>Ironwood Investigational Site, Ogden, Utah, United States</location>
      <location>Ironwood Investigational Site, Sandy, Utah, United States</location>
      <location>Ironwood Investigational Site, Christiansburg, Virginia, United States</location>
      <location>Ironwood Investigational Site, Lynchburg, Virginia, United States</location>
      <location>Ironwood Investigational Site, La Crosse, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02559206</url>
  </study>
  <study rank="231">
    <nct_id>NCT02959983</nct_id>
    <title>Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eluxadoline</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</outcome_measure>
      <outcome_measure>Percentage of Stool Consistency Responders</outcome_measure>
      <outcome_measure>Percentage of Pain Responders</outcome_measure>
      <outcome_measure>Percentage of Monthly Composite Responders</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Allergan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>346</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CMO-US-GI-0429</other_id>
    </other_ids>
    <start_date>October 25, 2016</start_date>
    <primary_completion_date>January 22, 2018</primary_completion_date>
    <completion_date>January 22, 2018</completion_date>
    <study_first_posted>November 9, 2016</study_first_posted>
    <results_first_posted>February 15, 2019</results_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Clinical Research Associates, LLC, Huntsville, Alabama, United States</location>
      <location>The Center for Clinical Trials, Saraland, Alabama, United States</location>
      <location>Elite Clinical Studies, Phoenix, Arizona, United States</location>
      <location>Arkansas Gastroenterology, North Little Rock, Arkansas, United States</location>
      <location>Med Investigations, Carmichael, California, United States</location>
      <location>GW Research Inc, Chula Vista, California, United States</location>
      <location>Diagnamics Inc, Encinitas, California, United States</location>
      <location>Behavioral Research Specialists, LLC, Irvine, California, United States</location>
      <location>Providence Clinical Research, North Hollywood, California, United States</location>
      <location>Shahram Jacobs MD INC., Sherman Oaks, California, United States</location>
      <location>Westlake Medical Research, Thousand Oaks, California, United States</location>
      <location>Upland Clinical Research, Upland, California, United States</location>
      <location>Advanced RX Clinicial Research Group, Inc., Westminster, California, United States</location>
      <location>Connecticut Clinical Research Foundation, Bristol, Connecticut, United States</location>
      <location>Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States</location>
      <location>Innovative Research of West Florida, Inc., Clearwater, Florida, United States</location>
      <location>Digestive Care of N. Broward, Coral Springs, Florida, United States</location>
      <location>Homestead Medical Research, Homestead, Florida, United States</location>
      <location>Clinical Neuroscience Solutions Inc., Jacksonville, Florida, United States</location>
      <location>Health Awareness, Inc., Jupiter, Florida, United States</location>
      <location>Precision Clinical Research LLC, Lauderdale Lakes, Florida, United States</location>
      <location>Ocean Blue Medical Research Center, Inc, Miami Springs, Florida, United States</location>
      <location>Pharmax Research Clinic Inc., Miami, Florida, United States</location>
      <location>Well Pharma Medical Research, Corp., Miami, Florida, United States</location>
      <location>Bravo Health Care Center, North Bay Village, Florida, United States</location>
      <location>Clinical Neuroscience Solutions Inc., Orlando, Florida, United States</location>
      <location>Clinical Research of West Florida Inc., Tampa, Florida, United States</location>
      <location>Meridien Research, Tampa, Florida, United States</location>
      <location>Emory University School of Medicine, Atlanta, Georgia, United States</location>
      <location>RNA America, LLC, Buford, Georgia, United States</location>
      <location>Northwestern University Feinbery School of Medicine, Chicago, Illinois, United States</location>
      <location>Pharmakon Inc, Evergreen Park, Illinois, United States</location>
      <location>Investigators Research, Brownsburg, Indiana, United States</location>
      <location>Radiant Research, Inc., Evansville, Indiana, United States</location>
      <location>Clinical Research Advantage Inc/Radiant Research Inc., Evansville, Indiana, United States</location>
      <location>Gtc Research, Shawnee Mission, Kansas, United States</location>
      <location>Investigative Clinical Research, Annapolis, Maryland, United States</location>
      <location>MGG Group Co. Inc. Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>MedVadis Research Corporation, Watertown, Massachusetts, United States</location>
      <location>Clinical Research Insititute of Michigan LLC, Chesterfield, Michigan, United States</location>
      <location>Gastroenterology Associates of Western Michigan, PLC, Wyoming, Michigan, United States</location>
      <location>The Center for Clinical Trials, Biloxi, Mississippi, United States</location>
      <location>Women's Clinic of Lincoln, P.C., Lincoln, Nebraska, United States</location>
      <location>Quality Clinical Research Inc., Omaha, Nebraska, United States</location>
      <location>Advanced Biomedical Research of America, Las Vegas, Nevada, United States</location>
      <location>Advanced Research Institute, Reno, Nevada, United States</location>
      <location>Drug Trials Brooklyn, Brooklyn, New York, United States</location>
      <location>NY Scientific, Brooklyn, New York, United States</location>
      <location>Long Island Gastrointestinal Group LLP, Great Neck, New York, United States</location>
      <location>IMA Medical Research, PC, Kew Gardens, New York, United States</location>
      <location>Charlotte Gastroenterology &amp; Hepatology, PLLC, Charlotte, North Carolina, United States</location>
      <location>Peters Medical Research LLC, High Point, North Carolina, United States</location>
      <location>North State Clincial Research PLLC, Lenoir, North Carolina, United States</location>
      <location>Wake Research Associates LLC, Raleigh, North Carolina, United States</location>
      <location>Trial Management Associates, LLC, Wilmington, North Carolina, United States</location>
      <location>Clinical Inquest Center Ltd, Beavercreek, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Cincinnati, Ohio, United States</location>
      <location>Buckeye Health and Research, Columbus, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Columbus, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Huber Heights, Ohio, United States</location>
      <location>Central Sooner Research, Norman, Oklahoma, United States</location>
      <location>The Oregon Center for Clinical Investigations, INC., Salem, Oregon, United States</location>
      <location>Partners in Clinical Research, Cumberland, Rhode Island, United States</location>
      <location>WR-ClinSearch, LLC, Chattanooga, Tennessee, United States</location>
      <location>New Phase Research &amp; Development, Knoxville, Tennessee, United States</location>
      <location>CNS Healthcare, Memphis, Tennessee, United States</location>
      <location>Premier Family Physicians, Austin, Texas, United States</location>
      <location>Family Medicine Associate of Texas, Carrollton, Texas, United States</location>
      <location>Multi-Phase Trials LLC, San Antonio, Texas, United States</location>
      <location>Health Texas Research Institute, San Antonio, Texas, United States</location>
      <location>Discovery Clinical Trials - Stone Oak, San Antonio, Texas, United States</location>
      <location>Carl Meisner Medical Clinic, Sugar Land, Texas, United States</location>
      <location>Advanced Research Institute - Ogden, Ogden, Utah, United States</location>
      <location>Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States</location>
      <location>Gastroenterology Associates of Northern Virginia, Fairfax, Virginia, United States</location>
      <location>Blue Ridge Medical Research, Lynchburg, Virginia, United States</location>
      <location>Corunna Medical Research Centre, Corunna, Ontario, Canada</location>
      <location>Manna Research, Etobicoke, Ontario, Canada</location>
      <location>SKDS Research Inc, Newmarket, Ontario, Canada</location>
      <location>University of Calgary, Calgary, Canada</location>
      <location>Viable Clinical Research Corp., Nova Scotia, Canada</location>
      <location>Centre de reserche St Louis, Quebec, Canada</location>
      <location>Dynamik Research Inc, Quebec, Canada</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02959983/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02959983/SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT02959983</url>
  </study>
  <study rank="232">
    <nct_id>NCT03471728</nct_id>
    <title>Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases)</condition>
      <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">linaclotide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of diarrhea</outcome_measure>
      <outcome_measure>Safety assessed by incidence of adverse drug reactions</outcome_measure>
      <outcome_measure>Efficacy assessed by Global assessment of relief of IBS and constipation symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>0456-MA-3141</other_id>
    </other_ids>
    <start_date>October 2, 2017</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>March 21, 2018</study_first_posted>
    <last_update_posted>May 10, 2019</last_update_posted>
    <locations>
      <location>Site JP00023, Aichi, Japan</location>
      <location>Site JP00005, Akita, Japan</location>
      <location>Site JP00002, Aomori, Japan</location>
      <location>Site JP00012, Chiba, Japan</location>
      <location>Site JP00038, Ehime, Japan</location>
      <location>Site JP00018, Fukui, Japan</location>
      <location>Site JP00040, Fukuoka, Japan</location>
      <location>Site JP00007, Fukushima, Japan</location>
      <location>Site JP00021, Gifu, Japan</location>
      <location>Site JP00010, Gunma, Japan</location>
      <location>Site JP00034, Hiroshima, Japan</location>
      <location>Site JP00001, Hokkaido, Japan</location>
      <location>Site JP00028, Hyogo, Japan</location>
      <location>Site JP00008, Ibaraki, Japan</location>
      <location>Site JP00017, Ishikawa, Japan</location>
      <location>Site JP00003, Iwate, Japan</location>
      <location>Site JP00037, Kagawa, Japan</location>
      <location>Site JP00046, Kagoshima, Japan</location>
      <location>Site JP00014, Kanagawa, Japan</location>
      <location>Site JP00039, Kochi, Japan</location>
      <location>Site JP00043, Kumamoto, Japan</location>
      <location>Site JP00026, Kyoto, Japan</location>
      <location>Site JP00024, Mie, Japan</location>
      <location>Site JP00004, Miyagi, Japan</location>
      <location>Site JP00045, Miyazaki, Japan</location>
      <location>Site JP00020, Nagano, Japan</location>
      <location>Site JP00042, Nagasaki, Japan</location>
      <location>Site JP00029, Nara, Japan</location>
      <location>Site JP00015, Niigata, Japan</location>
      <location>Site JP00044, Oita, Japan</location>
      <location>Site JP00033, Okayama, Japan</location>
      <location>Site JP00047, Okinawa, Japan</location>
      <location>Site JP00027, Osaka, Japan</location>
      <location>Site JP00041, Saga, Japan</location>
      <location>Site JP00011, Saitama, Japan</location>
      <location>Site JP00025, Shiga, Japan</location>
      <location>Site JP00032, Shimane, Japan</location>
      <location>Site JP00022, Shizuoka, Japan</location>
      <location>Site JP00009, Tochigi, Japan</location>
      <location>Site JP00036, Tokushima, Japan</location>
      <location>Site JP00013, Tokyo, Japan</location>
      <location>Site JP00031, Tottori, Japan</location>
      <location>Site JP00016, Toyama, Japan</location>
      <location>Site JP00030, Wakayama, Japan</location>
      <location>Site JP00006, Yamagata, Japan</location>
      <location>Site JP00035, Yamaguchi, Japan</location>
      <location>Site JP00019, Yamanashi, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03471728</url>
  </study>
  <study rank="233">
    <nct_id>NCT00846170</nct_id>
    <title>Probiotics in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">co-biotic</intervention>
      <intervention type="Drug">placebo 2T/day</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>clinical improvement as judged by IBS questionnaire, change in fecal bacterial composition secondary: change the composition of fecal bile acids, fatty acids and bacterial composition</outcome_measure>
      <outcome_measure>change the composition of fecal bile acids, fatty acids and bacterial composition</outcome_measure>
      <outcome_measure>clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Meir Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PB-01-09</other_id>
    </other_ids>
    <start_date>September 2010</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <study_first_posted>February 18, 2009</study_first_posted>
    <last_update_posted>March 10, 2015</last_update_posted>
    <locations>
      <location>Meir Medical center, Kefar Saba, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00846170</url>
  </study>
  <study rank="234">
    <nct_id>NCT00399542</nct_id>
    <title>Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall Responder Status</outcome_measure>
      <outcome_measure>Month 1 Spontaneous Bowel Movement Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Stool Consistency Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Bowel Straining Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Constipation Severity Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Symptom Relief</outcome_measure>
      <outcome_measure>Month 1 Responder Rate</outcome_measure>
      <outcome_measure>Month 2 Responder Rate</outcome_measure>
      <outcome_measure>Month 3 Responder Rate</outcome_measure>
      <outcome_measure>Month 1 Abdominal Pain Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Abdominal Pain Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Abdominal Pain Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Abdominal Bloating Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Abdominal Bloating Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Abdominal Bloating Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Spontaneous Bowel Movement Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Spontaneous Bowel Movement Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Stool Consistency Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Stool Consistency Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Bowel Straining Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Bowel Straining Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Constipation Severity Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Constipation Severity Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Symptom Relief</outcome_measure>
      <outcome_measure>Month 3 Symptom Relief</outcome_measure>
      <outcome_measure>Month 3 Quality of Life Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Bowel Movement Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Bowel Movement Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Bowel Movement Rates Change From Baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sucampo Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Takeda</collaborator>
      <collaborator>Sucampo Pharma Americas, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>581</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0211SIB-0432</other_id>
    </other_ids>
    <start_date>May 2005</start_date>
    <primary_completion_date>July 2006</primary_completion_date>
    <completion_date>July 2006</completion_date>
    <study_first_posted>November 15, 2006</study_first_posted>
    <results_first_posted>October 31, 2008</results_first_posted>
    <last_update_posted>October 29, 2013</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00399542</url>
  </study>
  <study rank="235">
    <nct_id>NCT00699166</nct_id>
    <title>Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym>CDNK333B2201</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DNK333</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in average stool form score at 2 weeks</outcome_measure>
      <outcome_measure>Change from baseline in average score at week 1, week 2: Abdominal pain/discomfort, bloating; satisfaction with bowel habits; weekly stool frequency; percent of days with satisfactory control of bowel urgency; satisfactory relief of overall IBS symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>135</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDNK333B2201</other_id>
    </other_ids>
    <start_date>April 2004</start_date>
    <primary_completion_date>September 2005</primary_completion_date>
    <completion_date>September 2005</completion_date>
    <study_first_posted>June 17, 2008</study_first_posted>
    <last_update_posted>June 17, 2008</last_update_posted>
    <locations>
      <location>Anniston, Alabama, United States</location>
      <location>Huntsville, Alabama, United States</location>
      <location>Northport, Alabama, United States</location>
      <location>Tucson, Arizona, United States</location>
      <location>North Little Rock, Arkansas, United States</location>
      <location>Orange, California, United States</location>
      <location>Riverside, California, United States</location>
      <location>San Diego, California, United States</location>
      <location>Torrance, California, United States</location>
      <location>Bristol, Connecticut, United States</location>
      <location>Hartford, Connecticut, United States</location>
      <location>Hollywood, Florida, United States</location>
      <location>Indianapolis, Indiana, United States</location>
      <location>Arkansas City, Kansas, United States</location>
      <location>Lexington, Kentucky, United States</location>
      <location>Boston, Massachusetts, United States</location>
      <location>Mexico, Missouri, United States</location>
      <location>Washington, Missouri, United States</location>
      <location>Lincoln, Nebraska, United States</location>
      <location>Dayton, Ohio, United States</location>
      <location>Oklahoma City, Oklahoma, United States</location>
      <location>Tulsa, Oklahoma, United States</location>
      <location>Beaver Falls, Pennsylvania, United States</location>
      <location>Chattanooga, Tennessee, United States</location>
      <location>Memphis, Tennessee, United States</location>
      <location>Nashville, Tennessee, United States</location>
      <location>Austin, Texas, United States</location>
      <location>Lake Jackson, Texas, United States</location>
      <location>Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00699166</url>
  </study>
  <study rank="236">
    <nct_id>NCT02387359</nct_id>
    <title>The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)</title>
    <acronym>IBS-C</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plecanatide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint is Overall Responder</outcome_measure>
      <outcome_measure>Abdominal Pain Intensity Weekly Responder</outcome_measure>
      <outcome_measure>Stool Frequency Responder</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowel Movement</outcome_measure>
      <outcome_measure>Spontaneous Bowel Movement</outcome_measure>
      <outcome_measure>Stool Consistency based upon the Bristol Stool Form Scale</outcome_measure>
      <outcome_measure>Sustained Efficacy Responder</outcome_measure>
      <outcome_measure>Time to first SBM and CSBM</outcome_measure>
      <outcome_measure>Change and Percent Change from baseline in abdominal pain</outcome_measure>
      <outcome_measure>Stool Frequency Responder for at least 6 of the 12 treatment weeks</outcome_measure>
      <outcome_measure>Time to first use of Rescue Medication (RM)</outcome_measure>
      <outcome_measure>Overall Responder for at least 9 of the 12 treatment weeks</outcome_measure>
      <outcome_measure>SBMs and CSBMs within 24 hours after first dose of study medication</outcome_measure>
      <outcome_measure>Symptoms associated with IBS-C</outcome_measure>
      <outcome_measure>Patient Global Questionnaires</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Synergy Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1050</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SP304203-04</other_id>
    </other_ids>
    <start_date>December 2014</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>February 2017</completion_date>
    <study_first_posted>March 13, 2015</study_first_posted>
    <last_update_posted>October 4, 2017</last_update_posted>
    <locations>
      <location>Synergy Research Site, Athens, Alabama, United States</location>
      <location>Synergy Research Site, Birmingham, Alabama, United States</location>
      <location>Synergy Research Site, Dothan, Alabama, United States</location>
      <location>Synergy Research Site, Foley, Alabama, United States</location>
      <location>Synergy Research Site, Huntsville, Alabama, United States</location>
      <location>Synergy Research Site, Montgomery, Alabama, United States</location>
      <location>Synergy Research Site, Chandler, Arizona, United States</location>
      <location>Synergy Research Site, Glendale, Arizona, United States</location>
      <location>Synergy Research Site, Phoenix, Arizona, United States</location>
      <location>Synergy Research Site, Tucson, Arizona, United States</location>
      <location>Synergy Research Site, Conway, Arkansas, United States</location>
      <location>Synergy Research Site, Little Rock, Arkansas, United States</location>
      <location>Synergy Research Site, Anaheim, California, United States</location>
      <location>Synergy Research Site, Artesia, California, United States</location>
      <location>Synergy Research Site, Chula Vista, California, United States</location>
      <location>Synergy Research Site, Corona, California, United States</location>
      <location>Synergy Research Site, Encino, California, United States</location>
      <location>Synergy Research Site, Fountain Valley, California, United States</location>
      <location>Synergy Research Site, Fresno, California, United States</location>
      <location>Synergy Research Site, Garden Grove, California, United States</location>
      <location>Synergy Research Site, La Mesa, California, United States</location>
      <location>Synergy Research Site, La Mirada, California, United States</location>
      <location>Synergy Research Site, Laguna Hills, California, United States</location>
      <location>Synergy Research Site, Lancaster, California, United States</location>
      <location>Synergy Research Site, North Hollywood, California, United States</location>
      <location>Synergy Research Site, Sacramento, California, United States</location>
      <location>Synergy Research Site, San Bernardino, California, United States</location>
      <location>Synergy Research Site, San Diego, California, United States</location>
      <location>Synergy Research Site, Thousand Oaks, California, United States</location>
      <location>Synergy Research Site, Upland, California, United States</location>
      <location>Synergy Research Site, Broomfield, Colorado, United States</location>
      <location>Synergy Research Site., Centennial, Colorado, United States</location>
      <location>Synergy Research Site, Bristol, Connecticut, United States</location>
      <location>Synergy Research Site, Hamden, Connecticut, United States</location>
      <location>Synergy Research Site, Boynton Beach, Florida, United States</location>
      <location>Synergy Research Site, Brandon, Florida, United States</location>
      <location>Synergy Research Site, DeLand, Florida, United States</location>
      <location>Synergy Research Site, Fort Lauderdale, Florida, United States</location>
      <location>Synergy Research Site, Homestead, Florida, United States</location>
      <location>Synergy Research Site, Inverness, Florida, United States</location>
      <location>Synergy Research Site, Jacksonville, Florida, United States</location>
      <location>Synergy Research Site, Miami Lakes, Florida, United States</location>
      <location>Synergy Research Site, Miami, Florida, United States</location>
      <location>Synergy Research Site, Orlando, Florida, United States</location>
      <location>Synergy Research Site, Ormond Beach, Florida, United States</location>
      <location>Synergy Research Site, Oviedo, Florida, United States</location>
      <location>Synergy Research Site, Pines, Florida, United States</location>
      <location>Synergy Research Site, Port Orange, Florida, United States</location>
      <location>Synergy Research Site, Saint Petersburg, Florida, United States</location>
      <location>Synergy Research Site, Tampa, Florida, United States</location>
      <location>Synergy Research Site, Atlanta, Georgia, United States</location>
      <location>Synergy Research Site, Marietta, Georgia, United States</location>
      <location>Synergy Research Site, Norcross, Georgia, United States</location>
      <location>Synergy Research Site, Stockbridge, Georgia, United States</location>
      <location>Synergy Research Site, Idaho Falls, Idaho, United States</location>
      <location>Synergy Research Site, Chicago, Illinois, United States</location>
      <location>Synergy Research Site, Evanston, Illinois, United States</location>
      <location>Synergy Research Site, Evergreen Park, Illinois, United States</location>
      <location>Synergy Research Site, Rockford, Illinois, United States</location>
      <location>Synergy Research Site, Evansville, Indiana, United States</location>
      <location>Synergy Research Site, Augusta, Kansas, United States</location>
      <location>Synergy Research Site, Newton, Kansas, United States</location>
      <location>Synergy Research Site, Topeka, Kansas, United States</location>
      <location>Synergy Research Site, Wichita, Kansas, United States</location>
      <location>Synergy Research Site, Baton Rouge, Louisiana, United States</location>
      <location>Synergy Research Site, Crowley, Louisiana, United States</location>
      <location>Synergy Research Site, Mandeville, Louisiana, United States</location>
      <location>Synergy Research Site, Metairie, Louisiana, United States</location>
      <location>Synergy Research Site, Monroe, Louisiana, United States</location>
      <location>Synergy Research Site, New Orleans, Louisiana, United States</location>
      <location>Synergy Research Site, Shreveport, Louisiana, United States</location>
      <location>Synergy Research Site, Baltimore, Maryland, United States</location>
      <location>Synergy Research Site, Hagerstown, Maryland, United States</location>
      <location>Synergy Research Site, Boston, Massachusetts, United States</location>
      <location>Synergy Research Site, Chesterfield, Michigan, United States</location>
      <location>Synergy Research Site, Flint, Michigan, United States</location>
      <location>Synergy Research Site, Rochester, Michigan, United States</location>
      <location>Synergy Research Site, Wyoming, Michigan, United States</location>
      <location>Synergy Research Site., Jackson, Mississippi, United States</location>
      <location>Synergy Research Site, Hazelwood, Missouri, United States</location>
      <location>Synergy Research Site, Omaha, Nebraska, United States</location>
      <location>Synergy Research Site, Las Vegas, Nevada, United States</location>
      <location>Synergy Research Site, Marlton, New Jersey, United States</location>
      <location>Synergy Research Site, Albuquerque, New Mexico, United States</location>
      <location>Synergy Research Site, Brooklyn, New York, United States</location>
      <location>Synergy Research Site, Great Neck, New York, United States</location>
      <location>Synergy Research Site, New Windsor, New York, United States</location>
      <location>Synergy Research Site, New York, New York, United States</location>
      <location>Synergy Research Site, North Massapequa, New York, United States</location>
      <location>Synergy Research Site, Asheboro, North Carolina, United States</location>
      <location>Synergy Research Site, Cary, North Carolina, United States</location>
      <location>Synergy Research Site, Charlotte, North Carolina, United States</location>
      <location>Synergy Research Site, Concord, North Carolina, United States</location>
      <location>Synergy Research Site, Davidson, North Carolina, United States</location>
      <location>Synergy Research Site, Greensboro, North Carolina, United States</location>
      <location>Synergy Research Site, Kinston, North Carolina, United States</location>
      <location>Synergy Research Site, Lenoir, North Carolina, United States</location>
      <location>Synergy Research Site, Raleigh, North Carolina, United States</location>
      <location>Synergy Research Site, Wilmington, North Carolina, United States</location>
      <location>Synergy Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Synergy Research Site, Fargo, North Dakota, United States</location>
      <location>Synergy Research Site, Beavercreek, Ohio, United States</location>
      <location>Synergy Research Site, Cincinnati, Ohio, United States</location>
      <location>Synergy Research Site, Cleveland, Ohio, United States</location>
      <location>Synergy Research Site, Englewood, Ohio, United States</location>
      <location>Synergy Research Site, Sylvania, Ohio, United States</location>
      <location>Synergy Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Synergy Research Site, Tulsa, Oklahoma, United States</location>
      <location>Synergy Research Site, Portland, Oregon, United States</location>
      <location>Synergy Research Site, Levittown, Pennsylvania, United States</location>
      <location>Synergy Research Site, Philadelphia, Pennsylvania, United States</location>
      <location>Synergy Research Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Synergy Research Site, Smithfield, Pennsylvania, United States</location>
      <location>Synergy Research Site, Uniontown, Pennsylvania, United States</location>
      <location>Synergy Research Site, Columbia, South Carolina, United States</location>
      <location>Synergy Research Site, Gaffney, South Carolina, United States</location>
      <location>Synergy Research Site., Greer, South Carolina, United States</location>
      <location>Synergy Research Site, North Charleston, South Carolina, United States</location>
      <location>Synergy Research Site, Rapid City, South Dakota, United States</location>
      <location>Synergy Research Site, Athens, Tennessee, United States</location>
      <location>Synergy Research Site, Chattanooga, Tennessee, United States</location>
      <location>Synergy Research Site, Memphis, Tennessee, United States</location>
      <location>Synergy Research Site., Nashville, Tennessee, United States</location>
      <location>Synergy Research Site, Arlington, Texas, United States</location>
      <location>Synergy Research Site, Austin, Texas, United States</location>
      <location>Synergy Research Site, Carrollton, Texas, United States</location>
      <location>Synergy Research Site, Dallas, Texas, United States</location>
      <location>Synergy Research Site, Houston, Texas, United States</location>
      <location>Synergy Research Site, Plano, Texas, United States</location>
      <location>Synergy Research Site, San Antonio, Texas, United States</location>
      <location>Synergy Research Site, Webster, Texas, United States</location>
      <location>Synergy Research Site, Bountiful, Utah, United States</location>
      <location>Synergy Research Site, Ogden, Utah, United States</location>
      <location>Synergy Research Site, Saint George, Utah, United States</location>
      <location>Synergy Research Site, Sandy City, Utah, United States</location>
      <location>Synergy Research Site, Alexandria, Virginia, United States</location>
      <location>Synergy Research Site, Charlottesville, Virginia, United States</location>
      <location>Synergy Research Site, Lynchburg, Virginia, United States</location>
      <location>Synergy Research Site, Newport News, Virginia, United States</location>
      <location>Synergy Research Site, Bellevue, Washington, United States</location>
      <location>Synergy Research Site, Spokane, Washington, United States</location>
      <location>Synergy Research Site, Charleston, West Virginia, United States</location>
      <location>Synergy Research Site, Morgantown, West Virginia, United States</location>
      <location>Synergy Research Site, Milwaukee, Wisconsin, United States</location>
      <location>Synergy Research Site, Wauwatosa, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02387359</url>
  </study>
  <study rank="237">
    <nct_id>NCT03613545</nct_id>
    <title>Fecal Microbiota Transplantation for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fecal Microbiota Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">fecal microbiota transplantation</intervention>
      <intervention type="Procedure">Infusion of sham</intervention>
      <intervention type="Drug">probiotics, antibiotics or antidepressants</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Irritable Bowel Syndrome assessed by Symptom Severity Score (IBS-SSS)</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome assessed by Quality of Life (IBS-QOL) Questionnaire Scores</outcome_measure>
      <outcome_measure>Change in Depression and Anxiety assessed by Hamilton Depression Rating Scale (HAMD) and Hamilton Anxiety Rating Scale(HAMA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guangzhou First People's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>K-2017-078-02</other_id>
    </other_ids>
    <start_date>August 10, 2018</start_date>
    <primary_completion_date>December 31, 2028</primary_completion_date>
    <completion_date>December 31, 2030</completion_date>
    <study_first_posted>August 3, 2018</study_first_posted>
    <last_update_posted>November 14, 2018</last_update_posted>
    <locations>
      <location>Guangzhou First People's Hospital, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03613545</url>
  </study>
  <study rank="238">
    <nct_id>NCT01551225</nct_id>
    <title>Escitalopram Trial for Irritable Bowel Syndrome (IBS) Patients With Panic Disorder</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escitalopram</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gastrointestinal Symptom Rating Scale (GSRS).</outcome_measure>
      <outcome_measure>State Trait Anxiety Inventory (STAI).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>102051</other_id>
    </other_ids>
    <start_date>January 2012</start_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <completion_date>September 2016</completion_date>
    <study_first_posted>March 12, 2012</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01551225</url>
  </study>
  <study rank="239">
    <nct_id>NCT00194922</nct_id>
    <title>Study to Determine the Effectiveness of the Probiotic E. Coli Strain M17 in Treating Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">E. Coli Strain M17 Probiotic</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Relief of pain and discomfort for at least 2 weeks per month over a 12 week period</outcome_measure>
      <outcome_measure>Changes in stool consistency, stool frequency, and bloating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>BioBalance Corporation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BB-03-02003</other_id>
    </other_ids>
    <start_date>August 2004</start_date>
    <primary_completion_date>November 2006</primary_completion_date>
    <completion_date>November 2006</completion_date>
    <study_first_posted>September 19, 2005</study_first_posted>
    <last_update_posted>April 4, 2008</last_update_posted>
    <locations>
      <location>Cornell Weill Medical College, New York City, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00194922</url>
  </study>
  <study rank="240">
    <nct_id>NCT02538692</nct_id>
    <title>Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tong-Xie-Yao-Fang</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the proportion of patients who had adequate relief of global IBS-D symptoms for at least 2 of the 4 weeks.</outcome_measure>
      <outcome_measure>Stool frequency per week</outcome_measure>
      <outcome_measure>An visual scale rating the degree of IBS-D symptoms</outcome_measure>
      <outcome_measure>Proportion of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chengdu University of Traditional Chinese Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>81373644</other_id>
    </other_ids>
    <start_date>December 2015</start_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <completion_date>March 2017</completion_date>
    <study_first_posted>September 2, 2015</study_first_posted>
    <last_update_posted>April 18, 2017</last_update_posted>
    <locations>
      <location>Teaching Hospital of Chengdu University of TCM, Chengdu, Sichuan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02538692</url>
  </study>
  <study rank="241">
    <nct_id>NCT02493452</nct_id>
    <title>Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym>IBS-C</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plecanatide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary efficacy endpoint is Overall Responder</outcome_measure>
      <outcome_measure>Abdominal Pain Intensity Weekly Responder</outcome_measure>
      <outcome_measure>Stool Frequency Responder</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowel Movement</outcome_measure>
      <outcome_measure>Spontaneous Bowel Movement</outcome_measure>
      <outcome_measure>Stool Consistency based upon the Bristol Stool Form Scale</outcome_measure>
      <outcome_measure>Sustained Efficacy Responder</outcome_measure>
      <outcome_measure>Time to first SBM and CSBM</outcome_measure>
      <outcome_measure>Change and Percent Change from baseline in abdominal pain</outcome_measure>
      <outcome_measure>Stool Frequency Responder for at least 6 of the 12 treatment weeks</outcome_measure>
      <outcome_measure>Time to first use of Rescue Medication (RM)</outcome_measure>
      <outcome_measure>Overall Responder for at least 9 of the 12 treatment weeks</outcome_measure>
      <outcome_measure>SBMs and CSBMs within 24 hours after first dose of study medication</outcome_measure>
      <outcome_measure>Symptoms associated with IBS-C</outcome_measure>
      <outcome_measure>Patient Global Questionnaires</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Synergy Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1050</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SP304203-05</other_id>
    </other_ids>
    <start_date>June 2015</start_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <completion_date>February 2017</completion_date>
    <study_first_posted>July 9, 2015</study_first_posted>
    <last_update_posted>October 4, 2017</last_update_posted>
    <locations>
      <location>Synergy Research Site, Birmingham, Alabama, United States</location>
      <location>Synergy Research Site, Guntersville, Alabama, United States</location>
      <location>Synergy Research Site, Huntsville, Alabama, United States</location>
      <location>Synergy Research Site, Saraland, Alabama, United States</location>
      <location>Synergy Research Site, Glendale, Arizona, United States</location>
      <location>Synergy Research Site, Phoenix, Arizona, United States</location>
      <location>Synergy Research Site, Surprise, Arizona, United States</location>
      <location>Synergy Research Site, Tucson, Arizona, United States</location>
      <location>Synergy Research Site, Conway, Arkansas, United States</location>
      <location>Synergy Research Site, Little Rock, Arkansas, United States</location>
      <location>Synergy Research Site, Canoga Park, California, United States</location>
      <location>Synergy Research Site, Carmichael, California, United States</location>
      <location>Synergy Research Site, Chino, California, United States</location>
      <location>Synergy Research Site, Chula Vista, California, United States</location>
      <location>Synergy Research Site, El Cajon, California, United States</location>
      <location>Synergy Research Site, Encino, California, United States</location>
      <location>Synergy Research Site, Foothill Ranch, California, United States</location>
      <location>Synergy Research Site, Garden Grove, California, United States</location>
      <location>Synergy Research Site, Huntington Beach, California, United States</location>
      <location>Synergy Research Site, Irvine, California, United States</location>
      <location>Synergy Research Site, Lomita, California, United States</location>
      <location>Synergy Research Site, Long Beach, California, United States</location>
      <location>Synergy Research Site, Los Angeles, California, United States</location>
      <location>Synergy Research Site, Mission Hills, California, United States</location>
      <location>Synergy Research Site, Montclair, California, United States</location>
      <location>Synergy Research Site, Northridge, California, United States</location>
      <location>Synergy Research Site, Norwalk, California, United States</location>
      <location>Synergy Research Site, Oceanside, California, United States</location>
      <location>Synergy Research Site, Orangevale, California, United States</location>
      <location>Synergy Research Site, Orange, California, United States</location>
      <location>Synergy Research Site, Placentia, California, United States</location>
      <location>Synergy Research Site, Riverside, California, United States</location>
      <location>Synergy Research Site, San Diego, California, United States</location>
      <location>Synergy Research Site, San Marino, California, United States</location>
      <location>Synergy Research Site, Santa Ana, California, United States</location>
      <location>Synergy Research Site, Sherman Oaks, California, United States</location>
      <location>Synergy Research Site, Colorado Springs, Colorado, United States</location>
      <location>Synergy Research Site, Denver, Colorado, United States</location>
      <location>Synergy Research Site, Hamden, Connecticut, United States</location>
      <location>Synergy Research Site, Atlantis, Florida, United States</location>
      <location>Synergy Research Site, Boca Raton, Florida, United States</location>
      <location>Synergy Research Site, Bradenton, Florida, United States</location>
      <location>Synergy Research Site, Brandon, Florida, United States</location>
      <location>Synergy Research Site, Brooksville, Florida, United States</location>
      <location>Synergy Research Site, Clearwater, Florida, United States</location>
      <location>Synergy Research Site, Cutler Bay, Florida, United States</location>
      <location>Synergy Research Site, Fort Lauderdale, Florida, United States</location>
      <location>Synergy Research Site, Hialeah, Florida, United States</location>
      <location>Synergy Research Site., Jacksonville, Florida, United States</location>
      <location>Synergy Research Site, Lauderdale Lakes, Florida, United States</location>
      <location>Synergy Research Site, Maitland, Florida, United States</location>
      <location>Synergy Research Site, Miami Lakes, Florida, United States</location>
      <location>Synergy Research Site, Miami Springs, Florida, United States</location>
      <location>Synergy Research Site, Miami, Florida, United States</location>
      <location>Synergy Research Site, Naples, Florida, United States</location>
      <location>Synergy Research Site, North Miami Beach, Florida, United States</location>
      <location>Synergy Research Site, Orange Park, Florida, United States</location>
      <location>Synergy Research Site., Orlando, Florida, United States</location>
      <location>Synergy Research Site, Orlando, Florida, United States</location>
      <location>Synergy Research Site, Ormond Beach, Florida, United States</location>
      <location>Synergy Research Site, Pembroke Pines, Florida, United States</location>
      <location>Synergy Research Site, Pinellas Park, Florida, United States</location>
      <location>Synergy Research Site, Port Orange, Florida, United States</location>
      <location>Synergy Research Site, Tamarac, Florida, United States</location>
      <location>Synergy Research Site, Tampa, Florida, United States</location>
      <location>Synergy Research Site, Williston, Florida, United States</location>
      <location>Synergy Research Site, Atlanta, Georgia, United States</location>
      <location>Synergy Research Site, Decatur, Georgia, United States</location>
      <location>Synergy Research Site, Lilburn, Georgia, United States</location>
      <location>Synergy Research Site, Marietta, Georgia, United States</location>
      <location>Synergy Research Site, Snellville, Georgia, United States</location>
      <location>Synergy Research Site, Blackfoot, Idaho, United States</location>
      <location>Synergy Research Site, Boise, Idaho, United States</location>
      <location>Synergy Research Site, Meridian, Idaho, United States</location>
      <location>Synergy Research Site, Blue Island, Illinois, United States</location>
      <location>Synergy Research Site, Chicago, Illinois, United States</location>
      <location>Synergy Research Site, Evanston, Illinois, United States</location>
      <location>Synergy Research Site, Hoffman Estates, Illinois, United States</location>
      <location>Synergy Research Site, Morton, Illinois, United States</location>
      <location>Synergy Research Site, Oak Lawn, Illinois, United States</location>
      <location>Synergy Research Site, Schaumburg, Illinois, United States</location>
      <location>Synergy Research Site, Brownsburg, Indiana, United States</location>
      <location>Synergy Research Site, Indianapolis, Indiana, United States</location>
      <location>Synergy Research Site, Wichita, Kansas, United States</location>
      <location>Synergy Research Site, Madisonville, Kentucky, United States</location>
      <location>Synergy Research Site, Owensboro, Kentucky, United States</location>
      <location>Synergy Research Site, Marrero, Louisiana, United States</location>
      <location>Synergy Research Site, Annapolis, Maryland, United States</location>
      <location>Synergy Research Site, Catonsville, Maryland, United States</location>
      <location>Synergy Research Site, Oxon Hill, Maryland, United States</location>
      <location>Synergy Research Site, Towson, Maryland, United States</location>
      <location>Synergy Research Site, Marlborough, Massachusetts, United States</location>
      <location>Synergy Research Site, Quincy, Massachusetts, United States</location>
      <location>Synergy Research Site, Kalamazoo, Michigan, United States</location>
      <location>Synergy Research Site, Port Gibson, Mississippi, United States</location>
      <location>Synergy Research Site, Chesterfield, Missouri, United States</location>
      <location>Synergy Research Site, Saint Louis, Missouri, United States</location>
      <location>Synergy Research Site, Missoula, Montana, United States</location>
      <location>Synergy Research Site, Omaha, Nebraska, United States</location>
      <location>Synergy Research Site, Las Vegas, Nevada, United States</location>
      <location>Synergy Research Site, Blackwood, New Jersey, United States</location>
      <location>Synergy Research Site, Egg Harbor City, New Jersey, United States</location>
      <location>Synergy Research Site, Vineland, New Jersey, United States</location>
      <location>Synergy Research Site, Albuquerque, New Mexico, United States</location>
      <location>Synergy Research Site, Hopewell Junction, New York, United States</location>
      <location>Synergy Research Site, Kew Gardens, New York, United States</location>
      <location>Synergy Research Site, New York, New York, United States</location>
      <location>Synergy Research Site, Poughkeepsie, New York, United States</location>
      <location>Synergy Research Site, Chapel Hill, North Carolina, United States</location>
      <location>Synergy Research Site, Fayetteville, North Carolina, United States</location>
      <location>Synergy Research Site, High Point, North Carolina, United States</location>
      <location>Synergy Research Site, Jacksonville, North Carolina, United States</location>
      <location>Synergy Research Site, Raleigh, North Carolina, United States</location>
      <location>Synergy Research Site, Salisbury, North Carolina, United States</location>
      <location>Synergy Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Synergy Research Site, Cincinnati, Ohio, United States</location>
      <location>Synergy Research Site, Columbus, Ohio, United States</location>
      <location>Synergy Research Site, Dayton, Ohio, United States</location>
      <location>Synergy Research Site, Franklin, Ohio, United States</location>
      <location>Synergy Research Site, Kettering, Ohio, United States</location>
      <location>Synergy Research Site, Mentor, Ohio, United States</location>
      <location>Synergy Research Site, Middleburg Heights, Ohio, United States</location>
      <location>Synergy Research Site, Wadsworth, Ohio, United States</location>
      <location>Synergy Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Synergy Research Site, Doylestown, Pennsylvania, United States</location>
      <location>Synergy Research Site, Lansdale, Pennsylvania, United States</location>
      <location>Synergy Research Site, Levittown, Pennsylvania, United States</location>
      <location>Synergy Research Site, Philadelphia, Pennsylvania, United States</location>
      <location>Synergy Research Site, Anderson, South Carolina, United States</location>
      <location>Synergy Research Site, Greer, South Carolina, United States</location>
      <location>Synergy Research Site, Mount Pleasant, South Carolina, United States</location>
      <location>Synergy Research Site, Fayetteville, Tennessee, United States</location>
      <location>Synergy Research Site, Franklin, Tennessee, United States</location>
      <location>Synergy Research Site, Hermitage, Tennessee, United States</location>
      <location>Synergy Research Site, Jackson, Tennessee, United States</location>
      <location>Synergy Research Site, Kingsport, Tennessee, United States</location>
      <location>Synergy Research Site, Knoxville, Tennessee, United States</location>
      <location>Synergy Research Site, Austin, Texas, United States</location>
      <location>Synergy Research Site, Baytown, Texas, United States</location>
      <location>Synergy Research Site, Beaumont, Texas, United States</location>
      <location>Synergy Research Site, Channelview, Texas, United States</location>
      <location>Synergy Research Site, Dallas, Texas, United States</location>
      <location>Synergy Research Site, Houston, Texas, United States</location>
      <location>Synergy Research Site, Humble, Texas, United States</location>
      <location>Synergy Research Site, Lampasas, Texas, United States</location>
      <location>Synergy Research Site, McKinney, Texas, United States</location>
      <location>Synergy Research Site, Missouri City, Texas, United States</location>
      <location>Synergy Research Site, Plano, Texas, United States</location>
      <location>Synergy Research Site, Port Arthur, Texas, United States</location>
      <location>Synergy Research Site, San Antonio, Texas, United States</location>
      <location>Synergy Research Site, Sugar Land, Texas, United States</location>
      <location>Synergy Research Site, Orem, Utah, United States</location>
      <location>Synergy Research Site, West Valley City, Utah, United States</location>
      <location>Synergy Research Site, Chesapeake, Virginia, United States</location>
      <location>Synergy Research Site, Fairfax, Virginia, United States</location>
      <location>Synergy Research Site, Norfolk, Virginia, United States</location>
      <location>Synergy Research Site, Richmond, Virginia, United States</location>
      <location>Synergy Research Site, Spokane, Washington, United States</location>
      <location>Synergy Research Site, Vancouver, Washington, United States</location>
      <location>Synergy Research Site, Kingwood, West Virginia, United States</location>
      <location>Synergy Research Site, La Crosse, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02493452</url>
  </study>
  <study rank="242">
    <nct_id>NCT02728063</nct_id>
    <title>Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance</title>
    <acronym>PILATE</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Lactibiane Tolerance</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline of intestinal permeability</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 1</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 2</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 3</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 4</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 5</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 6</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 7</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 8</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 9</outcome_measure>
      <outcome_measure>Change from baseline of intestinal permeability - secondary 10</outcome_measure>
      <outcome_measure>Change from the baseline of the inflammatory status - secondary 11</outcome_measure>
      <outcome_measure>Change from the baseline of the symptomatology - secondary 12</outcome_measure>
      <outcome_measure>Change from the baseline of the symptomatology - secondary 13</outcome_measure>
      <outcome_measure>Change from the baseline of the symptomatology - secondary 14</outcome_measure>
      <outcome_measure>Change from the baseline of the symptomatology - secondary 15</outcome_measure>
      <outcome_measure>Change from the baseline of the symptomatology - secondary 16</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pileje</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PEC15144</other_id>
    </other_ids>
    <start_date>March 2016</start_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <completion_date>May 2017</completion_date>
    <study_first_posted>April 5, 2016</study_first_posted>
    <last_update_posted>June 24, 2016</last_update_posted>
    <locations>
      <location>CHU-Hôtel-Dieu, Service d'Hépato-gastro-entérologie, Nantes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02728063</url>
  </study>
  <study rank="243">
    <nct_id>NCT00460811</nct_id>
    <title>Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide Acetate</intervention>
      <intervention type="Drug">Matching placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period</outcome_measure>
      <outcome_measure>CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)</outcome_measure>
      <outcome_measure>Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period</outcome_measure>
      <outcome_measure>Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period</outcome_measure>
      <outcome_measure>Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period</outcome_measure>
      <outcome_measure>Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period</outcome_measure>
      <outcome_measure>Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>420</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-202</other_id>
    </other_ids>
    <start_date>April 2007</start_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <completion_date>April 2008</completion_date>
    <study_first_posted>April 16, 2007</study_first_posted>
    <results_first_posted>January 30, 2013</results_first_posted>
    <last_update_posted>February 4, 2013</last_update_posted>
    <locations>
      <location>Microbia Investigational Site, Huntsville, Alabama, United States</location>
      <location>Microbia Investigational Site, Chandler, Arizona, United States</location>
      <location>Microbia Investigational Site, Tuscon, Arizona, United States</location>
      <location>Microbia Investigational Site, Sherwood, Arkansas, United States</location>
      <location>Microbia Investigational Site, Anaheim, California, United States</location>
      <location>Microbia Investigational Site, Garden Grove, California, United States</location>
      <location>Microbia Investigational Site, Sacramento, California, United States</location>
      <location>Microbia Investigational Site, San Diego, California, United States</location>
      <location>Microbia Investigational Site, Bristol, Connecticut, United States</location>
      <location>Microbia Investigational Site, Boynton Beach, Florida, United States</location>
      <location>Microbia Investigational Site, Dunedin, Florida, United States</location>
      <location>Microbia Investigational Site, Largo, Florida, United States</location>
      <location>Microbia Investigational Site, Ocala, Florida, United States</location>
      <location>Microbia Investigational Site, Port Orange, Florida, United States</location>
      <location>Microbia Investigational Site, Stuart, Florida, United States</location>
      <location>Microbia Investigational Site, Tampa, Florida, United States</location>
      <location>Microbia Investigational Site, Stockbridge, Georgia, United States</location>
      <location>Microbia Investigational Site, Libertyville, Illinois, United States</location>
      <location>Microbia Investigational Site, Peoria, Illinois, United States</location>
      <location>Microbia Investigational Site, Clive, Iowa, United States</location>
      <location>Microbia Investigational Site, Davenport, Iowa, United States</location>
      <location>Microbia Investigational Site, Mission, Kansas, United States</location>
      <location>Microbia Investigational Site, Shawnee, Kansas, United States</location>
      <location>Microbia Investigational Site, Baton Rouge, Louisiana, United States</location>
      <location>Microbia Investigational Site, Monroe, Louisiana, United States</location>
      <location>Microbia Investigational Site, West Monroe, Louisiana, United States</location>
      <location>Microbia Investigational Site, Annapolis, Maryland, United States</location>
      <location>Microbia Investigational Site, Silver Spring, Maryland, United States</location>
      <location>Microbia Investigational Site, Fall River, Massachusetts, United States</location>
      <location>Microbia Investigational Site, Ann Arbor, Michigan, United States</location>
      <location>Microbia Investigational Site, St. Louis, Missouri, United States</location>
      <location>Microbia Investigational Site, Missoula, Montana, United States</location>
      <location>Microbia Investigational Site, Henderson, Nevada, United States</location>
      <location>Microbia Investigational Site, Las Vegas, Nevada, United States</location>
      <location>Microbia Investigational Site, Blackwood, New Jersey, United States</location>
      <location>Microbia Investigational Site, Great Neck, New York, United States</location>
      <location>Microbia Investigational Site, Pittsford, New York, United States</location>
      <location>Microbia Investigational Site, Asheville, North Carolina, United States</location>
      <location>Microbia Investigational Site, Chapel Hill, North Carolina, United States</location>
      <location>Microbia Investigational Site, Elkin, North Carolina, United States</location>
      <location>Microbia Investigational Site, Greensboro, North Carolina, United States</location>
      <location>Microbia Investigational Site, Harrisburg, North Carolina, United States</location>
      <location>Microbia Investigational Site, Hickory, North Carolina, United States</location>
      <location>Microbia Investigational Site, Raleigh, North Carolina, United States</location>
      <location>Microbia Investigational Site, Statesville, North Carolina, United States</location>
      <location>Microbia Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>Microbia Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Microbia Investigational Site, Cleveland, Ohio, United States</location>
      <location>Microbia Investigational Site, Dayton, Ohio, United States</location>
      <location>Microbia Investigational Site, Sylvania, Ohio, United States</location>
      <location>Microbia Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>Microbia Investigational Site, Tulsa, Oklahoma, United States</location>
      <location>Microbia Investigational Site, Yukon, Oklahoma, United States</location>
      <location>Microbia Investigational Site, Medford, Oregon, United States</location>
      <location>Microbia Investigational Site, Levittown, Pennsylvania, United States</location>
      <location>Microbia Investigational Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Microbia Investigational Site, Reading, Pennsylvania, United States</location>
      <location>Microbia Investigational Site, Sellersville, Pennsylvania, United States</location>
      <location>Microbia Investigational Site, Anderson, South Carolina, United States</location>
      <location>Microbia Investigational Site, Mt. Pleasant, South Carolina, United States</location>
      <location>Microbia Investigational Site, Simpsonville, South Carolina, United States</location>
      <location>Microbia Investigational Site, Summerville, South Carolina, United States</location>
      <location>Microbia Investigational Site, Bristol, Tennessee, United States</location>
      <location>Microbia Investigational Site, Germantown, Tennessee, United States</location>
      <location>Microbia Investigational Site, Jackson, Tennessee, United States</location>
      <location>Microbia Investigational Site, Kingsport, Tennessee, United States</location>
      <location>Microbia Investigational Site, Beaumont, Texas, United States</location>
      <location>Microbia Investigational Site, Corsicana, Texas, United States</location>
      <location>Microbia Investigational Site, El Paso, Texas, United States</location>
      <location>Microbia Investigational Site, San Antonio, Texas, United States</location>
      <location>Microbia Investigational Site, Ogden, Utah, United States</location>
      <location>Microbia Investigational Site, Chesapeake, Virginia, United States</location>
      <location>Microbia Investigational Site, Lynchburg, Virginia, United States</location>
      <location>Microbia Investigational Site, Richmond, Virginia, United States</location>
      <location>Microbia Investigational Site, Lakewood, Washington, United States</location>
      <location>Microbia Investigational Site, Olympia, Washington, United States</location>
      <location>Microbia Investigational Site, Vancouver, Washington, United States</location>
      <location>Microbia Investigational Site, Charleston, West Virginia, United States</location>
      <location>Microbia Investigational Site, LaCrosse, Wisconsin, United States</location>
      <location>Microbia Investigational Site, Abbortsford, British Columbia, Canada</location>
      <location>Microbia Investigational Site, Winnipeg, Manitoba, Canada</location>
      <location>Microbia Investigational Site, Guelph, Ontario, Canada</location>
      <location>Microbia Investigational Site, Milton, Ontario, Canada</location>
      <location>Microbia Investigational Site, Toronto, Ontario, Canada</location>
      <location>Microbia Investigational Site, Saskatoon, Saskatchewan, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00460811</url>
  </study>
  <study rank="244">
    <nct_id>NCT01127828</nct_id>
    <title>Effects of Cultura Yoghurt in Irritable Bowel Syndrome (IBS) Patients on Intestinal and Immunological Changes</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Relief of Irritable Bowel Syndrome Symptoms</condition>
      <condition>Quality of Life</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Arla Yoghurt with no probiotic</intervention>
      <intervention type="Other">Probiotic yoghurt (Cultura)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Relief of IBS symptoms</outcome_measure>
      <outcome_measure>Effects on gastrointestinal and extraintestinal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Good Food Practice, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>U-05-008</other_id>
    </other_ids>
    <start_date>September 2005</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>May 21, 2010</study_first_posted>
    <last_update_posted>May 24, 2010</last_update_posted>
    <locations>
      <location>Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01127828</url>
  </study>
  <study rank="245">
    <nct_id>NCT02082457</nct_id>
    <title>Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation</title>
    <acronym>YKP</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YKP10811 5mg</intervention>
      <intervention type="Drug">YKP10811 20mg</intervention>
      <intervention type="Drug">YKP10811 placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain intensity &amp; stool frequency responder</outcome_measure>
      <outcome_measure>subject global assessment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SK Chemicals Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>273</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>YKP10811_IBS_II_2013</other_id>
    </other_ids>
    <start_date>December 2013</start_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>March 10, 2014</study_first_posted>
    <last_update_posted>June 12, 2015</last_update_posted>
    <locations>
      <location>Gang Nam Severance Hospital, Gang Nam Gu, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02082457</url>
  </study>
  <study rank="246">
    <nct_id>NCT01316718</nct_id>
    <title>Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym>MIBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhoea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalazine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in average stool frequency during weeks 11 and 12.</outcome_measure>
      <outcome_measure>Change from baseline of number of mast cell per mm2 at week 12</outcome_measure>
      <outcome_measure>Average daily severity of abdominal pain on a 0-10 scale</outcome_measure>
      <outcome_measure>Days with urgency</outcome_measure>
      <outcome_measure>Mean stool consistency using Bristol Stool Form Score</outcome_measure>
      <outcome_measure>Global satisfaction with control of IBS symptoms</outcome_measure>
      <outcome_measure>Mast cell tryptase release during 6 hour biopsy incubation</outcome_measure>
      <outcome_measure>IL-1β, TNF-a, histamine and serotonin secretion during same incubation</outcome_measure>
      <outcome_measure>Small bowel tone assessed by volume of fasting small bowel water</outcome_measure>
      <outcome_measure>Euro-Qol Score</outcome_measure>
      <outcome_measure>Centres for disease control and prevention health related quality of life healthy days core module score</outcome_measure>
      <outcome_measure>Hospital Anxiety Depression Scale Score</outcome_measure>
      <outcome_measure>Patient Health Questionnaire -15</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>10085</other_id>
    </other_ids>
    <start_date>March 2011</start_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <completion_date>September 2013</completion_date>
    <study_first_posted>March 16, 2011</study_first_posted>
    <last_update_posted>January 17, 2014</last_update_posted>
    <locations>
      <location>Queen's Medical Centre, Nottingham, Notts, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01316718</url>
  </study>
  <study rank="247">
    <nct_id>NCT01722318</nct_id>
    <title>The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)</title>
    <acronym>CIBS</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plecanatide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population)</outcome_measure>
      <outcome_measure>Change From Baseline in Abdominal Pain Intensity Scores Over 12-Week Treatment Period (mITT Population)</outcome_measure>
      <outcome_measure>Change From Baseline in Stool Consistency (BSFS) Over 12-Week Treatment Period (mITT Population)</outcome_measure>
      <outcome_measure>Change From Baseline in Straining Scores Over 12-Week Treatment Period (mITT Population)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>428</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SP304-20212</other_id>
    </other_ids>
    <start_date>November 2012</start_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <completion_date>October 2014</completion_date>
    <study_first_posted>November 6, 2012</study_first_posted>
    <results_first_posted>September 17, 2018</results_first_posted>
    <last_update_posted>May 27, 2019</last_update_posted>
    <locations>
      <location>Cahaba Research, Birmingham, Alabama, United States</location>
      <location>Digestive Health Specialists of the Southeast, Dothan, Alabama, United States</location>
      <location>Arrowhead Family Health Center PC dba Arrowhead Health Centers, Glendale, Arizona, United States</location>
      <location>Advanced Research Associates, LLC, Glendale, Arizona, United States</location>
      <location>Elite Clinical Trials, LLC, Phoenix, Arizona, United States</location>
      <location>Genova Clinical Research, Inc., Tucson, Arizona, United States</location>
      <location>Adobe Clinical Research, LLC, Tucson, Arizona, United States</location>
      <location>Lynn Institute of the Ozarks, Little Rock, Arkansas, United States</location>
      <location>Anaheim Clinical Trials, LLC, Anaheim, California, United States</location>
      <location>Advanced Rx Clinical Research, Inc., Artesia, California, United States</location>
      <location>GW Research, Inc., Chula Vista, California, United States</location>
      <location>SC Clinical Research, Inc., Garden Grove, California, United States</location>
      <location>Grossmont Center for Clinical Research, La Mesa, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>Healthcare Partners Medical Group, Pasadena, California, United States</location>
      <location>Medical Center for Clinical Research, San Diego, California, United States</location>
      <location>Memorial Research Medical Clinic d/b/a Orange Country Research Center, Tustin, California, United States</location>
      <location>Lynn Institute of the Rockies, Colorado Springs, Colorado, United States</location>
      <location>Horizons Clinical Research Center, LLC, Denver, Colorado, United States</location>
      <location>Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States</location>
      <location>Medical Research Unlimited, LLC, Hialeah, Florida, United States</location>
      <location>Eastern Research, Inc, Hialeah, Florida, United States</location>
      <location>Health Awareness, Inc., Jupiter, Florida, United States</location>
      <location>Jupiter Research, Inc., Jupiter, Florida, United States</location>
      <location>MNH Surgical Center, Maitland, Florida, United States</location>
      <location>San Marcus Research Clinic, Inc., Miami, Florida, United States</location>
      <location>Genoma Research Group, Inc., Miami, Florida, United States</location>
      <location>Columbus Clinical Services, LLC, Miami, Florida, United States</location>
      <location>South Medical Research Group, Inc., Miami, Florida, United States</location>
      <location>Compass Research, LLC, Orlando, Florida, United States</location>
      <location>Urology Center of Florida, Pompano Beach, Florida, United States</location>
      <location>Accord Clinical Research, LLC, Port Orange, Florida, United States</location>
      <location>Meridien Research, Tampa, Florida, United States</location>
      <location>Palm Beach Research Center, West Palm Beach, Florida, United States</location>
      <location>Clinical Research of Central Florida, Winter Haven, Florida, United States</location>
      <location>Georgia Regents University, Augusta, Georgia, United States</location>
      <location>Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States</location>
      <location>CTL Research, Eagle, Idaho, United States</location>
      <location>Medex Healthcare Research, Inc, Chicago, Illinois, United States</location>
      <location>Rockford Gastroenterology Associates, Rockford, Illinois, United States</location>
      <location>Heartland Research Associates, LLC, Augusta, Kansas, United States</location>
      <location>Research Integrity, LLC, Owensboro, Kentucky, United States</location>
      <location>Delta Research Partners, LLC, Bastrop, Louisiana, United States</location>
      <location>Gastroenterology Research of New Orleans, Hammond, Louisiana, United States</location>
      <location>Centex Studies, Inc., Lake Charles, Louisiana, United States</location>
      <location>Women Under Study, LLC, New Orleans, Louisiana, United States</location>
      <location>Louisiana Research Center, LLC, Shreveport, Louisiana, United States</location>
      <location>MGG Group Co., Inc., Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Boston Clinical Trials, Boston, Massachusetts, United States</location>
      <location>Novex Clinical Research, LLC, New Bedford, Massachusetts, United States</location>
      <location>Bay State Clinical Trials, Inc., Watertown, Massachusetts, United States</location>
      <location>IHA Chelsea Family &amp; Internal Medicine, Chelsea, Michigan, United States</location>
      <location>Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States</location>
      <location>Center for Digestive Health, Troy, Michigan, United States</location>
      <location>Ridgeview Research, Chaska, Minnesota, United States</location>
      <location>Prism Research, Saint Paul, Minnesota, United States</location>
      <location>The Center for Clinical Trials, Biloxi, Mississippi, United States</location>
      <location>Gastrointestinal Associates, PA, Jackson, Mississippi, United States</location>
      <location>St. Louis Center for Clinical Research, Saint Louis, Missouri, United States</location>
      <location>Montana Health Research Institute, Inc., Billings, Montana, United States</location>
      <location>Internal Medical Associates of Grand Island, PC, Grand Island, Nebraska, United States</location>
      <location>Quality Clinical Research, Inc., Omaha, Nebraska, United States</location>
      <location>Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States</location>
      <location>St. Luke's Hospital, New York, New York, United States</location>
      <location>Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States</location>
      <location>MediSpect Medical Research, LLC, Boone, North Carolina, United States</location>
      <location>Clinical Trials of North Carolina, LLC, Cary, North Carolina, United States</location>
      <location>Carolina Digestive Health Associates, Charlotte, North Carolina, United States</location>
      <location>On Site Clinical, LLC, Charlotte, North Carolina, United States</location>
      <location>Carolina Digestive Health Associates, Davidson, North Carolina, United States</location>
      <location>Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States</location>
      <location>LeBauer Research Associates, P.A., Greensboro, North Carolina, United States</location>
      <location>Medoff Medical / Vital re:Search, Greensboro, North Carolina, United States</location>
      <location>Wake Research Associates, LLC, Raleigh, North Carolina, United States</location>
      <location>PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States</location>
      <location>Hometown Urgent Care and Occupational Health, Columbus, Ohio, United States</location>
      <location>Great Lakes Gastroenterology, Mentor, Ohio, United States</location>
      <location>Central Sooner Research, Norman, Oklahoma, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Lynn Health Science Institute, Oklahoma City, Oklahoma, United States</location>
      <location>Options Health Research, LLC, Tulsa, Oklahoma, United States</location>
      <location>Consultants in Gastroenterology, Columbia, South Carolina, United States</location>
      <location>Southeast Medical Research, North Charleston, South Carolina, United States</location>
      <location>Palmetto Clinical Research, Summerville, South Carolina, United States</location>
      <location>Chattanooga Medical Research LLC, Chattanooga, Tennessee, United States</location>
      <location>ClinSearch, LLC, Chattanooga, Tennessee, United States</location>
      <location>Franklin Gastroenterology, PLLC, Franklin, Tennessee, United States</location>
      <location>Memphis Gastroenterology Group, PC, Germantown, Tennessee, United States</location>
      <location>Associates in Gastroenterology, Hermitage, Tennessee, United States</location>
      <location>Austin Center for Clinical Research, Austin, Texas, United States</location>
      <location>DCT-AACT, LLC dba Discovery Clinical Trials, Austin, Texas, United States</location>
      <location>Texas Tech Medical Center, El Paso, Texas, United States</location>
      <location>Centex Studies, Inc., Houston, Texas, United States</location>
      <location>North Texas Family Medicine, Plano, Texas, United States</location>
      <location>Quality Research, Inc., San Antonio, Texas, United States</location>
      <location>Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States</location>
      <location>Pioneer Research Solutions, Inc., Sugar Land, Texas, United States</location>
      <location>New River Valley Research Institute, Christiansburg, Virginia, United States</location>
      <location>Blue Ridge Medical Research/Gastroenterology Associates of Central Virginia, Lynchburg, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01722318</url>
  </study>
  <study rank="248">
    <nct_id>NCT03638544</nct_id>
    <title>Reduced Content of Gluten Diet on Patients With Irritable Bowel Syndrome (Pro.Ali.Fun.)</title>
    <acronym>PROALIFUN</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Gluten Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Reduced gluten bread and Pasta compared o normal gluten bread and Pasta</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Severity of IBS symptoms measured by Irritable Bowel Syndrome-Severity Score (IBS-SS)</outcome_measure>
      <outcome_measure>Change of IBS severity measured by Visual analogue scale (VAS)</outcome_measure>
      <outcome_measure>Change of Quality of life scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Bari</lead_sponsor>
    </sponsors>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PROALIFUN</other_id>
    </other_ids>
    <start_date>January 1, 2014</start_date>
    <primary_completion_date>December 31, 2016</primary_completion_date>
    <completion_date>December 31, 2017</completion_date>
    <study_first_posted>August 20, 2018</study_first_posted>
    <last_update_posted>August 20, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03638544</url>
  </study>
  <study rank="249">
    <nct_id>NCT01923428</nct_id>
    <title>The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AZD1722</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent Complete Spontaneous Bowel Movement responders vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ardelyx</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>371</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>D5612C00001</other_id>
    </other_ids>
    <start_date>August 2013</start_date>
    <primary_completion_date>October 2014</primary_completion_date>
    <completion_date>October 2014</completion_date>
    <study_first_posted>August 15, 2013</study_first_posted>
    <last_update_posted>February 26, 2015</last_update_posted>
    <locations>
      <location>Boulder, Colorado, United States</location>
      <location>Greensboro, North Carolina, United States</location>
      <location>Winston-Salem, North Carolina, United States</location>
      <location>Chattanooga, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01923428</url>
  </study>
  <study rank="250">
    <nct_id>NCT01060527</nct_id>
    <title>Altered Faecal Protease Activity in Irritable Bowel Syndrome Patients in China</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Health Science Center of Xi’an Jiaotong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
    </study_designs>
    <other_ids>
      <other_id>xi'an JTU091202</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <study_first_posted>February 2, 2010</study_first_posted>
    <last_update_posted>February 2, 2010</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01060527</url>
  </study>
  <study rank="251">
    <nct_id>NCT01896583</nct_id>
    <title>A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASP7147</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seldar Pharma, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>7147-CL-0003</other_id>
    </other_ids>
    <start_date>November 2013</start_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <completion_date>July 2014</completion_date>
    <study_first_posted>July 11, 2013</study_first_posted>
    <last_update_posted>June 6, 2019</last_update_posted>
    <locations>
      <location>Elite Clinical Studies, Phoenix, Arizona, United States</location>
      <location>Shahram Jacobs, M.D., Inc., Encino, California, United States</location>
      <location>Grossmont Center for Clinical Research, La Mesa, California, United States</location>
      <location>Probe Clinical Research Group, Santa Ana, California, United States</location>
      <location>San Marcus Research Clinic Inc, Miami, Florida, United States</location>
      <location>Suncoast Research Group, LLC, Miami, Florida, United States</location>
      <location>Meridien Research, Saint Petersburg, Florida, United States</location>
      <location>MedVadis Research Corporation, Watertown, Massachusetts, United States</location>
      <location>Sundance Clinical Research, Saint Louis, Missouri, United States</location>
      <location>OM Medical, Las Vegas, Nevada, United States</location>
      <location>PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States</location>
      <location>Remington-Davis, Inc., Columbus, Ohio, United States</location>
      <location>DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01896583</url>
  </study>
  <study rank="252">
    <nct_id>NCT01358708</nct_id>
    <title>Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LACTEOL® 340 mg</intervention>
      <intervention type="Drug">PLACEBO</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global Assessment of Relief During the Double-Blind Treatment Phase Using the Subject Global Assessment (SGA)</outcome_measure>
      <outcome_measure>Global Assessment of Relief During the Open-Label Treatment Phase Using the Subject Global Assessment (SGA)</outcome_measure>
      <outcome_measure>Symptom Severity During the Double-Blind Treatment Phase Using the IBS Symptom Severity Scale (IBS-SSS) Total Score</outcome_measure>
      <outcome_measure>Stool Characteristics During the Double-Blind Treatment Phase Using the Bristol Stool Form Scale</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS) Score During the Double-Blind Phase</outcome_measure>
      <outcome_measure>Symptom Severity During the Open-Label Treatment Phase Using the IBS Symptom Severity Scale (IBS-SSS) Total Score</outcome_measure>
      <outcome_measure>Stool Characteristics During the Open-Label Treatment Phase Using the BSFS</outcome_measure>
      <outcome_measure>Use of Rescue Medication During the Double-Blind and Open-Label Treatment Phases of the Study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Forest Laboratories</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MA-LA-IBS09-01</other_id>
    </other_ids>
    <start_date>June 2010</start_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <completion_date>September 2011</completion_date>
    <study_first_posted>May 24, 2011</study_first_posted>
    <results_first_posted>December 30, 2013</results_first_posted>
    <last_update_posted>March 21, 2017</last_update_posted>
    <locations>
      <location>Bordeaux, France</location>
      <location>Colombes, France</location>
      <location>Marseille, France</location>
      <location>Nice, France</location>
      <location>Rouen, France</location>
      <location>Berlin, Germany</location>
      <location>Hamburg, Germany</location>
      <location>Mannheim, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01358708</url>
  </study>
  <study rank="253">
    <nct_id>NCT01637714</nct_id>
    <title>The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Multi-strain probiotics</intervention>
      <intervention type="Drug">Placebo powder</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change of Irritable bowel syndrome symptom severity score (IBS-SSS)</outcome_measure>
      <outcome_measure>Stool frequency and form</outcome_measure>
      <outcome_measure>Symptom control of irritable bowel syndrome</outcome_measure>
      <outcome_measure>Improvement of overall symptom in patient with irritable bowel syndrome</outcome_measure>
      <outcome_measure>Assessment for quality of life related with irritable bowel syndrome</outcome_measure>
      <outcome_measure>Assessment for patient satisfaction after administration completion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Probiotics for IBS</other_id>
    </other_ids>
    <start_date>July 2012</start_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <completion_date>July 2013</completion_date>
    <study_first_posted>July 11, 2012</study_first_posted>
    <last_update_posted>June 18, 2013</last_update_posted>
    <locations>
      <location>Seoul National University Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01637714</url>
  </study>
  <study rank="254">
    <nct_id>NCT00961298</nct_id>
    <title>An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Generalized Anxiety Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Duloxetine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Global Impression Scale</outcome_measure>
      <outcome_measure>Hamilton Anxiety Rating Scale</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome-Quality of Life Scale</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Severity Scoring System</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>West Penn Allegheny Health System</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RC-4656</other_id>
    </other_ids>
    <start_date>September 2009</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>August 18, 2009</study_first_posted>
    <results_first_posted>July 9, 2014</results_first_posted>
    <last_update_posted>July 9, 2014</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00961298</url>
  </study>
  <study rank="255">
    <nct_id>NCT00938717</nct_id>
    <title>Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide or Matching Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder, 9 Out of 12 Weeks</outcome_measure>
      <outcome_measure>Abdominal Pain Responder, 9 Out of 12 Weeks</outcome_measure>
      <outcome_measure>Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 6 Out of 12 Weeks</outcome_measure>
      <outcome_measure>12-Week Complete Spontaneous Bowel Movement (CSBM) Frequency</outcome_measure>
      <outcome_measure>12-Week Spontaneous Bowl Movement (SBM) Frequency</outcome_measure>
      <outcome_measure>12-Week Change in Stool Consistency</outcome_measure>
      <outcome_measure>12-Week Change in Severity of Straining</outcome_measure>
      <outcome_measure>12-Week Change in Abdominal Pain Score</outcome_measure>
      <outcome_measure>12-Week Change in Abdominal Discomfort</outcome_measure>
      <outcome_measure>12-Week Change in Bloating</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowl Movement (CSBM) Responder for 6 Weeks Out of 12 Weeks of Treatment</outcome_measure>
      <outcome_measure>Abdominal Pain Responder for 6 Out of 12 Weeks</outcome_measure>
      <outcome_measure>12-Week Percent of Abdominal Pain-free Days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>805</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-302</other_id>
    </other_ids>
    <start_date>July 2009</start_date>
    <primary_completion_date>September 2010</primary_completion_date>
    <completion_date>September 2010</completion_date>
    <study_first_posted>July 14, 2009</study_first_posted>
    <results_first_posted>January 30, 2013</results_first_posted>
    <last_update_posted>November 5, 2013</last_update_posted>
    <locations>
      <location>Ironwood Investigational Site, Birmingham, Alabama, United States</location>
      <location>Ironwood Investigational Site, Huntsville, Alabama, United States</location>
      <location>Ironwood Investigational Site, Phoenix, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tempe, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tucson, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tucson, Arizona, United States</location>
      <location>Ironwood Investigational Site, Sherwood, Arkansas, United States</location>
      <location>Ironwood Investigational Site, Anaheim, California, United States</location>
      <location>Ironwood Investigational Site, Chula Vista, California, United States</location>
      <location>Ironwood Investigational Site, Encinitas, California, United States</location>
      <location>Ironwood Investigational Site, Garden Grove, California, United States</location>
      <location>Ironwood Investigational Site, Laguna Hills, California, United States</location>
      <location>Ironwood Investigational Site, Orange, California, United States</location>
      <location>Ironwood Investigational Site, San Carlos, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, Colorado Springs, Colorado, United States</location>
      <location>Ironwood Investigational Site, Bristol, Connecticut, United States</location>
      <location>Ironwood Investigational Site, Boynton Beach, Florida, United States</location>
      <location>Ironwood Investigational Site, Hollywood, Florida, United States</location>
      <location>Ironwood Investigational Site, Inverness, Florida, United States</location>
      <location>Ironwood Investigational Site, Jacksonville, Florida, United States</location>
      <location>Ironwood Investigational Site, Jacksonville, Florida, United States</location>
      <location>Ironwood Investigational Site, Lauderdale Lakes, Florida, United States</location>
      <location>Ironwood Investigational Site, Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Pinellas Park, Florida, United States</location>
      <location>Ironwood Investigational Site, Tampa, Florida, United States</location>
      <location>Ironwood Investigational Site, Newnan, Georgia, United States</location>
      <location>Ironwood Investigational Site, Peoria, Illinois, United States</location>
      <location>Ironwood Investigational Site, Anderson, Indiana, United States</location>
      <location>Ironwood Investigational Site, Clive, Iowa, United States</location>
      <location>Ironwood Investigational Site, Davenport, Iowa, United States</location>
      <location>Ironwood Investigational Site, Mission, Kansas, United States</location>
      <location>Ironwood Investigational Site, Overland Park, Kansas, United States</location>
      <location>Ironwood Investigational Site, Topeka, Kansas, United States</location>
      <location>Ironwood Investigational Site, Baton Rouge, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Metairie, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Monroe, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Shreveport, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Annapolis, Maryland, United States</location>
      <location>Ironwood Investigational Site, Baltimore, Maryland, United States</location>
      <location>Ironwood Investigational Site, Hollywood, Maryland, United States</location>
      <location>Ironwood Investigational Site, Laurel, Maryland, United States</location>
      <location>Ironwood Investigational Site, Chesterfield, Michigan, United States</location>
      <location>Ironwood Investigational Site, Traverse City, Michigan, United States</location>
      <location>Ironwood Investigational Site, Troy, Michigan, United States</location>
      <location>Ironwood Investigational Site, Plymouth, Minnesota, United States</location>
      <location>Ironwood Investigational Site, Jackson, Mississippi, United States</location>
      <location>Ironwood Investigational Site, Tupelo, Mississippi, United States</location>
      <location>Ironwood Investigational Site, Jefferson City, Missouri, United States</location>
      <location>Ironwood Investigational Site, Marlton, New Jersey, United States</location>
      <location>Ironwood Investigational Site, Albuquerque, New Mexico, United States</location>
      <location>Ironwood Investigational Site, Mineola, New York, United States</location>
      <location>Ironwood Investigational Site, Pittsford, New York, United States</location>
      <location>Ironwood Investigational Site, Asheboro, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Asheville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Chapel Hill, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Charlotte, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Charlotte, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Greensboro, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Greensboro, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Harrisburg, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Hickory, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Huntersville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, New Bern, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Statesville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Beachwood, Ohio, United States</location>
      <location>Ironwood Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Ironwood Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Ironwood Investigational Site, Dayton, Ohio, United States</location>
      <location>Ironwood Investigational Site, Mentor, Ohio, United States</location>
      <location>Ironwood Investigational Site, Sylvania, Ohio, United States</location>
      <location>Ironwood Investigational Site, Wadsworth, Ohio, United States</location>
      <location>Ironwood Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>Ironwood Investigational Site, Yukon, Oklahoma, United States</location>
      <location>Ironwood Investigational Site, Lancaster, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Levittown, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Reading, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Sellersville, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Washington, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Anderson, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Charleston, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Simpsonville, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Summerville, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Bristol, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Chattanooga, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Germantown, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Kingsport, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Nashville, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Beaumont, Texas, United States</location>
      <location>Ironwood Investigational Site, El Paso, Texas, United States</location>
      <location>Ironwood Investigational Site, Fort Worth, Texas, United States</location>
      <location>Ironwood Investigational Site, Houston, Texas, United States</location>
      <location>Ironwood Investigational Site, Irving, Texas, United States</location>
      <location>Ironwood Investigational Site, Longview, Texas, United States</location>
      <location>Ironwood Investigational Site, San Antonio, Texas, United States</location>
      <location>Ironwood Investigational Site, Sugarland, Texas, United States</location>
      <location>Ironwood Investigational Site, Ogden, Utah, United States</location>
      <location>Ironwood Investigational Site, Salt Lake City, Utah, United States</location>
      <location>Ironwood Investigational Site, Chesapeake, Virginia, United States</location>
      <location>Ironwood Investigational Site, Lynchburg, Virginia, United States</location>
      <location>Ironwood Investigational Site, Spokane, Washington, United States</location>
      <location>Ironwood Investigational Site, Vancouver, Washington, United States</location>
      <location>Ironwood Investigational Site, La Crosse, Wisconsin, United States</location>
      <location>Ironwood Investigational Site, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00938717</url>
  </study>
  <study rank="256">
    <nct_id>NCT01010191</nct_id>
    <title>Harnessing Placebo Effects: Non-Deceptive Use of Placebo in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Sugar pill</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Global Improvement Scale</outcome_measure>
      <outcome_measure>IBS Adequate Relief</outcome_measure>
      <outcome_measure>IBS quality of life (QoL)</outcome_measure>
      <outcome_measure>IBS Symptom Severity Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Harvard University Faculty of Medicine</lead_sponsor>
      <collaborator>Beth Israel Deaconess Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>M16986</other_id>
    </other_ids>
    <start_date>July 2008</start_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <completion_date>April 2010</completion_date>
    <study_first_posted>November 9, 2009</study_first_posted>
    <last_update_posted>June 22, 2011</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01010191</url>
  </study>
  <study rank="257">
    <nct_id>NCT00589771</nct_id>
    <title>Saccharomyces Boulardii in Irritable Bowel Syndrome</title>
    <acronym>SB-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Dominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Saccharomyces boulardii</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assess the efficacy of Saccharomyces boulardii in reducing clinical symptoms, improving cytokines levels and histology features</outcome_measure>
      <outcome_measure>Assess the efficacy of Saccharomyces boulardii in improving quality of life and safety of the drug</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aga Khan University</lead_sponsor>
      <collaborator>Biocodex</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>674- MED</other_id>
      <other_id>2007-674MED-ERC</other_id>
      <other_id>SB-IBS-674</other_id>
      <other_id>SB-IBS-cytokines-674</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>January 10, 2008</study_first_posted>
    <last_update_posted>October 16, 2012</last_update_posted>
    <locations>
      <location>Aga Khan University Hospital, Karachi, Sindh, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00589771</url>
  </study>
  <study rank="258">
    <nct_id>NCT01373034</nct_id>
    <title>The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Soy Dietary Fiber</intervention>
      <intervention type="Dietary Supplement">Rice powder</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>sum of irritable bowel syndrome symptom score</outcome_measure>
      <outcome_measure>irritable bowel syndrome symptom score</outcome_measure>
      <outcome_measure>Stool frequency and form</outcome_measure>
      <outcome_measure>Symptom control of irritable bowel syndrome</outcome_measure>
      <outcome_measure>Improvement of overall symptom in patient with irritable bowel syndrome</outcome_measure>
      <outcome_measure>Severity of overall symptom in patient with irritable bowel syndrome</outcome_measure>
      <outcome_measure>Severity of diarrhea</outcome_measure>
      <outcome_measure>Assessment for quality of life related with irritable bowel syndrome</outcome_measure>
      <outcome_measure>Assessment for patient satisfaction after administration completion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHUNG_SOY</other_id>
    </other_ids>
    <start_date>July 2011</start_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <completion_date>July 2012</completion_date>
    <study_first_posted>June 14, 2011</study_first_posted>
    <last_update_posted>June 14, 2011</last_update_posted>
    <locations>
      <location>Seoul National University Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01373034</url>
  </study>
  <study rank="259">
    <nct_id>NCT01162863</nct_id>
    <title>Effects of Lubiprostone on Gastrointestinal Transit &amp; pH in Irritable Bowel Syndrome (IBS) With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Other">Smartpill wireless motility capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline</outcome_measure>
      <outcome_measure>Change in Small Bowel pH and Colon pH From Baseline</outcome_measure>
      <outcome_measure>Change in Motility Pattern of the Small Bowel and Colon From Baseline as Defined by the Motility Index</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>Takeda Pharmaceuticals North America, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-028LUB</other_id>
    </other_ids>
    <start_date>November 2010</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>July 15, 2010</study_first_posted>
    <results_first_posted>January 27, 2017</results_first_posted>
    <last_update_posted>January 27, 2017</last_update_posted>
    <locations>
      <location>University of Michigan Health System, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01162863</url>
  </study>
  <study rank="260">
    <nct_id>NCT00552565</nct_id>
    <title>Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)</title>
    <acronym>ARDIS-1</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rezular 15mg</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Rezular</intervention>
      <intervention type="Drug">Rezular</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate Relief</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AGI Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>711</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ARDIS-1</other_id>
    </other_ids>
    <start_date>September 2007</start_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <completion_date>June 2009</completion_date>
    <study_first_posted>November 2, 2007</study_first_posted>
    <last_update_posted>June 11, 2009</last_update_posted>
    <locations>
      <location>PPD, Wilmington, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00552565</url>
  </study>
  <study rank="261">
    <nct_id>NCT01339117</nct_id>
    <title>Delivered Dietary Intervention for Children With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Abdominal Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low fermentable substrate diet</intervention>
      <intervention type="Other">High fermentable substrate diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Average daily abdominal pain frequency</outcome_measure>
      <outcome_measure>Abdominal pain severity</outcome_measure>
      <outcome_measure>Hydrogen gas production</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>NASPGHAN Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-28050</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>April 20, 2011</study_first_posted>
    <last_update_posted>August 2, 2017</last_update_posted>
    <locations>
      <location>Children's Nutrition Research Center, Houston, Texas, United States</location>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01339117</url>
  </study>
  <study rank="262">
    <nct_id>NCT01340053</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RDX5791</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Complete Spontaneous Bowel Movement (CSBM) Frequency change from baseline</outcome_measure>
      <outcome_measure>Abdominal Pain change from baseline</outcome_measure>
      <outcome_measure>Spontaneous Bowel Movement (SBM) Frequency change from baseline</outcome_measure>
      <outcome_measure>Straining change from baseline</outcome_measure>
      <outcome_measure>Bloating change from baseline</outcome_measure>
      <outcome_measure>Adequate relief of IBS Symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ardelyx</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>186</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RDX5791-201</other_id>
    </other_ids>
    <start_date>May 2011</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>February 2012</completion_date>
    <study_first_posted>April 22, 2011</study_first_posted>
    <last_update_posted>March 2, 2012</last_update_posted>
    <locations>
      <location>Ardelyx Investigational Site, San Diego, California, United States</location>
      <location>Ardelyx Investigational Site, Jupiter, Florida, United States</location>
      <location>Ardelyx Investigational Site, Pinellas Park, Florida, United States</location>
      <location>Ardelyx Investigational Site, Rockford, Illinois, United States</location>
      <location>Ardelyx Investigational Site, Mission, Kansas, United States</location>
      <location>Ardelyx Investigational Site, Monroe, Louisiana, United States</location>
      <location>Ardelyx Investigational Site, Annapolis, Maryland, United States</location>
      <location>Ardelyx Investigational Site, Chesterfield, Michigan, United States</location>
      <location>Ardelyx Investigational Site, St. Louis, Missouri, United States</location>
      <location>Ardelyx Investigational Site, Brooklyn, New York, United States</location>
      <location>Ardelyx Investigational Site, Greensboro, North Carolina, United States</location>
      <location>Ardelyx Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>Ardelyx Investigational Site, Simpsonville, South Carolina, United States</location>
      <location>Ardelyx Investigational Site, Bristol, Tennessee, United States</location>
      <location>Ardelyx Investigational Site, Ogden, Utah, United States</location>
      <location>Ardelyx Investigational Site, Lynchburg, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01340053</url>
  </study>
  <study rank="263">
    <nct_id>NCT00259155</nct_id>
    <title>Rifaximin for the Treatment of Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global improvement in IBS</outcome_measure>
      <outcome_measure>Improvement in abdominal pain, diarrhea, constipation and bloating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
      <collaborator>University of Chicago</collaborator>
      <collaborator>Bausch Health Americas, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>4166</other_id>
    </other_ids>
    <start_date>July 2003</start_date>
    <primary_completion_date>January 2007</primary_completion_date>
    <completion_date>January 2007</completion_date>
    <study_first_posted>November 29, 2005</study_first_posted>
    <last_update_posted>March 18, 2008</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00259155</url>
  </study>
  <study rank="264">
    <nct_id>NCT01787253</nct_id>
    <title>Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Lymphocyte characterization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Örebro University, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-05</other_id>
      <other_id>2010/261</other_id>
    </other_ids>
    <start_date>November 2010</start_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>February 8, 2013</study_first_posted>
    <last_update_posted>February 8, 2013</last_update_posted>
    <locations>
      <location>Örebro University Hospital, Örebro, Närke, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01787253</url>
  </study>
  <study rank="265">
    <nct_id>NCT01880424</nct_id>
    <title>A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym>D5630C00001</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Linaclotide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>12-week Abdominal Pain/Abdominal Discomfort Weekly Responder</outcome_measure>
      <outcome_measure>12-week Irritable Bowel Syndrome (IBS) Degree of Relief Responder</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Complete Spontaneous Bowel Movement Frequency Rate</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Spontaneous Bowel Movement Frequency Rate</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Stool Consistency</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Severity of Straining</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Abdominal Bloating</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Abdominal Pain</outcome_measure>
      <outcome_measure>Change From Baseline in 12-week Abdominal Discomfort</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>Ironwood Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1722</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ICP-103-307</other_id>
    </other_ids>
    <start_date>July 2013</start_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <completion_date>May 2015</completion_date>
    <study_first_posted>June 19, 2013</study_first_posted>
    <results_first_posted>September 27, 2016</results_first_posted>
    <last_update_posted>September 27, 2016</last_update_posted>
    <locations>
      <location>Research Site, Huntsville, Alabama, United States</location>
      <location>Research Site, North Little Rock, Arkansas, United States</location>
      <location>Research Site, Phoenix, Arkansas, United States</location>
      <location>Research Site, Artesia, California, United States</location>
      <location>Research Site, Chula Vista, California, United States</location>
      <location>Research Site, Encino, California, United States</location>
      <location>Research Site, North Hollywood, California, United States</location>
      <location>Research Site, Orange, California, United States</location>
      <location>Research Site, Riverside, California, United States</location>
      <location>Research Site, San Diego, California, United States</location>
      <location>Research Site, Boynton Beach, Florida, United States</location>
      <location>Research Site, Brandon, Florida, United States</location>
      <location>Research Site, Brooksville, Florida, United States</location>
      <location>Research Site, Doral, Florida, United States</location>
      <location>Research Site, Gainesville, Florida, United States</location>
      <location>Research Site, Hialeah, Florida, United States</location>
      <location>Research Site, Kissimmee, Florida, United States</location>
      <location>Research Site, Lauderdale Lakes, Florida, United States</location>
      <location>Research Site, Miami Lakes, Florida, United States</location>
      <location>Research Site, Miami, Florida, United States</location>
      <location>Research Site, Addison, Illinois, United States</location>
      <location>Research Site, Evansville, Indiana, United States</location>
      <location>Research Site, Crowley, Louisiana, United States</location>
      <location>Research Site, Monroe, Louisiana, United States</location>
      <location>Research Site, Shreveport, Louisiana, United States</location>
      <location>Research Site, Boston, Massachusetts, United States</location>
      <location>Research Site, Chesterfield, Michigan, United States</location>
      <location>Research Site, Wyoming, Michigan, United States</location>
      <location>Research Site, St. Louis, Missouri, United States</location>
      <location>Research Site, Billings, Montana, United States</location>
      <location>Research Site, Las Vegas, Nevada, United States</location>
      <location>Research Site, Brooklyn, New York, United States</location>
      <location>Research Site, Great Neck, New York, United States</location>
      <location>Research Site, New York, New York, United States</location>
      <location>Research Site, Raleigh, North Carolina, United States</location>
      <location>Research Site, Salisbury, North Carolina, United States</location>
      <location>Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Research Site, Cincinnati, Ohio, United States</location>
      <location>Research Site, Dayton, Ohio, United States</location>
      <location>Research Site, Franklin, Ohio, United States</location>
      <location>Research Site, Mentor, Ohio, United States</location>
      <location>Research Site, Greer, South Carolina, United States</location>
      <location>Research Site, Chattanooga, Tennessee, United States</location>
      <location>Research Site, Kingsport, Tennessee, United States</location>
      <location>Research Site, Knoxville, Tennessee, United States</location>
      <location>Research Site, Smyrna, Tennessee, United States</location>
      <location>Research Site, Houston, Texas, United States</location>
      <location>Research Site, San Antonio, Texas, United States</location>
      <location>Research Site, Webster, Texas, United States</location>
      <location>Research Site, Ogden, Utah, United States</location>
      <location>Research Site, Lynchburg, Virginia, United States</location>
      <location>Research Site, Morgantown, West Virginia, United States</location>
      <location>Research Site, Adelaide, Australia</location>
      <location>Research Site, Brisbane, Australia</location>
      <location>Research Site, Five Dock, Australia</location>
      <location>Research Site, Malvern, Australia</location>
      <location>Research Site, Maroubra, Australia</location>
      <location>Research Site, Melbourne, Australia</location>
      <location>Research Site, Parkville, Australia</location>
      <location>Research Site, Vaughan, Ontario, Canada</location>
      <location>Research Site, Beijing, China</location>
      <location>Research Site, Changsha, China</location>
      <location>Research Site, Chengdu, China</location>
      <location>Research Site, Chongqing, China</location>
      <location>Research Site, Guangzhou, China</location>
      <location>Research Site, Hangzhou, China</location>
      <location>Research Site, Harerbin, China</location>
      <location>Research Site, Hefei, China</location>
      <location>Research Site, Jinan, China</location>
      <location>Research Site, Nanchang, China</location>
      <location>Research Site, Qingdao, China</location>
      <location>Research Site, Shanghai, China</location>
      <location>Research Site, Shenyang, China</location>
      <location>Research Site, Shijiazhuang, China</location>
      <location>Research Site, Wuhan, China</location>
      <location>Research Site, Xi An, China</location>
      <location>Research Site, Xiamen, China</location>
      <location>Research Site, Auckland, New Zealand</location>
      <location>Research Site, Christchurch, New Zealand</location>
      <location>Research Site, Dunedin, New Zealand</location>
      <location>Research Site, Tauranga, New Zealand</location>
      <location>Research Site, Wellington, New Zealand</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01880424</url>
  </study>
  <study rank="266">
    <nct_id>NCT02077699</nct_id>
    <title>Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Lactobacillus casei DG</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intensity of painful symptoms</outcome_measure>
      <outcome_measure>Level of trypsin and tryptase in colonic mucosa</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SOFAR S.p.A.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-DG 10</other_id>
    </other_ids>
    <start_date>March 2012</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>March 4, 2014</study_first_posted>
    <last_update_posted>December 2, 2014</last_update_posted>
    <locations>
      <location>UOC di Gastroenterologia - Policlinico Tor Vergata, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02077699</url>
  </study>
  <study rank="267">
    <nct_id>NCT01085643</nct_id>
    <title>Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>A Change in Length of Spread of Antegrade Contractions After Placebo.</outcome_measure>
      <outcome_measure>A Change in Length of Spread of Antegrade Contractions After Lubiprostone</outcome_measure>
      <outcome_measure>A Change in Length of Spread of Long Distance Propagating Contractions After Placebo.</outcome_measure>
      <outcome_measure>A Change in Length of Spread of Retrograde Contractions After Placebo</outcome_measure>
      <outcome_measure>A Change in Length of Spread of Long Distance Propagating Contractions After Lubiprostone</outcome_measure>
      <outcome_measure>A Change in Length of Spread of Retrograde Contractions After Lubiprostone</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
      <collaborator>Takeda Pharmaceuticals North America, Inc.</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>17482</other_id>
    </other_ids>
    <start_date>March 2010</start_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <completion_date>December 2010</completion_date>
    <study_first_posted>March 12, 2010</study_first_posted>
    <results_first_posted>December 12, 2011</results_first_posted>
    <last_update_posted>December 12, 2011</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01085643</url>
  </study>
  <study rank="268">
    <nct_id>NCT00380250</nct_id>
    <title>Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall Responder Rate</outcome_measure>
      <outcome_measure>Month 1 Spontaneous Bowel Movement (SBM) Frequency Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Stool Consistency Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Bowel Straining Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Constipation Severity Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Symptom Relief</outcome_measure>
      <outcome_measure>Quality of Life Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Responder Rate</outcome_measure>
      <outcome_measure>Month 3 Responder Rate</outcome_measure>
      <outcome_measure>Month 1 Responder Rate</outcome_measure>
      <outcome_measure>Month 2 Abdominal Bloating Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Abdominal Bloating Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Spontaneous Bowel Movement Frequency Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Spontaneous Bowel Movement Frequency Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Stool Consistency Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Stool Consistency Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Bowel Straining Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Bowel Straining Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Constipation Severity Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Constipation Severity Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Symptom Relief</outcome_measure>
      <outcome_measure>Month 3 Symptom Relief</outcome_measure>
      <outcome_measure>Month 1 Abdominal Bloating Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Bowel Movement Frequency Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Bowel Movement Frequency Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Bowel Movement Frequency Rates Change From Baseline</outcome_measure>
      <outcome_measure>Month 1 Abdominal Pain Change From Baseline</outcome_measure>
      <outcome_measure>Month 2 Abdominal Pain Change From Baseline</outcome_measure>
      <outcome_measure>Month 3 Abdominal Pain Change From Baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sucampo Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Takeda</collaborator>
      <collaborator>Sucampo Pharma Americas, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>590</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0211SIB-0431</other_id>
    </other_ids>
    <start_date>May 2005</start_date>
    <completion_date>July 2006</completion_date>
    <study_first_posted>September 25, 2006</study_first_posted>
    <results_first_posted>February 11, 2014</results_first_posted>
    <last_update_posted>February 11, 2014</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00380250</url>
  </study>
  <study rank="269">
    <nct_id>NCT00189696</nct_id>
    <title>Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YM060</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>060-CL-202</other_id>
    </other_ids>
    <study_first_posted>September 19, 2005</study_first_posted>
    <last_update_posted>October 12, 2015</last_update_posted>
    <locations>
      <location>Chubu region, Japan</location>
      <location>Kanto region, Japan</location>
      <location>Shikoku region, Japan</location>
      <location>Tohoku Region, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00189696</url>
  </study>
  <study rank="270">
    <nct_id>NCT00511771</nct_id>
    <title>A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</title>
    <acronym/>
    <status open="N">No longer available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
      <condition>Chronic Idiopathic Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tegaserod</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>54 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>CHTF919A2433</other_id>
    </other_ids>
    <study_first_posted>August 6, 2007</study_first_posted>
    <last_update_posted>November 18, 2010</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00511771</url>
  </study>
  <study rank="271">
    <nct_id>NCT03466281</nct_id>
    <title>Patient Education for Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym>IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patient Education</condition>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Structured patient group education</intervention>
      <intervention type="Behavioral">Education via Internet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of GI symptoms</outcome_measure>
      <outcome_measure>Change of Quality of life</outcome_measure>
      <outcome_measure>Change of Psychological symptoms</outcome_measure>
      <outcome_measure>Change of GI specific anxiety</outcome_measure>
      <outcome_measure>Change of Perceived knowledge about IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS patient education</other_id>
    </other_ids>
    <start_date>August 1, 2016</start_date>
    <primary_completion_date>June 30, 2017</primary_completion_date>
    <completion_date>November 20, 2017</completion_date>
    <study_first_posted>March 15, 2018</study_first_posted>
    <last_update_posted>March 15, 2018</last_update_posted>
    <locations>
      <location>Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03466281</url>
  </study>
  <study rank="272">
    <nct_id>NCT00065403</nct_id>
    <title>Acupuncture for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Acupuncture</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Complementary and Integrative Health (NCCIH)</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01AT001414</other_id>
      <other_id>KaptchukTJ</other_id>
    </other_ids>
    <start_date>February 2004</start_date>
    <completion_date>September 2005</completion_date>
    <study_first_posted>July 23, 2003</study_first_posted>
    <last_update_posted>August 18, 2006</last_update_posted>
    <locations>
      <location>Harvard Medical School, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00065403</url>
  </study>
  <study rank="273">
    <nct_id>NCT03729271</nct_id>
    <title>Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
      <intervention type="Device">Glucose and lactulose hydrogen breath testing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of treatment responders</outcome_measure>
      <outcome_measure>Severity of abdominal pain by numeric rating scale (0-10)</outcome_measure>
      <outcome_measure>Stool consistency by Bristol Stool Form Scale (1-7)</outcome_measure>
      <outcome_measure>Severity of bloating by numeric rating scale (0-10)</outcome_measure>
      <outcome_measure>Severity of bowel urgency by rating scale (0-10)</outcome_measure>
      <outcome_measure>Compare the predictive value of a pre-treatment glucose vs. lactulose hydrogen breath test for symptomatic response to rifaximin in IBS-D patients.</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome - Quality of Life Measure responder</outcome_measure>
      <outcome_measure>Compare the predictive value of a pre-treatment glucose or lactulose hydrogen breath test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>Commonwealth Diagnostics International, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HUM00142925</other_id>
    </other_ids>
    <start_date>July 1, 2019</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>November 2, 2018</study_first_posted>
    <last_update_posted>May 2, 2019</last_update_posted>
    <locations>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03729271</url>
  </study>
  <study rank="274">
    <nct_id>NCT01276626</nct_id>
    <title>Study of Bacteria on Mood and Bowel Symptoms in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Bifidobacterium longum</intervention>
      <intervention type="Other">Maltodextrin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospital Anxiety and Depression (HAD) scale.</outcome_measure>
      <outcome_measure>Improvement in IBS symptoms.</outcome_measure>
      <outcome_measure>Improvement in objective biomarkers.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nestlé</lead_sponsor>
      <collaborator>McMaster University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Nestle 09.25.NRC</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>January 13, 2011</study_first_posted>
    <last_update_posted>August 5, 2014</last_update_posted>
    <locations>
      <location>McMaster University Medical Center, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01276626</url>
  </study>
  <study rank="275">
    <nct_id>NCT01774825</nct_id>
    <title>IQP-CL-101 in IBS Management</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">IQP-CL-101</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS-SSS (Severity Symptom Score)</outcome_measure>
      <outcome_measure>IBS-GIS (Global Improvement Score)</outcome_measure>
      <outcome_measure>IBS-QOL (Quality of Life)</outcome_measure>
      <outcome_measure>Pain and discomfort diary</outcome_measure>
      <outcome_measure>Efficacy assessment by investigator</outcome_measure>
      <outcome_measure>Efficacy assessment by subject</outcome_measure>
      <outcome_measure>Full blood count</outcome_measure>
      <outcome_measure>Clinical chemistry</outcome_measure>
      <outcome_measure>Fecal calprotectin</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Safety assessment by subject</outcome_measure>
      <outcome_measure>Safety assessment by investigator</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>InQpharm Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>INQ/028111</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <completion_date>February 2014</completion_date>
    <study_first_posted>January 24, 2013</study_first_posted>
    <last_update_posted>March 26, 2015</last_update_posted>
    <locations>
      <location>Barbara Grube, Berlin, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01774825</url>
  </study>
  <study rank="276">
    <nct_id>NCT03138980</nct_id>
    <title>Mobile Self-Management of Irritable Bowel Syndrome for Adolescents</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Abdominal Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">BodiMojo Buddy for IBS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ratio of the days during the 30-day intervention period during which participants use the app</outcome_measure>
      <outcome_measure>Acceptance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>BodiMojo, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>15-001825</other_id>
    </other_ids>
    <start_date>January 30, 2016</start_date>
    <primary_completion_date>September 22, 2016</primary_completion_date>
    <completion_date>September 22, 2016</completion_date>
    <study_first_posted>May 3, 2017</study_first_posted>
    <last_update_posted>June 27, 2017</last_update_posted>
    <locations>
      <location>UCLA Pediatric Pain Program Research Offices, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03138980</url>
  </study>
  <study rank="277">
    <nct_id>NCT01257477</nct_id>
    <title>LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym>RELIANCE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change in stool consistency</outcome_measure>
      <outcome_measure>IBS pain severity</outcome_measure>
      <outcome_measure>Change from baseline in quality of life scores (IBSQOL).</outcome_measure>
      <outcome_measure>Change from baseline stool frequency.</outcome_measure>
      <outcome_measure>Change from baseline in fecal urgency.</outcome_measure>
      <outcome_measure>Change from baseline in lost productivity.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Prometheus Laboratories</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>10LOT01</other_id>
    </other_ids>
    <start_date>November 2010</start_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <completion_date>March 2013</completion_date>
    <study_first_posted>December 9, 2010</study_first_posted>
    <last_update_posted>April 4, 2013</last_update_posted>
    <locations>
      <location>Gastroenterology Consultants Inc., Tuscaloosa, Alabama, United States</location>
      <location>Digestive Health Research Unit, Scottsdale, Arizona, United States</location>
      <location>Lynn Institute of the Ozarks, Little Rock, Arkansas, United States</location>
      <location>Adam D. Karns, MD, Beverly Hills, California, United States</location>
      <location>Behavioral Research Specialists, LLC, Irvine, California, United States</location>
      <location>Torrance Clinical Research, Lomita, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>Inland Gastroenterology Medical Associates, Redlands, California, United States</location>
      <location>Digestive Care Associates, San Carlos, California, United States</location>
      <location>Clinical Applications Laboratories, Inc., San Diego, California, United States</location>
      <location>Precision Research Institute, LLC, San Diego, California, United States</location>
      <location>Delta Waves Sleep Disorders &amp; Research Center, Colorado Springs, Colorado, United States</location>
      <location>Clinical Research of the Rockies, LaFayette, Colorado, United States</location>
      <location>Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States</location>
      <location>Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States</location>
      <location>Sanitas Research, Coral Gables, Florida, United States</location>
      <location>Avail Clinical Research, LLC, Deland, Florida, United States</location>
      <location>Southern Clinical Research Consultants, Hollywood, Florida, United States</location>
      <location>Borland-Groover Clinic, Jacksonville, Florida, United States</location>
      <location>Advanced Gastroenterology Associates, LLC, Palm Harbor, Florida, United States</location>
      <location>Gulf Regions Clinical Research Institute, Pensacola, Florida, United States</location>
      <location>Accord Clinical Research, LLC, Port Orange, Florida, United States</location>
      <location>Bearss Medical, Tampa, Florida, United States</location>
      <location>Florida Medical Clinic, PA, Zephyrhills, Florida, United States</location>
      <location>Illinois Gastroenterology Group, LLC/Northwest Gastroenterologists, Arlington Heights, Illinois, United States</location>
      <location>GI Solutions, Chicago, Illinois, United States</location>
      <location>Investigative Clinical Research of Indiana, LLC, Elwood, Indiana, United States</location>
      <location>Gastrointestinal Clinic of Quad Cities, Davenport, Iowa, United States</location>
      <location>Louisiana Research Center, LLC, Shreveport, Louisiana, United States</location>
      <location>Metropolitan Gastroenterology Group, PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Meritus Center for Clinical Research, Hagerstown, Maryland, United States</location>
      <location>Commonwealth Clinical Studies, Brockton, Massachusetts, United States</location>
      <location>Troy Gastroenterology, PC, Troy, Michigan, United States</location>
      <location>Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States</location>
      <location>Center for Digestive and Liver Diseases, Inc., Mexico, Missouri, United States</location>
      <location>Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States</location>
      <location>Howard Guss, DO, Ocean, New Jersey, United States</location>
      <location>Synergy First, LLC, Brooklyn, New York, United States</location>
      <location>Long Island Clinical Research Associates, Great Neck, New York, United States</location>
      <location>New York Center for Clinical Research, Lake Success, New York, United States</location>
      <location>Concorde Medical Group, New York, New York, United States</location>
      <location>NY Center for Women's Health Research, New York, New York, United States</location>
      <location>Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States</location>
      <location>Carolina Digestive Diseases, Greenville, North Carolina, United States</location>
      <location>Carolinas Research Associates, Harrisburg, North Carolina, United States</location>
      <location>Wake Research Associates, Raleigh, North Carolina, United States</location>
      <location>Consultants for Clinical Research of Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Gastroenterology Research Consultants of Greater Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Great Lakes Gastroenterology, Mentor, Ohio, United States</location>
      <location>Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States</location>
      <location>The Orgeon Clinic - West Hills Gastroenterology, Portland, Oregon, United States</location>
      <location>Pennsylvania Research Institute, Bensalem, Pennsylvania, United States</location>
      <location>Research Across America, Reading, Pennsylvania, United States</location>
      <location>Anderson Gastroenterology Associates, LLC, Anderson, South Carolina, United States</location>
      <location>Franklin Gastroenterology, PLLC, Franklin, Tennessee, United States</location>
      <location>HCCA Clinical Research Solutions, Jackson, Tennessee, United States</location>
      <location>Murfreesboro Medical Clinic, Murfreesboro, Tennessee, United States</location>
      <location>Academy of Clinical Research, Arlington, Texas, United States</location>
      <location>ARAYVAN Clinical Research, Arlington, Texas, United States</location>
      <location>Austin Center for Clinical Research, Austin, Texas, United States</location>
      <location>Trinity Clinical Research, Carrollton, Texas, United States</location>
      <location>Digestive Health Center, Pasadena, Texas, United States</location>
      <location>Spring Gastroenterology, Spring, Texas, United States</location>
      <location>Granger Medical Clinic, West Valley, Utah, United States</location>
      <location>Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States</location>
      <location>Digestive and Liver Disease Specialists, Norfolk, Virginia, United States</location>
      <location>Advanced Gastroenterology, Vancouver, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01257477</url>
  </study>
  <study rank="278">
    <nct_id>NCT02877654</nct_id>
    <title>Is There Any Correlation Between Plasmatic Zonulin and Expression of Intestinal Tight Junction Proteins in IBS Patients?</title>
    <acronym>BISII</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">colonoscopy with biopsies in the left colon to assess intestinal permeability</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>occludin level expression in left colonic biopsies</outcome_measure>
      <outcome_measure>plasmatic zonulin expression</outcome_measure>
      <outcome_measure>Claudin and ZO-1 level expression in left colonic biopsies</outcome_measure>
      <outcome_measure>Faecal calprotectin level</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Abdominal symptoms</outcome_measure>
      <outcome_measure>Anxiety and depression levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Rouen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015/174/HP</other_id>
    </other_ids>
    <start_date>February 2, 2017</start_date>
    <primary_completion_date>November 2019</primary_completion_date>
    <completion_date>February 2, 2020</completion_date>
    <study_first_posted>August 24, 2016</study_first_posted>
    <last_update_posted>May 30, 2018</last_update_posted>
    <locations>
      <location>Rouen University Hospital, Rouen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02877654</url>
  </study>
  <study rank="279">
    <nct_id>NCT00421707</nct_id>
    <title>Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GW876008</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants With Average Adequate Relief Rate During the Last 4 Weeks of the Treatment Periods (Weeks 3-6. in Period 1, Weeks 12-15 in Period 2).</outcome_measure>
      <outcome_measure>Number of Participants With Changes in Weekly Adequate Relief Rates During the Treatment Periods (Weeks 1-6 in Period 1 and Weeks 9-15 in Period 2).</outcome_measure>
      <outcome_measure>Number of Participants With Adequate Relief of IBS Pain and Discomfort on All 4 of the Last 4 Weeks of the Treatment Phase Treatment Periods 1 and 2</outcome_measure>
      <outcome_measure>Mean Global Improvement Scale (GIS) Responder Rate Over the Last Four Weeks by Regimen</outcome_measure>
      <outcome_measure>Ratings on Irritable Bowel Syndrome Quality of Life (IBSQoL) Scale</outcome_measure>
      <outcome_measure>Number of Participants With Improvements in Pain and Discomfort</outcome_measure>
      <outcome_measure>Change From Baseline in Pain Severity Scores</outcome_measure>
      <outcome_measure>Percentages of Pain-free Days</outcome_measure>
      <outcome_measure>Number of Participants With Improvements in Bowel Function and Changes in Individual Bowel Symptoms/Function</outcome_measure>
      <outcome_measure>Plasma Concentrations of GW876008 at Week 3 and 6</outcome_measure>
      <outcome_measure>IBS Composite Symptom Score</outcome_measure>
      <outcome_measure>Changes in Patient Health Questionnaire-15 Somatization Scale (PHQ-15) Score With Treatment</outcome_measure>
      <outcome_measure>Summary of Anxiety and/or Depression on Hospital Anxiety and Depression Scale (HAD)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CRI105626</other_id>
    </other_ids>
    <start_date>October 14, 2006</start_date>
    <primary_completion_date>June 25, 2008</primary_completion_date>
    <completion_date>June 25, 2008</completion_date>
    <study_first_posted>January 12, 2007</study_first_posted>
    <results_first_posted>December 26, 2017</results_first_posted>
    <last_update_posted>January 31, 2018</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Sherwood, Arkansas, United States</location>
      <location>GSK Investigational Site, Concord, California, United States</location>
      <location>GSK Investigational Site, Los Angeles, California, United States</location>
      <location>GSK Investigational Site, Tampa, Florida, United States</location>
      <location>GSK Investigational Site, Stockbridge, Georgia, United States</location>
      <location>GSK Investigational Site, Louisville, Kentucky, United States</location>
      <location>GSK Investigational Site, Monroe, Louisiana, United States</location>
      <location>GSK Investigational Site, Boston, Massachusetts, United States</location>
      <location>GSK Investigational Site, Saint Louis, Missouri, United States</location>
      <location>GSK Investigational Site, Greensboro, North Carolina, United States</location>
      <location>GSK Investigational Site, Anderson, South Carolina, United States</location>
      <location>GSK Investigational Site, Greer, South Carolina, United States</location>
      <location>GSK Investigational Site, Chattanooga, Tennessee, United States</location>
      <location>GSK Investigational Site, Germantown, Tennessee, United States</location>
      <location>GSK Investigational Site, Austin, Texas, United States</location>
      <location>GSK Investigational Site, San Antonio, Texas, United States</location>
      <location>GSK Investigational Site, Lynchburg, Virginia, United States</location>
      <location>GSK Investigational Site, Truro, Nova Scotia, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Toronto, Ontario, Canada</location>
      <location>GSK Investigational Site, Saskatoon, Saskatchewan, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00421707</url>
  </study>
  <study rank="280">
    <nct_id>NCT00394173</nct_id>
    <title>Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea (IBS-D)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DNK333</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Satisfactory relief of IBS-related abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Satisfactory relief of overall IBS-D symptoms</outcome_measure>
      <outcome_measure>Occurrence and control of bowel urgency</outcome_measure>
      <outcome_measure>Change in stool frequency</outcome_measure>
      <outcome_measure>Severity of abdominal bloating</outcome_measure>
      <outcome_measure>Severity of abdominal pain/discomfort</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDNK333B2202</other_id>
    </other_ids>
    <start_date>September 2006</start_date>
    <primary_completion_date>October 2007</primary_completion_date>
    <completion_date>October 2007</completion_date>
    <study_first_posted>October 31, 2006</study_first_posted>
    <last_update_posted>February 27, 2017</last_update_posted>
    <locations>
      <location>Investigative Site, Tucson, Arizona, United States</location>
      <location>Investigative Site, North Little Rock, Arkansas, United States</location>
      <location>Investigative Site, Los Angeles, California, United States</location>
      <location>Investigative Site, Orange, California, United States</location>
      <location>Investigative Site, Riverside, California, United States</location>
      <location>Investigative Site, Sacramento, California, United States</location>
      <location>Investigative Site, San Diego, California, United States</location>
      <location>Investigative Site, Colorado Springs, Colorado, United States</location>
      <location>Investigative Site, Bristol, Connecticut, United States</location>
      <location>Investigative Site, Hartford, Connecticut, United States</location>
      <location>Investigative Site, Boca Raton, Florida, United States</location>
      <location>Investigative Site, Gainesville, Florida, United States</location>
      <location>Investigative Site, Hollywood, Florida, United States</location>
      <location>Investigative Site, Jacksonville, Florida, United States</location>
      <location>Investigative Site, Miami, Florida, United States</location>
      <location>Investigative Site, New Smyrna Beach, Florida, United States</location>
      <location>Investigative Site, Tampa, Florida, United States</location>
      <location>Investigative Site, Arlington Heights, Illinois, United States</location>
      <location>Investigative Site, Rockford, Illinois, United States</location>
      <location>Investigative Site, Boston, Massachusetts, United States</location>
      <location>Investigative Site, Wellesley Hills, Massachusetts, United States</location>
      <location>Investigative Site, Mexico, Missouri, United States</location>
      <location>Investigative Site, Buffalo, New York, United States</location>
      <location>Investigative Site, Great Neck, New York, United States</location>
      <location>Investigative Site, Elkin, North Carolina, United States</location>
      <location>Investigative Site, Cincinatti, Ohio, United States</location>
      <location>Investigative Site, Oklahoma City, Oklahoma, United States</location>
      <location>Investigative Site, Portland, Oregon, United States</location>
      <location>Investigative Site, Chattanooga, Tennessee, United States</location>
      <location>Investigative Site, Lake Jackson, Texas, United States</location>
      <location>Investigative Site, San Antonio, Texas, United States</location>
      <location>Investigative Site, Salt Lake City, Utah, United States</location>
      <location>Investigative Site, Chesapeake, Virginia, United States</location>
      <location>Investigative Site, Bellevue, Washington, United States</location>
      <location>Investigative Site, Everett, Washington, United States</location>
      <location>Investigative Site, Monroe, Washington, United States</location>
      <location>Investigative Site, Seattle, Washington, United States</location>
      <location>Investigative Site, Calgary, Alberta, Canada</location>
      <location>Investigative Site, St John's, Newfoundland and Labrador, Canada</location>
      <location>Investigative Site, Hamilton, Ontario, Canada</location>
      <location>Investigative Site, Montreal, Quebec, Canada</location>
      <location>Investigative Site, Sherbrooke, Quebec, Canada</location>
      <location>Investigative Site, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00394173</url>
  </study>
  <study rank="281">
    <nct_id>NCT02306369</nct_id>
    <title>Internet-delivered CBT for Irritable Bowel Syndrome in Adolescents</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internetdelivered exposure-based CBT</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gastrointestinal Symptom Rating Scale-IBS Version (GSRS-IBS).</outcome_measure>
      <outcome_measure>Faces pain scale - R</outcome_measure>
      <outcome_measure>IBS-behavioral responses questionnaire (IBS-BRQ).</outcome_measure>
      <outcome_measure>Percieved Stress scale (PSS 10)</outcome_measure>
      <outcome_measure>Pain reactivity Scale (PRS)</outcome_measure>
      <outcome_measure>Pain interference index (PII)</outcome_measure>
      <outcome_measure>Functional disability index (FDI)</outcome_measure>
      <outcome_measure>Visceral sensitivity Index (IBS-VSI)</outcome_measure>
      <outcome_measure>Pediatric Quality of Life Inventory (PedsQL) Generic Core scales age 13-18</outcome_measure>
      <outcome_measure>Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptom Scale</outcome_measure>
      <outcome_measure>Children´s Somatization Inventory (CSI-24)</outcome_measure>
      <outcome_measure>Spence Children's Anxiety Scale (SCAS-C)</outcome_measure>
      <outcome_measure>TiC-P Adolescents revised version</outcome_measure>
      <outcome_measure>TIC-P Parent report</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder Screener (GAD-7)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire (PHQ 9)</outcome_measure>
      <outcome_measure>ARCS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ibs 13-17 år 2013</other_id>
    </other_ids>
    <start_date>November 2013</start_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <completion_date>November 18, 2017</completion_date>
    <study_first_posted>December 3, 2014</study_first_posted>
    <last_update_posted>August 10, 2018</last_update_posted>
    <locations>
      <location>Child and Adolescent Psychiatry (CAP) Research Center, Stockholm, County Of Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02306369</url>
  </study>
  <study rank="282">
    <nct_id>NCT02609529</nct_id>
    <title>SBI in Children With d-IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Medical Food</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of spontaneous bowel movements</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Laboratory values</outcome_measure>
      <outcome_measure>Psychosocial</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Louisiana State University Health Sciences Center in New Orleans</lead_sponsor>
      <collaborator>Entera Health, Inc</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB 8847</other_id>
    </other_ids>
    <start_date>November 2015</start_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <completion_date>March 2, 2017</completion_date>
    <study_first_posted>November 20, 2015</study_first_posted>
    <last_update_posted>March 9, 2017</last_update_posted>
    <locations>
      <location>Childrens Hospital, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02609529</url>
  </study>
  <study rank="283">
    <nct_id>NCT01950715</nct_id>
    <title>Multimodal Stimulation Before and After Sacral Nerve Stimulation for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">sacral nerve stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cross sectional area</outcome_measure>
      <outcome_measure>Wall stiffness</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Cold</outcome_measure>
      <outcome_measure>Heat</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
      <collaborator>Medtronic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>201302, JLF</other_id>
    </other_ids>
    <start_date>September 2013</start_date>
    <primary_completion_date>March 2018</primary_completion_date>
    <completion_date>March 2018</completion_date>
    <study_first_posted>September 25, 2013</study_first_posted>
    <last_update_posted>May 21, 2018</last_update_posted>
    <locations>
      <location>Surgical Research Unit, Department of Surgery P, Aarhus University Hospital, Aarhus, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01950715</url>
  </study>
  <study rank="284">
    <nct_id>NCT01337609</nct_id>
    <title>Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Major Depressive Disorder</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ganeden BC30</intervention>
      <intervention type="Other">Placebo (sugar pill)</intervention>
      <intervention type="Other">Ganeden BC30, Placebo (sugar pill)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)</outcome_measure>
      <outcome_measure>IBS Severity Scoring System (IBS-SSS)</outcome_measure>
      <outcome_measure>Visual Analog Scale (VAS)</outcome_measure>
      <outcome_measure>Adequate Relief of IBS Pain (AR-IBS)</outcome_measure>
      <outcome_measure>Patient Global Impression of Change (PGI-C) - IBS Symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Ganeden Biotech, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008P002387</other_id>
    </other_ids>
    <start_date>June 2011</start_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <completion_date>February 2012</completion_date>
    <study_first_posted>April 19, 2011</study_first_posted>
    <results_first_posted>August 9, 2013</results_first_posted>
    <last_update_posted>August 9, 2013</last_update_posted>
    <locations>
      <location>Burlington Medical Associates, Burlington, Massachusetts, United States</location>
      <location>Charles River Medical Associates, Westborough, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01337609</url>
  </study>
  <study rank="285">
    <nct_id>NCT02590432</nct_id>
    <title>An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
      <condition>Chronic Idiopathic Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide 290 micrograms</intervention>
      <intervention type="Drug">Linaclotide 145 micrograms</intervention>
      <intervention type="Drug">Linaclotide 72 micrograms</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of patients who meet treatment-related Anti Drug Antibody (ADA) positive status</outcome_measure>
      <outcome_measure>Descriptives of Patient Assessment of Constipation Severity at each postbaseline study visit</outcome_measure>
      <outcome_measure>Descriptives of Patient Assessment of IBS Symptom Severity at each postbaseline study visit</outcome_measure>
      <outcome_measure>Descriptives of Degree of Relief of IBS Symptoms at each postbaseline study visit</outcome_measure>
      <outcome_measure>Descriptives of IBS Treatment Satisfaction Assessment at each postbaseline study visit</outcome_measure>
      <outcome_measure>Descriptives of Constipation Treatment Satisfaction Assessment at each postbaseline study visit</outcome_measure>
      <outcome_measure>Frequency of patients who report treatment-emergent adverse events</outcome_measure>
      <outcome_measure>Frequency of patients who report a recurrence of diarrhea</outcome_measure>
      <outcome_measure>Frequency of patients who report a recurrence of intolerable diarrhea</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Forest Laboratories</lead_sponsor>
      <collaborator>Ironwood Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>829</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIN-MD-10</other_id>
    </other_ids>
    <start_date>November 1, 2015</start_date>
    <primary_completion_date>February 5, 2018</primary_completion_date>
    <completion_date>February 5, 2018</completion_date>
    <study_first_posted>October 29, 2015</study_first_posted>
    <last_update_posted>April 2, 2018</last_update_posted>
    <locations>
      <location>Pinnacle Research Group, LLC, Anniston, Alabama, United States</location>
      <location>North Alabama Research Center, LLC, Athens, Alabama, United States</location>
      <location>Alliance Clinical Research, Birmingham, Alabama, United States</location>
      <location>G &amp; L Research; LLC, Foley, Alabama, United States</location>
      <location>Radiant Research; Inc., Chandler, Arizona, United States</location>
      <location>Radiant Research - Scottsdale, Scottsdale, Arizona, United States</location>
      <location>Clinical Research Institute of Arizona, LLC, Surprise, Arizona, United States</location>
      <location>Clinical Research Consortium Arizona, Tempe, Arizona, United States</location>
      <location>Desert Sun Clinical Research LLC, Tucson, Arizona, United States</location>
      <location>Preferred Research Partners Inc., Little Rock, Arkansas, United States</location>
      <location>Applied Research Center of Arkansas, Little Rock, Arkansas, United States</location>
      <location>Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States</location>
      <location>Diagnamics, Encinitas, California, United States</location>
      <location>MD Studies; Inc., Fountain Valley, California, United States</location>
      <location>Research Center of Fresno, Inc., Fresno, California, United States</location>
      <location>Valley View Wellness and Medical Center - VVCRD, Garden Grove, California, United States</location>
      <location>Global Clinical Trials, Irvine, California, United States</location>
      <location>Facey Medical Foundation, Mission Hills, California, United States</location>
      <location>Clinical Trials Research; Inc., Sacramento, California, United States</location>
      <location>Northern California Research; Inc., Sacramento, California, United States</location>
      <location>Artemis Institute for Clinical Research, San Diego, California, United States</location>
      <location>Precision Research Institute; LLC, San Diego, California, United States</location>
      <location>Empire Clinical Research, Upland, California, United States</location>
      <location>Lynn Institute of Denver, Denver, Colorado, United States</location>
      <location>Zasa Clinical Research, Boynton Beach, Florida, United States</location>
      <location>Meridien Research, Bradenton, Florida, United States</location>
      <location>Clinical Research of Brandon, Brandon, Florida, United States</location>
      <location>Clinical Physiology Associates, Fort Myers, Florida, United States</location>
      <location>Direct Helpers Medical Center Inc., Hialeah, Florida, United States</location>
      <location>Eastern Research, Inc., Hialeah, Florida, United States</location>
      <location>Center for Advanced Gastroenterology LLC, Maitland, Florida, United States</location>
      <location>Florida Medical Center and Research, Inc., Miami, Florida, United States</location>
      <location>CNS Healthcare, Orlando, Florida, United States</location>
      <location>Accord Clinical Research; LLC, Port Orange, Florida, United States</location>
      <location>Meridien Research, Saint Petersburg, Florida, United States</location>
      <location>River Birch Research Alliance, LLC, Blue Ridge, Georgia, United States</location>
      <location>North Georgia Clinical Research, Woodstock, Georgia, United States</location>
      <location>Northwest Clinical Trials, Inc., Boise, Idaho, United States</location>
      <location>Rockford Gastroenterology Associates, Ltd., Rockford, Illinois, United States</location>
      <location>Heartland Medical Research; Inc., Clive, Iowa, United States</location>
      <location>University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States</location>
      <location>Integrated Clinical Trial Services Inc, West Des Moines, Iowa, United States</location>
      <location>Heartland Research Associates, Newton, Kansas, United States</location>
      <location>Health Science Research Center, Pratt, Kansas, United States</location>
      <location>Heartland Research Associates; LLC, Wichita, Kansas, United States</location>
      <location>Heartland Research Associates; LLC, Wichita, Kansas, United States</location>
      <location>KAMP Medical Research, Inc, Natchitoches, Louisiana, United States</location>
      <location>Bay State Clinical Trials, Inc., Watertown, Massachusetts, United States</location>
      <location>Coastal Research Associates; Inc., Weymouth, Massachusetts, United States</location>
      <location>Aa Mrc, Llc, Flint, Michigan, United States</location>
      <location>Beyer Research, Kalamazoo, Michigan, United States</location>
      <location>The Center for Clinical Trials, Biloxi, Mississippi, United States</location>
      <location>Sundance Clinical Research,LLC, Saint Louis, Missouri, United States</location>
      <location>Advanced Research Institute - Utah, Reno, Nevada, United States</location>
      <location>Albuquerque Clinical Trials; Inc., Albuquerque, New Mexico, United States</location>
      <location>Lovelace Scientific Resources - Albuquerque, Albuquerque, New Mexico, United States</location>
      <location>Drug Trials America, Hartsdale, New York, United States</location>
      <location>Manhattan Medical Research Practice; PLLC, New York, New York, United States</location>
      <location>DiGiovanna Institute for Medical Education &amp; Research, North Massapequa, New York, United States</location>
      <location>University of North Carolina Chapel HIll, Chapel Hill, North Carolina, United States</location>
      <location>PharmQuest; LLC, Greensboro, North Carolina, United States</location>
      <location>North State Clinical Research, Lenoir, North Carolina, United States</location>
      <location>Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States</location>
      <location>Dayton Gastroenterology, Inc., Beavercreek, Ohio, United States</location>
      <location>New Horizons Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Clinical Inquest Center, Ltd, Oakwood, Ohio, United States</location>
      <location>IPS Research Company, Oklahoma City, Oklahoma, United States</location>
      <location>The Clinical Trial Center, Jenkintown, Pennsylvania, United States</location>
      <location>Temple University, Philadelphia, Pennsylvania, United States</location>
      <location>Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States</location>
      <location>Montgomery Medical INC, Smithfield, Pennsylvania, United States</location>
      <location>Partners In Clinical Research; LLC, Cumberland, Rhode Island, United States</location>
      <location>Greenville Pharmaceutical Research, INC, Greenville, South Carolina, United States</location>
      <location>Radiant Research, Greer, South Carolina, United States</location>
      <location>Clinical Neuroscience Solutions, Inc, Memphis, Tennessee, United States</location>
      <location>Houston Endoscopy &amp; Research Center, Houston, Texas, United States</location>
      <location>Research Across America-Plano, Plano, Texas, United States</location>
      <location>Sun Research Institute; LLC, San Antonio, Texas, United States</location>
      <location>Charlottesville Medical Research Center; LLC, Charlottesville, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02590432</url>
  </study>
  <study rank="286">
    <nct_id>NCT02431585</nct_id>
    <title>Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics.</title>
    <acronym>GS-IBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Gluten Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">gluten</intervention>
      <intervention type="Dietary Supplement">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The standardized questionnaire (IBS-SS)</outcome_measure>
      <outcome_measure>Visual Analog Scale (VAS)</outcome_measure>
      <outcome_measure>Quality of life Questionnaire</outcome_measure>
      <outcome_measure>The Faces Pain Scale (FPS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Bari</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-IBS</other_id>
    </other_ids>
    <start_date>April 2015</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>May 1, 2015</study_first_posted>
    <last_update_posted>May 1, 2015</last_update_posted>
    <locations>
      <location>Pediatric Department &quot;B Trambusti&quot; Ospedale Giovanni XXIII Via Amendola 270, Bari, Ba, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02431585</url>
  </study>
  <study rank="287">
    <nct_id>NCT01674088</nct_id>
    <title>Sucrose Breath Test to Determine Intestinal Permeability in IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Area under the breath 13CO2 concentration versus time curve (AUC) of sucrose</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Metabolic Solutions Inc.</lead_sponsor>
      <collaborator>University of Florida</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>SBT-01</other_id>
    </other_ids>
    <start_date>October 2012</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>August 28, 2012</study_first_posted>
    <last_update_posted>February 10, 2014</last_update_posted>
    <locations>
      <location>University of Florida Shands Hospital, Gainesville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01674088</url>
  </study>
  <study rank="288">
    <nct_id>NCT00907790</nct_id>
    <title>Nursing Management of Irritable Bowel Syndrome (IBS) 2008</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Usual Care (Control Group)</intervention>
      <intervention type="Behavioral">Comprehensive Self-Management (CSM)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Daily abdominal pain</outcome_measure>
      <outcome_measure>IBS Quality of Life Questionnaire</outcome_measure>
      <outcome_measure>Salivary cortisol</outcome_measure>
      <outcome_measure>Interleukin-10(IL-10) and Interleukin-12(IL-12)</outcome_measure>
      <outcome_measure>Fecal calprotectin</outcome_measure>
      <outcome_measure>Intestinal permeability (urine)</outcome_measure>
      <outcome_measure>Brief Symptom Inventory</outcome_measure>
      <outcome_measure>Cognitive Scale for Functional Bowel Disorders</outcome_measure>
      <outcome_measure>Work Productivity &amp; Activity Impairment</outcome_measure>
      <outcome_measure>Daily symptoms(other GI and psychological)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>32722</other_id>
      <other_id>2R01NR004142</other_id>
    </other_ids>
    <start_date>March 2009</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>May 25, 2009</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Washington, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00907790</url>
  </study>
  <study rank="289">
    <nct_id>NCT01413945</nct_id>
    <title>Ileocecal Sphincter Reflex by Cecal Distension During Colonoscopy</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Pressure generated in ICV during Cecal distention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Northwell Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>13-216B</other_id>
    </other_ids>
    <start_date>June 21, 2013</start_date>
    <primary_completion_date>August 5, 2015</primary_completion_date>
    <completion_date>January 18, 2017</completion_date>
    <study_first_posted>August 10, 2011</study_first_posted>
    <last_update_posted>February 22, 2019</last_update_posted>
    <locations>
      <location>LIJ Medical Center- NSLIJ Health System, New Hyde Park, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01413945</url>
  </study>
  <study rank="290">
    <nct_id>NCT01149200</nct_id>
    <title>Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TC-6499</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in global IBS symptom relief score</outcome_measure>
      <outcome_measure>Weekly number of spontaneous bowel movements (SBM)</outcome_measure>
      <outcome_measure>Severity of pain, bloating, degree of straining, and stool consistency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Targacept Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TC-6499-12-CLP-004</other_id>
    </other_ids>
    <start_date>May 2010</start_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <completion_date>October 2010</completion_date>
    <study_first_posted>June 23, 2010</study_first_posted>
    <last_update_posted>December 2, 2013</last_update_posted>
    <locations>
      <location>Quotient Clinical Ltd, Edinburgh, United Kingdom</location>
      <location>Quotient Clinical Ltd, Ruddington, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01149200</url>
  </study>
  <study rank="291">
    <nct_id>NCT00765999</nct_id>
    <title>An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Chronic Constipation</condition>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Forest Laboratories</lead_sponsor>
      <collaborator>Ironwood Pharmaceuticals, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1559</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIN-MD-02</other_id>
    </other_ids>
    <start_date>October 31, 2008</start_date>
    <primary_completion_date>January 31, 2012</primary_completion_date>
    <completion_date>January 31, 2012</completion_date>
    <study_first_posted>October 3, 2008</study_first_posted>
    <results_first_posted>February 15, 2019</results_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Innovative Clinical Trials, Birmingham, Alabama, United States</location>
      <location>Parkway Medical Center, Birmingham, Alabama, United States</location>
      <location>Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States</location>
      <location>Radiant Research, Inc., Chandler, Arizona, United States</location>
      <location>Pivotal Research Centers, Peoria, Arizona, United States</location>
      <location>Pivotal Research Center, Peoria, Arizona, United States</location>
      <location>Carl T Hayden VA Medical Center GI Section-CS-111G, Phoenix, Arizona, United States</location>
      <location>Elite Clinical Studies, LLC, Phoenix, Arizona, United States</location>
      <location>Radiant Research, Inc., Scottsdale, Arizona, United States</location>
      <location>Genova Clinical Research, Inc., Tucson, Arizona, United States</location>
      <location>Adobe Clinical Research, LLC, Tucson, Arizona, United States</location>
      <location>Providence Clinical Research, Burbank, California, United States</location>
      <location>Encompass Clinical Research North Coast, Encinitas, California, United States</location>
      <location>Family Medical Center, Foothill Ranch, California, United States</location>
      <location>Axis Clinical Trials, Los Angeles, California, United States</location>
      <location>Facey Medical Foundation, Mission Hills, California, United States</location>
      <location>Advanced Clinical Research Institute, Orange, California, United States</location>
      <location>Westlake Medical Research, Westlake Village, California, United States</location>
      <location>Boulder Medical Center, P.C., Boulder, Colorado, United States</location>
      <location>Lynn Institute of the Rockies, Colorado Springs, Colorado, United States</location>
      <location>Colorado Gastroenterology, Prof LLC, Denver, Colorado, United States</location>
      <location>Longmont Medical Research Network, Longmont, Colorado, United States</location>
      <location>Western States Clinical Research, Wheat Ridge, Colorado, United States</location>
      <location>Chase Medical Research, LLC, Waterbury, Connecticut, United States</location>
      <location>Clinical Trials Management of Boca Raton, Inc., Boca Raton, Florida, United States</location>
      <location>Meridien Research, Bradenton, Florida, United States</location>
      <location>PAB Clinical Research, Brandon, Florida, United States</location>
      <location>Meridien Research, Brooksville, Florida, United States</location>
      <location>Clinical Physiology Associates Clinical Study Center, Fort Myers, Florida, United States</location>
      <location>Jupiter Research, Inc., Jupiter, Florida, United States</location>
      <location>FPA Clinical Research, Kissimmee, Florida, United States</location>
      <location>Pharmax Research Clinic, Miami, Florida, United States</location>
      <location>United Medical Research, New Smyrna Beach, Florida, United States</location>
      <location>RenStar Medical Research, Ocala, Florida, United States</location>
      <location>Compass Research, Orlando, Florida, United States</location>
      <location>Emerald Coast Research Associates, Panama City, Florida, United States</location>
      <location>University Clinical Research, Inc., Pembroke Pines, Florida, United States</location>
      <location>Meridien Research, Saint Petersburg, Florida, United States</location>
      <location>Miami Research Associates, South Miami, Florida, United States</location>
      <location>Meridien Research, Tampa, Florida, United States</location>
      <location>Advanced Research Institute, Trinity, Florida, United States</location>
      <location>Florida Medical Clinic, P.A. Clinical Research Division, Zephyrhills, Florida, United States</location>
      <location>Radiant Research, Inc., Atlanta, Georgia, United States</location>
      <location>Gastrointestinal Specialists of Georgia, PC, Marietta, Georgia, United States</location>
      <location>Atlanta Gastroenterology Associates, LLC, Marietta, Georgia, United States</location>
      <location>Clinical Research Atlanta, Stockbridge, Georgia, United States</location>
      <location>North Georgia Clinical Research, Woodstock, Georgia, United States</location>
      <location>Rosemark WomenCare Specialist, Idaho Falls, Idaho, United States</location>
      <location>Rockford Gastroenterology Associates, Ltd., Rockford, Illinois, United States</location>
      <location>MediSphere Medical Research Center, LLC, Evansville, Indiana, United States</location>
      <location>University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States</location>
      <location>Heartland Research Associates, LLC, Arkansas City, Kansas, United States</location>
      <location>Heartland Research Associates, LLC, Newton, Kansas, United States</location>
      <location>Heartland Research Associates, LLC, Wichita, Kansas, United States</location>
      <location>Heartland Research Associates, LLC, Wichita, Kansas, United States</location>
      <location>Central Kentucky Research Associates, Lexington, Kentucky, United States</location>
      <location>Trover Health System, Madisonville, Kentucky, United States</location>
      <location>Medical Development Centers, LLC, Baton Rouge, Louisiana, United States</location>
      <location>Clinical Trials of America, Inc., Shreveport, Louisiana, United States</location>
      <location>Metropolitan Gastroenterology Group PC, Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Meritus Center for Clinical Research, Hagerstown, Maryland, United States</location>
      <location>Charm City Research, Towson, Maryland, United States</location>
      <location>Boston Clinical Trials, Boston, Massachusetts, United States</location>
      <location>Kalamazoo Gastroenterology Hepatology, Kalamazoo, Michigan, United States</location>
      <location>Ridgeview Research Two Twelve Medical Center, Chaska, Minnesota, United States</location>
      <location>St. Louis Center for Clinical Research, Saint Louis, Missouri, United States</location>
      <location>The Gastroenterology Group of S.J., Vineland, New Jersey, United States</location>
      <location>New Mexico Clinical Research and Osteoporosis Center, Albuquerque, New Mexico, United States</location>
      <location>Lifeline Research Institute, Brooklyn, New York, United States</location>
      <location>Long Island Clinical Research Associates, LLP, Great Neck, New York, United States</location>
      <location>Long Island Gastrointestinal Research Group, Great Neck, New York, United States</location>
      <location>Gastrointestinal Research Associates, LLC, Setauket, New York, United States</location>
      <location>MediSpect, LLC, Boone, North Carolina, United States</location>
      <location>Cumberland Research Associates, LLC, Fayetteville, North Carolina, United States</location>
      <location>LeBauer Research Associates, P.A., Greensboro, North Carolina, United States</location>
      <location>Clinical Trials of America, INC, Hickory, North Carolina, United States</location>
      <location>Wake Research Associates, LLC, Raleigh, North Carolina, United States</location>
      <location>Hanover Medical Specialists, PA, Wilmington, North Carolina, United States</location>
      <location>Digestive Health Specialists, PA, Winston-Salem, North Carolina, United States</location>
      <location>Consultants for Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Rapid Medical Research, Inc., Cleveland, Ohio, United States</location>
      <location>Remington Davis, Columbus, Ohio, United States</location>
      <location>Hometown Urgent Care and Research, Dayton, Ohio, United States</location>
      <location>Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, United States</location>
      <location>Gastroenterology United of Tulsa, Tulsa, Oklahoma, United States</location>
      <location>Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States</location>
      <location>Upstate Pharmaceutical Research, Greenville, South Carolina, United States</location>
      <location>Mountain View Clinical Research, Greer, South Carolina, United States</location>
      <location>Radiant Research, Greer, South Carolina, United States</location>
      <location>Nashville Medical Research Institute, Nashville, Tennessee, United States</location>
      <location>Professional Quality Research, Inc., Austin, Texas, United States</location>
      <location>Research Across America RHD Professional Plaza IV, Dallas, Texas, United States</location>
      <location>Houston Digestive Diseases Clinic, Houston, Texas, United States</location>
      <location>Houston Medical Research Associates, Houston, Texas, United States</location>
      <location>R/D Clinical Research, Inc., Lake Jackson, Texas, United States</location>
      <location>Quality Research Inc., San Antonio, Texas, United States</location>
      <location>Diagnostics Research Group, San Antonio, Texas, United States</location>
      <location>Fatigue Consultation Clinic, Salt Lake City, Utah, United States</location>
      <location>Department of Gastroenterology University of Utah Hospital, Salt Lake City, Utah, United States</location>
      <location>Department of Veterans Affairs Research Department, Salt Lake City, Utah, United States</location>
      <location>Charlottesville Medical Research, Charlottesville, Virginia, United States</location>
      <location>New River Valley Research Institute, Christiansburg, Virginia, United States</location>
      <location>Health Research of Hampton Roads, Newport News, Virginia, United States</location>
      <location>National Clinical Research - Norfolk, Inc., Norfolk, Virginia, United States</location>
      <location>Clinical Research Associates of Tidewater, Norfolk, Virginia, United States</location>
      <location>National Clinical Research-Richmond, Inc., Richmond, Virginia, United States</location>
      <location>Northwest Gastroenterology Associates, Bellevue, Washington, United States</location>
      <location>Radiant Research, Inc., Lakewood, Washington, United States</location>
      <location>Wenatchee Valley Medical Center Clinical Research Dept., Wenatchee, Washington, United States</location>
      <location>Aurora Advanced Healthcare, Inc. Clinical Research Center, Milwaukee, Wisconsin, United States</location>
      <location>GI Research Institute, Vancouver, British Columbia, Canada</location>
      <location>St. Joseph Healthcare, Hamilton, Ontario, Canada</location>
      <location>MedPhase Canada, Newmarket, Ontario, Canada</location>
      <location>Meadowlands Family Health Center, Ottawa, Ontario, Canada</location>
      <location>London Road Diagnostic Clinic and Medical Center, Sarnia, Ontario, Canada</location>
      <location>Medicor Research, Inc., Sudbury, Ontario, Canada</location>
      <location>PrimeHealth Clinical Research, Toronto, Ontario, Canada</location>
      <location>Toronto Digestive Disease Associates, Inc., Vaughan, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00765999</url>
  </study>
  <study rank="292">
    <nct_id>NCT00355810</nct_id>
    <title>Probiotics for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">placebo followed by Lactobacillus plantarum MF 1298</intervention>
      <intervention type="Dietary Supplement">Lactobacillus plantarum MF1298 followed by placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Satisfactory relief of abdominal symptoms</outcome_measure>
      <outcome_measure>Graded measurement of abdominal symptoms</outcome_measure>
      <outcome_measure>Fecal bacterial count</outcome_measure>
      <outcome_measure>Abdominal gas</outcome_measure>
      <outcome_measure>Immunological parameters</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Norwegian University of Science and Technology</lead_sponsor>
      <collaborator>Norwegian Food Research</collaborator>
      <collaborator>Gilde</collaborator>
      <collaborator>Norwegian Foundation for Health and Rehabilitation</collaborator>
      <collaborator>Sykehuset Innlandet HF</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>REK 4.2005.2284</other_id>
    </other_ids>
    <start_date>January 2006</start_date>
    <primary_completion_date>April 2006</primary_completion_date>
    <completion_date>December 2006</completion_date>
    <study_first_posted>July 25, 2006</study_first_posted>
    <last_update_posted>July 19, 2016</last_update_posted>
    <locations>
      <location>Innlandet Hospital HF, Gjovik, Oppland, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00355810</url>
  </study>
  <study rank="293">
    <nct_id>NCT03052439</nct_id>
    <title>Diet Reintroduction Study in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">FODMAP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain</outcome_measure>
      <outcome_measure>Bloating</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>Stool Frequency</outcome_measure>
      <outcome_measure>Stool urgency</outcome_measure>
      <outcome_measure>Fatigue</outcome_measure>
      <outcome_measure>Sleep quality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HUM00122970</other_id>
    </other_ids>
    <start_date>July 5, 2017</start_date>
    <primary_completion_date>September 1, 2019</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>February 14, 2017</study_first_posted>
    <last_update_posted>September 27, 2018</last_update_posted>
    <locations>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03052439</url>
  </study>
  <study rank="294">
    <nct_id>NCT00829218</nct_id>
    <title>Clinical Trial Examining Effects of Monosodium Glutamate (MSG) on Irritable Bowel Syndrome (IBS) and Fibromyalgia (FM)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fibromyalgia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Glutamate additive-free diet</intervention>
      <intervention type="Other">Placebo diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the number of patients who have a positive response to a one month glutamate free diet, as measured by the Perception of Global Impression of Change (PGIC) scores</outcome_measure>
      <outcome_measure>To assess whether symptoms return with MSG challenge statistically more frequently than with placebo as measured by symptom scores.</outcome_measure>
      <outcome_measure>Improvement on Irritable Bowel Syndrome-Quality of Life (IBS-QOL) questionnaire</outcome_measure>
      <outcome_measure>Improvement in day-to-day functioning based on the Revised Fibromyalgia Impact Questionnaire</outcome_measure>
      <outcome_measure>A reduction in pain based on two visual analog scales, one for gut pain, and another for musculo-skeletal pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
      <collaborator>University of Arizona</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>4763</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <completion_date>May 2010</completion_date>
    <study_first_posted>January 26, 2009</study_first_posted>
    <last_update_posted>December 24, 2013</last_update_posted>
    <locations>
      <location>Oregon Health &amp; Science University, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00829218</url>
  </study>
  <study rank="295">
    <nct_id>NCT02880722</nct_id>
    <title>Experience Sampling Method for Symptom Assessment in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Abdominal pain scores as measured by the ESM tool.</outcome_measure>
      <outcome_measure>Abdominal pain scores as measured by the end-of-day diary.</outcome_measure>
      <outcome_measure>Abdominal pain scores as measured by the Gastrointestinal Symptom Rating Scale - IBS.</outcome_measure>
      <outcome_measure>Symptom scores (other than abdominal pain) as measured using the ESM-tool.</outcome_measure>
      <outcome_measure>Gastrointestinal symptom scores (other than abdominal pain) as measured using the end-of-day diary.</outcome_measure>
      <outcome_measure>Gastrointestinal symptom scores (other than abdominal pain) as measured using the GSRS-IBS.</outcome_measure>
      <outcome_measure>Psychological symptom scores as measured using the PHQ-9.</outcome_measure>
      <outcome_measure>Psychological symptom scores as measured using the GAD-7.</outcome_measure>
      <outcome_measure>Quality of life scores as measured using SF-36.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>Grünenthal GmbH</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>216</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL57473.068.16</other_id>
    </other_ids>
    <start_date>October 2016</start_date>
    <primary_completion_date>October 2018</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 26, 2016</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02880722</url>
  </study>
  <study rank="296">
    <nct_id>NCT01507922</nct_id>
    <title>Comparative Efficacy and Safety of Fenoverine</title>
    <acronym>FEN-401</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fenoverine</intervention>
      <intervention type="Drug">Timebutine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the proportion of subjects with improvement in abdominal pain or discomfort</outcome_measure>
      <outcome_measure>BSS scores (each and total)</outcome_measure>
      <outcome_measure>overall BSS score</outcome_measure>
      <outcome_measure>subject's satisfaction with treatment</outcome_measure>
      <outcome_measure>adverse event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bukwang Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>186</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FEN-401</other_id>
    </other_ids>
    <start_date>December 2011</start_date>
    <primary_completion_date>March 2013</primary_completion_date>
    <completion_date>June 2013</completion_date>
    <study_first_posted>January 11, 2012</study_first_posted>
    <last_update_posted>December 18, 2014</last_update_posted>
    <locations>
      <location>Korea University Ansan Hospital, Ansan, Korea, Republic of</location>
      <location>Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of</location>
      <location>Kangwon National University Hospital, Chuncheon, Korea, Republic of</location>
      <location>Gachon University Gil Hospital, Incheon, Korea, Republic of</location>
      <location>Inje University Seoul Paik Hospital, Seoul, Korea, Republic of</location>
      <location>Korea University Anam Hospital, Seoul, Korea, Republic of</location>
      <location>Korea University Guro Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01507922</url>
  </study>
  <study rank="297">
    <nct_id>NCT00945074</nct_id>
    <title>Acupuncture/Moxibustion for Irritable Bowel Syndrome (IBS)</title>
    <acronym>Acu/MoxaIBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard Acupuncture/Moxibustion (fixed protocol)</intervention>
      <intervention type="Other">Individualized Acupuncture/Moxibustion</intervention>
      <intervention type="Other">Sham/Placebo Acupuncture/Moxibustion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patient-rated abdominal pain/discomfort and IBS-Secondary symptom rating: intestinal gas, bloating and stool consistency</outcome_measure>
      <outcome_measure>Global improvement (CGIS)</outcome_measure>
      <outcome_measure>Quality of life (IBS-QOL &amp; SF-36)</outcome_measure>
      <outcome_measure>Psychological distress (SCL-90)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York University</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>171</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>7833948</other_id>
      <other_id>R01NR010730</other_id>
    </other_ids>
    <start_date>July 2009</start_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>July 23, 2009</study_first_posted>
    <last_update_posted>September 22, 2016</last_update_posted>
    <locations>
      <location>New York University, Division of Special Studies in Symptom Management, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00945074</url>
  </study>
  <study rank="298">
    <nct_id>NCT01754493</nct_id>
    <title>Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression</title>
    <acronym>IBS-MDD</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Major Depression</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Duloxetine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Montgomery-Asberg Depression Rating Scale (MADRS)</outcome_measure>
      <outcome_measure>Gastrointestinal Symptoms Rating Scale (GSRS)</outcome_measure>
      <outcome_measure>Clinician-Rated Global Impression Scales (CGI)</outcome_measure>
      <outcome_measure>Visual Analogue Scales (VAS)</outcome_measure>
      <outcome_measure>Somatization Module of the Patient's Health Questionnaire (PHQ-15)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>Eli Lilly and Company</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>17</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>#6479R</other_id>
      <other_id>F1J-US-X037</other_id>
    </other_ids>
    <start_date>December 2008</start_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>December 21, 2012</study_first_posted>
    <results_first_posted>November 25, 2016</results_first_posted>
    <last_update_posted>November 25, 2016</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, 1051 Riverside Drive, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01754493</url>
  </study>
  <study rank="299">
    <nct_id>NCT00461682</nct_id>
    <title>Sb-705498 Rectal Pain Study</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SB-705498</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Visual Analogue Scale (VAS) Pain Score to Rectal Distensions at Pre-dose and up to 6 Hours (h) Post-dose of Each Treatment Period</outcome_measure>
      <outcome_measure>Visual Analogue Scores for Rectal Distensions for Gas, Urgency to Defecate and Discomfort at Pre-dose and 6 h Post-dose of Each Treatment Period</outcome_measure>
      <outcome_measure>Rectal Sensory Thresholds to Thermal Stimulation (Contact Heat Device, Values Reported as in Study) at Pre-dose and 6h Post-dose of Each Treatment Period</outcome_measure>
      <outcome_measure>Peak Pain Intensity Difference (PPID6), as Derived From Maximum Pain Intensity (NRS) Difference From Baseline (Pre-dose on Day 1) by Single Measurement Recorded Over 0-6h of Each Treatment Period</outcome_measure>
      <outcome_measure>Pain Intensity Difference (SPID6), as Derived From Pain Intensity (NRS) Difference From Baseline (Pre-dose on Day 1) by Single Measurement Recorded Over 0-6h Post-dose of Each Treatment Period</outcome_measure>
      <outcome_measure>Somatic Heat Pain Thresholds (Hand and Foot) Assessed Pre-dose and 6h Post-dose of Each Treatment Period</outcome_measure>
      <outcome_measure>Contact Heat-evoked Potentials (CHEPs) - Optional, Assessed Pre-dose and 6h Post-dose of Each Treatment Period</outcome_measure>
      <outcome_measure>Number of Defecations Over 24h and Over 1 Week Following a Dose of SB-705498 (Monitored Using Bristol Stool Scoring Diary Kept 1 Week Pre- and 1 Week Post-dose)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Symptom Severity Score (IBS SSS) Calculated Over Approximately 10 Days Pre- and Post-dose</outcome_measure>
      <outcome_measure>Symptom Scoring and Quality of Life Assessments Over Period</outcome_measure>
      <outcome_measure>Average Daily Pain Scores at Baseline (Pre-dose), 1, 2, 3, 4, 5 and 6h Post-dose for Each Treatment Period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>VRA107438</other_id>
    </other_ids>
    <start_date>January 26, 2007</start_date>
    <primary_completion_date>September 1, 2007</primary_completion_date>
    <completion_date>September 1, 2007</completion_date>
    <study_first_posted>April 18, 2007</study_first_posted>
    <results_first_posted>May 8, 2017</results_first_posted>
    <last_update_posted>August 20, 2018</last_update_posted>
    <locations>
      <location>GSK Investigational Site, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00461682</url>
  </study>
  <study rank="300">
    <nct_id>NCT01678781</nct_id>
    <title>Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change in Irritable Bowel syndrome (IBS) quality of life (QoL) measure (IBS-QoL) to assess the impairment of QoL in IBS patients</outcome_measure>
      <outcome_measure>Change in abdominal pain</outcome_measure>
      <outcome_measure>Change in bloating</outcome_measure>
      <outcome_measure>Change in feeling of abdominal distension</outcome_measure>
      <outcome_measure>Change in stool frequency</outcome_measure>
      <outcome_measure>Change in stool form</outcome_measure>
      <outcome_measure>Change in straining of evacuation</outcome_measure>
      <outcome_measure>Change in urgency of evacuation</outcome_measure>
      <outcome_measure>Change in feeling of incomplete evacuation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abbott</lead_sponsor>
      <collaborator>CHILTERN International GmbH</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>607</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P13-678</other_id>
    </other_ids>
    <start_date>July 2012</start_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <completion_date>August 2013</completion_date>
    <study_first_posted>September 5, 2012</study_first_posted>
    <last_update_posted>September 9, 2013</last_update_posted>
    <locations>
      <location>Site reference ID/Investigator# 94519, Beijing, China</location>
      <location>Site reference ID/Investigator# 95475, Guangzhou City, China</location>
      <location>Site reference ID/Investigator# 94521, Guangzhou, China</location>
      <location>Site reference ID/Investigator # 94518, Shanghai, China</location>
      <location>Site reference ID/Investigator # 94517, Shanghai, China</location>
      <location>Site reference ID/Investigator # 94516, Shanghai, China</location>
      <location>Site reference ID/Investigator # 94515, Wuhan, China</location>
      <location>Site Reference ID/Investigator# 95908, Alexandria, Egypt</location>
      <location>Site reference ID/Investigator# 95900, Cairo, Egypt</location>
      <location>Site reference ID/Investigator# 95901, El Sharkya, Egypt</location>
      <location>Site reference ID/Investigator# 95902, Giza, Egypt</location>
      <location>Site reference ID/Investigator# 95903, Giza, Egypt</location>
      <location>Site Reference ID/Investigator# 95906, Port Said, Egypt</location>
      <location>Site reference ID/Investigaot# 94525, Guadalajara, Mexico</location>
      <location>Site refernce ID/Investigator# 94527, Mexico City, Mexico</location>
      <location>Site reference ID/Investigator# 94523, Tampico, Mexico</location>
      <location>Site reference ID/Investigator# 85314, Bialystok, Poland</location>
      <location>Site Reference ID/Investigator# 85297, Bialystok, Poland</location>
      <location>Site Reference ID/Investigator# 85298, Bydgoszcz, Poland</location>
      <location>Site Reference ID/Investigator# 85293, Katowice, Poland</location>
      <location>Site Reference ID/Investigator# 85296, Lodz, Poland</location>
      <location>Site reference ID/Investigator# 85313, Olsztyn, Poland</location>
      <location>Site Reference ID/Investigator# 85295, Poznan, Poland</location>
      <location>Site Reference ID/Investigator# 85294, Poznan, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01678781</url>
  </study>
  <study rank="301">
    <nct_id>NCT00911612</nct_id>
    <title>Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?</title>
    <acronym>welchol</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colesevelam</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Transit, Geometric Center at 24 Hours</outcome_measure>
      <outcome_measure>Ascending Colon Emptying T1/2</outcome_measure>
      <outcome_measure>Colonic Permeability as Measured by Cumulative Urinary Excretion of Mannitol 8-24 Hours</outcome_measure>
      <outcome_measure>Colonic Transit, Geometric Center at 48 Hours</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-007454</other_id>
      <other_id>R01DK054681</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>May 2009</primary_completion_date>
    <completion_date>May 2009</completion_date>
    <study_first_posted>June 2, 2009</study_first_posted>
    <results_first_posted>March 15, 2012</results_first_posted>
    <last_update_posted>April 4, 2012</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00911612</url>
  </study>
  <study rank="302">
    <nct_id>NCT03423069</nct_id>
    <title>Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant</title>
    <acronym>DIETSINIBS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Diet low in FODMAPs</intervention>
      <intervention type="Dietary Supplement">Specific dietary advice for IBS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the total score of the irritable bowel syndrome - severity scoring system (IBS-SSS) questionnaire</outcome_measure>
      <outcome_measure>Change in the score of the single symptom items of the irritable bowel syndrome - severity scoring system (IBS-SSS) questionnaire</outcome_measure>
      <outcome_measure>Change in the intestinal permeabily evaluation</outcome_measure>
      <outcome_measure>Change in the GI peptide concentrations</outcome_measure>
      <outcome_measure>Change in the lipidomic profile.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RC2018B</other_id>
    </other_ids>
    <start_date>February 5, 2018</start_date>
    <primary_completion_date>June 30, 2019</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>February 6, 2018</study_first_posted>
    <last_update_posted>March 5, 2018</last_update_posted>
    <locations>
      <location>IRCCS Saverio de Bellis, Castellana Grotte, Bari, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03423069</url>
  </study>
  <study rank="303">
    <nct_id>NCT00511563</nct_id>
    <title>A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GW876008 and GSK561679</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Serum cortisol / ACTH and DHEA levels</outcome_measure>
      <outcome_measure>Serum cytokine levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CRI109244</other_id>
    </other_ids>
    <start_date>August 2007</start_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <study_first_posted>August 6, 2007</study_first_posted>
    <last_update_posted>March 2, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00511563</url>
  </study>
  <study rank="304">
    <nct_id>NCT02242175</nct_id>
    <title>Efficacy of Hydrogen Breath Test in the Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Glucose breath test (hydrogen breath test)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The difference of H2 elevation level through the hydrogen breath test between the irritable bowel syndrome patients and the normal people</outcome_measure>
      <outcome_measure>The difference of methane level through the hydrogen breath test between the irritable bowel syndrome patients and the normal people</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>147</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>1-2014-0046</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>September 16, 2014</study_first_posted>
    <last_update_posted>March 28, 2019</last_update_posted>
    <locations>
      <location>Sevrance hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02242175</url>
  </study>
  <study rank="305">
    <nct_id>NCT02254629</nct_id>
    <title>The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic Clostridium Butyricum</intervention>
      <intervention type="Drug">Laxative Polyethylene Glycol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subject's Global Assessment of Relief</outcome_measure>
      <outcome_measure>The changes of symptom scores</outcome_measure>
      <outcome_measure>IBS patients'quality of life</outcome_measure>
      <outcome_measure>Composition of Microorganisms in stool</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014SDU-QILU-G04</other_id>
    </other_ids>
    <start_date>July 2014</start_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <completion_date>July 2016</completion_date>
    <study_first_posted>October 2, 2014</study_first_posted>
    <last_update_posted>August 31, 2016</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02254629</url>
  </study>
  <study rank="306">
    <nct_id>NCT02419027</nct_id>
    <title>A Multi-center Human Study to Evaluate the Efficacy and Safety of ®GI Flora in Subjects With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">GI Flora</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Visual Analogue Scale for abdominal pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CBT-GS14</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>April 17, 2015</study_first_posted>
    <last_update_posted>April 17, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02419027</url>
  </study>
  <study rank="307">
    <nct_id>NCT01776853</nct_id>
    <title>Fructose and Fructans in Irritabla Bowel Syndrome</title>
    <acronym>FABS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Glucose</intervention>
      <intervention type="Dietary Supplement">Fructose</intervention>
      <intervention type="Dietary Supplement">Fructans</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom response (yes/no)</outcome_measure>
      <outcome_measure>Symptom Intensity</outcome_measure>
      <outcome_measure>Breath Hydrogen</outcome_measure>
      <outcome_measure>Colonic Gas Volume</outcome_measure>
      <outcome_measure>Small Bowel Water Content</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>12102</other_id>
      <other_id>12/EM/0443</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <completion_date>February 2015</completion_date>
    <study_first_posted>January 28, 2013</study_first_posted>
    <last_update_posted>May 13, 2016</last_update_posted>
    <locations>
      <location>NIHR Biomedical Research Unit in Gastrointestinal and Liver Diseases at Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01776853</url>
  </study>
  <study rank="308">
    <nct_id>NCT02108119</nct_id>
    <title>The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotics</intervention>
      <intervention type="Dietary Supplement">Control placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Probi AB</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>197</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO008</other_id>
    </other_ids>
    <start_date>May 2, 2014</start_date>
    <primary_completion_date>November 30, 2015</primary_completion_date>
    <completion_date>November 30, 2015</completion_date>
    <study_first_posted>April 9, 2014</study_first_posted>
    <last_update_posted>June 16, 2017</last_update_posted>
    <locations>
      <location>PreCare Trial &amp; Recruitment, Beek, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02108119</url>
  </study>
  <study rank="309">
    <nct_id>NCT01144832</nct_id>
    <title>Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ebastine</intervention>
      <intervention type="Drug">placebo capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of treatment on visceral sensitivity measured with rectal barostat.</outcome_measure>
      <outcome_measure>Effect of treatment on IBS symptoms.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KU Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S51638</other_id>
    </other_ids>
    <start_date>October 2009</start_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <completion_date>May 2012</completion_date>
    <study_first_posted>June 16, 2010</study_first_posted>
    <last_update_posted>January 28, 2016</last_update_posted>
    <locations>
      <location>University hospitals Leuven, Leuven, Vlaams-Brabant, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01144832</url>
  </study>
  <study rank="310">
    <nct_id>NCT02154867</nct_id>
    <title>Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.</title>
    <acronym>REFIT</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Fecal transplantation</intervention>
      <intervention type="Other">Placebo fecal transplant</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in subjective symptom score</outcome_measure>
      <outcome_measure>Microbiome profile change</outcome_measure>
      <outcome_measure>Long term effects of fecal transplantation</outcome_measure>
      <outcome_measure>Safety of fecal transplantation in IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital of North Norway</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013/971/REK</other_id>
    </other_ids>
    <start_date>December 2014</start_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>June 3, 2014</study_first_posted>
    <last_update_posted>January 13, 2017</last_update_posted>
    <locations>
      <location>University Hospital of North Norway, Harstad, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02154867</url>
  </study>
  <study rank="311">
    <nct_id>NCT03561519</nct_id>
    <title>FMT in the Treatment of IBS</title>
    <acronym>FMT-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Fecal Microbiota Transplantation (FMT)</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS symptom relieve</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Joint Authority for Päijät-Häme Social and Health Care</lead_sponsor>
      <collaborator>Helsinki University Central Hospital</collaborator>
      <collaborator>Helsinki University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>40/13/03/01/15</other_id>
    </other_ids>
    <start_date>August 27, 2015</start_date>
    <primary_completion_date>July 1, 2018</primary_completion_date>
    <completion_date>July 1, 2018</completion_date>
    <study_first_posted>June 19, 2018</study_first_posted>
    <last_update_posted>August 15, 2018</last_update_posted>
    <locations>
      <location>Helsinki University Hospital, Helsinki, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03561519</url>
  </study>
  <study rank="312">
    <nct_id>NCT00100425</nct_id>
    <title>Characterization of Pain Processing Mechanisms in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Viceral Perception Testing</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>US Department of Veterans Affairs</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>72 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>CADE-ARCD2</other_id>
    </other_ids>
    <start_date>September 2000</start_date>
    <study_first_posted>December 31, 2004</study_first_posted>
    <last_update_posted>January 21, 2009</last_update_posted>
    <locations>
      <location>Malcolm Randall VA Medical Center, Gainesville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00100425</url>
  </study>
  <study rank="313">
    <nct_id>NCT03568513</nct_id>
    <title>Effect of Curcumin on Gut Microbiota in IBS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Curcumin</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Alteration in Gut Microbiota</outcome_measure>
      <outcome_measure>Comparison of GI Symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>Clinical &amp; Translational Science Institute of Southeast Wisconsin</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1120142</other_id>
      <other_id>UL1TR001436</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>March 2028</completion_date>
    <study_first_posted>June 25, 2018</study_first_posted>
    <last_update_posted>May 21, 2019</last_update_posted>
    <locations>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03568513/ICF_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03568513</url>
  </study>
  <study rank="314">
    <nct_id>NCT01094041</nct_id>
    <title>Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea</condition>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Gluten free diet</intervention>
      <intervention type="Other">Gluten rich diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Small bowel permeability</outcome_measure>
      <outcome_measure>Colonic permeability</outcome_measure>
      <outcome_measure>Colonic transit</outcome_measure>
      <outcome_measure>Colon transit</outcome_measure>
      <outcome_measure>Small bowel transit time</outcome_measure>
      <outcome_measure>Gastric emptying</outcome_measure>
      <outcome_measure>Colonic inflammatory response</outcome_measure>
      <outcome_measure>Stool frequency and consistency</outcome_measure>
      <outcome_measure>Small bowel inflammatory response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>09-007344</other_id>
    </other_ids>
    <start_date>February 2010</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>March 26, 2010</study_first_posted>
    <last_update_posted>May 10, 2013</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01094041</url>
  </study>
  <study rank="315">
    <nct_id>NCT03822299</nct_id>
    <title>Effects of Faecal Microbiota Transplantation in Patients With IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">healthy feces microbiota</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global improvement in IBS symptoms as assessed by IBS Symptom Severity Scale (IBS-SSS)</outcome_measure>
      <outcome_measure>Global improvement in IBS symptoms as assessed by Birmingham Symptom scale questionnaire</outcome_measure>
      <outcome_measure>Quality of life as assessed by IBS quality of life (IBSQoL) questionnaire</outcome_measure>
      <outcome_measure>Quality of life as assessed by Short form of Nepean Dyspepsia Index (SF-NDI) questionnaires</outcome_measure>
      <outcome_measure>Fatigue as assessed by: Fatigue Assessment Scale (FAS) questionnaire</outcome_measure>
      <outcome_measure>Stool microbiota changes as assessed by the Dysbiosis index (DI)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Helse Fonna</lead_sponsor>
      <collaborator>Helse Vest</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>164</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HelseFonna</other_id>
    </other_ids>
    <start_date>January 1, 2018</start_date>
    <primary_completion_date>April 30, 2019</primary_completion_date>
    <completion_date>May 5, 2019</completion_date>
    <study_first_posted>January 30, 2019</study_first_posted>
    <last_update_posted>May 7, 2019</last_update_posted>
    <locations>
      <location>Helse Fonna, Haugesund, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03822299</url>
  </study>
  <study rank="316">
    <nct_id>NCT01529567</nct_id>
    <title>Cognitive Behavioral Therapy With Our Without Exposure Therapy for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive Behavioral Therapy without exposure</intervention>
      <intervention type="Behavioral">Cognitive Behavioral Therapy with exposure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gastrointestinal symptom rating scale</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Quality of Life Instrument (IBS-QOL)</outcome_measure>
      <outcome_measure>Visceral Sensitivity Index (VSI)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>311</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-0</other_id>
    </other_ids>
    <start_date>November 2011</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>February 9, 2012</study_first_posted>
    <last_update_posted>February 15, 2013</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01529567</url>
  </study>
  <study rank="317">
    <nct_id>NCT00806104</nct_id>
    <title>Fructo-oligosaccharides and Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Fructo-oligosaccharides</intervention>
      <intervention type="Dietary Supplement">Maltodextrins</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>rectal sensitivity</outcome_measure>
      <outcome_measure>taxonomic composition of intestinal microbiota</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beghin-Meiji</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>FOS_QLV2</other_id>
    </other_ids>
    <start_date>March 2009</start_date>
    <primary_completion_date>July 2010</primary_completion_date>
    <completion_date>December 2010</completion_date>
    <study_first_posted>December 10, 2008</study_first_posted>
    <last_update_posted>January 17, 2011</last_update_posted>
    <locations>
      <location>CHU Clermont Ferrand, Clermont-Ferrand, France</location>
      <location>Vall Hebron Hospital, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00806104</url>
  </study>
  <study rank="318">
    <nct_id>NCT01268709</nct_id>
    <title>Effect of Doxepin and Nortriptyline on Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Doxepin</intervention>
      <intervention type="Drug">Nortriptyline</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Qom University of Medical Sciences</lead_sponsor>
      <collaborator>Young Researchers Club</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>YRC-1246</other_id>
    </other_ids>
    <study_first_posted>December 31, 2010</study_first_posted>
    <last_update_posted>December 31, 2010</last_update_posted>
    <locations>
      <location>Gastrointestinal Research center,Beheshti Hospital, Qom, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01268709</url>
  </study>
  <study rank="319">
    <nct_id>NCT03664531</nct_id>
    <title>Dietary Triggers of Gastrointestinal Symptoms in IBS Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Purified gluten</intervention>
      <intervention type="Other">Non-purified gluten (containing ATIs)</intervention>
      <intervention type="Other">Nocebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome (IBS) symptoms</outcome_measure>
      <outcome_measure>General gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Orocecal transit</outcome_measure>
      <outcome_measure>Anti-gliadin antibody (AGA) levels</outcome_measure>
      <outcome_measure>Gut microbiota profiles</outcome_measure>
      <outcome_measure>Genetic predisposition for celiac disease</outcome_measure>
      <outcome_measure>Depression, anxiety and stress</outcome_measure>
      <outcome_measure>Somatic symptoms</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Gluten levels in stool</outcome_measure>
      <outcome_measure>Diet assessment</outcome_measure>
      <outcome_measure>IBS symptom duration</outcome_measure>
      <outcome_measure>Systemic immune reactivity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>McMaster University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>Diet in IBS</other_id>
    </other_ids>
    <start_date>January 1, 2019</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>February 2021</completion_date>
    <study_first_posted>September 10, 2018</study_first_posted>
    <last_update_posted>May 15, 2019</last_update_posted>
    <locations>
      <location>McMaster University Medical Centre, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03664531</url>
  </study>
  <study rank="320">
    <nct_id>NCT03729622</nct_id>
    <title>Carbohydrate Reduction and Impact on Gastrointestinal System</title>
    <acronym>CRAIGS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low FODMAP Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate symptom relief between cases and controls</outcome_measure>
      <outcome_measure>Changes in colonic volume between cases and controls from baseline</outcome_measure>
      <outcome_measure>Changes in fermentation between cases and controls</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>King's College London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>15081</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>July 2017</primary_completion_date>
    <completion_date>August 2017</completion_date>
    <study_first_posted>November 2, 2018</study_first_posted>
    <last_update_posted>November 2, 2018</last_update_posted>
    <locations>
      <location>Nottingham Digestive Diseases Centre, Nottingham, Nottinghamshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03729622</url>
  </study>
  <study rank="321">
    <nct_id>NCT01483287</nct_id>
    <title>The Effects of Added Enzyme α-Galactosidase at a Carbohydrate-rich Meal in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Alpha-Galactosidase</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in symptoms</outcome_measure>
      <outcome_measure>Changes in expiration air</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Nogasin</other_id>
    </other_ids>
    <start_date>November 2011</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>August 2013</completion_date>
    <study_first_posted>December 1, 2011</study_first_posted>
    <last_update_posted>November 18, 2014</last_update_posted>
    <locations>
      <location>Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01483287</url>
  </study>
  <study rank="322">
    <nct_id>NCT03269032</nct_id>
    <title>Mediterranean Diet and the Gut Microbiome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">American Diet</intervention>
      <intervention type="Other">Mediterranean-style Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phase 1- Change in predominant enterotypes and diversity of fecal microbiota</outcome_measure>
      <outcome_measure>Phase 2-Change in predominant enterotypes and diversity of fecal microbiota</outcome_measure>
      <outcome_measure>Changes in plasma inflammatory marker - Erythrocyte sedimentation rate (ESR)</outcome_measure>
      <outcome_measure>Changes in plasma inflammatory marker - C-reactive protein (CPR)</outcome_measure>
      <outcome_measure>Changes in IBS Symptom Severity Scores</outcome_measure>
      <outcome_measure>Changes in Hospital Anxiety and Depression Scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wake Forest University Health Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00039422</other_id>
    </other_ids>
    <start_date>October 10, 2017</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 31, 2017</study_first_posted>
    <last_update_posted>December 3, 2018</last_update_posted>
    <locations>
      <location>Wake Forest Baptist Heath, Winston-Salem, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03269032</url>
  </study>
  <study rank="323">
    <nct_id>NCT02550704</nct_id>
    <title>Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients</title>
    <acronym>SIIMPA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Occludin level expression in left colonic biopsies</outcome_measure>
      <outcome_measure>Faecal calprotectin level</outcome_measure>
      <outcome_measure>Claudin level expression in left colonic biopsies</outcome_measure>
      <outcome_measure>Zonula Occludens (ZO)-1 level expression</outcome_measure>
      <outcome_measure>Pression pain threshold by rectal barostat</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Abdominal symptoms</outcome_measure>
      <outcome_measure>Anxiety and depression level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Rouen</lead_sponsor>
      <collaborator>Société Nationale Française de Gastroentérologie</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015/079/HP</other_id>
    </other_ids>
    <start_date>May 20, 2016</start_date>
    <primary_completion_date>October 2019</primary_completion_date>
    <completion_date>May 20, 2020</completion_date>
    <study_first_posted>September 15, 2015</study_first_posted>
    <last_update_posted>May 28, 2018</last_update_posted>
    <locations>
      <location>Rouen University Hospital, Rouen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02550704</url>
  </study>
  <study rank="324">
    <nct_id>NCT00730171</nct_id>
    <title>An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
      <condition>Chronic Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1743</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-305</other_id>
    </other_ids>
    <start_date>September 2008</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <completion_date>March 2012</completion_date>
    <study_first_posted>August 8, 2008</study_first_posted>
    <results_first_posted>February 16, 2018</results_first_posted>
    <last_update_posted>February 16, 2018</last_update_posted>
    <locations>
      <location>Ironwood Investigational Site, Birmingham, Alabama, United States</location>
      <location>Ironwood Investigational Site, Huntsville, Alabama, United States</location>
      <location>Ironwood Investigational Site, Chandler, Arizona, United States</location>
      <location>Ironwood Investigational Site, Phoenix, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tucson, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tucson, Arizona, United States</location>
      <location>Ironwood Investigational Site, Tucson, Arizona, United States</location>
      <location>Ironwood Investigational Site, Sherwood, Arkansas, United States</location>
      <location>Ironwood Investigational Site, Anaheim, California, United States</location>
      <location>Ironwood Investigational Site, Chula Vista, California, United States</location>
      <location>Ironwood Investigational Site, Encinitas, California, United States</location>
      <location>Ironwood Investigational Site, Garden Grove, California, United States</location>
      <location>Ironwood Investigational Site, Laguna Hills, California, United States</location>
      <location>Ironwood Investigational Site, Los Angeles, California, United States</location>
      <location>Ironwood Investigational Site, Orange, California, United States</location>
      <location>Ironwood Investigational Site, Sacramento, California, United States</location>
      <location>Ironwood Investigational Site, San Carlos, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, San Diego, California, United States</location>
      <location>Ironwood Investigational Site, Colorado Springs, Colorado, United States</location>
      <location>Ironwood Investigational Site, Bristol, Connecticut, United States</location>
      <location>Ironwood Investigational Site, Boynton Beach, Florida, United States</location>
      <location>Ironwood Investigational Site, Hollywood, Florida, United States</location>
      <location>Ironwood Investigational Site, Inverness, Florida, United States</location>
      <location>Ironwood Investigational Site, Jacksonville, Florida, United States</location>
      <location>Ironwood Investigational Site, Jacksonville, Florida, United States</location>
      <location>Ironwood Investigational Site, Lauderdale Lakes, Florida, United States</location>
      <location>Ironwood Investigational Site, Miami, Florida, United States</location>
      <location>Ironwood Investigational Site, Pinellas Park, Florida, United States</location>
      <location>Ironwood Investigational Site, Port Orange, Florida, United States</location>
      <location>Ironwood Investigational Site, Tampa, Florida, United States</location>
      <location>Ironwood Investigational Site, Newnan, Georgia, United States</location>
      <location>Ironwood Investigational Site, Peoria, Illinois, United States</location>
      <location>Ironwood Investigational Site, Anderson, Indiana, United States</location>
      <location>Ironwood Investigational Site, Clive, Iowa, United States</location>
      <location>Ironwood Investigational Site, Davenport, Iowa, United States</location>
      <location>Ironwood Investigational Site, Mission, Kansas, United States</location>
      <location>Ironwood Investigational Site, Overland Park, Kansas, United States</location>
      <location>Ironwood Investigational Site, Topeka, Kansas, United States</location>
      <location>Ironwood Investigational Site, Baton Rouge, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Metairie, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Monroe, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Shreveport, Louisiana, United States</location>
      <location>Ironwood Investigational Site, Annapolis, Maryland, United States</location>
      <location>Ironwood Investigational Site, Baltimore, Maryland, United States</location>
      <location>Ironwood Investigational Site, Hollywood, Maryland, United States</location>
      <location>Ironwood Investigational Site, Laurel, Maryland, United States</location>
      <location>Ironwood Investigational Site, Chesterfield, Michigan, United States</location>
      <location>Ironwood Investigational Site, Traverse City, Michigan, United States</location>
      <location>Ironwood Investigational Site, Troy, Michigan, United States</location>
      <location>Ironwood Investigational Site, Plymouth, Minnesota, United States</location>
      <location>Ironwood Investigational Site, Jackson, Mississippi, United States</location>
      <location>Ironwood Investigational Site, Tupelo, Mississippi, United States</location>
      <location>Ironwood Investigational Site, Jefferson City, Missouri, United States</location>
      <location>Ironwood Investigational Site, Henderson, Nevada, United States</location>
      <location>Ironwood Investigational Site, Las Vegas, Nevada, United States</location>
      <location>Ironwood Investigational Site, Cedar Knolls, New Jersey, United States</location>
      <location>Ironwood Investigational Site, Marlton, New Jersey, United States</location>
      <location>Ironwood Investigational Site, Ocean City, New Jersey, United States</location>
      <location>Ironwood Investigational Site, Albuquerque, New Mexico, United States</location>
      <location>Ironwood Investigational Site, Mineola, New York, United States</location>
      <location>Ironwood Investigational Site, Pittsford, New York, United States</location>
      <location>Ironwood Investigational Site, Asheboro, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Asheville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Chapel Hill, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Charlotte, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Greensboro, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Harrisburg, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Hickory, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Huntersville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Jacksonville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, New Bern, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Statesville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Summerville, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Wilmington, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>Ironwood Investigational Site, Beachwood, Ohio, United States</location>
      <location>Ironwood Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Ironwood Investigational Site, Cincinnati, Ohio, United States</location>
      <location>Ironwood Investigational Site, Dayton, Ohio, United States</location>
      <location>Ironwood Investigational Site, Mentor, Ohio, United States</location>
      <location>Ironwood Investigational Site, Sylvania, Ohio, United States</location>
      <location>Ironwood Investigational Site, Wadsworth, Ohio, United States</location>
      <location>Ironwood Investigational Site, Zanesville, Ohio, United States</location>
      <location>Ironwood Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>Ironwood Investigational Site, Yukon, Oklahoma, United States</location>
      <location>Ironwood Investigational Site, Lancaster, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Lancaster, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Levittown, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Pittsburgh, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Sellersville, Pennsylvania, United States</location>
      <location>Ironwood Investigational Site, Anderson, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Charleston, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Simpsonville, South Carolina, United States</location>
      <location>Ironwood Investigational Site, Bristol, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Chattanooga, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Germantown, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Kingsport, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Nashville, Tennessee, United States</location>
      <location>Ironwood Investigational Site, Beaumont, Texas, United States</location>
      <location>Ironwood Investigational Site, El Paso, Texas, United States</location>
      <location>Ironwood Investigational Site, Fort Worth, Texas, United States</location>
      <location>Ironwood Investigational Site, Houston, Texas, United States</location>
      <location>Ironwood Investigational Site, Irving, Texas, United States</location>
      <location>Ironwood Investigational Site, Longview, Texas, United States</location>
      <location>Ironwood Investigational Site, San Antonio, Texas, United States</location>
      <location>Ironwood Investigational Site, Sugar Land, Texas, United States</location>
      <location>Ironwood Investigational Site, Ogden, Utah, United States</location>
      <location>Ironwood Investigational Site, Salt Lake City, Utah, United States</location>
      <location>Ironwood Investigational Site, Chesapeake, Virginia, United States</location>
      <location>Ironwood Investigational Site, Lynchburg, Virginia, United States</location>
      <location>Ironwood Investigational Site, Spokane, Washington, United States</location>
      <location>Ironwood Investigational Site, Vancouver, Washington, United States</location>
      <location>Ironwood Investigational Site, La Crosse, Wisconsin, United States</location>
      <location>Ironwood Investigational Site, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00730171</url>
  </study>
  <study rank="325">
    <nct_id>NCT03459482</nct_id>
    <title>Endpoint Determination Study Protocol</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Food Elimination Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the IBS-API - Abdominal Pain Intensity. The IBS-API is being assessed daily from enrollment (baseline) to study completion; total 10 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Biomerica</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>EPT-InF24-001</other_id>
    </other_ids>
    <start_date>June 21, 2018</start_date>
    <primary_completion_date>June 2019</primary_completion_date>
    <completion_date>June 2019</completion_date>
    <study_first_posted>March 9, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>University of Michigan Health System, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03459482</url>
  </study>
  <study rank="326">
    <nct_id>NCT02847481</nct_id>
    <title>A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">fecal microbiota transplantation</intervention>
      <intervention type="Drug">placebo fecal microbiota transplantation</intervention>
      <intervention type="Procedure">FMT with antibiotic pre-treatment (v1)</intervention>
      <intervention type="Procedure">FMT with antibiotic pre-treatment (v2)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>stable engraftment of donor microbiota</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
      <collaborator>OpenBiome</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015P000211</other_id>
    </other_ids>
    <start_date>May 2016</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>July 28, 2016</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02847481</url>
  </study>
  <study rank="327">
    <nct_id>NCT01088971</nct_id>
    <title>Effect of Duolac 7S Administration on Improving Symptom in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Duolac7S</intervention>
      <intervention type="Dietary Supplement">starch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The improvement of IBS symptoms</outcome_measure>
      <outcome_measure>Changes in fecal microflora</outcome_measure>
      <outcome_measure>Changes of biochemical marker</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cell Biotech Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CellBiotech</other_id>
    </other_ids>
    <start_date>October 2009</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>March 18, 2010</study_first_posted>
    <last_update_posted>December 23, 2011</last_update_posted>
    <locations>
      <location>Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01088971</url>
  </study>
  <study rank="328">
    <nct_id>NCT02973542</nct_id>
    <title>Ethosuximide to Treat IBS</title>
    <acronym>IBSET</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ethosuximide</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>30% reduction in abdominal pain</outcome_measure>
      <outcome_measure>Score of 4 or 5 on the SGA scale</outcome_measure>
      <outcome_measure>Monthly assessment of abdominal pain</outcome_measure>
      <outcome_measure>Monthly assessment of score of Bristol scale</outcome_measure>
      <outcome_measure>Monthly evaluation of GIQLI questionnaire</outcome_measure>
      <outcome_measure>Monthly evaluation of EQ-5D questionnaire</outcome_measure>
      <outcome_measure>Monthly evaluation of IBS-SSS questionnaire</outcome_measure>
      <outcome_measure>Monthly evaluation of SGA scale.</outcome_measure>
      <outcome_measure>Monthly evaluation of the use of analgesics</outcome_measure>
      <outcome_measure>Monthly evaluation of the use of antispasmodic</outcome_measure>
      <outcome_measure>Monthly evaluation of the use of regulators transit.</outcome_measure>
      <outcome_measure>Monthly evaluation of medical response rate</outcome_measure>
      <outcome_measure>Monthly evaluation of stop work related to IBS.</outcome_measure>
      <outcome_measure>Evaluation of the tolerance of ethosuximide throughout the study.</outcome_measure>
      <outcome_measure>Evaluation of the discontinuation rate study because of adverse events throughout the study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Clermont-Ferrand</lead_sponsor>
      <collaborator>SFETD (Socièté Française d’Etude et de Traitement de la Douleur)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>286</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHU-289</other_id>
      <other_id>2016-002110-42</other_id>
    </other_ids>
    <start_date>April 30, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>November 25, 2016</study_first_posted>
    <last_update_posted>May 7, 2018</last_update_posted>
    <locations>
      <location>CHU Clermont-Ferrand, Clermont-Ferrand, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02973542</url>
  </study>
  <study rank="329">
    <nct_id>NCT02822677</nct_id>
    <title>A Cross-sectional Study on IBS Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>the Distribution of IBS Subtype and Their CM Pattern in Hong Kong Population.</outcome_measure>
      <outcome_measure>the Host-gut Microbiota Metabolic Interactions Associated with IBS Subtypes</outcome_measure>
      <outcome_measure>the Relationship Between CM Pattern and Their Microbiota</outcome_measure>
      <outcome_measure>the relationship between CM pattern and metabolic profiling</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hong Kong Baptist University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>504</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>HKBUIBS2016</other_id>
    </other_ids>
    <start_date>July 7, 2016</start_date>
    <primary_completion_date>January 16, 2017</primary_completion_date>
    <completion_date>January 30, 2017</completion_date>
    <study_first_posted>July 4, 2016</study_first_posted>
    <last_update_posted>August 16, 2017</last_update_posted>
    <locations>
      <location>School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02822677</url>
  </study>
  <study rank="330">
    <nct_id>NCT03251625</nct_id>
    <title>Multi-strain Probiotic in the Management of IBS-D</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic Formula Capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The change in severity and frequency of abdominal pain during treatment with a multi-strain probiotic or placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>No. BSMMU/2015/1011</other_id>
    </other_ids>
    <start_date>April 2015</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>April 2016</completion_date>
    <study_first_posted>August 16, 2017</study_first_posted>
    <last_update_posted>February 2, 2018</last_update_posted>
    <locations/>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03251625/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03251625</url>
  </study>
  <study rank="331">
    <nct_id>NCT02706483</nct_id>
    <title>Long Term Safety Study of Plecanatide</title>
    <acronym>IBS-C</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plecanatide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with treatment related adverse events.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SP304203-06</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <completion_date>June 2017</completion_date>
    <study_first_posted>March 11, 2016</study_first_posted>
    <last_update_posted>May 31, 2019</last_update_posted>
    <locations>
      <location>Synergy Research Site, Athens, Alabama, United States</location>
      <location>Synergy Research Site, Birmingham, Alabama, United States</location>
      <location>Synergy Research Site, Dothan, Alabama, United States</location>
      <location>Synergy Research Site, Foley, Alabama, United States</location>
      <location>Synergy Research Site, Guntersville, Alabama, United States</location>
      <location>Synergy Research Site, Huntsville, Alabama, United States</location>
      <location>Synergy Research Site, Saraland, Alabama, United States</location>
      <location>Synergy Research Site, Chandler, Arizona, United States</location>
      <location>Synergy Research Site, Phoenix, Arizona, United States</location>
      <location>Synergy Research Site, Surprise, Arizona, United States</location>
      <location>Synergy Research Site, Tucson, Arizona, United States</location>
      <location>Synergy Research Site, Conway, Arkansas, United States</location>
      <location>Synergy Research Site, Glendale, Arkansas, United States</location>
      <location>Synergy Research Site, Little Rock, Arkansas, United States</location>
      <location>Synergy Research Site, Artesia, California, United States</location>
      <location>Synergy Research Site, Canoga Park, California, United States</location>
      <location>Synergy Research Site, Carmichael, California, United States</location>
      <location>Synergy Research Site, Chula Vista, California, United States</location>
      <location>Synergy Research Site, Corona, California, United States</location>
      <location>Synergy Research Site, Costa Mesa, California, United States</location>
      <location>Synergy Research Site, El Cajon, California, United States</location>
      <location>Synergy Research Site, Encino, California, United States</location>
      <location>Synergy Research Site, Foothill Ranch, California, United States</location>
      <location>Synergy Research Site, Fountain Valley, California, United States</location>
      <location>Synergy Research Site, Garden Grove, California, United States</location>
      <location>Synergy Research Site, Huntington Beach, California, United States</location>
      <location>Synergy Research Site, La Mesa, California, United States</location>
      <location>Synergy Research Site, La Mirada, California, United States</location>
      <location>Synergy Research Site, Laguna Hills, California, United States</location>
      <location>Synergy Research Site, Lancaster, California, United States</location>
      <location>Synergy Research Site, Lomita, California, United States</location>
      <location>Synergy Research Site, Long Beach, California, United States</location>
      <location>Synergy Research Site, Los Angeles, California, United States</location>
      <location>Synergy Research Site, North Hollywood, California, United States</location>
      <location>Synergy Research Site, Northridge, California, United States</location>
      <location>Synergy Research Site, Orange, California, United States</location>
      <location>Synergy Research Site, Placentia, California, United States</location>
      <location>Synergy Research Site, Riverside, California, United States</location>
      <location>Synergy Research Site, San Bernardino, California, United States</location>
      <location>Synergy Research Site, San Diego, California, United States</location>
      <location>Synergy Research Site, San Marino, California, United States</location>
      <location>Synergy Research Site, Sherman Oaks, California, United States</location>
      <location>Synergy Research Site, Thousand Oaks, California, United States</location>
      <location>Synergy Research Site, Colorado Springs, Colorado, United States</location>
      <location>Synergy Research Site, Denver, Colorado, United States</location>
      <location>Synergy Research Site, Lafayette, Colorado, United States</location>
      <location>Synergy Research Site, Bristol, Connecticut, United States</location>
      <location>Synergy Research Site, Hamden, Connecticut, United States</location>
      <location>Synergy Research Site, Atlantis, Florida, United States</location>
      <location>Synergy Research Site, Boca Raton, Florida, United States</location>
      <location>Synergy Research Site, Boynton Beach, Florida, United States</location>
      <location>Synergy Research Site, Bradenton, Florida, United States</location>
      <location>Synergy Research Site, Brandon, Florida, United States</location>
      <location>Synergy Research Site, Brooksville, Florida, United States</location>
      <location>Synergy Research Site, Clearwater, Florida, United States</location>
      <location>Synergy Research Site, Cutler Bay, Florida, United States</location>
      <location>Synergy Research Site, DeLand, Florida, United States</location>
      <location>Synergy Research Site, Fort Lauderdale, Florida, United States</location>
      <location>Synergy Research Site, Hialeah, Florida, United States</location>
      <location>Synergy Research Site, Homestead, Florida, United States</location>
      <location>Synergy Research Site, Inverness, Florida, United States</location>
      <location>Synergy Research Site, Jacksonville, Florida, United States</location>
      <location>Synergy Research Site, Lauderdale Lakes, Florida, United States</location>
      <location>Synergy Research Site, Miami Lakes, Florida, United States</location>
      <location>Synergy Research Site, Miami Springs, Florida, United States</location>
      <location>Synergy Research Site, Miami, Florida, United States</location>
      <location>Synergy Research Site, Naples, Florida, United States</location>
      <location>Synergy Research Site, North Miami Beach, Florida, United States</location>
      <location>Synergy Research Site, Orange Park, Florida, United States</location>
      <location>Synergy Research Site, Orlando, Florida, United States</location>
      <location>Synergy Research Site, Ormond Beach, Florida, United States</location>
      <location>Synergy Research Site, Oviedo, Florida, United States</location>
      <location>Synergy Research Site, Pembroke Pines, Florida, United States</location>
      <location>Synergy Research Site, Pinellas Park, Florida, United States</location>
      <location>Synergy Research Site, Port Orange, Florida, United States</location>
      <location>Synergy Research Site, Saint Petersburg, Florida, United States</location>
      <location>Synergy Research Site, Tamarac, Florida, United States</location>
      <location>Synergy Research Site, Tampa, Florida, United States</location>
      <location>Synergy Research Site, Atlanta, Georgia, United States</location>
      <location>Synergy Research Site, Marietta, Georgia, United States</location>
      <location>Synergy Research Site, Snellville, Georgia, United States</location>
      <location>Synergy Research Site, Blackfoot, Idaho, United States</location>
      <location>Synergy Research Site, Boise, Idaho, United States</location>
      <location>Synergy Research Site, Meridian, Idaho, United States</location>
      <location>Synergy Research Site, Blue Island, Illinois, United States</location>
      <location>Synergy Research Site, Chicago, Illinois, United States</location>
      <location>Synergy Research Site, Evanston, Illinois, United States</location>
      <location>Synergy Research Site, Evergreen Park, Illinois, United States</location>
      <location>Synergy Research Site, Hoffman Estates, Illinois, United States</location>
      <location>Synergy Research Site, Morton, Illinois, United States</location>
      <location>Synergy Research Site, Oak Lawn, Illinois, United States</location>
      <location>Synergy Research Site, Schaumburg, Illinois, United States</location>
      <location>Synergy Research Site, Brownsburg, Indiana, United States</location>
      <location>Synergy Research Site, Indianapolis, Indiana, United States</location>
      <location>Synergy Research Site, Topeka, Kansas, United States</location>
      <location>Synergy Research Site, Wichita, Kansas, United States</location>
      <location>Synergy Research Site, Madisonville, Kentucky, United States</location>
      <location>Synergy Research Site, Owensboro, Kentucky, United States</location>
      <location>Synergy Research Site, Baton Rouge, Louisiana, United States</location>
      <location>Synergy Research Site, Crowley, Louisiana, United States</location>
      <location>Synergy Research Site, Mandeville, Louisiana, United States</location>
      <location>Synergy Research Site, Marrero, Louisiana, United States</location>
      <location>Synergy Research Site, Metairie, Louisiana, United States</location>
      <location>Synergy Research Site, New Orleans, Louisiana, United States</location>
      <location>Synergy Research Site, Shreveport, Louisiana, United States</location>
      <location>Synergy Research Site, Annapolis, Maryland, United States</location>
      <location>Synergy Research Site, Baltimore, Maryland, United States</location>
      <location>Synergy Research Site, Hagerstown, Maryland, United States</location>
      <location>Synergy Research Site, Oxon Hill, Maryland, United States</location>
      <location>Synergy Research Site, Marlborough, Massachusetts, United States</location>
      <location>Synergy Research Site, Chesterfield, Michigan, United States</location>
      <location>Synergy Research Site, Flint, Michigan, United States</location>
      <location>Synergy Research Site, Wyoming, Michigan, United States</location>
      <location>Synergy Research Site, Jackson, Mississippi, United States</location>
      <location>Synergy Research Site, Port Gibson, Mississippi, United States</location>
      <location>Synergy Research Site, Chesterfield, Missouri, United States</location>
      <location>Synergy Research Site, Hazelwood, Missouri, United States</location>
      <location>Synergy Research Site, Saint Louis, Missouri, United States</location>
      <location>Synergy Research Site, Missoula, Montana, United States</location>
      <location>Synergy Research Site, Omaha, Nebraska, United States</location>
      <location>Synergy Research Site, Marlton, New Jersey, United States</location>
      <location>Synergy Research Site, Albuquerque, New Mexico, United States</location>
      <location>Synergy Research Site, Brooklyn, New York, United States</location>
      <location>Synergy Research Site, Great Neck, New York, United States</location>
      <location>Synergy Research Site, Hopewell Junction, New York, United States</location>
      <location>Synergy Research Site, Kew Gardens, New York, United States</location>
      <location>Synergy Research Site, New Windsor, New York, United States</location>
      <location>Synergy Research Site, New York, New York, United States</location>
      <location>Synergy Research Site, North Massapequa, New York, United States</location>
      <location>Synergy Research Site, Poughkeepsie, New York, United States</location>
      <location>Synergy Research Site, Asheboro, North Carolina, United States</location>
      <location>Synergy Research Site, Cary, North Carolina, United States</location>
      <location>Synergy Research Site., Charlotte, North Carolina, United States</location>
      <location>Synergy Research Site, Charlotte, North Carolina, United States</location>
      <location>Synergy Research Site, Davidson, North Carolina, United States</location>
      <location>Synergy Research Site, Fayetteville, North Carolina, United States</location>
      <location>Synergy Research Site, High Point, North Carolina, United States</location>
      <location>Synergy Research Site, Jacksonville, North Carolina, United States</location>
      <location>Synergy Research Site, Kinston, North Carolina, United States</location>
      <location>Synergy Research Site, Raleigh, North Carolina, United States</location>
      <location>Synergy Research Site, Salisbury, North Carolina, United States</location>
      <location>Synergy Research Site, Wilmington, North Carolina, United States</location>
      <location>Synergy Research Site, Winston-Salem, North Carolina, United States</location>
      <location>Synergy Research Site, Fargo, North Dakota, United States</location>
      <location>Synergy Research Site, Beavercreek, Ohio, United States</location>
      <location>Synergy Research Site, Cincinnati, Ohio, United States</location>
      <location>Synergy Research Site, Columbus, Ohio, United States</location>
      <location>Synergy Research Site, Dayton, Ohio, United States</location>
      <location>Synergy Research Site, Englewood, Ohio, United States</location>
      <location>Synergy Research Site, Kettering, Ohio, United States</location>
      <location>Synergy Research Site, Mentor, Ohio, United States</location>
      <location>Synergy Research Site, Middleburg Heights, Ohio, United States</location>
      <location>Synergy Research Site, Oklahoma City, Oklahoma, United States</location>
      <location>Synergy Research Site, Portland, Oregon, United States</location>
      <location>Synergy Research Site, Lansdale, Pennsylvania, United States</location>
      <location>Synergy Research Site, Levittown, Pennsylvania, United States</location>
      <location>Synergy Research Site, Philadelphia, Pennsylvania, United States</location>
      <location>Synergy Research Site, Smithfield, Pennsylvania, United States</location>
      <location>Synergy Research Site, Anderson, South Carolina, United States</location>
      <location>Synergy Research Site, Gaffney, South Carolina, United States</location>
      <location>Synergy Research Site, Greer, South Carolina, United States</location>
      <location>Synergy Research Site, Rapid City, South Dakota, United States</location>
      <location>Synergy Research Site, Athens, Tennessee, United States</location>
      <location>Synergy Research Site, Chattanooga, Tennessee, United States</location>
      <location>Synergy Research Site, Fayetteville, Tennessee, United States</location>
      <location>Synergy Research Site, Franklin, Tennessee, United States</location>
      <location>Synergy Research Site, Hermitage, Tennessee, United States</location>
      <location>Synergy Research Site, Jackson, Tennessee, United States</location>
      <location>Synergy Research Site, Kingsport, Tennessee, United States</location>
      <location>Synergy Research Site, Knoxville, Tennessee, United States</location>
      <location>Synergy Research Site, Memphis, Tennessee, United States</location>
      <location>Synergy Research Site, Nashville, Tennessee, United States</location>
      <location>Synergy Research Site, Austin, Texas, United States</location>
      <location>Synergy Research Site, Beaumont, Texas, United States</location>
      <location>Synergy Research Site, Carrollton, Texas, United States</location>
      <location>Synergy Research Site, Channelview, Texas, United States</location>
      <location>Synergy Research Site, Dallas, Texas, United States</location>
      <location>Synergy Research Site, Houston, Texas, United States</location>
      <location>Synergy Research Site, Humble, Texas, United States</location>
      <location>Synergy Research Site, Lampasas, Texas, United States</location>
      <location>Synergy Research Site, McKinney, Texas, United States</location>
      <location>Synergy Research Site, Missouri City, Texas, United States</location>
      <location>Synergy Research Site, Plano, Texas, United States</location>
      <location>Synergy Research Site, Port Arthur, Texas, United States</location>
      <location>Synergy Research Site, San Antonio, Texas, United States</location>
      <location>Synergy Research Site, Sugar Land, Texas, United States</location>
      <location>Synergy Research Site, Ogden, Utah, United States</location>
      <location>Synergy Research Site, Orem, Utah, United States</location>
      <location>Synergy Research Site, Saint George, Utah, United States</location>
      <location>Synergy Research Site, Sandy, Utah, United States</location>
      <location>Synergy Research Site, Charlottesville, Virginia, United States</location>
      <location>Synergy Research Site, Chesapeake, Virginia, United States</location>
      <location>Synergy Research Site, Fairfax, Virginia, United States</location>
      <location>Synergy Research Site, Lynchburg, Virginia, United States</location>
      <location>Synergy Research Site, Newport News, Virginia, United States</location>
      <location>Synergy Research Site, Norfolk, Virginia, United States</location>
      <location>Synergy Research Site, Richmond, Virginia, United States</location>
      <location>Synergy Research Site, Bellevue, Washington, United States</location>
      <location>Synergy Research Site, Spokane, Washington, United States</location>
      <location>Synergy Research Site, Charleston, West Virginia, United States</location>
      <location>Synergy Research Site, Kingwood, West Virginia, United States</location>
      <location>Synergy Research Site, Morgantown, West Virginia, United States</location>
      <location>Synergy Research Site, La Crosse, Wisconsin, United States</location>
      <location>Synergy Research Site, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02706483</url>
  </study>
  <study rank="332">
    <nct_id>NCT03763175</nct_id>
    <title>Efficacy and Safety of SYN-010 in IBS-C</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SYN-010 21 mg</intervention>
      <intervention type="Drug">SYN-010 42 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in the weekly average number of completely spontaneous bowel movements (CSBM) during the 12-week Treatment Period</outcome_measure>
      <outcome_measure>Proportion of overall responders during the 12-week Treatment Period</outcome_measure>
      <outcome_measure>Proportion of overall stool frequency responders during the 12-week Treatment Period</outcome_measure>
      <outcome_measure>Proportion of overall abdominal pain intensity responders during the 12-week Treatment Period</outcome_measure>
      <outcome_measure>Proportion of overall bloating responders during the 12-week Treatment Period</outcome_measure>
      <outcome_measure>Proportion of patients using rescue medication</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
      <collaborator>Synthetic Biologics Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>54792</other_id>
    </other_ids>
    <start_date>December 24, 2018</start_date>
    <primary_completion_date>January 1, 2020</primary_completion_date>
    <completion_date>January 1, 2020</completion_date>
    <study_first_posted>December 4, 2018</study_first_posted>
    <last_update_posted>April 18, 2019</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03763175</url>
  </study>
  <study rank="333">
    <nct_id>NCT02653937</nct_id>
    <title>The Effect of Shigyakusan Used for IBS and MUPS Diagnosed by Abdominal N Line Tenderness</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tsumura's shigyakusan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants who were suffered from IBS or MUPS, prescribed shigyakusan and improved.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nakatani Clinic</lead_sponsor>
      <collaborator>Wakayama Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>001</other_id>
    </other_ids>
    <start_date>March 2013</start_date>
    <primary_completion_date>February 2015</primary_completion_date>
    <completion_date>March 2015</completion_date>
    <study_first_posted>January 13, 2016</study_first_posted>
    <last_update_posted>January 13, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02653937</url>
  </study>
  <study rank="334">
    <nct_id>NCT00738920</nct_id>
    <title>Self Administered Cognitive Behavior Therapy for Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Self Administered Cognitive Behavior Therapy</intervention>
      <intervention type="Behavioral">Therapist Administered Cognitive Behavior Therapy</intervention>
      <intervention type="Behavioral">Behavioral Education and Supportive Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global improvement of IBS symptoms (CGI)</outcome_measure>
      <outcome_measure>Quality of life (SF-36; IBS-QOL; Psychological distress (BSI); IBS Symptom Severity (IBSSSS); Coping (CSQ), Adverse Events; Cost; Health Care utilization; Patient Satisfaction (CSQ; Stool consistency (BSFS); Stool frequency; Abdominal Pain;</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>State University of New York at Buffalo</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>Feinberg School of Medicine, Northwestern University</collaborator>
      <collaborator>Frontier Science &amp; Technology Research Foundation, Inc.</collaborator>
      <collaborator>RTI International</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>462</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DK77738</other_id>
      <other_id>U01DK077738</other_id>
    </other_ids>
    <start_date>August 2010</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>August 31, 2017</completion_date>
    <study_first_posted>August 21, 2008</study_first_posted>
    <last_update_posted>October 4, 2017</last_update_posted>
    <locations>
      <location>Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States</location>
      <location>University at Buffalo School of Medicine, Buffalo, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00738920</url>
  </study>
  <study rank="335">
    <nct_id>NCT00731003</nct_id>
    <title>The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Oxitriptan</intervention>
      <intervention type="Other">Acute tryptophan depletion</intervention>
      <intervention type="Other">Amino acid drink with tryptophan</intervention>
      <intervention type="Drug">Placebo capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary aim is to assess intestinal permeability under altered serotonergic conditions by means of sugar permeability test</outcome_measure>
      <outcome_measure>To assess tight junction functionality and serotonin metabolism To assess visceral hypersensitivity under altered serotoninergic conditions To examine biopsy specimens for serotonergic and intestinal permeability parameters in ex vivo circumstances</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>Top Institute Food and Nutrition</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>MEC 08-2-070</other_id>
    </other_ids>
    <start_date>April 2009</start_date>
    <primary_completion_date>May 2011</primary_completion_date>
    <completion_date>May 2011</completion_date>
    <study_first_posted>August 8, 2008</study_first_posted>
    <last_update_posted>November 13, 2014</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center+, Maastricht, Limburg, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00731003</url>
  </study>
  <study rank="336">
    <nct_id>NCT02163213</nct_id>
    <title>Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Serum-derived bovine immunoglobulin protein isolate (SBI)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in epithelial barrier function, and mucosal expression of barrier-associated genes</outcome_measure>
      <outcome_measure>Change in body measurements, amino acid metabolism, abdominal pain, and baseline stool frequency and consistency.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-002151</other_id>
    </other_ids>
    <start_date>June 2014</start_date>
    <primary_completion_date>November 1, 2016</primary_completion_date>
    <completion_date>November 2, 2016</completion_date>
    <study_first_posted>June 13, 2014</study_first_posted>
    <last_update_posted>October 18, 2017</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02163213</url>
  </study>
  <study rank="337">
    <nct_id>NCT00376896</nct_id>
    <title>Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GW876008 200mcg</intervention>
      <intervention type="Drug">GW876008 20mcg</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Signal reductions in the amygdala during viewing of emotional faces and during abdominal pain threat as measured by the fMRI.</outcome_measure>
      <outcome_measure>Questionnaires to assess IBS symptoms and anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CRI103147</other_id>
    </other_ids>
    <start_date>November 2006</start_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <completion_date>October 2008</completion_date>
    <study_first_posted>September 15, 2006</study_first_posted>
    <last_update_posted>May 16, 2017</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00376896</url>
  </study>
  <study rank="338">
    <nct_id>NCT02504060</nct_id>
    <title>Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Starch Placebo</intervention>
      <intervention type="Drug">N-acetyl-D-glucosamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain Intensity</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>General symptoms feel grading</outcome_measure>
      <outcome_measure>defecation frequency</outcome_measure>
      <outcome_measure>abdominal distension</outcome_measure>
      <outcome_measure>Defecation urgency</outcome_measure>
      <outcome_measure>life quality parameters</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Third Military Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>720</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMMUBC</other_id>
      <other_id>dongying</other_id>
    </other_ids>
    <start_date>June 2015</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>July 2017</completion_date>
    <study_first_posted>July 21, 2015</study_first_posted>
    <last_update_posted>July 21, 2015</last_update_posted>
    <locations>
      <location>Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02504060</url>
  </study>
  <study rank="339">
    <nct_id>NCT02204891</nct_id>
    <title>Probiotics in Intestinal Bacterial Overgrowth</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotics in SIBO</intervention>
      <intervention type="Dietary Supplement">Probiotics</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>• The efficacy of probiotics in improvement of symptoms of IBS in patients with SIBO compared to their efficacy in patients with IBS without SIBO.</outcome_measure>
      <outcome_measure>• The efficacy of probiotics in symptoms of IBS in patients with SIBO compared to their efficacy in patients with IBS without SIBO.</outcome_measure>
      <outcome_measure>The efficacy of probiotics in specific symptoms of IBS both visits 2 and 3.</outcome_measure>
      <outcome_measure>• The importance of the inflammation cascade in the pathogenesis of SIBO-related IBS.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Athens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LACTO01</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <completion_date>September 2016</completion_date>
    <study_first_posted>July 31, 2014</study_first_posted>
    <last_update_posted>March 20, 2017</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, ATTIKON University Hospital, Athens, Attiki, Greece</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02204891</url>
  </study>
  <study rank="340">
    <nct_id>NCT00441766</nct_id>
    <title>Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome Pain</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AGN 203818</intervention>
      <intervention type="Drug">AGN 203818</intervention>
      <intervention type="Drug">AGN 203818</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Mean Highest-Average-Pain Score at Week 4</outcome_measure>
      <outcome_measure>Percentage of Patients Who Rated Their Condition as Improved on the Subject Global Impression of Change (SGIC) at Week 4</outcome_measure>
      <outcome_measure>Percentage of Patients Who Experienced Adequate Relief of Irritable Bowel Syndrome (IBS) Pain (AR-IBS) at Week 4</outcome_measure>
      <outcome_measure>Change From Baseline in Frequency of Bowel Movements at Week 4 Using the Bristol Stool Scale (BSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Allergan</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>213</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>203818-008</other_id>
    </other_ids>
    <start_date>March 2007</start_date>
    <primary_completion_date>February 2008</primary_completion_date>
    <completion_date>February 2008</completion_date>
    <study_first_posted>March 1, 2007</study_first_posted>
    <results_first_posted>January 20, 2012</results_first_posted>
    <last_update_posted>January 20, 2012</last_update_posted>
    <locations>
      <location>Orange, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00441766</url>
  </study>
  <study rank="341">
    <nct_id>NCT00067561</nct_id>
    <title>Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Alosetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events &amp; laboratory abnormalities.</outcome_measure>
      <outcome_measure>Comparison of treatment groups with respect to subject relief of IBS pain &amp; discomfort.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>702</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S3B30040</other_id>
    </other_ids>
    <start_date>June 2003</start_date>
    <primary_completion_date>January 2005</primary_completion_date>
    <completion_date>January 2005</completion_date>
    <study_first_posted>August 25, 2003</study_first_posted>
    <last_update_posted>April 16, 2015</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Birmingham, Alabama, United States</location>
      <location>GSK Investigational Site, Calera, Alabama, United States</location>
      <location>GSK Investigational Site, Tuscaloosa, Alabama, United States</location>
      <location>GSK Investigational Site, Phoenix, Arizona, United States</location>
      <location>GSK Investigational Site, Tucson, Arizona, United States</location>
      <location>GSK Investigational Site, Fayetteville, Arkansas, United States</location>
      <location>GSK Investigational Site, Chula Vista, California, United States</location>
      <location>GSK Investigational Site, Fountain Valley, California, United States</location>
      <location>GSK Investigational Site, Garden Grove, California, United States</location>
      <location>GSK Investigational Site, Lancaster, California, United States</location>
      <location>GSK Investigational Site, Los Angeles, California, United States</location>
      <location>GSK Investigational Site, Newport Beach, California, United States</location>
      <location>GSK Investigational Site, Rancho Cucamonga, California, United States</location>
      <location>GSK Investigational Site, Redlands, California, United States</location>
      <location>GSK Investigational Site, San Diego, California, United States</location>
      <location>GSK Investigational Site, San Diego, California, United States</location>
      <location>GSK Investigational Site, San Rafael, California, United States</location>
      <location>GSK Investigational Site, Santa Ana, California, United States</location>
      <location>GSK Investigational Site, Santa Ana, California, United States</location>
      <location>GSK Investigational Site, Upland, California, United States</location>
      <location>GSK Investigational Site, Vista, California, United States</location>
      <location>GSK Investigational Site, Yuba City, California, United States</location>
      <location>GSK Investigational Site, Boulder, Colorado, United States</location>
      <location>GSK Investigational Site, Colorado Springs, Colorado, United States</location>
      <location>GSK Investigational Site, Colorado Springs, Colorado, United States</location>
      <location>GSK Investigational Site, Englewood, Colorado, United States</location>
      <location>GSK Investigational Site, Wheat Ridge, Colorado, United States</location>
      <location>GSK Investigational Site, Manchester, Connecticut, United States</location>
      <location>GSK Investigational Site, Boca Raton, Florida, United States</location>
      <location>GSK Investigational Site, Boynton Beach, Florida, United States</location>
      <location>GSK Investigational Site, Boynton Beach, Florida, United States</location>
      <location>GSK Investigational Site, Coral Gables, Florida, United States</location>
      <location>GSK Investigational Site, Fort Myers, Florida, United States</location>
      <location>GSK Investigational Site, Fort Myers, Florida, United States</location>
      <location>GSK Investigational Site, Hialeah, Florida, United States</location>
      <location>GSK Investigational Site, Hollywood, Florida, United States</location>
      <location>GSK Investigational Site, Lake Worth, Florida, United States</location>
      <location>GSK Investigational Site, Longwood, Florida, United States</location>
      <location>GSK Investigational Site, Miami, Florida, United States</location>
      <location>GSK Investigational Site, Miami, Florida, United States</location>
      <location>GSK Investigational Site, Naples, Florida, United States</location>
      <location>GSK Investigational Site, New Port Richey, Florida, United States</location>
      <location>GSK Investigational Site, Ocala, Florida, United States</location>
      <location>GSK Investigational Site, Panama City, Florida, United States</location>
      <location>GSK Investigational Site, Sarasota, Florida, United States</location>
      <location>GSK Investigational Site, St. Petersburg, Florida, United States</location>
      <location>GSK Investigational Site, Tallahassee, Florida, United States</location>
      <location>GSK Investigational Site, Tampa, Florida, United States</location>
      <location>GSK Investigational Site, West Palm Beach, Florida, United States</location>
      <location>GSK Investigational Site, Zephyrhills, Florida, United States</location>
      <location>GSK Investigational Site, Atlanta, Georgia, United States</location>
      <location>GSK Investigational Site, Atlanta, Georgia, United States</location>
      <location>GSK Investigational Site, Atlanta, Georgia, United States</location>
      <location>GSK Investigational Site, Austell, Georgia, United States</location>
      <location>GSK Investigational Site, Decatur, Georgia, United States</location>
      <location>GSK Investigational Site, Marietta, Georgia, United States</location>
      <location>GSK Investigational Site, Martinez, Georgia, United States</location>
      <location>GSK Investigational Site, Savannah, Georgia, United States</location>
      <location>GSK Investigational Site, Peoria, Illinois, United States</location>
      <location>GSK Investigational Site, Riverside, Illinois, United States</location>
      <location>GSK Investigational Site, Indianapolis, Indiana, United States</location>
      <location>GSK Investigational Site, Indianapolis, Indiana, United States</location>
      <location>GSK Investigational Site, South Bend, Indiana, United States</location>
      <location>GSK Investigational Site, Overland Park, Kansas, United States</location>
      <location>GSK Investigational Site, Bowling Green, Kentucky, United States</location>
      <location>GSK Investigational Site, Louisville, Kentucky, United States</location>
      <location>GSK Investigational Site, Louisville, Kentucky, United States</location>
      <location>GSK Investigational Site, Madisonville, Kentucky, United States</location>
      <location>GSK Investigational Site, Davenport, Louisiana, United States</location>
      <location>GSK Investigational Site, Baltimore, Maryland, United States</location>
      <location>GSK Investigational Site, Laurel, Maryland, United States</location>
      <location>GSK Investigational Site, Silver Spring, Maryland, United States</location>
      <location>GSK Investigational Site, Silver Spring, Maryland, United States</location>
      <location>GSK Investigational Site, Towson, Maryland, United States</location>
      <location>GSK Investigational Site, Attleboro, Massachusetts, United States</location>
      <location>GSK Investigational Site, Boston, Massachusetts, United States</location>
      <location>GSK Investigational Site, Boston, Massachusetts, United States</location>
      <location>GSK Investigational Site, Ann Arbor, Michigan, United States</location>
      <location>GSK Investigational Site, Detroit, Michigan, United States</location>
      <location>GSK Investigational Site, Grand Rapids, Michigan, United States</location>
      <location>GSK Investigational Site, Oak Park, Michigan, United States</location>
      <location>GSK Investigational Site, St. Joseph, Michigan, United States</location>
      <location>GSK Investigational Site, Warren, Michigan, United States</location>
      <location>GSK Investigational Site, Chaska, Minnesota, United States</location>
      <location>GSK Investigational Site, St. Paul, Minnesota, United States</location>
      <location>GSK Investigational Site, Wentzville, Minnesota, United States</location>
      <location>GSK Investigational Site, Jackson, Mississippi, United States</location>
      <location>GSK Investigational Site, Jefferson City, Missouri, United States</location>
      <location>GSK Investigational Site, Jefferson City, Missouri, United States</location>
      <location>GSK Investigational Site, Kansas City, Missouri, United States</location>
      <location>GSK Investigational Site, Missoula, Montana, United States</location>
      <location>GSK Investigational Site, Lebanon, New Hampshire, United States</location>
      <location>GSK Investigational Site, Bloomfield, New Jersey, United States</location>
      <location>GSK Investigational Site, Egg Harbor Township, New Jersey, United States</location>
      <location>GSK Investigational Site, Ocean, New Jersey, United States</location>
      <location>GSK Investigational Site, Vineland, New Jersey, United States</location>
      <location>GSK Investigational Site, West Caldwell, New Jersey, United States</location>
      <location>GSK Investigational Site, Farmington, New Mexico, United States</location>
      <location>GSK Investigational Site, Bayshore, New York, United States</location>
      <location>GSK Investigational Site, Great Neck, New York, United States</location>
      <location>GSK Investigational Site, Merrick, New York, United States</location>
      <location>GSK Investigational Site, Rochester, New York, United States</location>
      <location>GSK Investigational Site, Stony Brook, New York, United States</location>
      <location>GSK Investigational Site, Syracuse, New York, United States</location>
      <location>GSK Investigational Site, Asheville, North Carolina, United States</location>
      <location>GSK Investigational Site, Cary, North Carolina, United States</location>
      <location>GSK Investigational Site, Chapel Hill, North Carolina, United States</location>
      <location>GSK Investigational Site, Charlotte, North Carolina, United States</location>
      <location>GSK Investigational Site, Fayetteville, North Carolina, United States</location>
      <location>GSK Investigational Site, Greenville, North Carolina, United States</location>
      <location>GSK Investigational Site, Hickory, North Carolina, United States</location>
      <location>GSK Investigational Site, High Point, North Carolina, United States</location>
      <location>GSK Investigational Site, Morehead City, North Carolina, United States</location>
      <location>GSK Investigational Site, Raleigh, North Carolina, United States</location>
      <location>GSK Investigational Site, Winston-Salem, North Carolina, United States</location>
      <location>GSK Investigational Site, Bismarck, North Dakota, United States</location>
      <location>GSK Investigational Site, Akron, Ohio, United States</location>
      <location>GSK Investigational Site, Beavercreek, Ohio, United States</location>
      <location>GSK Investigational Site, Cincinnati, Ohio, United States</location>
      <location>GSK Investigational Site, Cincinnati, Ohio, United States</location>
      <location>GSK Investigational Site, Cincinnati, Ohio, United States</location>
      <location>GSK Investigational Site, Cleveland, Ohio, United States</location>
      <location>GSK Investigational Site, Cleveland, Ohio, United States</location>
      <location>GSK Investigational Site, Columbus, Ohio, United States</location>
      <location>GSK Investigational Site, Dayton, Ohio, United States</location>
      <location>GSK Investigational Site, Kettering, Ohio, United States</location>
      <location>GSK Investigational Site, Lyndhurst, Ohio, United States</location>
      <location>GSK Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>GSK Investigational Site, Oklahoma City, Oklahoma, United States</location>
      <location>GSK Investigational Site, Tulsa, Oklahoma, United States</location>
      <location>GSK Investigational Site, Medford, Oregon, United States</location>
      <location>GSK Investigational Site, Altoona, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Fleetwood, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Hershey, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Lancaster, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Newtown, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Pittsburgh, Pennsylvania, United States</location>
      <location>GSK Investigational Site, Wyomissing, Pennsylvania, United States</location>
      <location>GSK Investigational Site, East Providence, Rhode Island, United States</location>
      <location>GSK Investigational Site, Columbia, South Carolina, United States</location>
      <location>GSK Investigational Site, Greenville, South Carolina, United States</location>
      <location>GSK Investigational Site, Simpsonville, South Carolina, United States</location>
      <location>GSK Investigational Site, Bristol, Tennessee, United States</location>
      <location>GSK Investigational Site, Kingsport, Tennessee, United States</location>
      <location>GSK Investigational Site, Memphis, Tennessee, United States</location>
      <location>GSK Investigational Site, Memphis, Tennessee, United States</location>
      <location>GSK Investigational Site, Murfreesboro, Tennessee, United States</location>
      <location>GSK Investigational Site, Nashville, Tennessee, United States</location>
      <location>GSK Investigational Site, Arlington, Texas, United States</location>
      <location>GSK Investigational Site, Austin, Texas, United States</location>
      <location>GSK Investigational Site, Corpus Christi, Texas, United States</location>
      <location>GSK Investigational Site, Dallas, Texas, United States</location>
      <location>GSK Investigational Site, Houston, Texas, United States</location>
      <location>GSK Investigational Site, Houston, Texas, United States</location>
      <location>GSK Investigational Site, Houston, Texas, United States</location>
      <location>GSK Investigational Site, Humble, Texas, United States</location>
      <location>GSK Investigational Site, Irving, Texas, United States</location>
      <location>GSK Investigational Site, San Antonio, Texas, United States</location>
      <location>GSK Investigational Site, San Antonio, Texas, United States</location>
      <location>GSK Investigational Site, Sugar Land, Texas, United States</location>
      <location>GSK Investigational Site, Tomball, Texas, United States</location>
      <location>GSK Investigational Site, Bountiful, Utah, United States</location>
      <location>GSK Investigational Site, Ogden, Utah, United States</location>
      <location>GSK Investigational Site, West Jordan, Utah, United States</location>
      <location>GSK Investigational Site, Alexandria, Virginia, United States</location>
      <location>GSK Investigational Site, Charlottesville, Virginia, United States</location>
      <location>GSK Investigational Site, Charlottesville, Virginia, United States</location>
      <location>GSK Investigational Site, Chesapeake, Virginia, United States</location>
      <location>GSK Investigational Site, Lacey, Washington, United States</location>
      <location>GSK Investigational Site, Spokane, Washington, United States</location>
      <location>GSK Investigational Site, Walla Walla, Washington, United States</location>
      <location>GSK Investigational Site, Wenatchee, Washington, United States</location>
      <location>GSK Investigational Site, Yakima, Washington, United States</location>
      <location>GSK Investigational Site, Milwaukee, Wisconsin, United States</location>
      <location>GSK Investigational Site, Milwaukee, Wisconsin, United States</location>
      <location>GSK Investigational Site, Milwaukee, Wisconsin, United States</location>
      <location>GSK Investigational Site, Milwaukee, Wisconsin, United States</location>
      <location>GSK Investigational Site, Nedlands, Western Australia, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00067561</url>
  </study>
  <study rank="342">
    <nct_id>NCT00171431</nct_id>
    <title>The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation Predominant</condition>
      <condition>Irritable Bowel Syndrome (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tegaserod</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the effects of tegaserod on motility and small intestinal flow patterns after meal in female patients with IBS-C</outcome_measure>
      <outcome_measure>by using Multiple Intraluminal Impedance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHTF919AUS33</other_id>
    </other_ids>
    <start_date>November 2004</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 15, 2005</study_first_posted>
    <last_update_posted>April 20, 2012</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00171431</url>
  </study>
  <study rank="343">
    <nct_id>NCT01893606</nct_id>
    <title>Multicenter Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-acetyl-D-glucosamine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain Intensity</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>General symptoms feel grading</outcome_measure>
      <outcome_measure>defecation frequency</outcome_measure>
      <outcome_measure>abdominal distension</outcome_measure>
      <outcome_measure>mucous stool</outcome_measure>
      <outcome_measure>life quality parameters</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Third Military Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>liujunkang</other_id>
      <other_id>dongying</other_id>
    </other_ids>
    <start_date>April 2013</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>July 2017</completion_date>
    <study_first_posted>July 9, 2013</study_first_posted>
    <last_update_posted>July 24, 2015</last_update_posted>
    <locations>
      <location>Daping hospital, Chongqing, Chongqing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01893606</url>
  </study>
  <study rank="344">
    <nct_id>NCT00977587</nct_id>
    <title>Saccharomyces Cerevisiae CNCM I-3856 Treatment in Irritable Bowel Syndrome With Diarrhea (IBS-D) and Post Infective Bowel Dysfunction</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Post Infective Bowel Dysfunction</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Saccharomyces Cerevisiae CNCM I-3856</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in faecal serine protease activity</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
      <outcome_measure>Number of mucus septae per high power filed</outcome_measure>
      <outcome_measure>In vitro effect of Saccharomyces cerevisiae CNCM I-3856 supernatant on IBS-D faecal proteases</outcome_measure>
      <outcome_measure>Bacterial diversity assessed by similarity indices</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>Lesaffre International</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>09075</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>July 2012</completion_date>
    <study_first_posted>September 16, 2009</study_first_posted>
    <last_update_posted>June 20, 2017</last_update_posted>
    <locations>
      <location>Nottingham University Hospital, Nottingham, Nottinghamshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00977587</url>
  </study>
  <study rank="345">
    <nct_id>NCT02681666</nct_id>
    <title>Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome</title>
    <acronym>MB-IBS-EAT</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Abdominal Pain</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Dietary intervention</intervention>
      <intervention type="Behavioral">Irritable Bowel Syndrome eating awareness training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Global Improvement Scale score</outcome_measure>
      <outcome_measure>Change in score of IBS-Quality of Life questionnaire</outcome_measure>
      <outcome_measure>Change in score of Irritable Bowel Syndrome - Severity Scoring System</outcome_measure>
      <outcome_measure>Change in score in Perceived Stress Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Miami</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20150591</other_id>
    </other_ids>
    <start_date>July 1, 2017</start_date>
    <primary_completion_date>December 26, 2017</primary_completion_date>
    <completion_date>December 26, 2017</completion_date>
    <study_first_posted>February 12, 2016</study_first_posted>
    <last_update_posted>June 12, 2018</last_update_posted>
    <locations>
      <location>University of Miami, Miami, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02681666</url>
  </study>
  <study rank="346">
    <nct_id>NCT02716285</nct_id>
    <title>Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery</title>
    <acronym>PERSUADE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Abdominal Pain</condition>
      <condition>Colonic Diseases, Functional</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ileocolonic release peppermint oil</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Small intestinal release peppermint oil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain response rate after 8 weeks of treatment</outcome_measure>
      <outcome_measure>Degree of relief response rate after 8 weeks of treatment.</outcome_measure>
      <outcome_measure>Global symptom improvement</outcome_measure>
      <outcome_measure>Abdominal Discomfort</outcome_measure>
      <outcome_measure>Bloating</outcome_measure>
      <outcome_measure>Regurgitation</outcome_measure>
      <outcome_measure>Nausea</outcome_measure>
      <outcome_measure>Urgency</outcome_measure>
      <outcome_measure>Abdominal cramps</outcome_measure>
      <outcome_measure>Average stool frequency and consistency</outcome_measure>
      <outcome_measure>Indirect costs</outcome_measure>
      <outcome_measure>Direct costs</outcome_measure>
      <outcome_measure>General Quality of Life</outcome_measure>
      <outcome_measure>IBS related Quality of Life</outcome_measure>
      <outcome_measure>Use of Over the counter medication and rescue medication</outcome_measure>
      <outcome_measure>Number and severity of side effects</outcome_measure>
      <outcome_measure>Responder rates following discontinuation of treatment at 3 and 6 months, different thresholds for the responder analysis of abdominal pain (e.g. 40 and 50 percent improvement);</outcome_measure>
      <outcome_measure>Responder rates when missing are interpreted as &quot;no effect&quot;</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL56000.068.16; METC162009</other_id>
      <other_id>2015-005467-16</other_id>
    </other_ids>
    <start_date>August 17, 2016</start_date>
    <primary_completion_date>May 1, 2018</primary_completion_date>
    <completion_date>October 1, 2018</completion_date>
    <study_first_posted>March 23, 2016</study_first_posted>
    <last_update_posted>November 2, 2018</last_update_posted>
    <locations>
      <location>Medical Center Leeuwarden, Leeuwarden, Friesland, Netherlands</location>
      <location>Gelderse Vallei Hospital, Ede, Gelderland, Netherlands</location>
      <location>Alrijne Hospital, Leiden, Zuid Holland, Netherlands</location>
      <location>Maastricht University Medical Center, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02716285</url>
  </study>
  <study rank="347">
    <nct_id>NCT00065754</nct_id>
    <title>Brain Imaging and Pain in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01AT001424-01</other_id>
    </other_ids>
    <start_date>September 2003</start_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <completion_date>December 2007</completion_date>
    <study_first_posted>August 1, 2003</study_first_posted>
    <last_update_posted>September 20, 2011</last_update_posted>
    <locations>
      <location>University of Florida, Gainesville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00065754</url>
  </study>
  <study rank="348">
    <nct_id>NCT03817645</nct_id>
    <title>Panaceo &quot;MED&quot; for IBS (Irritable Bowel Syndrome)</title>
    <acronym>PCeo-17</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Microbial Colonization</condition>
      <condition>Intestinal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Zeolite</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal discomfort or pain</outcome_measure>
      <outcome_measure>Symptom improvement with defaecation</outcome_measure>
      <outcome_measure>Stool frequency associated with abdominal discomfort or pain (more or less frequent)</outcome_measure>
      <outcome_measure>Stool consistency associated with abdominal discomfort or pain (softer or harder)</outcome_measure>
      <outcome_measure>Stool laboratory parameter: Firmicutes</outcome_measure>
      <outcome_measure>Stool laboratory parameter: Bacteroidetes</outcome_measure>
      <outcome_measure>Stool laboratory parameter: Ratio: Bacteroidetes/Firmicutes</outcome_measure>
      <outcome_measure>Stool laboratory parameter: Butyrat Producers</outcome_measure>
      <outcome_measure>Stool laboratory parameter: Clostridia</outcome_measure>
      <outcome_measure>Stool laboratory parameter: Histaminproducers,</outcome_measure>
      <outcome_measure>Stool laboratory parameter: H2S producers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Scigenia GmbH</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PCeo-17</other_id>
    </other_ids>
    <start_date>March 9, 2018</start_date>
    <primary_completion_date>June 30, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>January 25, 2019</study_first_posted>
    <last_update_posted>February 5, 2019</last_update_posted>
    <locations>
      <location>SCIgenia GmbH, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03817645</url>
  </study>
  <study rank="349">
    <nct_id>NCT00219505</nct_id>
    <title>Effect of Acupuncture on Symptoms of Diarrhea and Pain in IBS</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">acupuncture</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of bowel movement</outcome_measure>
      <outcome_measure>Abdominal pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Penn State University</lead_sponsor>
      <collaborator>American College of Gastroenterology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2000-343</other_id>
    </other_ids>
    <start_date>August 2001</start_date>
    <completion_date>January 2004</completion_date>
    <study_first_posted>September 22, 2005</study_first_posted>
    <last_update_posted>November 24, 2017</last_update_posted>
    <locations>
      <location>Hershey Medical Center, Hershey, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00219505</url>
  </study>
  <study rank="350">
    <nct_id>NCT01252550</nct_id>
    <title>Effects of Activia in IBS</title>
    <acronym>MOSAIC</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Activia® (125g/pot)</intervention>
      <intervention type="Dietary Supplement">Acidified non-fermented dairy product</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
      <collaborator>Danone Research</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NU341</other_id>
    </other_ids>
    <start_date>May 2010</start_date>
    <primary_completion_date>May 2014</primary_completion_date>
    <completion_date>August 2014</completion_date>
    <study_first_posted>December 3, 2010</study_first_posted>
    <last_update_posted>November 18, 2014</last_update_posted>
    <locations>
      <location>Sahlgrenska University Hospital, Gothenburg, Västra Götaland, Sweden</location>
      <location>Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
      <location>Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01252550</url>
  </study>
  <study rank="351">
    <nct_id>NCT00775060</nct_id>
    <title>Maastricht IBS Cohort</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MEC 08-3-066</other_id>
    </other_ids>
    <start_date>September 2009</start_date>
    <primary_completion_date>September 2024</primary_completion_date>
    <completion_date>September 2024</completion_date>
    <study_first_posted>October 17, 2008</study_first_posted>
    <last_update_posted>April 7, 2016</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00775060</url>
  </study>
  <study rank="352">
    <nct_id>NCT01801605</nct_id>
    <title>Repetitive Transcranial Magnetic Stimulation in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">rTMS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain or discomfort threshold volumes</outcome_measure>
      <outcome_measure>Amplitude of R3 reflex</outcome_measure>
      <outcome_measure>Visual analogic scale</outcome_measure>
      <outcome_measure>Symptoms diary</outcome_measure>
      <outcome_measure>Quality of life scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Rouen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>2007/053/HP</other_id>
      <other_id>2007-A00799-44</other_id>
    </other_ids>
    <start_date>August 2008</start_date>
    <primary_completion_date>January 2013</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>March 1, 2013</study_first_posted>
    <last_update_posted>March 1, 2013</last_update_posted>
    <locations>
      <location>Physiology Unit-Rouen university Hospital, Rouen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01801605</url>
  </study>
  <study rank="353">
    <nct_id>NCT01558284</nct_id>
    <title>The Effect of Neu-P11 on Symptoms in Patients With D-IBS</title>
    <acronym>Neu-P11</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea- Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Neu-P11</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The relief of symptoms of the D-IBS by the study medication.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ludwig-Maximilians - University of Munich</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>STO-010</other_id>
      <other_id>2011-002657-60</other_id>
    </other_ids>
    <start_date>February 2012</start_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <completion_date>February 2014</completion_date>
    <study_first_posted>March 20, 2012</study_first_posted>
    <last_update_posted>February 5, 2014</last_update_posted>
    <locations>
      <location>Klinikum Grosshadern Medizinische Klinik 2, Munich, Bavaria, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01558284</url>
  </study>
  <study rank="354">
    <nct_id>NCT00418340</nct_id>
    <title>Manipulation of Visceral Sensitivity and Immune System in IBS</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">probiotic (bacterial/dietary supplement)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary outcome measure is the change in physiological rectal sensitivity and before and after probiotic</outcome_measure>
      <outcome_measure>therapy.</outcome_measure>
      <outcome_measure>Secondary outcome measures are the change symptoms and QOL induced by probiotic therapy and the</outcome_measure>
      <outcome_measure>change in the immune response after probiotic therapy.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>London North West Healthcare NHS Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>07.IBS.1</other_id>
    </other_ids>
    <start_date>December 2007</start_date>
    <study_first_posted>January 4, 2007</study_first_posted>
    <last_update_posted>November 16, 2007</last_update_posted>
    <locations>
      <location>North West London Hospitals NHS Trust - St Mark's, London, Middlesex, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00418340</url>
  </study>
  <study rank="355">
    <nct_id>NCT03318614</nct_id>
    <title>Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Abdominal Pain</condition>
      <condition>Small Intestinal Bacterial Overgrowth</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotics M-63</intervention>
      <intervention type="Other">Control group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Symptom Severity Scale (IBS-SSS) scores</outcome_measure>
      <outcome_measure>36-Item Short Form Survey (SF-36) scores</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS) scores</outcome_measure>
      <outcome_measure>Breath-testing for small intestinal bacterial overgrowth (SIBO)</outcome_measure>
      <outcome_measure>Changes in gut microbiota at the phylum level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Science Malaysia</lead_sponsor>
      <collaborator>Morinaga Milk Industry Co. Ltd., Japan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>53</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>USM/JEPeM/15040133</other_id>
    </other_ids>
    <start_date>September 2015</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>October 24, 2017</study_first_posted>
    <last_update_posted>October 24, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03318614</url>
  </study>
  <study rank="356">
    <nct_id>NCT03186872</nct_id>
    <title>Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anxiety</condition>
      <condition>Irritable Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Digital behavioral program app</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>GAD7 Score (Anxiety)</outcome_measure>
      <outcome_measure>PHQ-8 (Depression)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>Mount Sinai Hospital, New York</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO17020464</other_id>
    </other_ids>
    <start_date>May 15, 2017</start_date>
    <primary_completion_date>October 31, 2019</primary_completion_date>
    <completion_date>October 31, 2019</completion_date>
    <study_first_posted>June 14, 2017</study_first_posted>
    <last_update_posted>December 13, 2018</last_update_posted>
    <locations>
      <location>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03186872</url>
  </study>
  <study rank="357">
    <nct_id>NCT03333291</nct_id>
    <title>Fecal Transplantation in Patients With IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">fecal suspension</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stool microbiota changes</outcome_measure>
      <outcome_measure>Global improvement in IBS symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Haukeland University Hospital</lead_sponsor>
      <collaborator>Helse Vest</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013/1497</other_id>
    </other_ids>
    <start_date>October 1, 2016</start_date>
    <primary_completion_date>June 15, 2017</primary_completion_date>
    <completion_date>June 30, 2017</completion_date>
    <study_first_posted>November 6, 2017</study_first_posted>
    <last_update_posted>November 6, 2017</last_update_posted>
    <locations>
      <location>Helse Bergen HF, Haukeland University Hospital, Bergen, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03333291</url>
  </study>
  <study rank="358">
    <nct_id>NCT03019861</nct_id>
    <title>Ayurvedic Nutritional Counseling for Patients With IBS in Comparison to Conventional Nutritional Counseling</title>
    <acronym>AYURDA</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Ayurvedic nutritional counseling</intervention>
      <intervention type="Behavioral">Conventional nutritional counseling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome-Severity Scoring System (IBS-SSS) - Change</outcome_measure>
      <outcome_measure>Cohen Perceived Stress Scale (CPSS) - Change</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS-D) - Change</outcome_measure>
      <outcome_measure>Irritable bowel Syndrome - Quality of life (IBS-QOL) - Change</outcome_measure>
      <outcome_measure>VAS: Pain, Sleep, General bothersomeness, Expectation - Change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>71</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AYURDA</other_id>
    </other_ids>
    <start_date>January 2017</start_date>
    <primary_completion_date>October 2018</primary_completion_date>
    <completion_date>February 2019</completion_date>
    <study_first_posted>January 13, 2017</study_first_posted>
    <last_update_posted>February 12, 2019</last_update_posted>
    <locations>
      <location>Kliniken Essen-Mitte, Essen, Am Deimelsberg 34 A, Germany</location>
      <location>Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus, Berlin, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03019861</url>
  </study>
  <study rank="359">
    <nct_id>NCT02875847</nct_id>
    <title>Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">HMO1</intervention>
      <intervention type="Dietary Supplement">HMO2</intervention>
      <intervention type="Dietary Supplement">Dextropur</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in intestinal bifidobacteria abundance</outcome_measure>
      <outcome_measure>Change from baseline of faecal microbiota profile</outcome_measure>
      <outcome_measure>Change from baseline of IBS symptoms as measured via the total score on the IBS Symptoms Severity Scale (IBS-SSS) and the proportion of responders in all patients and subgroup of patients</outcome_measure>
      <outcome_measure>Change from baseline of intensity of abdominal pain and number of days of abdominal pain as measured on the 11 point Numeric Rating Scale (NRS-11) in all patients and subgroups of patients</outcome_measure>
      <outcome_measure>Change from baseline of bowel habits as measured via the IBS-SSS, the Bristol Stool Form Scale (BSFS) and a bowel movement diary in all patients and subgroup of patients</outcome_measure>
      <outcome_measure>Change from baseline of abdominal distention as measured via the IBS-SSS in all patients and subgroups of patients</outcome_measure>
      <outcome_measure>Change from baseline of gastrointestinal symptoms as measured by the Gastrointestinal Symptom Rating Scale for IBS patients (GSRS-IBS) in all patients and subgroup of patients</outcome_measure>
      <outcome_measure>Change from baseline of quality of life in IBS patients as measured by the IBS-QOL in all patients and subgroups of patients</outcome_measure>
      <outcome_measure>Change from baseline of anxiety and depression as measured by the Hospital Anxiety and Depression Scales (HADS) in all patients and subgroups of patients</outcome_measure>
      <outcome_measure>Change from baseline of gastrointestinal symptom specific anxiety as measured by the Visceral Sensitivity Index (VSI) in all patients and subgroup of patients</outcome_measure>
      <outcome_measure>Change from baseline of severity of somatic symptoms as measured by the Patient Health Questionnaire-15 (PHQ-15) in all patients and subgroup of patients</outcome_measure>
      <outcome_measure>Change from baseline of biomarkers of inflammation in all patients and subgroups of patients</outcome_measure>
      <outcome_measure>Change from baseline of biomarkers of gut barrier function in all patients and subgroups of patients</outcome_measure>
      <outcome_measure>Change from baseline of biomarkers of the gut-brain axis in all patients and subgroups of patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Glycom A/S</lead_sponsor>
      <collaborator>Sahlgrenska University Hospital, Sweden</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NATRIBS</other_id>
      <other_id>Dnr: 548-16</other_id>
    </other_ids>
    <start_date>September 2016</start_date>
    <primary_completion_date>July 2018</primary_completion_date>
    <completion_date>July 2018</completion_date>
    <study_first_posted>August 23, 2016</study_first_posted>
    <last_update_posted>September 24, 2018</last_update_posted>
    <locations>
      <location>SU Sahlgrenska, Department of Internal Medicine, Göteborg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02875847</url>
  </study>
  <study rank="360">
    <nct_id>NCT00547469</nct_id>
    <title>A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DDP733</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall Subject Global Assessment (SGA) of relief of IBS symptoms, collected weekly</outcome_measure>
      <outcome_measure>Weekly assessments of abdominal discomfort/pain, bowel habit, and satisfaction with bowel habit.</outcome_measure>
      <outcome_measure>Other secondary efficacy variables reflecting IBS symptoms include daily assessments of abdominal discomfort/pain; abdominal bloating, the number and consistency of stools, straining at defecation, and feeling of incomplete evacuation.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dynogen Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DDP733-07-010</other_id>
    </other_ids>
    <start_date>October 2007</start_date>
    <study_first_posted>October 22, 2007</study_first_posted>
    <last_update_posted>April 8, 2008</last_update_posted>
    <locations>
      <location>Alliance Clinical Trials, Birmingham, Alabama, United States</location>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Medical Affiliated Research Center, Inc., Huntsville, Alabama, United States</location>
      <location>Mobile Medical Diagnostic, Mobile, Alabama, United States</location>
      <location>Pivotal Research Centers, Peoria, Arizona, United States</location>
      <location>Genova Clinical Research, Tucson, Arizona, United States</location>
      <location>Arkansas Gastroenterology, Sherwood, Arkansas, United States</location>
      <location>Impact Clinical Trials, Beverly Hills, California, United States</location>
      <location>Discovery Clinical Research, Encinitas, California, United States</location>
      <location>Family Medical Center, Foothill Ranch, California, United States</location>
      <location>Digestive and Liver Disease Specialist, A Medical Group, Inc., Garden Grove, California, United States</location>
      <location>Prime Care Clinical Research, Inc., Mission Vejo, California, United States</location>
      <location>California Research Foundation, San Diego, California, United States</location>
      <location>Medical Center for clinical research, San Diego, California, United States</location>
      <location>Westlake Medical Research, Westlake Village, California, United States</location>
      <location>Clinical Trial Center of Colorado, LLC, Castle Rock, Colorado, United States</location>
      <location>Clinical Trials Management of Boca Raton, Inc., Boca Raton, Florida, United States</location>
      <location>Jupiter Research, Jupiter, Florida, United States</location>
      <location>AppleMed Research Inc., Miami, Florida, United States</location>
      <location>Accord Clinical Research, LLC, Port Orange, Florida, United States</location>
      <location>Stedman Clinical Trials, Tampa, Florida, United States</location>
      <location>Mount Vernon Clinical Research, Atlanta, Georgia, United States</location>
      <location>Atlanta Gastroenterology Associates, LLC, Marietta, Georgia, United States</location>
      <location>North Georgia Clinical Research, Woodstock, Georgia, United States</location>
      <location>Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States</location>
      <location>Accelovance, Peoria, Illinois, United States</location>
      <location>Rockford Gastroenterology Associates, Ltd., Rockford, Illinois, United States</location>
      <location>Indiana Medical Research, LLC, Elkhart, Indiana, United States</location>
      <location>MediSphere Medical Research Center, LLC, Evansville, Indiana, United States</location>
      <location>University of Kansas Medical Center, Kansas City, Kansas, United States</location>
      <location>Heartland Research Associates, LLC, Wichita, Kansas, United States</location>
      <location>Louisiana Research Center, LLC, Shreveport, Louisiana, United States</location>
      <location>Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Maryland Digestive Disease Research, LLC, Laurel, Maryland, United States</location>
      <location>Boston Clinical Trials, INC., Boston, Massachusetts, United States</location>
      <location>Women's Health Care Specialists, PC, Paw Paw, Michigan, United States</location>
      <location>CRC of Jackson, LLC at Jackson Medical Clinic, Jackson, Mississippi, United States</location>
      <location>Gastrointestinal Associates, P.A., Jackson, Mississippi, United States</location>
      <location>Center for Digestive and Liver Diseases, Inc., Mexico City, Missouri, United States</location>
      <location>Lovelace Scientific Resources, Henderson, Nevada, United States</location>
      <location>LifeLine Research, Inc., Brooklyn, New York, United States</location>
      <location>UNC Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, United States</location>
      <location>Peters Medical Research dba Bethany Medical Center, High Point, North Carolina, United States</location>
      <location>Wake Research Associates, LLC, Raleigh, North Carolina, United States</location>
      <location>Piedmont Medical Research Associates, Winston-Salem, North Carolina, United States</location>
      <location>Hightop Medical Research Center, Cincinnati, Ohio, United States</location>
      <location>Gastroenterology Research Consultants of Greater Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Rapid Medical Research, Inc., Cleveland, Ohio, United States</location>
      <location>Gastrointestinal and Liver Diseases Consultants, Dayton, Ohio, United States</location>
      <location>Clinical Trials Research Services, LLC, Pittsburgh, Pennsylvania, United States</location>
      <location>Southeastern Clinical Research, Chattanooga, Tennessee, United States</location>
      <location>Jackson Clinic, PA, Jackson, Tennessee, United States</location>
      <location>Regional Research Institute, Jackson, Tennessee, United States</location>
      <location>Gastroenterology Associates Clinical Research, Kingsport, Tennessee, United States</location>
      <location>Baylor College of Medicine, Baylor Clinic, Houston, Texas, United States</location>
      <location>DCOL Center for Research, Longview, Texas, United States</location>
      <location>Advanced Research Institute, Ogden, Utah, United States</location>
      <location>Virginia Mason Meidical Center, Seattle, Washington, United States</location>
      <location>Rowan Research, Spokane, Washington, United States</location>
      <location>Spokane Internal Medicine, Spokane, Washington, United States</location>
      <location>Wisconsin Center for Advanced Research Division of GI Associates, LLC, Milwaukee, Wisconsin, United States</location>
      <location>Aurora Health Center, Waukesha, Wisconsin, United States</location>
      <location>McMaster University Dept of Gastrointerology St. Joseph's Healthcare, Hamilton, Ontario, Canada</location>
      <location>St. Joseph's Hospital, London, Ontario, Canada</location>
      <location>Meadowlands Family Health Center, Ottawa, Ontario, Canada</location>
      <location>London Road Diagnostic Clinic, Sarnia, Ontario, Canada</location>
      <location>Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada</location>
      <location>Canadian Phase Onward Inc., Toronto, Ontario, Canada</location>
      <location>Toronto Digestive Disease Associates, Inc., Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00547469</url>
  </study>
  <study rank="361">
    <nct_id>NCT00139672</nct_id>
    <title>A Study To Investigate The Effect Of PD-217,014 On Abdominal Pain/Discomfort In Patients With IBS.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PD-217,014</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assess the effect of PD-217,014 on the relief of abdominal pain/discomfort in patients with irritable bowel syndrome. Primary endpoint is a responder, defined by having adequate relief for &gt; or = 50% of the active treatment period (4 weeks).</outcome_measure>
      <outcome_measure>Assess the effect of PD-217,014 on the patient's global assessment of IBS symptoms, stool frequency &amp; consistency and on abdominal bloating (change from baseline to week 4).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>A4451007</other_id>
    </other_ids>
    <start_date>January 2004</start_date>
    <primary_completion_date>February 2005</primary_completion_date>
    <completion_date>February 2005</completion_date>
    <study_first_posted>August 31, 2005</study_first_posted>
    <last_update_posted>June 17, 2008</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00139672</url>
  </study>
  <study rank="362">
    <nct_id>NCT00925223</nct_id>
    <title>Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009SDU-QILU-G02</other_id>
      <other_id>NSFC30570831</other_id>
    </other_ids>
    <start_date>June 2009</start_date>
    <primary_completion_date>August 2009</primary_completion_date>
    <completion_date>November 2009</completion_date>
    <study_first_posted>June 22, 2009</study_first_posted>
    <last_update_posted>October 14, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00925223</url>
  </study>
  <study rank="363">
    <nct_id>NCT00258193</nct_id>
    <title>Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MD-1100 Acetate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>(Safety) AEs to be collected beginning with patient’s first administration of study medication through final study visit</outcome_measure>
      <outcome_measure>Clinical chemistry, hematology, and urinalyses to be performed before and after the Treatment Period</outcome_measure>
      <outcome_measure>Cardiac safety will be monitored by ECG recordings</outcome_measure>
      <outcome_measure>(Efficacy) Primary endpoints for analysis of efficacy are the colonic geometric center (GC) at 24 hours and ascending colon t1/2 values.</outcome_measure>
      <outcome_measure>Secondary transit endpoints will be gastric emptying t1/2, colonic filling at 6 hours, colonic GC at additional time points including 48 hours, and time to first bowel movement after the first dose of medication.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Protocol MCP-103-005</other_id>
    </other_ids>
    <start_date>January 2006</start_date>
    <completion_date>September 2006</completion_date>
    <study_first_posted>November 24, 2005</study_first_posted>
    <last_update_posted>October 20, 2006</last_update_posted>
    <locations>
      <location>Mayo Clinic Foundation, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00258193</url>
  </study>
  <study rank="364">
    <nct_id>NCT01436760</nct_id>
    <title>Genetic Contribution of Pain and Inflammation in IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Polymorphisms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>132-2011</other_id>
    </other_ids>
    <start_date>May 2011</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <completion_date>March 2012</completion_date>
    <study_first_posted>September 20, 2011</study_first_posted>
    <last_update_posted>March 26, 2012</last_update_posted>
    <locations>
      <location>University of Florida, Gainesville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01436760</url>
  </study>
  <study rank="365">
    <nct_id>NCT01475929</nct_id>
    <title>Effect of Probiotic Supplement on Bowel Function</title>
    <acronym>IBS2</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotic supplement</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in functional bowel symptoms</outcome_measure>
      <outcome_measure>Change in quality of life</outcome_measure>
      <outcome_measure>Adequate relief</outcome_measure>
      <outcome_measure>Change in faecal microbiota</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Danisco</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>149</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS2</other_id>
    </other_ids>
    <start_date>June 2011</start_date>
    <primary_completion_date>May 2012</primary_completion_date>
    <completion_date>May 2012</completion_date>
    <study_first_posted>November 22, 2011</study_first_posted>
    <last_update_posted>August 13, 2015</last_update_posted>
    <locations>
      <location>Herttoniemi Hospital, Helsinki, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01475929</url>
  </study>
  <study rank="366">
    <nct_id>NCT01791621</nct_id>
    <title>The Diagnostic Predictability of Food Allergy Testing</title>
    <acronym>FAST</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Elimination/Challenge Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intra-individual agreement: food elimination challenge versus non-immunoglobulin E (IgE) mediated food allergy test results</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Canadian College of Naturopathic Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>CCNM1301</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>April 2013</primary_completion_date>
    <completion_date>May 2013</completion_date>
    <study_first_posted>February 15, 2013</study_first_posted>
    <last_update_posted>July 18, 2013</last_update_posted>
    <locations>
      <location>The Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01791621</url>
  </study>
  <study rank="367">
    <nct_id>NCT02559245</nct_id>
    <title>Effect of Flixweed and Fig on Irritable Bowel Syndrome With Predominant Constipation: a Single Blind Randomized Clinical Trial.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Predominant Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Descurainia Sophia</intervention>
      <intervention type="Other">Ficus carica</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>irritable bowel syndrome constipation predominant symptom</outcome_measure>
      <outcome_measure>quality of life in IBS-C patients</outcome_measure>
      <outcome_measure>frequency of defecation and hard stool</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Isfahan University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>makan.pourmasoumi@gmail.com</other_id>
    </other_ids>
    <start_date>September 2015</start_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <completion_date>January 2016</completion_date>
    <study_first_posted>September 24, 2015</study_first_posted>
    <last_update_posted>May 22, 2018</last_update_posted>
    <locations>
      <location>Gastrointestinal Research Center, Isfahan, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02559245</url>
  </study>
  <study rank="368">
    <nct_id>NCT02136745</nct_id>
    <title>Effects of Relaxation Response Mind-body Intervention in Patients With IBS and IBD</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Relaxation Response Mind-Body Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Quality of Life</outcome_measure>
      <outcome_measure>IBS Symptom Severity Index</outcome_measure>
      <outcome_measure>IBD Questionnaire</outcome_measure>
      <outcome_measure>State-Trait Anxiety Inventory (STAI)</outcome_measure>
      <outcome_measure>Pain Catastrophizing Scale</outcome_measure>
      <outcome_measure>Brief Pain Inventory</outcome_measure>
      <outcome_measure>erythrocyte sedimentation rate</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009-P-000757/19</other_id>
      <other_id>R01DP000339</other_id>
    </other_ids>
    <start_date>May 2009</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>May 13, 2014</study_first_posted>
    <last_update_posted>May 13, 2014</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02136745</url>
  </study>
  <study rank="369">
    <nct_id>NCT03054506</nct_id>
    <title>The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation</condition>
      <condition>Chronic Idiopathic Constipation</condition>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Device">CSP01</intervention>
      <intervention type="Device">Carboxymethylcellulose (CMC)</intervention>
      <intervention type="Device">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Transit Time (CTT)</outcome_measure>
      <outcome_measure>Spontaneous Bowel Movement (SBM) frequency rate</outcome_measure>
      <outcome_measure>Complete Spontaneous Bowel Movement (CSBM) frequency rate</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>Straining</outcome_measure>
      <outcome_measure>Patient's assessment of abdominal discomfort using a numerical rating scale</outcome_measure>
      <outcome_measure>Patient's assessment of bloating using a numerical rating scale</outcome_measure>
      <outcome_measure>Patient's assessment of constipation severity using a numerical rating scale</outcome_measure>
      <outcome_measure>Patient's overall relief using a numerical rating scale</outcome_measure>
      <outcome_measure>Balloon Expulsion Time (BET) before and after</outcome_measure>
      <outcome_measure>Constipation symptom severity (PAC-SYM)</outcome_measure>
      <outcome_measure>Constipation quality of life (PAC-QOL)</outcome_measure>
      <outcome_measure>Need for rescue laxatives</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Gelesis, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016P001751</other_id>
    </other_ids>
    <start_date>March 7, 2017</start_date>
    <primary_completion_date>May 10, 2018</primary_completion_date>
    <completion_date>February 1, 2019</completion_date>
    <study_first_posted>February 15, 2017</study_first_posted>
    <last_update_posted>March 6, 2019</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03054506</url>
  </study>
  <study rank="370">
    <nct_id>NCT03824821</nct_id>
    <title>Assessing Associations Between IBS Symptoms, Nutrition and QoL in IBS Patients Using a Questionnaire</title>
    <acronym>IBSQUtrition</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS subtype</outcome_measure>
      <outcome_measure>IBS severity</outcome_measure>
      <outcome_measure>Nutrition questionnaire</outcome_measure>
      <outcome_measure>Birmingham symptom questionnaire</outcome_measure>
      <outcome_measure>Irritable bowel syndrome Quality of Life questionnaire</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Score (HADS)</outcome_measure>
      <outcome_measure>treatment options currently used</outcome_measure>
      <outcome_measure>Rome IV criteria</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wageningen University</lead_sponsor>
      <collaborator>Netherlands: Ministry of Health, Welfare and Sports</collaborator>
      <collaborator>Ingredia S.A.</collaborator>
      <collaborator>Nexira</collaborator>
      <collaborator>Naturex</collaborator>
      <collaborator>Bioiberica</collaborator>
      <collaborator>Wecare</collaborator>
      <collaborator>Roquette Freres</collaborator>
      <collaborator>Darling</collaborator>
      <collaborator>Winclove</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2076</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>18/06</other_id>
    </other_ids>
    <start_date>January 22, 2018</start_date>
    <primary_completion_date>May 31, 2018</primary_completion_date>
    <completion_date>May 31, 2018</completion_date>
    <study_first_posted>January 31, 2019</study_first_posted>
    <last_update_posted>January 31, 2019</last_update_posted>
    <locations>
      <location>Wageningen University &amp; Research, Wageningen, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03824821</url>
  </study>
  <study rank="371">
    <nct_id>NCT02003807</nct_id>
    <title>Incidence and Predictive Factor of Irritable Bowel Syndrome After Acute Diverticulitis in Korea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diverticulitis and Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The newly developed IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>102</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>4-2013-0326</other_id>
    </other_ids>
    <start_date>July 2013</start_date>
    <primary_completion_date>September 2013</primary_completion_date>
    <completion_date>September 2013</completion_date>
    <study_first_posted>December 6, 2013</study_first_posted>
    <last_update_posted>December 6, 2013</last_update_posted>
    <locations>
      <location>Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02003807</url>
  </study>
  <study rank="372">
    <nct_id>NCT02614313</nct_id>
    <title>Fructose Breath-testing in Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Open breath test with fructose</intervention>
      <intervention type="Procedure">Breath test with sweet placebo (Assugrin)</intervention>
      <intervention type="Procedure">Breath test with neutral placebo (still water)</intervention>
      <intervention type="Procedure">Blinded breath test with fructose</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Fructose intolerance, as percentage of patients</outcome_measure>
      <outcome_measure>Between-group comparisons of breath test gas concentrations and symptom indices</outcome_measure>
      <outcome_measure>Correlations between breath test gas concentrations, symptom indices and metabolite</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brain-Gut Research Group</lead_sponsor>
      <collaborator>New Jersey Medical School</collaborator>
      <collaborator>National University, Singapore</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>BGRG FBT-PLA</other_id>
    </other_ids>
    <start_date>June 2016</start_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <completion_date>August 2017</completion_date>
    <study_first_posted>November 25, 2015</study_first_posted>
    <last_update_posted>December 17, 2018</last_update_posted>
    <locations>
      <location>Gastoenterology Group Practice, Bern, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02614313</url>
  </study>
  <study rank="373">
    <nct_id>NCT01699438</nct_id>
    <title>Mesalazine Treatment in IBS (The MIBS Study)</title>
    <acronym>MIBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalazine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global Irritable Bowel Syndrome (IBS) symptoms</outcome_measure>
      <outcome_measure>Inflammatory mediators</outcome_measure>
      <outcome_measure>Effect on immune cells and cytokines in mucosal biopsies</outcome_measure>
      <outcome_measure>Levels of calprotectin in faeces</outcome_measure>
      <outcome_measure>Change in total IBS symptom severity score (IBS-SSS)</outcome_measure>
      <outcome_measure>Individual symptom parameters in IBS symptom severity score (IBS-SSS) and the IBS diary</outcome_measure>
      <outcome_measure>Exploratory responder variables</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hans Törnblom</lead_sponsor>
      <collaborator>Sahlgrenska University Hospital, Sweden</collaborator>
      <collaborator>Smerud Medical Research International AS</collaborator>
      <collaborator>Alimenta AB</collaborator>
      <collaborator>Tillotts Pharma AG</collaborator>
      <collaborator>Karolinska University Hospital</collaborator>
      <collaborator>Haukeland University Hospital</collaborator>
      <collaborator>Oslo University Hospital</collaborator>
      <collaborator>Sykehuset Innlandet HF</collaborator>
      <collaborator>Göteborg University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>211</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SMR-2268</other_id>
    </other_ids>
    <start_date>April 2012</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>February 2017</completion_date>
    <study_first_posted>October 3, 2012</study_first_posted>
    <last_update_posted>February 24, 2017</last_update_posted>
    <locations>
      <location>Sahlgrenska University Hospital, Göteborg, Sweden</location>
      <location>Karolinska University Hospital, Huddinge, Sweden</location>
      <location>Norrland's University Hospital, Umeå, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01699438</url>
  </study>
  <study rank="374">
    <nct_id>NCT00230581</nct_id>
    <title>8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DDP225</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>GI Transit</outcome_measure>
      <outcome_measure>Patient Reported Outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dynogen Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DDP225-04-006</other_id>
    </other_ids>
    <start_date>September 2005</start_date>
    <completion_date>August 2007</completion_date>
    <study_first_posted>October 3, 2005</study_first_posted>
    <last_update_posted>October 15, 2007</last_update_posted>
    <locations>
      <location>Radiant Research, Scottsdale, Arizona, United States</location>
      <location>Radiant Research, St. Louis, Missouri, United States</location>
      <location>Long Island Gastrointestinal Research, Great Neck, New York, United States</location>
      <location>Radiant Research, Mogadore, Ohio, United States</location>
      <location>Radiant Research, Greer, South Carolina, United States</location>
      <location>QE II Health Sciences Centre, Halifax, Nova Scotia, Canada</location>
      <location>McMaster University Medical Centre, Hamilton, Ontario, Canada</location>
      <location>St. Joseph's Healthcare, Hamilton, Ontario, Canada</location>
      <location>Hotel Dieu Hospital, Kingston, Ontario, Canada</location>
      <location>St. Joseph's Healthcare, London, Ontario, Canada</location>
      <location>Meadowlands Family Health Centre, Ottawa, Ontario, Canada</location>
      <location>London Road Diagnostic Clinic, Sarnia, Ontario, Canada</location>
      <location>Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada</location>
      <location>Canadian Phase Onward Inc., Toronto, Ontario, Canada</location>
      <location>Toronto Digestive Disease Associates, Inc., Toronto, Ontario, Canada</location>
      <location>Hopital St-Sacrement, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00230581</url>
  </study>
  <study rank="375">
    <nct_id>NCT03441581</nct_id>
    <title>3030-401-002 ELX BAM Study</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eluxadoline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in average Bristol Stool Form Scale (BSFS) score over 4 weeks of treatment period</outcome_measure>
      <outcome_measure>Percentage of Participants with Treatment Emergent Adverse Events</outcome_measure>
      <outcome_measure>Percentage of participants who experienced clinically significant change in Laboratory Tests</outcome_measure>
      <outcome_measure>Percentage of Participants who experienced clinically significant change in Vital Signs</outcome_measure>
      <outcome_measure>Percentage of Participants with Change from Baseline in General Physical Condition as Measured through General Physical Exam</outcome_measure>
      <outcome_measure>Change from baseline in the 4-week average of daily bowel movement frequency during the treatment period</outcome_measure>
      <outcome_measure>Change from baseline in the 4-week average of daily worst abdominal pain scores during the treatment period</outcome_measure>
      <outcome_measure>Change from baseline in the 4-week average of daily bloating scores during the treatment period</outcome_measure>
      <outcome_measure>Change from baseline in the 4-week average of urgency-free days in a week during the treatment period</outcome_measure>
      <outcome_measure>Proportion of participants with any fecal incontinence during the treatment period</outcome_measure>
      <outcome_measure>Change from baseline in IBS-QOL score at the end of the treatment period</outcome_measure>
      <outcome_measure>Change from baseline in serum 7αC4 levels at the end of the treatment period</outcome_measure>
      <outcome_measure>Cmax: Maximum Plasma concentration</outcome_measure>
      <outcome_measure>Cmin: Minimum Plasma Concentration</outcome_measure>
      <outcome_measure>AUCtau: Area under the plasma concentration-time curve during the dosing interval</outcome_measure>
      <outcome_measure>Tmax: Time to Cmax</outcome_measure>
      <outcome_measure>t1/2: Half-Life</outcome_measure>
      <outcome_measure>CL: Apparent clearance for eluxadoline</outcome_measure>
      <outcome_measure>V: Apparent volume of distribution for eluxadoline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Allergan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>3030-401-002</other_id>
    </other_ids>
    <start_date>February 23, 2018</start_date>
    <primary_completion_date>September 30, 2019</primary_completion_date>
    <completion_date>October 7, 2019</completion_date>
    <study_first_posted>February 21, 2018</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03441581</url>
  </study>
  <study rank="376">
    <nct_id>NCT03219528</nct_id>
    <title>A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin 550 MG</intervention>
      <intervention type="Other">Low FODMAP Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in Mean Daily Pain and/or Bloating</outcome_measure>
      <outcome_measure>IBS Symptom Severity Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>Michigan Institute for Clinical and Health Research (MICHR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HUM129427</other_id>
    </other_ids>
    <start_date>October 19, 2017</start_date>
    <primary_completion_date>February 2020</primary_completion_date>
    <completion_date>February 2020</completion_date>
    <study_first_posted>July 17, 2017</study_first_posted>
    <last_update_posted>October 11, 2018</last_update_posted>
    <locations>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03219528</url>
  </study>
  <study rank="377">
    <nct_id>NCT03336034</nct_id>
    <title>Assessment of Responsiveness to Treatment by Experience Sampling Method</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Mean abdominal pain scores as measured by the ESM tool.</outcome_measure>
      <outcome_measure>Maximum abdominal pain scores as measured by the ESM tool.</outcome_measure>
      <outcome_measure>Number of bowel movements.</outcome_measure>
      <outcome_measure>Symptom scores for other symptoms than abdominal pain, as measured by the ESM tool.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>METC 173007</other_id>
      <other_id>NL60925.068.17</other_id>
    </other_ids>
    <start_date>January 1, 2018</start_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>November 8, 2017</study_first_posted>
    <last_update_posted>March 19, 2018</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03336034</url>
  </study>
  <study rank="378">
    <nct_id>NCT02661425</nct_id>
    <title>Retrospective Study of IBS-D Patients Previously Receiving SBI</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhoea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">EnteraGam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in the combined score for stool frequency/consistency and abdominal pain intensity during the time that the patient is receiving EnteraGam.</outcome_measure>
      <outcome_measure>Improvement in stool frequency</outcome_measure>
      <outcome_measure>Improvement in stool consistency</outcome_measure>
      <outcome_measure>Improvement in abdominal pain intensity</outcome_measure>
      <outcome_measure>Improvement in urgency</outcome_measure>
      <outcome_measure>Improvement in flatulence</outcome_measure>
      <outcome_measure>Improvement in fecal incontinence</outcome_measure>
      <outcome_measure>Improvement in bloating</outcome_measure>
      <outcome_measure>Improvement in fatigue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Entera Health, Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>EH MA 1010</other_id>
    </other_ids>
    <start_date>December 2015</start_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <completion_date>September 2016</completion_date>
    <study_first_posted>January 22, 2016</study_first_posted>
    <last_update_posted>September 12, 2016</last_update_posted>
    <locations>
      <location>Greenwich, Connecticut, United States</location>
      <location>Hamdon, Connecticut, United States</location>
      <location>Coral Springs, Florida, United States</location>
      <location>Maitland, Florida, United States</location>
      <location>Orlando, Florida, United States</location>
      <location>Tampa, Florida, United States</location>
      <location>Winter Park, Florida, United States</location>
      <location>Smyrna, Georgia, United States</location>
      <location>Columbia, Maryland, United States</location>
      <location>St. Louis, Missouri, United States</location>
      <location>Lynbrook, New York, United States</location>
      <location>New York, New York, United States</location>
      <location>Kingsport, Tennessee, United States</location>
      <location>Knoxville, Tennessee, United States</location>
      <location>Morristown, Tennessee, United States</location>
      <location>Bedford, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02661425</url>
  </study>
  <study rank="379">
    <nct_id>NCT00680836</nct_id>
    <title>Gulf War Digestive Health Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Small Intestinal Bacterial Overgrowth</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Rifaximin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global Improvement Scale</outcome_measure>
      <outcome_measure>Change in Stool Frequency (Number of Bowel Movements Per Day)</outcome_measure>
      <outcome_measure>Change in Stool Consistency</outcome_measure>
      <outcome_measure>Change in Bowel Urgency</outcome_measure>
      <outcome_measure>Change in Abdominal Pain With Bowel Movement</outcome_measure>
      <outcome_measure>Change in Bloating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>US Department of Veterans Affairs</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>72 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GWRA-014-05F</other_id>
    </other_ids>
    <start_date>October 2007</start_date>
    <primary_completion_date>October 2008</primary_completion_date>
    <completion_date>December 2013</completion_date>
    <study_first_posted>May 20, 2008</study_first_posted>
    <results_first_posted>August 29, 2014</results_first_posted>
    <last_update_posted>August 29, 2014</last_update_posted>
    <locations>
      <location>Division of Epidemiology, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00680836</url>
  </study>
  <study rank="380">
    <nct_id>NCT00215566</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DDP733</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of the effect of DDP733 on gastrointestinal transit</outcome_measure>
      <outcome_measure>Evaluation of the effect of DDP733 on patient reported outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dynogen Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DDP733-04-007</other_id>
    </other_ids>
    <start_date>September 2005</start_date>
    <study_first_posted>September 22, 2005</study_first_posted>
    <last_update_posted>May 28, 2007</last_update_posted>
    <locations>
      <location>Hys Medical Centre, Edmonton, Alberta, Canada</location>
      <location>St Paul's Hospital, Vancouver, British Columbia, Canada</location>
      <location>West Vancouver, British Columbia, Canada</location>
      <location>QE II Health Sciences Centre, Halifax, Nova Scotia, Canada</location>
      <location>Surrey GI Clinic, Guelph, Ontario, Canada</location>
      <location>McMaster University Medical Centre, Hamilton, Ontario, Canada</location>
      <location>St. Joseph's Healthcare, Hamilton, Ontario, Canada</location>
      <location>Hotel Dieu Hospital, Kingston, Ontario, Canada</location>
      <location>St. Joseph's Healthcare, London, Ontario, Canada</location>
      <location>Meadowlands Family Health Centre, Ottawa, Ontario, Canada</location>
      <location>London Road Diagnostic Clinic, Sarnia, Ontario, Canada</location>
      <location>Sarnia Institute of Clinical Research, Sarnia, Ontario, Canada</location>
      <location>Canadian Phase Onward Inc., Toronto, Ontario, Canada</location>
      <location>Toronto Digestive Disease Associates, Inc, Toronto, Ontario, Canada</location>
      <location>Hopital St-Sacrement, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00215566</url>
  </study>
  <study rank="381">
    <nct_id>NCT02351635</nct_id>
    <title>BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">fecal calprotectin level</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical value of in vitro diagnostic (IVD) device</outcome_measure>
      <outcome_measure>normal Calprotectin values</outcome_measure>
      <outcome_measure>Clinical value of IVD device in pediatric population</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bühlmann Laboratories AG</lead_sponsor>
      <collaborator>ICON Clinical Research</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>478</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>ALP Cal01</other_id>
    </other_ids>
    <start_date>January 2015</start_date>
    <primary_completion_date>March 2018</primary_completion_date>
    <completion_date>April 2018</completion_date>
    <study_first_posted>January 30, 2015</study_first_posted>
    <last_update_posted>January 18, 2019</last_update_posted>
    <locations>
      <location>Stanford Center for Clinical &amp; Translational Research &amp; Education, Palo Alto, California, United States</location>
      <location>Gastro Health, Miami, Florida, United States</location>
      <location>Gastroenterology Assocaites of Central Georgia, Macon, Georgia, United States</location>
      <location>Carle Foundation, Center for Digestive and Liver Disease, Urbana, Illinois, United States</location>
      <location>Beth israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>Great Lakes Gastroenterology Research, LLC., Mentor, Ohio, United States</location>
      <location>Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02351635</url>
  </study>
  <study rank="382">
    <nct_id>NCT02727751</nct_id>
    <title>A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C</title>
    <acronym>T3MPO-3</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenapanor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Treatment - Emergent Adverse Events [Safety and Tolerability]</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ardelyx</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TEN-01-303</other_id>
    </other_ids>
    <start_date>March 2016</start_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <completion_date>December 2017</completion_date>
    <study_first_posted>April 5, 2016</study_first_posted>
    <last_update_posted>April 15, 2016</last_update_posted>
    <locations>
      <location>Ardelyx Clinical Site, Miami, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02727751</url>
  </study>
  <study rank="383">
    <nct_id>NCT01350570</nct_id>
    <title>Acupuncture for Patients With Diarrhea-predominant IBS or Functional Diarrhea: a Randomized Controlled Trial</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
      <condition>Functional Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Other">acupuncture</intervention>
      <intervention type="Other">acupuncture group2</intervention>
      <intervention type="Other">acupuncture group3</intervention>
      <intervention type="Drug">Loperamide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Average weekly stool frequency</outcome_measure>
      <outcome_measure>Assessment score of Bristol stool scale</outcome_measure>
      <outcome_measure>Assessment score of SF-36 scale</outcome_measure>
      <outcome_measure>Number of patients with adverse events after treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chengdu University of Traditional Chinese Medicine</lead_sponsor>
      <collaborator>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>449</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2011CB5200-Fd</other_id>
    </other_ids>
    <start_date>August 2011</start_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <completion_date>September 2014</completion_date>
    <study_first_posted>May 10, 2011</study_first_posted>
    <last_update_posted>April 10, 2015</last_update_posted>
    <locations>
      <location>First affiliated hospital of Chengdu university of TCM, Chengdu, Sichuan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01350570</url>
  </study>
  <study rank="384">
    <nct_id>NCT03150212</nct_id>
    <title>Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype</title>
    <acronym>IBS-GO</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Saccharomyces cerevisiae CNCM I-3856</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain/discomfort score rated with Likert scale (ranging from 0 to 7)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lesaffre International</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>456</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016-A01574-47</other_id>
    </other_ids>
    <start_date>March 20, 2017</start_date>
    <primary_completion_date>May 9, 2019</primary_completion_date>
    <completion_date>May 9, 2019</completion_date>
    <study_first_posted>May 12, 2017</study_first_posted>
    <last_update_posted>May 21, 2019</last_update_posted>
    <locations>
      <location>General pratices, France, France</location>
      <location>Eurofins Optimed, Gieres, France</location>
      <location>Créabio Rhône Alpes, Givors, France</location>
      <location>Institut Pasteur de Lille, Lille, France</location>
      <location>Biofortis Mérieux NutriSciences, Saint Herblain, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03150212</url>
  </study>
  <study rank="385">
    <nct_id>NCT02358694</nct_id>
    <title>Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Serum-Derived Bovine Immunoglobulin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Quality of Life Scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Connecticut Children's Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>SBI-IBS-D</other_id>
    </other_ids>
    <start_date>June 15, 2014</start_date>
    <primary_completion_date>June 1, 2015</primary_completion_date>
    <completion_date>June 1, 2015</completion_date>
    <study_first_posted>February 9, 2015</study_first_posted>
    <last_update_posted>February 18, 2019</last_update_posted>
    <locations>
      <location>Connecticut Childrens Medical Center, Farmington, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02358694</url>
  </study>
  <study rank="386">
    <nct_id>NCT03099785</nct_id>
    <title>Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifamycin SV 600mg t.i.d.</intervention>
      <intervention type="Drug">Rifamycin SV b.i.d. + Placebo</intervention>
      <intervention type="Drug">Placebo t.i.d.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with relief from abdominal pain and improved stool consistency.</outcome_measure>
      <outcome_measure>Proportion of subjects with relief of global IBS symptoms during weeks 3-12 [Efficacy]</outcome_measure>
      <outcome_measure>Proportion of subjects with monthly relief of global IBS symptoms [Efficacy]</outcome_measure>
      <outcome_measure>Proportion of subjects with relief of IBS-related bloating during weeks 3-12 [Efficacy]</outcome_measure>
      <outcome_measure>Proportion of subjects with monthly relief of IBS-related bloating [Efficacy]</outcome_measure>
      <outcome_measure>Proportion of subjects with weekly relief of IBS symptoms, bloating and abdominal pain [Efficacy]</outcome_measure>
      <outcome_measure>Number of weeks of IBS-symptom relief during follow-up [Efficacy]</outcome_measure>
      <outcome_measure>Number of weeks of bloating relief during follow-up [Efficacy]</outcome_measure>
      <outcome_measure>Change in IBS-symptoms, bloating and abdominal pain from baseline to 12 weeks - captured by a daily diary [Efficacy]</outcome_measure>
      <outcome_measure>Proportion of monthly responders for IBS-symptoms, bloating and abdominal pain [Efficacy]</outcome_measure>
      <outcome_measure>Change from baseline to each week during follow up for IBS-symptoms bloating, abdominal pain, stool consistency, urgency - captured by a daily diary [Efficacy]</outcome_measure>
      <outcome_measure>Change from baseline at weeks 4, 8 and 12 in quality of life assessment [Efficacy]</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cosmo Technologies Ltd</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>342</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CB-01-11/28</other_id>
    </other_ids>
    <start_date>December 18, 2017</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>February 28, 2020</completion_date>
    <study_first_posted>April 4, 2017</study_first_posted>
    <last_update_posted>November 20, 2018</last_update_posted>
    <locations>
      <location>University Hospital Gasthuisberg, Department of Gastroenterology, Leuven, Herestraat 49, Belgium</location>
      <location>St Lukas Ziekenhuis,, Brugge, Lucaslaan 29, Belgium</location>
      <location>Department of Gastroenterology, Erasme Hospital, 808 Route de Lennik, Brussels, Belgium</location>
      <location>Clinique universitaires Saint-Luc Gastroenterologie Route 606 Avenue Hippocrate, 10, Bruxelles, Belgium</location>
      <location>Maria Middelares, Digestief Centrum, Buitenring St-Denijs 30, Gent, Belgium</location>
      <location>University Hospital Gent, Depintelaan 185, Gent, Belgium</location>
      <location>Internistenzentrum Bahnhofstrasse 30, Gauting, Germany</location>
      <location>Gastroenterologie, Interventionelle Endoskopie, Diabetologie und Akutgeriatrie, KRH-Zentrumsgeschaftsfuhrer innere Medizin, KRK Klinikum Siloah-Oststadt-Heidehaus Stadionbrucke 4, Hannover, Germany</location>
      <location>AmBeNet GmbH, Wilhelm-Leuschner-Platz I2,, Leipzig, Germany</location>
      <location>Universitatsklinikum Magdeburg A.O.R. Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Leipziger Str.44, Magdeburg, Germany</location>
      <location>S.O.C Gastroenterologia Oncologica, Aviano, PN, Italy</location>
      <location>Azienda Ospedaliera G. Brotzu, U.O. di Gastroenterelogia, Via Peretti, Cagliari, Italy</location>
      <location>Istituto Clinico Humanitas, Centro Malattie Infiammatorie Croniche Intestinali, Milano, Italy</location>
      <location>Fonazione IRCCS Ospedale Maggiore, Milano, Italy</location>
      <location>Azienda Ospedaliero-Universitaria di Parma, Amb. Fisiopatologia Digestiva, Parma, Italy</location>
      <location>Fondazione IRCCS Policlinico S. Matteo, Dip Area Medica: Medicina Generale 1, Viale Camillo Golgi, 19, Pavia, Italy</location>
      <location>Polo Scienze Gastroenterologiche ed, Roma, Italy</location>
      <location>Universita Campus Bio Medico, U.O.C di Gastroenterologia ed Endoscopia Digestiva, Roma, Italy</location>
      <location>IRCCS Policlinico San Donato, Medicina Generale III- Gastroenterologia, San Donato Milanese, Italy</location>
      <location>Hospital Universitari Germans Trias i Pijol (Can Ruti). Servicio de Aparto Digestivo Carretera de Canyet, s/n, Badalona, Barcelona, Spain</location>
      <location>Hospital Universitario La Paz, Servicio de Aparato Digestivo Po de la Castellana 261, Castellana, Madrid, Spain</location>
      <location>Hospital Universitario Ramon Y Cajal, Servicio de Gastroenterologia y Hepatologia Ctra. de colmenar Viejo, Km 9,100, Colmenar Viejo, Madrid, Spain</location>
      <location>Centro Medico Teknon, Servicio de Aparato Digestivo, Carrer de Vilana 12, Barcelona, Spain</location>
      <location>Hospital Universitari vall d'Hebron, Servicio de Aparato Digestivo, Passeig Vall d'Hebron, 119-129, Barcelona, Spain</location>
      <location>Hospital Universitario Clinico San Carlos, Servicio de Aparato Digestivo, Calle del Prof Martin Lagos, s/n,, Madrid, Spain</location>
      <location>Fundacion de Investigacion Biomedica Hospital 12 de Octubre, Hospital Universitario 12 de Octubre, Servicio de Apartato Digestivo, Avenda de Cordoba s/n, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03099785</url>
  </study>
  <study rank="387">
    <nct_id>NCT02837783</nct_id>
    <title>A Study of the Effect of Linaclotide on Abdominal Girth in Participants With IBS-C</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean Change in Abdominal Girth (physical measure of bloating/distention)</outcome_measure>
      <outcome_measure>Change from Baseline in Abdominal Distension at Week 2</outcome_measure>
      <outcome_measure>Change from Baseline in Maximal Abdominal Distension at Week 4</outcome_measure>
      <outcome_measure>Change from Baseline of symptom severity (abdominal pain, discomfort, bloating, and distension)</outcome_measure>
      <outcome_measure>Change from Baseline in Digestive sensations (subjective bloating, abdominal discomfort, abdominal distension and abdominal pain) at Weeks 4 and 8</outcome_measure>
      <outcome_measure>Change from Baseline of Bristol Stool Form Scale at Weeks 4 and 8</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ironwood Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Manchester University NHS Foundation Trust</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MCP-103-403</other_id>
    </other_ids>
    <start_date>December 21, 2016</start_date>
    <primary_completion_date>October 31, 2018</primary_completion_date>
    <completion_date>October 31, 2018</completion_date>
    <study_first_posted>July 20, 2016</study_first_posted>
    <last_update_posted>March 13, 2019</last_update_posted>
    <locations>
      <location>Peter Whorwell, Wythenshawe, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02837783</url>
  </study>
  <study rank="388">
    <nct_id>NCT01726751</nct_id>
    <title>Spinal Cord Stimulation for Pain Relief in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
      <condition>Diarrhea</condition>
      <condition>Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Spinal Cord Stimultion (SCS)</intervention>
      <intervention type="Device">Spinal cord nerve stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To investigate if typical abdominal pain of IBS can be ameliorated by SCS?</outcome_measure>
      <outcome_measure>To record effects of SCS on diarrhea/constipation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uppsala University</lead_sponsor>
      <collaborator>Medtronics, Inc.</collaborator>
      <collaborator>Bengt Ihre Foundation</collaborator>
      <collaborator>The Swedish Society of Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SCS-IBS-004</other_id>
    </other_ids>
    <start_date>August 2005</start_date>
    <primary_completion_date>April 2014</primary_completion_date>
    <completion_date>April 2014</completion_date>
    <study_first_posted>November 15, 2012</study_first_posted>
    <last_update_posted>November 7, 2018</last_update_posted>
    <locations>
      <location>Karolinska University Hospital, Solna, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01726751</url>
  </study>
  <study rank="389">
    <nct_id>NCT01574209</nct_id>
    <title>Gut Peptides and Intestinal Permeability in Celiac Disease and Irritable Bowel Syndrome</title>
    <acronym>PPCD</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Plasma concentrations of GI peptides (Zonulin, GLP-2, Ghrelin and EGF)</outcome_measure>
      <outcome_measure>Intestinal permeability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CD5X1000</other_id>
    </other_ids>
    <start_date>April 2012</start_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <completion_date>October 2012</completion_date>
    <study_first_posted>April 10, 2012</study_first_posted>
    <last_update_posted>November 9, 2012</last_update_posted>
    <locations>
      <location>National Institute of Digestive Diseases IRCCS &quot;S. de Bellis&quot;, Castellana Grotte, Bari, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01574209</url>
  </study>
  <study rank="390">
    <nct_id>NCT02239926</nct_id>
    <title>Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D</title>
    <acronym>Ranolazine</acronym>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ranolazine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in Diarrhea Using the Bowel Symptom Score (BSS).</outcome_measure>
      <outcome_measure>Mean Abdominal Pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-000581</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <completion_date>September 2015</completion_date>
    <study_first_posted>September 15, 2014</study_first_posted>
    <results_first_posted>February 8, 2016</results_first_posted>
    <last_update_posted>March 15, 2016</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02239926</url>
  </study>
  <study rank="391">
    <nct_id>NCT02686138</nct_id>
    <title>A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C</title>
    <acronym>T3MPO-2</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenapanor</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Subjects with Overall Response for 6 out of 12 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 out of 12 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Abdominal Pain Response for 6 out of 12 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Response for 13 out of 26 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 out of 26 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Abdominal Pain Response for 13 out of 26 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Response for 9 out of 12 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 out of 12 Weeks</outcome_measure>
      <outcome_measure>Percentage of Subjects with Overall Abdominal Pain Response for 9 out of 12 Weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ardelyx</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>593</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TEN-01-302</other_id>
    </other_ids>
    <start_date>December 2015</start_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <completion_date>October 2017</completion_date>
    <study_first_posted>February 19, 2016</study_first_posted>
    <last_update_posted>March 14, 2019</last_update_posted>
    <locations>
      <location>Ardelyx Investigative Site 257, Dothan, Alabama, United States</location>
      <location>Ardelyx Investigative Site 200, Foley, Alabama, United States</location>
      <location>Ardelyx Investigative Site 103, Huntsville, Alabama, United States</location>
      <location>Ardelyx Investigative Site 244, Huntsville, Alabama, United States</location>
      <location>Ardelyx Investigative Site 251, Huntsville, Alabama, United States</location>
      <location>Ardelyx Investigative Site 100, Huntsville, Alabama, United States</location>
      <location>Ardelyx Investigative Site 209, Saraland, Alabama, United States</location>
      <location>Ardelyx Investigative Site 210, Phoenix, Arizona, United States</location>
      <location>Ardelyx Investigative Site 296, Phoenix, Arizona, United States</location>
      <location>Ardelyx Investigative Site 269, Tucson, Arizona, United States</location>
      <location>Ardelyx Investigative Site 256, Tucson, Arizona, United States</location>
      <location>Ardelyx Investigative Site 292, Conway, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 122, Little Rock, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 163, Anaheim, California, United States</location>
      <location>Ardelyx Investigative Site 105, Canoga Park, California, United States</location>
      <location>Ardelyx Investigative Site 143, Chula Vista, California, United States</location>
      <location>Ardelyx Investigative Site 147, Encino, California, United States</location>
      <location>Ardelyx Investigative Site 297, La Mesa, California, United States</location>
      <location>Ardelyx Investigative Site 284, La Mirada, California, United States</location>
      <location>Ardelyx Investigative Site 107, Lomita, California, United States</location>
      <location>Ardelyx Investigative Site 165, Long Beach, California, United States</location>
      <location>Ardelyx Investigative Site 211, Orange, California, United States</location>
      <location>Ardelyx Investigative Site 233, Wheat Ridge, Colorado, United States</location>
      <location>Ardelyx Investigative Site 212, Bristol, Connecticut, United States</location>
      <location>Ardelyx Investigative Site 176, Brandon, Florida, United States</location>
      <location>Ardelyx Investigative Site 178, Cutler Bay, Florida, United States</location>
      <location>Ardelyx Investigative Site 136, Hialeah, Florida, United States</location>
      <location>Ardelyx Investigative Site 130, Hialeah, Florida, United States</location>
      <location>Ardelyx Investigative Site 191, Lynn Haven, Florida, United States</location>
      <location>Ardelyx Investigative Site 127, Miami Lakes, Florida, United States</location>
      <location>Ardelyx Investigative Site 288, Miami, Florida, United States</location>
      <location>Ardelyx Investigative Site 106, Miami, Florida, United States</location>
      <location>Ardelyx Investigative Site 179, Orlando, Florida, United States</location>
      <location>Ardelyx Investigative Site 290, Tampa, Florida, United States</location>
      <location>Ardelyx Investigative Site 254, West Palm Beach, Florida, United States</location>
      <location>Ardelyx Investigative Site 138, Atlanta, Georgia, United States</location>
      <location>Ardelyx Investigative Site 148, Atlanta, Georgia, United States</location>
      <location>Ardelyx Investigative Site 253, Atlanta, Georgia, United States</location>
      <location>Ardelyx Investigative Site 272, Decatur, Georgia, United States</location>
      <location>Ardelyx Investigative Site 229, Decatur, Georgia, United States</location>
      <location>Ardelyx Investigative Site 250, Marietta, Georgia, United States</location>
      <location>Ardelyx Investigative Site 137, Norcross, Georgia, United States</location>
      <location>Ardelyx Investigative Site 213, Savannah, Georgia, United States</location>
      <location>Ardelyx Investigative Site 124, Snellville, Georgia, United States</location>
      <location>Ardelyx Investigative Site 268, Burr Ridge, Illinois, United States</location>
      <location>Ardelyx Investigative Site 227, Evergreen Park, Illinois, United States</location>
      <location>Ardelyx Investigative Site 291, Hoffman Estates, Illinois, United States</location>
      <location>Ardelyx Investigative Site 202, Oak Lawn, Illinois, United States</location>
      <location>Ardelyx Investigative Site 218, Evansville, Indiana, United States</location>
      <location>Ardelyx Investigative Site 158, Madisonville, Kentucky, United States</location>
      <location>Ardelyx Investigative Site 270, Mandeville, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 214, Marrero, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 154, Metairie, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 195, Shreveport, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 271, Bangor, Maine, United States</location>
      <location>Ardelyx Investigative Site 160, Annapolis, Maryland, United States</location>
      <location>Ardelyx Investigative Site 255, Towson, Maryland, United States</location>
      <location>Ardelyx Investigative Site 267, Brockton, Massachusetts, United States</location>
      <location>Ardelyx Investigative Site 260, Ann Arbor, Michigan, United States</location>
      <location>Ardelyx Investigative Site 283, Buckley, Michigan, United States</location>
      <location>Ardelyx Investigative Site 239, Flint, Michigan, United States</location>
      <location>Ardelyx Investigative Site 168, Troy, Michigan, United States</location>
      <location>Ardelyx Investigative Site 216, Wyoming, Michigan, United States</location>
      <location>Ardelyx Investigative Site 221, Biloxi, Mississippi, United States</location>
      <location>Ardelyx Investigative Site 282, Jefferson City, Missouri, United States</location>
      <location>Ardelyx Investigative Site 228, Saint Louis, Missouri, United States</location>
      <location>Ardelyx Investigative Site 156, Billings, Montana, United States</location>
      <location>Ardelyx Investigative Site 182, Las Vegas, Nevada, United States</location>
      <location>Ardelyx Investigative Site 175, Vineland, New Jersey, United States</location>
      <location>Ardelyx Investigative Site 222, Albuquerque, New Mexico, United States</location>
      <location>Ardelyx Investigative Site 264, Albuquerque, New Mexico, United States</location>
      <location>Ardelyx Investigative Site 230, Brooklyn, New York, United States</location>
      <location>Ardelyx Investigative Site 170, Great Neck, New York, United States</location>
      <location>Ardelyx Investigative Site 203, New Hyde Park, New York, United States</location>
      <location>Ardelyx Investigative Site 205, Fayetteville, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 190, Greensboro, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 194, Hickory, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 285, Wilmington, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 172, Beavercreek, Ohio, United States</location>
      <location>Ardelyx Investigative Site 204, Cincinnati, Ohio, United States</location>
      <location>Ardelyx Investigative Site 201, Cincinnati, Ohio, United States</location>
      <location>Ardelyx Investigative Site 173, Dayton, Ohio, United States</location>
      <location>Ardelyx Investigative Site 208, Franklin, Ohio, United States</location>
      <location>Ardelyx Investigative Site 171, Huber Heights, Ohio, United States</location>
      <location>Ardelyx Investigative Site 219, Lima, Ohio, United States</location>
      <location>Ardelyx Investigative Site 232, Wadsworth, Ohio, United States</location>
      <location>Ardelyx Investigative Site 236, Oklahoma City, Oklahoma, United States</location>
      <location>Ardelyx Investigative Site 273, Tulsa, Oklahoma, United States</location>
      <location>Ardelyx Investigative Site 220, Levittown, Pennsylvania, United States</location>
      <location>Ardelyx Investigative Site 248, East Providence, Rhode Island, United States</location>
      <location>Ardelyx Investigative Site 252, Columbia, South Carolina, United States</location>
      <location>Ardelyx Investigative Site 265, Gaffney, South Carolina, United States</location>
      <location>Ardelyx Investigative Site 246, Rapid City, South Dakota, United States</location>
      <location>Ardelyx Investigative Site 261, Sioux Falls, South Dakota, United States</location>
      <location>Ardelyx Investigative Site 217, Chattanooga, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 121, Franklin, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 189, Hermitage, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 133, Jackson, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 109, Knoxville, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 266, Memphis, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 235, Nashville, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 279, Spring Hill, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 180, Channelview, Texas, United States</location>
      <location>Ardelyx Investigative Site 286, Houston, Texas, United States</location>
      <location>Ardelyx Investigative Site 262, Houston, Texas, United States</location>
      <location>Ardelyx Investigative Site 185, Houston, Texas, United States</location>
      <location>Ardelyx Investigative Site 113, McKinney, Texas, United States</location>
      <location>Ardelyx Investigative Site 263, Port Arthur, Texas, United States</location>
      <location>Ardelyx Investigative Site 181, San Antonio, Texas, United States</location>
      <location>Ardelyx Investigative Site 186, San Antonio, Texas, United States</location>
      <location>Ardelyx Investigative Site 167, Salt Lake City, Utah, United States</location>
      <location>Ardelyx Investigative Site 249, Norfolk, Virginia, United States</location>
      <location>Ardelyx Investigative Site 231, Norfolk, Virginia, United States</location>
      <location>Ardelyx Investigative Site 258, Petersburg, Virginia, United States</location>
      <location>Ardelyx Investigative Site 245, Virginia Beach, Virginia, United States</location>
      <location>Ardelyx Investigative Site 242, Spokane, Washington, United States</location>
      <location>Ardelyx Investigative Site 195, Morgantown, West Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02686138</url>
  </study>
  <study rank="392">
    <nct_id>NCT02621892</nct_id>
    <title>A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C</title>
    <acronym>T3MPO-1</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenapanor</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>6 of 12 Week Overall Responder Rate</outcome_measure>
      <outcome_measure>6 of 12 Week Overall Complete Spontaneous Bowel Movement (CSBM)Responder Rate</outcome_measure>
      <outcome_measure>6 of 12 Week Overall Abdominal Pain Responder Rate</outcome_measure>
      <outcome_measure>9 of 12 Week Overall Responder Rate</outcome_measure>
      <outcome_measure>9 of 12 Week Overall CSBM Responder Rate</outcome_measure>
      <outcome_measure>9 of 12 Week Overall Abdominal Pain Responder Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ardelyx</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>629</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TEN-01-301</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <completion_date>April 2017</completion_date>
    <study_first_posted>December 4, 2015</study_first_posted>
    <last_update_posted>March 15, 2019</last_update_posted>
    <locations>
      <location>Ardelyx Investigative Site 149, Birmingham, Alabama, United States</location>
      <location>Ardelyx Investigative Site 114, Birmingham, Alabama, United States</location>
      <location>Ardelyx Investigative Site 103, Huntsville, Alabama, United States</location>
      <location>Ardelyx Investigative Site 100, Huntsville, Alabama, United States</location>
      <location>Ardelyx Investigative Site 145, Chandler, Arizona, United States</location>
      <location>Ardelyx Investigative Site 210, Phoenix, Arizona, United States</location>
      <location>Ardelyx Investigative Site 296, Phoenix, Arizona, United States</location>
      <location>Ardelyx Investigative Site 277, Tempe, Arizona, United States</location>
      <location>Ardelyx Investigative Site 269, Tucson, Arizona, United States</location>
      <location>Ardelyx Investigative Site 187, Tucson, Arizona, United States</location>
      <location>Ardelyx Investigative Site 199, Tucson, Arizona, United States</location>
      <location>Ardelyx Investigative Site 140, Harrisburg, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 274, Little Rock, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 161, Little Rock, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 122, Little Rock, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 129, North Little Rock, Arkansas, United States</location>
      <location>Ardelyx Investigative Site 105, Canoga Park, California, United States</location>
      <location>Ardelyx Investigative Site 143, Chula Vista, California, United States</location>
      <location>Ardelyx Investigative Site 146, Encino, California, United States</location>
      <location>Ardelyx Investigative Site 147, Encino, California, United States</location>
      <location>Ardelyx Investigative Site 107, Lomita, California, United States</location>
      <location>Ardelyx Investigative Site 112, North Hollywood, California, United States</location>
      <location>Ardelyx Investigative Site 110, Northridge, California, United States</location>
      <location>Ardelyx Investigative Site 294, San Diego, California, United States</location>
      <location>Ardelyx Investigative Site 108, Thousand Oaks, California, United States</location>
      <location>Ardelyx Investigative Site 178, Cutler Bay, Florida, United States</location>
      <location>Ardelyx Investigative Site 131, Fort Lauderdale, Florida, United States</location>
      <location>Ardelyx Investigative Site 136, Hialeah, Florida, United States</location>
      <location>Ardelyx Investigative Site 130, Hialeah, Florida, United States</location>
      <location>Ardelyx Investigative Site 287, Homestead, Florida, United States</location>
      <location>Ardelyx Investigative Site 127, Miami Lakes, Florida, United States</location>
      <location>Ardelyx Investigative Site 123, Miami Springs, Florida, United States</location>
      <location>Ardelyx Investigative Site 106, Miami, Florida, United States</location>
      <location>Ardelyx Investigative Site 126, Pompano Beach, Florida, United States</location>
      <location>Ardelyx Investigative Site 132, Port Orange, Florida, United States</location>
      <location>Ardelyx Investigative Site 150, Saint Petersburg, Florida, United States</location>
      <location>Ardelyx Investigative Site 254, West Palm Beach, Florida, United States</location>
      <location>Ardelyx Investigative Site 234, Athens, Georgia, United States</location>
      <location>Ardelyx Investigative Site 138, Atlanta, Georgia, United States</location>
      <location>Ardelyx Investigative Site 148, Atlanta, Georgia, United States</location>
      <location>Ardelyx Investigative Site 137, Norcross, Georgia, United States</location>
      <location>Ardelyx Investigative Site 213, Savannah, Georgia, United States</location>
      <location>Ardelyx Investigative Site 124, Snellville, Georgia, United States</location>
      <location>Ardelyx Investigative Site 157, Boise, Idaho, United States</location>
      <location>Ardelyx Investigative Site 102, Blue Island, Illinois, United States</location>
      <location>Ardelyx Investigative Site 162, Evanston, Illinois, United States</location>
      <location>Ardelyx Investigative Site 202, Oak Lawn, Illinois, United States</location>
      <location>Ardelyx Investigative Site 259, Topeka, Kansas, United States</location>
      <location>Ardelyx Investigative Site 192, Crowley, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 188, Metairie, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 177, Monroe, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 198, Zachary, Louisiana, United States</location>
      <location>Ardelyx Investigative Site 278, Hagerstown, Maryland, United States</location>
      <location>Ardelyx Investigative Site 255, Towson, Maryland, United States</location>
      <location>Ardelyx Investigative Site 135, Boston, Massachusetts, United States</location>
      <location>Ardelyx Investigative Site 267, Brockton, Massachusetts, United States</location>
      <location>Ardelyx Investigative Site 119, Caro, Michigan, United States</location>
      <location>Ardelyx Investigative Site 128, Chesterfield, Michigan, United States</location>
      <location>Ardelyx Investigative Site 224, Saginaw, Michigan, United States</location>
      <location>Ardelyx Investigative Site 125, Belton, Missouri, United States</location>
      <location>Ardelyx Investigative Site 156, Billings, Montana, United States</location>
      <location>Ardelyx Investigative Site 142, Omaha, Nebraska, United States</location>
      <location>Ardelyx Investigative Site 275, Las Vegas, Nevada, United States</location>
      <location>Ardelyx Investigative Site 276, Las Vegas, Nevada, United States</location>
      <location>Ardelyx Investigative Site 182, Las Vegas, Nevada, United States</location>
      <location>Ardelyx Investigative Site 175, Vineland, New Jersey, United States</location>
      <location>Ardelyx Investigative Site 293, Albuquerque, New Mexico, United States</location>
      <location>Ardelyx Investigative Site 151, Brooklyn, New York, United States</location>
      <location>Ardelyx Investigative Site 170, Great Neck, New York, United States</location>
      <location>Ardelyx Investigative Site 225, Hartsdale, New York, United States</location>
      <location>Ardelyx Investigative Site 206, New Windsor, New York, United States</location>
      <location>Ardelyx Investigative Site 183, New York, New York, United States</location>
      <location>Ardelyx Investigative Site 226, Asheville, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 166, Charlotte, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 205, Fayetteville, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 104, Greensboro, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 174, Kinston, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 280, Winston-Salem, North Carolina, United States</location>
      <location>Ardelyx Investigative Site 172, Beavercreek, Ohio, United States</location>
      <location>Ardelyx Investigative Site 223, Cincinnati, Ohio, United States</location>
      <location>Ardelyx Investigative Site 201, Cincinnati, Ohio, United States</location>
      <location>Ardelyx Investigative Site 139, Columbus, Ohio, United States</location>
      <location>Ardelyx Investigative Site 173, Dayton, Ohio, United States</location>
      <location>Ardelyx Investigative Site 171, Huber Heights, Ohio, United States</location>
      <location>Ardelyx Investigative Site 117, Mentor, Ohio, United States</location>
      <location>Ardelyx Investigative Site 247, Springfield, Ohio, United States</location>
      <location>Ardelyx Investigative Site 144, Jenkintown, Pennsylvania, United States</location>
      <location>Ardelyx Investigative Site 289, Mount Pleasant, South Carolina, United States</location>
      <location>Ardelyx Investigative Site 184, Myrtle Beach, South Carolina, United States</location>
      <location>Ardelyx Investigative Site 281, North Charleston, South Carolina, United States</location>
      <location>Ardelyx Investigative Site 261, Sioux Falls, South Dakota, United States</location>
      <location>Ardelyx Investigative Site 134, Chattanooga, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 121, Franklin, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 189, Hermitage, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 133, Jackson, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 109, Knoxville, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 235, Nashville, Tennessee, United States</location>
      <location>Ardelyx Investigative Site 164, Corpus Christi, Texas, United States</location>
      <location>Ardelyx Investigative Site 197, Corsicana, Texas, United States</location>
      <location>Ardelyx Investigative Site 185, Houston, Texas, United States</location>
      <location>Ardelyx Investigative Site 120, Houston, Texas, United States</location>
      <location>Ardelyx Investigative Site 113, McKinney, Texas, United States</location>
      <location>Ardelyx Investigative Site 111, Plano, Texas, United States</location>
      <location>Ardelyx Investigative Site 118, Plano, Texas, United States</location>
      <location>Ardelyx Investigative Site 101, San Antonio, Texas, United States</location>
      <location>Ardelyx Investigative Site 240, San Antonio, Texas, United States</location>
      <location>Ardelyx Investigative Site 159, Orem, Utah, United States</location>
      <location>Ardelyx Investigative Site 207, Sandy, Utah, United States</location>
      <location>Ardelyx Investigative Site 155, South Ogden, Utah, United States</location>
      <location>Ardelyx Investigative Site 231, Norfolk, Virginia, United States</location>
      <location>Ardelyx Investigative Site 141, Richmond, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02621892</url>
  </study>
  <study rank="393">
    <nct_id>NCT02111603</nct_id>
    <title>Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colesevelam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Total 48 Hour Fecal Bile Acids (BA) From Baseline in Response to Treatment With Colesevelam</outcome_measure>
      <outcome_measure>Change in Fasting Serum C4</outcome_measure>
      <outcome_measure>Change in Fecal Fat Excretion</outcome_measure>
      <outcome_measure>Change in Stool Consistency</outcome_measure>
      <outcome_measure>Change in Stool Frequency (Number of Stools Per Week)</outcome_measure>
      <outcome_measure>Concordance Correlation Coefficients of the Relative Composition of Stool Total and the Main Individual Bile Acids (BA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-000384</other_id>
      <other_id>R01DK092179</other_id>
      <other_id>UL1TR000135</other_id>
    </other_ids>
    <start_date>April 2014</start_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <completion_date>September 2015</completion_date>
    <study_first_posted>April 11, 2014</study_first_posted>
    <results_first_posted>January 27, 2016</results_first_posted>
    <last_update_posted>May 12, 2016</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02111603</url>
  </study>
  <study rank="394">
    <nct_id>NCT02493036</nct_id>
    <title>A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SYN-010</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Study 1 (NCT02495623) Baseline in the Area Under the Curve (AUC) of Breath CH4 Production, Based on a 180-minute Lactulose Breath Test (LBT) at Day 56 Post-dose.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Synthetic Biologics Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SB-2-010-002</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>July 9, 2015</study_first_posted>
    <results_first_posted>March 8, 2017</results_first_posted>
    <last_update_posted>November 27, 2018</last_update_posted>
    <locations>
      <location>Hialeah, Florida, United States</location>
      <location>Miami Lakes, Florida, United States</location>
      <location>Miami Springs, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Miami, Florida, United States</location>
      <location>Saint Petersburg, Florida, United States</location>
      <location>Tampa, Florida, United States</location>
      <location>Virginia Gardens, Florida, United States</location>
      <location>West Palm Beach, Florida, United States</location>
      <location>New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02493036</url>
  </study>
  <study rank="395">
    <nct_id>NCT00702026</nct_id>
    <title>The Effect of a Multispecies Probiotic on Hypersensitivity in Irritable Bowel Syndrome (IBS) Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Hypersensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">multispecies probiotic (Ecologic 801)</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain tolerance threshold</outcome_measure>
      <outcome_measure>VAS score for pain at pressure step 29 mmHg</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>Winclove Bio Industries BV</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MEC 08-1-031</other_id>
    </other_ids>
    <start_date>August 2008</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>December 2011</completion_date>
    <study_first_posted>June 19, 2008</study_first_posted>
    <last_update_posted>January 29, 2013</last_update_posted>
    <locations>
      <location>University Hospital Maastricht, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00702026</url>
  </study>
  <study rank="396">
    <nct_id>NCT02980406</nct_id>
    <title>The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">FODMAP</intervention>
      <intervention type="Dietary Supplement">Glucose (control)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in intragastric pressure measured by high resolution manometry</outcome_measure>
      <outcome_measure>Change in subjective gastrointestinal symptom scores measured by visual analogue scale of 100 mm</outcome_measure>
      <outcome_measure>Change in mood/emotion measured by Profile Of Mood States (POMS) questionnaire.</outcome_measure>
      <outcome_measure>Change in mood/emotion measured by Self Assessment Manikin (SAM) questionnaire.</outcome_measure>
      <outcome_measure>Change in mood/emotion measured by Positive and Negative Affect Scale (PANAS).</outcome_measure>
      <outcome_measure>Change in mood/emotion measured by State Trait Anxiety Index questionnaire.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universitaire Ziekenhuizen Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
    </study_designs>
    <other_ids>
      <other_id>FODMAP1</other_id>
    </other_ids>
    <start_date>September 2015</start_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>December 2, 2016</study_first_posted>
    <last_update_posted>December 2, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02980406</url>
  </study>
  <study rank="397">
    <nct_id>NCT01131442</nct_id>
    <title>Immunological Change and the Single Nucleotide Polymorphism (SNP) in Children With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Children</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>CMRPG270371</other_id>
    </other_ids>
    <start_date>November 2008</start_date>
    <study_first_posted>May 27, 2010</study_first_posted>
    <last_update_posted>May 27, 2010</last_update_posted>
    <locations>
      <location>Chang Gung Memeorial Hospital, Keelung, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01131442</url>
  </study>
  <study rank="398">
    <nct_id>NCT00948870</nct_id>
    <title>Trial of Chinese Prescription Shugan Decoction on Irritable Bowel Syndrome（Diarrhea Type）</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Traditional Chinese Medicine</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Shugan decoction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptoms and conditions of tongue and pulse</outcome_measure>
      <outcome_measure>Indicates of liver and renal function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai University of Traditional Chinese Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SHTCM-002</other_id>
    </other_ids>
    <start_date>August 2009</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>September 2011</completion_date>
    <study_first_posted>July 29, 2009</study_first_posted>
    <last_update_posted>March 7, 2013</last_update_posted>
    <locations>
      <location>Longhua hospital, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00948870</url>
  </study>
  <study rank="399">
    <nct_id>NCT03920410</nct_id>
    <title>Effect of Serotonergic Stimulation on the Gut-brain Axis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">serotonergic stimulation</intervention>
      <intervention type="Other">no serotonergic stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Differences in functional brain response pattern to the barostat in stimulated compared to unstimulated serotonergic activity</outcome_measure>
      <outcome_measure>Differences in functional brain response pattern to the Montreal Imaging Stress Task between stimulated and unstimulated serotonergic activity</outcome_measure>
      <outcome_measure>Differences in functional brain response pattern to the Emotional Attention Task between stimulated and unstimulated serotonergic activity</outcome_measure>
      <outcome_measure>Differences in functional brain response pattern to the barostat stimulus paradigm between irritable bowel syndrome patients and healthy controls for stimulated and unstimulated serotonergic activity</outcome_measure>
      <outcome_measure>Differences in functional brain response pattern to the Montreal imaging stress task (MIST) between irritable bowel syndrome patients and healthy controls for stimulated and unstimulated serotonergic activity</outcome_measure>
      <outcome_measure>Differences in functional brain response pattern to the emotional attention task (EAT) between irritable bowel syndrome patients and healthy controls for stimulated and unstimulated serotonergic activity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Örebro University, Sweden</lead_sponsor>
      <collaborator>Region Örebro County</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>5HT</other_id>
    </other_ids>
    <start_date>April 24, 2019</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 18, 2019</study_first_posted>
    <last_update_posted>May 30, 2019</last_update_posted>
    <locations>
      <location>Örebro University, Region Örebro County, Örebro, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03920410</url>
  </study>
  <study rank="400">
    <nct_id>NCT00584298</nct_id>
    <title>Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SMS995</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>- 5 sensory pressure thresholds [mmHg] from ascending method of limits (AML) barostat protocol. - 16 sensory intensity ratings from the random phasic distention (RPD) barostat protocol.</outcome_measure>
      <outcome_measure>- colorectal compliance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>CSMS995A2101</other_id>
    </other_ids>
    <start_date>January 2008</start_date>
    <primary_completion_date>April 2009</primary_completion_date>
    <study_first_posted>January 2, 2008</study_first_posted>
    <last_update_posted>May 8, 2009</last_update_posted>
    <locations>
      <location>Novartis Investigator Site, Boston, Massachusetts, United States</location>
      <location>Novartis Investigator Site, Rochester, Minnesota, United States</location>
      <location>Novartis Investigator Site, Hamilton, Canada</location>
      <location>Novartis Investigator Site, Gothenburg, Sweden</location>
      <location>Novartis Investigator Site, London, United Kingdom</location>
      <location>Novartis Investigator Site, Manchester, United Kingdom</location>
      <location>Novartis Investigator Site, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00584298</url>
  </study>
  <study rank="401">
    <nct_id>NCT00880256</nct_id>
    <title>Mindfulness-Based Stress Reduction for Bowel Symptoms: Collection of Pilot Survey Data</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">mindfulness-based stress reduction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS (Irritable Bowel Syndrome) Symptom Severity Score (Total Score)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome (IBS) Quality of Life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seattle Institute for Biomedical and Clinical Research</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>93</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0013</other_id>
    </other_ids>
    <start_date>September 2008</start_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <completion_date>October 2010</completion_date>
    <study_first_posted>April 13, 2009</study_first_posted>
    <results_first_posted>February 27, 2012</results_first_posted>
    <last_update_posted>February 27, 2012</last_update_posted>
    <locations>
      <location>VA Puget Sound Health Care System, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00880256</url>
  </study>
  <study rank="402">
    <nct_id>NCT02924493</nct_id>
    <title>Dietary Treatment of Endometriosis-related Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Endometriosis</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Visceral Syndrome</condition>
      <condition>Visceral Hypersensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Diet low in fermentable carbohydrates (low FODMAP diet)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Compliance to the diet measured by a self-administered questionnaire with a percentage scale for every meal consumed</outcome_measure>
      <outcome_measure>How manageable the participants experience the diet, measured by semi-quantitative questionnaire designed by the study group</outcome_measure>
      <outcome_measure>Identification of intervention group measured by the question: &quot;What group do you think you were assigned to?&quot;</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms measured by the questionnaire: The Gastrointestinal symptom rating scale (GSRS) irritable bowel syndrome (IBS) version</outcome_measure>
      <outcome_measure>IBS related quality of life measured by the questionnaire: Irritable bowel syndrome - Quality of Life</outcome_measure>
      <outcome_measure>Endometriosis related quality of life measured by the questionnaire: The Endometriosis Health Profile (EHP-30)</outcome_measure>
      <outcome_measure>Intake of nutrients calculated in by: The Monash University Comprehensive Food Frequency Questionnaire (CNAQ) based on the participants self-reported 7-days food registration</outcome_measure>
      <outcome_measure>Intermenstrual pain measured by VAS scale</outcome_measure>
      <outcome_measure>Global symptom relief measured by the question: &quot;Did you have sufficient relief in your IBS-symptoms during the last 7 days?&quot;</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Diet-in-endometriosis</other_id>
    </other_ids>
    <start_date>July 3, 2017</start_date>
    <primary_completion_date>December 1, 2017</primary_completion_date>
    <completion_date>February 1, 2018</completion_date>
    <study_first_posted>October 5, 2016</study_first_posted>
    <last_update_posted>May 17, 2018</last_update_posted>
    <locations>
      <location>Aarhus University Hospital, Aarhus, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02924493</url>
  </study>
  <study rank="403">
    <nct_id>NCT03125564</nct_id>
    <title>FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fecal Microbiota Transplantation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Fecal Microbiota Transplantation</intervention>
      <intervention type="Procedure">Sham</intervention>
      <intervention type="Procedure">Fecal and Mucosal Microbiota Assessment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of responder</outcome_measure>
      <outcome_measure>The proportion of patients who had adequate relief of global IBS symptoms</outcome_measure>
      <outcome_measure>Assess the onset and duration of relief of IBS symptoms</outcome_measure>
      <outcome_measure>The proportion of patients who had improvement on worst abdominal bloating</outcome_measure>
      <outcome_measure>Assess the onset and duration of worst abdominal bloating</outcome_measure>
      <outcome_measure>The proportion of patients who had improvement of abdominal discomfort</outcome_measure>
      <outcome_measure>Assess the onset and duration of abdominal discomfort</outcome_measure>
      <outcome_measure>IBS-d global symptoms score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FMT-IBS study</other_id>
    </other_ids>
    <start_date>April 12, 2017</start_date>
    <primary_completion_date>January 2, 2019</primary_completion_date>
    <completion_date>July 31, 2019</completion_date>
    <study_first_posted>April 24, 2017</study_first_posted>
    <last_update_posted>July 18, 2018</last_update_posted>
    <locations>
      <location>The Chinese University of Hong Kong, Sha Tin, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03125564</url>
  </study>
  <study rank="404">
    <nct_id>NCT00912301</nct_id>
    <title>Cheno Effect on Transit in Health and IBS-C</title>
    <acronym>Chenotransit</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Constipation-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sodium chenodeoxycholate (NaCDC)</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic Geometric Center at 24 Hours (GC24)</outcome_measure>
      <outcome_measure>Colonic Transit at 48 Hours (GC48)</outcome_measure>
      <outcome_measure>Ascending Colon Emptying (AC t_1/2)</outcome_measure>
      <outcome_measure>Stool Consistency</outcome_measure>
      <outcome_measure>Colonic Filling at 6 Hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>National Center for Research Resources (NCRR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-001003</other_id>
      <other_id>R01DK054681</other_id>
      <other_id>R01DK079866</other_id>
      <other_id>UL1RR024150</other_id>
      <other_id>1RC1DK086182</other_id>
    </other_ids>
    <start_date>April 2009</start_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <completion_date>December 2009</completion_date>
    <study_first_posted>June 3, 2009</study_first_posted>
    <results_first_posted>July 2, 2012</results_first_posted>
    <last_update_posted>July 2, 2012</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00912301</url>
  </study>
  <study rank="405">
    <nct_id>NCT03046667</nct_id>
    <title>Effect of 6 Weeks Daily Consumption of a Cereal-based Juice Beverage on Gastrointestinal Health</title>
    <acronym>NEWDRINK</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Barley β-glucan</intervention>
      <intervention type="Dietary Supplement">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stool volume</outcome_measure>
      <outcome_measure>Hydrogen</outcome_measure>
      <outcome_measure>Methane</outcome_measure>
      <outcome_measure>Hydrogen Area Under the Curve</outcome_measure>
      <outcome_measure>Methane Area Under the Curve</outcome_measure>
      <outcome_measure>Fecal concentrations of SCFA</outcome_measure>
      <outcome_measure>Determination and variations in fecal microbiota</outcome_measure>
      <outcome_measure>Fecal concentrations of calprotectin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Copenhagen</lead_sponsor>
      <collaborator>Carlsberg Group</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>M230</other_id>
    </other_ids>
    <start_date>February 8, 2017</start_date>
    <primary_completion_date>July 20, 2017</primary_completion_date>
    <completion_date>December 11, 2017</completion_date>
    <study_first_posted>February 8, 2017</study_first_posted>
    <last_update_posted>December 13, 2017</last_update_posted>
    <locations>
      <location>Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03046667</url>
  </study>
  <study rank="406">
    <nct_id>NCT02613078</nct_id>
    <title>Hypnotherapy vs. Probiotics in Children With IBS and Functional Abdominal Pain</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Abdominal Pain Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Gut-Directed Hypnotherapy</intervention>
      <intervention type="Dietary Supplement">Nutritional Supplement</intervention>
      <intervention type="Behavioral">Self-Monitoring</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in number of days with pain/discomfort</outcome_measure>
      <outcome_measure>Change in parental report on gastrointestinal symptoms (Abdominal Pain Index (API))</outcome_measure>
      <outcome_measure>Change in pain related disability (Pediatric Pain Disability Index (P-PDI))</outcome_measure>
      <outcome_measure>Change in somatic complaints (Children's Somatization Inventory (CSI))</outcome_measure>
      <outcome_measure>Change in health-related quality of life (KINDL-R Questionnaire)</outcome_measure>
      <outcome_measure>Change in pain-related coping (Pediatric Pain Coping Inventory (PPCI))</outcome_measure>
      <outcome_measure>Change in emotional and behavioural problems (Child Behaviour Checklist (CBCL))</outcome_measure>
      <outcome_measure>Change in heart rate variability</outcome_measure>
      <outcome_measure>Change in cortisol awakening response (amount of cortisol in saliva, nmol/l)</outcome_measure>
      <outcome_measure>Change in self-reported pain intensity (Visual Analog Scale)</outcome_measure>
      <outcome_measure>Change in self-reported pain duration (hours per day)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
      <collaborator>SymbioPharm GmbH</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MDG 082015</other_id>
    </other_ids>
    <start_date>March 2016</start_date>
    <primary_completion_date>April 2017</primary_completion_date>
    <completion_date>October 2017</completion_date>
    <study_first_posted>November 24, 2015</study_first_posted>
    <last_update_posted>March 3, 2016</last_update_posted>
    <locations>
      <location>University Clinic, Tübingen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02613078</url>
  </study>
  <study rank="407">
    <nct_id>NCT02727283</nct_id>
    <title>A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK3179106</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of subjects with adverse events (AE) and clinical observations as a measure of safety</outcome_measure>
      <outcome_measure>Assessment of physical examination findings as a measure of safety</outcome_measure>
      <outcome_measure>Safety as assessed by 12-lead electrocardiogram (ECG)</outcome_measure>
      <outcome_measure>Safety as assessed by systolic and diastolic blood pressure measurements</outcome_measure>
      <outcome_measure>Safety as assessed by temperature measurements</outcome_measure>
      <outcome_measure>Safety as assessed by pulse rate measurements</outcome_measure>
      <outcome_measure>Composite of clinical laboratory assessments as a measure of safety includes hematology, clinical chemistry and urinalysis</outcome_measure>
      <outcome_measure>Bristol Stool Form Scale</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve (AUC) from zero to time t (AUC [0-t]) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>AUC from zero to infinity (AUC [0-infinity]) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>AUC from zero to 24 h (AUC [0-24 h]) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax) of escalating single oral doses of GSK3179106 administered under fasting conditions</outcome_measure>
      <outcome_measure>Time to maximum observed plasma concentration (tmax) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>Apparent terminal phase half-life (t1/2) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>Clearance (CL/F) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>Volume of distribution (V/F) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>Absorption rate constant (Ka) of GSK3179106 administered under fasting condition</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve (AUC) from zero to time t (AUC [0-t]) of GSK3179106 administered under fasting and fed condition</outcome_measure>
      <outcome_measure>AUC from zero to infinity (AUC [0-infinity]) of GSK3179106 administered under fasting condition fasting and fed condition</outcome_measure>
      <outcome_measure>AUC from zero to 24 h (AUC [0-24 h]) of GSK3179106 administered under fasting condition fasting and fed condition</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration (Cmax) of escalating single oral doses of GSK3179106 administered under fasting and fed condition</outcome_measure>
      <outcome_measure>Time to maximum observed plasma concentration (tmax) of GSK3179106 administered under fasting and fed condition</outcome_measure>
      <outcome_measure>Apparent terminal phase half-life (t1/2) of GSK3179106 administered under fasting and fed condition</outcome_measure>
      <outcome_measure>Clearance (CL/F) of GSK3179106 administered under fasting and fed condition</outcome_measure>
      <outcome_measure>Volume of distribution (V/F) of GSK3179106 administered under fasting and fed condition</outcome_measure>
      <outcome_measure>Absorption rate constant (Ka) of GSK3179106 administered under fasting and fed condition</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>204729</other_id>
    </other_ids>
    <start_date>November 26, 2015</start_date>
    <primary_completion_date>March 18, 2016</primary_completion_date>
    <completion_date>March 18, 2016</completion_date>
    <study_first_posted>April 4, 2016</study_first_posted>
    <last_update_posted>May 8, 2017</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Adelaide, South Australia, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02727283</url>
  </study>
  <study rank="408">
    <nct_id>NCT00314886</nct_id>
    <title>Effect of Butyrogenic Fibers in IBS Patients</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Discomfort threshold to rectal distension</outcome_measure>
      <outcome_measure>Rectal sensitivity : first sensation and threshold for first sensation of the need to defecate.</outcome_measure>
      <outcome_measure>Intestinal discomfort (questionnaire)</outcome_measure>
      <outcome_measure>Quality of life (questionnaire)</outcome_measure>
      <outcome_measure>Taxonomic composition of colonic flora</outcome_measure>
      <outcome_measure>Functional composition of colonic flora</outcome_measure>
      <outcome_measure>Fermentation profile of ingested fibre</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Clermont-Ferrand</lead_sponsor>
      <collaborator>Institut National de la Recherche Agronomique</collaborator>
      <collaborator>EA 3848 UdA</collaborator>
      <collaborator>ERT: Clinical Trial Technology Solutions</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHU63-0009</other_id>
    </other_ids>
    <start_date>January 2005</start_date>
    <completion_date>July 2005</completion_date>
    <study_first_posted>April 17, 2006</study_first_posted>
    <last_update_posted>January 19, 2011</last_update_posted>
    <locations>
      <location>Clermont-Ferrand University Hospital, Clermont-Ferrand, Auvergne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00314886</url>
  </study>
  <study rank="409">
    <nct_id>NCT03823742</nct_id>
    <title>A Treatment Invention for Children With Functional Gastrointestinal Pain</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cognitive Behavioral Therapy</intervention>
      <intervention type="Other">Low FODMAP Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom Improvement</outcome_measure>
      <outcome_measure>Improvement in quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>University of Washington</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-43391</other_id>
    </other_ids>
    <start_date>February 22, 2019</start_date>
    <primary_completion_date>September 2022</primary_completion_date>
    <completion_date>March 2023</completion_date>
    <study_first_posted>January 30, 2019</study_first_posted>
    <last_update_posted>May 3, 2019</last_update_posted>
    <locations>
      <location>Children's Nutrition Research Center, Houston, Texas, United States</location>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03823742</url>
  </study>
  <study rank="410">
    <nct_id>NCT01728610</nct_id>
    <title>Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotic (Active high)</intervention>
      <intervention type="Dietary Supplement">Probiotic (Active low)</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in functional bowel symptoms</outcome_measure>
      <outcome_measure>Change in quality of life</outcome_measure>
      <outcome_measure>Change in anxiety and depression</outcome_measure>
      <outcome_measure>Adequate relief</outcome_measure>
      <outcome_measure>Change in faecal microbiota</outcome_measure>
      <outcome_measure>Safety of investigational product</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Danisco</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>391</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-2</other_id>
    </other_ids>
    <start_date>October 2012</start_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <completion_date>November 2014</completion_date>
    <study_first_posted>November 20, 2012</study_first_posted>
    <last_update_posted>January 26, 2016</last_update_posted>
    <locations>
      <location>Mehiläinen Töölö, Helsinki, Finland</location>
      <location>Mehiläinen Turku, Turku, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01728610</url>
  </study>
  <study rank="411">
    <nct_id>NCT01153295</nct_id>
    <title>&quot;Functional Bowel Disorder. Investigation in General Practice&quot;</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Clinical diagnosis based on symptom criteria</intervention>
      <intervention type="Procedure">Diagnosis of exclusion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Health related quality of life</outcome_measure>
      <outcome_measure>Findings of organic disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Southern Denmark</lead_sponsor>
      <collaborator>Mejeribrugets ForskningsFond</collaborator>
      <collaborator>Arla Foods</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>153</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>MFF080408-1</other_id>
    </other_ids>
    <start_date>December 2008</start_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <completion_date>June 2011</completion_date>
    <study_first_posted>June 30, 2010</study_first_posted>
    <last_update_posted>October 25, 2011</last_update_posted>
    <locations>
      <location>Research Unit for General Practice, Department of gastroenterology, Odense University hospital, Odense, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01153295</url>
  </study>
  <study rank="412">
    <nct_id>NCT03815617</nct_id>
    <title>A Novel Formulation of Bifidobacterium Longum BB536 and Lactobacillus Rhamnosus HN001 With Vitamin B6 on IBS Patients</title>
    <acronym>LLB</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Zircombi</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Visual Analogue Scale, ranging from 0 to 100</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Symptom Severity Score (IBS-SSS)</outcome_measure>
      <outcome_measure>Bristol Stool Form Scale (BSFS)</outcome_measure>
      <outcome_measure>MEDSTYLE questionnaire</outcome_measure>
      <outcome_measure>Intestinal permeability</outcome_measure>
      <outcome_measure>Cultivable intestinal microbiota</outcome_measure>
      <outcome_measure>Community level catabolic profiles</outcome_measure>
      <outcome_measure>Fecal metabolome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Bari</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>4651</other_id>
    </other_ids>
    <start_date>February 1, 2017</start_date>
    <primary_completion_date>May 31, 2018</primary_completion_date>
    <completion_date>December 31, 2018</completion_date>
    <study_first_posted>January 24, 2019</study_first_posted>
    <last_update_posted>January 24, 2019</last_update_posted>
    <locations>
      <location>Clinica Medica &quot;A. Murri&quot;, Department of Biomedical Sciences &amp; Human Oncology, University of Bari Medical School, Bari, BA, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03815617</url>
  </study>
  <study rank="413">
    <nct_id>NCT00368758</nct_id>
    <title>The Effect of Probioticson Bloating in IBS</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Probiotic bacteria (Trevis R)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>In-vitro production (quantified) of hydrogen and methane in feces</outcome_measure>
      <outcome_measure>Recovery of ingested bacteria in feces by PCR</outcome_measure>
      <outcome_measure>Quality of life (SF36-danish version)</outcome_measure>
      <outcome_measure>VAS-scores for bloating, distention, abdominal pain, abdominal discomfort, flatulence</outcome_measure>
      <outcome_measure>Abdominal height in lying position, waist circumference, weight</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Royal Veterinary and Agricultural University, Denmark</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>JRA1</other_id>
    </other_ids>
    <start_date>August 2006</start_date>
    <completion_date>September 2007</completion_date>
    <study_first_posted>August 25, 2006</study_first_posted>
    <last_update_posted>August 25, 2006</last_update_posted>
    <locations>
      <location>Dept. Human Nutrition, The Royal Veterinary and Agricultural University, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00368758</url>
  </study>
  <study rank="414">
    <nct_id>NCT03653689</nct_id>
    <title>Identification of IBS Metabotypes Based on Physiological Responses to Food</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">FODMAP</intervention>
      <intervention type="Dietary Supplement">Gluten</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS-SSS</outcome_measure>
      <outcome_measure>BMI</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uppsala University</lead_sponsor>
      <collaborator>Chalmers University of Technology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>OpDiMet1</other_id>
    </other_ids>
    <start_date>September 10, 2018</start_date>
    <primary_completion_date>September 10, 2020</primary_completion_date>
    <completion_date>September 10, 2020</completion_date>
    <study_first_posted>August 31, 2018</study_first_posted>
    <last_update_posted>January 9, 2019</last_update_posted>
    <locations>
      <location>Uppsala University Hospital, Uppsala, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03653689</url>
  </study>
  <study rank="415">
    <nct_id>NCT00555191</nct_id>
    <title>Fructose Malabsorption in Northern Norway</title>
    <acronym>FINN</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fructose Malabsorption</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">diet restriction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>VAS score og specific abdominal complaints.SGA score of relief related to abdominal complaints.</outcome_measure>
      <outcome_measure>Estimate sensitivity,specificity,negative and positive predictive value using 50 gm fructose in breath test.Validate questionary for intolerance.Validate VAS in judging changes in abdominal complaint.Examine polymorphism i Glut5 transporter gene.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital of North Norway</lead_sponsor>
      <collaborator>Nordlandssykehuset HF</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>182</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>N-136/2006(REK)</other_id>
      <other_id>2006/136(REK-N)</other_id>
      <other_id>15567/NSD</other_id>
      <other_id>Ref 1204 Biobankregisteret</other_id>
    </other_ids>
    <start_date>September 2007</start_date>
    <primary_completion_date>May 2016</primary_completion_date>
    <completion_date>May 2016</completion_date>
    <study_first_posted>November 8, 2007</study_first_posted>
    <last_update_posted>May 24, 2016</last_update_posted>
    <locations>
      <location>Hospital of Rana Medical Dep. Helgelandsykehuset HF, Mo i Rana, Nordland, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00555191</url>
  </study>
  <study rank="416">
    <nct_id>NCT00101725</nct_id>
    <title>A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Colonic Diseases</condition>
      <condition>Diarrhea</condition>
      <condition>Gastrointestinal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">crofelemer</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess the safety of TRN-002 when administered twice daily for 12 consecutive weeks.</outcome_measure>
      <outcome_measure>To assess the efficacy of TRN-002 when administered twice daily for 12 consecutive weeks.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>245</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TRN 002 201</other_id>
    </other_ids>
    <start_date>December 2004</start_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <completion_date>November 2005</completion_date>
    <study_first_posted>January 13, 2005</study_first_posted>
    <last_update_posted>November 22, 2010</last_update_posted>
    <locations>
      <location>Clinical Research Associates, Huntsville, Alabama, United States</location>
      <location>Radiant Research Phoenix Southeast, Chandler, Arizona, United States</location>
      <location>Arkansas Gastroenterology, North Little Rock, Arkansas, United States</location>
      <location>AGMG Clinical Research Institute, Anaheim, California, United States</location>
      <location>Community Clinical Trials, Orange, California, United States</location>
      <location>AGMG Clinical Research, Orange, California, United States</location>
      <location>Institute of Healthcare Assessment, Inc., San Diego, California, United States</location>
      <location>Washington Gastroenterology, Washington, District of Columbia, United States</location>
      <location>Consultants for Clinical Research of South Florida, Boynton Beach, Florida, United States</location>
      <location>University Clinical Research DeLand, DeLand, Florida, United States</location>
      <location>nTouch Research, Peoria, Illinois, United States</location>
      <location>Synergy Medical Education Alliance, Saginaw, Michigan, United States</location>
      <location>CRC of Jakson, Jackson, Mississippi, United States</location>
      <location>Mercy Medical Group, St. Louis,, Missouri, United States</location>
      <location>Tobey Village Office Park, Pittsford, New York, United States</location>
      <location>LeBauer Research Associates, PA, Greensboro, North Carolina, United States</location>
      <location>Medoff Medical / Vital Research, Greensboro, North Carolina, United States</location>
      <location>Hanover Medical Specialists, PA, Wilmington, North Carolina, United States</location>
      <location>Piedmont Medical Research Assoc., Inc., Winston-Salem, North Carolina, United States</location>
      <location>Consultants for Clinical Research, Cincinnati, Ohio, United States</location>
      <location>Radient Research, Columbus, Ohio, United States</location>
      <location>Grandview Medical Research, Inc, Sellersville, Pennsylvania, United States</location>
      <location>Anderson Gastroenterology, Anderson, South Carolina, United States</location>
      <location>TriCities Medical Research, Bristol, Tennessee, United States</location>
      <location>ClinSearch, Chattanooga, Tennessee, United States</location>
      <location>Jackson Clinic, Jackson, Tennessee, United States</location>
      <location>Memphis Gastroenterology, Memphis, Tennessee, United States</location>
      <location>Radiant Research Dallas-North, Dallas, Texas, United States</location>
      <location>Tacoma Digestive Disease Research Center, Tacoma, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00101725</url>
  </study>
  <study rank="417">
    <nct_id>NCT03225261</nct_id>
    <title>The Effect of Citrus Extract on Gastrointestinal Health</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Citrus extract</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The effect on intestinal inflammation, measured by fecal calprotectin levels.</outcome_measure>
      <outcome_measure>The effect on microbial metabolic activity, measured by fecal short chain fatty acids (SCFA).</outcome_measure>
      <outcome_measure>The effect on fecal microbiota composition, assessed by next generation sequencing.</outcome_measure>
      <outcome_measure>The effect on fecal microbiota functional capacity, assessed by next generation sequencing.</outcome_measure>
      <outcome_measure>The effect on the systemic immune response, measured by cytokine production capacity of stimulated whole blood</outcome_measure>
      <outcome_measure>The effect on disease symptoms, measured by patient reported outcomes (GSRS).</outcome_measure>
      <outcome_measure>The effect on disease symptoms, measured by patient reported outcomes (symptom diary).</outcome_measure>
      <outcome_measure>The effect on stool frequency, measured by Bristol Stool Chart.</outcome_measure>
      <outcome_measure>The effect on stool consistency, measured by Bristol Stool Chart.</outcome_measure>
      <outcome_measure>The effect on blood markers for oxidative stress, measured by MDA concentration in blood.</outcome_measure>
      <outcome_measure>The effect on blood markers for antioxidant capacity, measured by blood total antioxidant capacity.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>173003</other_id>
    </other_ids>
    <start_date>November 20, 2017</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>July 21, 2017</study_first_posted>
    <last_update_posted>March 6, 2019</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Limburg, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03225261</url>
  </study>
  <study rank="418">
    <nct_id>NCT03154086</nct_id>
    <title>A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK3352589</intervention>
      <intervention type="Drug">Matching Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of subjects with adverse event (AE) and serious adverse event (SAE) for Part A and Part B</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve (AUC) over the dose interval</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>207440</other_id>
    </other_ids>
    <start_date>May 17, 2017</start_date>
    <primary_completion_date>March 5, 2018</primary_completion_date>
    <completion_date>March 5, 2018</completion_date>
    <study_first_posted>May 15, 2017</study_first_posted>
    <last_update_posted>January 10, 2019</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Adelaide, South Australia, Australia</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03154086/SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03154086</url>
  </study>
  <study rank="419">
    <nct_id>NCT03035799</nct_id>
    <title>Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Paleolithic diet</intervention>
      <intervention type="Other">General Healthful Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Vitality</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Activity level</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Visceral sensitivity</outcome_measure>
      <outcome_measure>Overall health status (Short Health Scale)</outcome_measure>
      <outcome_measure>Overall health status (EQ-5D)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB00082222</other_id>
    </other_ids>
    <start_date>April 24, 2018</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>April 2020</completion_date>
    <study_first_posted>January 30, 2017</study_first_posted>
    <last_update_posted>May 3, 2019</last_update_posted>
    <locations>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03035799</url>
  </study>
  <study rank="420">
    <nct_id>NCT02888392</nct_id>
    <title>The Effect of Zespri Green Kiwifruit on Digestive and Gut Health Functions</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Kiwifruit</intervention>
      <intervention type="Dietary Supplement">Psyllium</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Complete Spontaneous Bowel Motions</outcome_measure>
      <outcome_measure>Daily Bowel Habit</outcome_measure>
      <outcome_measure>Weekly Gastrointestinal Symptom Rating Scale (GSRS)</outcome_measure>
      <outcome_measure>Rome III</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome Quality of Life (IBS-QoL) evaluation</outcome_measure>
      <outcome_measure>Profile of Mood Score (POMS)</outcome_measure>
      <outcome_measure>Irritable Bowel Syndrome severity score index (IBS-SSI)</outcome_measure>
      <outcome_measure>3-day Food Diary</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zespri International Limited</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HN1525</other_id>
    </other_ids>
    <start_date>December 18, 2015</start_date>
    <primary_completion_date>January 30, 2017</primary_completion_date>
    <completion_date>January 30, 2017</completion_date>
    <study_first_posted>September 5, 2016</study_first_posted>
    <last_update_posted>July 2, 2017</last_update_posted>
    <locations>
      <location>St. Orsola Hospital, Bologna, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02888392</url>
  </study>
  <study rank="421">
    <nct_id>NCT02881944</nct_id>
    <title>Effect of Diet on Gulf War Illness</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Low FODMAP Diet</intervention>
      <intervention type="Behavioral">High FODMAP Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in self-reported global Bowel Symptom Score</outcome_measure>
      <outcome_measure>Change in self-reported Irritable Bowel Syndrome Quality of Life (IBS-QOL) score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ashok Tuteja</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>VA Salt Lake City Health Care System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB_00087668</other_id>
    </other_ids>
    <start_date>August 2016</start_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <completion_date>September 2018</completion_date>
    <study_first_posted>August 29, 2016</study_first_posted>
    <last_update_posted>February 1, 2018</last_update_posted>
    <locations>
      <location>George E Wahlen VA Medical Center, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02881944</url>
  </study>
  <study rank="422">
    <nct_id>NCT02798991</nct_id>
    <title>A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK3179106</intervention>
      <intervention type="Drug">Matched Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of subjects with adverse event (AE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>205181</other_id>
    </other_ids>
    <start_date>June 2016</start_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <completion_date>November 2016</completion_date>
    <study_first_posted>June 14, 2016</study_first_posted>
    <last_update_posted>January 18, 2017</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Adelaide, South Australia, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02798991</url>
  </study>
  <study rank="423">
    <nct_id>NCT02512146</nct_id>
    <title>The Expression of the Ionotropic Glutamate Receptors in Colon of IBS</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">colonoscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the expression of the ionotropic glutamate receptors</outcome_measure>
      <outcome_measure>the relationship between the ionotropic glutamate receptors and IBS symptom</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015SDU-QILU-G03</other_id>
    </other_ids>
    <start_date>June 2015</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>July 30, 2015</study_first_posted>
    <last_update_posted>July 30, 2015</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02512146</url>
  </study>
  <study rank="424">
    <nct_id>NCT02386904</nct_id>
    <title>Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Phosphate Enema (Kleen® Enema)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Excellent Preparation for Sigmoidoscopy (efficacy)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nabiqasim Industries (Pvt) Ltd</lead_sponsor>
      <collaborator>Dow University of Health Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>• KLEE-EFF-002-01</other_id>
    </other_ids>
    <start_date>March 2015</start_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <completion_date>August 2015</completion_date>
    <study_first_posted>March 12, 2015</study_first_posted>
    <last_update_posted>March 17, 2015</last_update_posted>
    <locations>
      <location>National Institute of Liver and GI diseases, DUHS, Karachi, Sindh, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02386904</url>
  </study>
  <study rank="425">
    <nct_id>NCT02316132</nct_id>
    <title>Confocal Laser Endomicroscopy, IBS and Stress</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stress</intervention>
      <intervention type="Drug">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>visible marked increase of leaks/gaps with extrusion of fluorescein into the gut lumen.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Schleswig-Holstein</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS stress</other_id>
    </other_ids>
    <start_date>December 2014</start_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>December 12, 2014</study_first_posted>
    <last_update_posted>December 7, 2015</last_update_posted>
    <locations>
      <location>Interdisciplinary Endoscopy, University hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02316132</url>
  </study>
  <study rank="426">
    <nct_id>NCT02259465</nct_id>
    <title>The Effect of the Low FODMAP Diet and Dietary Oligofructose on Gastrointestinal Form, Function and Microbiota</title>
    <acronym>FOG</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">low FODMAP diet</intervention>
      <intervention type="Dietary Supplement">Oligofructose</intervention>
      <intervention type="Dietary Supplement">Maltodextrin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in colonic volume</outcome_measure>
      <outcome_measure>Change in whole gut transit time</outcome_measure>
      <outcome_measure>Change in colonic gas volume</outcome_measure>
      <outcome_measure>Change in fasting breath hydrogen</outcome_measure>
      <outcome_measure>Change in fasting breath methane</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>King's College London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>SoM A14082014 FOG</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>October 8, 2014</study_first_posted>
    <last_update_posted>March 18, 2015</last_update_posted>
    <locations>
      <location>Nottingham Digestive Diseases Centre, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02259465</url>
  </study>
  <study rank="427">
    <nct_id>NCT02107625</nct_id>
    <title>Traditional Dietary Advice Versus a Low FODMAP Diet Intake in IBS Patients</title>
    <acronym>KRIBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Diet A i.e. Low FODMAP diet</intervention>
      <intervention type="Behavioral">Diet B, i.e. Traditional IBS diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom alleviation through the questionnaire IBS-SSS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Göteborg University</lead_sponsor>
      <collaborator>Karolinska Institutet</collaborator>
      <collaborator>Aleris Specialistvård Sabbatsberg</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KRIBS1</other_id>
    </other_ids>
    <start_date>August 2013</start_date>
    <primary_completion_date>January 2015</primary_completion_date>
    <completion_date>January 2015</completion_date>
    <study_first_posted>April 8, 2014</study_first_posted>
    <last_update_posted>August 20, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02107625</url>
  </study>
  <study rank="428">
    <nct_id>NCT00370032</nct_id>
    <title>Study to Assess the Effect Of Alosetron On Mucosal Blood Flow</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alosetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Left Colon Mucosal Blood Flow (MBF)</outcome_measure>
      <outcome_measure>Rectal Mucosal Blood Flow (MBF)</outcome_measure>
      <outcome_measure>Left Colon and Rectal Mucosal Blood Flow Cohort Comparisons</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S3B40042</other_id>
    </other_ids>
    <start_date>December 2006</start_date>
    <primary_completion_date>December 2007</primary_completion_date>
    <completion_date>December 2007</completion_date>
    <study_first_posted>August 30, 2006</study_first_posted>
    <results_first_posted>April 2, 2009</results_first_posted>
    <last_update_posted>May 18, 2015</last_update_posted>
    <locations>
      <location>GSK Investigational Site, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00370032</url>
  </study>
  <study rank="429">
    <nct_id>NCT01887483</nct_id>
    <title>Vetal Laban Intervention Trial Assessing Bowel Symptoms</title>
    <acronym>KF_2013</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vetal Laban active</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change in functional bowel symptoms</outcome_measure>
      <outcome_measure>change in adequate relief of bowel symptoms</outcome_measure>
      <outcome_measure>change in stool defecation frequency</outcome_measure>
      <outcome_measure>change in stool microbiota</outcome_measure>
      <outcome_measure>change in prevalence of adverse events</outcome_measure>
      <outcome_measure>change in stool consistency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Danisco</lead_sponsor>
      <collaborator>Almarai</collaborator>
      <collaborator>Clinart International</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
    </study_designs>
    <other_ids>
      <other_id>KF_2013</other_id>
    </other_ids>
    <start_date>March 2014</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>June 27, 2013</study_first_posted>
    <last_update_posted>December 22, 2015</last_update_posted>
    <locations>
      <location>King Fahd Medical City, Riyadh, Saudi Arabia</location>
      <location>King Khalid University Hospital, Riyadh, Saudi Arabia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01887483</url>
  </study>
  <study rank="430">
    <nct_id>NCT03462966</nct_id>
    <title>Rifaximin on Visceral Hypersensitivity</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Visceral Hypersensitivity</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean change in the balloon volume (measured in mL) that leads to first urge to defecate.</outcome_measure>
      <outcome_measure>Association of urgency symptom and rectal sensitivity testing.</outcome_measure>
      <outcome_measure>Normalization of lactulose breath test as a potential predictor of improvement of rectal hypersensitivity.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
      <collaborator>Bausch Health Americas, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>49509</other_id>
    </other_ids>
    <start_date>July 1, 2018</start_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <completion_date>July 2019</completion_date>
    <study_first_posted>March 13, 2018</study_first_posted>
    <last_update_posted>October 10, 2018</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03462966/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03462966</url>
  </study>
  <study rank="431">
    <nct_id>NCT03675100</nct_id>
    <title>Neurotrophic Factors, Tight Junction Proteins, and Cytokines in IBS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Tight Junction Alteration</condition>
      <condition>Pathophysiology</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">colonoscopic mucosal biopsy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>NGF, GDNF, and TRPV-1 mRNA expression of colonic mucosa</outcome_measure>
      <outcome_measure>ZO-1, Occludin, and Claudin mRNA expression of colonic mucosa</outcome_measure>
      <outcome_measure>IL-8, TNF-a, and IL-1b mRNA expression of colonic mucosa</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seoul National University Bundang Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>B-1305/202-003</other_id>
    </other_ids>
    <start_date>June 2009</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>September 18, 2018</study_first_posted>
    <last_update_posted>September 18, 2018</last_update_posted>
    <locations>
      <location>Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03675100</url>
  </study>
  <study rank="432">
    <nct_id>NCT03224494</nct_id>
    <title>Evaluation of Bowel Sensitivity Threshold in IBS Patients Versus in Healthy Controls Using the Novel Rapid Barostat Bag</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Visceral Hypersensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Rapid Barostat Bag</intervention>
      <intervention type="Other">IBS severity scoring system questionnaire (IBS-SSS)</intervention>
      <intervention type="Other">HAD scale questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Bowel sensory threshold</outcome_measure>
      <outcome_measure>IBS-SSS Questionnaire</outcome_measure>
      <outcome_measure>HADS scale questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>6021016</other_id>
    </other_ids>
    <start_date>August 10, 2017</start_date>
    <primary_completion_date>July 15, 2019</primary_completion_date>
    <completion_date>July 15, 2019</completion_date>
    <study_first_posted>July 21, 2017</study_first_posted>
    <last_update_posted>October 4, 2017</last_update_posted>
    <locations>
      <location>Kingston Health Sciences Centre - HDH site, Kingston, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03224494</url>
  </study>
  <study rank="433">
    <nct_id>NCT01638208</nct_id>
    <title>Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VSL#3</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of symptoms after modulation of gut microbiota with probiotic, VSL#3</outcome_measure>
      <outcome_measure>Comparison of GI microbiota before and after treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Asian Institute of Gastroenterology, India</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AIG-VSL#3-IBS-NP</other_id>
    </other_ids>
    <start_date>August 2012</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>July 11, 2012</study_first_posted>
    <last_update_posted>July 11, 2012</last_update_posted>
    <locations>
      <location>Asian Institute of Gstroenterology, Hyderabad, Andhra Pradesh, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01638208</url>
  </study>
  <study rank="434">
    <nct_id>NCT01633723</nct_id>
    <title>Phase I Clinical Trial of DA-6886 in Healthy Male Subjects</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DA-6886</intervention>
      <intervention type="Drug">Placebo of DA-6886</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of safety</outcome_measure>
      <outcome_measure>Pharmacokinetics and Pharmacodynamics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dong-A Pharmaceutical Co., Ltd.</lead_sponsor>
      <collaborator>Dong-A ST Co., Ltd.</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DA6886_IBS_I</other_id>
    </other_ids>
    <start_date>August 2012</start_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <study_first_posted>July 4, 2012</study_first_posted>
    <last_update_posted>August 13, 2013</last_update_posted>
    <locations>
      <location>ASAN medical center, Seoul, Songpa-gu, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01633723</url>
  </study>
  <study rank="435">
    <nct_id>NCT01534507</nct_id>
    <title>Small and Large Bowel Transit Tests Using MRI (Study 1)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Study 1:Correlation between mean orocaecal transit time as assessed by MRI and lactose C13-ureide</outcome_measure>
      <outcome_measure>Study 1: Correlation between colonic transit as assessed by from the geometric centre of the PTFE capsule at time 24 and 48 hours and Metcalf Radio-opaque marker method</outcome_measure>
      <outcome_measure>Study 2: Fasting small bowel water content</outcome_measure>
      <outcome_measure>Study 1:To assess reproducibility of the using MRI for orocaecal transit time and colonic transit time</outcome_measure>
      <outcome_measure>Study 2: Orocaecal transit time using lactose C13-ureide</outcome_measure>
      <outcome_measure>Study 2: Area under the curve (AUC) post prandial SBWC</outcome_measure>
      <outcome_measure>Study 2: Ascending colon water content (ACWC) and colonic water index (CWI)</outcome_measure>
      <outcome_measure>Study 2: Colonic volumes both fasting and post prandial (divided into ascending transverse and descending colon)</outcome_measure>
      <outcome_measure>Study 2: Whole gut transit time assess by MRI marker capsule from study 1</outcome_measure>
      <outcome_measure>Study 2: Correlation between the Hospital Anxiety &amp; Depression Scale (HADS) and other measures of anxiety and stress score and (a) Oro-caecal transit time and (b)whoe gut transit time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>11038</other_id>
      <other_id>11/EM/0245 (Study 1)</other_id>
    </other_ids>
    <start_date>November 2011</start_date>
    <primary_completion_date>August 2014</primary_completion_date>
    <completion_date>August 2014</completion_date>
    <study_first_posted>February 16, 2012</study_first_posted>
    <last_update_posted>August 13, 2014</last_update_posted>
    <locations>
      <location>University of Nottingham, Nottingham, Notts, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01534507</url>
  </study>
  <study rank="436">
    <nct_id>NCT01411800</nct_id>
    <title>An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">250 mg capsule</intervention>
      <intervention type="Drug">250 mg tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Urinary 5-HIAA levels</outcome_measure>
      <outcome_measure>Plasma 5-HIAA levels</outcome_measure>
      <outcome_measure>Maximum observed plasma concentration</outcome_measure>
      <outcome_measure>Time at which maximum observed plasma concentration occurs</outcome_measure>
      <outcome_measure>Half-life of the drug in plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lexicon Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LX1033.1-103-NRM</other_id>
      <other_id>LX1033.103</other_id>
    </other_ids>
    <start_date>August 2011</start_date>
    <primary_completion_date>October 2011</primary_completion_date>
    <completion_date>May 2012</completion_date>
    <study_first_posted>August 8, 2011</study_first_posted>
    <last_update_posted>July 20, 2012</last_update_posted>
    <locations>
      <location>Lexicon Investigational Site, Overland Park, Kansas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01411800</url>
  </study>
  <study rank="437">
    <nct_id>NCT00796354</nct_id>
    <title>Constipation Associated With Irritable Bowel Syndrome (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MOVICOL</intervention>
      <intervention type="Drug">Sugar Pill</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy and safety of Movicol® versus placebo in the relief of constipation associated with IBS.</outcome_measure>
      <outcome_measure>To evaluate the effect of treatment on other symptoms of IBS.</outcome_measure>
      <outcome_measure>To evaluate the effect of treatment on patient's Quality Of Life (QOL).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Norgine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NRL920-01/2008 (IBSc)</other_id>
    </other_ids>
    <start_date>November 2008</start_date>
    <primary_completion_date>February 2010</primary_completion_date>
    <completion_date>February 2010</completion_date>
    <study_first_posted>November 24, 2008</study_first_posted>
    <last_update_posted>February 17, 2010</last_update_posted>
    <locations>
      <location>Gastroenterologie s.r.o., Hradec Králové, Czech Republic</location>
      <location>EGK.s.r.o, Sanatorium sv. Anny, Praha, Czech Republic</location>
      <location>Orlickoustecká Nemocnice a.s., Ústi Nad Orlicí, Czech Republic</location>
      <location>Hôpital Hotel Dieu, Clermont-Ferrand, France</location>
      <location>Hôpital Archet II, Nice, France</location>
      <location>Hôpital Charles Nicolles, Rouen, France</location>
      <location>Martin-Luther-Krankenhaus-Betriebs-GmbH, Berlin, Germany</location>
      <location>Gastroenterologische Gemeinschaftspraxis, Münster, Germany</location>
      <location>Facharztpraxis für Innere Medizin, Wiesbaden, Germany</location>
      <location>Policlinico S. Orsola Malpighi, Bologna, Italy</location>
      <location>Università degli Studi di Genova, Genova, Italy</location>
      <location>Università degli Studi di Palermo, Palermo, Italy</location>
      <location>Università La Sapienza, Roma, Italy</location>
      <location>Slaskie Centrum Osteoporozy, Katowice, Poland</location>
      <location>Centrum Onkologii ul.Rentgena 5, Warsaw, Poland</location>
      <location>Prosen SMO, Warszawa, Poland</location>
      <location>Katedra i Klinika Gastroenterologii i Hepatologii, Wroclaw, Poland</location>
      <location>Sodra Alvsborgs Hospital (SAS), Borås, Sweden</location>
      <location>Karolinska University Hospital Solna, Stockholm, Sweden</location>
      <location>St Marks Hospital, Harrow, United Kingdom</location>
      <location>John Radcliffe Hospital, Oxford, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00796354</url>
  </study>
  <study rank="438">
    <nct_id>NCT01347918</nct_id>
    <title>1H-19F Gastrointestinal MRI in Health and IBS</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">19F capsule</intervention>
      <intervention type="Dietary Supplement">sterculia</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Small intestinal transit time in minutes</outcome_measure>
      <outcome_measure>Small intestinal length and intestinal course</outcome_measure>
      <outcome_measure>Small intestinal motor activity index</outcome_measure>
      <outcome_measure>Small intestinal transport velocity</outcome_measure>
      <outcome_measure>Local intestinal residence times</outcome_measure>
      <outcome_measure>Volume and distribution of intestinal gas</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GI-MRI</other_id>
      <other_id>2011-MD-0005</other_id>
    </other_ids>
    <start_date>July 2011</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>May 5, 2011</study_first_posted>
    <last_update_posted>April 9, 2015</last_update_posted>
    <locations>
      <location>University Hospital Zurich, Gastroenterology, Zurich, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01347918</url>
  </study>
  <study rank="439">
    <nct_id>NCT02078323</nct_id>
    <title>Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linaclotide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>1: Change from baseline in Prolongation and normalization of anal CEP and rectal CEP responses at 10 weeks.</outcome_measure>
      <outcome_measure>Change from Baseline in Prolongation and normalization of rectal MEP and anal MEP at 10 weeks.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Augusta University</lead_sponsor>
      <collaborator>Forest Laboratories</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>LNZ-IT-01</other_id>
    </other_ids>
    <start_date>February 2014</start_date>
    <primary_completion_date>October 4, 2017</primary_completion_date>
    <completion_date>July 20, 2018</completion_date>
    <study_first_posted>March 5, 2014</study_first_posted>
    <last_update_posted>July 23, 2018</last_update_posted>
    <locations>
      <location>Augusta University, Augusta, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02078323</url>
  </study>
  <study rank="440">
    <nct_id>NCT03342287</nct_id>
    <title>Cognitive and Psychiatric Effects of Linaclotide on Patients With Constipation</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">questionnaires</intervention>
      <intervention type="Other">cognitive evaluation</intervention>
      <intervention type="Other">Blood</intervention>
      <intervention type="Other">Fecal sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To measure anxiety and depression using the Depression, Anxiety and Stress Scale (DASS) in patients with IBS-C and CIC before and after treatment with Linaclotide</outcome_measure>
      <outcome_measure>To measure neuropsychological performance in Patients with IBS-C and CIC using a standardized neuropsychological assessment in patients (CNS vital signs) before and after treatment with Linaclotide</outcome_measure>
      <outcome_measure>To determine changes in fecal microbiome profile before and after treatment with Linaclotide and whether these changes correlate with changes in psychiatric symptoms and cognition.</outcome_measure>
      <outcome_measure>To determine changes in inflammatory biomarker profile before and after treatment with Linaclotide and whether these changes correlate with changes in psychiatric symptoms and cognition.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>McMaster University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1088</other_id>
    </other_ids>
    <start_date>March 2016</start_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>November 14, 2017</study_first_posted>
    <last_update_posted>October 24, 2018</last_update_posted>
    <locations>
      <location>McMaster University Health Centre, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03342287</url>
  </study>
  <study rank="441">
    <nct_id>NCT01099787</nct_id>
    <title>Pediatric Alliance for International Neurogastrointestinal Functional Research</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Nationwide Children's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>348</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB10-00022</other_id>
    </other_ids>
    <start_date>April 2010</start_date>
    <primary_completion_date>June 2017</primary_completion_date>
    <completion_date>June 2017</completion_date>
    <study_first_posted>April 8, 2010</study_first_posted>
    <last_update_posted>July 19, 2018</last_update_posted>
    <locations>
      <location>Connecticut Children's Hospital, Hartford, Connecticut, United States</location>
      <location>Childrens Memorial Hospital, Chicago, Illinois, United States</location>
      <location>LSU Health Sciences Center, New Orleans, Louisiana, United States</location>
      <location>Children's Hospital Boston, Boston, Massachusetts, United States</location>
      <location>Nationwide Children's Hospital, Columbus, Ohio, United States</location>
      <location>Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States</location>
      <location>Emma Children's Hospital, Amsterdam, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01099787</url>
  </study>
  <study rank="442">
    <nct_id>NCT02880332</nct_id>
    <title>Pain Processing and Pain Neuroscience Education in Children With Chronic Abdominal Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Abdominal Pain</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Usual care</intervention>
      <intervention type="Other">Pain Neuroscience education</intervention>
      <intervention type="Other">Extra care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Parent's catastrophic thinking about their child's pain</outcome_measure>
      <outcome_measure>Pain intensity (child report)</outcome_measure>
      <outcome_measure>Pain-related fear (parent report)</outcome_measure>
      <outcome_measure>Functional disability (parent proxy report)</outcome_measure>
      <outcome_measure>Pain-related fear (child report)</outcome_measure>
      <outcome_measure>Hyperalgesia</outcome_measure>
      <outcome_measure>Endogenous pain inhibition</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vrije Universiteit Brussel</lead_sponsor>
      <collaborator>Universiteit Antwerpen</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AbdominalPainStudy</other_id>
    </other_ids>
    <start_date>February 9, 2017</start_date>
    <primary_completion_date>October 4, 2018</primary_completion_date>
    <completion_date>October 4, 2018</completion_date>
    <study_first_posted>August 26, 2016</study_first_posted>
    <last_update_posted>October 5, 2018</last_update_posted>
    <locations>
      <location>Antwerp University Hospital, Edegem, Antwerpen, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02880332</url>
  </study>
  <study rank="443">
    <nct_id>NCT02190526</nct_id>
    <title>Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea- Predominant Irritable Bowel Syndrome</condition>
      <condition>Quality of Life</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mesalazine(asacol 800 mg)</intervention>
      <intervention type="Drug">Amitriptyline</intervention>
      <intervention type="Drug">placebo like asacol</intervention>
      <intervention type="Drug">placebo like amitriptyline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>quality of life</outcome_measure>
      <outcome_measure>Serum immune biomarkers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
      <collaborator>Tillotts Pharma AG</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>8811215278</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>July 15, 2014</study_first_posted>
    <last_update_posted>April 15, 2016</last_update_posted>
    <locations>
      <location>Gastrointestinal Private Clinic, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02190526</url>
  </study>
  <study rank="444">
    <nct_id>NCT00213330</nct_id>
    <title>Cerebral Resonance Magnetic Imaging During Rectal Distention</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ulcerative Colitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">rectal distension</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University Hospital, Rouen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2001/105/HP</other_id>
    </other_ids>
    <start_date>April 2003</start_date>
    <completion_date>February 2006</completion_date>
    <study_first_posted>September 21, 2005</study_first_posted>
    <last_update_posted>April 23, 2012</last_update_posted>
    <locations>
      <location>University hospital of Rouen, Rouen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00213330</url>
  </study>
  <study rank="445">
    <nct_id>NCT01204515</nct_id>
    <title>Abdominal Symptom Phenotype Study in Children</title>
    <acronym>ASPPNB</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Compare biomarkers (tests) on girls with and without IBS</outcome_measure>
      <outcome_measure>Compare the response of stress in girls with and without IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
      <collaborator>University of Washington</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>7 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>25755</other_id>
      <other_id>RC2NR011959</other_id>
    </other_ids>
    <start_date>June 2010</start_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <completion_date>August 2012</completion_date>
    <study_first_posted>September 17, 2010</study_first_posted>
    <last_update_posted>February 6, 2013</last_update_posted>
    <locations>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01204515</url>
  </study>
  <study rank="446">
    <nct_id>NCT02388269</nct_id>
    <title>A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Dyspepsia</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">gammaCore®-G</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom Changes in Subjects With Functional Gastrointestinal Disorder (Functional Dyspepsia and Irritable Bowel Syndrome)</outcome_measure>
      <outcome_measure>Quality of Life (QoL) Using the Functional Digestive Disorder Quality of Life (FDDQL)</outcome_measure>
      <outcome_measure>Change in Frequency of Symptoms Using the Short-Form Leeds Dyspepsia Questionnaire (SFLDQ)</outcome_measure>
      <outcome_measure>Use of Concomitant Medication (Intake and Dose) During the Course of the Study</outcome_measure>
      <outcome_measure>Symptom Change at 8 Weeks Compared to 4 Weeks (GOS Dyspepsia or IBS Severity Scoring System)</outcome_measure>
      <outcome_measure>Number of Participants With Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ElectroCore INC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>GG-007</other_id>
    </other_ids>
    <start_date>June 2014</start_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <completion_date>June 2015</completion_date>
    <study_first_posted>March 13, 2015</study_first_posted>
    <results_first_posted>February 6, 2018</results_first_posted>
    <last_update_posted>March 7, 2018</last_update_posted>
    <locations>
      <location>Royal Free Hospital NHS Trust, Centre for Gastroenterology, 8th floor, Pond street, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02388269</url>
  </study>
  <study rank="447">
    <nct_id>NCT00331994</nct_id>
    <title>EFESO - EFficacy Enterogermina Small Intestinal Bacterial Overgrowth</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bacillus clausii</intervention>
      <intervention type="Drug">Metronidazole</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>eradication rate of the small intestinal bacterial overgrowth</outcome_measure>
      <outcome_measure>avoiding recurrence of the small intestinal bacterial overgrowth</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sanofi</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PM_L_0161</other_id>
      <other_id>EudraCT # : 2005-004934-42</other_id>
    </other_ids>
    <start_date>April 2006</start_date>
    <primary_completion_date>July 2008</primary_completion_date>
    <completion_date>July 2008</completion_date>
    <study_first_posted>May 31, 2006</study_first_posted>
    <last_update_posted>July 20, 2009</last_update_posted>
    <locations>
      <location>Sanofi-Aventis Administrative Office, Milan, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00331994</url>
  </study>
  <study rank="448">
    <nct_id>NCT03550742</nct_id>
    <title>Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients</title>
    <acronym>GRIPS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Fuco-N-Tetraose</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in bowel function</outcome_measure>
      <outcome_measure>Change in patients' perception of body function</outcome_measure>
      <outcome_measure>Evaluate tolerability of fuco-N-tetraose</outcome_measure>
      <outcome_measure>Change in satisfaction with bowel habits</outcome_measure>
      <outcome_measure>Change in IBS' interference in life in general</outcome_measure>
      <outcome_measure>Change in quality of life</outcome_measure>
      <outcome_measure>Change on somatic symptoms</outcome_measure>
      <outcome_measure>Change in anxiety and depression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Glycom, Inc.</lead_sponsor>
      <collaborator>University of North Carolina</collaborator>
      <collaborator>Glycom A/S</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>317</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>GRIPS</other_id>
      <other_id>CT-2017-01</other_id>
    </other_ids>
    <start_date>May 14, 2018</start_date>
    <primary_completion_date>March 20, 2019</primary_completion_date>
    <completion_date>March 20, 2019</completion_date>
    <study_first_posted>June 8, 2018</study_first_posted>
    <last_update_posted>April 25, 2019</last_update_posted>
    <locations>
      <location>University of North Carolina, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03550742</url>
  </study>
  <study rank="449">
    <nct_id>NCT02813616</nct_id>
    <title>Factors Affecting Dissatisfaction to Treatments in Patients With Chronic Constipation and IBS With Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number of patients achieving a sustained improvement</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Gender</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Age</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement; Somatisation score</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Quality of life</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Anal resting pressure</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Colonic transit time</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Monthly bowel frequency</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Monthly Stool form</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Defecatory symptoms</outcome_measure>
      <outcome_measure>Factors associated with sustained improvement: Abdominal pain severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>SC-2016</other_id>
    </other_ids>
    <start_date>February 2016</start_date>
    <primary_completion_date>July 2018</primary_completion_date>
    <completion_date>July 2018</completion_date>
    <study_first_posted>June 27, 2016</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02813616</url>
  </study>
  <study rank="450">
    <nct_id>NCT03492333</nct_id>
    <title>Gluten Free Diet in IBS Patients Stratified According to Their Antigliadin Status</title>
    <acronym>GFD_IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Gluten free diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement on gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Normalization of gastrointestinal transit</outcome_measure>
      <outcome_measure>Improvement anxiety and/or depression</outcome_measure>
      <outcome_measure>Improvement somatization</outcome_measure>
      <outcome_measure>Improvement quality of life and well-being</outcome_measure>
      <outcome_measure>Changes in gut microbiota</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>McMaster University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>AGA_GFD_in_IBS</other_id>
    </other_ids>
    <start_date>April 30, 2012</start_date>
    <primary_completion_date>May 30, 2016</primary_completion_date>
    <completion_date>May 30, 2016</completion_date>
    <study_first_posted>April 10, 2018</study_first_posted>
    <last_update_posted>April 10, 2018</last_update_posted>
    <locations>
      <location>Farncombe Institute, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03492333</url>
  </study>
  <study rank="451">
    <nct_id>NCT00401479</nct_id>
    <title>A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Solabegron (GW427353)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>colonic emptying rate by radiolabeled scintigraphy</outcome_measure>
      <outcome_measure>Safety and tolerability: ECG, vital signs, adverse events, clinical lab tests. Diary card collection of stool frequency Stool consistency and ease of passage Blood levels of GW427353</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>B3I106248</other_id>
    </other_ids>
    <start_date>October 2006</start_date>
    <study_first_posted>November 20, 2006</study_first_posted>
    <last_update_posted>October 16, 2008</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00401479</url>
  </study>
  <study rank="452">
    <nct_id>NCT02842281</nct_id>
    <title>Microbiome Fructan Metabolism and Symptoms in Childhood IBS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Fructan</intervention>
      <intervention type="Other">Maltodextrin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Operational Taxonomic Units (microbiome composition derived from 16s rRNA sequencing)</outcome_measure>
      <outcome_measure>Microbiome metabolic signatures related to fructan metabolism</outcome_measure>
      <outcome_measure>Metabolic products of fructan metabolism</outcome_measure>
      <outcome_measure>Microbiome related signatures</outcome_measure>
      <outcome_measure>Overall microbiome metabolic signatures</outcome_measure>
      <outcome_measure>Overall metabolic products</outcome_measure>
      <outcome_measure>Breath hydrogen and methane production symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-34372</other_id>
      <other_id>K23DK101688</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>March 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>July 22, 2016</study_first_posted>
    <last_update_posted>August 2, 2017</last_update_posted>
    <locations>
      <location>Children's Nutrition Research Center, Houston, Texas, United States</location>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02842281</url>
  </study>
  <study rank="453">
    <nct_id>NCT03306381</nct_id>
    <title>The Effect of Dietary Intervention on Symptoms, Epigenetics, and Gut Microbiota in IBS</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Dietary intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Genetic variation of enzymes regulating absorption of disaccharides</outcome_measure>
      <outcome_measure>Irritable bowel syndrome-subjective severity scores (IBS-SSS) ratings</outcome_measure>
      <outcome_measure>Visual analog scale for irritable bowel syndrome (VAS-IBS) ratings</outcome_measure>
      <outcome_measure>Gut microbiota composition</outcome_measure>
      <outcome_measure>Cytokines</outcome_measure>
      <outcome_measure>microRNA expression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Region Skane</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS-2017</other_id>
    </other_ids>
    <start_date>January 15, 2018</start_date>
    <primary_completion_date>October 2019</primary_completion_date>
    <completion_date>October 2019</completion_date>
    <study_first_posted>October 11, 2017</study_first_posted>
    <last_update_posted>May 7, 2018</last_update_posted>
    <locations>
      <location>Deartment of INternal Medicine, Malmö, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03306381</url>
  </study>
  <study rank="454">
    <nct_id>NCT02981888</nct_id>
    <title>Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome</title>
    <acronym>IBS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">X-Ray</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total and individual fecal bile acid excretion</outcome_measure>
      <outcome_measure>Total fecal excretion of short chain fatty acids</outcome_measure>
      <outcome_measure>Fecal microbial population and community from stool collection</outcome_measure>
      <outcome_measure>Fecal excretion of individual short chain fatty acids</outcome_measure>
      <outcome_measure>Stool characteristics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1606244063</other_id>
    </other_ids>
    <start_date>July 2016</start_date>
    <primary_completion_date>July 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>December 5, 2016</study_first_posted>
    <last_update_posted>March 1, 2019</last_update_posted>
    <locations>
      <location>Indiana University Hospital, Indianapolis, Indiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02981888</url>
  </study>
  <study rank="455">
    <nct_id>NCT01908465</nct_id>
    <title>Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ebastine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of treatment on global symptom relief (of IBS complaints)</outcome_measure>
      <outcome_measure>Effect of treatment on stool consistency and frequency and other common IBS associated complaints (flatulence, urgency,...)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KU Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S55485</other_id>
    </other_ids>
    <start_date>November 2013</start_date>
    <primary_completion_date>October 2017</primary_completion_date>
    <completion_date>March 2018</completion_date>
    <study_first_posted>July 25, 2013</study_first_posted>
    <last_update_posted>February 9, 2017</last_update_posted>
    <locations>
      <location>UZ Antwerpen, Edegem, Antwerpen, Belgium</location>
      <location>ZOL (Ziekenhuis Oost-Limburg), Genk, Limburg, Belgium</location>
      <location>UZ Gent, Gent, Oost-Vlaanderen, Belgium</location>
      <location>AZ Sint-Elizabeth Zottegem, Zottegem, Oost-Vlaanderen, Belgium</location>
      <location>UZ Leuven, Leuven, Vlaams-Brabant, Belgium</location>
      <location>AZ Sint-Lucas Brugge, Brugge, West-Vlaanderen, Belgium</location>
      <location>Rijnstate, Arnhem, Gelderland, Netherlands</location>
      <location>Medisch Spectrum Twente, Enschede, Limburg, Netherlands</location>
      <location>AZ Maastricht, Maastricht, Limburg, Netherlands</location>
      <location>Sint Lucas Andreas Ziekenhuis, Amsterdam, Noord-Holland, Netherlands</location>
      <location>Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands</location>
      <location>Tergooiziekenuizen Blaricum/Hilversum, Hilversum/Blaricum, Noord-Holland, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01908465</url>
  </study>
  <study rank="456">
    <nct_id>NCT01774695</nct_id>
    <title>Physical Activity in IBS - a Long Term Follow up</title>
    <acronym>IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Increased physical activity</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IBS Severity Scoring System (IBS-SSS)</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale (HADS)</outcome_measure>
      <outcome_measure>IBS Quality of Life (IBS-QoL)</outcome_measure>
      <outcome_measure>Short Form 36 (SF-36)</outcome_measure>
      <outcome_measure>Fatigue Impacts Scale(FIS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sahlgrenska University Hospital, Sweden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>VGFOUSA-181101</other_id>
    </other_ids>
    <start_date>June 2011</start_date>
    <primary_completion_date>September 2011</primary_completion_date>
    <completion_date>November 2011</completion_date>
    <study_first_posted>January 24, 2013</study_first_posted>
    <last_update_posted>January 24, 2013</last_update_posted>
    <locations>
      <location>Dept of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01774695</url>
  </study>
  <study rank="457">
    <nct_id>NCT02902926</nct_id>
    <title>Comparison of Microbiota and Quality of Life for a Low FODMAPs and Standard Dietary in Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Food Habits</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Low FODMAPs Diet</intervention>
      <intervention type="Behavioral">Diet instruction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Microbiota / Short chain fatty acids</outcome_measure>
      <outcome_measure>Irritable bowel syndrome severity scoring system scale</outcome_measure>
      <outcome_measure>The Short Form 36 (SF-36) scale</outcome_measure>
      <outcome_measure>Irritable bowel syndrome quality of life (IBS-QOL) scale</outcome_measure>
      <outcome_measure>Satisfaction questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jinsong Wang</lead_sponsor>
      <collaborator>Yangzhou University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20160805</other_id>
    </other_ids>
    <start_date>September 2016</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>March 2017</completion_date>
    <study_first_posted>September 16, 2016</study_first_posted>
    <last_update_posted>September 16, 2016</last_update_posted>
    <locations>
      <location>YangzhouUniversity, Yangzhou, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02902926</url>
  </study>
  <study rank="458">
    <nct_id>NCT02009618</nct_id>
    <title>The Effects of Rifaximin Therapy in Irritable Bowel Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rifaximin</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>patients will be evaluated using a symptom severity and treatment efficacy scale after rifaximin therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bezmialem Vakif University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>27.1.2013 / 1</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <completion_date>October 2013</completion_date>
    <study_first_posted>December 12, 2013</study_first_posted>
    <last_update_posted>December 12, 2013</last_update_posted>
    <locations>
      <location>Bezmialem Vakıf University, Gastroenterology Clinic, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02009618</url>
  </study>
  <study rank="459">
    <nct_id>NCT02612649</nct_id>
    <title>Special Drug Use Surveillance of Irribow in Female Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ramosetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidences of Adverse Drug Reactions</outcome_measure>
      <outcome_measure>Change from baseline in frequency of bowel movements</outcome_measure>
      <outcome_measure>Change from baseline in form of stool</outcome_measure>
      <outcome_measure>Change from baseline in sensation of incomplete bowel evacuation</outcome_measure>
      <outcome_measure>Change from baseline in defecation urgency</outcome_measure>
      <outcome_measure>Change from baseline in abdominal pain or discomfort</outcome_measure>
      <outcome_measure>Change from baseline in melena</outcome_measure>
      <outcome_measure>Overall improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Astellas Pharma Inc</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>793</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IB0002</other_id>
    </other_ids>
    <start_date>October 1, 2015</start_date>
    <primary_completion_date>March 31, 2018</primary_completion_date>
    <completion_date>March 31, 2018</completion_date>
    <study_first_posted>November 24, 2015</study_first_posted>
    <last_update_posted>October 17, 2018</last_update_posted>
    <locations>
      <location>Aichi, Japan</location>
      <location>Akita, Japan</location>
      <location>Chiba, Japan</location>
      <location>Fukui, Japan</location>
      <location>Fukuoka, Japan</location>
      <location>Fukushima, Japan</location>
      <location>Gifu, Japan</location>
      <location>Gunma, Japan</location>
      <location>Hiroshima, Japan</location>
      <location>Hyogo, Japan</location>
      <location>Ibaraki, Japan</location>
      <location>Iwate, Japan</location>
      <location>Kagoshima, Japan</location>
      <location>Kanagawa, Japan</location>
      <location>Kumamoto, Japan</location>
      <location>Kyoto, Japan</location>
      <location>Mie, Japan</location>
      <location>Miyagi, Japan</location>
      <location>Miyazaki, Japan</location>
      <location>Nagano, Japan</location>
      <location>Niigata, Japan</location>
      <location>Oita, Japan</location>
      <location>Okayama, Japan</location>
      <location>Okinawa, Japan</location>
      <location>Osaka, Japan</location>
      <location>Saitama, Japan</location>
      <location>Shiga, Japan</location>
      <location>Shizuoka, Japan</location>
      <location>Tochigi, Japan</location>
      <location>Tokyo, Japan</location>
      <location>Tottori, Japan</location>
      <location>Toyama, Japan</location>
      <location>Yamagata, Japan</location>
      <location>Yamaguchi, Japan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02612649</url>
  </study>
  <study rank="460">
    <nct_id>NCT01912313</nct_id>
    <title>Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>nerve activity in healthy subjects and IBS patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KU Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>99999999</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>S55484</other_id>
    </other_ids>
    <start_date>August 2013</start_date>
    <primary_completion_date>August 2019</primary_completion_date>
    <completion_date>August 2019</completion_date>
    <study_first_posted>July 31, 2013</study_first_posted>
    <last_update_posted>February 9, 2017</last_update_posted>
    <locations>
      <location>University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01912313</url>
  </study>
  <study rank="461">
    <nct_id>NCT03223077</nct_id>
    <title>Mucosal and Microbiota Changes During Acute Campylobacteriosis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Development of IBS is the endpoint.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-006180</other_id>
    </other_ids>
    <start_date>October 31, 2014</start_date>
    <primary_completion_date>June 30, 2022</primary_completion_date>
    <completion_date>June 30, 2022</completion_date>
    <study_first_posted>July 19, 2017</study_first_posted>
    <last_update_posted>June 4, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03223077</url>
  </study>
  <study rank="462">
    <nct_id>NCT02536131</nct_id>
    <title>Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
      <condition>IBD</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Gut-directed hypnotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in gut microbiome as assessed through analyzing fecal samples</outcome_measure>
      <outcome_measure>Perceived Stress Questionnaire</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Connor-Davidson Resilience Scale</outcome_measure>
      <outcome_measure>Severity Scoring System for Irritable Bowel Syndrome</outcome_measure>
      <outcome_measure>Faecal calprotectin</outcome_measure>
      <outcome_measure>Harvey-Bradshaw-Index</outcome_measure>
      <outcome_measure>Quality of life visual analogue scales</outcome_measure>
      <outcome_measure>GI single symptom visual analogue scales</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>EK 1502/2014</other_id>
    </other_ids>
    <start_date>August 2014</start_date>
    <primary_completion_date>August 2016</primary_completion_date>
    <completion_date>August 2016</completion_date>
    <study_first_posted>August 31, 2015</study_first_posted>
    <last_update_posted>October 5, 2016</last_update_posted>
    <locations>
      <location>Medical University of Vienna, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02536131</url>
  </study>
  <study rank="463">
    <nct_id>NCT02419963</nct_id>
    <title>Analyzing IBS to Identify Biomarkers and Microbiome Signatures</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhoea Predominant Irritable Bowel Syndrome</condition>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">endoscopy for tissue biopsy</intervention>
      <intervention type="Other">Blood Sample</intervention>
      <intervention type="Other">Stool Sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Serotonin level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-008799</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>December 12, 2016</primary_completion_date>
    <completion_date>December 12, 2016</completion_date>
    <study_first_posted>April 17, 2015</study_first_posted>
    <last_update_posted>July 7, 2017</last_update_posted>
    <locations>
      <location>Mayo Clinic in Arizona, Scottsdale, Arizona, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02419963</url>
  </study>
  <study rank="464">
    <nct_id>NCT03221790</nct_id>
    <title>Effect of FODMAPs on Mucosal Inflammation in IBS Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low FODMAP Diet followed by a High FODMAP Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Rheobase</outcome_measure>
      <outcome_measure>Questionnaires on IBS symptom severity, stool microbiota, urine and blood metabolome</outcome_measure>
      <outcome_measure>Questionnaire on psychological scores</outcome_measure>
      <outcome_measure>Stool microbiota analysis</outcome_measure>
      <outcome_measure>Urine Metabolome</outcome_measure>
      <outcome_measure>Blood metabolome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>29677</other_id>
    </other_ids>
    <start_date>November 1, 2017</start_date>
    <primary_completion_date>July 1, 2018</primary_completion_date>
    <completion_date>February 1, 2019</completion_date>
    <study_first_posted>July 19, 2017</study_first_posted>
    <last_update_posted>October 5, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03221790</url>
  </study>
  <study rank="465">
    <nct_id>NCT01072916</nct_id>
    <title>Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colon, Irritable</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>fecal serine protease activity</outcome_measure>
      <outcome_measure>intestinal permeability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-1149</other_id>
      <other_id>R24DK067674</other_id>
    </other_ids>
    <start_date>February 2009</start_date>
    <primary_completion_date>December 2015</primary_completion_date>
    <completion_date>December 2015</completion_date>
    <study_first_posted>February 22, 2010</study_first_posted>
    <last_update_posted>March 11, 2016</last_update_posted>
    <locations>
      <location>University of North Carolina at Chapel Hill, Program in Digestive Health and the Department of Gastroenterology and Hepatology, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01072916</url>
  </study>
  <study rank="466">
    <nct_id>NCT01619384</nct_id>
    <title>Mindfulness-Based Stress Reduction and the Microbiome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Posttraumatic Stress Disorder</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mindfulness-Based Stress Reduction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in intestinal microbiome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seattle Institute for Biomedical and Clinical Research</lead_sponsor>
      <collaborator>American College of Gastroenterology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MIRB# 00044</other_id>
    </other_ids>
    <start_date>July 2010</start_date>
    <primary_completion_date>December 2013</primary_completion_date>
    <completion_date>December 2013</completion_date>
    <study_first_posted>June 14, 2012</study_first_posted>
    <last_update_posted>November 19, 2014</last_update_posted>
    <locations>
      <location>VA Puget Sound, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01619384</url>
  </study>
  <study rank="467">
    <nct_id>NCT01779765</nct_id>
    <title>The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">PHGG</intervention>
      <intervention type="Dietary Supplement">Maltodextrin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in IBS score.</outcome_measure>
      <outcome_measure>Quality questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tel-Aviv Sourasky Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TASMC-12-NV-242-CTIL</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>January 30, 2013</study_first_posted>
    <last_update_posted>March 27, 2014</last_update_posted>
    <locations>
      <location>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01779765</url>
  </study>
  <study rank="468">
    <nct_id>NCT02657668</nct_id>
    <title>Emotion Focused Therapy in Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Emotion Focused Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stress</outcome_measure>
      <outcome_measure>Coping Strategies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Islamic Azad University, Najafabad Branch</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IslamicAUN</other_id>
    </other_ids>
    <start_date>September 2013</start_date>
    <primary_completion_date>January 2014</primary_completion_date>
    <completion_date>October 2014</completion_date>
    <study_first_posted>January 18, 2016</study_first_posted>
    <last_update_posted>January 18, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02657668</url>
  </study>
  <study rank="469">
    <nct_id>NCT02251483</nct_id>
    <title>Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea Predominant Irritable Bowel Syndrome</condition>
      <condition>Small Intestinal Bacterial Overgrowth</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Serum-derived bovine immunoglobulin protein isolate (SBI)</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to relapse (symptom recurrence) in subjects with IBS-D after successful treatment with rifaximin</outcome_measure>
      <outcome_measure>Change in symptoms based on comparison of baseline symptom questionnaire to weekly symptom questionnaires</outcome_measure>
      <outcome_measure>Comparison of baseline Bristol stool score based on 7 day stool diary</outcome_measure>
      <outcome_measure>Comparison of KT ratios in plasma samples</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
      <collaborator>Entera Health, Inc</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>35543</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <completion_date>July 2015</completion_date>
    <study_first_posted>September 29, 2014</study_first_posted>
    <last_update_posted>July 29, 2015</last_update_posted>
    <locations>
      <location>GI Motility Program Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02251483</url>
  </study>
  <study rank="470">
    <nct_id>NCT01890837</nct_id>
    <title>Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Intestinal Diseases</condition>
      <condition>Abdominal Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Daikenchuto (TU-100)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensation rating of urgency to defecate in response to 32 mmHg distension of rectum on a 100 mm VAS</outcome_measure>
      <outcome_measure>Sensation threshold for pain in response to distention of the rectum</outcome_measure>
      <outcome_measure>Rectal compliance at half-maximum pressure (Pr1/2)</outcome_measure>
      <outcome_measure>Rectal sensation thresholds (gas, urgency to defecate, first sensation)</outcome_measure>
      <outcome_measure>Rectal sensation ratings (pain, gas) in response to 32 mmHg distension of the rectum</outcome_measure>
      <outcome_measure>Rectal tone response to feeding 1,000 kcal meal</outcome_measure>
      <outcome_measure>Stool frequency</outcome_measure>
      <outcome_measure>Stool consistency as measured by the Bristol stool scale</outcome_measure>
      <outcome_measure>Daily average severity of abdominal pain on 100mm VAS</outcome_measure>
      <outcome_measure>Worst severity of abdominal pain each day measured on 100mm VAS scale</outcome_measure>
      <outcome_measure>Daily average severity of bloating on 100mm VAS scale</outcome_measure>
      <outcome_measure>IBS-QOL (Quality of Life) score</outcome_measure>
      <outcome_measure>Ease of bowel movements</outcome_measure>
      <outcome_measure>Completeness of evacuation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tsumura USA</lead_sponsor>
      <collaborator>Cato Research</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TU100CPT5</other_id>
    </other_ids>
    <start_date>August 2013</start_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <completion_date>March 2015</completion_date>
    <study_first_posted>July 2, 2013</study_first_posted>
    <last_update_posted>June 13, 2016</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester Methodist CRU, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01890837</url>
  </study>
  <study rank="471">
    <nct_id>NCT01602575</nct_id>
    <title>Neuroimaging and Biomarkers in Chronic Visceral Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mindfulness based Stress Reduction Training (MBSR)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Validate Optimal Biomarker candidates</outcome_measure>
      <outcome_measure>Specificity, generality and moderation of biomarker response to MBSR treatment.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01AT007137</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>March 20, 2016</primary_completion_date>
    <completion_date>March 20, 2018</completion_date>
    <study_first_posted>May 21, 2012</study_first_posted>
    <last_update_posted>May 14, 2018</last_update_posted>
    <locations>
      <location>Oppenheimer Center for Neurobiology of Stress, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01602575</url>
  </study>
  <study rank="472">
    <nct_id>NCT03087799</nct_id>
    <title>Brief Behavioral Treatment for Sleep Problems in IBS Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Sleep Disturbance</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Brief Behavioral Treatment for Sleep</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Irritable Bowel Syndrome Severity Scoring System</outcome_measure>
      <outcome_measure>Change in Insomnia Severity Index</outcome_measure>
      <outcome_measure>Change in Pittsburgh Sleep Quality Index</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016P000440</other_id>
    </other_ids>
    <start_date>March 3, 2017</start_date>
    <primary_completion_date>September 2019</primary_completion_date>
    <completion_date>September 2019</completion_date>
    <study_first_posted>March 23, 2017</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03087799</url>
  </study>
  <study rank="473">
    <nct_id>NCT01166802</nct_id>
    <title>Development of a Questionnaire to Measure Hypervigilance for Visceral Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>Takeda Pharmaceuticals North America, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>157</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>07-005L</other_id>
    </other_ids>
    <start_date>February 2008</start_date>
    <primary_completion_date>June 2010</primary_completion_date>
    <completion_date>June 2010</completion_date>
    <study_first_posted>July 21, 2010</study_first_posted>
    <last_update_posted>July 21, 2010</last_update_posted>
    <locations>
      <location>UNC Center for Clinical and Translational Research, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01166802</url>
  </study>
  <study rank="474">
    <nct_id>NCT01166789</nct_id>
    <title>Lubiprostone Effects on Visceral Pain Sensitivity</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain threshold</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>Takeda</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>07-004L</other_id>
    </other_ids>
    <start_date>February 2008</start_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <completion_date>August 2010</completion_date>
    <study_first_posted>July 21, 2010</study_first_posted>
    <last_update_posted>September 16, 2011</last_update_posted>
    <locations>
      <location>UNC Clinical and Translational Research Center, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01166789</url>
  </study>
  <study rank="475">
    <nct_id>NCT01887834</nct_id>
    <title>Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome</title>
    <acronym>IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Colonic Diseases, Functional</condition>
      <condition>Colitis, Mucous</condition>
      <condition>Colon, Irritable</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Kyodophilus multi-strain probiotic capsules</intervention>
      <intervention type="Dietary Supplement">Kyodophilus Matching Placebo Capsules</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome Severity</outcome_measure>
      <outcome_measure>Tolerability of the treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Canadian College of Naturopathic Medicine</lead_sponsor>
      <collaborator>Wakunaga Pharmaceutical Co., Ltd.</collaborator>
      <collaborator>Dicentra Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1302</other_id>
    </other_ids>
    <start_date>June 2013</start_date>
    <primary_completion_date>June 2014</primary_completion_date>
    <completion_date>July 2014</completion_date>
    <study_first_posted>June 27, 2013</study_first_posted>
    <last_update_posted>March 17, 2015</last_update_posted>
    <locations>
      <location>The Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01887834</url>
  </study>
  <study rank="476">
    <nct_id>NCT00561535</nct_id>
    <title>Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Lactobacillus FARCIMINIS</intervention>
      <intervention type="Dietary Supplement">placebo (starch)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall subject's assessment</outcome_measure>
      <outcome_measure>Decrease in abdominal pain, stool form and consistency, modifications in intestinal permeability, modification in fecal serine protease activity, modifications in interleukin seric concentrations</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Association pour l'Etude des Fonctions Digestives</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AEFD 2007-01</other_id>
    </other_ids>
    <start_date>October 2007</start_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <completion_date>June 2010</completion_date>
    <study_first_posted>November 21, 2007</study_first_posted>
    <last_update_posted>January 27, 2011</last_update_posted>
    <locations>
      <location>Hopital Louis Mourier, GI Unit, Colombes, Ile de France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00561535</url>
  </study>
  <study rank="477">
    <nct_id>NCT01176227</nct_id>
    <title>Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Colonic Diseases, Functional</condition>
      <condition>Colitis, Mucous</condition>
      <condition>Colon, Irritable</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Kyodophilus multi-strain probiotic capsules</intervention>
      <intervention type="Dietary Supplement">Kyodophilus Matching Placebo Capsules</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The irrtable bowel severity scoring system is the primary outcome measure</outcome_measure>
      <outcome_measure>Tolerability of the treatment will be assessed through the use of study diaries in which adverse events will be recorded.</outcome_measure>
      <outcome_measure>The Irritable Bowel Syndrome-Quality of Life Questionnaire</outcome_measure>
      <outcome_measure>Visual Analogue Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Canadian College of Naturopathic Medicine</lead_sponsor>
      <collaborator>Wakunaga Pharmaceutical Co., Ltd.</collaborator>
      <collaborator>Dicentra Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1001</other_id>
    </other_ids>
    <start_date>May 2010</start_date>
    <primary_completion_date>February 2011</primary_completion_date>
    <completion_date>February 2011</completion_date>
    <study_first_posted>August 5, 2010</study_first_posted>
    <last_update_posted>April 1, 2011</last_update_posted>
    <locations>
      <location>The Canadian College of Naturopathic Medicine, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01176227</url>
  </study>
  <study rank="478">
    <nct_id>NCT00235326</nct_id>
    <title>Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number of Participants With Post Infectious Irritable Bowel Syndrome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>McMaster University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4561</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>02-026; 05-346</other_id>
    </other_ids>
    <start_date>January 2002</start_date>
    <primary_completion_date>August 2008</primary_completion_date>
    <completion_date>August 2008</completion_date>
    <study_first_posted>October 10, 2005</study_first_posted>
    <results_first_posted>April 22, 2009</results_first_posted>
    <last_update_posted>April 22, 2009</last_update_posted>
    <locations>
      <location>Walkerton, Walkerton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00235326</url>
  </study>
  <study rank="479">
    <nct_id>NCT00189033</nct_id>
    <title>Dietary Interventions in Irritable Bowel Syndrome: Soluble, Insoluble or no Fibre?</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colonic Diseases, Functional</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">psyllium fibre (dietary supplement)</intervention>
      <intervention type="Drug">wheat bran (dietary supplement)</intervention>
      <intervention type="Drug">rice wheat (placebo)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate Relief of abdominal pain or discomfort.</outcome_measure>
      <outcome_measure>IBS symptoms (IBS symptom severity score)</outcome_measure>
      <outcome_measure>IBS related quality of life (IBSQOL)</outcome_measure>
      <outcome_measure>Fibre intake</outcome_measure>
      <outcome_measure>The number of doctor visits and costs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
      <collaborator>Maastricht University Medical Center</collaborator>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>285</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UJ6Z</other_id>
      <other_id>4200.0020</other_id>
    </other_ids>
    <start_date>April 2005</start_date>
    <completion_date>April 2007</completion_date>
    <study_first_posted>September 16, 2005</study_first_posted>
    <last_update_posted>April 20, 2007</last_update_posted>
    <locations>
      <location>University of Maastricht, CAPHRI institute, Department of General Practice, Maastricht, Netherlands</location>
      <location>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Department of General Practice, Utrecht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00189033</url>
  </study>
  <study rank="480">
    <nct_id>NCT01966341</nct_id>
    <title>Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease</title>
    <acronym>CAPP</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">CBT/ Hypnotherapy</intervention>
      <intervention type="Drug">Routine Management</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Functional Disability Inventory (FDI)</outcome_measure>
      <outcome_measure>Pain Beliefs Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seton Healthcare Family</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR-13-108</other_id>
    </other_ids>
    <start_date>April 2014</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>April 2016</completion_date>
    <study_first_posted>October 21, 2013</study_first_posted>
    <last_update_posted>May 21, 2019</last_update_posted>
    <locations>
      <location>'Specially for Children, Dell Children's Medical Center of Central Texas, Austin, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01966341</url>
  </study>
  <study rank="481">
    <nct_id>NCT03022994</nct_id>
    <title>Duodenal and Rectal Histology in Non-celiac Wheat Sensitivity and Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-celiac Wheat Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Duodenum and rectum examination</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Histological differences in duodenal biopsies between NCWS and IBS patients.</outcome_measure>
      <outcome_measure>Histological differences in rectal biopsies between NCWS and IBS patients.</outcome_measure>
      <outcome_measure>Identification of site (i.e. duodenal or rectal) with more inflammatory cells infiltration.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Palermo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACPM18</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>January 2017</primary_completion_date>
    <completion_date>July 2017</completion_date>
    <study_first_posted>January 18, 2017</study_first_posted>
    <last_update_posted>July 12, 2017</last_update_posted>
    <locations>
      <location>Department of Internal Medicine, Giovanni Paolo II Hospital of Sciacca, Sciacca, Agrigento, Italy</location>
      <location>Department of Internal Medicine, University Hospital of Palermo, Palermo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03022994</url>
  </study>
  <study rank="482">
    <nct_id>NCT03082287</nct_id>
    <title>ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Fecal Calprotectin Level</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>In vitro diagnostic value of Calprotectin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>American Laboratory Products Company</lead_sponsor>
      <collaborator>MDC Associates, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>ALPCOCAL</other_id>
    </other_ids>
    <start_date>May 1, 2017</start_date>
    <primary_completion_date>March 2018</primary_completion_date>
    <completion_date>March 2018</completion_date>
    <study_first_posted>March 17, 2017</study_first_posted>
    <last_update_posted>June 28, 2017</last_update_posted>
    <locations>
      <location>ALPCO, Salem, New Hampshire, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03082287</url>
  </study>
  <study rank="483">
    <nct_id>NCT02516683</nct_id>
    <title>The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Shigella Sonnei Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Shigella sonnei infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Questionnaire survey for bowel symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>229</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>3-2011-0242</other_id>
    </other_ids>
    <start_date>December 2001</start_date>
    <primary_completion_date>December 2011</primary_completion_date>
    <completion_date>July 2015</completion_date>
    <study_first_posted>August 6, 2015</study_first_posted>
    <last_update_posted>August 6, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02516683</url>
  </study>
  <study rank="484">
    <nct_id>NCT03778918</nct_id>
    <title>The Comparison Between the Biomarkers in Inflammatory Bowel Disease Patients and General Control Group</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">inflammatory bowel disease</intervention>
      <intervention type="Other">IBS or Normal Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>measurement of blood-based biomarkers to predict disease activity 1</outcome_measure>
      <outcome_measure>measurement of blood-based biomarkers to predict disease activity 2</outcome_measure>
      <outcome_measure>measurement of blood-based biomarkers to predict disease activity 3</outcome_measure>
      <outcome_measure>Age (years)</outcome_measure>
      <outcome_measure>Gender (M/F)</outcome_measure>
      <outcome_measure>disease duration (months)</outcome_measure>
      <outcome_measure>disease onset (years)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bo-In Lee</lead_sponsor>
      <collaborator>Incheon St.Mary's Hospital</collaborator>
      <collaborator>St. Vincent's Hospital-Manhattan</collaborator>
      <collaborator>Daejeon St. Mary's hospital</collaborator>
      <collaborator>Seoul St. Mary's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>XC18TEDI0027</other_id>
    </other_ids>
    <start_date>August 1, 2016</start_date>
    <primary_completion_date>August 31, 2019</primary_completion_date>
    <completion_date>February 28, 2020</completion_date>
    <study_first_posted>December 18, 2018</study_first_posted>
    <last_update_posted>April 8, 2019</last_update_posted>
    <locations>
      <location>Division of Gastroenterology; Seoul St. Mary's hospital, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03778918</url>
  </study>
  <study rank="485">
    <nct_id>NCT02732743</nct_id>
    <title>Food Supplement Physiomanna® Baby in Pediatric Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Physiomanna® Baby</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Spontaneous Bowel Movements (SBM) per week</outcome_measure>
      <outcome_measure>Safety: Adverse Events (AE) check; Investigator and Patient Global Assessment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Iuppa Industriale Srl</lead_sponsor>
      <collaborator>Opera CRO, a TIGERMED Group Company</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>8 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>IU01/016</other_id>
    </other_ids>
    <start_date>February 2016</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>April 2016</completion_date>
    <study_first_posted>April 11, 2016</study_first_posted>
    <last_update_posted>January 16, 2018</last_update_posted>
    <locations>
      <location>Opera Contract Research Organization SRL, Timisoara, Timis, Romania</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02732743</url>
  </study>
  <study rank="486">
    <nct_id>NCT03529318</nct_id>
    <title>Mucosal Innate Immune Activation in Chronic Intestinal Disorders</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Biopsies from endoscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The number of specimens showing elevated levels of mucosal innate immune activation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Arkansas</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>217718</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>January 1, 2020</primary_completion_date>
    <completion_date>January 1, 2020</completion_date>
    <study_first_posted>May 18, 2018</study_first_posted>
    <last_update_posted>October 16, 2018</last_update_posted>
    <locations>
      <location>University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03529318</url>
  </study>
  <study rank="487">
    <nct_id>NCT02144753</nct_id>
    <title>Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation-predominant IBS (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">NTX-1</intervention>
      <intervention type="Drug">psyllium (15 g)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite improvement in the following three areas: IBS global improvement score on the Likert Scale, frequency &amp; consistency of stools, &amp; severity of abdominal pain, discomfort and bloating</outcome_measure>
      <outcome_measure>Determine side effects of NTX-1</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nutrabiotix, LLC</lead_sponsor>
      <collaborator>Rush University Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>SBIR-2013-NTX</other_id>
    </other_ids>
    <start_date>March 2014</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>April 2016</completion_date>
    <study_first_posted>May 22, 2014</study_first_posted>
    <last_update_posted>May 2, 2016</last_update_posted>
    <locations>
      <location>Rush University Medical Center, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02144753</url>
  </study>
  <study rank="488">
    <nct_id>NCT03440255</nct_id>
    <title>Transcutaneous Vagus Nerve Stimulation in Private Healthcare Center</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Generalized Anxiety Disorder</condition>
      <condition>Chronic Pain</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Transcutaneous Vagus Nerve Stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline generalized anxiety disorder severity</outcome_measure>
      <outcome_measure>Change from baseline pain severity and pain interference</outcome_measure>
      <outcome_measure>Change from baseline irritable bowels syndrome severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kinesis Health Associates</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TaVNS_PHC</other_id>
    </other_ids>
    <start_date>July 1, 2017</start_date>
    <primary_completion_date>July 31, 2017</primary_completion_date>
    <completion_date>September 15, 2017</completion_date>
    <study_first_posted>February 21, 2018</study_first_posted>
    <last_update_posted>February 22, 2018</last_update_posted>
    <locations>
      <location>Kinesis Health Associates, Dartmouth, Nova Scotia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03440255</url>
  </study>
  <study rank="489">
    <nct_id>NCT00745004</nct_id>
    <title>Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Diarrhoea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ondansetron</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary outcome measure is the difference in average stool consistency during the last two week period of Ondansetron compared to placebo treatment.</outcome_measure>
      <outcome_measure>1) Proportion of patients preferring ondansetron versus placebo 2) Proportion wanting to continue with ondansetron versus placebo 3) Difference between ondansetron and placebo periods.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>08027</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>September 1, 2008</study_first_posted>
    <last_update_posted>January 24, 2012</last_update_posted>
    <locations>
      <location>University Hospital of South Manchester NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom</location>
      <location>University of Nottingham, Nottingham, Nottinghamshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00745004</url>
  </study>
  <study rank="490">
    <nct_id>NCT02495623</nct_id>
    <title>A Study of the Effect of SYN-010 on Subjects With IBS-C</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome With Constipation (IBS-C)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SYN-010 21 mg</intervention>
      <intervention type="Drug">SYN-010 42 mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change From Baseline in the Area Under the Curve (AUC) of Breath CH4 Production at Day 7</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Synthetic Biologics Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>63</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SB-2-010-001</other_id>
    </other_ids>
    <start_date>June 2015</start_date>
    <primary_completion_date>October 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>July 13, 2015</study_first_posted>
    <results_first_posted>March 8, 2017</results_first_posted>
    <last_update_posted>November 27, 2018</last_update_posted>
    <locations>
      <location>Miami, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02495623</url>
  </study>
  <study rank="491">
    <nct_id>NCT01370720</nct_id>
    <title>Safety and Efficacy Study of PEA and Polydatin on Intestinal Inflammation and Visceral Hyperalgesia in IBS Patients</title>
    <acronym>CMD-IBS09(2)</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Recoclix</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes from screening visit of mast cell infiltration and activation in biopsy samples of colon mucosa from IBS patients, following 12 weeks of dietary supplementation with palmitoylethanolamide (PEA) and polydatin</outcome_measure>
      <outcome_measure>Changes in biomarkers related to the endocannabinoid system</outcome_measure>
      <outcome_measure>Changes from screening visit of other inflammatory cell subsets in biopsy samples of colon mucosa from IBS patients, following 12 weeks of dietary supplementation with palmitoylethanolamide (PEA) and polydatin</outcome_measure>
      <outcome_measure>Safety assessment by no changes in laboratory parameters and vital signs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>MARIA CRISTINA COMELLI</lead_sponsor>
      <collaborator>CM&amp;D Pharma Limited</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>CM&amp;D Pharma Limited</other_id>
    </other_ids>
    <start_date>February 2010</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>January 2013</completion_date>
    <study_first_posted>June 10, 2011</study_first_posted>
    <last_update_posted>June 19, 2012</last_update_posted>
    <locations>
      <location>Dept Internal Medicine and Gastroenterology, Policlinico Sant'Orsola-Malpighi, Bologna, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01370720</url>
  </study>
  <study rank="492">
    <nct_id>NCT02433847</nct_id>
    <title>Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipated Irritable Bowel Syndrome</condition>
      <condition>Chronic Constipation</condition>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mosapride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>colonic transit time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seoul National University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Mosa_GIFx_1.0</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>May 5, 2015</study_first_posted>
    <last_update_posted>May 5, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02433847</url>
  </study>
  <study rank="493">
    <nct_id>NCT02572908</nct_id>
    <title>Effects of Wheat Breads on Symptoms of IBS, a Pilot Study</title>
    <acronym>Wheat-IBS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Wheat Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Sourdough wheat bread</intervention>
      <intervention type="Other">Regular yeast baked toast bread</intervention>
      <intervention type="Other">Gluten-free diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective symptoms using visual analog scale (VAS) daily</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oy Karl Fazer Ab</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Wheat-IBS</other_id>
    </other_ids>
    <start_date>August 2015</start_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <completion_date>March 2016</completion_date>
    <study_first_posted>October 9, 2015</study_first_posted>
    <last_update_posted>August 5, 2016</last_update_posted>
    <locations>
      <location>Aava Medical Centre, Helsinki, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02572908</url>
  </study>
  <study rank="494">
    <nct_id>NCT01028898</nct_id>
    <title>Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome</title>
    <acronym>IBS</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Digestive System Diseases</condition>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Intestinal Diseases</condition>
      <condition>Colonic Diseases</condition>
      <condition>Colonic Diseases, Functional</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Chinese PLA General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IBS and metabolism</other_id>
    </other_ids>
    <start_date>January 2006</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>December 9, 2009</study_first_posted>
    <last_update_posted>February 11, 2011</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01028898</url>
  </study>
  <study rank="495">
    <nct_id>NCT01205100</nct_id>
    <title>Treatment of Abdominal Distension by Biofeedback - a Randomized Controlled Trial</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Dyspepsia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Bio-feedback</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensation of abdominal distension</outcome_measure>
      <outcome_measure>Changes in thoraco-abdominal activity of the muscular walls.</outcome_measure>
      <outcome_measure>Changes in girth</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Universitari Vall d'Hebron Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PR(AG)60/2009</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>January 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>September 20, 2010</study_first_posted>
    <last_update_posted>July 27, 2016</last_update_posted>
    <locations>
      <location>University Hospital Vall d'Hebron, Barcelona, Catalunya, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01205100</url>
  </study>
  <study rank="496">
    <nct_id>NCT00934479</nct_id>
    <title>Intestinal Microecology in Chronic Constipation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Other Constipation</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lubiprostone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Identification of specific microorganisms associated with chronic constipation in comparison to healthy subjects and those with C-IBS</outcome_measure>
      <outcome_measure>Evaluate changes in the gut microbiota after lubiprostone treatment in the chronic constipation subjects and those with C-IBS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>Arizona State University</collaborator>
      <collaborator>Takeda Pharmaceuticals North America, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>09-001281</other_id>
    </other_ids>
    <start_date>April 2010</start_date>
    <primary_completion_date>February 2012</primary_completion_date>
    <completion_date>February 2012</completion_date>
    <study_first_posted>July 8, 2009</study_first_posted>
    <last_update_posted>July 17, 2013</last_update_posted>
    <locations>
      <location>Mayo Clinic Arizona, Scottsdale, Arizona, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00934479</url>
  </study>
  <study rank="497">
    <nct_id>NCT00142987</nct_id>
    <title>Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS-C and IBS With Mixed Bowel Habits</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tegaserod</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Weekly assessment of patient's overall satisfaction relief over 4 weeks of treatment of IBS symptoms</outcome_measure>
      <outcome_measure>Weekly assessment of patient's overall satisfaction relief.</outcome_measure>
      <outcome_measure>Over 4 weeks of treatment and during each week improvment of abdominal discomfort pain, bloating, stool frequency, stool consitency, straining urgency.</outcome_measure>
      <outcome_measure>During 4 week treatment period efficacy assessment in IBS-C subgroup and mixed IBS.</outcome_measure>
      <outcome_measure>Assessment of safety and tolerability.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>664</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHTF919A2417</other_id>
    </other_ids>
    <start_date>April 2004</start_date>
    <completion_date>June 2005</completion_date>
    <study_first_posted>September 2, 2005</study_first_posted>
    <last_update_posted>January 28, 2008</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00142987</url>
  </study>
  <study rank="498">
    <nct_id>NCT00130741</nct_id>
    <title>Combination Herbal Therapy (CHT) Versus Placebo in Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colonic Diseases, Functional</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CHT - herbal therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate whether CHT administered orally (PO) induces a change in the overall QOL score from baseline values at 4 weeks of treatment measured via the IBS 36 questionnaire in patients with irritable bowel syndrome, relative to placebo</outcome_measure>
      <outcome_measure>30% change on the IBS-36 from baseline to 4 weeks (&quot;no&quot; or &quot;yes&quot;)</outcome_measure>
      <outcome_measure>Change on IBS-36 from 4 weeks (last treatment taken) and 8 weeks (i.e., after 4 weeks of &quot;washout&quot;)</outcome_measure>
      <outcome_measure>Change in IBS symptoms severity score from baseline to 4 weeks</outcome_measure>
      <outcome_measure>Change in IBS symptoms severity score from 4 to 8 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hadassah Medical Organization</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>391-14.1.05-HMO-CTIL</other_id>
    </other_ids>
    <start_date>July 2005</start_date>
    <completion_date>January 2007</completion_date>
    <study_first_posted>August 16, 2005</study_first_posted>
    <last_update_posted>April 11, 2007</last_update_posted>
    <locations>
      <location>Hadassah Medical Organization, Jerusalem, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00130741</url>
  </study>
  <study rank="499">
    <nct_id>NCT03220711</nct_id>
    <title>Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colonic Dysplasia</condition>
      <condition>Adenomatous Polyps</condition>
      <condition>Irritable Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">confocal endomicroscope</intervention>
      <intervention type="Drug">Fluorescein</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depth-imaging capability of the confocal endomicroscope using an imaging contrast agent, fluorescein</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Device Feasibility</study_design>
    </study_designs>
    <other_ids>
      <other_id>HUM00124968</other_id>
    </other_ids>
    <start_date>July 28, 2017</start_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <completion_date>July 2019</completion_date>
    <study_first_posted>July 18, 2017</study_first_posted>
    <last_update_posted>February 6, 2019</last_update_posted>
    <locations>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03220711</url>
  </study>
  <study rank="500">
    <nct_id>NCT00728026</nct_id>
    <title>Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vomiting Syndrome</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Postural Orthostatic Tachycardia Syndrome</condition>
      <condition>Abdominal Pain</condition>
      <condition>Chronic Nausea</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To gather preliminary data to characterize autonomic function in children and adolescents with functional gastrointestinal disorders.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>Children's Hospital and Health System Foundation, Wisconsin</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>08/112</other_id>
      <other_id>GC 680</other_id>
    </other_ids>
    <start_date>June 2008</start_date>
    <primary_completion_date>September 16, 2016</primary_completion_date>
    <completion_date>September 16, 2016</completion_date>
    <study_first_posted>August 5, 2008</study_first_posted>
    <last_update_posted>August 14, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00728026</url>
  </study>
  <study rank="501">
    <nct_id>NCT03720314</nct_id>
    <title>Microbiota Profiling in IBS</title>
    <acronym>IBSQUtrition</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Microbial Colonization</condition>
      <condition>Dietary Habits</condition>
    </conditions>
    <interventions>
      <intervention type="Other">NA observational study</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in microbiota composition</outcome_measure>
      <outcome_measure>Change in Short chain fatty acid levels</outcome_measure>
      <outcome_measure>Dietary intake</outcome_measure>
      <outcome_measure>Change in Stool pattern</outcome_measure>
      <outcome_measure>Change in Gastro-intestinal complaints</outcome_measure>
      <outcome_measure>Change in Anxiety and Depression screening scores</outcome_measure>
      <outcome_measure>Change in Quality of Life scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wageningen University</lead_sponsor>
      <collaborator>Netherlands: Ministry of Health, Welfare and Sports</collaborator>
      <collaborator>Ingredia S.A.</collaborator>
      <collaborator>Nexira</collaborator>
      <collaborator>Naturex</collaborator>
      <collaborator>Bioiberica</collaborator>
      <collaborator>Wecare</collaborator>
      <collaborator>Roquette Freres</collaborator>
      <collaborator>Darling</collaborator>
      <collaborator>Winclove Bio Industries BV</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>121</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL64950.081.18</other_id>
    </other_ids>
    <start_date>September 6, 2018</start_date>
    <primary_completion_date>December 15, 2018</primary_completion_date>
    <completion_date>December 15, 2018</completion_date>
    <study_first_posted>October 25, 2018</study_first_posted>
    <last_update_posted>February 21, 2019</last_update_posted>
    <locations>
      <location>Wageningen University &amp; Research, Wageningen, Gelderland, Netherlands</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT03720314/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03720314</url>
  </study>
  <study rank="502">
    <nct_id>NCT03002584</nct_id>
    <title>International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)</title>
    <acronym>PRoVING</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
      <condition>General Population</condition>
    </conditions>
    <interventions>
      <intervention type="Other">completion of self-reported questionnaires</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Psychometric validation of the IGQ</outcome_measure>
      <outcome_measure>Electronic version of the IGQ</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Paris 7 - Denis Diderot</lead_sponsor>
      <collaborator>EA 7334, Patient-Centered Outcomes Research</collaborator>
      <collaborator>University of Manchester</collaborator>
      <collaborator>Hospital Vall d'Hebron</collaborator>
      <collaborator>Hôpital Louis Mourier</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IGQ</other_id>
    </other_ids>
    <start_date>February 10, 2017</start_date>
    <primary_completion_date>April 30, 2018</primary_completion_date>
    <completion_date>July 10, 2018</completion_date>
    <study_first_posted>December 26, 2016</study_first_posted>
    <last_update_posted>February 18, 2019</last_update_posted>
    <locations>
      <location>Hopital Louis Mourier, Colombes, France</location>
      <location>Centro de salud Chafarinas, Barcelona, Spain</location>
      <location>Horta, Hospital Universitari Vall d'Hebron, Barcelona, Spain</location>
      <location>Centre Mèdic Sant Andreu, Barcelona, Spain</location>
      <location>Wythenshawe Hospital, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03002584</url>
  </study>
  <study rank="503">
    <nct_id>NCT01686919</nct_id>
    <title>Effect of Milk-free Diet on Weight and Irritable Bowel Syndrome in Morbid Obesity</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity, Morbid</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">milk-free</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>weight loss</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms</outcome_measure>
      <outcome_measure>IgG antigen against milk</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Norwegian University of Science and Technology</lead_sponsor>
      <collaborator>Sykehuset Innlandet HF</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012/966</other_id>
    </other_ids>
    <start_date>December 2012</start_date>
    <primary_completion_date>December 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>September 18, 2012</study_first_posted>
    <last_update_posted>January 21, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01686919</url>
  </study>
  <study rank="504">
    <nct_id>NCT02358564</nct_id>
    <title>Gut Permeability, Sensitivity and Symptomatology</title>
    <acronym>GPSS</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Visceral Hypersensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Gastrointestinal Permeability Test</intervention>
      <intervention type="Procedure">Upper Endoscopy</intervention>
      <intervention type="Procedure">Rectal Barostat and Infusion of Fats</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean Percent of complete epithelial cell loss</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>University of Erlangen-Nürnberg</collaborator>
      <collaborator>Heidelberg University</collaborator>
      <collaborator>University of Leeds</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-000837</other_id>
      <other_id>UL1TR000135</other_id>
    </other_ids>
    <start_date>February 2015</start_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <completion_date>July 2019</completion_date>
    <study_first_posted>February 9, 2015</study_first_posted>
    <last_update_posted>May 15, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic in Florida, Jacksonville, Florida, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02358564</url>
  </study>
  <study rank="505">
    <nct_id>NCT01286597</nct_id>
    <title>The Effects of Lactose Intolerance on Gastrointestinal Function and Symptoms in a Chinese Population</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lactose Intolerance</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">dietary restriction</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess the effects of lactose intolerance on gastrointestinal function and symptoms</outcome_measure>
      <outcome_measure>To measure the intake of dietary lactose in the adult general population and in patients with IBS</outcome_measure>
      <outcome_measure>To assess genetic factors, tolerance to lactose challenge and visceral sensitivity.</outcome_measure>
      <outcome_measure>To assess appropriate dosage of lactose hydrogen breath test</outcome_measure>
      <outcome_measure>To determine the impact of a determined dietary intervention on abdominal symptoms compatible with D-IBS.</outcome_measure>
      <outcome_measure>To explore the association of visceral sensitivity induced by LI with mucosal immune activation and psychological factors in D-IBS patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sir Run Run Shaw Hospital</lead_sponsor>
      <collaborator>University Hospital, Zürich</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>120100047</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>December 2012</primary_completion_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>January 31, 2011</study_first_posted>
    <last_update_posted>July 10, 2012</last_update_posted>
    <locations>
      <location>Sir Run Run Shaw Hospital , College of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01286597</url>
  </study>
  <study rank="506">
    <nct_id>NCT03266068</nct_id>
    <title>Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Campylobacter Infections</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">DNA Analysis of Blood Sample</intervention>
      <intervention type="Procedure">Flexible sigmoidoscopy with colonic biopsies</intervention>
      <intervention type="Procedure">Small bowel and colonic gastrointestinal permeability</intervention>
      <intervention type="Diagnostic Test">Stool sample analysis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Colonic geometric center at 24 hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-006529</other_id>
      <other_id>K23DK103911</other_id>
      <other_id>P30DK084567</other_id>
      <other_id>UL1TR000135</other_id>
    </other_ids>
    <start_date>September 2016</start_date>
    <primary_completion_date>June 2019</primary_completion_date>
    <completion_date>August 2019</completion_date>
    <study_first_posted>August 29, 2017</study_first_posted>
    <last_update_posted>June 4, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03266068</url>
  </study>
  <study rank="507">
    <nct_id>NCT01072903</nct_id>
    <title>The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)</title>
    <acronym>K23</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammation</condition>
      <condition>Colon, Irritable</condition>
      <condition>Colonic Diseases, Functional</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-1106</other_id>
      <other_id>K23DK075621</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <completion_date>July 2012</completion_date>
    <study_first_posted>February 22, 2010</study_first_posted>
    <last_update_posted>December 12, 2013</last_update_posted>
    <locations>
      <location>University of North Carolina at Chapel Hill, Program in Digestive Health and the Department of Gastroenterology and Hepatology, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01072903</url>
  </study>
  <study rank="508">
    <nct_id>NCT00526903</nct_id>
    <title>Recurrent Abdominal Pain in Children</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Abdominal Pain</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Elimination Diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in pain and stooling symptoms</outcome_measure>
      <outcome_measure>Child anxiety, somatization, and coping</outcome_measure>
      <outcome_measure>Parental somatization, coping, and illness interaction</outcome_measure>
      <outcome_measure>Changes in GI Transit time</outcome_measure>
      <outcome_measure>Changes in Breath Hydrogen production</outcome_measure>
      <outcome_measure>Changes in GI Permeability</outcome_measure>
      <outcome_measure>Changes in fecal calprotectin concentration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>National Institute of Nursing Research (NINR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>17388</other_id>
      <other_id>R01NR005337</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <completion_date>March 2014</completion_date>
    <study_first_posted>September 10, 2007</study_first_posted>
    <last_update_posted>March 8, 2016</last_update_posted>
    <locations>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00526903</url>
  </study>
  <study rank="509">
    <nct_id>NCT01916200</nct_id>
    <title>Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depressive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paroxetine CR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>HDRS-17</outcome_measure>
      <outcome_measure>HDRS-17 item 10</outcome_measure>
      <outcome_measure>CGI-I</outcome_measure>
      <outcome_measure>CGI-S</outcome_measure>
      <outcome_measure>WHOQOL</outcome_measure>
      <outcome_measure>IBSSS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>117049</other_id>
    </other_ids>
    <start_date>January 2014</start_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <completion_date>September 2014</completion_date>
    <study_first_posted>August 5, 2013</study_first_posted>
    <last_update_posted>July 16, 2014</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01916200</url>
  </study>
  <study rank="510">
    <nct_id>NCT01705171</nct_id>
    <title>Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fructose Intolerance</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>mRNA and protein expression of Glut5</outcome_measure>
      <outcome_measure>mRNA and protein expression of Glut2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brain-Gut Research Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>GGP1345012</other_id>
      <other_id>GLUT5</other_id>
    </other_ids>
    <start_date>December 2011</start_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <completion_date>October 2013</completion_date>
    <study_first_posted>October 12, 2012</study_first_posted>
    <last_update_posted>December 17, 2018</last_update_posted>
    <locations>
      <location>Gastoenterology Group Practice, Bern, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01705171</url>
  </study>
  <study rank="511">
    <nct_id>NCT01114113</nct_id>
    <title>Assessment of Gastric Emptying Speed in Patients Who Experience Diarrhea Following a Trigger Meal</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Diarrhea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pancelipase/placebo</intervention>
      <intervention type="Device">SmartPill capsule</intervention>
      <intervention type="Device">SmartPill capsule</intervention>
      <intervention type="Device">SmartPill capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of intestinal speed of a &quot;trigger meal&quot; compared to a non-trigger meal baseline. Optional study comparing intestinal speed of trigger meal using Pancrelipase compared to placebo.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Money, Mary E., M.D.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010IBS-G/D eval</other_id>
    </other_ids>
    <start_date>April 2010</start_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <completion_date>January 2011</completion_date>
    <study_first_posted>April 30, 2010</study_first_posted>
    <last_update_posted>April 20, 2012</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01114113</url>
  </study>
  <study rank="512">
    <nct_id>NCT01268618</nct_id>
    <title>Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS-D and Functional Dyspepsia</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotic</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal pain severity</outcome_measure>
      <outcome_measure>Stool consistency (Bristol Stool Chart)</outcome_measure>
      <outcome_measure>Dyspepsia Symptom Severity Index (DSSI)</outcome_measure>
      <outcome_measure>Proportion of subjects with 1 or more adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sprim Advanced Life Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>10-SUS-05-NAT-01</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>August 2011</completion_date>
    <study_first_posted>December 31, 2010</study_first_posted>
    <last_update_posted>July 21, 2011</last_update_posted>
    <locations>
      <location>In-Quest Medical Research, LLC, Duluth, Georgia, United States</location>
      <location>Clinical Research Associates of Tidewater, Norfolk, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01268618</url>
  </study>
  <study rank="513">
    <nct_id>NCT03226145</nct_id>
    <title>Reclassifying Constipation Using Imaging and Manometry</title>
    <acronym>RECLAIM</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Constipation - Functional</condition>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">MRI Motility</intervention>
      <intervention type="Procedure">High Resolution Manometry</intervention>
      <intervention type="Drug">Bisacodyl</intervention>
      <intervention type="Drug">Hyoscine butylbromide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>MRI Endpoint: Maximal MRI Motility Index (MMI) of the ascending colon (AC)</outcome_measure>
      <outcome_measure>HRM Endpoint: Percentage time occupied by cyclical propagating activity following meal</outcome_measure>
      <outcome_measure>Difference in average worst daily pain, scored on a range 1-5 between buscopan and bisacodyl intervention periods.</outcome_measure>
      <outcome_measure>Maximal MMI of the descending colon (DC)</outcome_measure>
      <outcome_measure>Whole Gut Transit</outcome_measure>
      <outcome_measure>Number of complete spontaneous bowel movements.</outcome_measure>
      <outcome_measure>Stool consistency</outcome_measure>
      <outcome_measure>PAC-SYM Questionnaire Score</outcome_measure>
      <outcome_measure>Area Under the Curve for pressure 0-30 minute during HRM Number of High Amplitude Propagating Contractions (HAPCs)</outcome_measure>
      <outcome_measure>Number of High Amplitude Propagating Contractions (HAPCs) during HRM</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>University College, London</collaborator>
      <collaborator>Queen Mary University of London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>16105</other_id>
    </other_ids>
    <start_date>July 20, 2017</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>July 21, 2017</study_first_posted>
    <last_update_posted>April 17, 2019</last_update_posted>
    <locations>
      <location>University of Nottingham, Nottingham, Notts, United Kingdom</location>
      <location>Queen Mary University of London, London, United Kingdom</location>
      <location>University College London, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03226145</url>
  </study>
  <study rank="514">
    <nct_id>NCT02033161</nct_id>
    <title>Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internet-delivered CBT</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in gastrointestinal symptoms from baseline to 8 weeks, and from baseline to 6 months after treatment.</outcome_measure>
      <outcome_measure>Change in pain reactivity from baseline to 8 weeks, and from baseline to 6 months after treatment.</outcome_measure>
      <outcome_measure>Change in pain interference on activities from baseline to 8 weeks, and baseline to 6 months after treatment.</outcome_measure>
      <outcome_measure>Change in function from baseline to 8 weeks and from baseline to 6 months after treatment.</outcome_measure>
      <outcome_measure>Change in sensitivity to symptoms of anxiety from baseline to 8 weeks, and from baseline to 6 months after treatment.</outcome_measure>
      <outcome_measure>Change in level of depression from baseline to 8 weeks and from baseline to 6 months after treatment.</outcome_measure>
      <outcome_measure>Change in level of perceived stress from baseline to 8 weeks and from baseline to 6 months after treatment.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>icbt fgid pilot 2012</other_id>
    </other_ids>
    <start_date>March 2012</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>June 2013</completion_date>
    <study_first_posted>January 10, 2014</study_first_posted>
    <last_update_posted>January 10, 2014</last_update_posted>
    <locations>
      <location>Child and Adolescent Psychiatry, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02033161</url>
  </study>
  <study rank="515">
    <nct_id>NCT02566876</nct_id>
    <title>Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Dyspepsia Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mixture of three Bifidobacteria</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Abdominal Pain Frequency</outcome_measure>
      <outcome_measure>Functional Disability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>73</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>02122013</other_id>
    </other_ids>
    <start_date>December 2013</start_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <completion_date>September 2015</completion_date>
    <study_first_posted>October 2, 2015</study_first_posted>
    <last_update_posted>October 2, 2015</last_update_posted>
    <locations>
      <location>University of Naples &quot;Federico II&quot; Italy, Naples, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02566876</url>
  </study>
  <study rank="516">
    <nct_id>NCT01622972</nct_id>
    <title>Mode of Action of Moviprep</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Constipation</condition>
      <condition>Irritable Bowel Syndrome Characterized by Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Polyethyleneglycol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of 1 or 2 litre of Moviprep on area under curve (AUC) small bowel water content 0-6 hours on healthy volunteers</outcome_measure>
      <outcome_measure>To assess area under curve of small bowel water content following 1litre of Moviprep on patients with constipation</outcome_measure>
      <outcome_measure>Effect of 2 different dosing regimens of Moviprep on cleansing of the colon as assessed from colonic contents on the last scan at the end of purgation</outcome_measure>
      <outcome_measure>Effect of 2 different dosing regimens of Moviprep on the time course of the intestinal water content</outcome_measure>
      <outcome_measure>Effect of 2 different dosing regimens of Moviprep on the time course of the ascending colon total chyme volume</outcome_measure>
      <outcome_measure>Effect of 2 different dosing regimens of Moviprep on the time course of the Colonic motility index 'cine' MRI movies</outcome_measure>
      <outcome_measure>Effect of 2 different dosing regimens of Moviprep on the time course of the transit assessment from mean position of marker capsules</outcome_measure>
      <outcome_measure>Comparison of single dose versus split dose on above MRI parameters</outcome_measure>
      <outcome_measure>Rate of recovery of normal colonic microbiota over days 2-28 assessed by bacterial DNA data (HITChip) and SCFA concentration</outcome_measure>
      <outcome_measure>Correlation between microbiota, SCFA and colonic MRI parameters</outcome_measure>
      <outcome_measure>Ascending colon total chime volume</outcome_measure>
      <outcome_measure>Colonic motility index 'cine; MRI movies</outcome_measure>
      <outcome_measure>C) Comparison of the cross sectional area of the ascending colon with the cross sectional area of the transverse and descending colon</outcome_measure>
      <outcome_measure>Transit assessment from mean position of marker capsules at 24 hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>Norgine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>10050</other_id>
      <other_id>2010-021879-85</other_id>
    </other_ids>
    <start_date>September 2011</start_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <completion_date>February 2014</completion_date>
    <study_first_posted>June 19, 2012</study_first_posted>
    <last_update_posted>April 14, 2014</last_update_posted>
    <locations>
      <location>Nottingham Digestive Diseases Centre, University of Nottingham, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01622972</url>
  </study>
  <study rank="517">
    <nct_id>NCT03678935</nct_id>
    <title>Effect of FODMAP Restriction on Persistent GI-symptoms in Coeliac Patients</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Diet Modification</condition>
      <condition>Gluten Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low FODMAP diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in gastrointestinal symptoms</outcome_measure>
      <outcome_measure>Changes in biomarkers like faecal microbiota</outcome_measure>
      <outcome_measure>Quality of Life in patients with coeliac disease: Short form- 36 (SF-36)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018/1055</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>June 1, 2019</primary_completion_date>
    <completion_date>October 1, 2019</completion_date>
    <study_first_posted>September 20, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Rikshospitalet-Radiumhospitalet HF, Oslo University Hospital, Oslo, Postboks PB 4950 Nydalen, Norway</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03678935/Prot_002.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03678935</url>
  </study>
  <study rank="518">
    <nct_id>NCT02040922</nct_id>
    <title>Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota</title>
    <acronym>CERAMIC</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Campylobacter Infections</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Yes/ no: Post-Infective bowel dysfunction (PI-BD)</outcome_measure>
      <outcome_measure>Yes/ No: Post-Infective irritable bowel syndrome (PI-IBS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>Nottingham University Hospitals NHS Trust</collaborator>
      <collaborator>Department of Health, United Kingdom</collaborator>
      <collaborator>King's College London</collaborator>
      <collaborator>Helsinki University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>13091</other_id>
      <other_id>13/EM/0310</other_id>
    </other_ids>
    <start_date>January 2013</start_date>
    <primary_completion_date>February 2017</primary_completion_date>
    <completion_date>June 2017</completion_date>
    <study_first_posted>January 20, 2014</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Nottingham, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02040922</url>
  </study>
  <study rank="519">
    <nct_id>NCT01280864</nct_id>
    <title>MAPP Investigation of Pelvic Floor-Brain Neurobiologic Axis in IC/IBS and IBS</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Interstitial Cystitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Augusta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>200806750</other_id>
    </other_ids>
    <start_date>March 2010</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>August 2011</completion_date>
    <study_first_posted>January 21, 2011</study_first_posted>
    <last_update_posted>July 23, 2018</last_update_posted>
    <locations>
      <location>University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01280864</url>
  </study>
  <study rank="520">
    <nct_id>NCT01679730</nct_id>
    <title>Changes of Microbiota in Irritable Bowel Syndrome Patients</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mucosa Associated Bacteria in Small Intestine</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>difference in component of microbiota between cases and controls</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Far Eastern Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>FEMH-100126-F</other_id>
    </other_ids>
    <start_date>June 2012</start_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <study_first_posted>September 6, 2012</study_first_posted>
    <last_update_posted>March 10, 2015</last_update_posted>
    <locations>
      <location>Far Eastern Memorial Hospital, New Taipei City, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01679730</url>
  </study>
  <study rank="521">
    <nct_id>NCT03586622</nct_id>
    <title>One Year Home Monitoring and Treatment of IBS Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>eHealth</condition>
      <condition>Dietary Modification</condition>
      <condition>Probiotics</condition>
      <condition>Microbiome</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Low FODMAP diet (LFD)</intervention>
      <intervention type="Dietary Supplement">VSL#3®</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom Severity (5-Item visual analogue scale, IBS-SSS)</outcome_measure>
      <outcome_measure>Symptom Severity (IBS-SSS) area under the curve (AUC)</outcome_measure>
      <outcome_measure>Disease course, Copenhagen IBS Disease course Type</outcome_measure>
      <outcome_measure>Compliance, FODMAP adherence Report scale (FARS)</outcome_measure>
      <outcome_measure>Compliance, Medication Adherence Report Scale (MARS)</outcome_measure>
      <outcome_measure>Stool consistency, Bristol Stool Chart</outcome_measure>
      <outcome_measure>Low grade inflammation measured by Fecal calprotectin (FC) on any smart phone</outcome_measure>
      <outcome_measure>Microbiome</outcome_measure>
      <outcome_measure>Symptom Severity (Time to and time in symptom remission, IBS-SSS)</outcome_measure>
      <outcome_measure>Quality of life, IBS-QOL</outcome_measure>
      <outcome_measure>Food registration</outcome_measure>
      <outcome_measure>Patients feedback for improvement of the ehealth platform</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nordsjaellands Hospital</lead_sponsor>
      <collaborator>Colitis-Crohn Foreningen</collaborator>
      <collaborator>Ferring Pharmaceuticals</collaborator>
      <collaborator>Calpro AS</collaborator>
      <collaborator>Muusmann forlag</collaborator>
      <collaborator>Statens Serum Institut</collaborator>
      <collaborator>Genetic Analysis AS</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H16023499</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>July 16, 2020</primary_completion_date>
    <completion_date>July 16, 2020</completion_date>
    <study_first_posted>July 13, 2018</study_first_posted>
    <last_update_posted>August 20, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03586622</url>
  </study>
  <study rank="522">
    <nct_id>NCT00584571</nct_id>
    <title>Randomized Controlled Trial of Treating Rectal Hypersensitivity - Comparing Escitalopram With Sensory Adaptation Training</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rectal Hypersensitivity</condition>
      <condition>Irritable Bowel Syndrome-Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Sensory Adaptation Training</intervention>
      <intervention type="Drug">Escitalopram Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rectal Sensory Thresholds</outcome_measure>
      <outcome_measure>Global Symptom Assessment (GSA) of abdominal discomfort/pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Augusta University</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2R01 KD57100-05A2</other_id>
      <other_id>2R01DK057100-06A2</other_id>
    </other_ids>
    <start_date>December 2007</start_date>
    <primary_completion_date>December 31, 2015</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>January 2, 2008</study_first_posted>
    <last_update_posted>July 23, 2018</last_update_posted>
    <locations>
      <location>University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00584571</url>
  </study>
  <study rank="523">
    <nct_id>NCT01717404</nct_id>
    <title>Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mexiletine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change in the 48 hour Colon Transit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>60 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-006842</other_id>
    </other_ids>
    <start_date>October 2012</start_date>
    <primary_completion_date>November 2012</primary_completion_date>
    <completion_date>November 2012</completion_date>
    <study_first_posted>October 30, 2012</study_first_posted>
    <last_update_posted>October 1, 2013</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01717404</url>
  </study>
  <study rank="524">
    <nct_id>NCT01699191</nct_id>
    <title>Probiotics for the Treatment of Irritable Bowel Syndrome in Celiac Patients</title>
    <acronym>ProCel</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS in Celiac Desease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotic</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Treatment of abdominal pain in celiac patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Bari</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ProCeDo</other_id>
    </other_ids>
    <start_date>October 2012</start_date>
    <primary_completion_date>October 2013</primary_completion_date>
    <completion_date>January 2014</completion_date>
    <study_first_posted>October 3, 2012</study_first_posted>
    <last_update_posted>October 3, 2012</last_update_posted>
    <locations>
      <location>Clinica Pediatrica, Bari, Puglia, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01699191</url>
  </study>
  <study rank="525">
    <nct_id>NCT00883077</nct_id>
    <title>Assessment of Colonic Permeability by Confocal Laser Endomicroscopy</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Fluorescein leakage under confocal laser endomicroscopy observation of colonic mucosa.</outcome_measure>
      <outcome_measure>Total sucralose excretion.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009SDU-QILU-G01</other_id>
    </other_ids>
    <start_date>April 2009</start_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <completion_date>December 2009</completion_date>
    <study_first_posted>April 17, 2009</study_first_posted>
    <last_update_posted>October 14, 2009</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00883077</url>
  </study>
  <study rank="526">
    <nct_id>NCT01097993</nct_id>
    <title>A Single-centre, Randomised, Double-blind, Controlled, Parallel-group Study to Evaluate the Effect of a Fermented Dairy Product on Abdominal Distension, Digestive Symptoms and Rectal Sensitivity in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Women With IBS-C</condition>
    </conditions>
    <interventions>
      <intervention type="Other">1-fermented dairy product</intervention>
      <intervention type="Other">2- milk-based non-fermented dairy product (control product)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean abdominal distension after a 4-week period of product consumption in IBS-C patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Danone Research</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NU324</other_id>
    </other_ids>
    <start_date>February 2010</start_date>
    <primary_completion_date>June 2012</primary_completion_date>
    <completion_date>January 2014</completion_date>
    <study_first_posted>April 2, 2010</study_first_posted>
    <last_update_posted>January 20, 2017</last_update_posted>
    <locations>
      <location>Manchester Hospital, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01097993</url>
  </study>
  <study rank="527">
    <nct_id>NCT00222209</nct_id>
    <title>Clinical Study on Implicit Learning, Comorbidity and Stress Vulnerability in Chronic Functional Pain</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibromyalgia</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Experimental heat pain model</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Universitätsmedizin Mannheim</lead_sponsor>
      <collaborator>German Research Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>DFG HO 904/11-3,4</other_id>
    </other_ids>
    <start_date>September 2005</start_date>
    <completion_date>November 2007</completion_date>
    <study_first_posted>September 22, 2005</study_first_posted>
    <last_update_posted>August 3, 2006</last_update_posted>
    <locations>
      <location>University of Mannheim - Otto-Selz-Institute, Mannheim, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00222209</url>
  </study>
  <study rank="528">
    <nct_id>NCT03869372</nct_id>
    <title>Cerebral Cortical Influences on Autonomic Function</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Subjects</condition>
      <condition>Functional Dyspepsia</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">rTMS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Electrogastrogram (EGG)</outcome_measure>
      <outcome_measure>Volume threshold to satiety</outcome_measure>
      <outcome_measure>Colonic motility</outcome_measure>
      <outcome_measure>MEP responses</outcome_measure>
      <outcome_measure>Heart rate variability</outcome_measure>
      <outcome_measure>Cardiac Impedance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>David Levinthal</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>96</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY19010027</other_id>
      <other_id>5K08DK101756-05</other_id>
    </other_ids>
    <start_date>April 5, 2019</start_date>
    <primary_completion_date>January 2022</primary_completion_date>
    <completion_date>January 2022</completion_date>
    <study_first_posted>March 11, 2019</study_first_posted>
    <last_update_posted>April 9, 2019</last_update_posted>
    <locations>
      <location>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03869372</url>
  </study>
  <study rank="529">
    <nct_id>NCT02246647</nct_id>
    <title>Biomarkers for Intestinal Permeability in Patients With Constipation</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Intestinal Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">saccharides</intervention>
      <intervention type="Procedure">esophagogastroduodenoscopy</intervention>
      <intervention type="Procedure">flexible sigmoidoscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>8-24 hr cumulative excretion of mannitol.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>14-002382</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <completion_date>October 2017</completion_date>
    <study_first_posted>September 23, 2014</study_first_posted>
    <last_update_posted>September 16, 2016</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02246647</url>
  </study>
  <study rank="530">
    <nct_id>NCT02421705</nct_id>
    <title>Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
      <condition>Ulcerative Colitis, Active</condition>
      <condition>Ulcerative Colitis, Remission (3a: With IBS Symptoms, 3b: Without IBS Symptoms)</condition>
      <condition>Healthy Controls</condition>
      <condition>Crohn's Disease, Active</condition>
      <condition>Crohn's Disease, Remission (6a: With IBS Symptoms, 6b: Without IBS Symptoms)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Sample collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>differences in visceral sensitivity in different study groups (Visceral sensitivity will me measured by performing a rectal barostat test)</outcome_measure>
      <outcome_measure>immune activity (measuring release of mest cell mediators in rectal biopsies, measuring parameters of immune activity in blood)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KU Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>99999999</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>S51573</other_id>
    </other_ids>
    <start_date>February 2010</start_date>
    <primary_completion_date>January 2099</primary_completion_date>
    <completion_date>January 2099</completion_date>
    <study_first_posted>April 21, 2015</study_first_posted>
    <last_update_posted>February 8, 2017</last_update_posted>
    <locations>
      <location>University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02421705</url>
  </study>
  <study rank="531">
    <nct_id>NCT00423345</nct_id>
    <title>Colon Investigation - Factors Determining Choice of Procedure</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Colon</condition>
      <condition>Colorectal Cancer</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>findings compared across investigation modes</outcome_measure>
      <outcome_measure>Delayed diagnosis of CRC</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sykehuset Telemark</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>23504</other_id>
    </other_ids>
    <start_date>October 2006</start_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <completion_date>May 2015</completion_date>
    <study_first_posted>January 18, 2007</study_first_posted>
    <last_update_posted>April 8, 2019</last_update_posted>
    <locations>
      <location>Telemark Radiology center, Porsgrunn, Telemark, Norway</location>
      <location>Department of gastroentology, Telemark Hospital, Skien, Telemark, Norway</location>
      <location>Department of gastroentology, Blefjell Hospital Notodden, Notodden, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00423345</url>
  </study>
  <study rank="532">
    <nct_id>NCT02220348</nct_id>
    <title>A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically</title>
    <acronym>LIN-PK-01</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Feeding</condition>
      <condition>Constipation</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">linaclotide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Forest Laboratories</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>LIN-PK-01</other_id>
    </other_ids>
    <start_date>July 31, 2014</start_date>
    <primary_completion_date>May 31, 2019</primary_completion_date>
    <completion_date>May 31, 2019</completion_date>
    <study_first_posted>August 19, 2014</study_first_posted>
    <last_update_posted>March 22, 2019</last_update_posted>
    <locations>
      <location>University of Iowa, Iowa City, Iowa, United States</location>
      <location>Digestive Disease Specialists Inc (DDSI), Oklahoma City, Oklahoma, United States</location>
      <location>Temple University Hospital, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02220348</url>
  </study>
  <study rank="533">
    <nct_id>NCT01697397</nct_id>
    <title>Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastrointestinal Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Device Success defined as the ability to record myoelectric signals in study subjects.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>G-Tech Corporation</lead_sponsor>
      <collaborator>Eminence Clinical Research, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLP-2012-001</other_id>
    </other_ids>
    <start_date>July 2012</start_date>
    <primary_completion_date>June 2015</primary_completion_date>
    <completion_date>June 2015</completion_date>
    <study_first_posted>October 2, 2012</study_first_posted>
    <last_update_posted>August 13, 2015</last_update_posted>
    <locations>
      <location>G-Tech Corporation, Mountain View, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01697397</url>
  </study>
  <study rank="534">
    <nct_id>NCT01667627</nct_id>
    <title>Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea</title>
    <acronym>IBS-D</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Bio-25</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom relief (abdominal pain and stool consistency)</outcome_measure>
      <outcome_measure>Improvement in other specific IBS symptoms, i.e., gas and bloating, feeling of urgency</outcome_measure>
      <outcome_measure>Reduce hs-CRP levels</outcome_measure>
      <outcome_measure>Improve the cholinergic status</outcome_measure>
      <outcome_measure>Reduce calprotectin levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tel-Aviv Sourasky Medical Center</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TASMC-11-RD-0491-CTIL</other_id>
    </other_ids>
    <start_date>January 2014</start_date>
    <primary_completion_date>April 2015</primary_completion_date>
    <completion_date>April 2015</completion_date>
    <study_first_posted>August 17, 2012</study_first_posted>
    <last_update_posted>May 24, 2018</last_update_posted>
    <locations>
      <location>Tel-Aviv Sourasky Medical Center, Tel-Aviv, Central Israel, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01667627</url>
  </study>
  <study rank="535">
    <nct_id>NCT02802241</nct_id>
    <title>Effects of Open-label vs Double-blind Treatment in IBS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Placebo Effect</condition>
      <condition>Placebos</condition>
      <condition>Peppermint Oil</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Dietary Supplement">peppermint oil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Anthony Lembo</lead_sponsor>
      <collaborator>Beth Israel Deaconess Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015P000282</other_id>
    </other_ids>
    <start_date>June 2016</start_date>
    <primary_completion_date>January 2019</primary_completion_date>
    <completion_date>January 2019</completion_date>
    <study_first_posted>June 16, 2016</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02802241</url>
  </study>
  <study rank="536">
    <nct_id>NCT03644602</nct_id>
    <title>Low FODMAPs Diet in Gastrointestinal Disorders</title>
    <acronym>FODMAPs</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Coeliac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">low FODMAPs diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of IBS-SSS after 3 months</outcome_measure>
      <outcome_measure>Improvement of SF-36 after 3 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>285/16</other_id>
    </other_ids>
    <start_date>July 2016</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>August 23, 2018</study_first_posted>
    <last_update_posted>August 23, 2018</last_update_posted>
    <locations>
      <location>Aou Federico Ii, Naples, Italy</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03644602/Prot_SAP_000.pdf</url>
      </study_document>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03644602/ICF_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03644602</url>
  </study>
  <study rank="537">
    <nct_id>NCT01269671</nct_id>
    <title>Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain</title>
    <acronym>FAP</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Abdominal Pain</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Dyspepsia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Melatonin, Peppermint Oil (mentharil), and Simethicone</intervention>
      <intervention type="Other">Sugar pill</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain Reduction</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
      <outcome_measure>Anxiety Affects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHW 10/102</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>April 2012</completion_date>
    <study_first_posted>January 4, 2011</study_first_posted>
    <last_update_posted>August 24, 2015</last_update_posted>
    <locations>
      <location>Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01269671</url>
  </study>
  <study rank="538">
    <nct_id>NCT02476643</nct_id>
    <title>Integrative Gastroenterology - an Observational Trial</title>
    <acronym>InteGast</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohns Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Integrative Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptoms Severity IBS-SSS</outcome_measure>
      <outcome_measure>Symptoms Severity CAI</outcome_measure>
      <outcome_measure>Symptoms Severity CDAI</outcome_measure>
      <outcome_measure>Disability MYMOP</outcome_measure>
      <outcome_measure>Quality of Life IBS-QOL</outcome_measure>
      <outcome_measure>Quality of Life IBDQ</outcome_measure>
      <outcome_measure>Self efficacy questionnaire SWE</outcome_measure>
      <outcome_measure>Body awareness BAQ</outcome_measure>
      <outcome_measure>Body awareness BRS</outcome_measure>
      <outcome_measure>Adverse effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universität Duisburg-Essen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>15-6183-BO InteGast</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>April 2018</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>June 19, 2015</study_first_posted>
    <last_update_posted>May 2, 2018</last_update_posted>
    <locations>
      <location>Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Essen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02476643</url>
  </study>
  <study rank="539">
    <nct_id>NCT03148288</nct_id>
    <title>Vitamin D Supplementation in IBS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Vitamin D Deficiency</condition>
      <condition>Abdominal Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
      <intervention type="Dietary Supplement">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Irritable Bowel Syndrome - Symptom Severity Scale (IBS-SSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017P000133</other_id>
    </other_ids>
    <start_date>September 1, 2017</start_date>
    <primary_completion_date>December 14, 2019</primary_completion_date>
    <completion_date>December 14, 2019</completion_date>
    <study_first_posted>May 10, 2017</study_first_posted>
    <last_update_posted>January 29, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03148288</url>
  </study>
  <study rank="540">
    <nct_id>NCT03694223</nct_id>
    <title>Health Education Delivery Methods for a Low Fermentable Carbohydrate Diet in Patients With Functional Bowel Disorders</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Diarrhea</condition>
      <condition>Functional Bowel Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Health education delivery methods</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RECRUITMENT RATE</outcome_measure>
      <outcome_measure>RETENTION RATE (overall and within each study group)</outcome_measure>
      <outcome_measure>Compliance rates to the diet</outcome_measure>
      <outcome_measure>Satisfaction over the education delivery methods received</outcome_measure>
      <outcome_measure>Appropriateness of the education methods received in each study group</outcome_measure>
      <outcome_measure>Perceived fit of the education delivery methods within the NHS</outcome_measure>
      <outcome_measure>Willingness of participants being assigned to the study groups using a multiple choice questionnaire.</outcome_measure>
      <outcome_measure>Gastrointestinal symptom severity</outcome_measure>
      <outcome_measure>Health-related quality of life in irritable bowel syndrome</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms experienced</outcome_measure>
      <outcome_measure>Adequate relief of symptoms</outcome_measure>
      <outcome_measure>Estimates of the parameters required for calculation of the sample size for a future larger study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>51</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>206464</other_id>
    </other_ids>
    <start_date>January 3, 2016</start_date>
    <primary_completion_date>October 25, 2018</primary_completion_date>
    <completion_date>October 25, 2018</completion_date>
    <study_first_posted>October 3, 2018</study_first_posted>
    <last_update_posted>February 26, 2019</last_update_posted>
    <locations>
      <location>King's College London, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03694223</url>
  </study>
  <study rank="541">
    <nct_id>NCT00153751</nct_id>
    <title>The Efficacy of Herbal Medicine in Relieving Symptoms and Change of Quality of Life of Patients With Irritable Bowel Syndrome (IBS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colonic Diseases, Functional</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Traditional Chinese Medicine</intervention>
      <intervention type="Drug">Holopon</intervention>
      <intervention type="Other">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The global assessment of IBS symptom by patients.</outcome_measure>
      <outcome_measure>Individual IBS symptoms and QOL assessment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>JC_IBS</other_id>
    </other_ids>
    <start_date>September 2005</start_date>
    <primary_completion_date>May 2007</primary_completion_date>
    <completion_date>May 2007</completion_date>
    <study_first_posted>September 12, 2005</study_first_posted>
    <last_update_posted>May 13, 2008</last_update_posted>
    <locations>
      <location>Li Ka Shing Specialist Clinic, Prince of Wales Hospital, Hong Kong (SAR), China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00153751</url>
  </study>
  <study rank="542">
    <nct_id>NCT02693730</nct_id>
    <title>Phenotyping IBS: Perceptions and Modulations of Visceral Sensations</title>
    <acronym>PMVS-P</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Classifying patients with IBS and Ulcerative Colitis (UC) based on their brain &quot;signatures&quot; obtained from structural and functional MRI scanning.</outcome_measure>
      <outcome_measure>Global and regional brain network alterations in IBS.</outcome_measure>
      <outcome_measure>Possible biological mediators of observed IBS related brain network alterations</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>290</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>2R01DK048351-15A1</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>October 2019</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>February 29, 2016</study_first_posted>
    <last_update_posted>June 4, 2019</last_update_posted>
    <locations>
      <location>Oppenheimer Center for Neurobiology of Stress and Resilience, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02693730</url>
  </study>
  <study rank="543">
    <nct_id>NCT03270085</nct_id>
    <title>Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Diarrhea</condition>
      <condition>Irritable Bowel Syndrome With Diarrhea</condition>
      <condition>Bile Acid Malabsorption</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colesevelam</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patients with IBS-D with increased bowel bile acid will be treated with colesevelam to determine if stool frequency and consistency improves via daily bowel diaries.</outcome_measure>
      <outcome_measure>Patients with IBS-D with increased bowel bile acid will be treated with colesevelam to determine if stool frequency and consistency improves via fecal bile acids.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-004639</other_id>
    </other_ids>
    <start_date>December 7, 2017</start_date>
    <primary_completion_date>May 31, 2019</primary_completion_date>
    <completion_date>October 20, 2019</completion_date>
    <study_first_posted>September 1, 2017</study_first_posted>
    <last_update_posted>January 9, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03270085</url>
  </study>
  <study rank="544">
    <nct_id>NCT01047800</nct_id>
    <title>Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial</title>
    <acronym>FGISP-RCT</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-erosive Gastroesophageal Reflux Disease</condition>
      <condition>Functional Dyspepsia</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Counseling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Self-efficacy and decrease in psychological distress measured by Health status and management scales and Patient Health Questionnaire (PHQ)</outcome_measure>
      <outcome_measure>Rate of attendance to &quot;on-demand follow up within 1 year&quot; option given at Final visit</outcome_measure>
      <outcome_measure>Frequency of doctor's visits</outcome_measure>
      <outcome_measure>Use of emergency service</outcome_measure>
      <outcome_measure>Self-rated health measured by Health status and management scales</outcome_measure>
      <outcome_measure>Social/role activities limitation measured by Health status and management scales</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>FGISP-RCT</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>May 2015</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>January 13, 2010</study_first_posted>
    <last_update_posted>April 26, 2017</last_update_posted>
    <locations>
      <location>Prince of Wales Hospital, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01047800</url>
  </study>
  <study rank="545">
    <nct_id>NCT01736280</nct_id>
    <title>Evaluating and Treating Potential Research Participants With Digestive Disorders</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stress</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Obesity</condition>
      <condition>Abdominal Pain</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Evaluation and treatment training protocol</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Nursing Research (NINR)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>120195</other_id>
      <other_id>12-NR-0195</other_id>
    </other_ids>
    <start_date>August 30, 2012</start_date>
    <study_first_posted>November 29, 2012</study_first_posted>
    <last_update_posted>April 19, 2019</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01736280</url>
  </study>
  <study rank="546">
    <nct_id>NCT01098292</nct_id>
    <title>Observational Study of Control Participants for the MAPP Research Network</title>
    <acronym>MAPP-Control</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibromyalgia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fatigue Syndrome, Chronic</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Baseline outcome measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>University of Colorado, Denver</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>615</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>810668</other_id>
    </other_ids>
    <start_date>December 2009</start_date>
    <primary_completion_date>June 2013</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>April 2, 2010</study_first_posted>
    <last_update_posted>December 10, 2014</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham, Birmingham, Alabama, United States</location>
      <location>University of California, Los Angeles, Los Angeles, California, United States</location>
      <location>Stanford University, Stanford, California, United States</location>
      <location>Northwestern University, Chicago, Illinois, United States</location>
      <location>University of Iowa, Iowa City, Iowa, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Washington University, St Louis, Missouri, United States</location>
      <location>University of Washington, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01098292</url>
  </study>
  <study rank="547">
    <nct_id>NCT00468013</nct_id>
    <title>A Computer-Based Intervention for Medically Unexplained Physical Symptoms</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibromyalgia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Chronic Fatigue Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Resilience Building Exercises</intervention>
      <intervention type="Behavioral">Journaling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Quick Inventory of Depressive Symptoms</outcome_measure>
      <outcome_measure>Positive and Negative Affect Scale</outcome_measure>
      <outcome_measure>Satisfaction with Life Scale</outcome_measure>
      <outcome_measure>Patient Health Questionnaire</outcome_measure>
      <outcome_measure>Health Assessment Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Medicine and Dentistry of New Jersey</lead_sponsor>
      <collaborator>Rutgers, The State University of New Jersey</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>P15-MUPS-8484</other_id>
    </other_ids>
    <start_date>March 2007</start_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <completion_date>March 2010</completion_date>
    <study_first_posted>May 1, 2007</study_first_posted>
    <last_update_posted>February 9, 2015</last_update_posted>
    <locations>
      <location>UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00468013</url>
  </study>
  <study rank="548">
    <nct_id>NCT02291445</nct_id>
    <title>Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Abdominal Pain</condition>
      <condition>Colonic Diseases</condition>
      <condition>Visceral Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)</intervention>
      <intervention type="Drug">Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Difference in T-max</outcome_measure>
      <outcome_measure>Difference in C-max</outcome_measure>
      <outcome_measure>Difference in T-lag</outcome_measure>
      <outcome_measure>Difference in AUC</outcome_measure>
      <outcome_measure>T1/2</outcome_measure>
      <outcome_measure>Menthol-glucuronide urine exretion time curve</outcome_measure>
      <outcome_measure>L-Menthol concentration in feces</outcome_measure>
      <outcome_measure>Difference in total number of side effects per time point.</outcome_measure>
      <outcome_measure>Tolerability assessed by heart rate, blood pressure and reported side effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>50941</other_id>
      <other_id>2014-004195-32</other_id>
    </other_ids>
    <start_date>March 2015</start_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <completion_date>September 2015</completion_date>
    <study_first_posted>November 14, 2014</study_first_posted>
    <last_update_posted>September 22, 2015</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Limburg, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02291445</url>
  </study>
  <study rank="549">
    <nct_id>NCT00374673</nct_id>
    <title>Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibromyalgia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Burning Mouth Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Repetitive transcranial magnetic stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Average pain over the last 24 hours at each visit -pain diary at baseline to see the stability of the measures</outcome_measure>
      <outcome_measure>Sensory and affective pain scores (McGill pain questionnaire)</outcome_measure>
      <outcome_measure>Quality of life (brief pain inventory)</outcome_measure>
      <outcome_measure>Disability ( FIQ)</outcome_measure>
      <outcome_measure>Comorbidities (HAD)</outcome_measure>
      <outcome_measure>Catastrophizing (PCS)</outcome_measure>
      <outcome_measure>Predictors of the response based on psychological factors and measures of cortical excitability</outcome_measure>
      <outcome_measure>Safety including cognitive evaluation</outcome_measure>
      <outcome_measure>Comparison of the efficacy of TMS between 3 different pain disorders</outcome_measure>
      <outcome_measure>assessment of cortical excitability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Ambroise Paré Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMS-chronic pain 1</other_id>
    </other_ids>
    <start_date>October 2006</start_date>
    <primary_completion_date>March 2012</primary_completion_date>
    <completion_date>April 2012</completion_date>
    <study_first_posted>September 11, 2006</study_first_posted>
    <last_update_posted>December 3, 2015</last_update_posted>
    <locations>
      <location>Hôpital Ambroise Paré, Boulogne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00374673</url>
  </study>
  <study rank="550">
    <nct_id>NCT01718925</nct_id>
    <title>25-hydroxyvitamin D and Fatigue: The VITALITY Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Diabetes</condition>
      <condition>Rheumatoid Arthritis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Fatigue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ostfold Hospital Trust</lead_sponsor>
      <collaborator>Karolinska Institutet</collaborator>
      <collaborator>Aarhus University Hospital</collaborator>
      <collaborator>Oslo University Hospital</collaborator>
      <collaborator>Alesund Hospital</collaborator>
      <collaborator>Helse Stavanger HF</collaborator>
      <collaborator>Sykehuset Telemark</collaborator>
      <collaborator>Sykehuset Innlandet HF</collaborator>
      <collaborator>Ostfold University College</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>614</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>3256</other_id>
    </other_ids>
    <start_date>October 2012</start_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <completion_date>December 2014</completion_date>
    <study_first_posted>November 1, 2012</study_first_posted>
    <last_update_posted>October 15, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01718925</url>
  </study>
  <study rank="551">
    <nct_id>NCT01095042</nct_id>
    <title>Cognition and Emotion in the SII and IBD</title>
    <acronym>EMOTION</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Disease (IBD)</condition>
      <condition>Crohn's Disease(CD)</condition>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">emotion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RATE PLASMATIQUE OF CORTISOL COUPLED WITH THE CARDIAC VARIABILITY</outcome_measure>
      <outcome_measure>SCORES OF DEPRESSIVE SYMPTOMATOLOGIE AND ANXIETY, RATE PLASMATIQUES OF CATECHOLAMINES, LEPTINE, ADIPONECTINE AND PRO-INFLAMMATORY CYTOKINES.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Grenoble</lead_sponsor>
      <collaborator>French National Society of Gastroenterology</collaborator>
      <collaborator>Association François Aupetit</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>0817</other_id>
      <other_id>2008-A00994-51</other_id>
    </other_ids>
    <start_date>October 2008</start_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <completion_date>May 2013</completion_date>
    <study_first_posted>March 29, 2010</study_first_posted>
    <last_update_posted>January 28, 2014</last_update_posted>
    <locations>
      <location>Hôpital Michallon-CHU Grenoble, Grenoble, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01095042</url>
  </study>
  <study rank="552">
    <nct_id>NCT01099111</nct_id>
    <title>Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Colitis, Ulcerative</condition>
      <condition>Crohn Disease</condition>
      <condition>Colonic Neoplasms</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King Fahad Medical City</lead_sponsor>
      <collaborator>King AbdulAziz City for Science and Technology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>225</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>09 -116</other_id>
      <other_id>243 - 29 - AT</other_id>
    </other_ids>
    <start_date>July 2010</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>March 2012</completion_date>
    <study_first_posted>April 6, 2010</study_first_posted>
    <results_first_posted>May 22, 2014</results_first_posted>
    <last_update_posted>May 22, 2014</last_update_posted>
    <locations>
      <location>KFMC, Riyadh, Saudi Arabia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01099111</url>
  </study>
  <study rank="553">
    <nct_id>NCT03131414</nct_id>
    <title>The IMAGINE-SPOR CIHR Chronic Disease Network</title>
    <acronym>IMAGINE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBS - Irritable Bowel Syndrome</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Crohn Disease</condition>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Diet</intervention>
      <intervention type="Other">Gastrointestinal microbiome</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IMAGINE microbiome and diet</outcome_measure>
      <outcome_measure>IMAGINE metabolomics</outcome_measure>
      <outcome_measure>IMAGINE anxiety</outcome_measure>
      <outcome_measure>IMAGINE depression</outcome_measure>
      <outcome_measure>IMAGINE health related costs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hamilton Health Sciences Corporation</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>8000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>REB#3000</other_id>
    </other_ids>
    <start_date>October 1, 2017</start_date>
    <primary_completion_date>June 1, 2022</primary_completion_date>
    <completion_date>June 1, 2023</completion_date>
    <study_first_posted>April 27, 2017</study_first_posted>
    <last_update_posted>March 7, 2019</last_update_posted>
    <locations>
      <location>Hamilton Health Sciences / McMaster University, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03131414</url>
  </study>
  <study rank="554">
    <nct_id>NCT02872961</nct_id>
    <title>SIBO, Immune Activation, and FGIDs in Children</title>
    <acronym>SIBO</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Small Intestinal Bacterial Overgrowth</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Dyspepsia</condition>
      <condition>Functional Abdominal Pain</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Abdominal Pain Index</outcome_measure>
      <outcome_measure>Duodenal fluid microbiota</outcome_measure>
      <outcome_measure>Serum biomarker levels</outcome_measure>
      <outcome_measure>Duodenal tissue inflammatory cell infiltration</outcome_measure>
      <outcome_measure>Duodenal tissue toll-like receptor expression</outcome_measure>
      <outcome_measure>Duodenal tissue cytokine levels</outcome_measure>
      <outcome_measure>Wong-Baker FACES Pain Rating Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Texas Health Science Center, Houston</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>HSC-MS-11-0726</other_id>
    </other_ids>
    <start_date>April 2013</start_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <completion_date>October 2018</completion_date>
    <study_first_posted>August 19, 2016</study_first_posted>
    <last_update_posted>May 30, 2018</last_update_posted>
    <locations>
      <location>The University of Texas of Health Science Center at Houston, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02872961</url>
  </study>
  <study rank="555">
    <nct_id>NCT02389998</nct_id>
    <title>Efficacy of Open Label Placebo in Children With FGIDs</title>
    <acronym>Placebo</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Abdominal Pain</condition>
      <condition>Functional Dyspepsia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo Suspension</intervention>
      <intervention type="Drug">Hyoscyamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Satisfactory Relief of Symptoms and Overall Improvement (Patient Reported Outcome Measures)</outcome_measure>
      <outcome_measure>Catechol-O-methyl transferase (COMT) measurement</outcome_measure>
      <outcome_measure>Change in Results of Functional Disability Inventory (FDI)</outcome_measure>
      <outcome_measure>Change in Results of the Pediatric Quality of Life Questionnaire (PedsQoL)</outcome_measure>
      <outcome_measure>Change in Results of the Gastrointestinal Pediatric Quality of Life Questionnaire (GI PedsQoL)</outcome_measure>
      <outcome_measure>Change in Results of the Children's Somatization Inventory (CSI)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston Children’s Hospital</lead_sponsor>
      <collaborator>Nationwide Children's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>P00003158</other_id>
    </other_ids>
    <start_date>July 2014</start_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>March 17, 2015</study_first_posted>
    <last_update_posted>October 24, 2018</last_update_posted>
    <locations>
      <location>Boston Children's Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02389998</url>
  </study>
  <study rank="556">
    <nct_id>NCT00006157</nct_id>
    <title>Treatment of Functional Bowel Disorders</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
      <condition>Abdominal Pain</condition>
      <condition>Functional Colonic Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
      <intervention type="Behavioral">Cognitive Behavioral Treatment</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FBD (completed)</other_id>
      <other_id>R01DK049334</other_id>
    </other_ids>
    <start_date>July 1996</start_date>
    <completion_date>March 2001</completion_date>
    <study_first_posted>August 9, 2000</study_first_posted>
    <last_update_posted>January 13, 2010</last_update_posted>
    <locations>
      <location>UNC Center for Functional GI Motility Disorders, Chapel Hill, North Carolina, United States</location>
      <location>Centre for Addiction and Mental Health, Clark Site, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00006157</url>
  </study>
  <study rank="557">
    <nct_id>NCT00788658</nct_id>
    <title>Cognitive Behaviour Therapy for Patients With IBS</title>
    <acronym>EFI</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
      <condition>Abdominal Pain</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Diet modifications</intervention>
      <intervention type="Behavioral">Cognitive behavioral therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom score</outcome_measure>
      <outcome_measure>Quality of life assessment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rabin Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RMC 5139</other_id>
    </other_ids>
    <start_date>December 2008</start_date>
    <primary_completion_date>December 2010</primary_completion_date>
    <completion_date>December 2010</completion_date>
    <study_first_posted>November 11, 2008</study_first_posted>
    <last_update_posted>April 13, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00788658</url>
  </study>
  <study rank="558">
    <nct_id>NCT00846794</nct_id>
    <title>AcuGraph and Digestive Symptoms</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Digestive Disorders</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Constipation</condition>
      <condition>Diarrhea</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>AcuGraph: computerized device to analyze &amp; document the energetic status of the acupuncture meridians</outcome_measure>
      <outcome_measure>IBS Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Logan College of Chiropractic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>SR1219080169</other_id>
      <other_id>400</other_id>
    </other_ids>
    <start_date>February 2009</start_date>
    <primary_completion_date>March 2010</primary_completion_date>
    <completion_date>March 2010</completion_date>
    <study_first_posted>February 19, 2009</study_first_posted>
    <last_update_posted>September 15, 2016</last_update_posted>
    <locations>
      <location>Logan University, College of Chiropractic, Chesterfield, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00846794</url>
  </study>
  <study rank="559">
    <nct_id>NCT03011593</nct_id>
    <title>Effect of UGIR in Adults With Compromised Gut Function and Malabsorption</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Crohn Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Nutrition Support Product</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Gastrointestinal Quality of Life Index (GIQLI) Score</outcome_measure>
      <outcome_measure>Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Score</outcome_measure>
      <outcome_measure>Change in Celiac Disease Questionnaire (CDQ) Score</outcome_measure>
      <outcome_measure>Change in Digestive Symptom Frequency Questionnaire (DSFQ) Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Metagenics, Inc.</lead_sponsor>
      <collaborator>National University of Natural Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>UGIR</other_id>
    </other_ids>
    <start_date>November 2015</start_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>January 5, 2017</study_first_posted>
    <last_update_posted>January 5, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03011593</url>
  </study>
  <study rank="560">
    <nct_id>NCT03252743</nct_id>
    <title>ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Dyspepsia</condition>
      <condition>Functional Abdominal Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Exposure-based internet-delivered CBT</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Global gastrointestinal symptoms (CSI-24: subscale 7 items on GI-symptoms).</outcome_measure>
      <outcome_measure>Pain intensity (Faces Pain rating scale)</outcome_measure>
      <outcome_measure>Gastrointestinal symptoms module (PedsQL Gastro)</outcome_measure>
      <outcome_measure>Fear for symptoms (Visceral sensitivity index)</outcome_measure>
      <outcome_measure>Avoidant behavior (IBS-BRQ)</outcome_measure>
      <outcome_measure>Quality of life (PedsQL)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FGID IMP 2017</other_id>
    </other_ids>
    <start_date>September 1, 2017</start_date>
    <primary_completion_date>June 17, 2018</primary_completion_date>
    <completion_date>December 18, 2018</completion_date>
    <study_first_posted>August 17, 2017</study_first_posted>
    <last_update_posted>February 26, 2019</last_update_posted>
    <locations>
      <location>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03252743</url>
  </study>
  <study rank="561">
    <nct_id>NCT01618292</nct_id>
    <title>Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pelvic Organ Prolapse</condition>
      <condition>Constipation</condition>
      <condition>Bowel Dysfunction</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Robotic sacral colpopexy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in bowel function</outcome_measure>
      <outcome_measure>Objective anatomic outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Atlantic Health System</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>393</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>R11-08-011</other_id>
    </other_ids>
    <start_date>January 2007</start_date>
    <primary_completion_date>August 2012</primary_completion_date>
    <completion_date>August 2012</completion_date>
    <study_first_posted>June 13, 2012</study_first_posted>
    <last_update_posted>January 28, 2014</last_update_posted>
    <locations>
      <location>Atlantic Health System, Morristown, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01618292</url>
  </study>
  <study rank="562">
    <nct_id>NCT00824941</nct_id>
    <title>Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal Pain</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity</condition>
      <condition>Stress</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Women</condition>
      <condition>Abdominal Pain</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>No intervention. Natural history study</outcome_measure>
      <outcome_measure>Natural History study.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Nursing Research (NINR)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>090064</other_id>
      <other_id>09-NR-0064</other_id>
    </other_ids>
    <start_date>January 15, 2009</start_date>
    <study_first_posted>January 19, 2009</study_first_posted>
    <last_update_posted>June 3, 2019</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00824941</url>
  </study>
  <study rank="563">
    <nct_id>NCT00071162</nct_id>
    <title>Genetics of Fibromyalgia</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibromyalgia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Chronic Fatigue Syndrome</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>560</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIAMS-100</other_id>
    </other_ids>
    <start_date>September 1999</start_date>
    <study_first_posted>October 15, 2003</study_first_posted>
    <last_update_posted>April 1, 2009</last_update_posted>
    <locations>
      <location>University of Illinois at Peoria, Peoria, Illinois, United States</location>
      <location>University of Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Case Western Reserve University, Cleveland, Ohio, United States</location>
      <location>University of Texas Health Sciences Center, San Antonio, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00071162</url>
  </study>
  <study rank="564">
    <nct_id>NCT03931330</nct_id>
    <title>Does Improving Vagal Tone Increase Mitochondrial Bioenergetics</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Dyspepsia</condition>
      <condition>Functional Abdominal Pain Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Percutaneous neurostimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mitochondrial Bioenergetics</outcome_measure>
      <outcome_measure>Heart Rate Variability</outcome_measure>
      <outcome_measure>Functional Disability Inventory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1101710</other_id>
    </other_ids>
    <start_date>October 10, 2017</start_date>
    <primary_completion_date>September 2019</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 30, 2019</study_first_posted>
    <last_update_posted>April 30, 2019</last_update_posted>
    <locations>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03931330</url>
  </study>
  <study rank="565">
    <nct_id>NCT03669237</nct_id>
    <title>RCT on Postoperative Bowel Function Following SPS by Different Reconstruction Methods</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bowel; Functional Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">different reconstruction methods</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>LARS score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>YE Yingjiang</lead_sponsor>
      <collaborator>Peking University People's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>630</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FPOCS-1705</other_id>
    </other_ids>
    <start_date>January 1, 2019</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>September 13, 2018</study_first_posted>
    <last_update_posted>September 13, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03669237</url>
  </study>
  <study rank="566">
    <nct_id>NCT03051204</nct_id>
    <title>OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome</title>
    <acronym>OptiCal</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Celiac Disease</condition>
      <condition>Healthy</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Calprotectin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>Genova Diagnostics</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>175</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB#16-001499</other_id>
    </other_ids>
    <start_date>February 28, 2017</start_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <completion_date>February 2020</completion_date>
    <study_first_posted>February 13, 2017</study_first_posted>
    <last_update_posted>October 26, 2017</last_update_posted>
    <locations>
      <location>UCLA Center for Inflammatory Bowel Diseases, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03051204</url>
  </study>
  <study rank="567">
    <nct_id>NCT03395548</nct_id>
    <title>Stability of the Microbiome in IBD and IBS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Microbiota</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Macrogol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes of the microbiome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Graz</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>29-255 ex 16/17</other_id>
    </other_ids>
    <start_date>August 25, 2017</start_date>
    <primary_completion_date>August 1, 2019</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>January 10, 2018</study_first_posted>
    <last_update_posted>October 3, 2018</last_update_posted>
    <locations>
      <location>Universitätsklinikum Graz, Graz, Styria, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03395548</url>
  </study>
  <study rank="568">
    <nct_id>NCT01631500</nct_id>
    <title>Effects of an Integrative Treatment Model to Reduce Anxiety and Depression in Minor Mental Health Problems and Medically Unexplained Symptoms</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
      <condition>Anxiety</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Fibromyalgia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Conventional treatment</intervention>
      <intervention type="Other">Integrative treatment</intervention>
      <intervention type="Other">Therapeutic acupuncture</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pre-post treatment change in anxiety as assessed with the Hospital Anxiety and Depression scale (HAD)</outcome_measure>
      <outcome_measure>Pre-post treatment change in health-related quality of life (assessed with the SF-36 Mental Component Summary score(MCS))</outcome_measure>
      <outcome_measure>Pre-post treatment change in sense of coherence (SOC)</outcome_measure>
      <outcome_measure>Pre-post treatment change in depression as assessed with the Hospital Anxiety and Depression scale (HAD)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Göteborg University</lead_sponsor>
      <collaborator>Ekhagastiftelsen</collaborator>
      <collaborator>Fyrbodal Research and Development Council</collaborator>
      <collaborator>Vastra Gotaland Region</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>University of Gothenburg</other_id>
      <other_id>VGFOUREG-82511</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>January 2011</primary_completion_date>
    <completion_date>January 2011</completion_date>
    <study_first_posted>June 29, 2012</study_first_posted>
    <last_update_posted>August 30, 2012</last_update_posted>
    <locations>
      <location>Fyrbodal Research and Development Council, Vänersborg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01631500</url>
  </study>
  <study rank="569">
    <nct_id>NCT01692613</nct_id>
    <title>Endomicroscopy, IBS and Food Intolerance</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Endomicroscopy</condition>
      <condition>Inflammatory Bowel Syndrome</condition>
      <condition>Food Intolerance</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number of mucosal reaction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Schleswig-Holstein</lead_sponsor>
      <collaborator>Great Ormond Street Hospital for Children NHS Foundation Trust</collaborator>
      <collaborator>Johannes Gutenberg University Mainz</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>A139/12</other_id>
    </other_ids>
    <start_date>September 2012</start_date>
    <primary_completion_date>September 2014</primary_completion_date>
    <completion_date>September 2014</completion_date>
    <study_first_posted>September 25, 2012</study_first_posted>
    <last_update_posted>June 3, 2015</last_update_posted>
    <locations>
      <location>University Hospital Schleswig Holstein, Campus Kiel, Unit Experimental Endoscopy, Kiel, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01692613</url>
  </study>
  <study rank="570">
    <nct_id>NCT03078634</nct_id>
    <title>The Multi-disciplinary Treatment of Functional Gut Disorders Study</title>
    <acronym>MANTRA</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Functional Dyspepsia</condition>
      <condition>Constipation - Functional</condition>
      <condition>Faecal Incontinence</condition>
      <condition>Functional Abdominal Pain Syndrome</condition>
      <condition>Other Rome IV Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Multi-disciplinary clinic model</intervention>
      <intervention type="Other">Standard outpatient care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with global improvement in their condition.</outcome_measure>
      <outcome_measure>Proportion of subjects, with Irritable bowel syndrome or centrally mediated abdominal pain syndrome, with a 50% reduction in Irritable bowel syndrome severity scoring system (IBS-SSS)</outcome_measure>
      <outcome_measure>Proportion of subjects with constipation who score a 50% reduction in Cleveland clinic constipation scoring system</outcome_measure>
      <outcome_measure>Proportion of subjects with faecal incontinence who score a 50% reduction in St Mark's Incontinence score</outcome_measure>
      <outcome_measure>Proportion of subjects with functional dyspepsia who score a 50% reduction in the symptom score of the Nepean dyspepsia index</outcome_measure>
      <outcome_measure>Quality of life as measured by RAND SF-36 v1</outcome_measure>
      <outcome_measure>Quality of life as measured by Euro-QOL EQ-5D</outcome_measure>
      <outcome_measure>Psychological wellbeing as measured by hospital anxiety and depression score (HADS)</outcome_measure>
      <outcome_measure>Proportion of subjects with who answer yes to: In the past 7 days, have you had adequate relief of your gut condition? [YES/NO]</outcome_measure>
      <outcome_measure>Somatisation as measured by somatic symptom scale-8 (SSS-8)</outcome_measure>
      <outcome_measure>Cost to the healthcare system</outcome_measure>
      <outcome_measure>Proportion of subjects with a 50% reduction in gastrointestinal symptom severity index score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St Vincent's Hospital Melbourne</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>188</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>MANTRA</other_id>
    </other_ids>
    <start_date>March 16, 2017</start_date>
    <primary_completion_date>February 28, 2019</primary_completion_date>
    <completion_date>April 28, 2020</completion_date>
    <study_first_posted>March 13, 2017</study_first_posted>
    <last_update_posted>April 10, 2019</last_update_posted>
    <locations>
      <location>St Vincent's Hospital, Melbourne, Victoria, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03078634</url>
  </study>
  <study rank="571">
    <nct_id>NCT00618904</nct_id>
    <title>Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotics - Lactobacillus and bifidobacterium</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The primary outcome measure will be the global relief of GI symptoms as assessed by Global Symptom Assessment (GSA) of relief of functional GI symptoms.</outcome_measure>
      <outcome_measure>Assess the improvement of specific functional bowel disorders (FBD) related symptoms and Health Related Quality of Life (HRQOL).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>Danisco</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>04-1704</other_id>
    </other_ids>
    <start_date>December 2005</start_date>
    <primary_completion_date>February 2007</primary_completion_date>
    <completion_date>September 2007</completion_date>
    <study_first_posted>February 20, 2008</study_first_posted>
    <last_update_posted>July 9, 2013</last_update_posted>
    <locations>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00618904</url>
  </study>
  <study rank="572">
    <nct_id>NCT01449487</nct_id>
    <title>Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PPC-5650</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of PPC-5650</outcome_measure>
      <outcome_measure>Safety profile of PPC-5650</outcome_measure>
      <outcome_measure>Effect of PPC‐5650</outcome_measure>
      <outcome_measure>Central mechanisms</outcome_measure>
      <outcome_measure>Objective pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aros Pharma ApS</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>Aros-001</other_id>
    </other_ids>
    <start_date>January 2012</start_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <completion_date>May 2013</completion_date>
    <study_first_posted>October 10, 2011</study_first_posted>
    <last_update_posted>May 21, 2014</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, Gothenburg, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01449487</url>
  </study>
  <study rank="573">
    <nct_id>NCT01762579</nct_id>
    <title>Bio-markers of Not-celiac Wheat Sensitivity</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Not-celiac Wheat Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">wheat flour</intervention>
      <intervention type="Dietary Supplement">Xylose</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptoms/signs evaluation</outcome_measure>
      <outcome_measure>Bio-Markers evaluation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Palermo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACPM03</other_id>
    </other_ids>
    <start_date>January 2012</start_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <completion_date>June 2019</completion_date>
    <study_first_posted>January 7, 2013</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations>
      <location>Internal Medicine, &quot;Giovanni Paolo II&quot; Hospital, Sciacca, Agrigento, Italy</location>
      <location>Internal Medicine, University Hospital, Palermo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01762579</url>
  </study>
  <study rank="574">
    <nct_id>NCT01678911</nct_id>
    <title>Efficacy of Gralise® for Chronic Pelvic Pain</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Interstitial Cystitis</condition>
      <condition>Prostatitis</condition>
      <condition>Pelvic Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gralise</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>McGill Pain Questionnaire - Short Form</outcome_measure>
      <outcome_measure>Pain Anxiety Symptoms Scale</outcome_measure>
      <outcome_measure>Pain Disability Index</outcome_measure>
      <outcome_measure>Center for Epidemiologic Studies Depression Scale</outcome_measure>
      <outcome_measure>Patient Global Impression of Change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shirley Ryan AbilityLab</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RIC_Dep_CPP_2012</other_id>
    </other_ids>
    <start_date>August 2012</start_date>
    <primary_completion_date>March 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>September 5, 2012</study_first_posted>
    <results_first_posted>June 29, 2015</results_first_posted>
    <last_update_posted>June 29, 2015</last_update_posted>
    <locations>
      <location>Rehabilitation Institute Of Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01678911</url>
  </study>
  <study rank="575">
    <nct_id>NCT01517516</nct_id>
    <title>Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest.</title>
    <acronym>MMI</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Cyclical Vomiting Syndrome</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Vulvodynia</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Resting state networks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-000069</other_id>
      <other_id>RO1 DKO48351</other_id>
    </other_ids>
    <start_date>March 2011</start_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <completion_date>July 2015</completion_date>
    <study_first_posted>January 25, 2012</study_first_posted>
    <last_update_posted>January 14, 2016</last_update_posted>
    <locations>
      <location>Gail and Gerald Oppenheimer Family Center for Neurobiology of Stress, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01517516</url>
  </study>
  <study rank="576">
    <nct_id>NCT03920202</nct_id>
    <title>Long - Term Low Anterior Resection Syndrome</title>
    <acronym>LongLARS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bowel; Functional Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Bowel function assessment using Low anterior resection syndrome questionnaire</outcome_measure>
      <outcome_measure>Risk factors: age</outcome_measure>
      <outcome_measure>Risk factors: type of surgical procedure</outcome_measure>
      <outcome_measure>Risk factors: preoperative chemoradiotherapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Cancer Institute, Lithuania</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>LongLARS</other_id>
    </other_ids>
    <start_date>January 1, 2012</start_date>
    <primary_completion_date>January 1, 2014</primary_completion_date>
    <completion_date>December 31, 2018</completion_date>
    <study_first_posted>April 18, 2019</study_first_posted>
    <last_update_posted>April 18, 2019</last_update_posted>
    <locations>
      <location>National Cancer Institute, Vilnius, Lithuania</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03920202</url>
  </study>
  <study rank="577">
    <nct_id>NCT00920400</nct_id>
    <title>Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peptic Esophagitis</condition>
      <condition>Peptic Ulcer</condition>
      <condition>Functional Dyspepsia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University Hospital, Basel, Switzerland</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>287</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CALPROTECT</other_id>
    </other_ids>
    <start_date>March 2008</start_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <completion_date>December 2009</completion_date>
    <study_first_posted>June 15, 2009</study_first_posted>
    <last_update_posted>January 12, 2010</last_update_posted>
    <locations>
      <location>Department of Gastroenterology &amp; Hepatology, Basel, Basel-Stand, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00920400</url>
  </study>
  <study rank="578">
    <nct_id>NCT02113605</nct_id>
    <title>Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders</title>
    <acronym>CBT</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders (FGID)</condition>
      <condition>FGID According to the Rome III Criteria</condition>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
      <condition>Functional Abdominal Pain</condition>
      <condition>Functional Dyspepsia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cognitive behavior therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Faces Pain Rating Scale (FACES) from baseline to 10 weeks</outcome_measure>
      <outcome_measure>Change in Faces Pain Rating Scale (FACES) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Gastrointestinal Symptom Rating Scale (GSRS-IBS) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Children´s Somatization Inventory (CSI 24) from baseline to 10 weeks</outcome_measure>
      <outcome_measure>Change in Gastrointestinal Symptom Scale (PedsQL Gastro) from baseline to 10 weeks</outcome_measure>
      <outcome_measure>Change in Functional Disability Index (FDI) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Pain Reactivity Scale from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in IBS-behavioral responses questionnaires (IBS-BRQ) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Spence Children Anxiety Scale (SCAS) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Child Depression Inventory (CDI) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Pain Interference Index (PII) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Pediatric Quality of Life Inventory (Peds QL) from baseline to 10 weeks.</outcome_measure>
      <outcome_measure>Change in Gastrointestinal Symptom Rating Scale (GSRS-IBS) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Children´s Somatization Inventory (CSI 24) from baseline to 8 months</outcome_measure>
      <outcome_measure>Change in Gastrointestinal Symptom Scale (PedsQL Gastro) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Functional Disability Index (FDI) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in IBS-behavioral responses questionnaires (IBS-BRQ) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Spence Children Anxiety Scale (SCAS) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Child Depression Inventory (CDI) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Pain Interference Index (PII) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Pediatric Quality of Life Inventory (Peds QL) from baseline to 8 months.</outcome_measure>
      <outcome_measure>Change in Pain Reactivity Scale from baseline to 8 months.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FGID Child Pilot-0</other_id>
    </other_ids>
    <start_date>April 2014</start_date>
    <primary_completion_date>November 2015</primary_completion_date>
    <completion_date>November 2015</completion_date>
    <study_first_posted>April 14, 2014</study_first_posted>
    <last_update_posted>December 2, 2015</last_update_posted>
    <locations>
      <location>Child and Adolescent Psychiatry in Stockholm, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02113605</url>
  </study>
  <study rank="579">
    <nct_id>NCT01255345</nct_id>
    <title>Female Chronic Pelvic Pain</title>
    <acronym>Female CPP</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pelvic Pain</condition>
      <condition>Abdominal Pain</condition>
      <condition>Painful Bladder Syndrome</condition>
      <condition>Interstitial Cystitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Chronic pelvic pain</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Copenhagen University Hospital at Herlev</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-1-2010-037</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <completion_date>December 2012</completion_date>
    <study_first_posted>December 7, 2010</study_first_posted>
    <last_update_posted>June 27, 2011</last_update_posted>
    <locations>
      <location>Department of Anaesthesiology, Herlev University Hospital, Herlev, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01255345</url>
  </study>
  <study rank="580">
    <nct_id>NCT03143517</nct_id>
    <title>Fecal Calprotectin Collection Protocol</title>
    <acronym>CALFE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Crohn Disease</condition>
      <condition>Indeterminate Colitis</condition>
      <condition>Chronic Diarrhea</condition>
      <condition>Celiac Disease</condition>
      <condition>Diverticulitis</condition>
      <condition>Abdominal Pain</condition>
      <condition>Distension</condition>
      <condition>Weight Loss</condition>
      <condition>Food Intolerance</condition>
      <condition>Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Stool collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Calprotectin Stool Collection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>DiaSorin Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CALFE Sample Collection C-001</other_id>
    </other_ids>
    <start_date>April 19, 2017</start_date>
    <primary_completion_date>August 23, 2018</primary_completion_date>
    <completion_date>August 23, 2018</completion_date>
    <study_first_posted>May 8, 2017</study_first_posted>
    <last_update_posted>February 7, 2019</last_update_posted>
    <locations>
      <location>One (1) Location in Dothan, Alabama, Dothan, Alabama, United States</location>
      <location>One (1) Facility in Arkansas, Little Rock, Arkansas, United States</location>
      <location>One (1) Location in California, Mission Hills, California, United States</location>
      <location>One (1) Location in Colorado Springs, Colorado, Colorado Springs, Colorado, United States</location>
      <location>One (1) Location in Lauderdale Lakes, FL, Lauderdale Lakes, Florida, United States</location>
      <location>One (1) Location in Maitland, FL, Maitland, Florida, United States</location>
      <location>One (1) Location in Miami, Florida, Miami, Florida, United States</location>
      <location>One (1) Location in St. Augustine, FL, Saint Augustine, Florida, United States</location>
      <location>One (1) Location in Atlanta, GA, Atlanta, Georgia, United States</location>
      <location>One (1) Location in Minneapolis, MN, Minneapolis, Minnesota, United States</location>
      <location>One (1) Location in New York, New York, New York, New York, United States</location>
      <location>One (1) Location in North Carolina, Asheville, North Carolina, United States</location>
      <location>One (1) Location in Greenville, SC, Greenville, South Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03143517</url>
  </study>
  <study rank="581">
    <nct_id>NCT00554320</nct_id>
    <title>Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Pelvic Pain</condition>
      <condition>Interstitial Cystitis</condition>
      <condition>Post Traumatic Stress Disorder</condition>
      <condition>Fibromyalgia</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">tDCS</intervention>
      <intervention type="Procedure">tDCS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patient Global Assessment (PGA):</outcome_measure>
      <outcome_measure>Visual analog scale (VAS) for pain:</outcome_measure>
      <outcome_measure>Interstitial cystitis symptom index:</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Summa Health System</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RP07066</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>June 2009</primary_completion_date>
    <completion_date>June 2009</completion_date>
    <study_first_posted>November 6, 2007</study_first_posted>
    <last_update_posted>September 18, 2009</last_update_posted>
    <locations>
      <location>Summa Health System, Akron, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00554320</url>
  </study>
  <study rank="582">
    <nct_id>NCT02551029</nct_id>
    <title>fMRI and Visceral Perception Upon Capsaicin Infusion</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Colonic Diseases, Functional</condition>
      <condition>Dyspepsia</condition>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Abdominal Pain</condition>
      <condition>Visceral Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Capsaicin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Activation of the Nucleus of the Solitary Tract</outcome_measure>
      <outcome_measure>Activity and connectivity in the Cingulate Cortex, Insula, Thalamus, Prefrontal Cortex, Primary and Secondary Somatosensory Cortex, Amygdala, PAG</outcome_measure>
      <outcome_measure>Questionnaire for pain (Visual Analogue Scores)</outcome_measure>
      <outcome_measure>Questionnaire for depression and anxiety</outcome_measure>
      <outcome_measure>Questionnaire for depression</outcome_measure>
      <outcome_measure>Questionnaire for personality trait</outcome_measure>
      <outcome_measure>Questionnaire for quality of life</outcome_measure>
      <outcome_measure>Questionnaire for current affent scores</outcome_measure>
      <outcome_measure>Questionnaire for current pain</outcome_measure>
      <outcome_measure>Questionnaire for anxiety</outcome_measure>
      <outcome_measure>Questionnaire for the assessment of Gastrointestinal symptom scores</outcome_measure>
      <outcome_measure>Questionnaire for the assessment of early life traumata</outcome_measure>
      <outcome_measure>Questionnaire for the assessment of gastrointestinal specific anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University Medical Center</lead_sponsor>
      <collaborator>KU Leuven</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>METC 152048</other_id>
      <other_id>NL51770.068.15</other_id>
    </other_ids>
    <start_date>February 2016</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>September 16, 2015</study_first_posted>
    <last_update_posted>November 30, 2018</last_update_posted>
    <locations>
      <location>Maastricht University Medical Center, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02551029</url>
  </study>
  <study rank="583">
    <nct_id>NCT02197780</nct_id>
    <title>Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD</title>
    <acronym>CACATU</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Abdominal Pain</condition>
      <condition>Rectal Bloodloss</condition>
      <condition>Diarrhea</condition>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The difference in specificity between FC and S100A12 among the total number of non-IBD patients.</outcome_measure>
      <outcome_measure>The difference in sensitivity between FC and S100A12 among the total number of IBD patients.</outcome_measure>
      <outcome_measure>Diagnostic test accuracy characteristics for both FC and S100A12</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Medical Center Groningen</lead_sponsor>
      <collaborator>Cisbio Bioassays</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>355</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>UMCG-2013N636</other_id>
    </other_ids>
    <start_date>September 2014</start_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <completion_date>April 2017</completion_date>
    <study_first_posted>July 23, 2014</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>Sint Vincentiusziekenhuis, Antwerpen, Belgium</location>
      <location>University Hospital Antwerpen, Antwerpen, Belgium</location>
      <location>University Hospital Gent, Gent, Belgium</location>
      <location>ZGT Almelo, Almelo, Netherlands</location>
      <location>Wilhelmina Ziekenhuis, Assen, Netherlands</location>
      <location>Deventer Ziekenhuis, Deventer, Netherlands</location>
      <location>Ziekenhuis Nij Smellinghe, Drachten, Netherlands</location>
      <location>Scheper Ziekenhuis, Emmen, Netherlands</location>
      <location>Medisch Spectrum Twente, Enschede, Netherlands</location>
      <location>Admiraal de Ruyter ziekenhuis, Goes, Netherlands</location>
      <location>University Medical Center Groningen, Groningen, Netherlands</location>
      <location>Martini Ziekenhuis, Groningen, Netherlands</location>
      <location>Tjongerschans, Heerenveen, Netherlands</location>
      <location>Bethesda Hospital, Hoogeveen, Netherlands</location>
      <location>Medisch Centrum Leeuwarden (MCL), Leeuwarden, Netherlands</location>
      <location>Bravis ziekenhuis, Roosendaal, Netherlands</location>
      <location>Refaja Ziekenhuis, Stadskanaal, Netherlands</location>
      <location>Ommelander Ziekenhuis Groep, Winschoten, Netherlands</location>
      <location>Isala Kliniek, Zwolle, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02197780</url>
  </study>
  <study rank="584">
    <nct_id>NCT00810329</nct_id>
    <title>Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Fatigue Syndrome</condition>
      <condition>Fibromyalgia</condition>
      <condition>Gulf War Illness</condition>
      <condition>Multiple Chemical Sensitivity</condition>
      <condition>Interstitial Cystitis</condition>
      <condition>Irritable Bowel Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Differences in the proteins in the fluid around the brain, between Chronic fatigue syndrome and Healthy subjects. These proteins may identify the disease and define its mechanism.</outcome_measure>
      <outcome_measure>Blood pressure differences in response to exercise, blood test and cerebrospinal fluid, questionnaire results and sensory nerve testing to determine the role(s) of altered nerve and brain function in Chronic fatigue syndrome.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Georgetown University</lead_sponsor>
      <collaborator>National Institute of Environmental Health Sciences (NIEHS)</collaborator>
      <collaborator>University of South Alabama</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2006-481</other_id>
      <other_id>R01ES015382</other_id>
    </other_ids>
    <start_date>July 2007</start_date>
    <primary_completion_date>April 2011</primary_completion_date>
    <completion_date>April 2011</completion_date>
    <study_first_posted>December 18, 2008</study_first_posted>
    <last_update_posted>February 25, 2014</last_update_posted>
    <locations>
      <location>Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00810329</url>
  </study>
  <study rank="585">
    <nct_id>NCT03241368</nct_id>
    <title>Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.</title>
    <acronym>BLINK</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Capsule Endoscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensitivity for detecting active CD in the small bowel and colon by CE as compared to IC plus MRE</outcome_measure>
      <outcome_measure>Specificity, negative predictive value, and positive predictive value for active CD in the small bowel and colon by CE as compared to IC plus MRE.</outcome_measure>
      <outcome_measure>Senstivity, specificity, negative predictive value and positive predictive value for active CD in designated bowel segments (proximal small bowel terminal ileum, and colon) by Capsule Endoscopy as compared to IC plus MRE</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medtronic - MITG</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>352</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>COVSBCC0549</other_id>
    </other_ids>
    <start_date>December 21, 2017</start_date>
    <primary_completion_date>November 30, 2019</primary_completion_date>
    <completion_date>November 30, 2019</completion_date>
    <study_first_posted>August 7, 2017</study_first_posted>
    <last_update_posted>March 8, 2019</last_update_posted>
    <locations>
      <location>University of South Alabama, Mobile, Alabama, United States</location>
      <location>Mayo Clinic (Scottsdale, AZ), Scottsdale, Arizona, United States</location>
      <location>Borland Groover Clinic, Jacksonville, Florida, United States</location>
      <location>Shafran Gastroenterology Center, Winter Park, Florida, United States</location>
      <location>Children's Center for Digestive Healthcare, Atlanta, Georgia, United States</location>
      <location>Loyola University - Chicago, Maywood, Illinois, United States</location>
      <location>Indiana University, Indianapolis, Indiana, United States</location>
      <location>Indianapolis Gastroenterology Research Foundation, Indianapolis, Indiana, United States</location>
      <location>University of Kansas, Kansas City, Kansas, United States</location>
      <location>Louisiana State University Health Science Center, New Orleans, Louisiana, United States</location>
      <location>University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Mayo Clinic (Rochester, MN), Rochester, Minnesota, United States</location>
      <location>Washington University, Saint Louis, Missouri, United States</location>
      <location>Atlantic Health (Morristown), Morristown, New Jersey, United States</location>
      <location>Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States</location>
      <location>University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States</location>
      <location>The Ohio State University Medical Center, Columbus, Ohio, United States</location>
      <location>Digestive Disease Specialists Inc., Oklahoma City, Oklahoma, United States</location>
      <location>Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
      <location>Gastroenterology Associates of Tidewater, Chesapeake, Virginia, United States</location>
      <location>Carilion Clinic, Roanoke, Virginia, United States</location>
      <location>Virginia Gastroenterology Institute, Suffolk, Virginia, United States</location>
      <location>Virginia Mason Medical Center, Seattle, Washington, United States</location>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
      <location>Allgemeines Krankenhaus - Universitatskliniken Wein, Vienna, Austria</location>
      <location>Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03241368</url>
  </study>
  <study rank="586">
    <nct_id>NCT02789800</nct_id>
    <title>Patient-Centred Innovations for Persons With Multimorbidity - Quebec</title>
    <acronym>PACEinMM-QC</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertension</condition>
      <condition>Depression</condition>
      <condition>Anxiety</condition>
      <condition>Musculoskeletal Pain</condition>
      <condition>Arthritis</condition>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Osteoporosis</condition>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
      <condition>Asthma</condition>
      <condition>Chronic Bronchitis</condition>
      <condition>Cardiovascular Disease</condition>
      <condition>Heart Failure</condition>
      <condition>Stroke</condition>
      <condition>Transient Ischemic Attacks</condition>
      <condition>Ulcer</condition>
      <condition>Gastroesophageal Reflux</condition>
      <condition>Irritable Bowel</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Diverticulosis</condition>
      <condition>Chronic Hepatitis</condition>
      <condition>Diabetes</condition>
      <condition>Thyroid Disorder</condition>
      <condition>Cancer</condition>
      <condition>Kidney Disease</condition>
      <condition>Urinary Tract Problem</condition>
      <condition>Dementia</condition>
      <condition>Alzheimer's Disease</condition>
      <condition>Hyperlipidemia</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">DIMAC02</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Self-Management outcomes</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Chronic Diseases</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Health Status</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Quality of Life</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Psychological Well-being</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Equity</outcome_measure>
      <outcome_measure>Demographics</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Transitions of Care</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Self-Efficacy</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Patient-Centredness</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Université de Sherbrooke</lead_sponsor>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>Western University, Canada</collaborator>
      <collaborator>Agence de la Sante et des Services Sociaux du Saguenay-Lac-Saint-Jean</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1956</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013-010</other_id>
    </other_ids>
    <start_date>April 22, 2016</start_date>
    <primary_completion_date>March 8, 2019</primary_completion_date>
    <completion_date>March 1, 2020</completion_date>
    <study_first_posted>June 3, 2016</study_first_posted>
    <last_update_posted>December 15, 2017</last_update_posted>
    <locations>
      <location>Université de Sherbrooke, Chicoutimi, Quebec, Canada</location>
      <location>CIUSSS du Sageunay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02789800</url>
  </study>
  <study rank="587">
    <nct_id>NCT02742597</nct_id>
    <title>Patient-Centred Innovations for Persons With Multimorbidity - Ontario</title>
    <acronym>PACEinMM-ON</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertension</condition>
      <condition>Depression</condition>
      <condition>Anxiety</condition>
      <condition>Musculoskeletal Pain</condition>
      <condition>Arthritis</condition>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Osteoporosis</condition>
      <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
      <condition>Asthma</condition>
      <condition>Chronic Bronchitis</condition>
      <condition>Cardiovascular Disease</condition>
      <condition>Heart Failure</condition>
      <condition>Stroke</condition>
      <condition>Transient Ischemic Attacks</condition>
      <condition>Ulcer</condition>
      <condition>Gastroesophageal Reflux</condition>
      <condition>Irritable Bowel</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Diverticulosis</condition>
      <condition>Chronic Hepatitis</condition>
      <condition>Diabetes</condition>
      <condition>Thyroid Disorder</condition>
      <condition>Cancer</condition>
      <condition>Kidney Disease</condition>
      <condition>Urinary Tract Problem</condition>
      <condition>Dementia</condition>
      <condition>Alzheimer's Disease</condition>
      <condition>Hyperlipidemia</condition>
      <condition>HIV</condition>
      <condition>Multimorbidity</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">TIP / IMPACT Plus Care Coordination</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Self-Management outcomes</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Transitions of Care</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Self-Efficacy</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Patient-Centredness</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Chronic Diseases</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Health Status</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Quality of Life</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Psychological Well-being</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Equity</outcome_measure>
      <outcome_measure>Evaluation of Intervention Effectiveness - Change in Demographics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lawson Health Research Institute</lead_sponsor>
      <collaborator>Western University, Canada</collaborator>
      <collaborator>Université de Sherbrooke</collaborator>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>Sunnybrook Health Sciences Centre</collaborator>
      <collaborator>St. Michael's Hospital, Toronto</collaborator>
      <collaborator>University Health Network, Toronto</collaborator>
      <collaborator>Toronto East General Hospital</collaborator>
      <collaborator>Providence Healthcare</collaborator>
      <collaborator>Mount Sinai Hospital, Canada</collaborator>
      <collaborator>Toronto Central Community Care Access Centre</collaborator>
      <collaborator>Women's College Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1980</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>104191</other_id>
    </other_ids>
    <start_date>January 12, 2016</start_date>
    <primary_completion_date>April 7, 2019</primary_completion_date>
    <completion_date>March 1, 2020</completion_date>
    <study_first_posted>April 19, 2016</study_first_posted>
    <last_update_posted>December 18, 2017</last_update_posted>
    <locations>
      <location>Western University, London, Ontario, Canada</location>
      <location>Mount Sinai Hospital, Toronto, Ontario, Canada</location>
      <location>Providence Healthcare, Toronto, Ontario, Canada</location>
      <location>St. Michael's Hospital, Toronto, Ontario, Canada</location>
      <location>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</location>
      <location>Toronto Central Community Care Access Centre, Toronto, Ontario, Canada</location>
      <location>Toronto East General Hospital, Toronto, Ontario, Canada</location>
      <location>University Hospital Network, Toronto, Ontario, Canada</location>
      <location>Women's College Hospital, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02742597</url>
  </study>
  <study rank="588">
    <nct_id>NCT02113111</nct_id>
    <title>Effects of Fasting on Self Efficacy</title>
    <acronym>TheraFast</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Pain</condition>
      <condition>Fibromyalgia</condition>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Gout</condition>
      <condition>Headache</condition>
      <condition>Arthritis</condition>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Fasting</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Self efficacy questionnaire</outcome_measure>
      <outcome_measure>Bodily self-efficacy</outcome_measure>
      <outcome_measure>Ability and will to change</outcome_measure>
      <outcome_measure>Easiness of life</outcome_measure>
      <outcome_measure>Health-related quality of life</outcome_measure>
      <outcome_measure>Body responsiveness</outcome_measure>
      <outcome_measure>Body awareness and dissociation</outcome_measure>
      <outcome_measure>Body Awareness</outcome_measure>
      <outcome_measure>Symptoms</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Safety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universität Duisburg-Essen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>13-5522 TheraFast</other_id>
    </other_ids>
    <start_date>April 2014</start_date>
    <primary_completion_date>July 2015</primary_completion_date>
    <completion_date>September 2015</completion_date>
    <study_first_posted>April 14, 2014</study_first_posted>
    <last_update_posted>September 4, 2015</last_update_posted>
    <locations>
      <location>Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Essen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02113111</url>
  </study>
  <study rank="589">
    <nct_id>NCT01476995</nct_id>
    <title>Prognostic Indicators as Provided by the EPIC ClearView</title>
    <acronym>GBMC</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
      <condition>Congestive Heart Failure</condition>
      <condition>Valvular Heart Disease</condition>
      <condition>Atrial Fibrillation</condition>
      <condition>Hypertension</condition>
      <condition>Pyelonephritis</condition>
      <condition>Acute Renal Failure</condition>
      <condition>Renal Failure</condition>
      <condition>Viral Hepatitis</condition>
      <condition>Alcoholic Hepatitis</condition>
      <condition>Steatohepatitis</condition>
      <condition>Cirrhosis</condition>
      <condition>Asthma</condition>
      <condition>COPD</condition>
      <condition>Bronchitis</condition>
      <condition>Emphysema</condition>
      <condition>Pneumonia</condition>
      <condition>Inflammatory Bowel Disease</condition>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
      <condition>Diverticulitis</condition>
      <condition>Peptic Ulcer Disease</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Cholecystitis</condition>
      <condition>Pancreatitis</condition>
      <condition>Malabsorption Disorders</condition>
      <condition>Celiac Sprue</condition>
      <condition>Diabetes</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Agreement of ClearView Scan versus Active Diagnosis</outcome_measure>
      <outcome_measure>Sensitivity and Specificity of ClearView Scan versus Active Diagnosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Epic Research &amp; Diagnostics, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>GBMC Triage Study</other_id>
    </other_ids>
    <start_date>September 2010</start_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <completion_date>June 2011</completion_date>
    <study_first_posted>November 22, 2011</study_first_posted>
    <last_update_posted>November 22, 2011</last_update_posted>
    <locations>
      <location>Greater Baltimore Medical Cente, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01476995</url>
  </study>
  <study rank="590">
    <nct_id>NCT03844412</nct_id>
    <title>Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vestibulodynia</condition>
      <condition>Temporomandibular Disorder</condition>
      <condition>Fibromyalgia Syndrome</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Migraines</condition>
      <condition>Tension Headache</condition>
      <condition>Endometriosis</condition>
      <condition>Interstitial Cystitis</condition>
      <condition>Back Pain</condition>
      <condition>Chronic Fatigue Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">5% lidocaine/5 mg/ml estradiol compound cream</intervention>
      <intervention type="Drug">Nortriptyline</intervention>
      <intervention type="Drug">Placebo cream</intervention>
      <intervention type="Drug">Placebo pill</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in pain score during the tampon test</outcome_measure>
      <outcome_measure>Change in self-reported pain via the Short Form- McGill Pain Questionnaire (SF-MPQ)</outcome_measure>
      <outcome_measure>Change in self-reported physical/mental health via SF-12 Health Survey (SF12v2)</outcome_measure>
      <outcome_measure>Change in sexual health via Patient-Reported Outcomes Measurement Information System (PROMIS)</outcome_measure>
      <outcome_measure>Change in inflammation as measured by cytokine expression levels</outcome_measure>
      <outcome_measure>Change in regulators of pro-pain and pro-inflammatory genes, as measured by microRNA expression levels</outcome_measure>
      <outcome_measure>Change in pain level as measured by Vaginal Vestibule Pressure Pain Intensities (PPI)</outcome_measure>
      <outcome_measure>Levator Muscle Complex Pressure Pain Thresholds (PPTs)</outcome_measure>
      <outcome_measure>Change in pain level as measured by Remote Bodily PPTs</outcome_measure>
      <outcome_measure>Change in degree of overlapping pain, as measured by COPC follow-up survey</outcome_measure>
      <outcome_measure>Change in mood as measured by the Symptom Checklist-27 (SCL-27)</outcome_measure>
      <outcome_measure>Change in somatic awareness via Pennebaker Index of Limbic Languidness (PILL)</outcome_measure>
      <outcome_measure>Change in perceived stress via Perceived Stress Scale (PSS)</outcome_measure>
      <outcome_measure>Change in sleep as measured by the sleep scale</outcome_measure>
      <outcome_measure>Change in in pain score during the tampon test at other time points</outcome_measure>
      <outcome_measure>Change in in pain score via the SF-MPQ at other time points</outcome_measure>
      <outcome_measure>Change in self-reported health on the SF12v2 at other time points</outcome_measure>
      <outcome_measure>Change in self-reported health on the PROMIS at other time points</outcome_measure>
      <outcome_measure>Change in cytokine biomarkers at other time points</outcome_measure>
      <outcome_measure>Change in microRNA biomarkers at other time points</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Pro00100678</other_id>
      <other_id>1R01HD096331-01</other_id>
    </other_ids>
    <start_date>June 1, 2019</start_date>
    <primary_completion_date>October 1, 2022</primary_completion_date>
    <completion_date>December 1, 2022</completion_date>
    <study_first_posted>February 18, 2019</study_first_posted>
    <last_update_posted>May 15, 2019</last_update_posted>
    <locations>
      <location>University of California, Los Angeles, Los Angeles, California, United States</location>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03844412</url>
  </study>
  <study rank="591">
    <nct_id>NCT02868983</nct_id>
    <title>Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems</title>
    <acronym>IBHPC</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Arthritis</condition>
      <condition>Asthma</condition>
      <condition>Chronic Obstructive Lung Disease</condition>
      <condition>Diabetes</condition>
      <condition>Heart Failure</condition>
      <condition>Hypertension</condition>
      <condition>Anxiety</condition>
      <condition>Chronic Pain</condition>
      <condition>Depression</condition>
      <condition>Fibromyalgia</condition>
      <condition>Insomnia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Problem Drinking</condition>
      <condition>Substance Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Integration</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PROMIS-29 v2</outcome_measure>
      <outcome_measure>CAHPS 12-Month PCMH Adult Questionnaire 2.0</outcome_measure>
      <outcome_measure>Consultation and Relational Empathy measure</outcome_measure>
      <outcome_measure>Patient Activation Measure-13</outcome_measure>
      <outcome_measure>Modified Self-reported Medication-taking Scale</outcome_measure>
      <outcome_measure>Patient Report of Utilization</outcome_measure>
      <outcome_measure>Restricted Activity Days</outcome_measure>
      <outcome_measure>Duke Activity Status Index</outcome_measure>
      <outcome_measure>Hgb A1C</outcome_measure>
      <outcome_measure>30-day use</outcome_measure>
      <outcome_measure>Global Appraisal of Individual Needs - Short Screener</outcome_measure>
      <outcome_measure>Systolic blood pressure</outcome_measure>
      <outcome_measure>Asthma Symptom Utility Index</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>Arizona State University</collaborator>
      <collaborator>State University of New York at Buffalo</collaborator>
      <collaborator>Case Western Reserve University</collaborator>
      <collaborator>DARTNet</collaborator>
      <collaborator>National Committee for Quality Assurance</collaborator>
      <collaborator>University of Massachusetts, Worcester</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>WLPS-1409-24372</other_id>
    </other_ids>
    <start_date>April 2016</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>August 16, 2016</study_first_posted>
    <last_update_posted>April 17, 2019</last_update_posted>
    <locations>
      <location>University of Vermont, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02868983</url>
  </study>
  <study rank="592">
    <nct_id>NCT01050465</nct_id>
    <title>MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acne Vulgaris</condition>
      <condition>Allergic Rhinitis</condition>
      <condition>Anxiety</condition>
      <condition>Asthma</condition>
      <condition>Back Pain</condition>
      <condition>Prostatic Hyperplasia</condition>
      <condition>Bursitis</condition>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
      <condition>Cough</condition>
      <condition>Coronary Artery Disease</condition>
      <condition>Depression</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Diarrhea</condition>
      <condition>Gastroesophageal Reflux</condition>
      <condition>Fibromyalgia</condition>
      <condition>Headache</condition>
      <condition>HIV Infections</condition>
      <condition>Hypothyroidism</condition>
      <condition>Hyperlipidemia</condition>
      <condition>Hypertension</condition>
      <condition>Influenza</condition>
      <condition>Sleep Initiation and Maintenance Disorders</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Migraine Disorders</condition>
      <condition>Obesity</condition>
      <condition>Obstructive Sleep Apnea</condition>
      <condition>Osteoarthritis</condition>
      <condition>Senile Osteoporosis</condition>
      <condition>Shoulder Pain</condition>
      <condition>Sinusitis</condition>
      <condition>Smoking Cessation</condition>
      <condition>Tobacco Use Cessation</condition>
      <condition>Menopause</condition>
      <condition>Urinary Incontinence</condition>
      <condition>Urinary Tract Infection</condition>
      <condition>Vaginitis</condition>
      <condition>Vertigo</condition>
    </conditions>
    <interventions>
      <intervention type="Other">health information prescription</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>seeking information using MedlinePlus</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Missouri-Columbia</lead_sponsor>
      <collaborator>National Library of Medicine (NLM)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>907</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
    </study_designs>
    <other_ids>
      <other_id>HHSN276200800445P</other_id>
    </other_ids>
    <start_date>May 2009</start_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <completion_date>December 2010</completion_date>
    <study_first_posted>January 15, 2010</study_first_posted>
    <last_update_posted>September 30, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01050465</url>
  </study>
  <study rank="593">
    <nct_id>NCT01118988</nct_id>
    <title>Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Irritable Bowel Syndrome (IBS)</condition>
      <condition>Functional Abdominal Pain</condition>
      <condition>Fibromyalgia</condition>
      <condition>Complex Regional Pain Syndrome (CRPS)</condition>
      <condition>Myofacial Pain</condition>
      <condition>Chronic Daily Headaches</condition>
      <condition>Migraine Headaches</condition>
      <condition>Chronic Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mentorship</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adherence to Physician Recommended CAM Therapies</outcome_measure>
      <outcome_measure>Body Map and Pain Assessment</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index (PSQI)</outcome_measure>
      <outcome_measure>Child Symptom Inventory (CSI)</outcome_measure>
      <outcome_measure>Child Anxiety Sensitivity Inventory (CASI) - Child Report</outcome_measure>
      <outcome_measure>Health Belief Scale (HBS) Short Version - Child Report</outcome_measure>
      <outcome_measure>Emotion Regulation Questionnaire (ERQ) - Child Answer</outcome_measure>
      <outcome_measure>Emotion Expression Scale for Children (EESC)</outcome_measure>
      <outcome_measure>Functional Disability Inventory (FDI)</outcome_measure>
      <outcome_measure>Revised Child Anxiety and Depression Scale (RCADS) Child Report</outcome_measure>
      <outcome_measure>Beck Depression Inventory 2 (BDI-2) #18</outcome_measure>
      <outcome_measure>Child Health Questionnaire - Child Report (CHQ)</outcome_measure>
      <outcome_measure>Positive and Negative Affect Scale (PANAS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1R21HD057421-01A2</other_id>
    </other_ids>
    <start_date>December 2009</start_date>
    <primary_completion_date>June 2011</primary_completion_date>
    <completion_date>June 2011</completion_date>
    <study_first_posted>May 7, 2010</study_first_posted>
    <results_first_posted>March 9, 2016</results_first_posted>
    <last_update_posted>September 30, 2016</last_update_posted>
    <locations>
      <location>UCLA Pediatric Pain Management Clinic, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01118988</url>
  </study>
  <study rank="594">
    <nct_id>NCT00634608</nct_id>
    <title>Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Allergic Rhinitis</condition>
      <condition>Asthma</condition>
      <condition>Back Pain</condition>
      <condition>Benign Prostatic Hypertrophy</condition>
      <condition>Bursitis</condition>
      <condition>Depression</condition>
      <condition>Anxiety</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Esophageal Reflux</condition>
      <condition>HIV Infections</condition>
      <condition>Hyperlipidemia</condition>
      <condition>Hypertension</condition>
      <condition>Insomnia</condition>
      <condition>Irritable Bowel Syndrome</condition>
      <condition>Obesity</condition>
      <condition>Osteoporosis (Senile)</condition>
      <condition>Shoulder Pain</condition>
      <condition>Sinusitis</condition>
      <condition>Symptomatic Menopause</condition>
      <condition>Urinary Incontinence</condition>
      <condition>Urinary Tract Infection</condition>
      <condition>Vaginitis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Health Information Prescription</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>health information experiences of the patient</outcome_measure>
      <outcome_measure>clinician feedback on the health information prescription process</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Missouri-Columbia</lead_sponsor>
      <collaborator>National Library of Medicine (NLM)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
    </study_designs>
    <other_ids>
      <other_id>HHSN276200700263P</other_id>
    </other_ids>
    <start_date>February 2008</start_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <completion_date>September 2009</completion_date>
    <study_first_posted>March 13, 2008</study_first_posted>
    <last_update_posted>September 30, 2016</last_update_posted>
    <locations>
      <location>University of Missouri, Department of Internal Medicine, Columbia, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00634608</url>
  </study>
  <study rank="595">
    <nct_id>NCT02011542</nct_id>
    <title>Probiotic (VSL #3) for Gulf War Illness</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Gulf War Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VSL#3</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in the Bowel Symptom Scale (BSS) From Baseline</outcome_measure>
      <outcome_measure>Change in Chronic Fatigue (1-5 Scale) From Baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Utah</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>W81XWH-10-1-0593</other_id>
    </other_ids>
    <start_date>September 2013</start_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <completion_date>July 2016</completion_date>
    <study_first_posted>December 13, 2013</study_first_posted>
    <results_first_posted>January 16, 2018</results_first_posted>
    <last_update_posted>October 26, 2018</last_update_posted>
    <locations>
      <location>George E Wahlen VA Medical Center, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02011542</url>
  </study>
  <study rank="596">
    <nct_id>NCT01469936</nct_id>
    <title>Effect of PERMEAPROTECT on the Quality of Life of Patients With Fibromyalgia</title>
    <acronym>L2009-03</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fibromyalgia</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">PERMEAPROTECT</intervention>
      <intervention type="Dietary Supplement">PLACEBO</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of the Gastrointestinal Quality of Life Index (GIQLI) at the end of the supplementation period (5 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Improvement of the Gastrointestinal Quality of Life Index (GIQLI) at end of follow-up (2 weeks), compared with baseline</outcome_measure>
      <outcome_measure>Improvement of the Impact of Fibromyalgia on the Quality of life, measured by the Fibromyalgia Impact Questionnaire (FIQ), at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Improvement of the subjective evaluation, by the patient, of the intensity of gastrointestinal symptoms, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Improvement of the subjective evaluation, by the patient, of the satisfactory relief of gastrointestinal symptoms, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Improvement of the subjective evaluation, by the patient, of the satisfactory relief of gastrointestinal pain, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Reduction of the serum C-reactive Protein (usCRP), measured by the ultra-sensitive method, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Reduction of the intestinal permeability, measured by the urinary ratio of lactulose/mannitol, at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Reduction of blood oxidative stress markers (reduced glutathione, oxidized glutathione and malondialdehyde), at the end of the supplementation period (5 weeks), and at end of follow-up (2 weeks), compared with baseline.</outcome_measure>
      <outcome_measure>Improvement of the general Quality of Life, measured by the Medical Outcome Study Short Form (MOS SF-36), at the end of the supplementation period (5 weeks), and at the en of follow-up (2 weeks), compared with baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lescuyer Laboratory</lead_sponsor>
      <collaborator>Hospices Civils de Lyon</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010-A00971-38</other_id>
    </other_ids>
    <start_date>November 2011</start_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <completion_date>December 2016</completion_date>
    <study_first_posted>November 10, 2011</study_first_posted>
    <last_update_posted>September 7, 2016</last_update_posted>
    <locations>
      <location>Unité de Recherche Clinique en Immunologie de Lyon Sud, Pierre-Bénite, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01469936</url>
  </study>
  <study rank="597">
    <nct_id>NCT00617396</nct_id>
    <title>Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Functional Bowel Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Quetiapine (50 mg/day-100mg/day)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adequate Relief in Pain Score During Treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
      <collaborator>AstraZeneca</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRUSQUET0448</other_id>
    </other_ids>
    <start_date>February 2008</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>May 2012</completion_date>
    <study_first_posted>February 18, 2008</study_first_posted>
    <results_first_posted>March 21, 2014</results_first_posted>
    <last_update_posted>September 15, 2017</last_update_posted>
    <locations>
      <location>UNC Center for Functional GI &amp; Motility Disorders, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00617396</url>
  </study>
  <study rank="598">
    <nct_id>NCT01495806</nct_id>
    <title>Glucomannan for the Treatment of Abdominal Pain-related Functional Gastrointestinal Disorders in Childhood</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Glucomannan</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>number of patients with no abdominal pain at the end of the study</outcome_measure>
      <outcome_measure>number of patients with improvement in self-reported severity of pain</outcome_measure>
      <outcome_measure>number of patients suffered from abdominal pain &lt; 1/week</outcome_measure>
      <outcome_measure>number of patients who used medication for abdominal pain</outcome_measure>
      <outcome_measure>number of patients who lost min.1 school day because of abdominal pain</outcome_measure>
      <outcome_measure>Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Warsaw</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2010</other_id>
    </other_ids>
    <start_date>January 2010</start_date>
    <primary_completion_date>January 2012</primary_completion_date>
    <completion_date>January 2012</completion_date>
    <study_first_posted>December 20, 2011</study_first_posted>
    <last_update_posted>June 13, 2013</last_update_posted>
    <locations>
      <location>Dpt of Pediatrics Warsaw Medical University, Warsaw, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01495806</url>
  </study>
  <study rank="599">
    <nct_id>NCT02946827</nct_id>
    <title>A Low FODMAPs Diet in Celiac Patients With Persistent Gastrointestinal Symptoms</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Celiac Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Balanced low FODMAPs /gluten free diet</intervention>
      <intervention type="Dietary Supplement">Balanced gluten free diet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of VAS (psychometric response scale level continuous line between two end-points 0-10) values of globel well-being in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients in balanced gluten free diet.</outcome_measure>
      <outcome_measure>Improvement of VAS values of IBS symptoms in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients undergoing only a balanced gluten free diet.</outcome_measure>
      <outcome_measure>Improvement of quality of life assessed through SF-36 questionnaire (eight scale scores) in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients undergoing only a balanced gluten free diet.</outcome_measure>
      <outcome_measure>Improvement of psychological problems and symptoms of psychopathology through the symptom checklist 90 R (SCL 90 R) in patients undergoing a balanced Gluten Free/low FODMAPs diet compared to patients undergoing only a balanced gluten free diet.</outcome_measure>
      <outcome_measure>Evaluation of the dietary intake in micro and macro-nutrients before and after a Low FODMAP diet or a balanced Gluten Free diet through questionnaire.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016/464</other_id>
    </other_ids>
    <start_date>January 2016</start_date>
    <primary_completion_date>November 2016</primary_completion_date>
    <completion_date>January 2017</completion_date>
    <study_first_posted>October 27, 2016</study_first_posted>
    <last_update_posted>October 27, 2016</last_update_posted>
    <locations>
      <location>University of Milan, Milan, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02946827</url>
  </study>
  <study rank="600">
    <nct_id>NCT01053962</nct_id>
    <title>SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation</title>
    <acronym>CIC</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Idiopathic Constipation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SP-304</intervention>
      <intervention type="Drug">SP-304</intervention>
      <intervention type="Drug">SP-304</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">SP-304 0.3 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the safety of SP-304 (1.0 mg, 3.0 mg, 9.0 mg and 0.3 mg) for 14 days in patients with CIC</outcome_measure>
      <outcome_measure>To assess changes in bowel habits over time CSBM, SBM, Stool Consistency, Ease of Passage and Completeness of Evacuation in once daily oral dosing of SP-304 (1.0 mg, 3.0 mg, 9.0 mg and 0.3 mg) vs. placebo for 14 days in patients with CIC</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Synergy Pharmaceuticals Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SP-SP304201-09</other_id>
    </other_ids>
    <start_date>February 2010</start_date>
    <primary_completion_date>August 2010</primary_completion_date>
    <completion_date>August 2010</completion_date>
    <study_first_posted>January 22, 2010</study_first_posted>
    <last_update_posted>November 17, 2010</last_update_posted>
    <locations>
      <location>Novara Clinical Research, Mesa, Arizona, United States</location>
      <location>Genova Clinical Research, Tucson, Arizona, United States</location>
      <location>Advanced Clinical Research, Anaheim, California, United States</location>
      <location>Advanced Clinical Research, Orange, California, United States</location>
      <location>A.G.A. Clinical Trials, Hialeah, Florida, United States</location>
      <location>Miami Ressearch and Associates, Miami, Florida, United States</location>
      <location>Lee Research Institute, Shawnee, Kansas, United States</location>
      <location>Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States</location>
      <location>Universtiy of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
      <location>Wake Research Associates, Raleigh, North Carolina, United States</location>
      <location>Memphis Gastroenterology Group, Germantown, Tennessee, United States</location>
      <location>Nashville Medical Research Institute, Nashville, Tennessee, United States</location>
      <location>DCOL Center for Clinical Research, Longview, Texas, United States</location>
      <location>Pioneer Research Solutions, Sugarland, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01053962</url>
  </study>
  <study rank="601">
    <nct_id>NCT02731664</nct_id>
    <title>GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans</title>
    <acronym>GLPMOT</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">GLP-1</intervention>
      <intervention type="Biological">Intravenous saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Motility index (measure of contraction amplitude x duration; area for mmHg x sec)</outcome_measure>
      <outcome_measure>Smooth muscle relaxation induced by GLP-1</outcome_measure>
      <outcome_measure>Presence of GLP-1 and GLP-2 receptors in gastric and small bowel tissue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uppsala University</lead_sponsor>
      <collaborator>Karolinska Institutet</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRANDMOTGLP</other_id>
    </other_ids>
    <start_date>September 2012</start_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <completion_date>August 2017</completion_date>
    <study_first_posted>April 7, 2016</study_first_posted>
    <last_update_posted>August 9, 2018</last_update_posted>
    <locations>
      <location>Uppsala University, Uppsala, Uppsala County, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02731664</url>
  </study>
  <study rank="602">
    <nct_id>NCT02641392</nct_id>
    <title>A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GED-0301</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants With Treatment Emergent Adverse Events From Week 0 to Week 208</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Celgene</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GED-0301-CD-004</other_id>
    </other_ids>
    <start_date>July 25, 2016</start_date>
    <primary_completion_date>January 4, 2018</primary_completion_date>
    <completion_date>January 4, 2018</completion_date>
    <study_first_posted>December 29, 2015</study_first_posted>
    <results_first_posted>January 29, 2019</results_first_posted>
    <last_update_posted>January 29, 2019</last_update_posted>
    <locations>
      <location>Medical Associates Research Group Inc., San Diego, California, United States</location>
      <location>Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States</location>
      <location>Indiana University, Indianapolis, Indiana, United States</location>
      <location>Health Science Research Center, LLC, Pratt, Kansas, United States</location>
      <location>Via Christi Research a division of Via Christi Hospitals Wichita Inc, Wichita, Kansas, United States</location>
      <location>Gastroenterology Associates LLC, Baton Rouge, Louisiana, United States</location>
      <location>Metropolitan Gastroenterology, Chevy Chase, Maryland, United States</location>
      <location>Clinical Research Institute of Michigan, LLC, Chesterfield, Michigan, United States</location>
      <location>Gastroenterology Associates of Western Michigan PLC, Wyoming, Michigan, United States</location>
      <location>Ehrhardt Clinical Research LLC, Belton, Missouri, United States</location>
      <location>Columbia University Medical Center, New York, New York, United States</location>
      <location>Trial Management Associates LLC, Wilmington, North Carolina, United States</location>
      <location>ClinSearch LLC, Chattanooga, Tennessee, United States</location>
      <location>Texas Clinical Research Institute LLC, Arlington, Texas, United States</location>
      <location>Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States</location>
      <location>Texas Digestive Disease Consultants - Southlake, Flower Mound, Texas, United States</location>
      <location>University of Texas Health Science Center at Houston, Houston, Texas, United States</location>
      <location>Sagact Pllc, San Antonio, Texas, United States</location>
      <location>San Antonio Military Medical Center, San Antonio, Texas, United States</location>
      <location>Digestive Health Specialists of Tyler, Tyler, Texas, United States</location>
      <location>Virginia Mason Medical Center, Seattle, Washington, United States</location>
      <location>University of Washington School of Medicine, Seattle, Washington, United States</location>
      <location>The Vancouver Clinic, Vancouver, Washington, United States</location>
      <location>Concord Repatriation General Hospital, Concord, New South Wales, Australia</location>
      <location>Centre For Digestive Diseases, Five Dock, New South Wales, Australia</location>
      <location>Liverpool Hospital, Liverpool, New South Wales, Australia</location>
      <location>Mater Adult Hospital, South Brisbane, Queensland, Australia</location>
      <location>Royal Adelaide Hospital, Adelaide, South Australia, Australia</location>
      <location>Box Hill Hospital, Box Hill, Victoria, Australia</location>
      <location>The Alfred Hospital, Melbourne, Victoria, Australia</location>
      <location>Monash Medical Centre Clayton, Bentleigh East, Australia</location>
      <location>LKH Universitaetsklinikum Graz, Graz, Austria</location>
      <location>Medizinische Universitat Innsbruck, Innsbruck, Austria</location>
      <location>KH der Barmherzigen Bruder Linz, Linz, Austria</location>
      <location>LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria</location>
      <location>KH der Barmherzigen Brüder St.Veit an der Glan, St Veit An Der Glan, Austria</location>
      <location>Krankenanstalt Rudolfstiftung Wien, Wein, Austria</location>
      <location>AKH Medizinische Universitat Wien, Wein, Austria</location>
      <location>Universitair Ziekenhuis Brussel, Brussels, Belgium</location>
      <location>UZ Leuven, Leuven, Belgium</location>
      <location>CHU Sart Tilman, Liege, Belgium</location>
      <location>MHAT Kaspela EOOD, Plovdiv, Bulgaria</location>
      <location>MHAT Ruse AD, Ruse, Bulgaria</location>
      <location>Second MHAT Sofia AD, Sofia, Bulgaria</location>
      <location>City Clinic UMHAC EOOD, Sofia, Bulgaria</location>
      <location>UMHAT Sv Ivan Rilski EAD, Sofia, Bulgaria</location>
      <location>UMHAT Tsaritsa Yoanna - ISUL EAD, Sofia, Bulgaria</location>
      <location>MHAT Doverie AD, Sofia, Bulgaria</location>
      <location>University of Calgary, Calgary, Alberta, Canada</location>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
      <location>South Edmonton Gastroenterology, Edmonton, Alberta, Canada</location>
      <location>Vancouver General Hospital, Vancouver, British Columbia, Canada</location>
      <location>GI Research Institute, Vancouver, British Columbia, Canada</location>
      <location>PerCuro Clinical Research, Victoria, British Columbia, Canada</location>
      <location>Brandon Medical Arts Clinic, Brandon, Manitoba, Canada</location>
      <location>McMaster University Health Sciences Center, Hamilton, Ontario, Canada</location>
      <location>London Health Science Center U. Hospital, London, Ontario, Canada</location>
      <location>LHSC Victoria Hospital, London, Ontario, Canada</location>
      <location>Montfort Hospital, Ottawa, Ontario, Canada</location>
      <location>Mount Sinai Hospital, Toronto, Ontario, Canada</location>
      <location>Toronto Digestive Disease Associates Inc, Vaughan, Ontario, Canada</location>
      <location>Medicine Professional Corporation, Waterloo, Ontario, Canada</location>
      <location>Centre de sante et de services sociaux Champlain Charles Le Moyne, Greenfield Park, Quebec, Canada</location>
      <location>McGill University Health Centre Glen Site Royal Victoria Hospital, Montreal, Quebec, Canada</location>
      <location>Clinical Hospital Centre Osijek, Osijek, Croatia</location>
      <location>Fakultni nemocnice u sv Anny v Brne, Brno, Czechia</location>
      <location>Hepato-Gastroenterologie HK, Hradec Kralove, Czechia</location>
      <location>PreventaMed, Olomouc, Czechia</location>
      <location>CCBR Prague CZ, Praha 3, Czechia</location>
      <location>Aarhus Universitetshospital, Aahus C, Denmark</location>
      <location>Alborg Universitets Hospital, Alborg, Denmark</location>
      <location>Nordsjaellands Hospital Frederikssund, Frederikssund, Denmark</location>
      <location>Herlev Hospital, Herlev, Denmark</location>
      <location>Koge Sygehus, Koge, Denmark</location>
      <location>Regionshospitalet Silkeborg, Silkeborg, Denmark</location>
      <location>CHU Amiens Hopital Sud, Amiens Cedex, France</location>
      <location>CHU Besancon Hopital Jean Minjoz, Besancon Cedex, France</location>
      <location>CHU Tours Hopital Trousseau, Chambray les Tours, France</location>
      <location>CHU Clermont Ferrand, Clermont-Ferrand, France</location>
      <location>Hopital Beaujon, Clichy cedex, France</location>
      <location>CHU Nantes Hotel Dieu, Nantes Cedex 1, France</location>
      <location>CHU Nice Hopital de lArchet 2, Nice Cedex 3, France</location>
      <location>Groupe Hospitalier Sud Hopital Haut Leveque USN, Pessac, France</location>
      <location>Centre Hospitalier Lyon Sud, Pierre Benite cedex, France</location>
      <location>CHU Reims Hopital Robert Debre, Reims, France</location>
      <location>CHU Rennes Hopital Pontchaillou, Rennes cedex 09, France</location>
      <location>CHU Saint Etienne Hopital Nord, Saint Etienne, France</location>
      <location>CHU Strasbourg Hopital Hautepierre, Strasbourg Cedex, France</location>
      <location>CHU de Toulouse Hopital Rangueil, Toulouse Cedex 09, France</location>
      <location>Hopital de Brabois Adultes, Vandoeuvre les Nancy, France</location>
      <location>Charite Universitaetsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany</location>
      <location>DRK Kliniken Berlin Westend, Berlin, Germany</location>
      <location>Krankenhaus Waldfriede e V, Berlin, Germany</location>
      <location>Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH, Bochum, Germany</location>
      <location>Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany</location>
      <location>Universitaetsklinikum Erlangen, Erlangen, Germany</location>
      <location>Kliniken Essen-Mitte, Essen, Germany</location>
      <location>Agaplesion Markus Krankenhaus, Frankfurt, Germany</location>
      <location>Universitaetsklinikum Halle Saale, Halle, Germany</location>
      <location>Asklepios Klinik Hamburg, Hamburg, Germany</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Universitaetsklinikum Heidelberg, Heidelberg, Germany</location>
      <location>Praxis fuer Gastroenterologie Dr Ehehal Dr Helmstaedter, Heidelberg, Germany</location>
      <location>Universitaetsklinikum Jena, Jena, Germany</location>
      <location>Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, Germany</location>
      <location>University Leipzig, Leipzig, Germany</location>
      <location>EUGASTRO GmbH, Leipzig, Germany</location>
      <location>Medizinisches Zentrum Klinikum Lueneburg, Lueneburg, Germany</location>
      <location>Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Germany</location>
      <location>Gastro Campus Research, Muenster, Germany</location>
      <location>Klinikum der Universitaet Muenchen, München, Germany</location>
      <location>Staedtisches Klinikum Braunschweig gGmbH Standort Salzdahlumer, Niedersachsen, Germany</location>
      <location>Universitaetsklinikum Regensburg, Regensburg, Germany</location>
      <location>Universitaetsklinikum Ulm, Ulm, Germany</location>
      <location>University General Hospital of Alexandroupolis, Alexandroupolis, Greece</location>
      <location>General Hospital of Athens Evangelismos, Athens, Greece</location>
      <location>Athens Medical Center, Athens, Greece</location>
      <location>University General Hospital of Patras, Rio Patras, Greece</location>
      <location>DRC Gyogyszervizsgalo Kozpont Kft, Balatonfured, Hungary</location>
      <location>Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary</location>
      <location>Semmelweis Egyetem AOK, Budapest, Hungary</location>
      <location>Endomedix Diagnosztikai Kozpont, Budapest, Hungary</location>
      <location>Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary</location>
      <location>Szent Pantaleon Korhaz Rendelointezet Dunaujvaros, Dunaujvaros, Hungary</location>
      <location>Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary</location>
      <location>Clinfan Szolgaltato Kft, Szekszard, Hungary</location>
      <location>HaEmek Medical Center, Afula, Israel</location>
      <location>Soroka University Medical Center, Beer Sheva, Israel</location>
      <location>Rambam Health Care Campus, Haifa, Israel</location>
      <location>Shaare Zedek Medical Center, Jerusalem, Israel</location>
      <location>Hadassah University Hospital, Jerusalem, Israel</location>
      <location>Rabin Medical Center, Petah Tikva, Israel</location>
      <location>Chaim Sheba Medical Center, Ramat Gan, Israel</location>
      <location>Kaplan Medical Center, Rechovot, Israel</location>
      <location>Tel Aviv Sourasky Medical Center Department of Hematology, Tel Aviv, Israel</location>
      <location>The Baruch Padeh MC, Poriya, Tiberias, Israel</location>
      <location>Assaf Harofeh Medical Center, Zerifin, Israel</location>
      <location>Azienda Ospedaliera Universitaria Policlinico Sant Orsola Malpighi, Bologna, Italy</location>
      <location>Azienda Ospedaliera Universitaria Policlinico G Martino, Messina, Italy</location>
      <location>Fondazione IRCCS CA Granda Ospedale Maggiore Policlinico, Milano, Italy</location>
      <location>Azienda Ospedaliera Vincenzo Cervello, Palermo, Italy</location>
      <location>Fondazione IRCCS Policlinico San Matteo, Pavia, Italy</location>
      <location>Universita Campus Bio Medico di Roma, Roma, Italy</location>
      <location>Policlinico Universitario Agostino Gemelli, Roma, Italy</location>
      <location>Azienda Ospedaliera San Camillo Forlanini, Rome, Italy</location>
      <location>Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy</location>
      <location>Istituto Clinico Humanitas, Rozzano (MI), Italy</location>
      <location>IRCCS Policlinico San Donato, San Donato Milanese, Italy</location>
      <location>IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy</location>
      <location>Dong-A University Hospital, Busan, Korea, Republic of</location>
      <location>Pusan National University Hospital, Busan, Korea, Republic of</location>
      <location>Yeungnam University Medical Center, Daegu, Korea, Republic of</location>
      <location>Hanyang University Guri Hospital, Guri-si, Korea, Republic of</location>
      <location>CHA Bundang Medical Center CHA University, Seongnam-si,, Korea, Republic of</location>
      <location>Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of</location>
      <location>Kyung Hee University Hospital, Seoul, Korea, Republic of</location>
      <location>Kangbuk Samsung Hospital, Seoul, Korea, Republic of</location>
      <location>Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of</location>
      <location>Samsung Medical Center, Seoul, Korea, Republic of</location>
      <location>Digestive Diseases Center Gastro, Riga, Latvia</location>
      <location>Pauls Stradins Clinical University Hospital, Riga, Latvia</location>
      <location>VU Medisch Centrum, Amsterdam, Netherlands</location>
      <location>Academisch Medisch Centrum, Amsterdam, Netherlands</location>
      <location>Amphia Ziekenhuis, Breda, Netherlands</location>
      <location>Radboudumc, Nijmegen, Netherlands</location>
      <location>Zuyderland Medisch Centrum, Sittard-Geleen, Netherlands</location>
      <location>St. Elisabeth Ziekenhuis, Tilburg, Netherlands</location>
      <location>Akershus universitetssykehus HF, Lørenskog, Norway</location>
      <location>Oslo Universitetssykehus Rikshospitalet, Oslo, Norway</location>
      <location>Niepubliczny Zaklad Opieki Zdrowotnej POLIMEDICA, Kielce, Poland</location>
      <location>Indywidualna Praktyka Lekarska Maciej Zymla, Knurow, Poland</location>
      <location>SPZOZ Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej - Centralny Szpital Weteranow, Lodz, Poland</location>
      <location>Centrum Medyczne Medyk, Rzeszow, Poland</location>
      <location>Endoskopia Sp. z o.o., Sopot, Poland</location>
      <location>Hospital de Braga, Braga, Portugal</location>
      <location>Hospital da Senhora da Oliveira Guimaraes, Guimaraes, Portugal</location>
      <location>S.C MedLife S.A, Bucuresti, Romania</location>
      <location>CMI Dr. Tirnaveanu Amelita, Oradea, Romania</location>
      <location>Centrul de Gastroenterologie Dr. Goldis, Timisoara, Romania</location>
      <location>TSBIH Territorial Clinical Hospital, Krasnoyarsk, Russian Federation</location>
      <location>SBHI of NN region RCH of NN n.a. N.A.Semashko, Nizhny Novgorod, Russian Federation</location>
      <location>SBEIHPE Novosibirsk State Medical University, Novosibirsk, Russian Federation</location>
      <location>FSBI Scientific Research Institute of Physyology and Basic Medicine under the SB of RAMS, Novosibirsk, Russian Federation</location>
      <location>Evromedservis, Pushkin, Russian Federation</location>
      <location>SEIHPE Rostov State Medical University of MoH of RF, Rostov-on-Don, Russian Federation</location>
      <location>SPb SBIH City Hospital # 26, Saint-Petersburg, Russian Federation</location>
      <location>NonState Healthcare Institution Central Clinical Hospital, Samara station JSC Russian Railways, Samara, Russian Federation</location>
      <location>Clinical Center Zvezdara, Belgrade, Serbia</location>
      <location>Military Medical Academy, Belgrade, Serbia</location>
      <location>Clinical Center Bezanijska Kosa, Belgrade, Serbia</location>
      <location>Fakultna nemocnica s poliklinikou F. D. Roosevelta, Banska Bystrica, Slovakia</location>
      <location>Alian s.r.o., Bardejov, Slovakia</location>
      <location>Gastroeneterologicka ambulancia MUDr. Peter Hegyi s.r.o., Malacky, Slovakia</location>
      <location>Fakultna nemocnica Nitra, Nitra, Slovakia</location>
      <location>KM Management, spol. s r.o., Nitra, Slovakia</location>
      <location>GASTRO I., s.r.o., Presov, Slovakia</location>
      <location>Hospital del Mar, Barcelona, Spain</location>
      <location>Hospital Clinic I Provincial de Barcelona, Barcelona, Spain</location>
      <location>Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain</location>
      <location>Corporacion Sanitaria Parc Tauli, Sabadell, Spain</location>
      <location>Hospital Universitario Miguel Servet, Zaragoza, Spain</location>
      <location>Danderyds Sjukhus AB, Stockholm, Sweden</location>
      <location>Crohn-Colitis Zentrum Bern Gemeinschaftspraxis Balsiger Seibold und Partner, Bern, Switzerland</location>
      <location>Ankara University Medical Faculty, Ankara, Turkey</location>
      <location>Yeditepe University Medical School Hospital, Istanbul, Turkey</location>
      <location>Istanbul University Cerrahpasa Medical Faculty Hospital, Istanbul, Turkey</location>
      <location>Acibadem Fulya Hospital, Istanbul, Turkey</location>
      <location>Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey</location>
      <location>Istanbul Medeniyet Uni Goztepe Training&amp;Res Hosp, Istanbul, Turkey</location>
      <location>Marmara University Pendik Training and Research Hospital, Istanbul, Turkey</location>
      <location>Ege University Medical Faculty, Izmir, Turkey</location>
      <location>Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey</location>
      <location>RCI Chernivtsi Regional Clinical Hospital Dept of Surgery Bukovinian SMU, Chernivtsi, Ukraine</location>
      <location>CI of PH Kharkiv CCH #2, Kharkiv, Ukraine</location>
      <location>Treatment-Diagnostic Center of Private Enterprise of PMF Atsynus, Kirovohrad, Ukraine</location>
      <location>Ukrainian-German Antiulcer Gastroenterological Center BYK-Kyiv LLC, Kyiv, Ukraine</location>
      <location>Kyiv City Clinical Hospital #1, Kyiv, Ukraine</location>
      <location>SI Republican Clinical Hospital of the MOHU Dept of Gastroenterology O.O.Bogomolets NMU, Kyiv, Ukraine</location>
      <location>CI Odesa Regional Clinical Hospital, Odessa, Ukraine</location>
      <location>Ternopil City Communal Emergency Medical Care Hospital, Ternopil, Ukraine</location>
      <location>CI Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporozhje, Ukraine</location>
      <location>Royal Devon and Exeter Hospital Wonford, Exeter, United Kingdom</location>
      <location>Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom</location>
      <location>Queen Elizabeth University Hospital, Glasgow, United Kingdom</location>
      <location>Hull Royal Infirmary, Hull, United Kingdom</location>
      <location>Royal London Hospital, London, United Kingdom</location>
      <location>St Marys Hospital, London, United Kingdom</location>
      <location>Manchester Royal Infirmary, Manchester, United Kingdom</location>
      <location>Nottingham University Hospitals Queens Medical Centre, Nottingham, United Kingdom</location>
      <location>John Radcliffe Hospital, Oxford, United Kingdom</location>
      <location>Royal Shrewsbury Hospital, Shrewsbury, United Kingdom</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02641392/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02641392/SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT02641392</url>
  </study>
  <study rank="603">
    <nct_id>NCT01864993</nct_id>
    <title>Symptomatic Response to Gluten Challenge in Patients With Suspected Non Celiac Gluten Sensitivity</title>
    <acronym>Glutox</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non Celiac Gluten Sensitivity</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">gluten</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain Scores on the Visual Analogue Scales</outcome_measure>
      <outcome_measure>Quality of Life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>1876/2012</other_id>
      <other_id>1876</other_id>
    </other_ids>
    <start_date>March 2013</start_date>
    <primary_completion_date>February 2016</primary_completion_date>
    <completion_date>February 2016</completion_date>
    <study_first_posted>May 30, 2013</study_first_posted>
    <last_update_posted>February 24, 2016</last_update_posted>
    <locations>
      <location>Ospedale Di Busto Arsizio, Busto Arsizio, Lombardia, Italy</location>
      <location>Ospedale Valduce di Como, Como, Lombardia, Italy</location>
      <location>Ospedale Maggiore di Crema, Crema, Italy</location>
      <location>Ospedale S. Maria, Feltre, Italy</location>
      <location>Arcispedale S. Maria Nuova, Reggio Emilia, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01864993</url>
  </study>
  <study rank="604">
    <nct_id>NCT02421796</nct_id>
    <title>Malnutrition In Non-Celiac Wheat Sensitivity Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-Celiac Wheat Sensitivity</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change in body mass index (BMI)</outcome_measure>
      <outcome_measure>Change in triceps skinfold thicknesses</outcome_measure>
      <outcome_measure>Change in biometric impedance</outcome_measure>
      <outcome_measure>Change in serum albumin</outcome_measure>
      <outcome_measure>Change in serum transferrin</outcome_measure>
      <outcome_measure>Change in total serum cholesterol</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Palermo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACPM08</other_id>
    </other_ids>
    <start_date>May 2015</start_date>
    <primary_completion_date>October 2016</primary_completion_date>
    <completion_date>June 2019</completion_date>
    <study_first_posted>April 21, 2015</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations>
      <location>Antonio Carroccio, Sciacca, Agrigento, Italy</location>
      <location>Pasquale Mansueto, Palermo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02421796</url>
  </study>
  <study rank="605">
    <nct_id>NCT02232373</nct_id>
    <title>Campylobacter Enteritis and PI-BD: Dietary Reduction in Carbohydrates</title>
    <acronym>CEDRIC</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Post-infective Bowel Dysfunction</condition>
      <condition>Functional Gastrointestinal Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">low FODMAP dietary advice</intervention>
      <intervention type="Dietary Supplement">Maltodextrin</intervention>
      <intervention type="Dietary Supplement">Oligofructose</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Moderate or substantial improvement in irritable bowel syndrome (IBS) symptoms on IBS-GIS</outcome_measure>
      <outcome_measure>Moderate or substantial improvement in IBS symptoms</outcome_measure>
      <outcome_measure>Adequate control of IBS symptoms</outcome_measure>
      <outcome_measure>Percentage of days with loose stool</outcome_measure>
      <outcome_measure>Change from baseline in IBSS</outcome_measure>
      <outcome_measure>Change from baseline in fasting colonic volume</outcome_measure>
      <outcome_measure>Change in fasting colonic gas volume</outcome_measure>
      <outcome_measure>Change from baseline in stool concentration of Bifidobacteria</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nottingham</lead_sponsor>
      <collaborator>Nottingham University Hospitals NHS Trust</collaborator>
      <collaborator>King's College London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UoN14048</other_id>
      <other_id>14GA012</other_id>
    </other_ids>
    <start_date>August 2014</start_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <completion_date>August 2015</completion_date>
    <study_first_posted>September 5, 2014</study_first_posted>
    <last_update_posted>May 13, 2016</last_update_posted>
    <locations>
      <location>University of Nottingham, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02232373</url>
  </study>
  <study rank="606">
    <nct_id>NCT02895438</nct_id>
    <title>Non Coeliac Gluten Sensitivity in Children</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diet, Gluten-Free</condition>
      <condition>Gluten-Sensitive Enteropathy</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">gluten</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of IBS</outcome_measure>
      <outcome_measure>change in gastro-intestinal symptoms</outcome_measure>
      <outcome_measure>Change in quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Saint Etienne</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>1408204</other_id>
      <other_id>2015-A00060-49</other_id>
    </other_ids>
    <start_date>May 27, 2015</start_date>
    <primary_completion_date>October 4, 2017</primary_completion_date>
    <completion_date>November 22, 2017</completion_date>
    <study_first_posted>September 9, 2016</study_first_posted>
    <last_update_posted>October 29, 2018</last_update_posted>
    <locations>
      <location>CHU Saint-Etienne, Saint-Etienne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02895438</url>
  </study>
  <study rank="607">
    <nct_id>NCT02248545</nct_id>
    <title>Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-Celiac Wheat Sensitivity</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Organ- and non-organ specific autoantibodies</outcome_measure>
      <outcome_measure>Questionnaire for autoimmunity.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Palermo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ACPM06</other_id>
    </other_ids>
    <start_date>July 2011</start_date>
    <primary_completion_date>July 2013</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>September 25, 2014</study_first_posted>
    <last_update_posted>September 25, 2014</last_update_posted>
    <locations>
      <location>Internal Medicine Department of the Hospital of Sciacca (Agrigento), Sciacca, Agrigento, Italy</location>
      <location>Gastroenterology Unit of the &quot;Civico&quot; Hospital of Palermo, Palermo, Italy</location>
      <location>Internal Medicine Department of the University Hospital of Palermo, Palermo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02248545</url>
  </study>
  <study rank="608">
    <nct_id>NCT03078530</nct_id>
    <title>Probiotic (Visbiome) for Gulf War Illness</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gulf War Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Visbiome</intervention>
      <intervention type="Drug">VSL#3</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the bowel symptom scale from the baseline</outcome_measure>
      <outcome_measure>Change in chronic fatigue (1-5 scale) from baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ashok Tuteja</lead_sponsor>
      <collaborator>United States Department of Defense</collaborator>
      <collaborator>VA Salt Lake City Health Care System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB_00059006</other_id>
    </other_ids>
    <start_date>September 13, 2013</start_date>
    <primary_completion_date>May 31, 2018</primary_completion_date>
    <completion_date>May 31, 2018</completion_date>
    <study_first_posted>March 13, 2017</study_first_posted>
    <last_update_posted>December 13, 2017</last_update_posted>
    <locations>
      <location>George E Wahlen VA Medical Center, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03078530</url>
  </study>
  <study rank="609">
    <nct_id>NCT01426568</nct_id>
    <title>A Trial of Multi-convergent Therapy for Functional Symptoms and Stress in Patients With Inflammatory Bowel Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Multi-Convergent Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Quality of Life in Inflammatory Bowel Disease Questionnaire</outcome_measure>
      <outcome_measure>Change in Irritable Bowel Syndrome Symptom Severity Score</outcome_measure>
      <outcome_measure>Change in Levenstein Perceived Stress Score</outcome_measure>
      <outcome_measure>Change in Hospital Anxiety and Depression Score</outcome_measure>
      <outcome_measure>Abdominal Symptoms Global Improvement Score</outcome_measure>
      <outcome_measure>Relapse rate in inflammatory bowel disease</outcome_measure>
      <outcome_measure>Feasibility of Treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cardiff and Vale University Health Board</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>10-CMC-4876</other_id>
    </other_ids>
    <start_date>January 2011</start_date>
    <primary_completion_date>May 2013</primary_completion_date>
    <completion_date>May 2013</completion_date>
    <study_first_posted>August 31, 2011</study_first_posted>
    <last_update_posted>August 28, 2013</last_update_posted>
    <locations>
      <location>Cardiff and Vale University Health Board, Cardiff, South Glamorgan, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01426568</url>
  </study>
  <study rank="610">
    <nct_id>NCT01595932</nct_id>
    <title>Efficacy and Tolerability of α-galactosidase in Treating Gas-related Symptoms in Children</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gas Pain Related Intake</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">α-galactosidase</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy</outcome_measure>
      <outcome_measure>Clinical tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azienda Policlinico Umberto I</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>α-galactosidase</other_id>
    </other_ids>
    <start_date>June 2009</start_date>
    <primary_completion_date>May 2010</primary_completion_date>
    <completion_date>May 2010</completion_date>
    <study_first_posted>May 10, 2012</study_first_posted>
    <last_update_posted>May 10, 2012</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01595932</url>
  </study>
  <study rank="611">
    <nct_id>NCT03269617</nct_id>
    <title>PHAGE Study: Bacteriophages as Novel Prebiotics</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastrointestinal Disorder, Functional</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Bacteriophage mixture</intervention>
      <intervention type="Other">Placebo Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Microbiota modulation</outcome_measure>
      <outcome_measure>Local inflammation</outcome_measure>
      <outcome_measure>Systemic Inflammation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Colorado State University</lead_sponsor>
      <collaborator>George Mason University</collaborator>
      <collaborator>Metabiomics Corp</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>16-6666HH</other_id>
    </other_ids>
    <start_date>October 1, 2016</start_date>
    <primary_completion_date>May 30, 2017</primary_completion_date>
    <completion_date>May 30, 2017</completion_date>
    <study_first_posted>September 1, 2017</study_first_posted>
    <last_update_posted>April 4, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03269617</url>
  </study>
  <study rank="612">
    <nct_id>NCT03555617</nct_id>
    <title>Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Inflammatory Bowel Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TD-1473</intervention>
      <intervention type="Drug">Itraconazole</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum observed concentration (Cmax) in Plasma</outcome_measure>
      <outcome_measure>Time to maximum observed concentration (tmax) in Plasma</outcome_measure>
      <outcome_measure>Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma</outcome_measure>
      <outcome_measure>Area under the concentration-time curve extrapolated to infinity (AUC0-inf) in Plasma</outcome_measure>
      <outcome_measure>Apparent terminal elimination half-life (t1/2) in Plasma</outcome_measure>
      <outcome_measure>Apparent clearance (Cl/F) in Plasma</outcome_measure>
      <outcome_measure>Apparent volume of distribution (Vz/F) in Plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Theravance Biopharma</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>0174</other_id>
    </other_ids>
    <start_date>June 13, 2018</start_date>
    <primary_completion_date>July 15, 2018</primary_completion_date>
    <completion_date>July 15, 2018</completion_date>
    <study_first_posted>June 13, 2018</study_first_posted>
    <last_update_posted>September 10, 2018</last_update_posted>
    <locations>
      <location>Celerion, Lincoln, Nebraska, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03555617</url>
  </study>
  <study rank="613">
    <nct_id>NCT00790478</nct_id>
    <title>Melatonin &amp; Ulcerative Colitis</title>
    <acronym>Melatonin &amp; UC</acronym>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Melatonin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To estimate treatment effect of 12 weeks of 5 mg/day supplementation with melatonin on UC remission, and to use the estimate of this effect and its variability to calculate the sample size needed for a presumably larger and more definitive trial.</outcome_measure>
      <outcome_measure>Investigate whether responses to treatment vary according to certain other factors, such as age, sex, duration of disease, clinical symptoms, sleep duration and quality during the trial, and baseline endogenous melatonin.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>69 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>8173</other_id>
      <other_id>IBD-0223</other_id>
    </other_ids>
    <start_date>January 2009</start_date>
    <primary_completion_date>April 2010</primary_completion_date>
    <completion_date>April 2010</completion_date>
    <study_first_posted>November 13, 2008</study_first_posted>
    <last_update_posted>December 23, 2009</last_update_posted>
    <locations>
      <location>Emory University, Atlanta, Georgia, United States</location>
      <location>Consultative Gastroenterology, Atlanta, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00790478</url>
  </study>
  <study rank="614">
    <nct_id>NCT01199302</nct_id>
    <title>Safety Study in Subjects With Crohn's Disease</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AMG 827</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the efficacy of AMG 827 as measured by the Harvey-Bradshaw Index (HBI) and Crohn's Disease Activity Index (CDAI). To evaluate the maintenance of effect as measured by the HBI and CDAI</outcome_measure>
      <outcome_measure>To evaluate the safety of long-term exposure with AMG 827 in subjects with Crohn's disease.</outcome_measure>
      <outcome_measure>To determine if subjects develop anti-AMG 827 antibodies; to evaluate the change of EQ-5D from baseline at all timepoints, the effect of treatment on inflammatory markers (C-reactive protein [CRP]) at post-base, and the pharmacokinetics of AMG 827.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Amgen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>67</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20100008</other_id>
      <other_id>Crohn's OLE</other_id>
    </other_ids>
    <start_date>December 2010</start_date>
    <primary_completion_date>August 2011</primary_completion_date>
    <completion_date>August 2011</completion_date>
    <study_first_posted>September 10, 2010</study_first_posted>
    <last_update_posted>January 14, 2016</last_update_posted>
    <locations>
      <location>Research Site, Birmingham, Alabama, United States</location>
      <location>Research Site, Jacksonville, Florida, United States</location>
      <location>Research Site, Hammond, Louisiana, United States</location>
      <location>Research Site, Chevy Chase, Maryland, United States</location>
      <location>Research Site, Rochester, Minnesota, United States</location>
      <location>Research Site, Mexico, Missouri, United States</location>
      <location>Research Site, Great Neck, New York, United States</location>
      <location>Research Site, Charlotte, North Carolina, United States</location>
      <location>Research Site, Nashville, Tennessee, United States</location>
      <location>Research Site, San Antonio, Texas, United States</location>
      <location>Research Site, Ogden, Utah, United States</location>
      <location>Research Site, Kurralta Park, South Australia, Australia</location>
      <location>Research Site, Box Hill, Victoria, Australia</location>
      <location>Research Site, Fitzroy, Victoria, Australia</location>
      <location>Research Site, Fremantle, Western Australia, Australia</location>
      <location>Research Site, Bonheiden, Belgium</location>
      <location>Research Site, Gent, Belgium</location>
      <location>Research Site, Leuven, Belgium</location>
      <location>Research Site, Roeselare, Belgium</location>
      <location>Research Site, Vancouver, British Columbia, Canada</location>
      <location>Research Site, Winnipeg, Manitoba, Canada</location>
      <location>Research Site, Hamilton, Ontario, Canada</location>
      <location>Research Site, Montreal, Quebec, Canada</location>
      <location>Research Site, Lille cedex, France</location>
      <location>Research Site, Nice Cedex 3, France</location>
      <location>Research Site, Paris Cedex 10, France</location>
      <location>Research Site, Paris, France</location>
      <location>Research Site, Toulouse Cedex 09, France</location>
      <location>Research Site, Vandoeuvre les Nancy, France</location>
      <location>Research Site, Amsterdam, Netherlands</location>
      <location>Research Site, Bydgoszcz, Poland</location>
      <location>Research Site, Sopot, Poland</location>
      <location>Research Site, Barcelona, Cataluña, Spain</location>
      <location>Research Site, Pontevedra, Galicia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01199302</url>
  </study>
  <study rank="615">
    <nct_id>NCT02327377</nct_id>
    <title>Web-based Management of Pediatric Functional Abdominal Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastrointestinal Disorders, Functional</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Online Cognitive Behavior Therapy</intervention>
      <intervention type="Behavioral">Online Education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline somatic symptoms</outcome_measure>
      <outcome_measure>Change from baseline abdominal pain</outcome_measure>
      <outcome_measure>Change from baseline activity limitations</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanderbilt University Medical Center</lead_sponsor>
      <collaborator>Seattle Children's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>11 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>344</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>140559</other_id>
    </other_ids>
    <start_date>April 2014</start_date>
    <primary_completion_date>January 16, 2019</primary_completion_date>
    <completion_date>January 28, 2019</completion_date>
    <study_first_posted>December 30, 2014</study_first_posted>
    <last_update_posted>March 28, 2019</last_update_posted>
    <locations>
      <location>Vanderbilt Children's Hospital, Nashville, Tennessee, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02327377/ICF_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT02327377</url>
  </study>
  <study rank="616">
    <nct_id>NCT01912391</nct_id>
    <title>Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Borderline Personality Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
      <intervention type="Drug">Placebo (for Selegiline)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Primary Efficacy Measurement: Changes in the Hopkins Symptom Checklist 90-Revised (SCL 90-R) scale</outcome_measure>
      <outcome_measure>Secondary Efficacy Measurement: Change in Hamilton Depression Inventory 17 Questions (HAM-D)</outcome_measure>
      <outcome_measure>Clinical Global Impression of Change- Clinician (CGIc)</outcome_measure>
      <outcome_measure>Clinical Global Impression Change- Patient (CGIp)</outcome_measure>
      <outcome_measure>Sheehan Disability Scale (SDS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mood and Anxiety Research, Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PJM-01</other_id>
      <other_id>WV26504-4245</other_id>
    </other_ids>
    <start_date>October 2012</start_date>
    <primary_completion_date>March 2015</primary_completion_date>
    <completion_date>March 2015</completion_date>
    <study_first_posted>July 31, 2013</study_first_posted>
    <last_update_posted>October 8, 2015</last_update_posted>
    <locations>
      <location>Mood and Anxiety Research, Inc, Fresno, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01912391</url>
  </study>
  <study rank="617">
    <nct_id>NCT00740233</nct_id>
    <title>Web-Based Survey of Pain, Stress and Complementary and Alternative Medicine</title>
    <acronym>PROCAIM</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Chronic Pain</condition>
      <condition>Stress</condition>
      <condition>Anxiety</condition>
      <condition>Depression</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Perceived Stress, Mindfulness, Somatization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Center for Complementary and Integrative Health (NCCIH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PROCAIM2008</other_id>
    </other_ids>
    <start_date>June 2008</start_date>
    <primary_completion_date>October 2010</primary_completion_date>
    <completion_date>October 2010</completion_date>
    <study_first_posted>August 22, 2008</study_first_posted>
    <last_update_posted>March 27, 2014</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00740233</url>
  </study>
  <study rank="618">
    <nct_id>NCT03932474</nct_id>
    <title>EVALUATION OF EFFICACY OF SAMEUP IN SUBJECTS WITH DEPRESSION SYMPTOMS: A RANDOMIZED STUDY</title>
    <acronym>SAMEUP</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depressive Symptoms</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">SAMEUp</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in the overall depression symptomatology assessed by the Zung's Self-Rating Depression Scale</outcome_measure>
      <outcome_measure>Improvement in the core depression symptomatology assessed by Zung's Self-Rating Depression Scale</outcome_measure>
      <outcome_measure>Improvement in the patient's cognition assessed by Zung's Self-Rating Depression Scale</outcome_measure>
      <outcome_measure>Improvement in the anxiety condition assessed by Zung's Self-Rating Depression Scale</outcome_measure>
      <outcome_measure>Improvement in the somatic condition assessed by Zung's Self-Rating Depression Scale</outcome_measure>
      <outcome_measure>Improvement in the overall symptomatology of depression assessed by Zung's Self-Rating Depression Scale</outcome_measure>
      <outcome_measure>Improvement in the insomnia condition evaluated through the Insomnia Severity Index</outcome_measure>
      <outcome_measure>Improvement in IBS (Irritable Bowel Syndrome) symptoms evaluated through the IBS questionnaire</outcome_measure>
      <outcome_measure>Improvement in IBS symptoms evaluated through the IBS questionnaire</outcome_measure>
      <outcome_measure>Improvement in the overall health status as measured by the EQ-5D-3L questionnaire</outcome_measure>
      <outcome_measure>Evaluation of the patient's satisfaction grade</outcome_measure>
      <outcome_measure>Incidence of adverse events described as per frequency and relationship with the study product</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nutrilinea srl</lead_sponsor>
      <collaborator>Hippocrates Research</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SAMEUP</other_id>
    </other_ids>
    <start_date>September 17, 2018</start_date>
    <primary_completion_date>November 20, 2018</primary_completion_date>
    <completion_date>November 20, 2018</completion_date>
    <study_first_posted>April 30, 2019</study_first_posted>
    <last_update_posted>May 2, 2019</last_update_posted>
    <locations>
      <location>Hippocrates Research, Genoa, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03932474</url>
  </study>
  <study rank="619">
    <nct_id>NCT03058003</nct_id>
    <title>Correlation Between Central Sensitization Inventory and Posturographic Data</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Central Nervous System Sensitization</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Posturography Evaluation</intervention>
      <intervention type="Other">Central Sensitization Inventory</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stability Score</outcome_measure>
      <outcome_measure>CSI</outcome_measure>
      <outcome_measure>CSI-SS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Caps Research Network</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>CI-IRB-20170124001</other_id>
    </other_ids>
    <start_date>May 2016</start_date>
    <primary_completion_date>January 2018</primary_completion_date>
    <completion_date>April 2020</completion_date>
    <study_first_posted>February 20, 2017</study_first_posted>
    <last_update_posted>April 25, 2018</last_update_posted>
    <locations>
      <location>Innova Brain Rehabilitation, Marietta, Georgia, United States</location>
      <location>Small Street Clinic, Hampton, Victoria, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03058003</url>
  </study>
  <study rank="620">
    <nct_id>NCT01291758</nct_id>
    <title>Exercise in Gulf War Illness (GWI)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gulf War Illness</condition>
      <condition>Persian Gulf Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To assess the alterations due to exercise in Gulf War Veterans</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Georgetown University</lead_sponsor>
      <collaborator>U.S. Army Medical Research and Materiel Command</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>38 Years</min_age>
    <max_age>86 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>2009-229</other_id>
      <other_id>USAMRMC PR# W81XWH-09-1-0526</other_id>
      <other_id>HRPO Log No. A-15547</other_id>
    </other_ids>
    <start_date>July 2009</start_date>
    <primary_completion_date>September 2012</primary_completion_date>
    <completion_date>September 2012</completion_date>
    <study_first_posted>February 8, 2011</study_first_posted>
    <last_update_posted>February 25, 2014</last_update_posted>
    <locations>
      <location>Georgetown University, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01291758</url>
  </study>
  <study rank="621">
    <nct_id>NCT00810368</nct_id>
    <title>Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Persian Gulf Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carnosine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of Carnosine Supplementation on Chronic Fatigue Syndrome Severity Scores</outcome_measure>
      <outcome_measure>Subjects With Improved Diarrhea Symptoms</outcome_measure>
      <outcome_measure>Incremental Change in Fatigue Score From Baseline to Week 12</outcome_measure>
      <outcome_measure>SF36 Bodily Pain</outcome_measure>
      <outcome_measure>Incremental Change in Generalized Anxiety Scale (GAD) Scores From Baseline to Week 12</outcome_measure>
      <outcome_measure>Incremental Change in SF36 General Health Between Baseline and Week 12</outcome_measure>
      <outcome_measure>Digit Symbol Substitution (WAIS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Georgetown University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>34 Years</min_age>
    <max_age>82 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008-068</other_id>
      <other_id>USAMRMC PR# W91ZSQ-7149-N602</other_id>
      <other_id>HRPO Log No. A-14542.2</other_id>
    </other_ids>
    <start_date>August 2008</start_date>
    <primary_completion_date>July 2012</primary_completion_date>
    <completion_date>July 2012</completion_date>
    <study_first_posted>December 18, 2008</study_first_posted>
    <results_first_posted>August 18, 2016</results_first_posted>
    <last_update_posted>May 8, 2018</last_update_posted>
    <locations>
      <location>Georgetown University, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00810368</url>
  </study>
  <study rank="622">
    <nct_id>NCT00810225</nct_id>
    <title>Study of Gulf War Illness (GWI) by Comparing GWI and Healthy Veterans</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gulf War Illness</condition>
      <condition>Persian Gulf War Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Georgetown University</lead_sponsor>
      <collaborator>U.S. Army Medical Research and Materiel Command</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>516</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>2008-012</other_id>
      <other_id>USAMRMC PR# W81XWH-07-1-0618</other_id>
      <other_id>HRPO Log No. A-14542.1</other_id>
    </other_ids>
    <start_date>August 2008</start_date>
    <primary_completion_date>July 2011</primary_completion_date>
    <completion_date>July 2011</completion_date>
    <study_first_posted>December 18, 2008</study_first_posted>
    <last_update_posted>June 18, 2018</last_update_posted>
    <locations>
      <location>Georgetown University, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00810225</url>
  </study>
  <study rank="623">
    <nct_id>NCT02426788</nct_id>
    <title>CBT Plus SMC Compared to SMC for Persistent Physical Symptoms in Secondary Care (PRINCE)</title>
    <acronym>PRINCE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Persistent Physical Symptoms (PPS)</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive behavioural therapy (CBT)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Work and social adjustment scale</outcome_measure>
      <outcome_measure>Persistent Physical Symptom Questionnaire</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-15 (PHQ-15)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9)</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder-7 (GAD-7)</outcome_measure>
      <outcome_measure>Clinical Global Impression (CGI)</outcome_measure>
      <outcome_measure>Client Service Receipt Inventory (CSRI)</outcome_measure>
      <outcome_measure>EuroQol-5D (EQ-5D)</outcome_measure>
      <outcome_measure>Cognitive Behavioural Responses Questionnaire</outcome_measure>
      <outcome_measure>Acceptance scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
      <collaborator>South London and Maudsley NHS Foundation Trust</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>324</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STR130202 (Secondary)</other_id>
    </other_ids>
    <start_date>July 2015</start_date>
    <primary_completion_date>January 2019</primary_completion_date>
    <completion_date>January 2019</completion_date>
    <study_first_posted>April 27, 2015</study_first_posted>
    <last_update_posted>May 9, 2019</last_update_posted>
    <locations>
      <location>Guy's Hospital, London, United Kingdom</location>
      <location>King's College Hospital, London, United Kingdom</location>
      <location>Queen Elizabeth Hospital, London, United Kingdom</location>
      <location>Royal Free Hospital, London, United Kingdom</location>
      <location>St Thomas' Hospital, London, United Kingdom</location>
      <location>University Hospital Lewisham, London, United Kingdom</location>
      <location>Princess Royal University Hospital, Orpington, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02426788</url>
  </study>
</search_results>
